The Mouse in Biomedical Research, 2nd Edition Volume IV Immunology
This page intentionally left blank
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION Volume IV Immunology EDITED
BY
James G. Fox
Muriel T. Davisson
Fred W. Quimby
Division of Comparative Medicine, MIT Cambridge, MA
The Jackson Laboratory Bar Harbor, ME
Laboratory Animal Research Center The Rockefeller University New York, NY
Stephen W. Barthold
Christian E. Newcomer
Abigail L. Smith
Center for Comparative Medicine Schools of Medicine and Veterinary Medicine University of California Davis, CA
Research Animal Resources and Department of Molecular and Comparative Pathobiology Johns Hopkins University Baltimore, MD
School of Veterinary Medicine University of Pennsylvania Philadelphia, PA
AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD PARIS • SAN DIEGO • SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier
Academic Press is an imprint of Elsevier 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, California 92101-4495, USA 84 Theobald’s Road, London WC1X 8RR, UK
This book is printed on acid-free paper.
Copyright © 2007, Elsevier, Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.
Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail:
[email protected]. You may also complete your request on-line via the Elsevier homepage (http://elsevier.com), by selecting “Support & Contact” then “Copyright and Permission” and then “Obtaining Permissions.”
Library of Congress Cataloging-in-Publication Data Application Submitted British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library.
ISBN 13: 978-0-12-369458-4 (v. 4) ISBN 10: 0-12-369458-2 (v.4) ISBN-Set: 0-12-369454-X
For information on all Academic Press publications visit our Web site at www.books.elsevier.com
Printed in the United States of America 07 08 09 10 9 8 7 6 5 4
3
2
1
Table of Contents Volume I History, Wild Mice, and Genetics List of Reviewers List of Contributors Foreword Preface
1.
Building a Better Mouse: One Hundred Years of Genetics and Biology
x xi xiii xv
10. 1
Herbert C. Morse III
Mouse Embryology: Research Techniques and a Comparison of Embryonic Development between Mouse and Man
165
Matthew H. Kaufman 2.
Systematics of the genus Mus
13
Priscilla K. Tucker
11.
Gamete and Embryo Manipulation
211
K.C. Kent Lloyd 3.
The Secret World of Wild Mice
25
Grant R. Singleton and Charles J. Krebs 12. 4.
Breeding Systems: Considerations, Genetic Fundamentals, Genetic Background, and Strain Types
Mouse Strain and Genetic Nomenclature: an Abbreviated Guide
225
Martin Hrabé de Angelis, Dian Michel, Sibylle Wagner, Sonja Becker, and Johannes Beckers 53
Melissa L. Berry and Carol Cutler Linder 5.
Chemical Mutagenesis in Mice
13.
Gene-Specific Mutagenesis
261
K.C. Kent Lloyd 79
Janan T. Eppig
14.
Gene Transfer Studies Using Mouse Models
267
Robert G. Pergolizzi and Ronald G. Crystal 6.
The Mouse Genome
99
Mark D. Adams 7.
Gene Mapping
15.
Mouse and Human Pluripotent Stem Cells
281
Leslie F. Lock
115
Muriel T. Davisson 16. 8.
Genetic Monitoring
135
Cytogenetics Muriel T. Davisson and Mary Ann Handel
289
Lucia F. Jorge-Nebert, Sandrine Derkenne, and Daniel W. Nebert
Richard R. Fox, Michael V. Wiles, and Petko M. Petkov 9.
Drugs and the Mouse: Pharmacology, Pharmacogenetics, and Pharmacogenomics
145 Index
321
v
vi
TA B L E O F C O N T E N T S
Volume II Diseases
10.
Retroelements in the Mouse
269
Herbert C. Morse III List of Reviewers List of Contributors Foreword Preface
x xi xiv xv
Viral Diseases
11.
Sendai Virus and Pneumonia Virus of Mice (PVM)
281
David G. Brownstein
12.
DNA Viruses
Cardioviruses: Encephalomyocarditis Virus and Theiler’s Murine Encephalomyelitis Virus
311
Howard L. Lipton, A.S. Manoj Kumar, and Shannon Hertzler 1.
Murine Cytomegalovirus and Other Herpesviruses
1 Bacterial Diseases
Geoffrey R. Shellam, Alec J. Redwood, Lee M. Smith, and Shelley Gorman 13. 2.
Mouse Adenoviruses
325
Roger G. Rank
49
Katherine R. Spindler, Martin L. Moore, and Angela N. Cauthen
Chlamydial Diseases
14.
Clostridial Species
349
Kimberly S. Waggie 3.
Mousepox
67
R. Mark L. Buller and Frank Fenner
4.
Parvoviruses
15.
Enterobacteriaceae, Pseudomonas aeruginosa, and Streptobacillus moniliformis
365
Hilda Holcombe and David B. Schauer
93
Robert O. Jacoby and Lisa Ball-Goodrich 16. 5.
Polyoma Viruses
Aerobic Gram-Positive Organisms
389
Cynthia Besch-Williford and Craig L. Franklin
105
Thomas L. Benjamin 17.
RNA Viruses
Helicobacter Infections in Mice
407
James G. Fox and Mark T. Whary 6.
Mouse Hepatitis Virus
141 18.
Stephen W. Barthold and Abigail L. Smith
Mycoplasma pulmonis, Other Murine Mycoplasmas, and Cilia-Associated Respiratory Bacillus
437
Trenton R. Schoeb 7.
Lymphocytic Choriomeningitis Virus
179
Stephen W. Barthold and Abigail L. Smith
19.
Pasteurellaceae
469
Werner Nicklas 8.
Lactate Dehydrogenase-Elevating Virus
215 Mycotic and Parasitic Diseases
Jean-Paul Coutelier and Margo A. Brinton
9.
Reoviridae Richard L. Ward, Monica M. McNeal, Mary B. Farone, and Anthony L. Farone
235
20.
Fungal Diseases in Laboratory Mice Virginia L. Godfrey
507
vii
TA B L E O F C O N T E N T S
21.
Protozoa
517
3.
Katherine Wasson
22.
Helminth Parasites of Laboratory Mice
Reproductive Biology of the Laboratory Mouse
91
Kathleen R. Pritchett and Robert Taft
551
4.
Kathleen R. Pritchett
Endocrinology: Bone as a Target Tissue for Hormonal Regulation
123
Krista M. Delahunty and Wesley G. Beamer 23.
Arthropods
565 5.
David G. Baker
Hematology of the Laboratory Mouse
133
Nancy E. Everds Miscellaneous Diseases 6. 24.
The Tumor Pathology of Genetically Engineered Mice: A New Approach to Molecular Pathology 581
Spontaneous Diseases in Commonly Used Mouse Strains
171
Fred W. Quimby and Richard H. Luong
Robert D. Cardiff, Robert J. Munn, and Jose J. Galvez
25.
Clinical Chemistry of the Laboratory Mouse
Management, Techniques, and Husbandry
7. 623
Gnotobiotics
217
Richard J. Rahija
Cory Brayton 8. 26.
Zoonoses and Other Human Health Hazards
Management and Design: Breeding Facilities
235
William J. White
719
Christian E. Newcomer and James G. Fox 9. Index
747
Design and Management of Research Facilities for Mice
271
Neil S. Lipman
Volume III Normative Biology, Husbandry, and Models List of Reviewers List of Contributors Foreword Preface
10.
Nutrition
321
Graham Tobin, Karla A. Stevens, and Robert J. Russell x xi xiv xv
Normative Biology
11.
Health Delivery and Quality Assurance Programs for Mice
385
Diane J. Gaertner, Glen Otto, and Margaret Batchelder
12.
Environmental and Equipment Monitoring
409
J. David Small and Rick Deitrich 1.
Gross Anatomy
1
Vladimír Komárek
2.
Mouse Physiology Robert F. Hoyt, Jr., James V. Hawkins, Mark B. St. Claire, and Mary B. Kennett
13.
23
Biomethodology and Surgical Techniques
437
Alison M. Hayward, Laura B. Lemke, Erin C. Bridgeford, Elizabeth J. Theve, Courtnye N. Jackson, Terrie L. Cunliffe-Beamer, and Robert P. Marini
viii 14.
TA B L E O F C O N T E N T S
In-Vivo Whole-Body Imaging of the Laboratory Mouse 489 Simon R. Cherry Use of Mice in Biomedical Research
Foreword Preface
xiii xv
Overview
1
Fred W. Quimby and David D. Chaplin 15.
Behavioral Testing
513
Douglas Wahlsten and John C. Crabbe
16.
Cardiovascular Disease: Mouse Models of Atherosclerosis
1.
The Molecular Basis of Lymphoid Architecture in the Mouse
57
Carola G. Vinuesa and Matthew C. Cook 535
Nobuyo Maeda, Raymond C. Givens, and Robert L. Reddick
2.
The Biology of Toll-Like Receptors in Mice
109
Osamu Takeuchi and Shizuo Akira 17.
Convulsive Disorders
565 3.
Mariana T. Todorova and Thomas N. Seyfried
Genomic Organization of the Mouse Major Histocompatibility Complex
119
Attila Kumánovics 18.
Eye Research
595
Richard S. Smith, Patsy M. Nishina, John P. Sundberg, Johann Zwaan, and Simon W.M. John
4.
Some Biological Features of Dendritic Cells in the Mouse
135
Kang Liu, Anna Charalambous, and Ralph M. Steinman 19.
Genetic Analysis of Rodent Obesity and Diabetes
617
Sally Chiu, Janis S. Fisler, and Craig H. Warden 5. 20.
Mouse Models in Aging Research
637
Kevin Flurkey, Joanne M. Currer, and D.E. Harrison
21.
Mouse Models of Inherited Human Neurodegenerative Disease 673
Mouse Skin Ectodermal Organs
155
Maria D. Iglesias-Ussel, Ziqiang Li, and Matthew D. Scharff
6.
Karl Herrup
22.
Mouse Models Revealed the Mechanisms for Somatic Hypermutation and Class Switch Recombination of Immunoglobulin Genes
Mouse Natural Killer Cells: Function and Activation
169
Francesco Colucci 691 7.
Maksim V. Plikus, John P. Sundberg, and Cheng-Ming Chuong
Cytokine-Activated JAK-STAT Signaling in the Mouse Immune System 179 Bin Liu and Ke Shuai
23.
Quality Control Testing of Biologics
731 8.
William R. Shek
Signal Transduction Events Regulating Integrin Function and T Cell Migration in the Mouse
195
Lakshmi R. Nagarajan and Yoji Shimizu Index
759 9.
Volume IV Immunology List of Reviewers List of Contributors
x xi
Mouse Models of Negative Selection Troy A. Baldwin, Timothy K. Starr, and Kristin A. Hogquist
207
ix
TA B L E O F C O N T E N T S
10.
Peripheral Tolerance of T Cells in the Mouse
223
14.
Vigo Heissmeyer, Bogdan Tanasa, and Anjana Rao
Mouse Models to Study the Pathogenesis of Allergic Asthma
291
Chad E. Green, Nicholas J. Kenyon, Scott I. Simon, and Fu-Tong Liu 11.
The Genetics of Mouse Models of Systemic Lupus
243
Srividya Subramanian and Edward K. Wakeland 15. 12.
Inhibitory Receptors and Autoimmunity in the Mouse 261
The Mouse Trap: How Well Do Mice Model Human Immunology?
303
Christopher C.W. Hughes and Javier Mestas
Menna R. Clatworthy and Kenneth G.C. Smith Index 13.
Mouse Models of Immunodeficiency B. Anne Croy, James P. Di Santo, Marcus Manz, and Richard B. Bankert
275
313
List of Reviewers for Chapters in this Volume Altmann, Danny M. Bankert, Richard Eckhardt, Laurel Fischer-Lindahl, Kristen Fu, Yang-Xin Kinashi, Tatsuo Kulski, Jerzy Latour, Sylvain Lee, James J. McGaha, Tracy Nimmerjahn, Falk Pernis, Alessandra B. Schultz, Leonard D. Skokos, Dimitris
x
Imperial College, London, UK State University of NY, Buffalo, NY Hunter College of CUNY, New York City, NY University of Texas Southwestern Medical Center, Dallas, TX University of Chicago, Dept of Pathology, Chicago, IL Kansai Medical School, Japan Murdoch University, Perth, Western Australia Hôpital Necker-Enfants Malades, Paris, France Mayo Clinic College of Medicine, Rochester, MN The Rockefeller University, New York, NY The Rockefeller University, New York, NY Columbia University, New York, NY The Jackson Laboratory, Bar Harbor, ME The Rockefeller University, New York, NY
Contributors Shizuo Akira Department of Host Defense Research Institute for Microbial Diseases Osaka University Osaka, Japan
B. Anne Croy Department of Anatomy and Cell Biology Faculty of Health Sciences Kingston Ontario, Canada
Troy A. Baldwin Center for Immunology University of Minnesota Minneapolis, MN 55455
James P. Di Santo Unite des Cytokines et Developpement Lymphoide Institut Pasteur Département d’Immunologie Paris, France
Richard B. Bankert Department of Microbiology and Immunology State University of New York Buffalo, NY 14260 David D. Chaplin Department of Microbiology University of Alabama at Birmingham Birmingham, AL 35294 Anna Charalambous Laboratory of Cellular Physiology and Immunology The Rockefeller University New York, NY 10021 Menna R. Clatworthy Cambridge Institute for Medical Research Department of Medicine University of Cambridge Cambridge, United Kingdom Francesco Colucci The Babraham Institute Babraham Research Campus Cambridge, United Kingdom Matthew C. Cook Department of Immunology The Canberra Hospital Woden, ACT, Australia
Chad E. Green Department of Biomedical Engineering School of Engineering University of California at Davis Davis, CA 95616 Vigo Heissmeyer National Research Center for Environment and Health-GSF Institute of Molecular Immunology Marchioninistr Munich, Germany Kristin A. Hogquist Center for Immunology University of Minnesota Minneapolis, MN 55455 Christopher C.W. Hughes Department of Molecular Biology & Biochemistry University of California at Irvine Irvine, CA 92697 Maria D. Iglesias-Ussel Department of Cell Biology Albert Einstein College of Medicine New York, NY 10461 Nicholas J. Kenyon Division of Pulmonary and Critical Care Medicine Department of Internal Medicine University of California at Davis School of Medicine Davis, CA 95616 xi
xii Attila Kumánovics Department of Pathology Division of Immunology and Cell Biology University of Utah School of Medicine Salt Lake City, UT 84132 Ziqiang Li Department of Cell Biology Albert Einstein College of Medicine New York, NY 10461 Bin Liu Division of Hematology/Oncology University of California Los Angeles Los Angeles, CA 90095 Fu-Tong Liu Department of Dermatology University of California at Davis Davis, CA 95616 Kang Liu Laboratory of Cellular Physiology and Immunology The Rockefeller University New York, NY 10021 Marcus Manz Institute for Research in Biomedicine (IRB) Bellinzona, Switzerland Javier Mestas Center for Immunology University of California at Irvine Irvine, CA 92697 Lakshmi R. Nagarajan Department of Laboratory Medicine and Pathology University of Minnesota Medical School Minneapolis, MN 55455 Fred W. Quimby Laboratory Animal Research Center The Rockefeller University New York, NY 10021 Anjana Rao Department of Pathology Harvard Medical School and the CBR Institute for Biomedical Research Boston, MA 02115 Matthew D. Scharff Department of Cell Biology Albert Einstein College of Medicine Bronx, New York, NY 10461
CONTRIBUTORS
Yoji Shimizu Department of Laboratory Medicine and Pathology University of Minnesota Medical School Minneapolis, MN 55455 Ke Shuai Division of Hematology/Oncology University of California Los Angeles Los Angeles, CA 90095 Scott I. Simon Department of Biomedical Engineering School of Engineering University of California at Davis Davis, CA 95616 Kenneth G.C. Smith Cambridge Institute for Medical Research Department of Medicine University of Cambridge Cambridge, United Kingdom Timothy K. Starr Center for Immunology University of Minnesota Minneapolis, MN 55455 Ralph M. Steinman Laboratory of Cellular Physiology and Immunology The Rockefeller University New York, NY 10021 Srividya Subramanian Center for Immunology University of Texas Southwestern Medical Center Dallas, TX 75390 Osamu Takeuchi Department of Host Defense Research Institute for Microbial Diseases Osaka University Osaka, Japan Bogdan Tanasa Department of Pathology Harvard Medical School and the CBR Institute for Biomedical Research Boston, MA 02115 Carola G. Vinuesa Division of Immunology and Genetics John Curtin School of Medical Research Canberra City, ACT, Australia Edward K. Wakeland Center for Immunology University of Texas Southwestern Medical Center Dallas, TX 75390
Foreword for Volume IV
More than 30 years ago, Rolf Zinkernagel and I made the chance discovery that virus-specific “killer” T cells only destroyed virus-infected target cells that shared at least one H2 haplotype. This very clear result depended on the use of a few, standard inbred mouse strains—CBA/H (H2k), BALBc/J (H2d), and C57BL/6J (H2b). Like any young scientists, we simply took it for granted that these mice were available for us to use in our experiments and didn’t think much about where or why they were developed. Years later, at a meeting that celebrated “50 years of H2” held at The Jackson Laboratory in Bar Harbor, Maine, Jan Klein and others told us some of the story1. In trying to study cancer, George Snell discovered that the tumor cells he was transplanting were being rapidly rejected. He quickly realized that it wasn’t something specific to the tumor that the recipients were recognizing, but the identity of the donor mouse strain. Together with serological observations made by Peter Gorer in London, this began the story of what we now know as the major histocompatibility complex (MHC). Klein traced for us how C.C. Little, the founder of The Jackson Laboratories, had used founder stock inbred to select ornamental mouse strains by Abbie Lathrop, a commercial breeder in Vermont. Lathrop is, in a sense, the mother of mouse transplantation genetics. Genetics is now, and has long been, the most powerful analytical tool available to biologists. Without the further development of recombinant and mutant mice that mapped and defined the MHC class I genes, the observation that Rolf and I made would not have gone very far. As our discovery and the way we interpreted our results led to a Nobel Prize, we owe an enormous debt to George Snell, Peter Gorer, Don Bailey, Chella David, Don Shreffler, Hugh McDevitt, Jack Stimpfling, Igor Egorov, and a host of other geneticists who were trying to understand transplantation and the so-called immune response (Ir) genes.
1. David, C.S. Ed H-2 Antigens: Genes, Molecules and Function NATO AASI Series, Plenum Press, New York, 1987
In short, we were able to exploit an extraordinarily elegant genetic system to answer the linked questions, “What do killer T cells see, and how do they see it?” Some similar observations had been made in humans, but the interpretation of these results was quite wrong and the area was immensely confused. Without mouse transplantation genetics and the ready, open availability of those inbred mouse strains, our understanding of T cell recognition would have been delayed for decades. I think it must have hurt just a little when these two, young, naive nonentities came along and told the mouse genetics community the nature of what it was they had been investigating for all those years. That is, though, how science works. The breakthrough discoveries are often made by chance, and come from the most unlikely direction. As late as 1987, some of the geneticists still had difficulty acknowledging that the primary function of the transplantation antigens was to serve as targets for “surveillance of self.” The development of transgenic “knock-out” and “knock-in” mice is now, of course, central to almost every in vivo investigation in mammalian cell biology. Although cancer biologists had largely lost interest in mouse experiments by the mid1980s—and the experimental immunologists had few friends when they argued that it was necessary to build bigger animal facilities—that changed dramatically in the 1990s and we soon found it hard to hold on to whatever space we had. Now, making the relevant mutant mouse is a prerequisite for any serious study of a potential cancer gene. Any honest commentator on the laboratory mouse must acknowledge that these genetic analyses are essential to contemporary biomedical research. Of course, there are many opponents who—because they are hostile to molecular genetics, animal experimentation, or both—use emotionally charged arguments to convince the public and the politicians that this is not the case. We have a constant battle on our hands as we try to ensure that there is no interruption in that rapid progress through transgenic mouse studies that has been our experience over the past 15 or so years.
xiii
xiv Of course, the rules have changed over the past 5 to 10 years and if the more regressive elements in society succeeded in shutting down animal experiments tomorrow in the United States and Europe, we would simply see an exacerbation of the progressive move of such research to emerging Asian centers of excellence. As science and technology are tightly tied to economic development, this could be disastrous for the so-called “knowledge” economies of the West.
FOREWORD
PETER C. DOHERTY, DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY, UNIVERSITY OF MELBOURNE, VICTORIA 3010, AUSTRALIA
[email protected] and, DEPARTMENT OF IMMUNOLOGY, ST. JUDE CHILDREN’S RESEARCH HOSPITAL, MEMPHIS, TN 38105
[email protected] Preface The American College of Laboratory Animal Medicine (ACLAM) was formed in 1957 in response to the need for specialists in laboratory animal medicine. The college has promoted high standards for laboratory animal medicine by providing a structured framework to achieve certification for professional competency and by stressing the need for scientific inquiry and exchange via progressive continuing education programs. The first edition of “The Mouse in Biomedical Research” consisting of four volumes, and published in 19811983 was a part of the College’s effort to fulfill those goals. It is one of a series of comprehensive texts on laboratory animals developed by ACLAM over the past three decades: “The Biology of the Laboratory Rabbit” was published in 1974, “The Biology of The Guinea Pig” in 1976 and a two-volume work “Biology of The Laboratory Rat” in 1979 and 1980. Also, in 1979 the College published a two-volume text on “Spontaneous Animal Models of Human Disease”. In 1984 the first edition of “Laboratory Animal Medicine” appeared in print followed by “Laboratory Hamsters” in 1987. The second edition of The Biology of the Laboratory Rabbit was published in 1994. A two-volume treatise on “Nonhuman Primates in Biomedical Research” was published in 1995 and 1998. A text “Anesthesia and Analgesia in Laboratory Animals” was published in 1997 followed by the second edition of “Laboratory Animal Medicine” in 2002. Most recently, the second edition of “The Laboratory Rat” was published in 2005. The estimated annual use of 100 million-plus mice worldwide attests to the importance of the mouse in experimental research. The introduction of genetically engineered mice has only increased the usefulness of the mouse model in biomedical research. In no other species of animal has such a wealth of experimental data been utilized for scientific pursuits. Knowledge of the mouse that has been accumulated is, for the most part, scattered throughout a multitude of journals, monographs and symposia. It has been 25 years since the publication of the first edition of the “Mouse in Biomedical Research”. The intent of this second edition is to build upon the framework of the first edition, rather than simply to update and duplicate the earlier effort. The intended purpose of this text is to assemble established scientific data emphasizing recent information on the biology and use of the laboratory mouse. Separation of the material into multiple volumes was essential because of the number of
subject areas covered. The four volumes consist of 80 chapters coauthored by 167 scientists. The information in Volume 1 serves as a primer for scientists new to the field of mouse research. It provides information about the history, basic biology and genomics of the laboratory mouse (Mus musculus), as well as basic information on maintenance and use of mouse stocks. Mouse origins and relationships are covered in chapters on history, evolutionary taxonomy and wild mice. Genetics and genomics of the mouse are covered in chapters on genetic nomenclature, gene mapping, cytogenetics and the molecular organization of the mouse genome. Maintenance of laboratory mice is described in chapters on breeding systems for various types of strains and stocks and genetic monitoring. Use of the mouse as a model system for basic biomedical research is described in chapters on chemical mutagenesis, gene trapping, gene therapy, pharmacogenetics and embryo manipulation. Volume 2 entitled Diseases departs from the first edition of the same title by discussing specific disease-causing microorganisms, whereas the first edition discussed infectious diseases affecting specific organs and tissues. This volume consists of 26 chapters subdivided into RNA viruses and DNA viruses, as well as bacterial, mycotic and parasitic infections. These chapters not only provide updates on pathogenesis, epidemiology and prevention of previously recognized murine pathogens, but also include chapters on newly recognized disease-causing organisms: mouse parvovirus, cilia-associated respiratory bacilli and Helicobacter spp. A separate category, consisting of 3 chapters, discusses zoonoses, tumor pathology of genetically engineered mice and spontaneous diseases in commonly used mouse strains. Volume 3 encompasses 23 chapters whose contents provide a broad overview on the laboratory mouse’s normative biology, husbandry and its use as a model in biomedical research. This consists of chapters on behavior, physiology, reproductive physiology, anatomy, endocrinology, hematology and clinical chemistry. Other chapters cover management, as well as nutrition, gnotobiotics and disease surveillance. Individual chapters describe the mouse as a model for the study of aging, eye research, neurodegenerative diseases, convulsive disorders, diabetes and cardiovascular and skin diseases. Chapters on imaging, surgical and other research techniques and the use of the mouse in assays of biological products also are included.
xv
xvi Volume 4 is a completely new addition to this series, dedicated to mouse immunology. It is based on the vast body of knowledge which has made the mouse the model of choice when studying immunity in human beings. Arguably more is known about the immune system in mice than any other species except human. In large part this is due to the power of genetic engineering to delineate molecular mechanisms. This volume includes an overview of mouse immunology, including both the innate and adaptive immune systems, followed by 15 chapters (mini-reviews), each dealing with a specific area of immunology. The overview addresses broad concepts concerning molecular and cellular immunology and cites both current references and the appropriate chapter, for more detailed information, from the mini-reviews which follow. The 15 chapters illustrate the power of genetic engineering in dissecting each component of the immune response from the development of lymphoid tissues to signal transduction pathways in activated cells. Individual chapters address: The Genomic Organization of the MHC, Toll-like Receptors, The Molecular Basis of Lymphoid Architecture, The Biology of Dendritic Cells, Somatic Hypermutation and Class Switching, Natural Killer Cell Function and Activation, Cytokine Mediated Signaling, Signal Transduction Events Regulating Integrin Function and T-Cell Migration, Central Tolerance in T-Cells, Peripheral Tolerance in T-cells, Inhibitory Receptors and Autoimmunity. The volume also includes the use of mice in studies of Systemic Autoimmunity, Immunodeficiency, Allergic Airway Inflammation and the Differences Between Mouse and Human Immunology. This treatise was conceived with the intent to offer information suitable to a wide cross section of the scientific community. It is hoped that the four volumes will serve as a standard reference source for scientists using mice in biomedical research. Students embarking on scientific careers also will benefit from the broad coverage of material presented in compendium format. Certainly, specialists in laboratory animal
P R E FA C E
science will benefit from these volumes; technicians in both animal care and research will find topics on surgical techniques, management and environmental monitoring of particular value. The editors wish to extend special appreciation to the contributors to these volumes. Authors were selected because of knowledge and expertise in their respective fields. Each individual contributed his or her time, expertise and considerable effort to compile this resource treatise. In addition, the contributors and editors of this book, as with all volumes of the ACLAM series texts, have donated publication royalties to the American College of Laboratory Animal Medicine for the purpose of continuing education in laboratory animal science and comparative medicine. This book could not have been completed without the full support and resources of the editors’ parent institutions which allowed us the time and freedom to assemble this text. A special thanks is also extended to the numerous reviewers of the edited work whose suggestions helped the authors and editors present the material in a meaningful and concise manner. We also thank the editorial staff of Elsevier for their assistance. Finally, we especially acknowledge with deep appreciation the editorial assistance of Lucille Wilhelm, whose dedication and tireless commitment, as well as good humor, throughout this project were of immeasurable benefit to the editors in the completion of this text.
JAMES G. FOX STEPHEN W. BARTHOLD MURIEL T. DAVISSON CHRISTIAN E. NEWCOMER FRED W. QUIMBY ABIGAIL L. SMITH
Overview Overview of Immunology in the Mouse: Molecular and Cellular Immunology Fred W. Quimby and David D. Chaplin
I. II.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Molecular Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Receptors and Ligands of the Innate Immune System . . . . . . . . . . . . . 1. Toll-Like Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. TLR1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c. TLR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . d. TLR3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e. TLR4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . f. TLR5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g. TLR6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . h. TLR7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . i. TLR8 and TLR10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . j. TLR9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . k. TLR11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Fc Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. Poly-Ig Receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c. The Neonatal FcR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . d. FcγRIIB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e. Activating FcγRI and FcγRIII . . . . . . . . . . . . . . . . . . . . . . . . . . f. FcγRIV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g. FcεRI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . h. Other FcRs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Complement and Complement Receptors . . . . . . . . . . . . . . . . . . . . a. Overview of the Complement System . . . . . . . . . . . . . . . . . . . b. Types of Complement Receptors . . . . . . . . . . . . . . . . . . . . . . . i. CR1 and CR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii. CR3 and CR4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii. Receptors for Anaphylatoxins . . . . . . . . . . . . . . . . . . . . . .
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
3 3 3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 6 6 7 7 7 8 8 8 10 10 11 11 Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
1
2
FRED
W.
QUIMBY
4. C-Type Lectin Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. Type I Receptor Family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c. Type II CLRs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . d. Collectins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e. Type V Family Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. NK Cell Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. Ly49 Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c. CD94/NKG2 Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. The Major Histocompatibility Complex . . . . . . . . . . . . . . . . . . . . . . . . 1. Classic Class I Molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Classic Class II Molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Nonclassic Class I and Class II Molecules . . . . . . . . . . . . . . . . . . . 4. Molecules Associated with Antigen Processing . . . . . . . . . . . . . . . a. TAP Proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. H2-DM and H2-DO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. The CD1 Family of Molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Antigen Receptors and Coreceptors in Adaptive Immunity . . . . . . . . . 1. Antibodies and the B-Cell Receptor (BCR) . . . . . . . . . . . . . . . . . . a. Primary Antibody Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . b. Secondary, Tertiary, and Quaternary Structure . . . . . . . . . . . . . c. Antibody Classes and Subclasses . . . . . . . . . . . . . . . . . . . . . . . d. The BCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e. BCR Coreceptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. The T-Cell Receptor (TCR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. The Antigen-Binding Complex . . . . . . . . . . . . . . . . . . . . . . . . . b. The Signal-Transducing Complex . . . . . . . . . . . . . . . . . . . . . . c. T Cell Coreceptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. Costimulatory Receptors and Ligands in Adaptive Immunity . . . . . . . 1. The B7 Family and Its Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . a. B7-1 and B7-2 and Their Receptors . . . . . . . . . . . . . . . . . . . . . b. ICOS and ICOS-L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c. PD-1 and Its Ligands PD-L1 and PD-L2 . . . . . . . . . . . . . . . . . 2. CD40 and CD40 Ligand (CD154) . . . . . . . . . . . . . . . . . . . . . . . . . . E. Cytokines, Chemokines, and Their Receptors . . . . . . . . . . . . . . . . . . . . III. Cellular Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Cells of the Innate Immune System . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Cells That Provide Anatomical Barriers . . . . . . . . . . . . . . . . . . . . . a. Physical Epithelial Barriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. Secreted Protective Proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. The Phagocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. Neutrophils . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. Monocytes and Macrophages . . . . . . . . . . . . . . . . . . . . . . . . . . c. Eosinophils . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Mast Cells and Basophils . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4. DCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. NK Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Cells of the Adaptive Immune System . . . . . . . . . . . . . . . . . . . . . . . . . 1. T Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. Early T Cell Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . b. Gene Rearrangements in γδ T Cells . . . . . . . . . . . . . . . . . . . . . c. Thymic Selection of CD4+ and CD8+ T Cells . . . . . . . . . . . . . d. Differentiation of T Cells into the Type 1 and Type 2 Phenotype . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e. Differentiation of Th17 Cells . . . . . . . . . . . . . . . . . . . . . . . . . . f. Regulatory T Cells and T Cell Tolerance . . . . . . . . . . . . . . . . . g. NKT Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. B Cells and Plasma Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a. B Cell Development before Encounter with Antigen . . . . . . . . b. B Cell Development after Encounter with Antigen: The Germinal Center, Affinity Maturation, and Differentiation of Plasma Cells . . . . . . . . . . . . . . . . . . . . . . . . . c. Receptor Editing and B Cell Tolerance . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AND
13 13 13 13 14 14 14 14 14 15 15 15 17 17 18 19 20 20 21 21 21 21 22 23 24 24 24 25 25 26 26 26 28 28 28 29 31 32 32 32 32 32 33 33 33 35 35 37 38 38 38 39 39 40 41 42 43 43 44
46 48 48
D AV I D
D.
CHAPLIN
OVERVIEW
OF
IMMUNOLOGY
I.
IN
THE
MOUSE
INTRODUCTION
As in man, the immune system of the mouse can be divided into innate and adaptive components. The innate immune response is evolutionally primitive with functions such as phagocytosis present in protozoa and sponges. Cells have receptors capable of recognizing structural motifs shared by families of infectious agents, and these cells are capable of making an immediate response. The adaptive immune response first appeared in jawed fish, agnathia, and, in contrast to the innate system, requires time after foreign agent recognition to develop effector mechanisms. It incorporates fine specificity for molecular sequences unique to individual infectious agents as well as the capacity for immunological memory. Because the development of immunological specificity also introduced the chance for self-recognition, cells of the adaptive response have developed a sophisticated mechanism for induction of tolerance to “self.” At many levels there is cross-talk between innate and adaptive immune responses. The cells of the innate system recruit cells of the adaptive responses to sites of inflammation, they process and present antigens to cells of the adaptive system, and at many levels they modify adaptive immune responses. In this volume a general overview of molecular and cellular immunology in the mouse is first presented. It is followed by 15 chapters, each of which is a mini-review concentrating on a specific immunological concept, cell type, or effector process. These chapters are meant to illustrate how mutant mice have been used to better understand immune mechanisms in mice and man. Chapter 15, entitled “The Mouse Trap: How Well do Mice Model Human Immunology?” details differences discovered between the species. This volume does not provide a section on techniques used in immunological research. A complete and up-to-date listing of these techniques may be obtained through reading Current Protocols in Immunology by Coligan et al. (2006). In addition, the modifications in engineering and husbandry needed to maintain immunodeficient mice are not addressed in this volume; that subject is discussed of chapter 3 in Volume 3, entitled “Management and Design: Research Facilities for Mice.”
II. A. 1.
MOLECULAR IMMUNOLOGY
Receptors and Ligands of the Innate Immune System Toll-Like Receptors
a. INTRODUCTION In the mouse nine Toll-like receptors (TLRs) have been recognized. Those receptors are conserved throughout evolution from flies to humans and are composed of an extracellular peptide containing leucine-rich repeat (LRR)
3 motifs, a transmembrane region and a cytoplasmic Toll/interleukin (IL)-1 receptor homology domain (TIR). Through the LRR motif TLRs bind pathogen-associated molecular patterns (PAMPs), which are molecular configurations common to groups of bacteria, fungi, or viruses. Intracellular triggering is initiated through the TIR. Ligand binding and signaling may require homodimerization or heterodimerization between two TLRs. The basic structure is shown in Fig. 1. TLRs are found on the cells of the innate immune system (e.g., monocytes, macrophages, neutrophils, mast cells, and dendritic cells [DCs]), where they signal the cell to induce phagocytosis and activate the transcription factors nuclear factor (NF)-κB and adaptor protein (AP)-1), leading to cytokine secretion and the initiation of inflammation. The fusion event between the phagosome and lysosome, resulting in the acquisition of hydrolase enzymes necessary for bacterial degradation, is greatly accelerated by TLR signaling (Blander and Medzhitov 2004). On DCs, TLRs play an important role preparing molecules derived from pathogens for antigen presentation to cells of the adaptive immune response. This is accomplished by the upregulation of both major histocompatability complex (MHC) class I and class II on the surface of DCs as well as the upregulation of costimulatory molecules necessary for triggering responses by B and T cells (West et al. 2004). TLRs can also be found on B cells, fibroblasts, intestinal epithelial cells, and vascular endothelial cells. On vascular endothelium bacterial products elicit upregulation of adhesion molecules contributing to the recruitment of leukocytes (Vasselon and Detmers 2002). All TLRs have at least one signaling pathway–dependent adaptor molecule called myeloid differentiation factor 88 (MyD88). This feature is also shared with IL-1 and IL-18 receptor signaling (Scanga et al. 2004). Additional signaling pathway adaptor proteins vary according to the TLR activated. Readers desiring more information on murine TLRs should refer to chapter 2 in this volume, entitled “The Biology of Toll-Like Receptors in Mice.” b. TLR1 TLR1 shares amino acid sequence homology with TLR2 and TLR6 and these form a subfamily of receptors, which also share in ligand recognition. Expression of TLR-1 alone fails to impart recognition but coexpression with TLR-2 results in activation in response to triacyl-lipopeptide (Takeuchi et al. 2002). The heterodimer utilizes both the signal adapter molecule MyD88 and MyD88 adaptor-like (MAL) protein to initiate intracellular signaling (O’Neill et al. 2003). c. TLR2 TLR2 recognizes PAMPs derived from a broad range of infectious agents including bacterial lipoprotein, lipoteichoic acid, and glycosylphosphatidylinositol (GPI) anchors. In TLR2 knockout mice these substances fail to activate macrophages, rendering the mice highly susceptible to agents such as Staphylococcus aureus and Streptococcus pneumoniae, to name a few. TLR2 heterodimers with TLR1 recognize bacterial lipopeptides, whereas heterodimers with TLR6 recognize mycoplasmal lipopeptides (O’Neill et al. 2003).
4
FRED
A TLR Structure
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
B Specificities of TLRs TLR
Ligand
Microbial Source
TLR2
Lipoproteins Peptidoglycan Zymosan LPS GPI anchor Lipoarabinomannan Phosphatidylinositol dimannoside
Bacteria Gram-positive bacteria Fungi Leptospira Trypansosomes Mycobacteria Mycobacteria
TLR3
Double-standard RNA
Viruses
TLR7/8
Single-standard RNA
Viruses
TLR4
LPS HSP60
Gram-negative bacteria Chlamydia
TLR5
Flagellin
Various bacteria
TLR9
CpG DNA
Bacteria, protozoans
Leucine-Rish Repeat Motifs Cysteine-Rich Flanking Motif
TIR Domain
C TLR Signal Transduction LPS-Binding Protein
TIR Domain
LPS Death Domain TLR4 CD14 MD2
Active AP-1
MyD88
TRAF6 (Inactive)
IRAK
Inactive NF-IκB MAP Kinase Cascade
P TRAF6 (Active)
Gene Transcription; Inflammatory Response
Jun– P
IκB
IκB Kinase Cascade Active NF-IκB
NF-IκB IκB
P
IκB
P
Fig. 1 Mammalian TLRs. A typical TLR contains conserved extracellular and cytoplasmic domains. Different TLRs contain different numbers and arrangements of the extracellular leucine-rich and cysteine-rich motifs. Different TLRs are involved in responses to different microbial products. Some of the specificities listed may require heterodimerization with other TLRs (e.g., TLR2 with TLR6). The signaling pathway triggered by TLRs that results in the generation of the NF-κB transcription factor is shown. Intracellular adapter proteins other than MyD88 may also be involved in some TLR signaling pathways. In addition to NF-κB activation, TLRs are also linked to AP-1 activation. Reproduced from Abbas, A.K., and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
OVERVIEW
OF
IMMUNOLOGY
IN
THE
5
MOUSE
d. TLR3 TLR3 binds to and is activated by viral doublestranded RNA or the synthetic polyinosinic:polycytidylic acid. Homodimers also appear to be activated by lipopolysaccharides (LPSs). Intracellular signaling leads to the production of type I interferons (IFNs) and inflammatory cytokines. The TIR domain-containing adapter inducing interferon TRIF (which is also involved with TLR2, 4, and 7) prevents activation of the IFNβ promoter (O’Neill et al. 2003). TRIF has a receptor-interacting domain similar to MyD88 and may inactivate MyD88. A mutation in TRIF called Lps2 severely impairs responses mediated through TLR3 and TLR4 (Hoebe et al. 2003). Mice lacking both TRIF and MyD88 cannot be activated by LPSs. Thus, like MAL, which is used by TLR2, TRIF may collaborate with MyD88 to produce different signaling outcomes. e. TLR4 TLR4 binds to and is activated by LPSs. TLR4 knockout mice have macrophages unresponsive to LPSs, and the mice are highly resistant to LPS-induced shock. The extracellular domain of TLR4 associates with MD-2, which enhances the response to LPS. Although intracellular signaling may be mediated by MyD88, TLR4 can also activate NF-κB without MyD88 by utilizing the TIR domain containing adaptor protein, MAL (also called TIRAP). MAL, in addition to mimicking MyD88 has unique functions and is not required for activation of the transcription factor, IFN regulatory factor 3 (IRF3) which regulates IFN-β production and other IFN-dependent genes (O’Neill et al. 2003). TLR4 has been shown to protect mice against Pasteurella pneumotropica (Hart et al. 2003). f. TLR5 TLR5 recognizes bacterial flagellin through the conserved amino- and carboxyl-terminal regions shared among many Gram-negative bacteria (Takeda et al. 2003). TLR expression–deficient mice are more susceptive to infection by Salmonella typhimurium. g. TLR6 TLR6, after heterodimerizing to TLR2, recognizes diacyl lipopeptides. Expressed alone, TLR6 fails to respond to lipopeptide. The heterodimer uses both MyD88 and MAL signal adaptor molecules. h. TLR7 TLR7 forms a subfamily with TLR8 and TLR9 based on genomic structure and sequence similarities. Murine TLR7 has been shown to bind single-stranded (ss) RNA and activate the transcription factor NF-κB through MyD88. Using guanosine (G)- and uridine (U)-rich ssRNA oligonucleotides derived from human immunodeficiency virus (HIV), mouse DCs and macrophages were shown to be activated by and secrete IFN-α and proinflammatory and regulatory cytokines (Heil et al. 2004). Similarly stimulation of murine TLR7 by influenza ssRNA demonstrated that TLR7 sense endosomal ssRNA and produce large amounts of IFN-α in response to it (Diebold et al. 2004). i. TLR8 AND TLR10 Whereas mice express TLR8, they do not appear to have any specific phenotype. Unlike human TLR8, mouse TLR8 is not activated by ssRNA (Heil et al. 2004). There is a missense mutation in the mouse TLR10 gene that prevents its expression.
j. TLR9 Unmethylated CpG motifs, which are infrequent in the human genome, are common in bacterial and viral DNA and are known to bind and activate murine TLR9 (Takeda et al. 2003). Like TLR7, TLR9 is located in the endosome and endosomal reticulum in which nucleotides are transported. Mice with a mutated TLR9 were susceptible to murine cytomegalovirus (MCMV) infection. Normal mice recognize MCMV DNA and induce IL-12- and IFN-promoting natural killer (NK) cell clearance of the virus (Krug et al. 2004). k. TLR11 Mice express a functional TLR11 on macrophages, liver, kidney, and bladder epithelial cells. Although a natural ligand for this receptor is not known, knockout mice are highly susceptible to infection of the kidneys by uropathogenic bacteria, suggesting an important role for TLR11 in preventing infection in those organs (Zhang et al. 2004). 2.
Fc Receptors
a. OVERVIEW Many cells have membrane glycoproteins called Fc receptors (FcRs) due to their affinity to bind the Fc portion of the mouse immunoglobulins. They act as a bridge between innate and adaptive immunity by transporting antibodies across cell membranes and across the placenta, by activating or inhibiting the functions of lymphocytes, by modulating inflammation including phagocytosis and the proliferation of monocytes, and by triggering effector functions such as antibody-dependent cellular cytotoxicity (ADCC). Recent information suggests that FcRs play a role in maintaining peripheral tolerance (Fukuyama et al. 2005; Samsom et al. 2005). FcRs always have a transmembrane ligand-binding protein composed of an extracellular domain, a transmembrane domain, and a cytoplasmic domain, this protein is called the α chain α, and structurally it belongs to the immunoglobulin (Ig) superfamily of proteins because the genes are derive from a primordial gene encoding basic domain structure. Several of the FcRs have transmembrane domains that physically associate with other accessory polypeptide chains via a charged amino acid residue found in the transmembrane domain. Together with accessory polypeptides, these FcRs engage in signal transduction. Depending on the receptor, the accessory polypeptides may be composed of two γ chains or combinations of γ and β chains (Goldsby et al. 2003). More on this subject is presented in chapter 12. b. POLY-IG RECEPTOR Mouse poly-Ig receptor (pIgR) is a single glycoprotein of 120 kDa capable of binding IgA and IgM (Asano et al. 1998). The pIgR is expressed on the basolateral surfaces of mucosal cells and the glandular epithelia of mammary, salivary and lacrimal glands, where it binds polymeric immunoglobulins via their J chains and transports them into mucus or glandular secretions. In mice pIgR is also expressed in the liver and is involved in IgA transport into bile. Mice differ from humans in that most of their proximal intestinal secretory IgA comes from hepatobiliary transfer (Johansen and Brandtzaeg 2004).
6
FRED
Approximately 80% of mouse plasma cells are located in the mucosal lamina propria of the gut and respiratory tracts and most of them secrete IgA with J chains. Mice differ from humans in that J chain mRNA is not expressed until the antigen-driven stages of B cell development. The J chain is an inherent part of polymeric immunoglobulins and allows for the pIgR-mediated vesicular trafficking to the luminal side of the mucosae. The extracellular domain of pIgR is cleaved and remains attached as secretory component (SC) to the secreted IgA or IgM after release into the lumen. Covalently bound SC confers extra stability to the immunoglobulin (Fig. 2). The abundance of IgA-secreting plasma cells in the gut has been attributed to a number of factors, however, in the mouse, a class switch to IgA in the lamina propria is probably restricted to the T-independent B1 cell, derived from the mouse peritoneal cavity (Johansen and Brandtzaeg 2004). This appears to differ from the situation humans in whom ligation of CD40 on B cells with CD154 (CD40 ligand [CD40L]) on T helper (Th) cells is a prerequisite for class switch. Epithelial cell expression of pIgR may be seen as early as 20 weeks of gestation in humans but does not appear until weaning in mice, suggesting that it is dependent on exogenous stimuli for induction. pIgR expression in the mouse gut is both constitutive and induced by proinflammatory and immunoregulatory cytokines; however, pIgR expression in the female genital tract, lacrimal glands, and mammary glands is regulated by steroid hormones using the glucocorticoid response element in humans and an androgen response element in the upstream promoter of the murine gene. pIgR knockouts accumulate IgA in serum and intestinal lamina propria but thrive under conventional conditions, implicating a critical role for intraepithelial lymphocytes in the homeostatic control of intestinal microflora (Yamazaki et al. 2005).
Lamina Propria
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
A mouse pIgR that is nearly identical to epithelial cell pIgR has been reported on a mouse B cell lymphoma; however, this receptor binds IgM with higher affinity than IgA, making it similar to human pIgR but different from mouse epithelial cell pIgR (Phillips-Quagliata et al. 2000). c. THE NEONATAL FCR The neonatal FcR (FcRn) is a distant member of the MHC class I protein family that diverged in evolution to bind the hinge region of IgG Fc. The α chain has three immunoglobulin-like loop structures, and the functional molecule is dependent on dimerization with β2-microglobulin. Mouse FcRn has a broad range of binding specificities for IgGs in contrast to the stringent binding specificity of human FcRn. These differences in IgG binding specificity are due to residues close to the interaction site and a shorter α1 helix in the human molecule (Zhou et al. 2005). The FcRns are responsible for transfer and protection of IgG from mother to fetus (across placenta) or to neonate. In the neonate the FcRn is expressed in the gut and, more weakly, in adult tissues including vascular endothelium (in which protection occurs). Intracellular FcRn resides primarily in endosomal vesicles where it binds and recycles endocytosed IgG destined for degradation. This latter protective function may explain why murine IgG has a longer half life (t1/2 6–8 days) compared with that of non-IgG classes (t1/2 1–2 days) (Roopenian et al. 2003). d. FCγRIIB FcγRIIB (CD32) is a 40-kDa protein composed of an α chain with two disulfide bond loops in the extracellular domain and transmembrane and cytoplasmic domains. The cytoplasmic domain contains one immunoreceptor tyrosine-based inhibitory motif (ITIM) sequence. Phosphorylation of the ITIM leads to recruitment of the src homology (SH) 2 containing inositol polyphosphate phosphatase (SHIP) and the hydrolysis of phosphatidylinositol 3-kinase (PI3K) products. FcγRIIB binds immune complexes (ICs) containing IgG1 only.
Mucosal Epithelial Cell
Lumen
Poly-Ig Receptor with Bound IgA J Chain Secreted IgA IgA-Producing Plasma Cell Dimeric IgA
Endocytosed Complex of IgA and Poly-Ig Receptor
Proteolytic Cleavage
Fig. 2 Transport of IgA through epithelial cells. IgA is produced by plasma cells in the lamina propria of mucosal tissue and binds to the poly-Ig receptor at the base of an epithelial cell. The complex is actively transported through the epithelial cell, and the bound IgA is released into the lumen by proteolytic cleavage. The process of active transport through the cell is called transcytosis. Reproduced from Abbas and A.K., Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
OVERVIEW
OF
IMMUNOLOGY
IN
THE
MOUSE
Because this is the most common isotype in mice, this inhibitory receptor probably prevents incidental activation of circulating myeloid cells by ICs and the systemic inflammation that ensues. FcγRIIB is found on B cells, monocytes, macrophages, activated neutrophils, and mast cells. There are two isoforms of FcγRIIB, one on B cells, which prevents internalization of ICs, and another on myeloid cells, which initiates phagocytosis. Through its ITIM, this receptor can inhibit the activating signals for other FcRs as well as for the B cell receptor (BCR) and T cell receptor (TCR). The FcγRIIB is required to maintain tolerance in mice. Mice lacking FcγRIIB spontaneously develop autoimmunity. Lupusprone strains such as NZM, BXSB, and B6 Fcgr2b−/−, when given bone marrow cells transfected to express FcγRIIB, stop developing autoimmune disease (McGaha et al. 2005). FcγRIIB knockout mice failed to develop mucosal tolerance to ovalbumin, and CD4+ ovalbumin-responding T cells failed to differentiate into IgE class–restricted regulatory T (Treg) cells. The receptor was found to play a critical role in modulating antigen presentation by DCs (Samsom et al. 2005). Disruption of FcγRIIB leads to enhanced inflammation, phagocytosis, and ADCC. Anaphylatoxin (C5a), intravenous immunoglobulin, and IFNγ each modulate inflammation by acting on FcγRs. Both FcγRIIB and the activatory receptor FcγRIII are present on antigenpresenting cells (APCs) and ICs containing IgG can bind either receptor. The ratio of these opposing signaling receptors is critical for setting thresholds for inflammatory activity. As myeloid cells leave the bone marrow they contain mostly FcγRIIB with little FcγRIII. Within an inflammatory environment, C5a, IFN-γ, and tumor necrosis factor (TNF) reverse the ratio of FcRs favoring FcγRIII, whereas intravenous immunoglobulin up-regulates FcγRIIB, making it more difficult for ICs to induce FcγRIII (Ravetch 2002; Shushakova et al. 2002). Mice lack FcγRIIA, which is found in man; however, transgenic mice expressing the human FcγRIIA receptor were able to functionally remove human IgG1-coated erythrocytes from the circulation (van Royen-Kerkhof et al. 2005). e. ACTIVATING FCγRI AND FCγRIII FcγRI (CD64) and FcγRIII (CD16) are multichain receptors, each having a ligand binding α chain associated with one or two accessory signal-transducing subunits containing immunoreceptor tyrosine-based activating motif (ITAM) sequences. These γ chains are transmembrane polypeptides with a cytoplasmic tail containing ITAM in their cytoplasmic tail. Activation responses are dependent on the sequential activation of members of the src and syk kinase families. Whereas α chains are unique to either FcγRI or FcγRIII, both receptors use a common γ chain. FcγRI binds ICs containing IgG1 and IgG2b (Rivera and Casadevall 2005). In addition mouse FcγRI is a high-affinity FcR capable of binding monomeric IgG. FcγRI is expressed on macrophages, monocytes, and neutrophils, whereas FcγRIII is expressed on macrophages, activated monocytes, NK cells, pre-B cells, γδ T cells and serosal and mucosal mast cells. Mice, with disruption of the
7 IgE heavy chain gene and incapable of making IgE, do make IgG and develop anaphylaxis. However, disruption of the FcγRIII gene abolishes IgG IC-induced mast cell degranulation, IgG-induced passive cutaneous anaphylaxis (PCA), and the Arthus reactions (Daeron 1997). Likewise, mice with a disrupted FcγRIII gene failed to mount ADCC against NK-resistant IgG-coated target cells. Abolishing the common γ chain also abolishes ADCC by NK cells and the Arthus reaction. FcγRI mediates ADCC by macrophages and monocytes and triggers superoxide production and secretion of inflammatory cytokines. f. FCγRIV FcγRIV is unique to the mouse; it has an α chain encoded by a gene on chromosome 1 adjacent to genes for FcγRIIB and FcγRIII. The α chain has two disulfide loops in the extracellular domain, a transmembrane domain containing a charged amino acid residue and a cytoplasmic domain. The transmembrane domain is physically associated with the common γ chain. FcγRIV is expressed on myeloid cells including monocytes, splenic and bone marrow DCs, macrophages, and neutrophils; it is not expressed on lymphocytes. Expression is upregulated by IFN-γ and LPSs and downregulated by transforming growth factor (TGF)-β and IL-4. FcγRIV selectively binds IgG2a and IgG2b with affinity intermediate between that for high-affinity FcγRI and low-affinity FcγRIIB and FcγRIII. ICs containing these IgG subclasses induce calcium influx characteristic of FcR signaling. Whereas IgG2a can activate complement via the classic pathway, it mediates its in vivo effects by preferentially binding activator FcγRIV (over the inhibitory FcγRIIB). Thus, IgG2a functions as a highly effective opsonin (Nimmerjahn et al. 2005). g. FCεRI FcεRI is a high-affinity IgE binding receptor composed of a single α chain with two disulfide loops in the extracellular domain and transmembrane and cytoplasmic domains. The transmembrane domain is associated with two γ chains and a β chain, each containing ITAM motifs. The α chain is encoded by a single gene located on chromosome 1 near the gene for the α subunit of FcγRIII. FcεRI is expressed on mast cells and basophils. Within 15 seconds after FcεRI aggregation by antigen on mast cells, the γ and β subunits become tyrosine phosphorylated. As with other activatory FcRs, phosphorylation of ITAMs correlates with the activation of several sets of tyrosine kinases including the src, lyn, and syk family kinases (Daeron 1997). Activation of FcεRI leads to mast cell release of inflammatory mediators including granular and lipid mediators and cytokines. FcεRI mediates local and systemic anaphylaxis. Disruption of the FcεRI gene abolishes PCA in mice. When monomeric IgE binds the receptor, it upregulates expression of FcεRI and enhances survival. When monovalent hapten binds receptor IgE, it prevents receptor upregulation and aggregation but allows receptor internalization, degranulation, and IL-6 production. Receptor aggregation is induced by multivalent antigen and leads to ITAM phosphorylation (Kitaura et al. 2004). IgE class-restricted tolerance may be induced in mice by
8
FRED
neonatal treatment with monoclonal IgE; it is unique to the IgE class of immunoglobulins and involves both failure to develop FcεR+ cells and the production of Treg cells (Chen et al. 1984). Recently, FcεRI has been documented on mouse sensory neurons; its significance is unknown (Andoh and Kuraishi 2004). More on this receptor is found in chapter 14 in this volume, entitled “Mouse Models to Study the Pathogenesis of Allergic Asthma.” h. OTHER FCRS It appears that there is no true homolog of human FcαRI (Monteiro and Van De Winkel 2003), although recently an FcR for IgM was described on murine oligodendrocytes and myelin which may be an Fcα/µR (Nakahara et al. 2003). The transferrin receptor (TfR) has been shown to serve as an IgA receptor on mouse eosinophils. Two isoforms are made by the mouse. Binding by IgA blocks transferrin-induced synthesis of reactive oxygen species and eosinophil-derived neurotoxin (Decot et al. 2005). FREB is a unique FcR in that it lacks a transmembrane domain and is expressed intracellularly in germinal center B cells of mouse and man. It is a homolog of FcγRI found on mouse B cells and contains three immunoglobulin-like domains and a C terminus containing a proline-rich stalk region followed by a leucine-rich amphipathic α helix. It is thought to play a role in regulating clonal expansion or differentiation of B cells during the germinal center reaction (Wilson and Colonna 2005). 3.
Complement and Complement Receptors
a. OVERVIEW OF THE COMPLEMENT SYSTEM The complement system provides a vital link between innate and adaptive immunity. It is evolutionarily highly conserved and is composed of approximately 20 serum glycoproteins that circulate in an inactive form. Various foreign substances may interact with a complement component, initiating proteolysis and subsequently generating a proteolytic product with enzymatic activity. This product then participates in an enzymatic cascade with tremendous amplification. The biologically active cleavage products of complement proteins bind covalently to microbes, antibodies of certain isotypes, and tissues in which complement is activated. Regulatory proteins, found on normal host cells, minimize complement-mediated damage to the host. Four pathways lead to complement activation: the classical pathway, in which mouse IgM and IgG2b bound to antigen initiates the cascade; the alternative pathway in which activation is induced by a microbial cell surface without antibody; the lectin pathway which is activated by a plasma lectin that binds mannose residues on microbial cells; and the pentraxin pathway in which C-reactive protein, serum amyloid P component, and PTX3 bind to C1q and activate the classic pathway. The latter appears to be an important mechanism for the removal of apoptotic cells. Regardless of the pathway activated, the central event in each cascade is the proteolysis of complement protein 3 to produce biologically active split products with one product, C3b,
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
becoming covalently attached to microbial cell surfaces or antibody bound to antigen. A second product, C3a, binds to a specific receptor found on inflammatory cells (C3aR), inducing a series of biological activities from opsonization and phagocytosis to degranulation of intracytoplasmic granules. In the classic pathway IgM or IgG2b bound to antigen exposes a binding site for C1q on the Fc region of the µ or γ heavy chain. Each heavy chain has a single C1q binding site and each C1q molecule must bind two or more Ig heavy chains to be activated. Once activated, C1q leads to the enzymatic activation of C1r, which cleaves and activates C1s. Activated C1s cleave and activate C4 to generate C4b (with C4a being released as an anaphylatoxin). The attachment of C4b to the cell surface next to cell-bound C1s leads to C2 activation. C2 binds to C4b and is cleaved by C1s to generate C2b. This C4b2b complex acts as a C3 convertase. Once C3b is bound to the surface it can bind factor B and generate more C3 convertase. Through this mechanism thousands of C3b molecules can be deposited on the surface where complement is activated. The C4b2b3b complex acts as a C5 convertase needed to generate the late stage of the cascade. The alternative pathway of activation is based on the phenomenon of continual low level plasma cleavage of C3 to C3b. Some C3b reacts with amino or hydroxyl groups on cell surfaces or with polysaccharides to form amide or ester bonds. If these bonds are not generated, C3b becomes inactivated in the fluid phase. However, once the bonds are formed, the C3b can bind Factor B and then Factor B is cleaved by Factor D to generate the Bb fragment. This C3bBb complex is also a C3 convertase and cleaves more C3 molecules, resulting in tremendous amplification. C3Bb complexes on mammalian cells are rapidly degraded by regulatory proteins not found on microbial cells. On microbial cells some of the C3b generated by C3 convertase binds to the complex, producing the C5 convertase, C3bBb3b (see Fig. 3). In both the lectin and pentraxin pathways, complexes formed activate C1 and the classic pathway. Plasma mannose binding lectin binds mannose residues on microbial polysaccharides, and because it is structurally similar to C1q, it triggers the activation of the C1r-C1s complex. In the late steps of complement activation C5 convertases cleave C5 into C5a and C5b. The C5a split product is a biologically active anaphylatoxin (like C3a and C4a). C5b remains bound to the complex and binds both C6 and C7. The resulting C5b, 6, and 7 complex inserts into the lipid bilayer of cell membranes and is a C8 receptor. The resulting complex of C5b, 6, 7, and 8 (C5b-8) attracts C9, which polymerizes at the complex site and forms pores in plasma membranes. The C5b-9 complex is known as the membrane attack complex (MAC) and the pores allow for the exchange of ions across the membrane, leading to cell death (see Fig. 4). The C9 serum protein is homologous to perforin, which is found in cytotoxic T lymphocytes and NK cells. Readers interesting in more detail concerning the regulation of the complement cascade in mice
OVERVIEW
OF
IMMUNOLOGY
A
IN
THE
9
MOUSE
B
Alternative Pathway
Classical Pathway
Microbo
Binding of Complement Proteins to Microbial Cell Surface or Antibody
IgG Antibody C1
Formation of C3 Convertase
Bb
C5 Convertase
C2b C3 Convertase
C4b
Cleavage of C3
Covalent Binding of C3b to Microbial Surface
Bb
C2b
C5 Convertase
C4b C5 Convertase
Late Steps of Complement Activation Fig. 3 The early steps of complement activation by the alternative and classical pathways. The alternate pathway (A) is activated by C3b binding to various activating surfaces, such as microbial cell walls, and the classical pathway (B) is initiated by C1 binding to antigen-antibody complexes. The C3b that is generated by the action of the C3 convertase binds to the microbial cell surface or the antibody and becomes a component of the enzyme that cleaves C5 (C5 convertase) and initiates the late steps of complement activation. The late steps of both pathways are the same (not shown here), and complement activated by both pathways serves the same functions. The lectin pathway (not shown) activates C1 in the absence of antibody, and the remaining steps are the same as in the classical pathway. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
10
FRED
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
Inflammation
C5 Convertase
Poly-C9 Cell Lysis
Plasma Membrane
Membrane Attack Complex (MAC) Fig. 4 Late steps of complement activation and formation of the MAC. Schematic view of the cell surface events leading to formation of the MAC is shown. Cell-associated C5 convertase cleaves C5 and generates C5b, which becomes bound to the convertase. C6 and C7 bind sequentially, and the C5b, 6, 7 complex becomes directly inserted into the lipid bilayer of the plasma membrane, followed by stable insertion of C8. Up to 15 C9 molecules may then polymerize around the complex to form the MAC, which creates pores in the membrane and induces cell lysis. C5a released on proteolysis of C5 stimulates inflammation. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
and differences between the complement system in mice and man are encouraged to read chapter 6, entitled “Clinical Chemistry of the Laboratory Mouse” in Volume 3. Those interested in a more detailed explanation of the pathways may consult several recent reviews (Abbas and Lichtman 2005; Goldsby et al. 2003; Lambris et al. 1999). b. TYPES OF COMPLEMENT RECEPTORS Complement receptors are varied: structurally, in cell distribution, and in function. They are capable of binding C3b and its degradation products, C3dg, C3d, and iC3b, and C4b and the anaphylatoxins, C3a, C5a, and C5a desArg. C3b is converted to the inactive iC3b and subsequently to C3dg by fluid-phase Factor I and Factor H. C3dg can be further cleaved to C3d by serum proteases; however, the biological functions of C3d and C3dg appear to be identical (Rickert 2005). C3a desArg and C5a desArg are generated when serum carboxypeptidase N rapidly removes the C-terminal arginyl residue of C3a or C5a, respectively. I. CR1 AND CR2 Complement 1 and complement 2 receptors (CR1 and CR2) are both encoded by the same gene, Cr2, by alternative splicing. Both CR1 and CR2 are single-chain transmembrane glycoproteins with a large extracellular domain. The CR1 (CD35) receptor is generated by the addition of six short consensus repeat units (SCRs) to the amino-terminal
end of the CR2 (CD21) protein. Thus, the extracellular domain of CR1 has 22 SCRs whereas CR2 has 15–16 SCRs. In mice, but not man, CR1 serves as a receptor for C4b and C3b in addition to C3d and iC3b. CR2 binds C3d and iC3b. In mice, both CR1 and CR2 are expressed on mature B cells and follicular DCs (FDCs). CR1 is also expressed on monocytes, neutrophils, and eosinophils. Unlike humans, mouse CR1 is not expressed on erythrocytes or platelets and thus is not an immune adherence receptor (Haas et al. 2002; Molina et al. 1996). CR1 on phagocytes causes internalization of particles opsonized with C3b or C4b. The receptor also transduces signals that activate microbicidal mechanisms, especially if there is simultaneous engagement of FcγRI and FcγRIII receptors. CR1 and CR2, present on B cells and FDCs, are critical regulators of both thymic-independent (TI) and thymic-dependent (TD) antibody responses. In mice CR1 and CR2 play a unique role in promoting IgG3 antibody responses (isotype responsive toTI-2 antigens); this is due to their ability to localize bloodborne antigen-C3d complexes to marginal zone B cells of the spleen and cause immediate isotype switch (Haas et al. 2002; Zandvoort and Timens 2002). Mice lacking CR1 and CR2 have normal serum levels of total IgM and the various IgG isotypes and have no evidence of
OVERVIEW
OF
IMMUNOLOGY
IN
THE
MOUSE
altered B or T cell development or germinal center formation. However, their humoral responses to TD antigens, especially secondary responses, are markedly impaired. CR2 is noncovalently associated with other molecules to form a multimolecular signal transduction complex on the B cell surface. One molecule in this complex, CD19, is a glycoprotein belonging to the immunoglobulin superfamily and is involved with B cell activation and proliferation. When CR2 interacts with C3d-coated surface IgM-bound antigens, CD19 acts as the signaling component initiating intracellular events that amplify and facilitate B cell activation (Molina et al. 1996). In addition, expression of CR1 and CR2 on FDCs is essential for the development of long-term memory B- cells (Barrington et al. 2001). Finally, the Cr2 gene is a candidate for the Sle1c lupus susceptibility locus (Boackle et al. 2001); also see the chapter 11 in this volume, entitled “The Genetics of Mouse Models of Systemic Lupus”. Altered expression of CR2 has been associated with systemic lupus erythematosus in multiple mouse strains and in man. A mutation in Cr2 of mice leads to a polymorphism in the SCR1–2 site near the N terminus of the extracellular domain. The mutation introduced a unique glycosylation site, which molecular modeling, based on the crystal structure of CR2-C3d, predicts will interfere with ligand binding and receptor dimerization. This mutation is seen in many lupus-prone strains. CR2 is also required to develop autoimmunity to murine cardiac myosin (Hannan et al. 2002). II. CR3 AND CR4 Complement receptors 3 and 4 (CR3 and CR4) are integrin molecules found on the surface of mononuclear phagocytes, neutrophils, and NK cells. CR3 (CD11b CD18) is composed of a unique 165-kDa α chain (CD11b) also called Mac-1 and a common 95-kDa β chain (CD18). The two chains are noncovalently linked and bind iC3b, a degradation product of C3b. The β chain is identical in two closely related molecules, leukocyte function-associated-antigen-1 (LFA-1) and p150, 95. The CR3 receptor promotes phagocytosis of iC3b-coated microbes and also acts as an adhesion molecule by binding intercellular adhesion molecule (ICAM)-1 on endothelial cells, promoting stable attachment of leukocytes to endothelium without complement (see Fig. 5). CR4 is composed of a unique 150-kDa α chain (CD11c) and the 95-kDa common β chain (CD18). It is found on the surface of phagocytes and especially DCs where it binds iC3b and induces phagocytosis. Recent reports suggest that both CR3 and CR4 play a role in the removal of iC3b opsonized apoptotic cells. Here, complement may be activated by the lectin or pentraxin pathways. Uptake of apoptotic cells by phagocytes has an immunomodulatory effect, which favors T cell tolerance (Pittoni and Valesini 2002). III. RECEPTORS FOR ANAPHYLATOXINS Receptors for anaphylatoxins include the C3aR and the C5aR, both of which are members of the rhodopsin-type receptor superfamily and have seven transmembrane domains. In this respect, they are similar to other chemoattractant receptors, for example, the receptors for N-formyl peptides, leukotriene B4, and various α- and
11 β-chemokines. The coding sequence for all these receptors except C5aR is contained on a single exon. In the case of C5aR, the initiating methionine codon is separated from the rest of the coding sequence by a single large intron, similar to the human sequence (Gerard et al. 1992). Both receptors couple to pertussis toxin-sensitive and -insensitive G proteins. Mouse C3aR is composed of 477 amino acids and shares 65% sequence identity with human C3aR. The large second extracellular loop is the most divergent, containing only 44% identity (Hollmann et al. 1998). In man, C3aR is a chemoattractant receptor that mediates directed chemotaxis of eosinophils and mast cells. It also mediates histamine release from mast cells and IL-3-treated basophils, smooth muscle contraction, and modulation of cellular and humoral immune responses. In mice, C3aR is found on bronchial epithelium, endothelium, and smooth muscle in the lung where binding to the C3a ligand leads to hyperresponsiveness to aerosolized methacholine. C3aR is also present in parasympathetic ganglia cells in the airway, and it can modulate the effects of muscarinic cholinergic receptors. C3aR knockout mice have protection from airway reduction, reduced levels of IL-4, reduced antigen- specific IgE and IgG, and reduced eosinophil infiltration in the ovalbumin challenge model (Gerard and Gerard 2002) and Aspergillus fumigatus extract model of allergic asthma (Baelder et al. 2005). Paradoxically, C3aR knockouts are more susceptible to intravenous injection with LPSs. This finding suggests that although most C3aR functions are proinflammatory in nature, their responses to LPSs may be anti-inflammatory, suppressing LPS-induced secretion of TNFα, IL-1β, and IL-6 from peripheral blood mononuclear cells and B cells (Kildsgaard et al. 2000). Presentation of ovalbumin to APCs in the skin lacking C3aR resulted in more IL-4 and IL-5 secretion by T cells. C3a inhibited the ability of splenocytes to secrete Th2 cytokines (Kawamoto et al. 2004). C3aR also appears to play a significant role in murine autoimmune diseases. Receptor blockade of C3aR in MRLlpr mice prolonged survival and reduced the number of neutrophils, monocytes, and apoptotic cells in the kidneys of this lupus-prone strain (Bao, Osawe, Haas, et al. 2005). Boos et al. (2004) found that transgenic mice overexpressing C3a under the glial fibrillary acid protein promoter expressed much more C3a in the brain, which was associated with massive meningeal and perivascular infiltration of macrophages and CD4 lymphocytes in a model of experimental autoimmune encephalitis (EAE). They also showed that C3aR knockouts had a significantly attenuated course of EAE with greatly reduced macrophage and lymphocyte infiltration into the spinal cord. The C5aR of mice, as in man, contains a single N-linked glycosylation site near the amino terminus and a general acidic property for the first extracellular region. Overall mouse C5aR shares 65% sequence homology with human C5aR with the most divergence appearing in the extracellular positions of the molecule. Despite these differences, mouse C5aR binds human C5a
12
FRED
Microbes Bind to Phagocyte Receptors
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
Phagocyte Membrane Zips Up around Microbe
Mac-1 Integrin Mannose Receptor
Scavenger Receptor
Lysosome
Microbe Ingested in Phagosome
Fusion of Phagosome with Lysosome Phagosome with Ingested Microbe
Lysosome with Enzymes
Activation of Phagocyte
Phagolysosome
iNOS Arginine
NO
Killing of Microbes by Lysosomal Enzymes in Phagolysosomes
ROI
Phagocyte Oxidase Killing of Phagocytosed Microbes by ROIs and NO Fig. 5 Phagocytosis and intracellular destruction of microbes. Microbes may be ingested by different membrane receptors of phagocytes; some directly bind microbes, and others bind opsonized microbes. (Note that the Mac-1 integrin binds microbes opsonized with complement proteins [not shown].) The microbes are internalized into phagosomes, which fuse with lysosomes to form phagolysosomes, where the microbes are killed by reactive oxygen and nitrogen intermediates. iNOS, inducible nitric oxide synthase; NO, nitric oxide; ROIs, reactive oxygen intermediates. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
OVERVIEW
OF
IMMUNOLOGY
IN
THE
MOUSE
with high affinity and mediates mast cell vascular permeability and smooth muscle contraction (Gerard et al. 1992). This result is consistent with the fact that only the amino terminus is useful for ligand affinity chromatography (Gerard and Gerard 1994). In man, C5aR is found on mast cells, basophils, granulocytes, mononuclear phagocytes, platelets, and endothelial cells, and ligation of the receptor is responsible for mast cell and basophil degranulation. In mice, C5aR induces IL-6 and TNF-α in response to sepsis and suppresses neutrophil function. In contrast C5aR protects mice from Pseudomonas pneumonia when it activates lung macrophages essential for bacterial phagocytosis. A deficit of C5a was associated with decreased bronchial responsiveness to antigenic challenge, and at least part of this effect is mediated through IL-12 release that induces a Th1 helper response from monocytes and macrophages. In the absence of C5, a more vigorous Th2 response ensues (Gerard and Gerard 2002). Furthermore airway hyperresponsiveness was substantially improved after C5aR blockade in an Aspergillus extract model. In addition C5aR blockade was associated with reduced lymphocyte numbers in bronchoalveolar lavage fluid (Baelder et al. 2005). C5aR was shown to control the migration of neutrophils into the intraperitoneal cavity where they served as killer cells for iC3b-antibody opsonized tumor cells (Allendorf et al. 2005). C5aR also controlled the development and progression of lupus nephritis in MRLlpr mice (Bao, Osawe, Puri, et al. 2005; Wenderfer et al. 2005). An orphan receptor, C5L2, which binds both C5a and C5a desArg, has been reported in mice. This enigmatic serpentine receptor is coexpressed with the C5aR on many cells including neutrophils. C5L2 is uncoupled from G proteins and may modulate the activity of C5a by acting as a decoy receptor and limiting the proinflammatory activities of C5a. Recently the rat homolog of this receptor was found to be a noradrenalininduced anti-inflammatory receptor on brain astrocytes (Gavrilyuk et al. 2005). 4.
C-Type Lectin Receptors
a. INTRODUCTION Antigen uptake by cells for processing and presentation is mediated in part by C-type lectin receptors (CLRs). The CLRs contain one or more carbohydrate recognition domains (CRD) used by the CLRs to bind carbohydrates found on pathogens and host cells. Host cell carbohydrate binding is involved in cell adhesion, glycoprotein regulation, tissue repair, and healing. There are four families of CLRs based on differences in molecular structure: type I (mannose receptors); type II receptors; collectins; and NK cell receptors (type V). b. TYPE 1 RECEPTOR FAMILY Type 1 receptors include the macrophage mannose receptor (CD206) and the Endo 180 receptor. These transmembrane receptors have an N-terminal cysteine-rich domain followed by a fibronectin type II domain and a series of eight tandemly arranged CRDs, all in the extracellular portion of the molecule. They also contain a short
13 cytoplasmic tail that confers the ability to rapidly recycle between the cell surface and the intracellular compartment (McGreal et al. 2004). CD206 displays a calcium-dependent lectin activity toward terminal mannose, fucose, and N-acetylglucosamine residues. Among the eight CRDs only CRD4 and 5 show true affinity for monosaccharides. CD206 has been shown to be a pattern recognition receptor for a broad range of bacteria including Klebsiella pneumoniae. The CRDs of CD206 also bind a range of self-ligands including many mediators of inflammation. In this respect they are thought to play a major role in homeostasis and the resolution of inflammation. Anti-inflammatory mediators such as IL-4, IL-10, and IL-13 upregulate CD206 expression. CD206 is expressed on macrophages, DCs, and lymphatic and hepatic endothelium (Fig. 5) (McGreal et al. 2004). Although CD206-positive DCs are not found in T cell areas of lymphoid organs, and thus may not target ligands for antigen presentation to T cells, DCs expressing DEC-205 (CD205) are abundant in T cell areas. DEC-205 is structurally similar to CD206 except that it has 10 CRDs on the extracellular segment. After ligand binding, CD206 recycles quickly through cells via early endosomes, and by contrast ligand-bound DEC205 localized both to early endosomes and MHC class II late endosomes and lysosomes. The EDE sequence on the cytoplasmic domain of DEC-205 enables the receptor to target MHC II compartments. In addition, ligands for DEC-205 are processed via the exogenous pathway to MHC class I in a “transporters for antigenic peptides” (TAP) dependent manner (Steinman et al. 2003). More on the role of CLRs in DC biology is presented in chapter 4 in this volume, entitled “Some Biological Features of Dendritic Cells in the Mouse.” Endo 180, expressed on fibroblasts, macrophages, and certain endothelial cells, has been shown to bind mannose, fructose and N-acetylglucosamine via its CRD2 domain. In addition, the fibronectin type II (FNII) domain has a novel receptor for collagen. Mice with a targeted mutation of FNII exhibited defective collagen uptake and reduced migration of fibroblast and a defect in chemotactic activity to urokinase-type plasminogen activator. Whereas the pathogen recognition capacity of Endo 180 is largely unknown, this receptor appears to be involved in tissue remodeling and repair. c. TYPE II CLRS Type II CLRs include the specific intracellular adhesion molecule-3 grabbing non-integrin (SIGN) family including mDC-SIGN, mSIGNR1, mSIGNR2, mSIGNR3, and mSIGNR4 as well as Dectin-1, Dectin-2 and Langerin. They are all type II CLRs containing a single CRD. Genes for the SIGN CLRs are located on adjacent regions of chromosome 8 in close proximity to the CD23 gene. mSIGNR1, mSIGNR3, and mSIGNR4 are transmembrane receptors whereas mSIGNR2 lacks the transmembrane domain and is a soluble receptor. The CRD is found on the N terminus of the extracellular domain. All mouse SIGNs, except mSIGNR4, have a highly conserved EPN sequence within the CRD, which recognizes
14 mannose-containing structures. mSIGNR4 has a QPN motif instead and probably recognizes another ligand specificity, possibly galactose. Within the cytoplasmic tail several internalization motifs are found. All membrane-bound SIGNs have a triacidic cluster motif, whereas mDC-SIGN also has a di-leucine motif and mSIGNR1 and R3 have a tyrosine-based motif. These various cytoplasmic tail motifs are important for antigen internalization (Koppel et al. 2005). These CLRs tend to form tetramers by interactions between neck domains. mDC-SlGN is abundant on DCs in tissues throughout the body. There are also low levels of expression on B cells but not on T cells. mSIGNR1 mRNA is expressed in high levels in liver and lymph nodes and in moderate levels in spleen. No mSIGNR1 is found on DCs, B cells, or T cells. In lymph node, mSIGNR1 is expressed on medullary and subcapsular macrophages, whereas in the spleen it is expressed on the marginal zone macrophages (MZMs). mSIGNR1 is also expressed on liver sinusoidal endothelial cells and peritoneal macrophages. mSIGNR2 mRNA is present in testes and in LPS-stimulated B cells, mSIGNR3 RNA has been detected in spleen and lymph node, and mSlGNR4 mRNA is detected in testes and spleen. Little is known about the function of mSIGNR2, mSIGNR3, or mSIGNR4. The CRDs of mSIGNR1 and R3 bind mannose-, fucose-, and N-acetylglucosamine-terminating oligosaccharides. Fucose recognition was demonstrated by binding Lewis antigens. The binding specificity of mDC-SIGN is unknown. mSIGNR1 can interact with ICAM-2 expressed widely on leukocytes and especially on lymphocytes and may serve to bring mSIGNR1 cells in contact with lymphocytes. In addition, mouse L-selectin may bind circulating leukocytes using the same interaction. Likewise mSIGNR1 on MZMs may interact with lymphocytes migrating through the marginal sinus of the spleen, attracting them to the white pulp. Here MZMs are among the first cells to see blood-borne antigens including carbohydrates on Candida albicans, Mycobacterium tuberculosis, Escherichia coli, and Streptococcus typhimurium, leading to their internalization, degradation, and shedding, where they are taken up by marginal zone B cells after opsonization by complement. Dectin-2 is a type II receptor with a classical calciumdependent CRD. It appears to bind mannose residues although a ligand is also present on CD4+ CD25+ T cells. Dectin-2 is expressed on macrophages, DCs, and Langerhans cells. Langerin (CD207) is a type II CLR with binding specificity for mannose, fucose, and N-acetylglucosamine. It is expressed on Langerhans cells and subpopulations of DCs. Langerin appears to form trimers by interactions between the neck domains. After ligand binding, Langerin is rapidly internalized but does not traffic to MHC II compartments. Langerin induces the formation of Birbeck granules (Cambi et al. 2005; McGreal et al. 2004). d. COLLECTINS Collectins comprise a family of CLRs that are not transmembrane proteins but rather are soluble proteins that tend to form trimers or oligomers. They include the lung
FRED
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
surfactant proteins SP-A and SP-D and mannose binding protein. SP-A and SP-D are secreted at the luminal surface of pulmonary epithelial cells and form oligomers necessary for regulating surfactant phospholipid homeostasis and reducing surface tension within alveoli, allowing less pressure to maintain them open; they also have broad specificities for pathogen-associated molecular patterns. SP-A and SP-D interact with allergens and immune cells and modulate cytokine and chemokine profiles during the hypersensitivity response (Madan et al. 2005). Mannose-binding protein is a plasma protein with a single CRD, but its ability to form oligomers correlates with complement activation (Cambi et al. 2005). e. TYPE V FAMILY RECEPTORS Dectin-1 is a unique type V CLR because it is one of the only CLRs that recognizes carbohydrate ligands in the absence of calcium, and its carbohydrate-binding motif is not the classic CRD. The gene for Dectin-1 is located in the NK gene complex. This CLR is a 28-kDa transmembrane receptor that contains an ITAM motif in its cytoplasmic tail. It is expressed on leukocytes targeted for β-glucan activity: monocytes, macrophages, DCs, and Langerhans cells but not NK cells. Dectin-1 expression is upregulated by IL-4 and IL-13 and is downregulated by IL-10 and glucocorticoids. Dectin-1 has specificity for β-1,3 and β-1,6 linked glucans found in fungi, plant cell walls, and some bacteria. It appears to be primarily involved with protection against pathogenic yeast infections where it mediates phagocytic uptake, killing, and the release of TNF-α and macrophage inflammatory protein (MIP)-2 by macrophages. Dectin-1 accomplishes this by cooperating with the TLR-2 signaling pathway through the activation of its ITAM (McGreal et al. 2004). 5.
NK Cell Receptors
a. INTRODUCTION NK cells were originally described for their ability to kill tumor target cells without the necessity of prior sensitization. They also are effectors against viruses, parasites, and intracellular bacteria. After antigen recognition they secrete chemokines and cytokines, which regulate the adaptive immune response. Upon contact with antigen on cells, both stimulatory and inhibitory receptors on the NK cells are activated. The balance between these opposing signals will either favor NK cell cytotoxicity or tolerance to self. A more complete discussion on NK cells and their biology is presented in chapter 6 in this volume, entitled “Mouse Natural Killer Cells: Function and Activation.” b. LY49 RECEPTORS Ly49 receptors belong to the family of lectin-like type II transmembrane receptors. They are expressed as disulfide-bonded homodimers on NK cells and some T-cell subsets. Ligands for these receptors include MHC class II molecules and MCMV. After ligand engagement, the receptors may either stimulate or inhibit further NK responses. Inhibitory receptors have ITIM motifs in their cytoplasmic domain, which, upon ligand binding, become tyrosine phosphorylated and recruit intracellular phosphatases such as Src homology
OVERVIEW
OF
IMMUNOLOGY
IN
THE
15
MOUSE
domain-2–containing protein tyrosine phosphatase-1 (SHP-1). SHP-1 is responsible for dephosphorylating downstream signaling proteins in the activation pathway. By contrast, stimulatory Ly49 receptors have short cytoplasmic tails lacking signal-transducing elements. They associate with and signal through adaptor molecules such as DNAX-activation protein-12 (DAP-12). More than 24 genes or pseudo genes have been found for Ly49 receptors. The C57BL/6 strain has 11 active Ly49 genes and 5 pseudogenes. Of these Ly49A, Ly49B, Ly49C, Ly49E, Ly49F, Ly49G, Ly49I, Ly49J, and Ly49Q are inhibitory and only two, Ly49D and Ly49H, are stimulatory. The ligand for Ly49D is H-2Dd, Dr, and Dspz, and the ligand for Ly49H is involved with resistance to MCMV. In the 129 strain MCMV protein m157 binds inhibitory receptor Ly49I, since this strain does not express Ly49H (Backstrom et al. 2004; Kane et al. 2004). c. CD94/NKG2 RECEPTORS CD94/NKG2 receptors are CRLs and together with Ly49 they stimulate or inhibit NK cell activation. NKG2 belongs to the type V lectin-like transmembrane receptor family; NKG2A and NKG2B have two ITIM motifs in their cytoplasm domain. The NKG2 molecule forms a heterodimer with CD94 that is required for cell surface expression and recognition of the nonclassic MHC class I molecule, Qalb. Qalb displays peptides derived from the signal sequences of classical MHC class I molecules. NK cells indirectly monitor the expression of classical MHC class I by having CD94/NKG2 monitor the expression of nonclassic MHC class I molecules. When CD94 forms heterodimers with NKG2C and E they form stimulatory receptors that recognize Qalb. However, the binding affinity of NKG2C/E is much lower than that of NKG2A/B, thus favoring inhibition. CD94/NKG2A only binds Qalb loaded with the peptide, Qdm, and replacement of this defined peptide results in loss of NK cell inhibition (Backstrom et al. 2004). NKG2C/E contains ITAM motifs in its adaptor molecule. NKG2D is unique among CD94/NKG2 family members in that it forms homodimers, only shares about 20% amino acid homology with other members, and does not bind Qa-1b. Two charged amino acid residues in the transmembrane domain associate with the adaptor molecules DAP-10 or DAP-12. DAP-10 contains an YxxM motif whereas DAP-12 contains an ITAM motif. The adaptors are selectively expressed in different cell types and mediate signaling via different pathways. Mouse NKG2D-short (S) can associate with either DAP-10 or DAP-12; however, NKG2D-long (L) associates only with DAP-10. Naive NK cells express only NKG2D-L but activated NK cells can express both isoforms. Activated CD8+ T cells express both isoforms but mediate effects through DAP-10 only. Ligands for NKG2D include two proteins distantly related to MHC class 1 molecules, having MHC class 1–like α1 and α2 domains but no α3 domain. RAE1α, β, γ, δ, and ε are GPIlinked proteins, whereas H60 is a transmembrane protein with
a short cytoplasmic tail. RAE1 family members are expressed during embryonic days 9–14 and not in adults. These proteins have been induced by MCMV infection. H60 is not expressed in C57BL/6 mice but is found in thymocytes and lymphoblasts of BALB/c mice. The mouse UL16 binding protein–like transcript 1 (MULT1) possesses MHC class 1–like α1 and α2 domains and has a long cytoplasmic domain. MULT1 is expressed widely in mice (Backstrom et al. 2004). Figure 6 is a diagram of the role of activating and inhibitory receptors of NK cells.
B.
The Major Histocompatibility Complex
The major histocompatibility complex (MHC), also called H-2 in the mouse, encodes a large number of genes found on chromosome 17. The first genes studied in this region encoded proteins that served as the basis for allograft rejection, so called histo-incompatibility, which provided the name for this complex. Within the MHC there are three classes, clusters of closely linked genes, named class I, II, and III. Class III genes encoded several proteins of the complement system as well as genes that aid in the regulation of the immune system. MHC class I and II genes encode highly polymorphic molecules that play a role in antigen presentation to BCRs and TCRs, in addition to their role in graft rejection. Haplotypes of the MHC complex are determined by the combination of alleles of the class I (K, D, L, Q, T, and M), class II (I-Aa, I-Ab, I-Ea, and I-Eb), and class III (S region) genes. Table 1 lists the allelic designations for the MHC for inbred and recombinant strains. Readers should refer to chapter 3 in this volume, entitled “Genomic Organization of the Mouse Major Histocompatability Complex,” for further information. 1.
Classic Class I Molecules
Classic class I molecules are composed of a 45-kDa α chain noncovalently linked to a 12-kDa β2-microglobulin molecule and are expressed on a wide variety of cells. The α chain is encoded by highly polymorphic genes found within the K and D/L regions of the mouse MHC. The α chain has three extracellular domains, each containing 90 amino acids, a transmembrane domain, and a cytoplasmic anchor segment. The transmembrane domain contains about 25 hydrophobic amino acids on the extracellular side of the membrane, followed by a short segment of charged (hydrophilic) residues. β2-Microglobulin does not have a transmembrane segment and is noncovalently linked to the α3 domain, with which it shares sequence homology. Crystallization studies have shown there are two pairs of interacting domains in the extracellular fragment: a membrane-distal pair made up of the α chain α1 and α2 domains and a membrane-proximal pair composed of the α3 domain and β2-microglobulin. The α1 and α2 domains form a platform of eight antiparallel β strands bordered by two
16
FRED
A
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
Inhibitory Receptor Engaged Removal of Phosphates and Inhibition
Activating Signals
P P PTK PTP
P
Inhibitory Receptor
Activating Receptor Ligand for NK Cell
Self Class I MHC–Self Peptide Complex
NK Cell Not Activated; No Cell Killing
Normal Autologous Cell
B
Inhibitory Receptor Not Engaged
Virus Inhibits Class I MHC Expression
NK Cell Activated; Killing of Infected Cell
Virus-Infected Cell (Class I MHC Negative) Fig. 6 Activating and inhibitory receptors of NK cells. Activating receptors of NK cells recognize ligands on target cells and activate protein tyrosine kinase (PTK), whose activity is inhibited by inhibitory receptors that recognize class 1 MHC molecules and activate protein tyrosine phosphatase (PTP). As a result, NK cells do not efficiently kill class 1 MHC–expressing targets. If a virus infection inhibits class 1 MHC expression on infected cells, the NK cell inhibitory receptor is not engaged, and the activating receptor functions unopposed to trigger responses of NK cells, such as cytolysin secretion. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
OVERVIEW
OF
IMMUNOLOGY
IN
THE
17
MOUSE
TABLE 1
ALLELIC DESIGNATIONS OF THE H2 COMPLEX OF SOME INBRED, CONGENIC, AND RECOMBINANT STRAINS MHC (H2) Loci Haplotype
Strains
K
I-Ab
I-Aa
I-Eb
I-Ea*
S
D
L
Qa2
T18
Qa1
a b
A/J, AXB-5/Pgn, BXA-4/Pgn CXBK 129P2/J, C57L/J, BXSB/MpJ, C57BL/10J, C57BL/6J BALB/cJ, DBA/2J, AKXD13/Ty BIO.M–H2f/nMob, A.CAH2fH2-T18d/Sn WB/ReJ+/+, WC/ReJ+/+ MRL/MpJ, AKR/J, C58/5, CBA/J, RF/J NOD/LtJ, NOR/LtJ, NOcCB1/Lt R III/J, R III/DmMob ALS/LtJ, NON/LtJ P/J, C3H.NB-H2PH2-T18c/Sn DBA/1J, FVB/NJ, SWR/J B10.R III-H2r (71NS)/nMob SJL/J, CXJ-15/SlkJ, SWXJ-8/Bm PL/J, B10.PL-H2u H2-T18a (73NS)/Sn SM/J, NXSM-I/Ei, NXSM-L/Ei NZM64/J, NZ0/HEllJ, NZW/LacJ
k b
k b
k b
k b
k b
d b
d b
d b
a a
a b
a b
d
d
d
d
d
d
d
d
b
d
b
f
f
f
f
f
f
f
f
b
d
b
j k
j k
j k
j k
j k
j k
b k
b k
a b
b b
b b
d k b p q r s u
g7 k nb1 p q r s u
g7 k nb1 p q r s u
— k k p q r s u
— k k p q r s u
— k — p q r s u
b q b p q r s d
— q — p q r s d
— a — b a b a a
— a — e b b b a
— a — a b b b a
v u
v u
v u
v u
v u
v z
v z
v z
a b
b b
b b
d f j k g7 m nb1 p q r s u v z
*Strains that are I-Ea null: 129, ASW/Sn, BALB.B, C57BL/6, C57BL/10, DBA/1, NOD/LtJ, NOR/LtJ, SJL/J. Adapted from the JAX MICE Catalog 2000, The Jackson Laboratory, Bar Harbor, ME.
α-helical regions to form a deep groove known as the peptidebinding cleft. The cleft is displayed on the top surface of the MHC molecule and can bind a peptide of 8–10 amino acids with interactions between conserved residues and the bound peptide, resulting in a closed groove; these structural features are shared between mouse and man (Fig. 7). The α3 domain is highly conserved among class I molecules and together with β2-microglobulin it forms an immunoglobulin fold structure that interacts with the CD8 membrane molecule on T cells (see section II.C.2.c.). β2-Microglobulin also interacts with a peptide in the class I α chain, and this interaction is essential for proper fold conformation and delivery of the class I molecule and peptide to the cell surface (Abbas and Lichtman 2005; Goldsby et al. 2003). 2.
Classic Class II Molecules
Classic class II molecules contain a 33-kDa α chain and a 28-kDa β chain, which are noncovalently linked. Genes encoding these classic class II molecules are located in the IA or IE regions of the MHC. Inbred strains of the H2 haplotypes b, s, f, and g do not express E class II molecules. Each membrane-bound chain has two extracellular domains, α1 and α2, on the α chain and β1 and β2 on the β chain. The membrane-proximal α2β2 domains have an immunoglobulin fold structure, whereas the
membrane-distal α1β1 form the antigen-binding cleft (Fig. 8). Crystallographic studies show marked similarities between the antigen-binding cleft of classic class I and classic class II molecules. Both have a floor of β pleated sheets and sides of antiparallel α helices; however, the class II cleft does not have residues that interact with the ends of the bound peptide, and thus class II molecules have a open-ended groove. CD4 binding sites are found on opposite sides of the class II molecule in the α2β2 domains (Abbas and Lichtman 2005; Goldsby et al. 2003). 3.
Nonclassic Class I and Class II Molecules
Nonclassic class I molecules (also called class 1b) lack one or more features of the classic molecules and thus either have limited tissue distributions, low polymorphism, and unknown function or lack the ability to present antigen to CD8 T cells. Class Ib molecules are encoded by genes in the H2-Q, T, and M regions. Molecules derived from the Q region have either unknown function or, like Qa2, can protect from NKmediated lysis and play a role in defense against tumors or in resistance to parasites. Molecules derived from T region genes may be found on leukemia cells or, like Qa1, regulate NK cells (see chapter 6 and section II.A.5.). Molecules of the H2-T10 and T22 gene pair form a modified class I fold but together with
18
FRED
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
Class I MHC Peptide-Binding Cleft Peptide
α1
α2 α1
N
α2
N α3
α3 β2m
β2Microglobulin Transmembrane Region
C
Disulfide Bond lg Domain C Fig. 7 Structure of a class 1 MHC molecule. The schematic diagram (left) illustrates the different regions of the MHC molecules (not drawn to scale). Class 1 molecules are composed of a polymorphic α chain noncovalently attached to the nonpolymorphic β2-microglobulin (β2m). The α chain is glycosylated; carbohydrate residues are not shown. The ribbon diagram (right) shows the structure of the extracellular portion of the HLA-B27 molecule (human class I) with a bound peptide, resolved by x-ray crystallography. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
β2-microglobulin can bind to γδ T cells. M region proteins are thought to participate in pheromone receptor function. Nonclassic class II molecules encoded in the H2-DM and DO regions are involved with peptide loading into classic class II molecules and are referred to as accessory molecules (Braud et al. 1999; Goldsby et al. 2003; Jensen et al. 2004; Ploss et al. 2003; Rodgers and Cook 2005). 4.
Molecules Associated with Antigen Processing
Two different pathways are used to eliminate intracellular and extracellular antigens; they are the cytosolic and endocytic pathways, respectively. The cytosolic pathway involves degradation of ubiquitin-protein conjugates within a multifunctional protease complex called the proteasome. The proteasome is composed of three subunits with peptidase activity, low molecular mass polypeptides LMP2, LMP7, and LMP10, which generate peptides that preferentially bind MHC class I molecules. Peptides generated from the proteasome are transported to the rough
endoplasmic reticulum (RER) by a transporter called transporter associated with antigen processing (TAP). Class I molecules are assembled in the RER with the assistance of molecular chaperones that facilitate folding. Calnexin is a chaperone that associates with free class 1 α chain to promote folding. As β2-microglobulin binds the α chain, calnexin is released, and the chaperone calreticulin and tapasin (TAP-associated protein) become involved. Tapasin brings the TAP transporter next to class I and allows the peptide to be captured in the cleft. Unbound peptides are rapidly degraded. Once peptide is bound, the complex is transported to the plasma membrane through the Golgi. It is known that each type of class I MHC binds a unique set of peptides; however, regardless of class I type (K, D, or L), all bound peptides are 8–10 amino acids long and contain similar amino acid residues at defined positions, called anchor residues. All peptides that bind class I contain a carboxyl-terminal anchor that is hydrophobic (leucine or isoleucine) and makes contact with class I in the groove region (Goldsby et al. 2003; Kloetzel and Ossendorp 2004; Lehner and Cresswell 2004).
OVERVIEW
OF
IMMUNOLOGY
IN
THE
19
MOUSE
Class I MHC Peptide-Binding Cleft Peptide β1
α1
NN
β1
α1
β2
α2
α2
β2
Transmembrane Region Disulfide Bond lg Domain C
C
Fig. 8 Structure of a class I MHC molecule. The schematic diagram (left) illustrates the different regions of the MHC molecule (not drawn to scale). Class II molecules are composed of a polymorphic α chain non-covalently attached to a polymorphic β chain. Both chains are glycosylated; carbohydrate residues are not shown. The ribbon diagram (right) shows the structure of the extracellular portion of the HLA-DR1 (human class II) molecule with a bound peptide, resolved by x-ray crystallography. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
Antigens external to the cell are internalized by phagocytosis (macrophages) or endocytosis (receptor-mediated endocytosis or pinocytosis). B cells use their membrane-bound antibody as a receptor for receptor-mediated endocytosis. Internalized antigen moves through three increasingly acidic compartments—the early endosome, the late endosome (endolysosome), and the lysosome—in which they encounter hydrolytic enzymes and are degraded into oligopeptides of 13–18 residues. While MHC class II molecules are being assembled in the RER, their binding cleft associates with a preassembled trimer of a protein known as invariant chain (CD74). This trimer interacts with the binding grooves of three class II molecules, prevents endogenously derived peptides from binding, aids in the folding of α and β chains (so class II can exit the RER), and routs the complex to the endocytic-processing pathway via the trans-Golgi network. As the complex moves through the endosomes, the invariant chain is degraded, leaving only a small fragment, called class II-associated invariant chain peptide (CLIP), occupying the peptide groove. A nonclassic,
nonpolymorphic class II MHC molecule, H2-DM, catalyzes the exchange of CLIP for antigenic peptide. Another molecule, H2-DO, inhibits the activity of DM. Once peptide is bound, the peptide-MHC class II complex is transported to the plasma membrane. Unlike peptide binding class I molecules, class II peptides have no anchor residues; however, they have an internal sequence of 7–10 residues that provide contact points with class II. Pathways leading to antigen presentation by MHC class I and class II molecules are illustrated in Fig. 9. a. TAP PROTEINS TAP1 and TAP2 are encoded within the class II region of the mouse MHC adjacent to genes for LMP2 and LMP7. Together they form membrane-spanning heterodimers with each protein having multiple transmembrane segments. Each protein has a domain projecting into the lumen of the RER and an ATP-binding domain that projects into the cytosol. Peptides generated in the cytosol by the proteasome are translocated into the RER by TAP via a process involving the hydrolysis of ATP (Lehner and Cresswell 2004).
20
FRED
Antigen Uptake
Antigen Processing
MHC Biosynthesis
QUIMBY
AND
D AV I D
D.
CHAPLIN
Peptide-MHC Association
CD4+ T Cell
Endocytosis of Extracellular Protein
Invariant Chain (Ii)
ER
Proteasome
Class I MHC Pathway
Class II MHC
Peptides in Cytosol
Cytosilic Protein
W.
TAP
Class I MHC
CD8+ CTL ER
Class I MHC Pathway
Fig. 9 Pathways of antigen processing and presentation. In the class II MHC pathway (top panel), extracellular protein antigens are endocytosed into vesicles, where the antigens are processed and the peptides bind to class II MHC molecules. In the class I MHC pathway (bottom panel), protein antigens in the cytosol are processed by proteasomes, and peptides are transported into the endoplasmic reticulum (ER), where they bind to class I MHC molecules. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
b. H2-DM AND H2-DO DM and DO are heterodimers of α and β chains encoded by genes in the mouse MHC class II region adjacent to genes for TAP and LMP. H2-DM is not expressed on the cell membrane but exclusively in the endosomal compartment and is induced by IFN-γ. The exchange of CLIP for antigenic peptide is impaired in the presence of H2-DO. DO binds DM and reduces its efficacy. DO is expressed only in B cells and the thymus and is not induced by IFN-γ. Because higher acidity weakens the association of DO with DM, it is possible that in the B cell there is preferential selection of class II peptides from lysosomal compartments (Bryant and Ploegh 2004; Goldsby et al. 2003). 5.
The CD1 Family of Molecules
The CD1 genes encoded a family of nonpolymorphic cell surface glycoproteins that are highly conserved in mammals. CD1 proteins are structurally related to the MHC class I gene family but diverged from class I in the structure of their antigen-binding domains, allowing them to present lipids and
glycolipids to T cells. The CD1 locus is not linked to MHC and, in fact, it is found on chromosome 3. CD1d, the only member found in mice, is composed of a heavy chain containing extracellular, transmembrane, and cytoplasmic tail domains. It associates with β2-microglobulin to form a heterodimer that colocalizes with lysosomal associated membrane protein-1 in lysosomal vesicles. In addition to deep penetration into the endosomal system, the CD1d cytoplasmic tail binds the AP-3 adaptor complex, which mediates sorting of cargo proteins in late endosomes and lysosomes. This allows CD1d to sample more intracellular compartments and acquire self-lipids for presentation on APCs (Dascher and Brenner 2003). CD1d is the antigen-presenting molecule that restricts natural killer T (NKT) cells. Mouse NKT cells are defined as a population of T cells that express an invariant TCR α chain (Vα14/Jα281) in association with Vβ2, -7, or -8 and express the NK1.1 antigen (NKR-P1C), a cell surface C-type lectin. Phenotypically NK1.1+ T cells are either CD4+CD8− or CD4−CD8− and represent a major fraction of the mature T cells in thymus and liver and about 5% of splenic T cells. They are rare in lymph nodes
OVERVIEW
OF
IMMUNOLOGY
IN
THE
MOUSE
(Skold and Behar 2003). By using CD1d tetramers loaded with the synthetic glycolipid α-galactosyl-ceramide (α-GalCer), murine NKT cells have been characterized into three populations based on their binding of the tetramer and expression of NK1.1 (MacDonald 2002). Injection of α-GalCer into mice leads to activation of many immune cell types and is dependent on the presence of both CD1d and invariant NKT (iNKT) cells. It is known that under these conditions iNKT cells activate NK cells to produce IFN-γ. This form of immunological stimulation has been shown to enhance host resistance to a wide variety of pathogens including bacteria, yeast, viruses, and protozoans (Skold and Behar 2003) and stimulates tumor rejection and suppresses autoimmunity (Vincent et al. 2003).
C.
Antigen Receptors and Coreceptors in Adaptive Immunity
1.
Antibodies and the B-Cell Receptor (BCR)
a. PRIMARY ANTIBODY STRUCTURE Antibodies are the antigen-binding glycoproteins found in plasma and certain secretions; the membrane-bound versions are the antigen-binding portions of the BCR. All antibody molecules have, as a common structural feature, four peptide chains. The basic structure consists of two identical heavy chains (H) of 50 kDa and two identical light chains (L) of 25 kDa molecule mass. One light chain is bound to a heavy chain by a disulfide bond as well as salt linkages, hydrophobic bonds, and hydrogen bonds to form a H-L heterodimer. The two H chains are bound to each other using similar bonds including at least one interchain disulfide bond. The N-terminal 110 amino acids of both the L chains and H chains are highly variable between antibody molecules and constitute the variable (V) region, which is the antigen binding site. These V regions are called complementarity-determining regions (CDRs) and will be discussed in more detail later in this section. Beyond the V region, both H and L chains of an antibody class have a constant sequence. Enzymatic cleavage of the molecules using papain leads to two heterodimers, each consisting of an L chain bonded to the N-terminal half of the H chain (called the Fab fragment) and a homodimer consisting of the carboxyl-terminal half of each H chain bonded to one another (called the Fc fragment) as depicted in Fig. 10. The Fab fragment is responsible for antigen binding whereas the Fc fragment imparts many other functions to the antibody, such as complement fixation, FcR binding, and transcytosis. Sequencing L chains elucidated the N-terminal V region and a carboxyl-terminal C region. The C region has two basic sequences that correspond to the κ and λ light chain types. Of all mouse antibodies, 95% are of a single κ-chain type. The remaining 5% that are λ chains consist of three subtypes based on their amino acid sequence (Goldsby et al. 2003). Sequencing of H chains elucidated an N-terminal V region followed by one of five difference constant regions known as µ,
21 δ, γ, ε, and α. Each of these five heavy chain types is known as an isotype. Whereas the δ, γ, and α chains have approximately 330 amino acids in their constant regions, µ and ε chains have 440 amino acids. These H-chain isotypes determine the class of antibody molecule: IgM (µ), IgG /(γ), IgA (α), IgD (δ), and IgE (ε). Further variations in amino acid sequence of the IgG isotype determine subisotypic specificities; mice have four subisotypes: IgG1, IgG2a, IgG2b, and IgG3. Certain inbred strains do not have IgG2a but rather have IgG2c. In addition, genetic loci that are allelic within a species determine amino acid sequences on both the light and heavy chains; these specificities among different inbred strains of mice are known as allotypes. A full discussion of isotype and allotype specificities in inbred strains is found in Bankert and Mazzaferro (1999). The N-terminal variable regions of light and heavy chains are folded and bound into globular units through the formation of covalent and noncovalent linkages to be described later under secondary and tertiary structure. Antigen-binding sites were found to be complementary to the structure of the portion of antigen bound (epitope), and thus they are known as CDRs. There are three heavy and three light chain CDRs in each N-terminal variable region domain, and the great diversity of antigen-binding sites is due to variations in the length and amino acid sequence of the six CDRs in each Fab fragment. X-ray diffraction studies of antigen-antibody complexes have shown that all six CDRs bind the antigenic epitope but that the VH domain contributes more to antigen binding than the VL domain. In some instances, antigen binding causes further conformational changes in both the antigen and antibody, which lead to more effective epitope binding. b. SECONDARY, TERTIARY, AND QUATERNARY STRUCTURE The secondary structure of antibodies is formed by folding of the polypeptide chains into antiparallel β-pleated sheets. Both heavy and light chains are composed of multiple homologous sequences of 110 amino acid residues, termed domains, which have intrachain disulfide bonds forming loops of approximately 60 amino acid residues. Light chains have one N-terminal variable domain (VL) and one constant domain (CL), whereas heavy chains, depending on the class of antibody, have an N-terminal variable domain (VH) followed by three or four constant domains (CH1–CH4). Each domain is folded into a sandwich of two β-pleated sheets, stabilized by hydrogen bonds, which connect NH groups of one strand with carbonyl groups of the other strand. Hydrophobic amino acids orientate toward the center of the sandwich whereas hydrophilic groups are oriented outward. This characteristic compact structure is known as the “immunoglobulin fold” and is characteristic of all members of the immunoglobulin superfamily of proteins, which include FcRs, the T-cell receptor, MHC class I and II molecules, T-cell accessory proteins such as CD2, CD4, and CD8 and various adhesion molecules. The tertiary structure is formed by these chains then folding into compact globular domains, which are connected to each other by the continuation of the polypeptide chains (both heavy
22
FRED
A
W.
QUIMBY
AND
D AV I D
D.
CHAPLIN
B N N
Heavy Chain
N
N
VH
N
VL
Heavy Chain
VL
Cγ1
N Cγ1
CL
Light Chain
CL
N
VH
N
C
C
Pepsin
Pepsin Papain
Papain
Cγ2
Cγ2
Cγ3
Cγ3
C
N
Light Chain
C
C
C
N N
N
F(ab')2
N
Fab
N
N C C C
C
N
N
Fab N Papain Products
C
C C
C
Papain Products FC Papain Fragments C C Fig. 10 Proteolytic fragments of an IgG molecule. IgG molecules are cleaved by the enzymes papain (A) and pepsin (B) at the sites indicated by arrows. Papain digestion allows separation of two antigen-binding regions (the Fab fragments) from the portion of the IgG molecules that binds to complement and Fc receptors (the Fc fragment). Pepsin generates a single bivalent antigen-binding fragment, F(ab’)2. Reproduced from Abbas, A.K. and Lichtman, A.H. (2005) Cellular and Molecular Immunology, 5th ed. Elsevier Saunders, Philadelphia.
and light) that fall outside of the β-pleated sheets. The globular domains of adjacent heavy and light chains interact to form the quaternary structure, and this structure, situated at the N-terminal of nonidentical chains (VH-VL), forms the antigen-binding site. Similar noncovalent interactions occur between identical domains (CH2-CH2) (Goldsby et al. 2003). c. ANTIBODY CLASSES AND SUBCLASSES Mice have five major classes of immunoglobulins that differ in both structure and function. The most abundant class in serum is IgG, and
mice make four subclasses IgG1, IgG2a, IgG2b, and IgG3, all of which circulate as 150-kDa glycoproteins. These subclasses do not necessarily correlate exactly with the human counterparts. The four subclasses are distinguished by amino acid sequences encoded in germline CH genes. In addition, their structures are affected by the size of the hinge region, although all four subclasses have three disulfide bonds between heavy chains. These characteristics also affect the biological function of the subclasses. Unlike humans, the four mouse IgG
OVERVIEW
OF
IMMUNOLOGY
IN
THE
MOUSE
subclasses have a complex banding pattern on electrophoresis. IgG1 has a serum half-life of 4 days and mean serum concentration of 6.5mg/mL, is cytophilic for mast cells, and causes a homologous PCA reaction. IgG2a has a serum half-life of 5 days and a mean concentration of 4.2 mg/mL, can cross the placenta by FcRn transcytosis, is cytophilic for macrophages, and causes a heterologous PCA reaction. IgG2a is preferentially expressed in the host response to viral infections (Greenspan and Cooper 1992). IgG2b has a short half-life (t1/2 = 2 days), mean serum concentration of 1.2 mg/mL, crosses the placenta, activates complement by the classical pathway but is not cytophilic. IgG3 has a long half-life (t1/2 = 4 days) but is present in very low serum concentrations (100–200 µg/mL). Unlike the other IgG subclasses, IgG3 predominates in the humoral response to bacterial polysaccharides (TI type 2). The binding characteristics of IgG3 antibodies against N-acetylglucosamine residues on group A streptococci are markedly different from those of variable domain-identical IgG1 and IgG2b antibodies and involve noncovalent interactions between Fc fragments of adjacent molecules, leading to oligomerization and cooperativity in binding multivalent antigens. IgG3 can also cross the placenta (Greenspan and Cooper 1992). Cytokines involved in a subclass switch to IgG2a, IgG2b, and IgG3 are elaborated by Th1 responses (IFN-γ), whereas those for IgG1 are elaborated by Th2 responses (IL-4). TGF-β induces a class switch to IgG2b (Nimmerjahn and Ravetch 2005) (also see chapter 5 in this volume, entitled “Mouse Models Revealed the Mechanisms for Somatic Hypermutation and Class Switch Recombination of Immunoglobulin Genes”). Binding of the various IgG subclasses to FcRs is discussed in section II.A.2. IgM accounts for approximately 5% of serum immunoglobulin in outbred mice with average concentrations of ~1 mg/mL. B cell surface IgM exists as a monomer with the heavy chain bound by a single disulfide bond at cysteine position 575. Secreted IgM exists primarily as a pentamer of five monomeric units held together by disulfide bonds between heavy chains. The pentamer is arranged with the antigenbinding Fab subunits facing outside (peripheral). Monomeric subunits are larger than typical IgG monomers because the heavy chain contains an extra, fourth, constant region domain. They generally have higher carbohydrate contents as well. In the pentamer, a J chain is disulfide bonded to the penultimate half-cysteine residue of the heavy chains. These J chains ensure that the five subunits are held in a closed ring, aid in transcytosis, and are highly conserved among species (Matsuuchi et al. 1986). In mice, IgM appears as a single class with no subclasses and mutation of cysteine at position 575 is known to inactivate complement fixation (Bankert and Mazzaferro 1999). IgA is a class found in secretions (saliva, bile, colostrums, and tears) and serum. In serum it may exist as either a monomer or dimer, whereas the secreted form is typically a dimer with two monomeric units linked by both a J chain and a secretory
23 component (SC). The J chain is similar to that described for IgM. The SC is derived from the PIgR (see section II.A.2.b.) responsible for transporting IgA across the epithelial cells into mucosal or glandular secretions. The SC is bound to mouse IgA by both disulfide and noncovalent bonds. Mice have two subclasses of IgA, one with the normal disulfide linked structure (as seen in the NZB strain) and another in which the light chains are linked to each other by disulfide bonds but not to the heavy chains (as seen in BALB/c mice) (Bankert and Mazzaferro 1999). IgE, also known as reaginic antibody, exists in serum as a fourchain monomer of 185–200 kDa. Like IgM, the IgE monomers contain a fourth constant region domain. Serum concentrations of IgE are reported to be 1.5-Mb YAC contigs from the H2-M region. Genomics 27, 40–51. Klein, J., Sato, A. (1998). Birth of the major histocompatibility complex. Scand J Immunol 47, 199–209. Kulski, J.K., Anzai, T., Shiina, T., Inoko, H. (2004). Rhesus macaque class I duplicon structures, organization, and evolution within the alpha block of the major histocompatibility complex. Mol Biol Evol 21, 2079–2091. Kulski, J.K., Shiina, T., Anzai, T., Kohara, S., Inoko, H. (2002). Comparative genomic analysis of the MHC: the evolution of class I duplication blocks, diversity and complexity from shark to man. Immunol Rev 190, 95–122. Kumánovics, A., Fischer Lindahl, K. (2004). Good copy, bad copy: choosing animal models for HLA-linked diseases. Curr Opin Genet Dev 14, 258–263. Kumánovics, A., Madan, A., Qin, S., Rowen, L., Hood, L., Fischer Lindahl, K. (2002). Quod erat faciendum: sequence analysis of the H2-D and H2-Q regions of 129/SvJ mice. Immunogenetics 545, 479–489.
AT T I L A K U M Á N O V I C S
Kumánovics, A., Takada, T., Lindahl, K.F. (2003). Genomic organization of the mammalian MHC. Annu Rev Immunol 21, 629–657. Lambracht-Washington, D., Fischer Lindahl K., (2004). Active MHC class Ib genes in rat are pseudogenes in the mouse. Immunogenetics 56, 118–121. Lambracht-Washington, D., Fischer Lindahl, K., Wonigeit, K. (2000). Promoter structures suggest independent translocations of ancestral rat RT1.A and mouse H2-K class I genes. Immunogenetics 51, 873–877. Le Bouteiller, P. (1997). HLA-G: on the track of immunological functions. Eur J Immunogenet 24, 397–408. Levy-Nissenbaum, E., Betz, R.C., Frydman, M., Simon, M., Lahat, H., Bakhan, T., et al. (2003). Hypotrichosis simplex of the scalp is associated with nonsense mutations in CDSN encoding corneodesmosin. Nat Genet 34, 151–153. Li, J., Jiang, T., Mao, J.H., Balmain, A., Peterson, L., Harris, C., Rao, P.H., et al. (2004). Genomic segmental polymorphisms in inbred mouse strains. Nat Genet 36, 952–954. Litaker, W., Peace-Brewer, A., Frelinger J.A. (1996). A physical map of the Q region of B10.P. Mamm Genome 7, 200–205. Loconto, J., Papes, F., Chang, E., Stowers, L., Jones, E.P., Takada, T., et al. (2003). Functional expression of murine V2R pheromone receptors involves selective association with the M10 and M1 families of MHC class Ib molecules. Cell 112, 607–618. Mao, J.R., Taylor, G., Dean, W.B., Wagner, D.R., Afzal, V., Lotz, J.C., et al. (2002). Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat Genet 30, 421–425. Marino, M.W., Dunn, A., Grail, D., Inglese, M., Noguchi, Y., Richards, E., et al. (1997). Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 94, 8093–8098. Matsuura, A., Schloss, R., Shen, F.W., Tung, J.S., Hunt, S.W., 3rd, Fisher, D.A., et al. (1989). Expression of the Q8/9d gene by T cells of the mouse. Immunogenetics 30, 156–161. Matsuzaka, Y., Tounai, K., Danda, A., Tomizawa, M., Makino, S., Okamoto, K., et al. (2002). Identification of novel candidate genes in the diffuse panbronchiolitis critical region of the class I human MHC. Immunogenetics 54, 301–309. Mauff, G., Bender, K., Giles, C.M., Goldmann, S., Opferkuch, W., Wachauf, B. (1984). Human C4 polymorphism: pedigree analysis of qualitative, quantitative, and functional parameters as a basis for phenotype interpretations. Hum Genet 65, 362–372. Mauff, G., Brenden, M., Braun-Stilwell, M., Doxiadis, G., Giles, C.M., Hauptmann, G., et al. (1990). C4 reference typing report. Complement Inflamm 7, 193–212. Mauff, G., Luther, B., Schneider, P.M., Rittner, C., Stradmann-Bellinghausen, B., Dawkins, R., et al. (1998). Reference typing report for complement component C4. Exp Clin Immunogenet 15, 249–260. Meyer, M., Gaudieri, S., Rhodes, D.A., Trowsdale, J. (2003). Cluster of TRIM genes in the human MHC class I region sharing the B30.2 domain. Tissue Antigens 61, 63–71. The MHC Sequencing Consortium (1999). Complete sequence and gene map of a human major histocompatibility complex. Nature 401, 921–923. Miller, R.D., Aizawa, Y., Shreffler, D.C. (1992). Restriction fragment length polymorphism of the murine C4 and Slp genes: two C4 groups. J Immunol 149, 2926–2934. Moore, Y.F., Lambracht-Washington, D., Tabaczewski, P., Fischer Lindahl, K. (2004). Murine MHC class Ib gene, H2-M2, encodes a conserved surfaceexpressed glycoprotein. Immunogenetics 56, 1–11. Nair, R.P., Stuart, P., Henseler, T., Jenisch, S., Chia, N.V., Westphal, E., et al. (2000). Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66, 1833–1844. Nei, M., Gu, X., Sitnikova, T. (1997). Evolution by the birth-and-death process in multigene families of the vertebrate immune system. Proc Natl Acad Sci USA 94, 7799–7806. Nunes, M., Peelman, L., Vaiman, M., Bourgeaux, N, Chardon, P. (1994). Characterization of six new loci within the swine major histocompatibility complex class III region. Mamm Genome 5, 616–622.
3 . G E N O M I C O R G A N I Z AT I O N O F T H E M O U S E M A J O R H I S T O C O M PAT I B I L I T Y C O M P L E X
Ohta, Y., Okamura, K., McKinney, E.C., Bartl, S., Hashimoto, K., Flajnik, M.F. (2000). Primitive synteny of vertebrate major histocompatibility complex class I and class II genes. Proc Natl Acad Sci USA 97, 4712–4717. Oka, A., Tamiya, G., Tomizawa, M., Ota, M., Katsuyama, Y., Makino, S., et al. (1999). Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet 8, 2165–2170. Old, L.J., Boyse, E. A. (1963). Antigenic properties of experimental leukemias. I. Serological studies in vitro with spontaneous and radiation-induced leukemias. J Natl Cancer Inst 31, 977–986. Olson, R., Huey-Tubman, K.E., Dulac, C., Bjorkman, P.J. (2005). Structure of a pheromone receptor-associated MHC molecule with an open and empty groove. PLoS Biol 3, e257. O’Neill, A.E., Reid, K., Garberi, J.C., Karl, M., Flaherty, L. (1986). Extensive deletions in the Q region of the mouse major histocompatibility complex. Immunogenetics 24, 368–373. Otting, N., Heijmans, C.M., Noort, R.C., de Groot, N.G., Doxiadis, G.G., March, S.G., et al. (2005). Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci USA 102, 1626–1631. Pal, D.K., Evgrafov, O.V., Tabares, P., Zhang, F., Durner, M., Greenberg, D.A. (2003). BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy. Am J Hum Genet 73, 261–270. Pattanakitsakul, S., Nakayama, K., Takahashi, M., Nonaka, M. (1990). Three extra copies of a C4-related gene in H-2w7 mice are C4/Slp hybrid genes generated by multiple recombinational events. Immunogenetics 32, 431–439. Pattanakitsakul, S., Zheng, J.H., Natsuume-Sakai, S., Takahashi, M., Nonaka, M. (1992). Aberrant splicing caused by the insertion of the B2 sequence into an intron of the complement C4 gene is the basis for low C4 production in H-2k mice. J Biol Chem 267, 7814–7820. Pearson, H. (2004). Mouse sequencing plan aims to boost models. Nature 432, 5. Peelman, L.J., Chardon, P., Vaiman, M., Mattheeuws, M., Van Zeveran, A., Van de Weghe, A., et al. (1996). A detailed physical map of the porcine major histocompatibility complex (MHC) class III region: comparison with human and mouse MHC class III regions. Mamm Genome 7, 363–367. Pullen, J.K., Horton, R.M., Cai, Z.L., Pease, L.R. (1992). Structural diversity of the classical H-2 genes: K, D, and L. J Immunol 148, 953–967. Renard, C., Chardon, P., Vaiman, M. (2003). The phylogenetic history of the MHC class I gene families in pig, including a fossil gene predating mammalian radiation. J Mol Evol 57, 420–434. Renard, C., Vaiman, M., Chiannilkulchai, N., Cattolico, L., Robert, C., Chardon, P. (2001). Sequence of the pig major histocompatibility region containing the classical class I genes. Immunogenetics 53, 490–500. Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., et al. (2001). The tripartite motif family identifies cell compartments. EMBO J 20, 2140–2151. Rodgers, J.R., Cook, R.G. (2005). MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 5, 459–471. Roos, C., Dressel, R., Schmidt, B., Gunther, E., Walter, L. (2005). The rat expresses two complement factor C4 proteins, but only one isotype is expressed in the liver. J Immunol 174, 970–975. Roos, C., Walter, L. (2005). Considerable haplotypic diversity in the RT1-CE class I gene region of the rat major histocompatibility complex. Immunogenetics 56, 773–777. Rubocki, R.J., Lee, D.R., Lie, W.R., Myers, N.B., Hansen, T.H. (1990). Molecular evidence that the H-2D and H-2L genes arose by duplication. Differences between the evolution of the class I genes in mice and humans. J Exp Med 171, 2043–2061. Satta, Y., Mayer, W.E., Klein, J. (1996). HLA-DRB intron 1 sequences: implications for the evolution of HLA-DRB genes and haplotypes. Hum Immunol 51, 1–12. Schöpfer, R., Figueroa, F., Nizetic, D., Nevo, E., Klein, J. (1987). Evolutionary diversification of class II P loci in the Mhc of the mole-rat Spalax ehrenbergi. Mol Biol Evol 4, 287–299.
133
Shigenari, A., Ando, A., Renard, C., Chardon, P., Siina, T., Kulski, J.K., et al. (2004). Nucleotide sequencing analysis of the swine 433-kb genomic segment located between the non-classical and classical SLA class I gene clusters. Immunogenetics 55, 695–705. Shiina, T., Inoko, H., Kulski, J.K. (2004). An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 64, 631–649. Shiina, T., Tamiya, G., Oka, A., Takishima, N., Yamagata, T., Kikkawa, E., et al. (1999). Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region. Proc Natl Acad Sci USA 96, 13282–13287. Shin, S., El-Diwany, R., Schaffert, S., Adams, E.J., Garcia, K.C., Pereira, P., et al. (2005). Antigen recognition determinants of γδ T cell receptors. Science 308, 252–255. Shiroishi, T., Sagai, T., Natsuume-Sakai, S., Moriwaki, K. (1987). Lethal deletion of the complement component C4 and steroid 21-hydroxylase genes in the mouse H-2 class III region, caused by meiotic recombination. Proc Natl Acad Sci USA 84, 2819–2823. Sipes, S.L., Medaglia, M.V., Stabley, D.L., DeBruyn, C.S., Alden, M.S., Catenacci, V., et al. (1996). A new major histocompatibility complex class Ib gene expressed in the mouse blastocyst and placenta. Immunogenetics 45, 108–120. Sivakamasundari, R., Raghunathan, A., Zhang, C.Y., Chowdhury, R.R., Weissman, S.M. (2000). Expression and cellular localization of the protein encoded by the 1C7 gene: a recently described component of the MHC. Immunogenetics 51, 723–732. Snell, G.D. (1992). The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980: Studies in histocompatibility. Scand J Immunol 36, 513–526. Snijders, A.M., Nowak, N.J., Huey, B., Fridlyand, J., Law, S., Conroy, J., et al. (2005). Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res 15, 302–311. Snoek, M., van Dinten, L., van Vugt, H. (1996). A novel gene, G7e, resembling a viral envelope gene, is located at the recombinational hot spot in the class III region of the mouse MHC. Genomics 38, 5–12. Stammers, M., Rowen, L., Rhodes, D., Trowsdale, J., Beck, S. (2000). BTL-II: a polymorphic locus with homology to the butyrophilin gene family, located at the border of the major histocompatibility complex class II and class III regions in human and mouse. Immunogenetics 51, 373–382. Stavenhagen, J.B., Robins, D.M. (1988). An ancient provirus has imposed androgen regulation on the adjacent mouse sex-limited protein gene. Cell 55, 247–254. Stephan, D., Sun, H., Fischer Lindahl, K.F., Meyer, E., Hammerling, G., Hood, L., et al. (1986). Organization and evolution of D region class I genes in the mouse major histocompatibility complex. J Exp Med 163, 1227–1244. Stephens, R., Horton, R., Humphray, S., Rowen, L., Trowsdale, J., Beck, S. (1999). Gene organisation, sequence variation and isochore structure at the centomeric boundary of the human MHC. J Mol Biol 291, 789–799. Stewart, C.A., Horton, R., Allcock, R.J., Ashurst, J.L., Atrazhev, A.M., Coggill, P., et al. (2004). Complete MHC haplotype sequencing for common disease gene mapping. Genome Res 14, 1176–1187. Sültmann, H., Sato, A., Murray, B.W., Takezaki, N., Geisler, R., Rauch, G.J., et al. (2000). Conservation of Mhc class III region synteny between zebrafish and human as determined by radiation hybrid mapping. J Immunol 165, 6984–6993. Tabaczewski, P., Chiang, E., Henson, M., Stroynowski, I. (1997). Alternative peptide binding motifs of Qa-2 class Ib molecules define rules for binding of self and nonself peptides. J Immunol 159, 2771–2781. Tabaczewski, P., Shirwan, H., Kewis, K., Stroynowski, I. (1994). Alternative splicing of class Ib major histocompatibility complex transcripts in vivo leads to the expression of soluble Qa-2 molecules in murine blood. Proc Natl Acad Sci USA 91, 1883–1887. Tacchini-Cottier, F., Mayer, W.E., Begovich, A.B., Jones, P.P. (1995). Inactivation of Eα and Eβ expression in inbred and wild mice by multiple
134 distinct mutations, some of which predate speciation within Mus species. Int Immunol 7, 1459–1471. Tajima, A., Tanaka, T., Ebata, T., Takeda, K., Kawasaki, A., Kelly, J.M., et al. (2003). Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivo. J Immunol 171, 1715–1721. Takada, T., Kumánovics, A., Amadou, C., Yoshino, M., Jones, E.P., Athanasiou, M., et al. (2003). Species-specific class I gene expansions formed the telomeric 1 mb of the mouse major histocompatibility complex. Genome Res 13, 589–600. Tanaguchi, Y., Matsuzaka, Y., Fujimoto, H., Miyado, K., Kohda, A., Okumura, K., et al. (1998). Nucleotide sequence of the Ring3 gene in the class II region of the mouse MHC and its abundant expression in testicular germ cell. Genomics 51, 114–123. Teitell, M., Cheroutre, H., Ranwala, C., Holcombe, H., Eghtesady, P., Kronenberg, M. (1994). Structure and function of H-2 T (Tla). region class I MHC molecules. Crit Rev Immunol 14, 1–27. Thorpe, K.L., Abdulla, S., Kaufman, J., Trowsdale, J., Beck, S. (1996). Phylogeny and structure of the RING3 gene. Immunogenetics 44, 391–396. Tine, J.A., Walsh, A., Rathbun, D., Leonard, L., Wakeland, E.K., Dilwith, R., et al. (1990). Genetic polymorphisms of Q region genes from wildderived mice: implications for Q region evolution. Immunogenetics 31, 315–325. Walter, L., Günther, E. (2000). Physical mapping and evolution of the centromeric class I gene-containing region of the rat MHC. Immunogenetics 51, 829–837. Wang, C.-R., Fischer Lindahl, K. (1993). Organization and structure of the H-2M4-M8 class I genes in the mouse major histocompatibility complex. Immunogenetics 38, 258–271. Watanabe, Y., Maruoka, T., Walter, L., Kasahara, M. (2004). Comparative genomics of the Mill family: a rapidly evolving MHC class I gene family. Eur J Immunol 34, 1597–1607. Waterston, R.H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J.F., Agarwal, R., et al. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520–562. Watts, S., Davis, A.C., Gaut, B., Wheeler, C., Hill, L., Goodenow, R.S. (1989). Organization and structure of the Qa genes of the major histocompatibility complex of the C3H mouse: implications for Qa function and class I evolution. EMBO J 8, 1749–1759.
AT T I L A K U M Á N O V I C S
Weiss, E.H., Bevec, D., Messer, G., Schwemmle, S., Grosshaus, C., Steinmetz, M., et al. (1989). Organization of the AKR Qa region: structure of a divergent class I sequence, Q5k. J Immunogenet 16, 283–290. Weiss, E.H., Golden, L., Fahner, K., Mellor, A.L., Devlin, J.J., Bullman, H., et al. (1984). Organization and evolution of the class I family in the major histocompatibility complex of the C57BL/10 mouse. Nature 310, 650–655. Williams, A.P., Peh, C.A., Purcell, A.W., McCluskey, J., Elliott, T. (2002). Optimization of the MHC class I peptide cargo is dependent on Tapasin. Immunity 16, 509–520. Wingren, C., Crowley, M.P., Degano, M., Chien, Y., Wilson, I.A. (2000). Crystal structure of a γδ T cell receptor ligand T22: a truncated MHC-like fold. Science 287, 310–314. Wroblewski, J.M., Kaminsky, S.G., Nakamura, I. (1994). Bat-1 genes and the origin of multiple class I loci in the H-2D region. Immunogenetics 39, 276–280. Wu, L., Feng, H., Warner, C.M. (1999). Identification of two major histocompatibility complex class Ib genes, Q7 and Q9, as the Ped gene in the mouse. Biol Reprod 60, 1114–1119. Wu, M., van Kaer, L., Itohara, S., Tonegawa, S. (1991). Highly restricted expression of the thymus leukemia antigens on intestinal epithelial cells. J Exp Med 174, 213–218. Xie, T., Rowen, L., Aguado, B., Ahearn, M.F., Medan, A., Qin, S., et al. (2003). Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse. Genome Res 13, 2621–2636. Yang, Z., Mendoza, A.R., Welch, T.R., Zipf, W.B., Yu, C.Y. (1999). Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module): a mechanism for gene deletions and disease associations. J Biol Chem 274, 12147–12156. Yeager, M., Kumar, S., Hughes, A.L. (1997). Sequence convergence in the peptide-binding region of primate and rodent MHC class Ib molecules. Mol Biol Evol 14, 1035–1041. Younger, R.M., Amadou, C., Bethel, G., Ehlers, A., Lindahl, K.F., Forbes, S., et al. (2001). Characterization of clustered MHC-linked olfactory receptor genes in human and mouse. Genome Res 11, 519–530. Yuhki, N., Beck, T., Stephens, R.M., Nishigaki, Y., Newmann, K., O’Brien, S.J. (2003). Comparative genome organization of human, murine, and feline MHC class II region. Genome Res 13, 1169–1179. Zinkernagel, R.M., Doherty, P.C. (1997). The discovery of MHC restriction. Immunol Today 18, 14–17.
Chapter 4 Some Biological Features of Dendritic Cells in the Mouse Kang Liu, Anna Charalambous, and Ralph M. Steinman
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II. Some Properties That Have Been Used to Identify Mouse Dendritic Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III. Generation of DCs from Proliferating Progenitors . . . . . . . . . . . . . . . . . . . IV. Distribution of DCs in Lymphoid Tissues . . . . . . . . . . . . . . . . . . . . . . . . . . V. DCs in Nonlymphoid Tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VI. Life Span and Turnover of DCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII. Features of DCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Morphology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Antigen Handling: Uptake, Processing, Presentation . . . . . . . . . . . . . . C. Maturation of DCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. DC Subsets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E. Migration of DCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VIII. Functions of DCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Innate Responses via Toll-Like Receptors and Interactions with Innate Lymphocytes . . . . . . . . . . . . . . . . . . . . . . . . . . B. Initiating Adaptive T Cell Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Controlling the Quality of the T Cell Response . . . . . . . . . . . . . . . . . . D. Initiating Different Types of Tolerance . . . . . . . . . . . . . . . . . . . . . . . . . E. Interactions with Antibody-Forming B Cells . . . . . . . . . . . . . . . . . . . . . IX. Summary of Approaches to Analyzing DC Function in Mice . . . . . . . . . . . A. DCs Studied Ex Vivo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. DCs Generated Ex Vivo from Proliferating Progenitors . . . . . . . . . . . . C. Direct Targeting of Antigens to DCs within Intact Lymphoid Tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. Creation of Improved Mice Carrying Human Immune Systems . . . . . . X. Appendix: Protocols for the Isolation of DCs . . . . . . . . . . . . . . . . . . . . . . . A. Isolating Spleen Dendritic Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Isolating Bone Marrow Dendritic Cells . . . . . . . . . . . . . . . . . . . . . . . . . Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
136 138 139 139 140 141 141 141 141 142 142 143 144 144 144 145 145 146 146 146 147 147 147 147 147 148 149 149
Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
135
136
KANG
I.
LIU,
ANNA
INTRODUCTION
The discovery of dendritic cells (DCs) was the result of an effort to understand the initiation of immunity. The mouse as an experimental animal was critical because of a system, developed by Mishell and Dutton (1967), in which spleen cell suspensions could be stimulated to generate antibody responses in culture. At the time, this was the one system in which a primary immune response could be induced to an added antigen, sheep red blood cells. In contrast, other studies of immune responses were emphasizing the use of polyclonal mitogens, rather than specific antigens, or the use of cells that had already
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
been primed or immunized beforehand in vivo. Distinctive DCs were recognized in mouse spleen. Subsequent investigations revealed that these previously unknown cells could organize many layers of immune function, both initiating and restraining (tolerizing) antigen-specific immunity and recently, immune memory. In this chapter, we discuss the preparation of DCs from mice, as well as the tissues in which they are found and through which they migrate. Some methods that are currently used to study mouse DCs are provided in the Appendix. Then we outline some of the special features and functions of DCs, with emphasis on knowledge gained from genetically defined mice. The mouse strains cited in this review are listed in Table 4-1.
TABLE 4-1
GENETICALLY MODIFIED MOUSE STRAINS USEFUL FOR THE STUDY OF DENDRITIC CELLS Modifications that primarily affect DCs CD11c−DTR A diphtheria toxin receptor (DTR)/DT−based system that allows the inducible, short−term (1–2 days) ablation of DCs, e.g., DC−depleted mice fail to present cell−associated antigen to cross−prime cytotoxic T lymphocyte (CTL) precursors (Jung et al. 2002) and develop maximal memory T cell responses (Zammit et al. 2005). Bone marrow chimeras allow for repeated injection of DT and long−term ablation of DCs (Zammit et al. 2005). Langerin (CD207)−DTR mice
A DTR/DT−based system for inducible ablation of LCs up to 4 weeks without affecting the skin environment. The dermal DC compartment remains normal. In Langerin−DTR mice, contact hypersensitivity is decreased but not absent, indicating that dermal DCs also contribute (Bennett et al. 2005).
B6CD11c−Eα
Targeted expression of MHC class II gene (I−E) to DCs in vivo to show that thymic DCs are sufficient to negatively select I−E reactive CD4+ T cells (Brocker et al. 1997).
Langerin−/−
Disruption of the langerin/CD207 gene abolishes Birbeck granules without affecting LC function (Kissenpfennig, Ait−Yahia, et al. 2005).
Langerin−EGFP, Langerin−DTREGFP
LC motility and migration to lymph nodes are triggered by skin inflammation. Dermal DCs arrive in lymph nodes earlier than LCs and colonize distinct areas (Kissenpfennig, Henri, et al. 2005).
Antigen capture and presentation RIP−mOVA, RIP−YSS
Transgenic mice expressing ovalbumin (OVA) specifically in pancreatic β−islet cells. OVA−specific, OT−I, T cells only proliferate in the draining pancreatic lymph nodes, and the presentation of tissue−specific antigen depends on bone marrow–derived CD8α+ DCs (Belz et al. 2002; Kurts et al. 1996).
DEC−205−/− (or CD205−/−)
DEC−205 is a multilectin receptor on a subset of DCs. Antigens delivered to DEC−205 are endocytosed and processed efficiently for T cell priming (Bonifaz et al. 2002; Hawiger et al. 2001).
MR−/− (mannose receptor) (or CD206−/−)
MR, a multilectin receptor on macrophages and DCs, is homologous to DEC−205/CD205. It influences serum glycoprotein homeostasis; e.g., MR−/− mice are defective in clearing proteins bearing accessible mannose and N−acetylglucosamine residues and have elevated levels of eight different lysosomal hydrolases (Lee et al. 2002).
cx3cr1GFP/GFP
Transgenic mice with fractalkine receptor CX3CR1 replaced by green fluorescent protein. CX3CR1−dependent processes control host interactions of specialized DCs with commensal and pathogenic bacteria; e.g., lamina propria DCs depend on the CX3CR1 to form transepithelial dendrites, which enable the cells to directly sample luminal antigens. CX3CR1 also controls the clearance of entero−invasive pathogens by DCs (Niess et al. 2005).
Development, differentiation and homeostasis
Because none of these transcription factors is DC−restricted, these knockout mice often have defects in other cells, e.g., T cells and B cells.
Fms−like tyrosine kinase 3 ligand (flt3L)4−/−
Flt3L−/− mice have deficient hematopoiesis affecting DCs and NK cells (McKenna et al. 2000).
IRF−2−/−
IRF−2−/− mice have a selective loss of the CD8α− DC subset (Honda et al. 2004; Ichikawa et al. 2004).
IRF−4−/−
IRF−4−/− mice have a selective loss of the CD8α− DC subset (Suzuki et al. 2004).
IRF−8−/−
IRF−8 is essential for the development of mouse type I interferon−producing cells and CD8α+ DCs (Schiavoni et al. 2002). IRF−8 is involved in the maturation of CD8α− DCs (Aliberti et al. 2003).
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
CELLS
IN
THE
137
MOUSE
TABLE 4-1
GENETICALLY MODIFIED MOUSE STRAINS USEFUL FOR THE STUDY OF DENDRITIC CELLS—cont’d NF−κB (RelB−/−, p50−/−RelA−/−, p50−/−cRel−/−)
DC development and survival require distinct nuclear factor (NF)−κB subunits. DC development in doubly deficient p50−/−RelA−/− mice is significantly impaired. In contrast, DCs from p50−/−cRel−/− mice develop normally, but survival and IL−12 production are impaired (Ouaaz et al. 2002). RelB is important for normal thymic medullary structure and development of splenic CD8α− DCs (Wu et al. 1998).
TGF−β−/−, Id2−/−
Id2−/− mice lack LCs, and the splenic CD8α+ DC subset is markedly reduced. Mice deficient for TGF−β also lack LCs. In DCs, TGF−β induces Id2 expression, which represses B cell genes (Borkowski et al. 1996; Hacker et al. 2003).
Ikaros−/−
Ikaros−/− mice have reduced numbers of T cells and CD8α+ DCs (Wu et al. 1997).
LT−βR−/−
LT−βR is required for homeostasis of splenic DCs (Kabashima et al. 2005).
DC-T cell interaction CD11c−EYFP
Transgenic mice with DCs expressing enhanced yellow fluorescence protein at high levels permit examination of DCs with two−photon microscopy in live mice. Steady−state DCs form an extensive network in which the DCs do not move translationally but instead probe adjacent T cells with their processes. Early antigen−dependent T cell arrest on DCs is a shared feature of the tolerance and priming that is associated with T cell proliferation (Lindquist et al. 2004; Shakhar et al. 2005).
TSLP−/−
TSLP is required to mount a CD4+ T cell–mediated inflammatory response. It not only acts directly on naive CD4+ T cells to promote their proliferation in response to antigen but also exerts an effect indirectly through DCs to promote Th2 differentiation of CD4+ T cells (Al-Shami et al. 2005).
Signaling and survival MyD88−/−
MyD88−deficient mice have a profound defect in the activation of antigen−specific Th1 but not Th2 immune responses (Schnare et al. 2001). MyD88 is indispensable for inflammatory cytokine production in IL−1 receptor/TLR signaling. DCs from MyD88−deficient mice fail to produce inflammatory cytokines (TNF−α, IL−6, and IL−12) in response to IL−1 or other TLR ligands, such as pam−3−cys and CpG−DNA. However, they do mature in response to lipopolysaccharide (TLR4 ligand) or double−stranded RNA (TLR3 ligand) (Kaisho et al. 2001), which uses TRIF as a TLR adapter.
CD40−/−, CD40L−/−
Signaling through CD40 can replace the requirement for TH cells, indicating that T−cell “help,” at least for generation of CTLs by cross−priming, is mediated by signaling through CD40 on the antigen−presenting cell (Bennett et al. 1998). CD40 ligand−independent T helper cell activation requires the TNF family member, TRANCE (Bachmann et al. 1999). CD40 is critical for NKT cell–activated DC maturation (Fujii et al. 2004). Other than CD40L, there may be alternative ligands for CD40 such as Mycobacterium tuberculosis hsp70 (Lazarevic et al. 2003).
γ chain−/−, FcγRIIB−/−
Immune complexes can function to maintain tolerance through binding to inhibitory FcγRIIB on DCs, but immune complexes can also serve as potent immunogenic stimuli by selective engagement of activating FcγRs (Kalergis and Ravetch 2002).
TRAF6−/−
TRAF6 is an adapter molecule for signaling through IL−1 receptors, TLRs, and TNF receptors. TRAF6 is required for DC responses to some maturation stimuli. TRAF6−/− bone marrow chimeras lack the CD8α− DC subset (Kobayashi et al. 2003).
DC-B cell interaction SOCS1−/−
SOCS1 plays an essential role in normal DC functions and suppression of systemic autoimmunity. SOCS1−/− DCs accumulate in the thymus and spleen and produce high levels of BAFF/BLyS and APRIL, resulting in the aberrant expansion of B cells and autoreactive antibody formation in vivo (Hanada et al. 2003).
DC-innate lymphocyte interaction Jα18−/−, MyD88−/−, CD40−/−
NKT cells mediate DC maturation in a MyD88−independent but CD40−dependent manner (Fujii et al. 2003, 2004).
CXCR3−/−, CCR7−/−, IFN−γ−/−
Mature DCs recruit NK cells to lymph nodes in a CCR7− and CXCR3−dependent manner, and the NK cells provide IFN−γ for Th1 priming (Martin-Fontecha et al. 2004).
IL−15−/−
The IL−15/IL−15R interaction is critical in the early activation of antigen−presenting cells and plays an important role in the innate immune system (Ohteki et al. 2001). Continued
138
KANG
LIU,
ANNA
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
TABLE 4-1
GENETICALLY MODIFIED MOUSE STRAINS USEFUL FOR THE STUDY OF DENDRITIC CELLS—cont’d DC migration CCR2−/−, CCR5−/−
The recruitment of new LCs is dependent on their expression of the CCR2 chemokine receptor and on the secretion of CCR2−binding chemokines by inflamed skin (Merad et al. 2002). Recruitment of the TNF/iNOS−producing (Tip)−DC subset in spleens of L. monocytogenes–infected mice is dependent on CCR2 and independent of CCR5 (Serbina et al. 2003; Zhong et al. 2004).
CCR6−/−
CCR6 mediates DC localization, lymphocyte homeostasis, and immune responses in mucosal tissue. In CCR6−/− mice, DCs expressing CD11c and CD11b are absent from the subepithelial dome region of Peyer’s patches (Cook et al. 2000).
CCR7−/−, plt/plt (CCL19 and CCL21−/−)
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs (Forster et al. 1999). plt/plt mice lacking CCR7 ligands, CCL19 and CCL21, have defects in lymphocyte homing and DC localization (Gunn et al. 1999). CCR7 also governs skin DC migration under inflammatory and steady−state conditions (Ohl et al. 2004). CCR7 ligands, CCL19 and CCL21, induce a proinflammatory differentiation program in DCs (Marsland et al. 2005).
CCR8−/−
CCR7 and CCR8 pathways are used by monocyte−derived DCs during mobilization from skin to lymph nodes (Qu et al. 2004).
CXCR3−/−, IFNR−/−
Plasmacytoid DCs migrate to inflamed lymph nodes, produce INF−α, and help lymph node DCs to induce antiviral CTLs (Asselin-Paturel et al. 2005; Yoneyama et al. 2004, 2005)
II.
SOME PROPERTIES THAT HAVE BEEN USED TO IDENTIFY MOUSE DENDRITIC CELLS
Morphological and physical properties were helpful in the initial research on DCs, which occurred before the monoclonal antibody (mAb) revolution (reviewed in Steinman 2004). A useful feature was the low buoyant density of DCs, which permitted enrichment over density gradients, for example, in dense bovine serum albumin solutions (Steinman and Cohn 1974). Many of the DCs from mouse spleen were adherent cells, but, in contrast to macrophages and many other types of cultured cells, the DCs only had a transient capacity to adhere to plastic. The DCs could then be enriched by successive adherence and culture steps (Steinman et al. 1979). Before or after enrichment, DCs had an unusual cell shape, continually forming and retracting cell processes or dendrites in many different directions. Interestingly, these morphological features of DCs have now been observed in vivo in studies of living lymph nodes, using mice genetically modified so that DCs brightly express enhanced yellow fluorescent protein under the control of a CD11c promoter. With two-photon microscopy, one can observe the processes of DCs by constantly probing the environment in situ (Lindquist et al. 2004). In addition to their morphology, the cell surface composition of the newly discovered DCs proved to be distinct. Unlike other accessory cells such as macrophages and B cells, DCs were found to express high levels of major histocompatibility complex (MHC) products (Nussenzweig et al. 1981; Steinman et al. 1979), which are required for antigen presentation to T lymphocytes. At the time, the function of the MHC in presenting antigenic peptides was not known, but the MHC was known to
be responsible for encoding major antigens to stimulate transplant rejection. DCs were tested as stimulators of rejection in vitro in the mixed leukocyte reaction (MLR, originally known as the mixed lymphocyte reaction), in which MHC class II products on the cells from one mouse strain stimulate vigorous proliferation by T cells of another strain. Surprisingly DCs were unusually potent, whereas other class II–bearing cells were inactive, including MHC class II–bearing B lymphocytes and macrophages (Steinman and Witmer 1978; Steinman et al. 1980, 1983; Van Voorhis et al. 1983). Likewise, DCs were powerful accessory cells for inducing a T cell response to a so-called “nominal” antigen (Nussenzweig et al. 1980). These experiments were the basis for two new streams of research: DCs were a distinct type of leukocyte, and the initiation of T-cell mediated immunity could be achieved when DCs were presenting antigen. A series of DC-restricted mAbs was also made in the 1980s, including 33D1 (Nussenzweig et al. 1982), NLDC-145 (specific for the adsorptive endocytosis receptor, DEC205/ CD205; Kraal et al. 1986), and N418 (specific for the CD11c integrin; Metlay et al. 1990). These mAbs helped to establish the distinct functions of DCs within heterogeneous cell suspensions from mouse spleen, in which the DCs comprised only ~1% of the leukocytes. 33D1, for example, was used to selectively deplete DCs from mouse spleen, and this ablated the bulk of the MLR stimulating activity (Steinman et al. 1983) and the primary antibody response (Inaba et al. 1983). N418 was used to select DCs by fluorescence-activated cell sorting, and this process showed that the CD11c+ cells were the principal stimulators of the MLR (Crowley, Inaba, Steinman, 1990). 33D1 and N418 were also used in experiments in which DCs proved to be the major cells capturing soluble protein antigens that
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
were administered intravenously to mice (Crowley, Inaba, Witmer-Pack, et al. 1990). Antibodies to DEC-205 and 33D1 now have a new role in studies of DC function in intact lymphoid organs. The approach is to introduce antigens into the antibodies by chemical conjugation or genetic engineering. The antibodies then target the antigen selectively and efficiently to DCs in situ. This permits an interrogation of DC function in situ under different conditions, either in the steady state without ostensible infection or inflammation and after administration of various DC stimuli (Bonifaz et al. 2002, 2004; Boscardin et al. 2006; Hawiger et al. 2001; Trumpfheller et al. 2006). Selective delivery of antigens within antibodies to these DC receptors increases the efficiency of antigen presentation to T cells more than 100-fold. Anti-CD11c antibodies also are frequently used to select DCs from different mouse tissues. The distinguishing feature of DCs is that they express very high levels of CD11c. Other cells, in particular some stimulated natural killer (NK) cells, can express CD11c to some extent. In contrast to DCs, NK cells are DX5/CD49b positive and express only low levels of CD80, CD86, and MHC class II products. In tissue sections of normal mice and in mice in which the CD11c promoter is used to express various markers such as MHC class II or green fluorescent proteins (Brocker 1997; Brocker et al. 1997; Kerksiek et al. 2005; Lindquist et al. 2004), the MHC class II-rich DCs are the main cell type that is identified as CD11c positive.
III.
GENERATION OF DCS
FROM PROLIFERATING PROGENITORS Cytokines that allow DC progenitors to expand in culture have been identified. The resulting increased availability of DCs has significantly stimulated research. The first system to be identified involved the application of granulocyte-macrophage colony-stimulating factor (GM-CSF) to blood (Inaba, Steinman, et al. 1992) and bone marrow cell suspension cultures (Inaba, Inaba, et al. 1992) (see Appendix). Some laboratories find it valuable to add interleukin (IL)-4 to these cultures. More recently, flt-3 ligand (flt-3L) has been used. flt-3L appears to be the major cytokine responsible for the production of DCs in vivo (D’Amico and Wu 2003; Maraskovsky et al. 2000; McKenna et al. 2000; Tussiwand et al. 2005), whereas GM-CSF may primarily be used to mobilize DCs during infection, the setting in which GM-CSF was first identified (reviewed in Metcalf 1985). To use flt-3L, the cytokine is given for at least 7 days, whereupon the numbers of DCs in various lymphoid tissues expands >10-fold. The DCs that are produced in GM-CSF– and flt3L–expanded cultures have some differences, particularly with regard to subsets of DCs. DCs generated with GM-CSF consist primarily of cells termed myeloid, DCs that resemble the CD8α− DC subset in mouse spleen (see below). flt-3L–expanded DCs, on the other hand, include both plasmacytoid and myeloid DCs
CELLS
IN
THE
MOUSE
139
(Gilliet et al. 2002), and the latter include cells with features of CD8α+ spleen DCs, such as enhanced presentation of ovalbumin antigen on MHC class I products (Naik et al. 2005). At this point, neither GM-CSF nor flt-3L is being used to generate cells with the properties of Langerhans cells (LCs), although a recent report indicates that the addition of estrogen to the GM-CSF cultures can increase the development of cells with properties of LCs (Mao et al. 2005). In contrast, LCs are readily identified in an important human cell culture system in which CD34+ progenitors are expanded with GM-CSF and tumor necrosis factor (TNF)-α (Caux et al. 1992). In all systems used for the expansion of DC progenitors, the progeny are primarily in an immature functional state, which means that the cells are able to capture antigens but require further stimuli to differentiate into cells that in turn initiate many pathways of lymphocyte differentiation (Inaba et al. 2000; Pierre et al. 1997; Turley et al. 2000). One stimulus for maturation is to disrupt the clusters of immature DCs and replate the cells in a fresh culture vessel, whereas other stimuli include ligands for Toll-like receptors, for example, lipopolysaccharide.
IV.
DISTRIBUTION OF DCS
IN LYMPHOID TISSUES DCs are abundant in lymphoid tissues. In the thymus, DCs are restricted to the medulla. The thymus is the primary lymphoid organ in which developing T cells rearrange T cell receptor genes to produce a diverse repertoire of clones, each with a single receptor. These T cells are then educated, undergoing positive selection for affinity to self-MHC products followed by elimination, tolerance, or negative selection against reactivity to self-antigens. DCs function in this central tolerance (Matzinger and Guerder 1989, Zal et al. 1994). When antigens are selectively expressed under the control of the mouse CD11c promoter, the thymic DCs function in negative rather than positive selection (Brocker et al. 1997). Recent data with human thymus reveal that thymic DCs, when matured by thymic stromal lymphopoietin, are also able to stimulate CD4+ CD25− single positive thymocytes to proliferate and differentiate into CD4+ CD25+ suppressor or regulatory T cells (Watanabe et al. 2005). This would mean that DCs play a critical role in the thymic development of natural suppressor T cells, which is a dominant or regulatory form of peripheral tolerance. In peripheral lymphoid tissues, DCs are most abundant in the T cell areas, that is, the periarterial sheaths of spleen, the deep cortex of lymph nodes, and the interfollicular zones of mucosaassociated lymphoid tissues such as Peyer’s patches and nasal-associated lymphoid tissue. As mentioned, DCs in the T cell area of living lymph nodes comprise a widely distributed network in which the DCs constantly probe adjacent T cells with their dendrites (Lindquist et al. 2004). There are additional important pools of DCs in lymphoid tissues, that is, DCs
140
KANG
LIU,
ANNA
in the marginal zone of the spleen, the subcapsular sinus, and the outer cortex of lymph nodes and beneath the antigen-transporting epithelium of mucosa-associated lymphoid tissue. These DCs can function in antigen capture. In the B cell area, the major accessory cell is the follicular dendritic cell (FDC). The nomenclature may seem confusing, but at the time of the discovery of DCs, FDCs were known as “dendritic macrophages” and “dendritic reticular cells” (Nossal et al. 1968), and there was a possibility that these two new cell types—eventually to be called DCs and FDCs—were related (Chen, Adams, et al. 1978; Chen, Frank, et al. 1978). However, FDCs are nonhematopoietic cells, and they specialize in retention of intact antigens on their labyrinthine cell surface. The antigens are retained via Fc receptors or C3 receptors. DCs, in contrast, are bone marrow derived and specialize in the presentation of processed antigens. Nevertheless, DCs also are able to present intact antigens to B cells (Balazs et al. 2002; Wykes et al. 1998). Although this may take place primarily in extrafollicular sites in the so-called “plasmablast reaction” (Garcia De Vinuesa et al. 1999), it is possible that DCs enter B cell follicles under some conditions.
V.
DCS IN NONLYMPHOID TISSUES
The bone marrow is the source for DCs in several sites. The rat was used in many of the early studies of DCs in nonlymphoid tissues. For example, DCs were found in the interstitial spaces of many organs, such as heart and kidney but not brain (Hart and Fabre 1981). DCs were noted along mucosal surfaces such as the airway (Holt et al. 1987) and intestine (Maric et al. 1996). Using genetically modified mice, Niess et al. (2005) have demonstrated that in the ileum, DCs can extend processes through the epithelium, without disrupting the epithelial barrier, and that this requires CX3CR1 fractalkine receptors. DCs are also found in the circulation, both blood and afferent lymphatics (reviewed in Randolph et al. 2005). An important discovery was that bone marrow progenitors gave rise to LCs in the skin (Frelinger et al. 1979; Katz et al. 1979). Formally speaking, LCs were the first DCs to be visualized in 1868 by Paul Langerhans, although over the ensuing century, scientists considered LCs to be of neural or neural crest origin (reviewed in Rowden 1981; Stingl and Shevach 1991). This view changed with the discoveries that mouse LCs were bone marrow derived and that LCs in other species had many features that were more typical of leukocytes, including Fc receptors (Stingl et al. 1977), MHC class II antigens (Rowden et al. 1977), and antigen presentation to primed T cells (Stingl et al. 1978). Recent experiments in bone marrow chimeras and in parabiotic mice have demonstrated, surprisingly, that whereas LCs are hematopoietic cells, the bone marrow input is primarily used during inflammation and not in the steady state, in which LCs primarily undergo self-regeneration (Merad et al. 2002, 2004).
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
Mouse LCs have been valuable for discovering the basic properties of DCs, particularly their differentiation from immature antigen-capturing cells to mature immunostimulatory ones (Inaba et al. 1986, Pure et al. 1990; Romani, Inaba, et al. 1989, Romani, Koide, et al. 1989; Schuler and Steinman 1985). LCs also provide a model to study DC migration from a tissue such as skin via lymphatics to the draining lymph node (Larsen et al. 1990; Macatonia et al. 1987). LCs in the epithelial layer of the skin can take up particles (Reis e Sousa et al. 1993) and contain distinct granules, known as Birbeck granules, which are a type of endocytic organelle (Romani et al. 2005). LCs express Fc receptors and MHC class II products in situ, but the expression of FcR drops dramatically in maturing cultured LCs (Romani, Inaba, et al. 1989; Schuler and Steinman 1985), whereas the MHC class II molecules redistribute from intracellular compartments to the cell surface (Pierre et al. 1997). Cells similar to LCs are found in other stratified squamous epithelia such as the vagina, cervix, anus, pharynx, and esophagus. Many other tissues of the mouse contain DCs in an immature state, including the dermis and the interstitial spaces of other organs. However, Birbeck granules and high levels of intracellular MHC class II products are not typically found in interstitial DCs in mouse peripheral tissues. LCs can act as potent inducers of T cell responses when they are allowed to mature in suspension culture (Schuler and Steinman 1985) or after migration from skin explants (Larsen et al. 1990). However, the roles of LCs in vivo are less clear and are coming under renewed scrutiny. For example, in herpes infection of the skin and vagina, LCs are not the major presenting cells for viral antigens in the draining lymph nodes (Allan et al. 2003; Zhao et al. 2003). It is possible that the infected LCs die and are presented by other DCs in the dermis or in the lymph node (Inaba et al. 1998). New genetic tools for studying LCs in mice have recently been generated. When the Langerin gene is ablated, the LCs lack Birbeck granules, but other abnormalities have yet to be defined (Kissenpfennig, Ait-Yahia, et al. 2005). Of some interest are mice that express a diphtheria toxin receptor under the control of the Langerin/CD207 promoter (Bennett et al. 2005) (where Langerin is a lectin that is abundant in LCs and is responsible for the formation of Birbeck granules; Valladeau et al. 2000). Administration of diphtheria toxin leads to the selective depletion of LCs for several weeks. Another tool is a CD207 promoter knockin mouse, which expresses enhanced green fluorescent protein (EGFP) only in LCs (Kissenpfennig, Henri, et al. 2005). These new mouse models make it possible to distinguish the behavior and functions of LCs from those of dermal DCs. LCs are for the most part sessile in the steady state, but application of a contact allergen induces increased LC motility and migration to lymph nodes. Dermal DCs also migrate to the lymph nodes during contact sensitization, but they do so earlier than LCs, and they colonize distinct areas after they arrive in the lymph nodes (Kissenpfennig, Henri, et al. 2005). Ablation of LCs does not ablate contact hypersensitivity, suggesting that dermal DCs contribute to T cell priming in this
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
strong cell-mediated immune response (Bennett et al. 2005; Kissenpfennig, Henri, et al. 2005).
VI.
LIFE SPAN AND TURNOVER OF DCS
Irradiation eliminates many DCs in lymphoid organs, whereas reconstitution with bone marrow cells leads to their recovery in 1–2 weeks. Many DCs have a short life span, with a half-life of 1.5–3 days (Kamath et al. 2000). In contrast, a recent study with bromodeoxyuridine pulse labeling and with parabiotic mice has revealed that 5–10% of the DCs are in cell cycle and that the replacement of DCs from the blood is actually relatively slow (Kabashima et al. 2005). In other words, DCs in spleen, surprisingly, have some of the features recently documented for LCs, which regenerate locally and resist repopulation from the blood and marrow unless inflammation in the skin is induced (most likely through the production of CCR2-binding chemokines; Merad et al. 2002, 2004). Therefore, homeostasis of DCs in lymphoid organs is maintained through a balance of rapid local regeneration, death, and slow replenishment of precursors from blood. Current thinking is that when bone marrow–derived DC precursors arrive in lymphoid organs, they seed the tissue and wait for cues from their microenvironment (e.g., lymphotoxin β) to develop into DC subsets, at least some of which have the capacity to divide locally.
VII. FEATURES OF DCS A.
Morphology
No other blood cell exhibits the shape and motility that are the basis for the term dendritic cell (Romani et al. 2005; Steinman and Cohn 1973). In situ, as in the skin, airways, and lymphoid organs, DCs are stellate and motile. When isolated and spun onto slides, DCs display many fine dendrites. In the electron microscope, the processes are long (>10 µm) and thin, either spiny or sheet-like. When alive and viewed by phasecontrast microscopy, DCs extend large, delicate processes or veils in many directions from the cell body. These bend, retract, and re-extend in a nonpolarized fashion for a day or more. Actin cables are scarce. The shape and motility of DCs fit their function, which is to select antigen-specific T cells for the initiation of adaptive T cell immunity and for clonal selection for purposes of antigen-specific tolerance and memory.
B.
Antigen Handling: Uptake, Processing, Presentation
During the early years of DC research, antigen handling by DCs was mostly taken for granted. In other words, one would
CELLS
IN
THE
MOUSE
141
inject an antigen and assume that DCs would capture it and present it to the immune system. Although this is true to some extent, it is now evident that DCs possess multiple specializations for the capture, processing, and presentation of antigens. Studies with mouse and human DCs reveal the existence of multiple endocytic receptors (reviewed in Figdor et al. 2002; Mellman and Steinman 2001). These include Fcγ receptors for immune complexes and antibody-coated cells; several C-type lectin receptors that are often restricted to select subsets of DCs such as the macrophage mannose receptor/CD206, Langerin/CD207, DC-SIGN/CD209, and DEC-205/CD205; several potential receptors for the uptake of dying cells; and receptors for heat shock proteins such as CD91 (Basu et al. 2001) and LOX-1 (Delneste et al. 2002). By delivering antigen to DCs via these receptors, the efficiency of antigen presentation in vivo can be enhanced by 100-fold or more (Bonifaz et al. 2002; Hawiger et al. 2001; Liu et al. 2002). After uptake, DCs process the ingested antigens via both MHC class I and MHC class II pathways. This leads to recognition by CD8+ and CD4+ T cells, respectively. The processing of nonreplicating or exogenous antigens onto MHC class I molecules is called “cross-presentation” or the “exogenous” pathway of antigen presentation. To assess the contribution of DCs to this nontraditional pathway, Jung et al. (2002) generated mice in which the CD11c promoter was used to drive expression of the human diphtheria toxin receptor (mice are not normally sensitive to diphtheria toxin). This development permitted the ablation of DCs in lymphoid tissues for 1–2 days. The mice were unable to process several different antigens through the exogenous pathway, indicating that DCs were a major cell type for cross-presentation to CD8+ T cells in vivo (Jung et al. 2002). DCs also are a major site for the expression of CD1 molecules (CD1d in mice and CD1a, b, c, and d in humans). These molecules are used to present different forms of glycolipid. The mouse has been of major importance in delineating the immunological consequences of presentation of glycolipids on CD1d. The pivotal discovery was that natural killer T (NKT) cells bear invariant T cell receptors specific for CD1d-glycolipid complexes (Kawano et al. 1997). The glycolipids can be of endogenous (Zhou et al. 2004), microbial (Kinjo et al. 2005; Mattner et al. 2005), or synthetic (Gonzalez-Aseguinolaza et al. 2002; Schmieg et al. 2003, 2005) origin. When mouse DCs present the synthetic glycolipid α-galactosyl ceramide, the DCs undergo extensive maturation and become potent stimulators of combined CD4+ and CD8+ T cell–mediated immunity (Fujii et al. 2003, 2004; Hermans et al. 2003). However multiple doses of this glycolipid can lead to the development of DCs that produce IL-10 and have regulatory properties (Kojo et al. 2005). Antigen uptake and/or processing seems to be particularly efficient in DCs, because nanomolar concentrations of antigen can suffice. This is much less than the micromolar levels typically employed to load antigens into other antigenpresenting cells. Extensive studies by Mellman and colleagues (reviewed in Trombetta and Mellman 2005) have uncovered another special feature of DCs, which is their extensive regulation
142
KANG
LIU,
ANNA
of the endocytic system during stimulus-dependent maturation (see next section). The uptake or endocytic activity of the DCs is dampened, the acidity and proteolytic activity of the deep endosomal lysosomal system are enhanced, and peptide MHC class II complexes actively form and move to the surface in discrete nonlysosomal organelles.
C.
Maturation of DCs
The development of DCs comprises two functionally distinct and phenotypically different stages. In most tissues, DCs are present in a so-called immature state, equipped to capture antigens but unable to carry out one of their classic functions, the initiation of a primary T cell response. These immature DCs can take up particles and microbes by phagocytosis, they can form large pinocytic vesicles in which extracellular fluid and solutes are sampled (“macropinocytosis”), and they express several receptors on their surface that mediate adsorptive endocytosis (e.g., C-type lectin receptors such as the macrophage mannose receptor and DEC-205 and Fc receptors). Immature DCs also express receptors that allow them to sense changes in the environment, including many Toll-like receptors (TLRs) for microbial ligands as well as receptors for different inflammatory cytokines. DCs then undergo extensive differentiation or maturation in response to different microbial and nonmicrobial stimuli. The differentiation program varies with the type of maturation stimulus. The stimuli can be microbial ligands for TLRs, TNF family members such as TNF and CD40 ligand (CD40L), heat shock proteins, different types of innate lymphocytes (NK, NKT, and γδ T cells), and immune complexes for Fc receptors. Genetically defined mice have been essential to uncover the intricate function of the Fcγ receptor (FcγR) family (Ravetch and Lanier 2000). FcγRs have activating and inhibitory forms, the latter being due to the presence of an immunoreceptor tyrosine-based inhibition motif that was first discovered in the mouse FcγRIIB (Muta et al. 1994). Mice that genetically lack the FcγRIIB undergo maturation when challenged with immune complexes, because the activating, immunoreceptor tyrosine-based activation motif–associated FcγRIIA is no longer subject to inhibition (Kalergis and Ravetch 2002). These observations have been extended in mice and humans through the identification of mAbs that selectively block inhibitory receptors (Dhodapkar et al. 2005; Samuelsson et al. 2001). Once DCs have captured antigen, the capacity to take up additional antigens rapidly declines if there is also a signal to mature (Garrett et al. 2000; Romani, Koide, et al. 1989). During maturation, antigen–MHC class II complexes are formed within deep endosomal and MHC class II–positive compartments (Inaba et al. 2000). The complexes move to the cell surface within distinct nonlysosomal vesicles, which also contain high levels of the CD86 costimulator (Chow et al. 2002; Turley et al. 2000). Functional maturation of DCs also includes
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
major changes in cytokine and chemokine profiles (and their receptors) (Sallusto et al. 1999), many of which, such as IL-12 and type I interferons, are immune enhancing (Honda et al. 2005; Takaoka et al. 2005). In sum, maturing DCs increase the display of surface MHC-peptide complexes, produce large amounts of cytokines, and upregulate numerous cell surface costimulatory molecules such as CD40 and CD86. This maturation process endows the DCs with the molecular machinery for the initiation of immunity, but the specific maturation program and type of immune response is influenced by the nature of the maturation stimulus (described later). Transcriptional profiling with gene chips has shown the extensive nature of the differentiation of DCs during maturation. Expression of hundreds of genes changes by 4-fold or more after triggering of immature mouse DCs with a single TLR ligand. These changes are not coordinated, with some genes changing rapidly within hours and others taking much longer (Granucci et al. 2001). One of the features of the maturing DC is a high level of the cell surface costimulator, CD86 or B7-2 (Caux et al. 1994; Inaba et al. 1994). However, increased CD86 does not by itself dictate the development of T cell immunity. Fujii et al. (2004) showed that DCs maturing in response to NKT cells are able to present antigens on MHC class I and II, produce cytokines, and express high levels of CD86. Yet CD40 ligation was additionally vital to initiate immunity. Likewise Sporri and Reis e Sousa (2005) showed that DCs lacking the appropriate TLR could express high levels of CD86 when the cells were bystanders to other DCs that were directly responding to TLR ligation. However, bystander DCs were unable to initiate immunity. Thus, CD86 upregulation accompanies DC maturation in many instances but is by itself insufficient to explain the T cell immunizing properties of mature DCs.
D.
DC Subsets
DCs are composed of several subsets that differ significantly in their phenotype, localization, and function. In mouse lymphoid tissues, the subsets are often identified on the basis of CD4 and CD8 expression (reviewed in Shortman and Liu 2002). One functional difference involves receptors for antigen uptake. CD8+ DCs express high levels of DEC-205/CD205, Langerin/CD207, and CD36 molecules, whereas CD8− DCs express 33D1 (Crowley et al. 1989). DCs subsets are found in the thymus, spleen, lymph nodes, Peyer’s patches, and the liver, although the percentage of each subset and often cell surface markers vary from organ to organ. LCs and dermal DCs in the skin are a source of at least two other DC subsets in lymph nodes. LCs give rise to lymph node DCs that express Langerin and DEC-205 but low levels of CD8 (Henri et al. 2001). The expression of the CD45 isoform B220 was important in defining the mouse functional counterpart of human plasmacytoid DCs (Asselin-Paturel et al. 2001; Bjorck 2001;
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
Nakano et al. 2001). These are found in all mouse lymphoid organs and are characterized by a capacity to produce large amounts of type I interferon in response to nucleic acids, including inactivated viruses (Asselin-Paturel et al. 2001). Plasmacytoid DCs are a major cell type expressing the TLR7 and TLR9 receptors for RNA and DNA. For a period of time, CD8+ and CD8− DC subsets were thought to have distinct origins from lymphoid and myeloid progenitors, respectively. More direct studies on this issue have indicated that each subset, as well as plasmacytoid DCs, can derive from either type of progenitor (Chicha et al. 2004; Manz et al. 2001; Traver et al. 2000). At this point, it should be mentioned that DC reconstitution assays utilize irradiated recipients, which might allow DC precursors to express homing and differentiation potentials that are not identical to normal physiology. With analyses of knockout mice, researchers have begun to identify transcription factors that play an important role in controlling the development of different DC subsets, for example, RelB, interferon regulatory factor (IRF)-2, and IRF-4 for CD8− DCs and IRF-8 and Ikaros for CD8+ DCs. Although these transcription factors are not DC specific, the findings indicate that DC subsets result from distinct transcriptional programs. DC subsets are also proving to have distinct functional properties, and the definition of these functions, particularly in vivo, represents a major frontier in DC biology. As mentioned, DC subsets differ in their ability to capture antigens, depending on their cell surface receptor expression. CD8+ splenic DCs specialize in capturing many sources of dying cells, including targets killed by NK cells; yet both CD8+ and CD8− splenic DCs phagocytose other particles such as injected latex beads (Iyoda et al. 2002). DC subsets also differentially express receptors for maturation stimuli. TLR3 is preferentially expressed on CD8+ DCs, TLR5 on CD8− DCs, and TLR7 and TLR9 primarily on plasmacytoid DCs (Edwards et al. 2003). This specialization suggests that different DC subsets respond to different infections, depending on their cell surface receptor profile. On the other hand, both CD8+ and CD8− DC subsets express CD40 in the steady state and mature in response to αCD40 injection. Antigen processing by different DC subsets also can differ. The CD8+ subset of DCs more effectively presents exogenous antigens onto MHC class I (Wilson et al. 2004), whereas plasmacytoid DCs are typically weak at processing nonreplicating antigens onto either MHC class I or II products. More recently, a type of DC termed the Tip-DC has been identified during infection of mice with Listeria monocytogenes. During this bacterial infection, Tip-DCs are evident in the white pulp of the spleen and produce high amounts of the protective molecules, TNF-α, and inducible nitric oxide synthase (iNOS; Serbina et al. 2003).
E.
Migration of DCs
The proper localization of DCs to secondary lymphoid tissues is a critical event for optimal immune responses (reviewed
CELLS
IN
THE
MOUSE
143
in Randolph et al. 2005). In the steady state, expression of lymphotoxin β receptor (LT-βR) by circulating DC precursors promotes DC homeostasis in the spleen and lymph nodes. Lymphotoxin 1 and 2, typically secreted by B cells, regulates cell division. Therefore, mice lacking LTβR have reduced numbers of DCs in lymphoid tissues (Kabashima et al. 2005). In the steady state, DCs also reside in peripheral tissues where they exert a sentinel function for incoming antigens (self, environmental, tumor, and microbial). Upon microbial contact or stimulation by inflammatory cytokines, these DCs traffic in increased numbers via the afferent lymphatics to the T cell areas of the lymph node to initiate immune responses. Increased expression of CCR7 is a characteristic feature of conventional DC maturation induced by many different stimuli, and the corresponding chemokines, CCL19 and CCL21, are expressed in vivo by lymphatic endothelium and stromal cells in the lymph nodes (Cyster 1999; Martin-Fontecha et al. 2003). However, additional lipid mediators also influence migration (Angeli et al. 2004; Kabashima et al. 2003; Robbiani et al. 2000). During maturation of plasmacytoid DCs in response to TLR7 or TLR9 agonists, the cells move outward from the central to peripheral (marginal zone) regions of the splenic white pulp nodule, and this maturation is dependent on type I interferons; in contrast, conventional DCs are only partially dependent on type I interferons for their maturation and do not require these cytokines for activation-induced migration from the marginal zone to the central T cell zones in the spleen (Asselin-Paturel et al. 2005). It is often not appreciated that, even in the absence of invading pathogens, some DCs are always migrating from tissues in lymphatics to lymph nodes. Studies of afferent lymph are currently difficult in mice, but in rats, for example, DCs along liver sinusoids move in hepatic lymphatics to celiac lymph nodes (Matsuno and Ezaki, 2000; Matsuno et al. 1996), and DCs from intestine migrate to mesenteric lymph nodes (Huang et al. 2000; Pugh et al. 1983). These cells are not found in the efferent lymph, indicating that most of the migrating DCs die after their arrival in lymphoid tissues. The DCs that migrate in the steady state might have several functions: to replenish immature populations, to transport self or environmental antigens, or to be on patrol to identify invaders. Thus, DC migration in vivo has many potential roles in DC homeostasis and function. DC migration is a regulated process, controlled, for example, at the level of chemokine production and chemokine receptor expression and function (reviewed in Randolph et al. 2005). Some immature DCs can express a repertoire of chemokine receptors (e.g., CCR1, CCR2, CCR5, CCR6, and CXCR4) that bind inflammatory chemokines (e.g., CCL5, CCL2, CCL3, CCL4, CCL20, and CXCL12). Subsequent DC activation and maturation are associated with the downregulation of chemokine receptors and the de novo expression of CCR7, the receptor for CCL19 and CCL21. The crucial role of CCR7 and its ligands is clearly observed in vivo in mice deficient for these proteins. In mice homozygous for an autosomal recessive
144
KANG
LIU,
ANNA
mutation, paucity of lymph node T cells (plt), naive T cells fail to home to secondary lymphoid organs. The plt mutation is associated with a deficit in the expression of CCL21 within secondary lymphoid organs and a defect in CCL19 as well. As a consequence of the lack of CCL21 within secondary lymphoid organs, DCs from these mice fail to accumulate in the spleen and in the T cell areas of lymph nodes (Gunn et al. 1999). Similarly, CCR7−/− mice show defective architecture of secondary lymphoid organs, a defective homing of DCs and lymphocytes, and defective entry of DCs into lymphatic vessels at peripheral sites both in the steady state and inflammation conditions (Forster et al. 1999). CCL19 and CCL21 also increase the maturation and proinflammatory differentiation of DCs (Marsland et al. 2005). Therefore, chemokine–chemokine receptor interactions not only orchestrate the migration of DCs migration but also influence their immunogenic potential for T cells. There are many other examples in which specific chemokines control the traffic of select populations of DCs (Table 4-1). In skin exposed to ultraviolet light, LCs disappear and are replaced in 2 weeks. The recruitment of LC precursors from blood is dependent on their expression of CCR2 (Merad et al. 2004). During murine listeriosis, CCR2 is also required for Tip-DCs to migrate into the spleen (Serbina et al. 2003). Migration of plasmacytoid DCs into inflamed lymph nodes and their redistribution during inflammation depend on CXCR3 and CCR7. CCR6 is used by DCs to populate epithelial surfaces during inflammation (Dieu et al. 1998; Greaves et al. 1997; Iwasaki and Kelsall 2000). In the steady state, recent evidence shows that CXCL14 is important for LC progenitors to establish themselves in the skin (Schaerli et al. 2005). All of these findings indicate that the differential expression of chemokine receptors by DCs (and their subsets) at different stages of their life history determines their location in vivo.
VIII. A.
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
[Toll/IL-1 receptor domain-containing adaptor inducing IFN-β], TRAF6 [TNF receptor–associated factor], and IRFs) have benefited enormously from genetic alterations in mice (Alexopoulou et al. 2001; Hayashi et al. 2001; Hemmi et al. 2000, 2002; Hoebe et al. 2003; Honda et al. 2005; Kaisho and Akira 2001; Kawai et al. 1999; Kobayashi et al. 2003; Poltorak et al. 1998, Takaoka et al. 2005). Interestingly, simultaneous signaling through two TLRs, which use MyD88 and TRIF adapters, leads to greatly enhanced IL-12 production in a type I interferon– dependent manner (Gautier et al. 2005). In addition to TLR ligands, DCs can show evidence for maturation and IL-12 production in response to heat shock proteins, which may be released by the pathogen (Lazarevic et al. 2003), tumor cells (Somersan et al. 2001), or stressed cells (Basu et al. 2000). DCs and innate lymphocytes (e.g., NK, NKT, and γδ T cells) interact in ways that enhance the function of each cell type. DCs produce IL-12, IL-15, IL-2, and IFNα/β, which affect different facets of NK cell function, whereas the innate lymphocytes act back to mature the DCs (reviewed in Munz et al. 2005; Walzer et al. 2005). Injection of mature DCs leads to the recruitment of NK cells into the draining lymph nodes, whereas exposure of DCs to TLR stimuli induces IL-2 and IL-12 production, which in turn activates NK cells to produce IFN-γ. DCs also present different glycolipids on CD1d molecules to the invariant T cell receptor on NKT cells. These include endogenous lysosomal glycosphingolipids (e.g., iGb3; Zhou et al. 2004), microbial lipids (Kinjo et al. 2005; Mattner et al. 2005), or synthetic glycolipids (e.g., α-GalCer; Fujii et al. 2003; Hermans et al. 2003) to activate NKT cells in vivo. The interaction of innate lymphocytes and DCs is not yet known to involve TLR signaling pathways. Recall that many of the classic areas of DC function and maturation involve nonmicrobial settings, such as transplantation and contact sensitivity, so that there may well be signal transduction pathways for maturation that are independent of TLRs and other microbial sensors.
FUNCTIONS OF DCS
Innate Responses via Toll-Like Receptors
and Interactions with Innate Lymphocytes Innate responses are the first line of defense against microbial invasion and tumor growth. DCs, like other hematopoietic and nonhematopoietic cells, have important roles in innate immunity. On the one hand, some DCs directly mediate innate responses through TLRs that recognize microbial ligands expressed by viruses, bacteria, fungi, and protozoa. As a result, DCs can be the major source in vivo for the production of IL12 and interferon (IFN)-α in response to microbial stimulation (Dalod et al. 2002; Reis e Sousa et al. 1997). Although the function of TLRs in innate immunity was first evaluated in flies (Lemaitre et al. 1996) and human cells (Medzhitov et al. 1997), the dissection of TLR function and the identification of the molecules used during signal transduction (e.g., MyD88, TRIF
B.
Initiating Adaptive T Cell Immunity
As discussed in the section on features of DCs, immature DCs can endocytose a diverse array of antigens through multiple receptors on their cell surface. However, immature DCs typically express relatively low levels of surface MHC class I and II products and only low levels of costimulatory molecules (e.g., CD80 and CD86). MHC class II molecules are sequestered intracellularly in late endocytic lysosomal compartments (Inaba et al. 2000; Pierre et al. 1997; Turley et al. 2000). Upon receipt of a maturation stimulus, DCs undergo extensive differentiation, and they migrate in increased numbers to secondary lymphoid tissues. For example, maturation is required to reduce the acidity of lysosomes and permit proteolysis of antigens as well as the invariant chain chaperone for MHC class II products (Trombetta et al. 2003). In contrast, immature DCs may retain intact protein for relatively long periods and then
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
form MHC class II–peptide complexes subsequently in maturing intracellular compartments (Delamarre et al. 2005). DC–T cell interactions in the lymph nodes have now been studied in the living state with two-photon microscopy (Bousso and Robey 2003; Hugues et al. 2004; Mempel et al. 2004; Miller et al. 2004; Shakhar et al. 2005). Antigen-specific T cells arrest on antigen-presenting DCs, and this stable interaction lasts for at least 18 hours. If DCs remain immature, this stable DC–T cell interaction leads to tolerance, whereas a maturation signal allows DCs to initiate immunity. Maturation includes a massive redistribution of MHC class II molcules from intracellular compartments to the plasma membrane, the upregulation of costimulatory molecules such as CD40, CD80, and CD86, and changes in the profiles of cytokine and chemokines such as TNF-α and IL-12. All of these changes probably contribute to the initiation of T cell immunity. The communication between DCs and T cells is a dialog in which the DCs also respond to T cells. For example, CD40 and TRANCE (TNF-related activation-induced cytokine)/RANK (receptor activator of nuclear factor-κB) receptor on DCs are ligated by the corresponding TNF family member expressed on activated and memory T cells, that is, CD40L and RANK-L (Anderson et al. 1997; Van Kooten and Banchereau 1997; Wong et al. 1997). This leads to increased DC survival and, in the case of CD40, upregulation of CD80 and CD86, secretion of IL-12, and release of chemokines such as IL-8 and macrophage inflammatory protein (MIP)-1α and -1β. The dialog between DCs and T cells thus allows for the expansion of T cell immunity.
C.
Controlling the Quality of the T Cell Response
The T cell repertoire generated in the thymus is formed by a spectrum of clones that together provide exquisite receptor diversity. After the generation of this repertoire, DCs are required for critical decisions such as clonal selection and expansion, tolerance versus immunity, T helper (Th) 1 versus Th2 cells, and even memory. In the presence of mature DCs producing IL-12 or interferons (as might occur when DCs are ligated by CD40L or infected with viruses), the CD4+ T cells differentiate along a Th1 pathway for IFN-γ production. The latter in turn activates the antimicrobial activities of macrophages and promotes killer T cell differentiation. In the presence of exogenous IL-4, however, DCs induce T cells to differentiate into Th2 cells, which secrete IL-4, IL-5, and IL-13. These cytokines help B cells to make antibodies of the immunoglobulin (Ig) G1 and IgE isotypes, activate eosinophils, and stimulate fibrosis. A new and striking pathway that was first discovered with human myeloid DCs involves the epithelium-derived cytokine, thymic stromal lymphopoietin (TSLP). This matures DCs to induce “inflammatory Th2 cells,” which produce TNF-α (rather than IL-10), in addition to IL-4, IL-5, and IL-13 (Soumelis et al. 2002). Recent studies have shown that TSLP receptor (TSLPR) knockout mice exhibit strong Th1
CELLS
IN
THE
MOUSE
145
responses, with high levels of IL-12, IFN-γ, and IgG2a, but low production of IL-4, -5, -10, and -13 and IgE (Al-Shami et al. 2005). DCs that are matured with either CD40L or TSLP are similar in appearance, being highly dendritic and rich in MHC class II and CD86 stimulatory molecules. However, they differ significantly in cytokine and chemokine production, and as mentioned, the functional consequences for T cells vary enormously (Soumelis et al. 2002).
D.
Initiating Different Types of Tolerance
The mechanisms used by DCs to initiate immunity against pathogens pose a major risk for the development of autoimmunity, allergy, and chronic inflammatory disease. Maturation takes place in response to microbial components that signal through Toll-like receptors, but an additional consequence of infection is the death of some infected cells as well as adjacent self-tissues. Therefore, when immature DCs are capturing pathogens, they are also capturing dying cells, which are processed efficiently (Iyoda et al. 2002; Liu et al. 2002). Likewise, at body surfaces, maturing DCs are also capturing environmental antigens to which the body must remain unresponsive. How then do maturing DCs focus the immune response on antigens derived from the pathogen and avoid inducing immunity to self and environmental antigens? It is becoming evident that DCs are responsible for different types of immune silencing or tolerance of reactivity to these self-antigens. First, DCs mediate central tolerance that takes place in the thymus. Self-antigens for negative selection in the thymus include universal self-antigens that are expressed by DCs and antigens that enter the thymus through the bloodstream for capture by DCs. Also in the thymus, medullary epithelial cells can express and tolerize to self-antigens, expressed under the control of the autoimmune regulator “AIRE” (Anderson et al. 2002). Nonetheless, self-reactive T cells capable of causing autoimmune disease can escape negative selection. Central tolerance also may not have a chance to operate if the expression of a self-antigen occurs after the lymphocyte repertoire has been produced, typically before birth in humans. Furthermore, the immune system must remain tolerant to harmless or “noninfectious” antigens in the environment to which we are exposed after the lymphocyte repertoire has already formed. Central tolerance, therefore, has its limitations and does not by itself fully prevent autoimmunity and chronic inflammatory diseases. DCs also mediate tolerance in the periphery. Recent studies show that DCs constantly carry innocuous antigens from the periphery, for example, from the skin, airways, stomach, intestine, and pancreas (reviewed in Steinman et al. 2003). An important finding is that bone marrow–derived cells in the pancreatic lymph nodes present peptides derived from insulinproducing β cells of the pancreatic islets. Presentation of tissue antigens to T cells in the draining lymph nodes leads to tolerance (Kurts et al. 1996, 1997). Accordingly DCs may be able
146
KANG
LIU,
ANNA
to present many self-antigens, probably derived from the normal turnover of somatic cells, to T cells and thus induce tolerance to self-proteins that have no access to the thymus. In a recent study a subset of mouse DCs (CD8+ DEC-205+) was found to be specialized in capturing dying cells (Iyoda et al. 2002). In the steady state, the phagocytic DCs remained immature, as defined by a lack of increase in costimulatory molecules, even though the DCs efficiently presented antigens to CD8+ and CD4+ T cells. Although T cells underwent clonal expansion in vivo when antigen was presented by steady state DCs, tolerance eventually developed (Liu et al. 2002). Likewise, when DCs capture innocuous proteins from the airway, profound tolerance develops even though the T cells can initially proliferate extensively to the antigen-capturing DCs in the draining lymph nodes (Brimnes et al. 2003). Mechanisms for peripheral tolerance can be intrinsic (deletion and anergy) or extrinsic (through suppressor T cells) to the tolerized T cells. Interestingly, the former seems to require expression of B7 family members on the steady-state DCs, for example, PD-L1 and CD86, which then ligate PD-1 and CTLA-4 on the T cells to be tolerized. This requirement for “costimulation” is contrary to the classic view that tolerance is the result of presentation of MHC peptide (“signal one”) in the absence of costimulation (“signal two”). In mice, the targeting of antigen to DCs in vivo (using anti-DEC-205 antibody) leads to deletion of CD4+ and CD8+ T cells (Bonifaz et al. 2002; Hawiger et al. 2001). Previously, peripheral tolerance was difficult to induce, requiring large doses of antigen if successful, whereas the targeting of low doses of antigen to DCs can lead to tolerance. Importantly, DCs are able to expand CD4+ CD25+ regulatory T cells (Yamazaki et al. 2003), and these cells have been used to inhibit autoimmunity mediated by self-reactive T cells in a mouse diabetic model (Tarbell et al. 2004). Also, DCs are able to induce the Tr1 type of regulatory T cells (Levings et al. 2005; Menges et al. 2002), although more research is needed on this pathway in intact mice. In sum, DCs have the capacity to induce tolerance by several mechanisms, which enable DCs to subsequently generate resistance selectively to microbial antigens.
E.
Interactions with Antibody-Forming B Cells
DCs have important effects on B cell growth and immunoglobulin secretion. This involves both direct DC-B cell interactions as well as indirect activation through helper T cells primed by DCs (Boscardin et al. 2006). DCs are able to retain unprocessed antigens for presentation to naive B cells, which initiate an antigen-specific antibody response (Wykes et al. 1998). There is also evidence showing that monocyte-derived CD11clow, B220− DCs from the blood bind and transport bacterial antigen to the splenic marginal zone, where it becomes accessible to B cells for initiation of T cell–independent antibody production (Balazs et al. 2002).
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
The DC-B cell interaction is important for B cell proliferation and survival. The classic pathway for a T cell–dependent response is that DCs activate and expand T helper cells, which then provide cytokine and cell-bound “help” to B cells to induce B cell growth and antibody production (Inaba and Steinman 1984, 1985). However, by secretion of soluble factors, including IL-12, DCs can directly stimulate the production of antibodies and the proliferation of B cells, which have also been stimulated by CD40L on activated T cells. Furthermore, during the DC-B cell interaction in the spleen bridging channel area and the lymph node medulla, DC-derived TNF-family ligands APRIL and/or BAFF enhance plasmablast survival and differentiation to plasma cells for a T cell–independent antibody response (Balazs et al. 2002; MacLennan and Vinuesa 2002). DCs influence immunoglobulin class-switching of B cells activated by T cells. Type I interferon stimulation of DCs in vivo contributes to the production of all IgG subclasses and longlived antibody responses (Le Bon et al. 2001). Intestinal DCs carrying commensal bacteria selectively induce production of protective IgA (Macpherson and Uhr 2004). In cultures of human cells, myeloid DCs are able to stimulate class switching to IgA (Fayette et al. 1997), whereas plasmacytoid DCs enhance antibody responses and induce nonselective Ig class switching (Jego et al. 2003). Although the traditional understanding is that CD40L on activated T cells binds CD40 on B cells and induces class switching, a recent study concludes that DCs can directly induce CD40-independent, Ig class switching (Litinskiy et al. 2002). The scenario is that DC upregulate BlyS/BAFF and APRIL upon exposure to IFN-α, IFN-γ, or CD40L. BlyS/BAFF and APRIL on DCs interact with their respective receptors on B cells. In the milieu of appropriate cytokines (such as IL-10, transforming growth factor-β, and IL-4), BlyS/BAFF and APRIL induce class-switch DNA recombination from Cµ to Cγ and/or Cα genes or Cε in B cells. These B cells differentiate along the plasma cell pathway for antibody secretion upon B cell antigen receptor engagement and exposure to IL-15. BlyS/BAFF and APRIL expression levels in DCs is controlled by SOCS1 (suppressor of cytokine-signaling 1). DCs from SOCS1-deficient mice express these molecules at high levels, and this expression is associated with autoantibody production (Hanada et al. 2003). In sum, different DC subsets in different anatomic locations can contribute to the development, activation, and survival of antibody-producing B cells.
IX.
SUMMARY OF APPROACHES TO ANALYZING DC FUNCTION IN MICE A.
DCs Studied Ex Vivo
Mouse spleen remains the major source for studying the properties of DCs ex vivo. In addition, mouse spleen DCs that
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
have captured antigens can be transferred to naïve mice and used to study DC function in controlling immunity (Fujii et al. 2004; Inaba et al. 1990; Liu et al. 2005). Using positive selection with anti-CD11c mAbs, one obtains 1–2 million DCs from a spleen. These DCs are composed of at least three major subsets: CD8+ and CD8− myeloid DCs and plasmacytoid DCs. Most are in an immature state but begin to differentiate as soon as they are released from the spleen. One way to document the immature state of DCs taken from mice is to lightly fix the cells immediately after their isolation with formaldehyde. When DCs are isolated from mice in the steady state, the fixed cells are virtually inactive as mixed leukocyte reaction stimulators, but if the mice are given a maturation stimulus beforehand, the fixed DCs are potent stimulators (Fujii et al. 2003). Another way to follow DC maturation is to examine the intracellular distribution of MHC class II products, which are primarily localized within late endosomal compartments in immature cells and on the cell surface in mature ones (Pierre et al. 1997; Wilson et al. 2004).
B. DCs Generated Ex Vivo from Proliferating Progenitors As mentioned at the start of this chapter, research on DCs has been greatly stimulated by the ability to grow large numbers of these cells from bone marrow progenitors. This source of DCs has been especially valuable for cell biological studies of antigen presentation, especially for studying the properties of immature and mature stages of DC development. A valuable source of cells has been the D1 cell line, which also can be studied in immature and mature forms (Winzler et al. 1997). Ex vivo generated DCs are contributing to the science of immunotherapy, because the DCs can be loaded ex vivo with defined tumor or microbial antigens and then reinfused to initiate immunity (Inaba et al. 1993). It is important to add a maturation stimulus to achieve immunity (Schuurhuis et al. 2000). These experiments nevertheless have a major unresolved problem, which is the very low efficiency with which injected DCs are able to gain access to the draining lymph nodes (Josien et al. 2000).
CELLS
IN
THE
MOUSE
147
Hawiger et al. 2001, 2004). Previously one had to administer very large doses of antigens to induce peripheral tolerance, and often the tolerance was incomplete. In the presence of a maturation stimulus, immunity and memory can develop after receptor-mediated delivery of antigens to DCs. The immune responses include combined CD4+ and CD8+ immunity, protection against infection and tumors, and strong helper T cell–dependent antibody responses (Bonifaz et al. 2004; Boscardin et al. 2006; Trumpfheller et al. 2006). It will be important to assess different targets on DCs and other antigenpresenting cells, DC subsets, and maturation stimuli. Work in this field is just beginning, and we suspect that research in mice will set the stage for translation of the approach into nonhuman primates and humans.
D.
Creation of Improved Mice Carrying Human Immune Systems
Progress is being made in the creation of humanized mice because of the recognition that human DCs will need to be engrafted to gain more authentic control on the function of other human lymphoid components. The use of populations enriched in human hematopoietic stem cells represents one component of achieving engraftment with human DCs (Palucka et al. 2003). Another important step is to use mice that are not only deficient in mouse lymphocytes (RAG knockouts and scid mice) but also deficient in critical components of the innate immune system, such as the type I interferon receptor (Boyman et al. 2004; Nestle et al. 2005) and the common γ chain signaling molecule for many hematopoietins (Traggiai et al. 2004; Weijer et al. 2002). These developments are permitting the formation of organized human lymphoid organs in mice, which should allow mice to be used as a more direct preclinical model for studies of the human immune system.
X.
APPENDIX: PROTOCOLS FOR THE ISOLATION OF DCS
C.
Direct Targeting of Antigens to DCs within Intact
A.
Isolating Spleen Dendritic Cells
Lymphoid Tissues Materials: A new and promising approach to studying DC function in situ is to identify ligands that target selectively to these cells and to do this in either the steady state or after the coadministration of maturation stimuli. This identification has been achieved using mAbs to DCs, for example, with an antibody to the uptake receptor DEC-205/CD205. In the steady state, tolerance can be induced after DC targeting, but interestingly only small doses of antigen are needed (Bonifaz et al. 2002;
1. 2. 3. 4.
Hanks’ balanced salt solution (Gibco 14175-095) Collagenase D, 400 units/ml (Roche 1088882) EDTA solution, 0.5 M (Gibco 15575-038) FACS buffer, 2% fetal bovine serum (FBS) in 500 ml of phosphate buffered saline (PBS) 5. Automated magnetic cell sorting (MACS) buffer, 8.3 ml of 30% bovine serum albumin (BSA) + 2 ml of 0.5 M EDTA
148
KANG
LIU,
ANNA
6. R5 medium, 5% FBS in 500 ml of RPMI medium 1640 + L-Glutamine + antibiotics + HEPES buffer 7. Anti-mouse CD11c MicroBeads (Miltenyi Biotec 130-042-201) 8. LS MACS separation columns (Miltenyi Biotec 130-042-401) Procedure: 1. Prepare Petri dishes with 4.5 ml of Hanks’ balanced salt solution/spleen. 2. Sacrifice mice by approved euthanasia techniques. 3. Remove spleen. 4. Add 500 µl of 400 units/ml collagenase D per dish. 5. Using a 3-ml syringe and a 25 5/8-gauge needle, take up 3 ml of the Hanks’/collagenase mixture and inject this into the spleen to balloon the organ. 6. Then tease the spleen into very small pieces. 7. Incubate at 37°C for 25 minutes. 8. Add 100 µl of 0.5 M EDTA and mix. 9. Incubate at 37°C for 5 minutes (spleen should be spindly in texture). 10. Place a cell strainer on a 15-ml Falcon tube and using a Pasteur pipette, pipette spleen up and down until dissolved. 11. Pass through strainer and wash dish with 5–10 ml of FACS buffer. 12. Spin down at 1200 rpm for 10 minutes. For low-density cell enrichment: a. Resuspend the cells in 3 ml of BSA and carefully lay 1 ml of cold PBS on top. b. Spin at 2200 rpm for 30 minutes at 4°C. c. Remove the cells at the interface between the BSA and PBS (low-density cells) collecting into 15-ml tubes. d. Wash twice with cold PBS and count the cells. Without low-density cell enrichment: a. Lyse red blood cells by resuspending in 1 ml of ACK lysing buffer/spleen (Biosource International p304-100) and incubating at room temperature for 4 minutes. b. Wash twice with FACS buffer and count the cells. 13. Resuspend the cells in 460 µl of FACS buffer and add 40 µl of anti-mouse CD11c MicroBeads/spleen. 14. Incubate at 4°C for 20 minutes. 15. After incubation, fill tube with FACS buffer and spin down for 10 minutes at 1200 rpm. 16. Place an LS column (two spleens/column) in the magnet. 17. Place a filter on top of the column, and calibrate the column with 3 ml of MACS buffer. 18. Resuspend the cells with 3 ml of MACS buffer, and pass through the column. 19. Wait until flow has stopped. 20. Wash tubes with 3 ml of MACS and pass through. 21. Repeat two more times. 22. Remove the column from the magnet and elute the positive cells with 5 ml of MACS buffer.
CHARALAMBOUS,
B.
AND
RALPH
M.
STEINMAN
Isolating Bone Marrow Dendritic Cells
Materials: 1. 2. 3. 4. 5. 6.
RPMI medium 1640 (Gibco 11875-093) 1 M HEPES solution (Gibco 15630-080) Gentamicin (BioWhittaker 17-5192) Cell strainers (Falcon 352350) ACK lysing buffer (Biofluids P304-100) Rabbit complement (Pel-Freez 31038-100)
Procedure: 1. Sacrifice mice by prescribed and approved euthanasia techniques. 2. Remove femurs and tibias and place into a small Petri dish with RPMI medium 1640. 3. Clean bones with a gauze to remove adjacent muscles. 4. Incubate bones in 70% ethanol in a Petri dish (2 minutes). 5. Wash the bones with RPMI twice. 6. Cut off the tips of the bones. 7. Use a 3-ml syringe and 25-gauge needle to flush the cells out of the bones. 8. Cut up the bones into small pieces. 9. Disrupt the clumps with a pipette. 10. Filter everything through a cell strainer in a 50-ml tube. 11. Lyse the red blood cells (in 100 µl of ACK lysing buffer) for 1 minute at room temperature and count the cells. 12. Centrifuge (for 10 minutes at 1200 rpm). 13. Resuspend the cells at 10 million/ml in 5% FCS medium (RPMI) containing the following antibodies: a. Tib-120 (anti-I-A, MHC II) b. GK1.5 (anti-CD4) c. Tib-146 (anti-B220) d. Tib-211 (anti-CD8) e. Rabbit complement 14. Incubate at 37°C for 1 hour to lyse the B and T cells in bone marrow. Although this step adds time to the procedure, the resulting smaller numbers of bone marrow cells reduce the numbers of cultures and increase the occurrence of DCs, which saves time. 15. Wash the cells three times in RPMI and count. 16. Resuspend the cells at 1 million/ml in the following medium: a. RPMI medium 1640 b. 5% heat activated FCS c. 10 mM HEPES d. 50 mM 2-mercaptoethnol, gentamicin (The medium should have granulocyte-macrophage colonystimulating factor (GMCSF) (1:30 GMCSF containing supernatant from a stably transfected J558 cell line or recombinant GMCSF)
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
17. Culture in a 24-well plate, 1 ml/well. 18. On day 2 and day 4 gently wash adherent cells by slowly going around the rim of the well with a Pasteur pipette. 19. Remove medium and replace with fresh GMCSF-containing medium. 20. On day 6, dislodge the clusters of immature DCs and transfer to a 100-mm culture dish at 1 million/ml, 7.5 ml/plate. 21. Incubate 24 h with 10 µg/ml of lipopolysaccharide. 22. Use the cells on day 7 or 8. Two hours before use, transfer the cells in a new dish to deplete adherent cells. The expected yield is between 2 and 5 million DCs/mouse.
ACKNOWLEDGMENT This work was supported by Grant AI13013 from the National Institutes of Health.
REFERENCES Alexopoulou, L., Holt, A.C., Medzhitox, R., Flavell, R.A. (2001). Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738. Aliberti, J., Schultz, O., Pennington, D.J., Tsujimura, H., Reis e Sousa, C., Ozata, K., et al. (2003). Essential role for ICSBP in the in vivo development of murine CD8α+ dendritic cells. Blood 101, 305–310. Allan, R.S., Smith, C.M., Belz, G.T., van Lint, A.L., Wakim, L.M., Heath, W.R., et al. (2003). Epidermal viral immunity induced by CD8α+ dendritic cells but not by Langerhans cells. Science 301, 1925–1928. Al-Shami, A., Spolski, R., Kelly, J., Keane-Myers, A., Leonard, W.J., et al. (2005). A role for TSLP in the development of inflammation in an asthma model. J Exp Med 202, 829–839. Anderson, D.M., Maraskovsky, E., Billingsley, W.L., Dougall, W.C., Tometsko, M.E., Roux, E.R., et al. (1997). A homologue of the TNF receptor and its ligand enhance T cell growth and dendritic-cell function. Nature 390, 175–179. Anderson, M.S., Venanzi, E.S., Klein, L., Chan, Z., Berzins, S.P., Turley, S.J., et al. (2002). Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395–1401. Angeli, V., Llodra, J., Rong, J.X., Satoh, K., Ishii, S., Shimizu, T. (2004). Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21, 561–574. Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., et al. (2001). Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2, 1144–1150. Asselin-Paturel, C., Brizard, G., Chemin, K., Boonstra, A., O’Garra, A., Vicari, A., et al. (2005). Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201, 1157–1167. Bachmann, M.F., Wong, B.R., Josien, R., Steinman, R.M., Oxenius, A., Choi, Y. (1999). TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189, 1025–1031. Balazs, M., Martin, F., Zhou, T., Kearney, J. (2002). Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17, 341–352. Basu, S., Binder, R.J., Ramalingam, T., Srivastava, P.K. (2001). CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14, 303–313.
CELLS
IN
THE
MOUSE
149
Basu, S., Binder, R.J., Suto, R., Anderson, K.M., Srivastava, P.K. (2000). Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int Immunol 12, 1539–1546. Belz, G.T., Behrens, G.M.N., Smith, C.M., Miller, J.F.A.P., Jones, C., Lejon, K., et al. (2002). The CD8α+ dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 196, 1099–1104. Bennett, C.L., van Rijn, E., Jung, S., Inaba, K., Steinman, R.M., Kapsenberg, M.L., et al. (2005). Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 169, 569–576. Bennett, S.R.M., Carbone, F.P., Karamalis, R., Flavell, R.A., Miller, J.F., Heath, W.R. (1998). Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478–480. Bjorck, P. (2001). Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factortreated mice. Blood 98, 3520–3526. Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M.C., Steinman, R.M. (2002). Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196, 1627–1638. Bonifaz, L.C., Bonnyay, D.P., Charalambous, A., Darguste, D.I., Fujii, S., Soares, H., et al. (2004). In vivo targeting of antigens to the DEC-205 receptor on maturing dendritic cells improves T cell vaccination. J Exp Med 199, 815–824. Borkowski, T.A., Letterio, J.J., Farr, A.G., Udey, M.C. (1996). A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor β1 null mice is devoid of epidermal Langerhans cells. J Exp Med 184, 2417–2422. Boscardin, S.B., Hafalla, J.C.R., Masilamani, R.F., Kamphorst, A.O., Zeboski, H.A., Rai, U., et al. (2006). Antigen targeting to dendritic cells elicits improved and long-lived T cell help for antibody responses. J Exp Med 203, 599–606. Bousso, P., Robey, E. (2003). Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 4, 579–585. Boyman, O., Hefti, H.P., Conrad, C., Nickoloff, B.J., Suter, M., Nestle, F.O. (2004). Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J Exp Med 199, 731–736. Brimnes, M.K., Bonifaz, L., Steinman, R.M., Moran, T.M. (2003). Influenza virus-induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J Exp Med 198, 133–144. Brocker, T. (1997). Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J Exp Med 186, 1223–1232. Brocker, T., Miedinger, M., Karjalainen, K. (1997). Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 185, 541–550. Caux, C., Dezutter-Dambuyant, C., Schmitt, D., Banchereau, J. (1992). GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–261. Caux, C., Vanbervliet, B., Massacrier, C., Azuma, M., Okumura, K., Lanier, L.L., et al. (1994). B70/B7–2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 180, 1841–1847. Chen, L.L., Adams, J.C., Steinman, R.M. (1978). Anatomy of germinal centers in mouse spleen with special reference to “follicular dendritic cells.” J Cell Biol 77, 148–164. Chen, L.L., Frank, A.M., Adams, J.C., Steinman, R.M. (1978). Distribution of horseradish peroxidase [HRP]-anti HRP immune complexes in mouse spleen, with special reference to follicular dendritic cells. J Cell Biol 79, 184–199. Chicha, L., Jarrossay, D., Manz, M.G. (2004). Clonal type I interferon-producing and dendritic cell precursors are contained in both human lymphoid and myeloid progenitor populations. J Exp Med 200, 1519–1524.
150
KANG
LIU,
ANNA
Chow, A., Toomre, D., Garrett, W., Mellman, I. (2002). Dendritic cell maturation triggers retrograde transport of MHC class II transport from lysosomes to the plasma membrane. Nature 418, 988–994. Cook, D.N., Prosser, D.M., Forster, R., Zhang, J., Kuklin, N.A., Abbondanzo, S.J., et al. (2000). CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12, 495–503. Crowley, M., Inaba, K., Steinman, R.M. (1990). Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. J Exp Med 172, 383–386. Crowley, M., Inaba, K., Witmer-Pack, M., Steinman, R.M. (1989). The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell Immunol 118, 108–125. Crowley, M.T., Inaba, K., Witmer-Pack, M.D., Gezelter, S., Steinman, R.M. (1990). Use of the fluorescence activated cell sorter to enrich dendritic cells from mouse spleen. J Immunol Methods 133, 55–66. Cyster, J.G. (1999). Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 189, 447–450. Dalod, M., Salazar-Mather, T.P., Malmgaard, L., Lewis, C., Asselin-Paturel, C., Briére, F.,, et al. (2002). Interferon α/β and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 195, 517–528. D’Amico, A., Wu, L. (2003). The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med 198, 293–303. Delamarre, L., Pack, M., Chang, H., Mellman, I, Trombetta, E.S. (2005). Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307, 1630–1634. Delneste, Y., Magistrelli, G., Gauchat J., Haeuw, J., Aubry, J., Nakamura, K., et al. (2002). Involvement of LOX-1 in dendritic cell-mediated antigen crosspresentation. Immunity 17, 353–362. Dhodapkar, K.M., Kaufman, J.L., Ehlers, M., Banerjee, D.K., Bonvini, E., Koenig, S., et al. (2005). Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 102, 2910–2915. Dieu, M.-C., Vanbervliet, B., Vicari, A., Bridon, J.-M., Oldham, E., Aït-Yahia, S., et al. (1998). Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188, 373–386. Edwards, A.D., Chaussabel, D., Tomlinson, S., Schulty, O., Sher, A., Reis e Sousa, C. (2003). Relationships among murine CD11chigh dendritic cell subsets as revealed by baseline gene expression patterns. J Immunol 171, 47–60. Fayette, J., Dubois, B., Vandenabeele, S., Bridon, J.-M., Vanberliet, B., Durand, I., et al. (1997). Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 185, 1909–1918. Figdor, C.G., van Kooyk, Y., Adema, G.J. (2002). C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2, 77–84. Forster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Muller, I., Wold, E., et al. (1999). CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23–33. Frelinger, J.G., Hood, L., Hill, S., Frelinger, J.A. (1979). Mouse epidermal Ia molecules have a bone marrow origin. Nature 282, 321–323. Fujii, S., Liu, K., Smith, C., Bonito, A.J., Steinman, R.M. (2004). The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199, 1607–1618. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., Steinman, R.M. (2003). Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J Exp Med 198, 267–279. Garcia De Vinuesa, C., Gulbranson-Judge, A., Khan, M., O’Leary, P., Cascalo, M., Wabl, M., et al. (1999). Dendritic cells associated with plasmablast survival. Eur J Immunol 29, 3712–3721.
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
Garrett, W.S., Chan, L.M., Kroschewski, R., Ebersold, M., Turley, S., Tormbetta, S., et al. (2000). Developmental control of endocytosis in dendritic cells by Cdc42. Cell 102, 325–334. Gautier, G., Humbert, M., Deauvieau, F., Scuiller, M., Hiscott, J., Bates, E.E.M., et al. (2005). A type I interferon autocrine-paracrine loop is involved in Tolllike receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 201, 1435–1446. Gilliet, M., Boonstra, A., Paturel, C., Antonenko, S., Xu, X.-L., Trinchieri, G., et al. (2002). The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 195, 953–958. Gonzalez-Aseguinolaza, G., Van Kaer, L., Bergmann, C.C., Wilson, J.M., Schmieg, J., Kronenberg, M., et al. (2002). Natural killer T cell ligand αgalactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195, 617–624. Granucci, F., Vizzardelli, C., Pavelka, N., Feau, S., Persico, M., Virzi, E., et al. (2001). Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2, 882–888. Greaves, D.R., Wang, W., Dairaghi, D.J., Dieu, C., de Saint-Vis, B., Franz-Bacon, K., et al. (1997). CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3α and is highly expressed in human dendritic cells. J Exp Med 186, 837–844. Gunn, M.D., Kyuwa, S., Tam, C., Kakiuchi, T., Matsuzawa, A., Williams, L.T., et al. (1999). Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 189, 451–460. Hacker, C., Kirsch, R.D., Ju, X.S., Hieronymus, T., Gust, T.C., Kuhl, C., et al. (2003). Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4, 380–386. Hanada, T., Yoshida, H., Kato, S., Tanaka, K., Masutani, K., Tsukada, J., et al. (2003). Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19, 437–450. Hart, D.N.J., Fabre, J.W. (1981). Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J Exp Med 154, 347–361. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., et al. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194, 769–780. Hawiger, D., Masilamani, R.F., Bettelli, E., Kuchroo, V.K., Nussenzweig, M.C., et al. (2004). Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20, 695–705. Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C., Goodlett, D.R., et al. (2001). The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099–1103. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., et al. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3, 196–200. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., et al. (2000). A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745. Henri, S., Vremac, D., Kamath, A., Waithman, J., Williams, S., Benoist, C., et al. (2001). The dendritic cell populations of mouse lymph nodes. J Immunol 167, 741–748. Hermans, I.F., Silk, J.D., Gileadi, U., Salio, M., Mathew, B., Ritter, G., et al. (2003). NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171, 5140–5147. Hoebe, K., Du X., Georgel, P., Janssen, E., Tabeta, K., Kim, S.O., et al. (2003). Identification of Lps2 as a key transducer of MyD88-independent TIR signaling. Nature 424, 743–748. Holt, P.G., Schon-Hegard, M.A., Oliver, J. (1988). MHC class II antigen-bearing dendritic cells in pulmonary tissues of the rat: regulation of antigen presentation activity by endogenous macrophage populations. J Exp Med 167, 262–274.
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
Honda, K., Mizutani, T., Taniguchi, T. (2004). Negative regulation of IFN-α/β signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells. Proc Natl Acad Sci USA 101, 2416–2421. Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., et al. (2005). IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772–777. Huang, F.-P., Platt, N., Wykers, M., Major, J.R., Powell, T.J., Jenkins, C.D., et al. (2000). A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 191, 435–442. Hugues, S., Fetler, L., Bonifaz, L., Helft, J., Amblard, F., Amigorena, S. (2004). Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 5, 1235–1242. Ichikawa, E., Hida, S., Omatsu, Y., Shimoyama, S., Takahara, K., Miyagawa, S., et al. (2004). Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2. Proc Natl Acad Sci USA 101, 3909–3914. Inaba, K., Granelli-Piperno, A., Steinman, R.M. (1983). Dendritic cells are critical accessory cells for thymus-dependent antibody responses in mouse and man. Proc Natl Acad Sci USA 80, 6041–6045. Inaba, K., Inaba, M., Naito, M., Steinman, R.M. (1993). Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 178, 479–488. Inaba, K., Inaba, M., Romani, N., Aya, H., Seguchi, M., Ikehara, S., et al. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176, 1693–1702. Inaba, K., Metlay, J.P., Crowley, M.T., Steinamn, R.M (1990). Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHCrestricted T cells in situ. J Exp Med 172, 631–640. Inaba, K., Schuler, G., Witmer, M.D., Valinksy, B., Atassi, B., Steinman, R.M. (1986). The immunologic properties of purified Langerhans cells: distinct requirements for the stimulation of unprimed and sensitized T lymphocytes. J Exp Med 164, 605–613. Inaba, K., Steinman, R.M. (1984). Resting and sensitized T lymphocytes exhibit distinct stimulatory [antigen-presenting cell] requirements for growth and lymphokine release. J Exp Med 160, 1717–1735. Inaba, K., Steinman, R.M. (1985). Protein-specific helper T lymphocyte formation initiated by dendritic cells. Science 229, 475–479. Inaba, K., Steinman, R.M., Pack, M.W., Aya, H., Inaba, M., Sudo, T., et al. (1992). Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 175, 1157–1167. Inaba, K., Turley, S., Iyoda, T., Yamaide, F., Shimoyama, S., Reis e Sousa, C., et al. (2000). The formation of immunogenic MHC class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 191, 927–936. Inaba, K., Turley, S., Yamaide, F., Iyoda, T., Mahnke, K., Inaba, M., et al. (1998). Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells. J Exp Med 188, 2163–2173. Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K.S., Sakuta, H., Azuma, M., et al. (1994). The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 180, 1849–1860. Iwasaki, A., Kelsall, B.L. (2000). Localization of distinct Peyer’s patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α, MIP-3β, and secondary lymphoid organ chemokine. J Exp Med 191, 1381–1394. Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Akiyama, Y., Maeda, Y., et al. (2002). The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 195, 1289–1302. Jego, G., Palucka, A.K., Lanck, J.P., Chalouni, C., Pascual, V., Banchereau, J. (2003). Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225–234. Josien, R., Li, H.-L., Ingulli, E., Sarma, S., Wong, B.R., Vologodskaia, M., et al. (2000). TRANCE, a tumor necrosis family member, enhances the
CELLS
IN
THE
MOUSE
151
longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191, 495–501. Jung, S., Unutmaz, D., Wong, P., Sano, G., De los Santos, K., Sparwasser, T., et al. (2002). In vivo depletion of CD11c+ dendritic cells abrogation priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211–220. Kabashima, K., Banks, T.A., Ansel, K.M., Lu, T.T., Ware, C.F., Cyster, J.G. (2005). Intrinsic lymphotoxin-β receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 22, 439–450. Kabashima, K., Sakata, D., Nagamachi, M., Miyachi, Y., Inaba, K., Narumiya, S. (2003). Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 9, 744–749. Kaisho, T., Akira, S. (2001). Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol 22, 78–83. Kaisho, T., Takeuchi, O., Kawai, T., Hoshino, K., Akira, S. (2001). Endotoxininduced maturation of MyD88-deficient dendritic cells. J Immunol 166, 5688–5694. Kalergis, A.M., Ravetch, J.V. (2002). Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J Exp Med 195, 1653–1659. Kamath, A.T., Pooley, J., O’Keeffe, M.A., Vremec, D., Lew, A.M., D’Amico, A., et al. (2000). The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 165, 6762–6770. Katz, S.I., Tamaki, K., Sachs, D.H. (1979). Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 282, 324–326. Kawai, T., Adachi, O., Ogawa, T., Takeda, K., Akira, S. (1999). Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115–122. Kawano, T., Cui, J., Keizuka, Y., Toura, I., Kaneko, Y., Motoki, K., et al. (1997). CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278, 1626–1629. Kerksiek, K.M., Niedergang, F., Chavrier, P., Busch, D.H., Brocker, T. (2005). Selective Rac1 inhibition in dendritic cells diminishes apoptotic cell uptake and cross-presentation in vivo. Blood 105, 742–749. Kinjo, Y., Wu, D., Kim G., Xing, G.W., Poles, M.A., Ho, D.D., et al. (2005). Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434, 520–525. Kissenpfennig, A., Ait-Yahia S., Clair-Moninot V., Stossel, H., Badell, E., Bordat, Y., et al. (2005). Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol Cell Biol 25, 88–99. Kissenpfennig, A., Henri, S., Dubois, B., Laplace-Builhe, C., Perrin, P., Romani, N., et al. (2005b). Dynamics and function of Langerhans cells in vivo dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643–654. Kobayashi, T., Walsh, P.T., Walsh, M.C., Speirs, K.M., Chiffoleau, E., King, C.G., et al. (2003). TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 19, 353–363. Kojo, S., Seino, K., Harada, M., Watarai, H., Wakao, H., Uchida, T., et al. (2005). Induction of regulatory properties in dendritic cells by Vα14 NKT cells. J Immunol 175, 3648–3655. Kraal, G., Breel, M., Janse, M., Bruin, G. (1986). Langerhans cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J Exp Med 163, 981–997. Kurts, C., Heath, W.R., Carbone, F.R., Allison, J., Miller, J.F., Kosada, H. (1996). Constitutive class I-restricted exogenous presentation of self-antigens in vivo. J Exp Med 184, 923–930. Kurts, C., Kosaka, H., Carbone, F.R., Miller, J.F.A.P., Heath, W.R. (1997). Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J Exp Med 186, 239–245. Larsen, C.P., Steinman, R.M., Witmer-Pack, M., Hankins, D.F., Morris, P.J., Austyn, J.M. (1990). Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 172, 1483–1493. Lazarevic, V., Myers, A.J., Scanga, C.A., Flynn, J.L. (2003). CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M. tuberculosis infection. Immunity 19, 823–835.
152
KANG
LIU,
ANNA
Le Bon, A., Schiavoni, G., D’Agostino, G., Gresser, I., Belardelli, F., Tough, D.F. (2001). Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461–470. Lee, S.J., Evers, S., Roeder, D., Parlow, A.F., Risteli, J., Lee, Y.C., et al. (2002). Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295, 1898–1901. Lemaitre, B., Nicholas, E., Michaut, L., Reichhart, J.M., Hoffmann, J.A. (1996). The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86, 973–983. Levings, M.K., Gregori, S., Tresoldi, E., Cazzaninga, S., Bonini, C., Roncarolo, M.G. (2005). Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105, 1162–1169. Lindquist, R.L., Shakhar, G., Dudziak, D., Wardemann, H., Eisenreich, T., Dustin, M.L., et al. (2004). Visualizing dendritic cell networks in vivo. Nat Immunol 5, 1243–1250. Litinskiy, M.B., Nardelli, B., Hilbert, D.M., He., B., Schaffer, A., Casali, P., et al. (2002). DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3, 822–829. Liu, K., Idoyaga, J., Charalambous, A., Fujii, S., Bonito, A., Mordo, J., et al. (2005). Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202, 1507–1516. Liu, K., Iyoda, T., Saternus, M., Kimura, Y., Inaba, K., Steinman, R.M. (2002). Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196, 1091–1097. Macatonia, S.E., Knight, S.C., Edwards, A.J., Griffiths, S., Fryer, P. (1987). Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. J Exp Med 166, 1654–1667. MacLennan, I.C.M., Vinuesa, C.G. (2002). Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 17, 235–238. Macpherson, A.J., Uhr, T. (2004). Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303, 1662–1665. Manz, M.G., Traver, D., Akashi, K., Merad, M., Miyamoto, T., Engleman, E.G., et al. (2001). Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97, 3333–3341. Mao, A., Paharkova-Vatchkova, R., Hardy, J., Miller, M.M., Kovats, S. (2005). Estrogen selectively promotes the differentiation of dendritic cells with characteristics of Langerhans cells. J Immunol 175, 5146–5151. Maraskovsky, E., Daro, E., Roux, E., Teepe, M., Maliszewski, C.R., Hoek, J., et al. (2000). In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96, 878–884. Maric, I., Holt, P.G., Perdue, M.H., Bienenstock, J (1996). Class II MHC antigen (Ia)-bearing dendritic cells in the epithelium of the rat intestine. J Immunol 156, 1408–1414. Marsland, B.J., Battig, P., Bauer, M., Ruedl, C., Lassing, U., Beerli, R.R., et al. (2005). CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22, 493–505. Martin-Fontecha, A., Sebastiani, S., Höpken, U.E., Uguccioni, M., Lipp, M., Lanzavecchia, A., et al. (2003). Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198, 615–621. Martin-Fontecha, A., Thomsen, L.L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., et al. (2004). Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming. Nat Immunol 5, 1260–1265. Matsuno, K., Ezaki, T. (2000). Dendritic cell dynamics in the liver and hepatic lymph. Int Rev Cytol 197, 83–136. Matsuno, K., Ezaki, T., Kudo, S., Uehara, Y.. (1996). A life stage of particleladen rat dendritic cells in vivo: their terminal division, active phagocytosis and translocation from the liver to hepatic lymph. J Exp Med 183, 1865–1878. Mattner, J., Debord, K.L., Ismail, N., Goff, R.D., Cantu, C., 3rd, Zhou, D., et al. (2005). Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434, 525–529. Matzinger, P., Guerder, S. (1989). Does T-cell tolerance require a dedicated antigen-presenting cell? Nature 338, 74–76.
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
McKenna, H.J., Stocking, K.L., Miller, R.E., Brasel, K., DeSmedt, T., Maraskovsky, E., et al. (2000). Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95, 3489–3497. Medzhitov, R., Preston-Hurlburt, P., Janeway, C.A., Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394–397. Mellman, I., Steinman, R.M. (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255–258. Mempel, T.R., Henrickson, S.E., Von Andrian, U.H. (2004). T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154–159. Menges, M., Röβner S., Voigtländer, C., Schindler, H., Kukutsch, N.A., Bogdan, C., et al. (2002). Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity. J Exp Med 195, 15–22. Merad, M., Hoffmann, P., Renheim, E., Slaymaker, S., Manz, M.G., Lira, S.A., et al. (2004). Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10, 510–517. Merad, M., Manz, M.G., Karsunky, H., Wagers, A., Peters, W., Charo, I., et al. (2002). Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3, 1135–1141. Metcalf, D. (1985). The granulocyte-macrophage colony-stimulating factors. Science 229, 16–22. Metlay, J.P., Witmer-Pack, M.D., Agger, R., Crowley, M.T., Lawless, D., Steinman, R.M., et al. (1990). The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med 171, 1753–1771. Miller, M.J., Safrina, O., Parker, I., Calahan, M.D. (2004). Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med 200, 847–856. Mishell, R.I., Dutton, R.W. (1967). Immunization of dissociated spleen cell cultures from normal mice. J Exp Med 126, 423–442. Munz, C., Steinman, R.M., Fujii, S. (2005). Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 202, 203–207. Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M.C., Ravetch, J.V. (1994). A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling. Nature 368, 70–73. Naik, S.H., Proietto, A.I., Wilson, N.S., Dakic, A., Schnorrer, P., Fuchsberger, M., et al. (2005). Generation of splenic CD8+ and CD8− dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 174, 6592–6597. Nakano, H., Yanagita, M., Gunn, M.D. (2001). CD11c+ B220+ GR-1+ cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 194, 1171–1178. Nestle, F.O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O. (2005). Plasmacytoid predendritic cells initiate psoriasis through interferonα production. J Exp Med 202, 135–143. Niess, J.H., Brand, S., Gu, X., Landsman, L., Jung, S., McCormick, B.A., et al. (2005). CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307, 254–258. Nossal, G.J.V., Abbot, A., Mitchell, J., Lummus, Z. (1968). Antigen in immunity. XV. Ultrastructural features of antigen capture in primary and secondary lymphoid follicles. J Exp Med 127, 277–296. Nussenzweig, M.C., Steinman, R.M., Gutchinov, B., Cohn, Z.A. (1980). Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. J Exp Med 152, 1070–1084. Nussenzweig, M.C., Steinman, R.M., Unkeless, J.C., Witmer, D., Gutchinov, B., Cohn, Z.A. (1981). Studies of the cell surface of mouse dendritic cells and other leukocytes. J Exp Med 154, 168–187. Nussenzweig, M.C., Steinman, R.M., Witmer, D., Gutchinov, B. (1982). A monoclonal antibody specific for mouse dendritic cells. Proc Natl Acad Sci USA 79, 161–165.
4. SOME
BIOLOGICAL
FEATURES
OF
DENDRITIC
Ohl, L., Mohaupt, M., Czeloth, N., Hintzen, G., Keafard, Z., Zwirner, J., et al. (2004). CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21, 279–288. Ohteki, T., Suzue, K., Maki, C., Ota, T., Koyasu, S. (2001). Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat Immunol 2, 1138–1143. Ouaaz, F., Aaron, J., Zheng, Y., Choi, Y., Beg, A.A. (2002). Dendritic cell development and survival require distinct NF-κB subunits. Immunity 16, 257–270. Palucka, A.K., Gatlin J., Blanck, J.P., Melkus, M.W., Clayton, S., Ueno, H., et al. (2003). Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood 102, 3302–3310. Pierre, P., Turley, S.J., Gatti, E., Hull, M., Meltzer, J., Mirza, A., et al. (1997). Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388, 787–792. Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., et al. (1998). Defective LPS signaling in C3H/Hej and C57BL/10ScCr Mice: mutations in TLr4 gene. Science 282, 2085–2088. Pugh, C.W., MacPherson, G.G., Steer, H.W. (1983). Characterization of nonlymphoid cells derived from rat peripheral lymph. J Exp Med 157, 1758–1779. Pure, E., Inaba, K., Crowley, M.T., Tardelli, L., Witmer-Pack, M.D., Ruberti, G., et al. (1990). Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. J Exp Med 172, 1459–1469. Qu, C., Edwards E.W., Tacke, F., Angeli, V., Llorda, J., Sanchez-Schmitz, G., et al. (2004). Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med 200, 1231–1241. Randolph, G.J., Angeli, V., Swartz, M.A. (2005). Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5, 617–628. Ravetch, J.V., Lanier, L.L. (2000). Immune inhibitory receptors. Science 290, 84–89. Reis e Sousa, C., Hieny, S., Scharton-Kersten, T., Jankovic, D., Charest, H., Germain, R.N., et al. (1997). In vivo microbial stimulation induces rapid CD40L-independent production of IL-12 by dendritic cells and their re-distribution to T cell areas. J Exp Med 186, 1819–1829. Reis e Sousa, C., Stahl, P.D., Austyn, J.M. (1993). Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 178, 509–519. Robbiani, D.F., Finch R.A., Jager, D., Muller, W.A., Sartorelli, A.C., Randolph, G.J. (2000). The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103, 757–768. Romani, N., Inaba, K., Pure, E., Crowley, M., Witmer-Pack, M, Steinman, R.M. (1989). A small number of anti-CD3 molecules on dendritic cells stimulate DNA synthesis in mouse T lymphocytes. J Exp Med 169, 1153–1168. Romani, N., Koide, S., Crowley, M., Witmer-Pack, M., Livingstone, A.M., Fathman, C.G., et al. (1989). Presentation of exogenous protein antigens by dendritic cells to T cell clones: intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169, 1169–1178. Romani, N., Turley, S., Pypaert, M., Ebersold, M., Mellman, I., Schuler, G., et al. (2005). Dendritic cells. In Atlas of Blood Cells—Function and Pathology, D. Zucker-Franklin, C.E. Grossi, eds., vol. 1, pp. 449–478. Arti Grafiche Salea, Milan. Rowden, G. (1981). The Langerhans cell. CRC Crit Rev Immunol 3, 95–180. Rowden, G., Lewis, M.G., Sullivan, A.K. (1977). Ia antigen expression on human epidermal Langerhans cells. Nature 268, 247–248. Sallusto, F., Palermi, B., Lenig, D., Miettinen, M., Matikainen, S, Julkunn, I., et al. (1999). Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 29, 1617–1625. Samuelsson, A., Towers, T.L., Ravetch, J.V. (2001). Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484–486. Schaerli, P., Willimann, K., Ebert, L.M., Walz, A., Moser, B. (2005). Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23, 331–342. Schiavoni, G., Mattei, F., Sestili, P., Borghi, P., Venditti, M., Morse, H.C. III (2002). ICSBP is essential for the development of mouse type I interferon-
CELLS
IN
THE
MOUSE
153
producing cells and for the generation and activation of CD8α+ dendritic cells. J Exp Med 196, 1415–1425. Schmieg, J., Yang, G., Franck, R.W., Tsuji, M. (2003). Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J Exp Med 198, 1631–1641. Schmieg, J., Yang, G., Franck, R.W., Van Rooijen, N., Tsuji, M. (2005). Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci USA 102, 1127–1132. Schnare, M., Barton, G.M., Holt, A.C., Takeda, K., Akira, S., Medzhitov, R. (2001). Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2, 947–950. Schuler, G., Steinman, R.M. (1985). Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 161, 526–546. Schuurhuis, D.H., Laban, S., Toes, R.E.M., Ricciardi-Castabnoli, P., Kleijmeer, M.J., van der Voort, E.I.H., et al. (2000). Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 192, 145–150. Serbina, N.V., Salazar-Mather, T.P., Biron, C.A., Kuziel, W.A., Pamer, E.G. (2003). TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19, 59–70. Shakhar, G., Lindquist, R.L., Skokos, D., Dudziak, D., Huang, J.H., Nussenzweig, M.C., et al. (2005). Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat Immunol 6, 707–714. Shortman, K., Liu, Y.-J. (2002). Mouse and human dendritic cell subtypes. Nat Rev Immunol 2, 151–161. Somersan, S., Larsson, M., Fonteneau, J.F., Basu, S., Srivastava, P., Bhardwaj, N. (2001). Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 167, 4844–4852. Soumelis, V., Reche, P.A., Kanzler, H., Juan, W., Edward, G., Homey, B., et al. (2002). Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nat Immunol 3, 673–680. Sporri, R., Reis e Sousa, C. (2005). Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 6, 163–170. Steinman, R.M. (2004). Dendritic cells: from the fabric of immunology. Clin Invest Med 27, 231–236. Steinman, R.M., Cohn, Z.A. (1973). Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137, 1142–1162. Steinman, R.M., Cohn, Z.A. (1974). Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med 139, 380–397. Steinman, R.M., Gutchinov, B., Witmer, M.D., Nussenzweig, M.C. (1983). Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice. J Exp Med 157, 613–627. Steinman, R.M., Hawiger, D., Nussenzeig, M.C. (2003). Tolerogenic dendritic cells. Annu Rev Immunol 21, 685–711. Steinman, R.M., Kaplan, G., Witmer, M.D., Cohn, Z.A. (1979). Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J Exp Med 149, 1–16. Steinman, R.M., Nogueira, N., Witmer, M.D., Tydings, J.D., Mellman, I.S. (1980). Lymphokine enhances the expression and synthesis of Ia antigen on cultured mouse peritoneal macrophages. J Exp Med 152, 1248–1261. Steinman, R.M., Witmer, M.D. (1978). Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 75, 5132–5136. Stingl, G., Katz, S.I., Clement, L., Green, I., Shevach, E.M. (1978). Immunologic functions of Ia-bearing epidermal Langerhans cells. J Immunol 121, 2005–2013.
154
KANG
LIU,
ANNA
Stingl, G., Shevach, E.M. (1991). Langerhans cells as antigen-presenting cells. In Epidermal Langerhans Cells, G. Schuler, ed., pp. 159–190. CRC Press, Boca Raton, FL. Stingl, G., Wolff-Schreiner, E.C., Pichler, W.J., Gschnait, F., Knapp, W., Wolff, K. (1977). Epidermal Langerhans cells bear Fc and C3 receptors. Nature 268, 245–246. Suzuki, S., Honma, K., Matsuyama, T., Suzuki, K., Toriyama, K., Akitoyo, I., et al. (2004). Critical roles of interferon regulatory factor 4 in CD11bhighCD8α− dendritic cell development. Proc Natl Acad Sci USA 101, 8981–8986. Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., et al. (2005). Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243–249. Tarbell, K.V., Yamazaki, S., Olson, K., Toy, P, Steinman, R.M. (2004). CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 199, 1467–1477. Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.C., Lanzavecchia, A., et al. (2004). Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304, 104–107. Traver, D., Akashi, K., Manz, M., Merad, M., Miyamoto, T., Engleman E.G., et al. (2000). Development of CD8α-positive dendritic cells from a common myeloid progenitor. Science 290, 2152–2154. Trombetta, E.S., Ebersold, M., Garrett, W., Pypaert, M., Mellman, I. (2003). Activation of lysosomal function during dendritic cell maturation. Science 299, 1400–1403. Trombetta, E.S., Mellman, I. (2005). Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23, 975–1028. Trumpfheller, C., Finke, J.S., Lopez, C.B., Moran, T.M., Moltedo, B., Soares, H., et al. (2006). Intensified and protective CD4+ T cell immunity at a mucosal surface after a single dose of anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 203, 607–617. Turley, S.J., Inaba, K., Garrett, W.S., Ebersold, M., Unternaehrer, J. Steinman, R.M., et al. (2000). Transport of peptide-MHC class II complexes in developing dendritic cells. Science 288, 522–527. Tussiwand, R., Onai, N., Mazzucchelli, L., Manz, M.G. (2005). Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity. J Immunol 175, 3674–3680. Valladeau, J., Ravel, O., Dezutter-Dambuyant C., Moore, K., Kleijmeer, M., Liu, Y., et al. (2000). Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12, 71–81. Van Kooten, C., Banchereau, J. (1997). Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 9, 330–337. Van Voorhis, W.C., Valinsky, J., Hoffman, E., Luban, J., Hair, L.S., Steinman, R.M. (1983). Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med 158, 174–191. Walzer, T., Dalod, M., Robbins, S.H., Zitvogel, L., Vivier, E. (2005). Naturalkiller cells and dendritic cells: “l’union fait la force.” Blood 106, 2252–2258. Watanabe, N., Wang, Y.H., Lee, H.K., Ito, T., Wang, Y.H., Cao, W., et al. (2005). Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436, 1181–1185.
CHARALAMBOUS,
AND
RALPH
M.
STEINMAN
Weijer, K., Wittenbogaart, C.H., Voordouw, A., Couwenberg, F., Seppen, J., Blom, B., et al. (2002). Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. Blood 99, 2752–2759. Wilson, N.S., El-Sukkari, D., Villadangos, J.A. (2004). Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 103, 2187–2195. Winzler, C., Rovere, P., Rescigno, M., Granucci, R., Penna, G., Adorini, L., et al. (1997). Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 185, 317–328. Wong, B.R., Josien, R., Lee, S.Y., Sauter, B., Li, H.-L., Steinman, R.M., et al. (1997). TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell specific survival factor. J Exp Med 186, 2075–2080. Wu, L., D’Amico, A., Winkel, K.D., Suter, M., Lo, D., Shortman, K. (1998). RelB is essential for the development of myeloid-related CD8α- dendritic cells but not of lymphoid-related CD8α+ dendritic cells. Immunity 9, 839–847. Wu, L., Nichogiannopoulou, A., Shortman, K., Georgopoulos, K. (1997). Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. Immunity 7, 483–492. Wykes, M., Pombo, A., Jenkins, C., MacPherson, G.G. (1998). Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 161, 1313–1319. Yamazaki, S., Okoshi, Y., Shibuya, K., Yamazaki, S., Tahara-Haraoka, S., Honda, S., et al. (2003). Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen processing dendritic cells. J Exp Med 198, 235–247. Yoneyama, H., Matsuno, K., Toda, E., Nishiwaki, T., Matsuo, N., Nakano, A., et al. (2005). Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 202, 425–435. Yoneyama, H., Matsuno, K., Zhang, Y., Nishiwaki, T., Kitabatake, M., Ueha, S., et al. (2004). Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 16, 915–928. Zal, T., Volkmann, A., Stockinger, B. (1994). Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 180, 2089–2099. Zammit, D.J., Cauley, L.S., Pham, Q.M., Lefrancois, L. (2005). Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 22, 561–570. Zhao, X., Deak, E., Soderberg, K., Linehan, M., Spezzano, D., Zhu, J., et al. (2003). Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 197, 153–162. Zhong, M.X., Kuziel, W.A., Pamer, E.G., Serbina, N.V (2004). Chemokine receptor 5 is dispensable for innate and adaptive immune responses to Listeria monocytogenes infection. Infect Immun 72, 1057–1064. Zhou, D., Mattner, J., Cantu, C., 3rd, Schrantz, N., Yin, N., Gao, Y., et al. (2004). Lysosomal glycosphingolipid recognition by NKT cells. Science 306, 1786–1789.
Chapter 5 Mouse Models Revealed the Mechanisms for Somatic Hypermutation and Class Switch Recombination of Immunoglobulin Genes Maria D. Iglesias-Ussel, Ziqiang Li, and Matthew D. Scharff
I. The Generation of Antibody Diversity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Somatic Hypermutation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Class Switch Recombination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II. Activation-Induced Cytidine Deaminase and Uracil N-Glycosylase . . . . . . III. Mismatch Repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Error-Prone DNA Polymerases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. NHEJ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VI. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I. THE GENERATION OF ANTIBODY DIVERSITY The production of specific antibodies involves three diversification processes: V(D)J recombination, somatic hypermutation (SHM), and class switch recombination (CSR). At the beginning of B lymphocyte development in the bone marrow,
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
155 156 157 157 162 164 164 165 165 165
immunoglobulin (Ig) variable (V) regions are assembled by V(D)J and VJ rearrangements of heavy- and light-chain Ig genes, respectively, to produce a primary repertoire of IgM antibodies with typically low-affinity binding for the antigen. Once antigen appears and is taken up by the B cells through the surface IgM molecules, it is processed and presented by the major histocompatability complex (MHC) class II complex to helper T cells. This interaction results in the activation of the
Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
155
156
MARIA
D.
IGLESIAS-USSEL,
B cells and their rapid proliferation and migration into the dark zone of the germinal center in peripheral lymphoid organs, such as spleen, lymph node, tonsil, and Peyer’s patches, where they become centroblasts. The differentiation of the activated B cells into centroblasts is associated with the expression of activation-induced cytidine deaminase (AID), which alters the Ig genes by triggering SHM and CSR (Fig. 5-1). Once these processes are completed, the cells differentiate into centrocytes in the light zone of the germinal center. Centrocytes making antibodies that have acquired a higher affinity for antigen as a result of SHM successfully compete for antigen presented by follicular dendritic cells and are positively selected to differentiate into plasma or memory B cells, whereas those B cells that have not undergone affinity maturation or have become autoreactive either undergo apoptosis or become anergic (MacLennan 1994).
A.
Somatic Hypermutation
SHM occurs at a rate of ~1 × 10−3 mutations per base per generation (McKean et al. 1984; Rajewsky et al. 1987), which
Iµ Sµ V(D)J
ZIQIANG
Iγ1 Sγ1 Cµ3
Cδ
AND
MATTHEW
D.
SCHARFF
is nearly a million times higher than the rate of mutation of housekeeping genes. These mutations occur more often at G:C pairs within DGYW (D = A/G/T, Y = C/T, and W = A/T) and the complementary WRCH (R = A/G and H = A/C/T) hotspot motifs (Rogozin and Diaz 2004). Some hotspots are targeted more than others and transition mutations (purine to purine or pyrimidine to pyrimidine) are more frequent than transversions (purine to pyrimidine or pyrimidine to purine) (Golding et al. 1987). SHM begins 200 base pairs downstream from the V region transcriptional start site, occurs most frequently at the hypervariable regions (CDRs) that encode the antigen-binding site, and extends 1.5 kilobases downstream from the promoter. Transgenic mice with deletions in their Ig genes have been used to search for cis-acting sequences that target SHM to the V regions but not the C region of Ig genes. These in vivo studies showed that ectopically located Ig genes undergo SHM in an apparently normal fashion, suggesting that all of the information required for targeting SHM was present in the Ig gene and its immediate flanking sequences, including its promoter, intronic, and 3’ enhancers (Betz et al. 1994; Giusti and Manser 1993; O’Brien et al. 1987; Peters and Storb 1996; Sharpe et al.
Iγ Sγ3 Cµ
LI,
Iα Sα Cα
Cγ1
µGLT
γ1GLT
Activation-induced cytidine deaminase (AID) Somatic hypermutation (SHM)
Class switch recombination (CSR)
3
Cγ
Cµ
Sγ3 Cδ
V(D)J Sγ3 Cµ
Cδ
Sγ1 Cγ3
Sα Cγ1
Sα Cγ1
Cα Sγ3
Cα
Cδ
Cγ3
Cµ
***** V(D)J
Sµ
* * Sµ Sγ1
*mutations
** Sµ/γ1 Sµ/γ1 V(D)J
**
Sα Cγ1
Cα
Fig. 5-1 Schematic representation of the mouse heavy chain locus and the AID dependent changes that it undergoes during SHM and CSR. The right panel shows the model for class switch recombination. An example of switching of IgM to IgG1 is shown. After induction with specific cytokines, germline transcription takes place and the primary mRNA is spliced, so that the I and C exons are fused. AID initiates CSR (right panel) by introducing C to U mutations (*) into the donor (Sµ) and recipient (Sγ1) switch regions. As a result, double-stranded DNA breaks are generated, mediating the recombination of the involved switch regions, with the looping out of the intervening sequence as a circle. As a consequence, IgG1 is now expressed. The left panel represents the point mutations introduced by AID in the variable (V) region of the immunoglobulin, which results in a change in the affinity of the antibody. I = intronic region, which includes the promoter of germline transcription; S = switch region; Cµ = IgM constant region exon; Cδ = IgD constant region exon; Cγ = a IgG constant region exon; Cα = IgA constant region exon; GLT = germline transcript.
5. MOUSE
MODELS
REVEALED
THE
MECHANISMS
1991; Sohn et al. 1993; Storb et al. 1998; Tumas-Brundage et al. 1996, 1997). However, many different foreign sequences have been substituted for the Ig regulatory regions or for the V region itself without disrupting the targeting and characteristics of SHM, suggesting that no particular motifs are required for this process (reviewed in Jolly et al. 1996; Storb et al. 1998). Transcription is required for SHM (Fukita et al. 1998). This is supported by the finding that SHM also occurs in some non-Ig genes that are highly expressed in centroblast B cells such as Bcl-6 (Pasqualucci et al. 1998; Shen et al. 1998), fas/CD95 (reviewed in Muschen et al. 2002), mb1/Igα, and B29/Igβ (Gordon et al. 2003). In malignant cells, such as subtypes of diffuse large B cell lymphoma and AIDS-associated non-Hodgkin lymphoma, the proto-oncogenes PIM1, c-myc, RhoH/TTF, and Pax5 are also found to be mutated (Gaidano et al. 2003; Pasqualucci et al. 2001). In addition, AID itself has also been reported to hypermutate when overexpressed in cultured B and non-B cells (Martin and Scharff 2002). Nonetheless, in vivo these non-Ig genes mutate at rates that are at least 10 times lower than those in Ig genes whereas other genes that are highly expressed in centroblast B cells do not undergo mutation (Shen et al. 2000). Targeting of SHM to nonIg loci could be accomplished either by virtue of as yet unidentified cis-acting elements, by features such as a high density of hotspots, by the propensity to form susceptible DNA secondary structures, or as a result of an increase in chromatin accessibility (reviewed in Li et al. 2004).
FOR
SOMATIC
HYPERMUTATION
157
each of the S regions are differentially responsive to mitogens and cytokines and various combinations of these direct transcription and class switching to specific isotypes (reviewed in Stavnezer 2000). For instance, lipopolysaccharide (LPS) induces sterile transcription of and class switching to Cγ2b and Cγ3, whereas LPS plus interleukin (IL)-4 induces switching to Cγ1 and Cε (reviewed in Coffman et al. 1993). Enhancers that are located at the 3′ end of the heavy-chain locus appear to regulate the CSR, since the deletion of HS3b and HS4 is associated with the loss of switching to some isotypes (Pinaud et al. 2001). AID initiates CSR by introducing G:U mismatches into the donor Sµ and recipient S regions (see Fig. 5-1). Doublestranded DNA breaks (DSBs) most probably originate from closely spaced staggered single-stranded breaks resulting from the action of downstream repair processes (Arudchandran et al. 2004; Imai et al. 2003; Rush et al. 2004). The DSB mediates the recombination between the donor Sµ and recipient S regions. The role of the S regions has been supported by in vivo mouse studies in which either the donor Sµ or the recipient Sγ region have been removed or manipulated (reviewed in Chaudhuri and Alt 2004). As with SHM, it has not been possible to identify particular cis-acting motifs for DNA binding proteins that are required for CSR except possibly a p50 nuclear factor-κb binding site in the Sγ3 region (Kenter et al. 2004).
II.
ACTIVATION-INDUCED CYTIDINE DEAMINASE AND URACIL
B.
Class Switch Recombination
CSR exchanges the isotype of the antibody produced by a B cell from IgM or IgD to IgG, IgE, or IgA, adding diverse effector functions while preserving antigen specificity. The heavy-chain constant (CH) region in mouse contains eight different genes organized in the 5′ to 3′ order: Cµ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε, and Ca (Fig. 5-1). CSR occurs by intrachromosomal recombination between large repetitive switch (S) regions located upstream of each CH region gene, except for δ, with the excision and loss of all intervening sequences (reviewed in Stavnezer 2000). When CSR occurs, the first CH (Cµ) expressed during development is replaced with one of the downstream CH exons (Cγ, Cε, or Cα). The CH region determines whether the antibody will fix complement, bind to Fc receptors on phagocytic cells, remain in the circulation, diffuse into tissues and body spaces, or polymerize to increase avidity. Like SHM, CSR requires transcription. These sterile or germline transcripts (GLTs) do not encode a protein and are spliced, so that the I exon and CH region are fused (Fig. 5-1). The nascent GLT corresponding to the S region remains stably associated with the DNA template strand and forms RNA-DNA hybrids, whereas the displaced G-rich nontemplate DNA strand exists in a single-stranded state. Such a structure is called an R loop (Shinkura et al. 2003; Yu et al. 2003). The promoters 5′ to
N-GLYCOSYLASE As described above, mice with engineered deletions of various parts of the Ig genes have been very useful in defining critical regulatory elements that are required for SHM and CSR and in revealing the need for transcription for both of these processes. In addition, the examination of some patients with immunodeficiencies has provided important insights (reviewed in Durandy et al. 2003, 2004). However, the major breakthroughs in our understanding of the enzymes responsible for SHM and CSR and of the relationship of these two processes have come primarily from studies with mice that are genetically deficient in the proteins involved (Table 5-1). This is best illustrated by the discovery of AID. Little was known about the biochemical basis of SHM and CSR until 1999 when “the master molecule” essential for the initiation of these two processes, AID, was discovered by Honjo and his colleagues (Muramatsu et al. 1999). They found a 10-fold increase in the expression of this previously unknown gene when a murine B lymphoma line, CH12F3-2, was induced to undergo CSR. They went on to show that AID is selectively expressed in germinal center B cells, where SHM and CSR occur. They then generated AID-deficient mice and found that these mice could not carry out either SHM or CSR (Muramatsu et al. 2000).
TABLE 5-1
PROTEINS DETERMINED TO BE INVOLVED IN SHM AND CSR FROM STUDIES WITH DEFICIENT MICE Effects in CSR in Its Absence Protein Knocked Out
Function
Effect in SHM in Its Absence
Isotype Switching
Targeting of Consensus Motif
Positioning of Junctions
Blunt Junctions
Microhomologies at Junctions
Insertions
References
ND
ND
ND
ND
In patients (Revy et al. 2000); in mice (Muramatsu et al. 2000; Petersen et al. 2001; Reina-SanMartin et al. 2003) Ehrenstein and Neuberger, 1999; Martin et al. 2003; Min et al. 2003; Phung et al. 1998; Rada et al. 1998; Schrader et al. 1999, 2002, 2003; Vora et al. 1999
AID
Cytidine deaminase in ssDNA.
Abolished
Abolished
ND
Msh2
MMR: recognition of point mutations, short mismatches (in complex with Msh6), large mismatches, insertions, deletions (with Msh3); recruitment of accessory proteins involved in processing of mismatch Recognizes mismatch but fails to repair it; signals apoptosis.
No effect in frequency of mutations to 5-fold reduction in mutation frequency; reduced mutations at A:T; increase in hotspot targeting
*Impairment: 80% reduction in switching to IgG3 and 35% reduction in switching to IgG1
Increase in ND consensus targeting at Sµ
Increase
Decreased length of microhomologies at Sµ-Sγ3 junctions.
Increase
Decrease in mutation frequency; reduced mutations at A:T; increase in Ts at G:C; increase in hotspot targeting No effect in mutation frequency; decrease in Ts at G:C in V
Impairment: 50% reduction in switching to IgG3 and 25% reduction in switching to IgG1
ND
ND
Decrease
Increase in long microhomologies
Increase in long insertions
Martin et al. 2003
No effect; decrease in Ts at G:C in Sµ regions
No effect in consensus targeting
No effect
No effect
No effect
Increase
Li et al. 2004; Wiesendanger et al. 2000
Decrease in mutation frequency (Wiesendanger); reduced mutations at A:T; increase in Ts at G:C; increase in hotspot targeting
Impairment; no effect in frequency of mutation at S regions to slight decrease; slight increase of G:C mutations at S regions; high increase of hotspot targeting at recombined Sµ-Sγ3 regions ND
Increase in Changed consensus targeting in Sγ3 but not in Sµ
No effect
No effect
No effect
Li et al. 2004; Martomo et al. 2004; Wiesendanger et al. 2000
ND
ND
ND
ND
ND
Wiesendanger et al. 2000
3.4-fold reduction in switching to IgG1 and 1.4-fold reduction in switching to IgG3
No effect in consensus targeting
Shifted toward ND 3′ part of Sµ and 5′ of Sγ1
Increase in long microhomologies
No effect
Cascalho et al. 1998; Ehrenstein et al. 2001; Kim et al. 1999; Kong and Maizels 1999; Schrader et al. 2002; Winter et al. 1998
~3-fold reduction in switching; increase of mutations at S regions
ND
ND
Increase in long microhomologies
No effect
Kim et al. 1999; Schrader et al. 2002, 2003
Msh2 G674A
Msh3
Msh6
MMR: recognition of large mismatches, insertions, deletions (in complex with Msh2) MMR: recognition of point mutations, short mismatches (in complex with Msh2)
Msh3/Msh6 double knockout
MMR
Pms2
MMR
Mlh1
MMR
Decrease in the frequency of mutation; reduced mutations at A:T; increase in hotspot targeting No effect/∼2-fold reduction in mutation frequency; high frequency of dinucleotide mutations; slight increase of mutations at G:C ∼2-fold reduction in mutation frequency (Kim); slight increase of mutations at G:C
ND
Msh2/Mlh1 double knockout
MMR
ND
UNG
Base excision repair: excises dU creating an abasic site MMR/base excision repair pathway
95% of Ts at G:C; unaffected pattern of mutations at A:T. Ablation of mutations at A:T pairs; 99% of Ts at G:C pairs Reduced mutations at A:T; increase in Ts at G:C; increase in hotspot targeting
Msh2/UNG double knockout Exo1
Exonuclease involved in MMR
DNA-PKcs
DSB repair by NHEJ
No effect
DNA-PKcs (mutant) Ku70
DSB repair by NHEJ
Small to no effect
DSB repair by NHEJ
No effect
Ku86
DSB repair by NHEJ
No effect
γH2AX
DSB repair
No effect
53BP1
DSB repair
No effect
ATM
DSB repair
No effect in SHM
Rad10 (mammalian homolog ERCC1)
Nucleotide excision repair ND endonuclease; cleavage of R loops in vitro
Xpg (homolog of XPG)
Nucleotide excision repair 3-fold reduction in endonuclease; cleavage of mutation frequency; R loops in vitro increase in mutations at A:T pairs
22–45% reduction in switching to all isotypes increase of mutations at S regions Severe impairment: reduced levels of IgG3; no effect in GLT Total ablation of CSR in vitro; reduction of 50% in vivo 70% reduction
ND
ND
ND
Increase in long microhomologies
Slight increase
Schrader et al. 2003
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
In mice (Begum et al. 2004; Rada et al. 2002); in patients (Imai et al. 2003) Rada et al. 2004
ND
ND
Increase
Increase in long insertions
Bardwell et al. 2004
Abrogated switching to all isotypes but not to IgG1 No effect
ND
No effect
ND
Decrease in long microhomologies and increase in short microhomologies ND
ND
Manis et al. 2002
ND
No effect
ND
ND
ND
Lack of CSR; no effect in GLT Severe impairment; absence of mutations at Sµ Impairment: 50–86% reduction in switching to IgG1; no effect in GLT; no effect in mutation at S regions Modest impairment of CSR: 10% reduction in switching to IgG and 20% reduction in switching to IgA; no effect in GLT Severely impaired CSR; no effect in GLT but reduced expression of postswitch transcripts; lower to normal frequency of hypermutation at S regions; no effect in intraswitch recombination 20–55% reduction in switching to all isotypes in vitro; increase in hotspot targeting at S regions No effect
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
Bemark et al. 2000; Bosma et al. 2002 Gu et al. 1997; Manis et al. 1998 Casellas et al. 1998; Reina-SanMartin et al. 2003
ND
No effect
ND
No effect
ND
Petersen et al. 2001; Reina-SanMartin et al. 2003
ND
ND
ND
No effect
No effect
Manis et al. 2004
ND
ND
ND
Increased microhomology at Sµ-γ1 junctions/no effect
ND
Lumsden et al. 2004; Reina-SanMartin et al. 2004
ND
ND
ND
No effect
No effect
Schrader et al. 2004
ND
ND
ND
ND
ND
Shiomi et al. 2001; Tian et al. 2004
Continued
TABLE 5-1
PROTEINS DETERMINED TO BE INVOLVED IN SHM AND CSR FROM STUDIES WITH DEFICIENT MICE—cont’d Effects in CSR in Its Absence Protein Knocked Out NF-κB (p50)
Function
Effect in SHM in Its Absence
Isotype Switching
Transcription factor
ND
Decrease of CSR to
involved in B cell
IgG3 and no effect in
activation
CSR to IgG1
Polymerase ζ (antisense)
DNA replication; role in SHM
Polymerase η
DNA replication; role in SHM
Decreased frequency of mutation no effect in pattern of mutations Decreased mutations at A:T (mainly A to C or T to G changes)
ND
Increase of mutations at G:C in Sµ regions
Targeting of Consensus Motif Increase in
Positioning of Junctions
Blunt Junctions
Microhomologies at Junctions
Insertions
References
ND
ND
Decreased length of
ND
Kenter et al. 2004
consensus
microhomologies
targeting at Sγ3 ND
ND
ND
ND
ND
Diaz et al. 2001
ND
ND
ND
ND
ND
Delbos et al. 2005; Martomo et al. 2005
ND, not determined; S, switch region; Ts, transition mutations; GLT, germ line transcript; MMR, mismatch repair.
in Sµ-γ3 junctions
5. MOUSE
MODELS
REVEALED
THE
MECHANISMS
These mice were the equivalent of a subset of patients with hyper-IgM syndrome, who were found to have inactivating mutations in the AID gene (Revy et al. 2000). Thus, AID deficiency leads to the production of low-affinity, unmutated IgM antibodies and no IgG, IgE, or IgA. The IgM antibodies are able to protect mice from death after primary and secondary infections with influenza virus, but after the secondary infection AID−/− mice have a high morbidity, due to the absence of other Ig classes and/or high-affinity antibodies (Harada et al. 2003). Activated IgM B cells and IgM plasma cells accumulate in lymphoid tissues, especially in the intestine, but IgA is absent, resulting in proliferation of anaerobic bacteria and a change in the gut microflora (Fagarasan et al. 2002). When splenic B cells from these AID-deficient mice were stimulated in vitro with LPS and cytokines, they failed to undergo class switch recombination, although they expressed GLTs (Muramatsu et al. 2000). A primary role for AID was confirmed by showing that the ectopic expression of AID can induce CSR and/or SHM in B-cells at the wrong stage of differentiation (Martin et al. 2002), in non-B cells, such as fibroblasts (Okazaki et al. 2002; Yoshikawa et al. 2002) and Chinese hamster ovary cells (Martin and Scharff 2002), and even in Escherichia coli (Petersen-Mahrt et al. 2002; Ramiro et al. 2003; Sohail et al. 2003) and yeast (Poltoratsky et al. 2004). These findings suggest that AID might be the only B-cell specific factor required for these processes whereas the other factors involved in SHM and CSR are ubiquitously expressed. AID is a small protein of 198 amino acids containing a conserved cytidine deaminase motif. AID possesses a 34% amino acid identity to apolipoprotein B editing complex catalytic subunit 1 (APOBEC1) (Muramatsu et al. 1999). APOBEC1 deaminates the cytidine at position 6666 in the apolipoprotein B (ApoB) mRNA to uracil, creating a nonsense codon that results in a truncated ApoB100, ApoB48, which has an entirely different function. AID, based on its homology with APOBEC1 and by comparison of APOBEC1 with the three-dimensional structure of E. coli metabolic cytidine deaminase (Navaratnam et al. 1998), was predicted to have the same four functional domains: 1) an N-terminal α helix domain (residues 1–20), that contains a potential nuclear localization signal; 2) an active cytidine deaminase motif (residues 20–110), which contains the residues that coordinate Zn; 3) a linker motif (residues 110–148); and 4) a cytidine deaminase pseudoactive site (residues 148–198), which has homology with the active site of the enzyme but presumably has no enzymatic activity. The C terminus contains a nuclear export signal. Two models have been proposed to describe the role of cytidine deamination in SHM and CSR: the RNA editing model, that has been championed by Honjo, proposes that AID, like APOBEC1, deaminates C to U at a specific position of a yet to be identified messenger RNA, which encodes an unknown DNA endonuclease that would cleave the V or S regions.
FOR
SOMATIC
HYPERMUTATION
161
This hypothesis is supported by the finding that de novo protein synthesis is required for AID activity, suggesting that a messenger RNA edited by AID has to be translated (Doi et al. 2003) before the cleavage step (Begum et al. 2004). The hypothesis that AID was acting as an RNA editing enzyme became less tenable when it was shown that mice with a genetic deficiency in uracil N-glycosylase (UNG), a DNA uracil glycosylase, had a distorted spectrum of somatic mutation and a decrease in CSR (Rada et al. 2002). Just as the phenotype of the AID−/− mice revealed a critical role for cytidine deamination in initiating both SHM and CSR, the phenotype of the UNG−/− mice (see Table 5-1) tipped the balance between RNA and DNA as the potential substrates for AID. A role for UNG was also reported in chicken B cells in culture (Di Noia and Neuberger 2002), in bacteria (Petersen-Mahrt et al. 2002), and subsequently in humans (Imai et al. 2003). In fact, it seemed very unlikely that AID was editing a messenger RNA in non-B cells (Martin and Scharff 2002; Okazaki et al. 2002; Yoshikawa et al. 2002) and bacteria (Petersen-Mahrt et al. 2002; Ramiro et al. 2003; Sohail et al. 2003), in which AID itself is not normally expressed. The DNA deamination model for SHM was confirmed in vitro when semipurified AID deaminated dC in a SHM-like manner in single-stranded DNA (ssDNA), but not in double-stranded DNA, RNA, or DNA:RNA hybrids (Bransteitter et al. 2003; Pham et al. 2003). Other laboratoriess have also reported that ssDNA is the substrate for AID purified from B cells (Chaudhuri et al. 2003; Ramiro et al. 2003) and bacteria (Dickerson et al. 2003; Sohail et al. 2003). The biochemical studies with AID made from transfected insect cells and from B cells are especially interesting because they suggest that AID itself has the inherent ability to recognize the same hotspot motifs that are targeted in vivo (Chaudhuri et al. 2003; Pham et al. 2003). The finding that ssDNA was the substrate for AID provided an explanation for why transcription was required, since AID recognized the ssDNA in the nontranscribed strand in transcription bubbles and in the R loops in the S regions. Although biochemical studies suggest that AID acting alone can target hotspots on ssDNA, there is also evidence that this AID-initiated process is facilitated by replication protein A (RPA), a ssDNA binding protein (Chaudhuri et al. 2004) with roles in replication, repair, and recombination. RPA could facilitate the mutation of both V and S regions by binding to ssDNA and/or through its association with RNA polymerase II and UNG. Additional as yet undiscovered associated proteins may be required to target AID to the V or S regions. Alterations (deletion, insertion, or frameshift replacement) in the 8–17 amino acids in the C-terminal region of AID, found in patients with the hyper-IgM type 2 syndrome, cause complete loss of CSR activity whereas SHM activity is retained (Ta et al. 2003). Similarly, deletion of C-terminal amino acids 189–198 of AID also causes loss of CSR while unexpectedly displaying higher levels of SHM than the wild-type AID (Barreto et al. 2003). Mutants in the N-terminal region of AID have decreased
162
MARIA
D.
IGLESIAS-USSEL,
LI,
AND
MATTHEW
D.
SCHARFF
2002). dU can be 1) replicated to produce a C to T (G to A on the other strand) transition mutation (Fig. 5-2a), 2) removed by UNG to create an abasic site that can be bypassed by errorprone DNA polymerase(s) to generate transition and transversion mutations in SHM (Figs. 5-2b and 5-3) recognized by the Msh2-Msh6 complex of the mismatch repair pathway so that the dU:dG mismatch is excised and resynthesized by errorprone polymerases that will create additional mutations including mutations at A:T base pairs (Fig. 5-2c). To initiate CSR, the dU created by AID in the S region is removed by UNG, creating an abasic site that is converted into a single-stranded nick by endonuclease. Close spaced nicks on both strands are converted into double-stranded breaks, which are then processed by NHEJ (reviewed in Chaudhuri and Alt 2004) (not shown).
ability to carry out SHM while retaining CSR activity (Shinkura et al. 2004). These results raise the possibility that AID activity in SHM and CSR depends on the recruitment of separate cofactors that have yet to be identified. Although both SHM and CSR take place in centroblast B cells, they can occur independently, since there are IgM antibodies with somatic mutations and IgG antibodies with unmutated V regions. Moreover, stimulation of spleen B cells in vitro induces CSR but not SHM. Although these two processes share factors such as AID, UNG, and mismatch repair (MMR) proteins and require transcription, they also differ in that CSR requires DSB, looping out and excision of S regions and the proteins involved in nonhomologous end joining (NHEJ) to complete the recombination process, whereas recombination and NHEJ are not required for SHM (Table 5-1). These similarities and differences, which were revealed primarily through the examination of genetically deficient mice (see Table 5-1), have led to a model (Rada et al. 1998) in which both SHM and CSR are initiated by AID-dependent deamination of dC either in the V region or the S region. For SHM, the dU created in the V region by AID may be subsequently processed in different ways (Petersen-Mahrt et al.
C
ZIQIANG
III.
MISMATCH REPAIR
Mismatch repair machinery recognizes and corrects the mismatched base pairs that arise during DNA replication or other
Co-factors
RPAAID G RNAP
RNA polymerase complex
AID U
AID-derived G-U mismatch
RPA AID G RNAP
Replication
Ts
T
UNG
G : abasic site
A C
Replication (error-prone DNA polymerases)
G
Phase 1a
C
or Ts
G
MLH1/PMS2/EXO1
G
Error-prone DNA polymerase ***** **
A:T mutations
T A
or
Phase 2
A
Tv or Tv
Msh2-Msh6
T G C
Phase 1b Fig. 5-2 Model of AID-induced mutations in SHM. An AID molecule along with some associated molecules is shown in a moving transcription bubble. AID deaminates deoxycytosines (C) to deoxyuracil (U) in ssDNA. The dU can be (a) replicated, creating C to T and G to A transition mutations (Ts); (b) removed by UNG to create an abasic site that can bypassed by error-prone DNA polymerases to create transition and transversion mutations (Tv); or (c) recognized by the mismatch repair complex Msh2-Msh6, excised, and resynthesized by error-prone DNA polymerases, creating additional mutations at A:T pairs. RNAP = RNA polymerase II; RPA = replication protein A.
5. MOUSE
MODELS
REVEALED
THE
MECHANISMS
FOR
SOMATIC
HYPERMUTATION
MSH6
163
MSH3
MSH2
Mismatch recognition MSH6 or MSH3 MSH2 RFC EXO1 MLH1
MSH6 or MSH3
PCNA
PMS2
RFC MSH2 PCNA
EXO1
Excision
MLH1 PMS2
DNA Polymerase
Resynthesis & ligation DNA Ligase
Fig. 5-3 The major known mismatch repair proteins are shown recognizing and repairing a mismatch. Small mismatches are recognized by Msh2 in complex with Msh6 and large mismatches by the Msh2-Msh3 complex. The heterodimer moves away from the mismatch and recruits additional mismatch repair proteins, such as Mlh1, Pms2, Exo1, PCNA and replication factor C (RFC). As a result, a DNA patch containing the mismatch is excised, and the resulting gap is filled in and repaired by DNA polymerase and DNA ligase.
DNA repair processes. Deficiency or malfunction in MMR results in genomic instability and, as a consequence, tumors in humans and in mice (reviewed in Wei et al. 2002). The basic process of MMR includes mismatch recognition, excision of the mismatch through digestion of the DNA containing the mismatch, and filling the gap by error-free DNA polymerases (reviewed in Wei et al. 2002) (Fig. 5-3). Mismatch recognition is usually carried out by mammalian MutS homolog (Msh) 2, which forms a heterodimer with either Msh6 or Msh3. The Msh2-Msh6 heterodimer mainly recognizes single base mismatches and short mismatches, whereas the Msh2-Msh3 heterodimer recognizes larger mismatches and insertion/deletion loop mismatches (reviewed in Buermeyer et al. 1999). Msh2 and Msh6 proteins have intrinsic ATP binding and hydrolysis activities that are not required for the recognition of the mismatch (Alani et al. 1997). However, the conversion of ATP to ADP is necessary for the Msh2-Msh6 dimers to move away from the mismatch (Blackwell et al. 1998) and allow the recruitment of downstream MMR repair proteins such as
exonuclease 1 (Exo1), postmeiotic segregation (Pms) 2, MutL homologue (Mlh) 1, proliferating-cell nuclear antigen (PCNA), and presumably an unknown endonuclease, which makes a nick at some distance from the mismatch. Then, the nicked DNA containing the mismatch can be digested by Exo1. Filling in the gap by DNA polymerases and the ligation by DNA ligases complete the MMR process (reviewed in Edelmann and Edelmann 2004; Kolodner 1996; Wei et al. 2002). Interestingly, when Pms2−/− mice were examined for SHM, the rate of SHM was found to be lower, as opposed to higher, as one would predict for MMR deficiency (Cascalho et al. 1998). These results indicate that MMR is necessary for efficient SHM. In addition, the pattern of SHM from Msh2−/−, Msh6−/−, or Exo1 mutant mice shows a loss of A:T mutations and, as a consequence, a very high percentage of mutations at G:C bases (reviewed in Li et al. 2004) (see Table 5-1). However, mice deficient in Pms2 or Mlh1, two important downstream MMR proteins (Fig. 5-3), do not have as significant a reduction in A:T mutations as Msh2−/−, Msh6−/−, or Exo1 mutant mice
164
MARIA
D.
IGLESIAS-USSEL,
(see Table 5-1). Deficiency of either Pms2 or Mlh1 ablates mismatch repair activity. Thus, these two proteins could have different functions in SHM and MMR. Nonetheless, it appears that MMR proteins are needed to generate more mutations, including mutations at A:T bases, during SHM. A recent article (Rada et al. 2004) showing that in UNG/Msh2 double knockout mice there were no mutations at A:T bases and no transversion mutations, further supports the idea that MMR and UNG are competing pathways in processing the AID-generated G:U mismatches in SHM. MMR proteins are also implicated in efficient CSR. A deficiency in Msh2, Msh6, Mlh1, Pms2, or Exo1 results in reduced efficiency in CSR (see Table 5-1). In addition, in UNG/Msh2 double knockout mice there was virtually no switching (Rada et al. 2004). This suggests that MMR and UNG are alternative pathways for processing the AID-generated G:U mismatches to generate the DSBs required to initiate recombination and complete CSR. What is puzzling is that different MMR deficiencies exhibited different features in the recombined DNA segments. An increase in blunt junctions and insertions and a decreased length of microhomologies were observed in the switch junctions from Msh2−/− mice. Exo1 mutant mice also exhibited a similar, although less dramatic S junction pattern. Interestingly, Msh6−/− mice do not show these kinds of changes, even though both Msh2−/− and Msh6−/− mice exhibited a similar extent of reduction in CSR frequency. A deficiency in Msh6 increases the targeting of GAGCT/GGGGT consensus motifs in Sγ3 and in RGYW/ WRCY hotspot motifs and changes the usage of different subsegments of switch regions in CSR. In addition, Mlh1- or Pms2-deficient mice showed longer microhomologies in the switch junctions than Msh2−/− mice (see Table 5-1). Although Msh3-deficient mice have normal levels of CSR and SHM, they exhibited more insertions in the switch junctions, suggesting that Msh3 is not involved in processing of G:U mismatches but does participate in certain stages of CSR, possibly via mediation of the resolution of DNA breaks (Li et al. 2004). Collectively, MMR proteins may have other distinct functions in addition to processing G:U mismatches to generated DSBs to promote CSR (reviewed in Li et al. 2004). The role of MMR proteins in SHM and CSR appears to depend upon their ATPase activity, because mice harboring a point mutation in the ATPase domain of Msh2 (G674A) have a phenotype in CSR and SHM that is similar to that of Msh2−/− mice (Martin et al. 2003). Msh2 protein with this point mutation is able to recognize the mismatch but unable to initiate downstream MMR repair processes because of a lack of ATPase activity. Nonetheless, Msh2 protein lacking ATPase activity is able to trigger apoptosis, allowing the dissection of the role of Msh2 in SHM and in CSR without affecting other functions. Interestingly, these mice showed a mixed phenotype in switch junctions, that is, more insertions, which resembles findings in Msh2−/− mice, and longer microhomologies, like those found in Mlh1−/−, Pms2−/−, or Msh2−/−/Mlh1−/− mice.
ZIQIANG
IV.
LI,
AND
MATTHEW
D.
SCHARFF
ERROR-PRONE DNA POLYMERASES
Recently discovered error-prone DNA polymerases are not processive and are involved in bypassing various types of DNA lesions during DNA replication (reviewed in Tippin et al. 2004). Therefore, they could act on G:abasic sites, generating transition and transversion mutations during SHM (see Fig. 5-2b), which is essentially mediated by AID. Mice deficient in the catalytic subunit of polymerase ζ (Rev3) are embryonic lethal, making it difficult to evaluate the role of polymerase ζ in SHM in vivo. However, downregulation of Rev3 by antisense expression in transgenic mouse and in cell lines (Diaz et al. 2001; Zan et al. 2001) decreases the rate of SHM. In addition, complete deletion of polymerase ι in human Burkitt′s lymphoma BL-2 cells results in a significant reduction of SHM frequency (Faili et al. 2002), although 129/SvJ-derived strains of mice are naturally deficient in polymerase ι and show normal levels of SHM (McDonald et al. 2003). These two contradictory results could reflect the mechanistic difference in SHM between mouse and human or could be peculiar to the BL-2 cell line. Polymerase η, a very error-prone polymerase when one is replicating an undamaged DNA template, is clearly involved in SHM. When patients with xeroderma pigmentosum variant who have a polymerase η deficiency were examined for V region hypermutation, they exhibited a spectrum similar to that of Msh2- or Msh6-deficient mice, that is, a loss of mutations at A:T bases and, as a consequence, a high percentage of mutations at G:C bases (Zeng et al. 2001). The same result was observed in mice lacking polymerase η (Delbos et al. 2005; Martomo et al. 2005). Because of this finding, it was proposed that MMR and polymerase η are involved in the second phase of SHM to generate additional mutations via the error-prone replication of polymerase η when filling in the gap created by Exo1 during the resolution of the G:U mismatch repair (see Fig. 5-3). Indeed, in vitro studies showed that Msh2-Msh6 is able to bind to G:U mismatches (Gu et al. 2002; Wilson et al. 2005). The puzzling part is why polymerase η is used instead of a high-fidelity DNA polymerase during the final step of G:U mismatch repair in SHM.
V.
NHEJ
NHEJ is required for V(D)J recombination during B-cell development and DNA repair via its ability to repair DSBs. The key components include the DNA-dependent protein kinase, consisting of Ku70, Ku86, and the catalytic subunit (DNAPKcs), as well as p53 binding protein 1 (53BP1), Xrcc4, and ligase IV (reviewed in Chaudhuri and Alt 2004) (see Table 5-1). Because CSR requires the generation and repair of DSBs, NHEJ-deficient mice are defective in CSR but normal in SHM
5. MOUSE
MODELS
REVEALED
THE
MECHANISMS
(see Table 5-1), supporting the idea that repairing DSBs is not required for SHM. In addition, proteins that are important for signaling the repair of DSBs are also implicated in CSR. Mice deficient in ataxia telangiectasia mutated (ATM) kinase (Lumsden et al. 2004; Reina-San-Martin et al. 2004) and H2AX (Reina-San-Martin et al. 2003) show defects in CSR. Indeed, phosphorylated H2A histone family member X (γ-H2AX), which facilitates DSB repair, forms foci that colocalized with IgH foci from in vitro stimulated primary B cells (Petersen et al. 2001). The presence of proficient CSR and SHM in homologous recombination-deficient mice, such as Rad54 (Essers et al. 1997) or Rad52 knockout mice (Rijkers et al. 1998), suggests that homologous recombination is not a major factor in CSR.
VI.
CONCLUSION
In the previous sections, we have reviewed much of the current state of our knowledge about mechanisms responsible in mice and humans for the production of high-affinity isotype switched antibodies that are distributed throughout the body to deal with pathogenic organisms and their products. In the course of this discussion and in Table 5-1, we have summarized the many genetically manipulated mice that form the basis for our understanding of the biochemical basis of SHM and CSR. Although genetic defects in humans and studies done with cultured cells and cell-free biochemical systems have been very important in advancing our knowledge about the enzymes involved in these processes, it should be evident that mouse models lacking each of these enzymes were absolutely crucial, not only because they revealed the various pathways and activities in which they were involved but also because they provided an understanding of the relative importance of each of these pathways in vivo.
ACKNOWLEDGMENTS Maria D. Iglesias-Ussel is supported by a Northeast Biodefense Center Postdoctoral Fellowship. Ziqiang Li is supported by a Cancer Research Institute Postdoctoral Fellowship and is a special fellow of the Leukemia and Lymphoma Society. Matthew D. Scharff is supported by the Harry Eagle Chair provided by the National Women’s Division of the Albert Einstein College of Medicine.
REFERENCES Alani, E., Sokolsky, T., Studamire, B., Miret, J., Lahue, R.S. (1997). Genetic and biochemical analysis of Msh2p-Msh6p: role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition. Mol Cell Biol 17, 2436–2447. Arudchandran, A., Bernstein, R.M., Max, E.E. (2004). Single-stranded DNA breaks adjacent to cytosines occur during Ig gene class switch recombination. J Immunol 173, 3223–3229.
FOR
SOMATIC
HYPERMUTATION
165
Bardwell, P.D., Woo, C.J., Wei, K., Li, Z., Martin, A., Sack, S.Z., et al. (2004). Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. Nat Immunol 5, 224–229. Barreto, V., Reina-San-Martin, B., Ramiro, A.R., McBride, K.M., Nussenzweig, M.C. (2003). C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol Cell 12, 501–508. Begum, N.A., Kinoshita, K., Muramatsu, M., Nagaoka, H., Shinkura, R., Honjo, T. (2004). De novo protein synthesis is required for activationinduced cytidine deaminase-dependent DNA cleavage in immunoglobulin class switch recombination. Proc Natl Acad Sci USA 101, 13003–13007. Bemark, M., Sale, J.E., H.-Kim, J., Berek, C., Cosgrove, R.A., Neuberger, M.S. (2000). Somatic hypermutation in the absence of DNA-PK or Rag1 activity. Exp J Med 192, 1509–1514. Betz, A.G., Milstein, C., Gonzalez-Fernandez, A., Pannell, R., Larson, T., Neuberger, M.S. (1994). Elements regulating somatic hypermutation of an immunoglobulin kappa gene: critical role for the intron enhancer/matrix attachment region. Cell 77, 239–248. Blackwell, L.J., Martik, D., Bjornson, K.P., Bjornson, E.S., Modrich, P. (1998). Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is consistent with an ATP-dependent translocation mechanism. J Biol Chem 273, 32055–32062. Bosma, G.C., Kim, J., Urich, T., Fath, D.M., Cotticelli, M.G., Ruetsch, N.R., Radic, M.Z., Bosma, M.J. (2002). DNA-dependent protein kinase activity is not required for immunoglobulin class switching. J Exp Med 196, 1483–1495. Bransteitter, R., Pham, P., Scharff, M.D., Goodman, M.F. (2003). Activationinduced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA 100, 4102–4107. Buermeyer, A.B., Deschenes, S.M., Baker, S.M., Liskay, R.M. (1999). Mammalian DNA mismatch repair. Annu Rev Genet 33, 533–564. Cascalho, M., Wong, J., Steinberg, C., Wabl, M. (1998). Mismatch repair co-opted by hypermutation. Science 279, 1207–1210. Casellas, R., Nussenzweig, A., Wuerffel, R., Pelanda, R., Reichlin, A., Suh, H., et al. (1998). Ku80 is required for immunoglobulin isotype switching. EMBO J 17, 2404–2411. Chaudhuri, J., Alt, F.W. (2004). Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol 4, 541–552. Chaudhuri, J., Khuong, C., Alt, F.W. (2004). Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 430, 992–998. Chaudhuri, J., Tian, M., Khuong, C., Chua, K., Pinaud, E., Alt, F.W. (2003). Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 422, 726–730. Coffman, R.L., Lebman, D.A., Rothman, P. (1993). Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54, 229–270. Delbos, F., De, Smet, A., Faili, A., Aoufouchi, S., Weill, J.C., Reynaud, C.A. (2005). Contribution of DNA polymerase η to immunoglobulin gene hypermutation in the mouse. J Exp Med 201, 1191–1196. Di Noia, J., Neuberger, M.S. (2002). Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419, 43–48. Diaz, M., Verkoczy, L.K., Flajnik, M.F., Kleinman, N.R. (2001). Decreased frequency of somatic hypermutation and impaired affinity maturation but intact germinal center formation in mice expressing antisense RNA to DNA polymerase ζ. J Immunol 167, 327–335. Dickerson, S.K., Market, E., Besmer, E., Papavasiliou, F.N. (2003). AID mediates hypermutation by deaminating single stranded DNA. J Exp Med 197, 1291–1296. Doi, T., Kinoshita, K., Ikegawa, M., Muramatsu, M., Honjo, T. (2003). De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination. Proc Natl Acad Sci USA 100, 2634–2638. Durandy, A., Revy, P., Fischer, A. (2003). Hyper-immunoglobulin-M syndromes caused by an intrinsic B cell defect. Curr Opin Allergy Clin Immunol 3, 421–425.
166
MARIA
D.
IGLESIAS-USSEL,
Durandy, A., Revy, P., Fischer, A. (2004). Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes). Adv Immunol 82, 295–330. Edelmann, L., Edelmann, W. (2004). Loss of DNA mismatch repair function and cancer predisposition in the mouse: animal models for human hereditary nonpolyposis colorectal cancer. Am J Med Genet C Semin Med Genet 129, 91–99. Ehrenstein, M.R., Neuberger, M.S. (1999). Deficiency in msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation. EMBO J 18, 3484–3490. Ehrenstein, M.R., Rada, C., Jones, A.M., Milstein, C., Neuberger, M.S. (2001). Switch junction sequences in PMS2-deficient mice reveal a microhomologymediated mechanism of Ig class switch recombination. Proc Natl Acad Sci USA 98, 14553–14558. Essers, J., Hendriks, R.W., Swagemakers, S.M., Troelstra, C., de Wit, J., Bootsma, D., et al. (1997). Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination. Cell 89, 195–204. Fagarasan, S., Muramatsu, M., Suzuki, K., Nagaoka, H., Hiai, H., Honjo, T. (2002). Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 298, 1424–1427. Faili, A., Aoufouchi, S., Flatter, E., Gueranger, Q., Reynaud, C.A., Weill, J.C. (2002). Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase ι. Nature 419, 944–947. Fukita, Y., Jacobs, H., Rajewsky, K. (1998). Somatic hypermutation in the heavy chain locus correlates with transcription. Immunity 9, 105–114. Gaidano, G., Pasqualucci, L., Capello, D., Berra, E., Deambrogi, C., Rossi, D., et al. (2003). Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 102, 1833–1841. Giusti, A.M., Manser, T. (1993). Hypermutation is observed only in antibody H chain V region transgenes that have recombined with endogenous immunoglobulin H DNA: implications for the location of cis-acting elements required for somatic mutation. J Exp Med 177, 797–809. Golding, G.B., Gearhart, P.J., Glickman, B.W. (1987). Patterns of somatic mutations in immunoglobulin variable genes. Genetics 115, 169–176. Gordon, M.S., Kanegai, C.M., Doerr, J.R., Wall, R. (2003). Somatic hypermutation of the B cell receptor genes B29 (Igβ, CD79b) and mb1 (Igα, CD79a) Proc Natl Acad Sci USA 100, 4126–4131. Gu, L., Wu, J., Qiu, L., Jennings, C.D., Li, G.M. (2002). Involvement of DNA mismatch repair in folate deficiency-induced apoptosis small star, filled. J Nutr Biochem 13, 355–363. Gu, Y., Jin, S., Gao, Y., Weaver, D.T., Alt, F.W. (1997). Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci USA 94, 8076–8081. Harada, Y., Muramatsu, M., Shibata, T., Honjo, T., Kuroda, K. (2003). Unmutated immunoglobulin M can protect mice from death by influenza virus infection. J Exp Med 197, 1779–1785. Imai, K., Slupphaug, G., Lee, W.I., Revy, P., Nonoyama, S., Catalan, N., et al. (2003). Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 4, 1023–1028. Jolly, C.J., Wagner, S.D., Rada, C., Klix, N., Milstein, C., Neuberger, M.S. (1996). The targeting of somatic hypermutation. Semin Immunol 8, 159–168. Kenter, A.L., Wuerffel, R., Dominguez, C., Shanmugam, A., Zhang, H. (2004). Mapping of a functional recombination motif that defines isotype specificity for µ→γ3 switch recombination implicates NF-κB p50 as the isotype-specific switching factor. J Exp Med 199, 617–627. Kim, N., Bozek, G., Lo, J.C., Storb, U. (1999). Different mismatch repair deficiencies all have the same effects on somatic hypermutation: intact primary mechanism accompanied by secondary modifications. J Exp Med 190, 21–30. Kolodner, R. (1996). Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 10, 1433–1442.
ZIQIANG
LI,
AND
MATTHEW
D.
SCHARFF
Kong, Q., Maizels, N. (1999). PMS2-deficiency diminishes hypermutation of a λ1 transgene in young but not older mice. Mol Immunol 36, 83–91. Li, Z., Scherer, S.J., Ronai, D., Iglesias-Ussel, M.D., Peled, J.U., Bardwell, P.D., et al (2004). Examination of Msh6- and Msh3-deficient mice in class switching reveals overlapping and distinct roles of MutS homologues in antibody diversification. J Exp Med 200, 47–59. Li, Z., Woo, C.J., Iglesias-Ussel, M.D., Ronai, D., Scharff, M.D. (2004). The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev 18, 1–11. Lumsden, J.M., McCarty, T., Petiniot, L.K., Shen, R., Barlow, C., Wynn, T.A., et al. (2004). Immunoglobulin class switch recombination is impaired in Atm-deficient mice. J Exp Med 200, 1111–1121. MacLennan, I.C. (1994). Germinal centers. Annu Rev Immunol 12, 117–139. Manis, J.P., Dudley, D., Kaylor, L., Alt, F.W. (2002). IgH class switch recombination to IgG1 in DNA-PKcs-deficient B cells. Immunity 16, 607–617. Manis, J.P., Gu, Y., Lansford, R., Sonoda, E., Ferrini, R., Davidson, L., et al. (1998). Ku70 is required for late B cell development and immunoglobulin heavy chain class switching. J Exp Med 187, 2081–2089. Manis, J.P., Morales, J.C., Xia, Z., Kutok, J.L., Alt, F.W., Carpenter, P.B. (2004). 53BP1 links DNA damage-response pathways to immunoglobulin heavy chain class-switch recombination. Nat Immunol 5, 481–487. Martin, A., Bardwell, P.D., Woo, C.J., Fan, M., Shulman, M.J., Scharff, M.D. (2002). Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature 415, 802–806. Martin, A., Li, Z., Lin, D., Bardwell, P.D., Iglesias-Ussel, M.D., Edelmann, W., et al. (2003). Msh2 ATPase activity is essential for somatic hypermutation at A-T base pairs and for efficient class switch recombination. J Exp Med 198, 1171–1178. Martin, A., Scharff, M.D. (2002). Somatic hypermutation of the AID transgene in B and non-B cells. Proc Natl Acad Sci USA 99, 12304–12308. Martomo, S.A., Yang, W.W., Gearhart, P.J. (2004). A role for Msh6 but not Msh3 in somatic hypermutation and class switch recombination. J Exp Med 200, 61–68. Martomo, S.A., Yang, W.W., Wersto, R.P., Ohkumo, T., Kondo, Y., Yokoi, M., et al. (2005). Different mutation signatures in DNA polymerase η- and MSH6-deficient mice suggest separate roles in antibody diversification. Proc Natl Acad Sci USA 102, 8656–8661. McDonald, J.P., Frank, E.G., Plosky, B.S., Rogozin, I.B., Masutani, C., Hanaoka, F., et al. (2003). 129-derived strains of mice are deficient in DNA polymerase ι and have normal immunoglobulin hypermutation. J Exp Med 198, 635–643. McKean, D., Huppi, K., Bell, M., Staudt, L., Gerhard, W., Weigert, M. (1984). Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci USA 81, 3180–3184. Min, I.M., Schrader, C.E., Vardo, J., Luby, T.M., D′Avirro, N., Stavnezer, J., et al. (2003). The Smu tandem repeat region is critical for Ig isotype switching in the absence of Msh2. Immunity 19, 515–524. Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., Honjo, T. (2000). Class switch recombination and hypermutation require activationinduced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553–563. Muramatsu, M., Sankaranand, V.S., Anant, S., Sugai, M., Kinoshita, K., Davidson, N.O., et al. (1999). Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 274, 18470–18476. Muschen, M., Rajewsky, K., Kronke, M., Kuppers, R. (2002). The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol 23, 75–80. Navaratnam, N., Fujino, T., Bayliss, J., Jarmuz, A., How, A., Richardson, N., et al. (1998). Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition. J Mol Biol 275, 695–714. O’Brien, R.L., Brinster, R.L., Storb, U. (1987). Somatic hypermutation of an immunoglobulin transgene in κ transgenic mice. Nature 326, 405–409.
5. MOUSE
MODELS
REVEALED
THE
MECHANISMS
Okazaki, I.M., Kinoshita, K., Muramatsu, M., Yoshikawa, K., Honjo, T. (2002). The AID enzyme induces class switch recombination in fibroblasts. Nature 416, 340–345. Pasqualucci, L., Migliazza, A., Fracchiolla, N., William, C., Neri, A., Baldini, L., et al. (1998). BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 95, 11816–11821. Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R.S., Kuppers, R., et al. (2001). Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341–346. Peters, A., Storb, U. (1996). Somatic hypermutation of immunoglobulin genes is linked to transcription initiation. Immunity 4, 57–65. Petersen, S., Casellas, R., Reina-San-Martin, B., Chen, H.T., Difilippantonio, M.J., Wilson, P.C., et al. (2001). AID is required to initiate Nbs1/γ-H2AX focus formation and mutations at sites of class switching. Nature 414, 660–665. Petersen-Mahrt, S.K., Harris, R.S., Neuberger, M.S. (2002). AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418, 99–103. Pham, P., Bransteitter, R., Petruska, J., Goodman, M.F. (2003). Processive AIDcatalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424, 103–107. Phung, Q.H., Winter, D.B., Cranston, A., Tarone, R.E., Bohr, V.A., Fishel, R., et al. (1998). Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. J Exp Med 187, 1745–1751. Pinaud, E., Khamlichi, A.A., Le Morvan, C., Drouet, M., Nalesso, V., Le Bert, M., et al. (2001). Localization of the 3’ IgH locus elements that effect long-distance regulation of class switch recombination. Immunity 15, 187–199. Poltoratsky, V.P., Wilson, S.H., Kunkel, T.A., Pavlov, Y.I. (2004). Recombinogenic phenotype of human activation-induced cytosine deaminase. J Immunol 172, 4308–4313. Rada, C., Di, J.M., Noia Neuberger, M.S. (2004). Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. Mol Cell 16, 163–171. Rada, C., Ehrenstein, M.R., Neuberger, M.S., Milstein, C. (1998). Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. Immunity 9, 135–141. Rada, C., Williams, G.T., Nilsen, H., Barnes, D.E., Lindahl, T., Neuberger, M.S. (2002). Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr Biol 12, 1748–1755. Rajewsky, K., Forster, I., Cumano, A. (1987). Evolutionary and somatic selection of the antibody repertoire in the mouse. Science 238, 1088–1094. Ramiro, A.R., Stavropoulos, P., Jankovic, M., Nussenzweig, M.C. (2003). Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat Immunol 4, 452–456. Reina-San-Martin, B., Chen, H.T., Nussenzweig, A., Nussenzweig, M.C. (2004). ATM is required for efficient recombination between immunoglobulin switch regions. J Exp Med 200, 1103–1110. Reina-San-Martin, B., Difilippantonio, S., Hanitsch, L., Masilamani, R.F., Nussenzweig, A., Nussenzweig, M.C. (2003). H2AX is required for recombination between immunoglobulin switch regions but not for intra-switch region recombination or somatic hypermutation. J Exp Med 197, 1767–1778. Revy, P., Muto, T., Levy, Y., Geissmann, F., Plebani, A., Sanal, O., et al. (2000). Activation-induced cytidine deaminase (AID). deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102, 565–575. Rijkers, T., Van Den Ouweland, J., Morolli, B., Rolink, A.G., Baarends, W.M., Van, P.P., et al. (1998). Targeted inactivation of mouse RAD52 reduces homologous recombination but not resistance to ionizing radiation. Mol Cell Biol 18, 6423–6429. Rogozin, I.B., Diaz, M. (2004). Cutting edge: DGYW/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW/WRCY motif and probably reflects a two-step activation-induced cytidine deaminase-triggered process. J Immunol 172, 3382–3384.
FOR
SOMATIC
HYPERMUTATION
167
Rush, J.S., Fugmann, S.D., Schatz, D.G. (2004). Staggered AID-dependent DNA double strand breaks are the predominant DNA lesions targeted to Sµ in Ig class switch recombination. Int Immunol 16, 549–557. Schrader, C.E., Edelmann, W., Kucherlapati, R., Stavnezer, J. (1999). Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes. J Exp Med 190, 323–330. Schrader, C.E., Vardo, J., Linehan, E., Twarog, M.Z., Niedernhofer, L.J., Hoeijmakers, J.H., et al. (2004). Deletion of the nucleotide excision repair gene Ercc1 reduces immunoglobulin class switching and alters mutations near switch recombination junctions. J Exp Med 200, 321–330. Schrader, C.E., Vardo, J., Stavnezer, J. (2002). Role for mismatch repair proteins Msh2, Mlh1, and Pms2 in immunoglobulin class switching shown by sequence analysis of recombination junctions. J Exp Med 195, 367–373. Schrader, C.E., Vardo, J., Stavnezer, J. (2003). Mlh1 can function in antibody class switch recombination independently of Msh2. J Exp Med 197, 1377–1383. Sharpe, M.J., Milstein, C., Jarvis, J.M., Neuberger, M.S. (1991). Somatic hypermutation of immunoglobulin κ may depend on sequences 3’ of Cκ and occurs on passenger transgenes. EMBO J 10, 2139–2145. Shen, H.M., Michael, N., Kim, N., Storb, U. (2000). The TATA binding protein, c-Myc and survivin genes are not somatically hypermutated, while Ig and BCL6 genes are hypermutated in human memory B cells. Int Immunol 12, 1085–1093. Shen, H.M., Peters, A., Baron, B., Zhu, X., Storb, U. (1998). Mutation of BCL6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280, 1750–1752. Shinkura, R., Ito, S., Begum, N.A., Nagaoka, H., Muramatsu, M., Kinoshita, K., et al. (2004). Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol 5, 707–712. Shinkura, R., Tian, M., Smith, M., Chua, K., Fujiwara, Y., Alt, F.W. (2003). The influence of transcriptional orientation on endogenous switch region function. Nat Immunol 4, 435–441. Shiomi, N., Hayashi, E., Sasanuma, S., Mita, K., Shiomi, T. (2001). Disruption of Xpg increases spontaneous mutation frequency, particularly A:T to C:G transversion. Mutat Res 487, 127–135. Sohail, A., Klapacz, J., Samaranayake, M., Ullah, A., Bhagwat, A.S. (2003). Human activation-induced cytidine deaminase causes transcriptiondependent, strand-biased C to U deaminations. Nucleic Acids Res 31, 2990–2994. Sohn, J., Gerstein, R.M., Hsieh, C.L., Lemer, M., Selsing, E. (1993). Somatic hypermutation of an immunoglobulin mu heavy chain transgene. J Exp Med 177, 493–504. Stavnezer, J. (2000). Molecular processes that regulate class switching. Curr Top Microbiol Immunol 245, 127–168. Storb, U., Peters, A., Klotz, E., Kim, N., Shen, H.M., Hackett, J., et al. (1998). Cis-acting sequences that affect somatic hypermutation of Ig genes. Immunol Rev 162, 153–160. Ta, V.T., Nagaoka, H., Catalan, N., Durandy, A., Fischer, A., Imai, K., et al. (2003). AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol 4, 843–848. Tian, M., Shinkura, R., Shinkura, N., Alt, F.W. (2004). Growth retardation, early death, and DNA repair defects in mice deficient for the nucleotide excision repair enzyme XPF. Mol Cell Biol 24, 1200–1205. Tippin, B., Pham, P., Goodman, M.F. (2004). Error-prone replication for better or worse. Trends Microbiol 12, 288–295. Tumas-Brundage, K., Vora, K.A., Giusti, A.M., Manser, T. (1996). Characterization of the cis-acting elements required for somatic hypermutation of murine antibody V genes using conventional transgenic and transgene homologous recombination approaches. Semin. Immunol 8, 141–150. Tumas-Brundage, K.M., Vora, K.A., Manser, T. (1997). Evaluation of the role of the 3′α heavy chain enhancer [3′α E(hs1,2)] in Vh gene somatic hypermutation. Mol Immunol 34, 367–378. Vora, K.A., Tumas-Brundage, K.M., Lentz, V.M., Cranston, A., Fishel, R., Manser, T. (1999). Severe attenuation of the B cell immune response in Msh2-deficient mice. J Exp Med 189, 471–481.
168
MARIA
D.
IGLESIAS-USSEL,
Wei, K., Kucherlapati, R., Edelmann, W. (2002). Mouse models for human DNA mismatch-repair gene defects. Trends Mol Med 8, 346–353. Wiesendanger, M., Kneitz, B., Edelmann, W., Scharff, M.D. (2000). Somatic mutation in MSH3, MSH6, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. J Exp Med 191, 579–584. Wilson, T.M., Vaisman, A., Martomo, S.A., Sullivan, P., Lan, L., Hanaoka, F., et al. (2005). MSH2-MSH6 stimulates DNA polymerase η, suggesting a role for A:T mutations in antibody genes. J Exp Med 201, 637–645. Winter, D.B., Phung, Q.H., Umar, A., Baker, S.M., Tarone, R.E., Tanaka, K., et al. (1998). Altered spectra of hypermutation in antibodies from mice deficient for the mismatch repair protein PMS2. Proc Natl Acad Sci USA 95, 6953–6958.
ZIQIANG
LI,
AND
MATTHEW
D.
SCHARFF
Yoshikawa, K., Okazaki, I.M., Eto, T., Kinoshita, K., Muramatsu, M., Nagaoka, H., et al. (2002). AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 296, 2033–2036. Yu, K., Chedin, F., Hsieh, C.L., Wilson, T.E., Lieber, M.R. (2003). R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nat Immunol 4, 442–451. Zan, H., Komori, A., Li, Z., Cerrutti, M., Flajnik, M.F., Diaz, M., et al. (2001). The translesional polymerase ζ plays a major role in Ig and Bcl-6 somatic mutation. Immunity 14, 643–653. Zeng, X., Winter, D.B., Kasmer, C., Kraemer, K.H., Lehmann, A.R., Gearhart, P.J. (2001). DNA polymerase η is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol 2, 537–541.
Chapter 6 Mouse Natural Killer Cells: Function and Activation Francesco Colucci
I. Historical Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II. Development and Surface Markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Morphology and Surface Markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Tissue Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III. Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Cytotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Cytokine and Chemokine Production . . . . . . . . . . . . . . . . . . . . . . . . . . C. Tumor Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. Viral Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E. Autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F. Reproduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Inhibitory Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Activating Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. A Dynamic View of NK Cell Activation . . . . . . . . . . . . . . . . . . . . . . . . . . . VI. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I.
HISTORICAL PERSPECTIVE
In the 1960s, Cudkowicz described a phenomenon that could not be explained by the current thinking in transplantation biology. Hybrid mice from a cross between two inbred strains accept grafts of solid tissues from either parents but, in certain combinations, they rejected parental bone marrow grafts. This exception to the laws of transplantation was called hybrid
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
169 170 170 171 171 171 171 171 172 172 173 173 174 174 174 175 176 176
resistance (Cudkowicz and Stimpfling 1964). A decade later, Kiessling and Herberman independently discovered white blood cells in the mouse capable of killing tumors cells in vitro. Because the killing process was spontaneous and did not require any previous immunization, these lymphocytes were called natural killer (NK) cells (Herberman et al. 1975; Kiessling et al. 1975). Similar lymphoid cells were also described in humans (Ortaldo et al. 1977). The potential implications for tumor
Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
169
170
FRANCESCO
immunology were clear, but the recognition mechanisms of NK cells remained elusive. Kärre discovered that NK cells preferentially killed tumor cells with no or low expression of major histocompatability (MHC) class I antigens (Kärre et al. 1986). This observation led to a prediction of the existence of inhibitory MHC receptors that were later found on both murine and human NK cells (Colonna and Samaridis 1995; Karlhofer et al. 1992). Thus, hybrid resistance in mice could be explained on the basis of the missing self-MHC on the parental cells. The absence of one set of MHC class I antigens on the transplanted parental bone marrow cells triggered activation of the hybrid NK cells. Later it was discovered that, in addition to the activation that follows the absence of inhibitory signals, NK cells could also respond to the presence of activating signals expressed by malignant or infected cells. Experimental evidence in mice (Bukowski et al. 1985) and clinical observations in a child with multiple episodes of viral infections and defective NK cell functions (Biron et al. 1989) led to the appreciation of the role of NK cells in infectious biology. Resistance to mouse cytomegalovirus was genetically linked to a chromosomal region encompassing genes encoding for NK receptors (Scalzo et al. 1992), including a lectin-like activating receptor that, about a decade later, was found to directly bind a viral glycoprotein (Arase et al. 2002). Another activating receptor found in mouse and human recognizes MHC class I–like cellular molecules induced by stress, transformation, and viral infection (Raulet 2003). Work in the mouse, as well as in human cells, will help define the receptor-ligand systems and the intracellular signal transduction pathways that regulate NK cell functions and activation.
II.
DEVELOPMENT AND SURFACE MARKERS A.
Development
This chapter is focused on the function and activation of mouse NK cells, but a short section on their development and surface phenotype may be a useful complement. During embryonic development, NK cell precursors are found in the thymus, blood, liver, and spleen. NK cell precursors isolated from embryonic tissues give rise to NK, natural killer T (NKT), and T cells and are therefore referred to as common T/NK progenitors. NK-committed precursors (NKPs) can be found in the bone marrow of adult mice, and it is thought that they originate from common lymphoid precursors, under the action of earlyacting cytokine stem cell factor (SCF; also known as c-Kit ligand or KL), FMS-like tyrosine kinase 3 ligand (FLT3L; also known as fetal liver kinase 2 ligand, Flk2, or FL), and interleukin (IL)-7 (Colucci et al. 2003). NKP cells express the IL-2 receptor β chain (IL2Rβ; also known as CD122), which is also part of the IL-15 receptor.
COLUCCI
The expression of CD122 marks the commitment to the NK cell lineage, that is, NKPs lose the potential to differentiate in B or T lymphocytes or myeloid-erythroid lineages. At this stage of development, the precursors acquire the capacity to respond to a key cytokine in NK cell development, that is, IL-15. Bone marrow CD122+ NKPs do not express other NK cell markers such as NK1.1 (also known as NKR-P1C; expressed by NK cells in some mouse strains) or the integrin DX5 (α2 integrin, very late antigen-2; also known as CD49b, which is expressed on most mature NK cells in all mouse strains). Thus, NKP cells may be defined as CD122+ lymphoid cells that do not express any lineage-specific marker, including CD3, CD4, CD8, CD19, NK1.1, DX5, Mac-1 (also known as CD11b), Gr-1, and Ter119. NKP cells proceed along the pathway of NK cell development, and the next detectable event is the acquisition of the NK1.1 marker. At this stage, CD122+NK1.1+DX5−, immature NK cells are still incapable of cytotoxicity. This function is acquired coincidentally with the expression of DX5. Thus, the first lytic developmental intermediates are CD122+NK1.1+DX5+ cells. It is not clear how NK cell functions are regulated during ontogeny, but it is likely that the factors governing regulation of NK cell activity may be different in immature and mature NK cells. For example, the regulation of mature NK cells is mediated mostly by Ly49 receptors that bind MHC class I (see below), but cytotoxic, immature CD122+NK1.1+DX5+ cells do not express Ly49 receptors. Therefore, there may be alternative mechanisms of regulation of NK cell functions, some of which may be independent of MHC receptors. One possible mechanism of regulation during ontogeny is provided by the expression of CD94/NKG2 heterodimers that bind to nonclassic MHC class I. Early in ontogeny, virtually all NK cells express CD94/NKG2 receptors, whereas in adult mice most NK cells express Ly49 receptors, and CD94/NKG2 are found only in about half of NK cells. A similar sequence of events occurs also during human NK cell ontogeny. Ly49 receptors are the functional homologs of human killer cell immunoglobulin-like receptors (KIRs). Most of them are inhibitory, but some are activating. The factors dictating the expression of the Ly49 repertoire are not yet fully understood, but the induction of these receptors requires that developing NK cells interact with bone marrow stromal cells. The expression of Ly49 genes is regulated by a stochastic mechanism, is monoallelic, and is a late event during the developmental program of NK cells. Each NK cell, after expressing one Ly49, can go on expressing up to four distinct Ly49 receptors. However, each NK cell expresses at least one inhibitory receptor that binds to the MHC alleles present in the environment. Thus, host MHC shapes the Ly49 repertoire, both in term of selection and expression intensity. The final maturation step is marked by the acquisition of high levels of CD43 and CD11b, at which point NK cells are exported from the bone marrow out to peripheral lymphoid organs (Yokoyama et al. 2004). NK cells have a low rate of cell
6. MOUSE
NATURAL
KILLER
CELLS:
FUNCTION
division in the steady state (90% sequence homology. Studies with Stat5a- and Stat5bdeficient mice revealed both redundant and nonredundant roles of STAT5A and STAT5B in cytokine signaling (Table 7-3). Stat5a-deficient mice appeared to be normal except for defects in mammary gland development and lactation, indicating an essential role of STAT5A in prolactin (PRL) signaling (Liu et al. 1997). Furthermore, bone marrow–derived macrophages (BMMs) from Stat5a-deficient mice showed impaired proliferation and gene transcription in response to GM-CSF (Feldman et al. 1997). In contrast, Stat5b-null mice showed defects in GH-mediated sexual dimorphic growth, indicating a specific role of STAT5B in GH signaling (Udy et al. 1997). Further studies with Stat5a- and Stat5b-null mice revealed that IL-2-mediated T cell proliferation and NK cell functions were defective in both mice, although the defects appeared to be more severe in Stat5b-null mice (Imada et al. 1998; Nakajima et al. 1997). Stat5a/5b double knockout mice showed even more severe phenotypes: These mice had no NK cells, and T cells from these mice were defective in anti-CD3mediated cell proliferation (Teglund et al. 1998). These studies demonstrate the specific as well as redundant functions of STAT5A and STAT5B in mediating cytokine pathways. 6.
AND
KE
SHUAI
IL-4 and IL-13 but responded normally to other cytokines. These results confirmed the essential role of STAT6 in IL-4/IL-13 signaling.
Stat4-Deficient Mice
Biochemical studies suggest that STAT4 is activated mainly by IL-12. Consistent with this observation, Stat4-deficient mice showed impaired TH1 differentiation (Kaplan, Sun, et al. 1996; Thierfelder et al. 1996) (Table 7-3). In addition, decreased natural killer (NK) cell cytotoxicity and abrogated IFN-γ production upon IL-12 treatment had been observed in Stat4-null mice. These data indicate that STAT4 primarily mediates IL-12 signaling. 5.
LIU
Stat6-Deficient Mice
STAT6 is mainly activated by IL-4 and IL-13. Stat6-null mice consistently exhibited defective TH2 responses and enhanced TH1 differentiation (Kaplan, Schindler, et al. 1996; Shimoda et al. 1996; Takeda et al. 1996) (Table 7-3). These mice showed abrogation of eosinophilia, airway inflammation, and airway hyperresponsiveness (Akimoto et al. 1998; Kuperman et al. 1998). In addition, Stat6-null mice were defective in IL-4/IL-13-mediated expulsion of the gastrointestinal parasite Nippostrongylus brasiliensis (Urban et al. 1998). Stat6-deficient lymphoid cells were not responsive to
C. 1.
SOCSs
Socs1-Deficient and Transgenic Mice
Genetic studies with Socs1−/− mice indicated that SOCS1 is essential for the regulation of IFN-γ signaling and T cell homeostasis (Alexander et al. 1999; Marine, Topham, et al. 1999) (Table 7-4). Socs1-null mice died within 3 weeks after birth with extensive fatty degeneration of the liver and hematopoietic infiltration of multiple organs, including liver, heart, and lung. Socs1−/− mice showed lymphopenia and increased apoptosis in lymphoid organs (Naka et al. 1998; Starr et al. 1998). In addition, aberrant T cell activation and altered CD4+ and CD8+ ratios of T lymphocytes were observed in Socs1−/− mice (Cornish et al. 2003; Marine, Topham, et al. 1999). Treatment of the newborn Socs1-null mice with neutralizing antibodies against IFN-γ rescued the lethal phenotype of these mice. Furthermore, Socs1−/−IFNγ−/− mice were healthy and showed no histological defects as observed in Socs1-null mice. These results demonstrate that dysregulated IFN-γ signaling is the main cause of the phenotypes of Socs1−/− mice. Interestingly, constitutive activation of T cells and altered CD4+ and CD8+ ratios were also observed in Socs1−/−IFNγ−/− mice, suggesting that these phenotypes are independent of IFN-γ (Metcalf, Di Rago, et al. 2000). In addition to IFN-γ signaling, Socs1−/− mice also showed defects in signaling by other cytokines, such as IL-4, IL-12, TNF-α, LPS, insulin, and prolactin (Eyles et al. 2002; Kawazoe et al. 2001; Kinjyo et al. 2002; Morita et al. 2000; Naka et al. 1998; Nakagawa et al. 2002). Although elevated serum levels of IFN-γ were observed in Socs1−/− mice, the main feature of Socs1−/− cells was that they were hypersensitive to IFN-γ stimulation. For example, BMMs from Socs1−/− mice showed comparable capability for clearing intracellular parasites Leishmania major after IFN-γ stimulation at a dose approximately 100-fold less than that required for wildtype cells (Alexander et al. 1999). Consistently, Socs1−/− mice showed resistance to viral infection. In agreement with these results, biochemical studies with Socs1−/− cells revealed prolonged STAT1 phosphorylation in these cells, whereas the magnitude of STAT1 phosphorylation was not increased (Brysha et al. 2001). These data indicate that SOCS1 specifically controls the duration of IFN-γ signaling but has no effect on the initial activation process of the signaling pathway. Genetic studies with Socs1-null mice revealed the important role of SOCS1 in T cell development independent of IFN-γ signaling. Studies with Socs1 transgenic mice with enforced expression of SOCS1 in T lymphocytes further illustrated the inhibitory role of SOCS1 in multiple T cell cytokines, including IFN-γ, IL-6, and the cytokines signaling through the
7. C Y T O K I N E - A C T I VAT E D
JAK-STAT
SIGNALING
IN
THE
MOUSE
IMMUNE
SYSTEM
187
TABLE 7-4
IN VIVO FUNCTIONS OF SOCS PROTEINS SOCS
Phenotypes of Null Mice
Transgenic Mice
Reference
Cis
No abnormalities
Li et al. 2000; Marine, McKay, et al. 1999; Matsumoto et al. 1999
Socs1
Neonatal lethality Liver degeneration Lymphopenia Hematopoietic infiltration Apoptosis in lymphoid organs Altered CD4+ and CD8+ ratio of T cells Aberrant T-cell activation Elevated serum levels of IFN-γ Hyperactivated IFN-γ signaling Hypersensitive to LPS-induced shock Defects in γ-C-dependent cytokines and IL-12, TNF-α, insulin, PRL pathways Gigantism Dysregulated GH signaling Embryonic lethality with placental insufficiency Defective IL-6, LIF pathways
Runted Lactation defects Reduced splenic γδT, NK, NKT Preferential TH2 differentiation Abnormal T cell receptor responses Suppressed cytokine signaling Defective T cell development Spontaneous T cell activation
Socs2 Socs3
Socs5 Socs6
Mild growth retardation
Socs7
Mild growth retardation 50% adult mice die of hydrocephalus
Gigantism Dysregulated GH signaling Embryonic lethality with anemia T cell-specific transgenic mice develop asthma and increased TH2 response
Repressed TH2 responses Inhibited IL-4 signaling Improved glucose metabolism
common γ chain receptor, such as IL-4 and IL-7 (Fujimoto et al. 2000; Trop et al. 2001). Consistently, these mice showed defective T cell development and aberrant T cell activation. These results, together with the evidence from Socs1−/− mice, strongly indicate that SOCS1 is an important negative regulator of multiple cytokine pathways in addition to IFN-γ signaling, both of which are essential for T cell homeostasis. 2.
Socs3-Deficient and Transgenic Mice
Socs3−/− mice were embryonic lethal, probably due to placental insufficiency and erythrocytosis (Marine, McKay, et al. 1999; Roberts et al. 2001; Takahashi et al. 2003) (Table 7-4). Studies with conditional Socs3 deletions in liver and macrophages have revealed a specific role of SOCS3 in the negative regulation of IL-6 signaling (Croker et al. 2003; Lang et al. 2003; Yasukawa et al. 2003). Both SOCS1 and SOCS3 are induced by IFN-γ and IL-6, and both can inhibit IFN-γ and IL-6 responses when overexpressed. However, genetic studies
Alexander et al. 1999; Brysha et al. 2001; Cornish et al. 2003; Eyles et al. 2002; Fujimoto et al. 2000; Kawazoe et al. 2001; Kinjyo et al. 2002; Marine, Topham, et al. 1999; Metcalf, DiRigo, et al. 2000; Morita et al. 2000; Naka et al. 1998; Nakagawa et al. 2002; Starr et al. 1998; Trop et al. 2001 Greenhalgh et al. 2002; Metcalf, Greenhalgh, et al. 2000 Croker et al. 2003; Lang et al. 2003; Marine, McKay, et al. 1999a; Roberts et al. 2001; Seki et al. 2003; Takahashi et al. 2003; Yasukawa et al. 2003 Seki et al. 2002 Krebs et al. 2002; Li et al. 2004 Krebs et al. 2004
have demonstrated the in vivo specificity of SOCS1 and SOCS3 in the negative regulation of cytokine signaling. In Socs3−/− macrophages, the activation of STAT1 and STAT3 by IL-6 was prolonged, whereas the activation of STAT1 by IFN-γ was normal. In contrast, in Socs1−/− macrophages, the opposite is true. In addition, although STAT3 is activated by both IL-6 and IL-10, the tyrosine phosphorylation of STAT3 induced by IL-6, but not IL-10, was prolonged in Socs3−/− macrophages. Thus, SOCS proteins display specificity toward cytokines but not JAKs or STATs. Interestingly, the prolonged STAT activation induced by cytokines in the absence of SOCS proteins resulted in altered cytokine responses. For example, microarray analysis showed that the gene activation profile induced by IL-6 in Socs3−/− macrophages mimics that induced by IFN-γ in wild-type cells, suggesting a role for SOCS3 in the control of the specificity of cytokine responses. A similar alteration of the IL-6 response has been observed in Stat3−/− cells, in which STAT1 activation was prolonged (Costa-Pereira et al. 2002). One explanation is that
188
BIN
the expression of SOCS3 is STAT3 dependent. In the absence of STAT3, SOCS3 is not induced by IL-6; therefore, prolonged STAT1 activation leads to an IFN-γ-like inflammatory response. These studies indicate that SOCS1 and SOCS3 play important roles in defining the specificity of cytokine responses in vivo. Studies with Socs3 transgenic mice further revealed important functions of SOCS3 in cytokine signaling. Enforced expression of SOCS3 inhibited fetal erythropoiesis, resulting in embryonic lethality (Marine, McKay, et al. 1999). Recently, a T cell–specific Socs3 transgenic mouse model has been established (Seki et al. 2003). These mice showed enhanced TH2 responses and pathological features of asthma in an airway hypersensitivity model. Thus, these studies indicated that SOCS3 is important for the regulation of TH2-mediated allergic responses. 3.
Socs5 Transgenic Mice
Socs5 is expressed primarily in TH1 cells and is associated with the IL-4 receptor. Consistently, Socs5 transgenic mice showed defective TH2 differentiation and reduced TH2 production of cytokines, such as IL-4, IL-5, and IL-10 (Seki et al. 2002) (Table 7-4). These results suggest a role of SOCS5 in the regulation of IL-4 and STAT6 signaling. However, the function of SOCS5 in physiological settings needs to be addressed with Socs5-null mouse models. 5.
AND
KE
SHUAI
TABLE 7-5
IN VIVO FUNCTIONS OF PIAS PROTEINS PIAS
Phenotypes of Null Mice
Reference
Pias1
Resistant to viral and bacterial infections Hypersensitivity to LPS Elevated serum levels of proinflammatory cytokines Growth retardation and perinatal lethality Enhanced STAT1 and NF-κB signaling No abnormality in 129 genetic background Mild defects in IFN and Wnt signaling in 129/C57 mice Viable and fertile Reduced testis weight and sperm count Increased apoptosis of testicular cells
Liu et al. 2004; 2005
Piasy
Piasx
Roth et al. 2004; Wong et al. 2004
Santti et al. 2005
Cis Transgenic Mice
Cis-deficient mice appeared to be normal (Marine, McKay, et al. 1999). Transgenic mice with widespread expression of Cis showed growth retardation and lactation defects, which is reminiscent of the phenotypes observed in Stat5a−/− and/or Stat5b−/− mice (Li et al. 2000; Matsumoto et al. 1999) (Table 74). In addition, T cells from Cis transgenic mice failed to proliferate in response to IL-2 and IL-2-induced STAT5 activation was absent in these cells. Furthermore, these mice showed reduced numbers of T and NK cells, as well as preferential TH2 differentiation. Similar phenotypes have been observed in Stat5−/− mice, suggesting that enforced expression of CIS may inhibit STAT5-mediated cytokine signaling. However, since Cis−/− mice appeared to be normal, the precise role of CIS in immune regulation in vivo remains unclear. 4.
LIU
Socs2-Deficient and Transgenic Mice
Socs2 deficiency in mice resulted in gigantism, implicating dysregulated GH signaling in these mice (Metcalf, Greenhalgh, et al. 2000) (Table 7-4). Socs2−/− cells showed prolonged STAT5 activation, and the gigantic phenotype of Socs2−/− mice was rescued when these mice were crossed onto the Stat5b−/− background. These data indicate that SOCS2 regulates GH signaling and STAT5 activation in vivo. Surprisingly, transgenic mice with widespread expression of Socs2 also showed the gigantism phenotype, indicating that SOCS2 can both positively
and negatively regulate GH signaling (Greenhalgh et al. 2002). One possible explanation is that when overexpressed, SOCS2 can prevent other negative regulators from binding to the GH receptor, thus resulting in increased growth. The function of SOCS2 in immune regulation has not been documented. D. 1.
PIASs
Pias1-Deficient Mice
Pias1-null mice were runted and showed perinatal lethality (Liu et al. 2004) (Table 7-5). Consistent with a role of PIAS1 as a negative regulator of activated STAT1, Pias1-null mice displayed resistance to viral infection and hypersensitivity to LPS-induced endotoxic shock. Detailed gene transcription profiling analyses revealed elevated expression of STAT1-dependent genes in Pias1-null cells. Interestingly, PIAS1 deficiency affected only a subset of IFN-inducible genes. Consistent with the in vitro studies suggesting that PIAS1 inhibits the DNA-binding activity of STAT1, chromatin immunoprecipitation assays revealed enhanced STAT1 binding to the endogenous promoters of PIAS1-regulated genes in Pias1-null cells. In addition to a negative regulatory role in IFN signaling, PIAS1 has been shown to inhibit nuclear factor (NF)-κB signaling (Liu et al. 2005). Elevated NF-κB-mediated transcription in response to TNF-α and LPS was observed in Pias1-null cells. Serum levels of proinflammatory cytokines, such as TNF-α and IL-1β, were consistently increased in Pias1- null mice. These studies established an essential role of PIAS1 in both STAT1 and NF-κB signaling pathways. 2.
Piasy-Deficient Mice
Piasy null mice have been reported to be either grossly normal or to show mild defects in IFN and Wnt signaling pathways (Roth et al. 2004; Wong et al. 2004) (Table 7-5).
7. C Y T O K I N E - A C T I VAT E D
JAK-STAT
SIGNALING
It has been shown that both PIAS1 and PIASy can interact with activated STAT1 in vivo and can regulate STAT1-dependent transcription (Liu et al. 1998, 2001). It remains to be determined whether the lack of profound phenotypes of Piasy null mice may be due to the redundant functions of other PIAS proteins, such as PIAS1. 3.
Piasx-Deficient Mice
Piasx knockout mice have been reported recently (Santti et al. 2005). Although Piasx null mice were viable and fertile, they displayed reduced testis weight and decreased sperm count. The increased number of apoptotic testicular cells was consistently observed in Piasx-null mice. These data indicate that PIASx is involved in spermatogenesis. E.
CONCLUSIONS
Genetic studies using various mouse models have contributed significantly to our understanding of the physiological TABLE 7-6
IN VIVO FUNCTIONS OF PTPS PTP
Phenotypes of Null Mice
Reference
Tcptp
Hematopoietic defects Impaired T and B cell functions Hypersensitivity to insulin Defects in leptin signaling
Simoncic et al. 2002; You-Ten et al. 1997 Cheng et al. 2002; Elchebly et al. 1999; Zabolotny et al. 2002
Defective thymic development Increased apoptosis and impaired TCR signaling Increased erythroid colony formation Enhanced antiviral activity Autoimmunity Hyperproliferation of myeloid cells Anemia Embryonic lethality Hematopoietic defects
Byth et al. 1996; IrieSasaki et al. 2001; Kishihara et al. 1993
Ptp1b
Cd45
Shp1
Shp2
THE
MOUSE
IMMUNE
SYSTEM
189
functions of the JAK-STAT signaling pathways in immune regulation. In addition, these genetic studies have revealed unexpected in vivo signaling specificity. Understanding the molecular basis of signaling specificity may be a benefit in the design of more efficient therapeutic strategies using cytokines. Clearly, genetic systems with the disruption of multiple components of the JAK-STAT pathways are needed to address the potential redundant functions of these molecules in the regulation of immune responses. Finally, genetic models that mimic immunological disorders should facilitate the development of therapeutic drugs. ACKNOWLEDGMENTS This work was supported by grants from National Institutes of Health (to K.S.). B.L. is a Leukemia and Lymphoma Special Fellow.
PTPs
Several phosphatases have been implicated in the regulation of the JAK-STAT pathway, including TC-PTP, PTP1b, SHP-1, SHP2, and CD45. Genetic studies with targeted deletions of these molecules revealed important functions of these proteins in the immune system (Table 7-6). However, these phosphatases have also been implicated in other pathways, such as the role of SHP1 and SHP-2 in B and T cell receptors and c-Kit receptor signaling. Therefore, the phenotypes of these mice may be the cumulative results of the defects in multiple pathways.
IV.
IN
Shultz et al. 1984; 1997
Qu et al. 2001; You et al. 1999
REFERENCES Akimoto, T., Numata, F., Tamura, M., Takata, Y., Higashida, N., Takashi, T., et al. (1998). Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription STAT 6-deficient mice. J Exp Med 187, 1537–1542. Alexander, W.S. (2002). Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2, 410–416. Alexander, W.S., Hilton, D.J. (2004). The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22, 503–529. Alexander, W.S., Starr, R., Fenner, J.E., Scott, C.L., Handman, E., Sprigg, N.S., et al. (1999). SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597–608. Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., Poli, V. (2001). Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol 21, 1621–1632. Alonzi, T., Middleton, G., Wyatt, S., Buchman, V., Betz, U.A., Muller, W., et al. (2001). Role of STAT3 and PI 3-kinase/Akt in mediating the survival actions of cytokines on sensory neurons. Mol Cell Neurosci 18, 270–282. Aoki, N., Matsuda, T. (2000). A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 275, 39718–39726. Aravind, L., Koonin, E.V. (2000). SAP—a putative DNA-binding motif involved in chromosomal organization. Trends Biochem Sci 25, 112–114. Aringer, M., Cheng, A., Nelson, J.W., Chen, M., Sudarshan, C., Zhou, Y.J., et al. (1999). Janus kinases and their role in growth and disease. Life Sci 64, 2173–2186. Arora, T., Liu, B., He, H., Kim, J., Murphy, T.L., Murphy, K.M., et al. (2003). PIASx Is a transcriptional co-repressor of signal transducer and activator of transcription 4. J Biol Chem 278, 21327–21330. Brysha, M., Zhang, J.G., Bertolino, P., Corbin, J.E., Alexander, W.S., Nicola, N.A., et al. (2001). Suppressor of cytokine signaling-1 attenuates the duration of interferon γ signal transduction in vitro and in vivo. J Biol Chem 276, 22086–22089. Byth, K.F., Conroy, L.A., Howlett, S., Smith, A.J., May, J., Alexander, D.R., et al. (1996). CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. J Exp Med 183, 1707–1718. Cao, X., Shores, E.W., Hu-Li, J., Anver, M.R., Kelsall, B.L., Russell, S.M., et al. (1995). Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2, 223–238.
190 Chapman, R.S., Lourenco, P.C., Tonner, E., Flint, D.J., Selbert, S., Takeda, K., et al. (1999). Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13, 2604–2616. Chen, Y., Wen, R., Yang, S., Schuman, J., Zhang, E.E., Yi, T., et al. (2003). Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem 278, 16520–16527. Cheng, A., Uetani, N., Simoncic, P.D., Chaubey, V.P., Lee-Loy, A., McGlade, C.J., et al. (2002). Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2, 497–503. Cheng, F., Wang, H.W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., et al. (2003). A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425–436. Chughtai, N., Schimchowitsch, S., Lebrun, J.J., Ali, S. (2002). Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the β-casein gene promoter in mammary cells. J Biol Chem 277, 31107–31114. Chung, C.D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., et al. (1997). Specific inhibition of Stat3 signal transduction by PIAS3. Science 278, 1803–1805. Cornish, A.L., Chong, M.M., Davey, G.M., Darwiche, R., Nicola, N.A., Hilton, D.J., et al. (2003). Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other γc-dependent cytokines in peripheral T cells. J Biol Chem 278, 22755–22761. Costa-Pereira, A.P., Tininini, S., Strobl, B., Alonzi, T., Schlaak, J.F., Is’harc, H., et al. (2002). Mutational switch of an IL-6 response to an interferon-γ-like response. Proc Natl Acad Sci USA 99, 8043–8047. Croker, B.A., Krebs, D.L., Zhang, J.G., Wormald, S., Willson, T.A., Stanley, E.G., et al. (2003). SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4, 540–545. Darnell, J.E., Jr. (1997). STATs and gene regulation. Science 277, 1630–1635. David, M., Chen, H.E., Goelz, S., Larner, A.C., Neel, B.G. (1995). Differential regulation of the α/β interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 15, 7050–7058. DiSanto, J.P., Muller, W., Guy-Grand, D., Fischer, A., Rajewsky, K. (1995). Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γ chain. Proc Natl Acad Sci USA 92, 377–381. Durbin, J.E., Hackenmiller, R., Simon, M.C., Levy, D.E. (1996). Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84, 443–450. Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A.L., et al. (1999). Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544–1548. Endo, T.A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., et al. (1997). A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921–924. Eyles, J.L., Metcalf, D., Grusby, M.J., Hilton, D.J., Starr, R. (2002). Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J Biol Chem 277, 43735–43740. Feldman, G.M., Rosenthal, L.A., Liu, X., Hayes, M.P., Wynshaw-Boris, A., Leonard, W.J., et al. (1997). STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 90, 1768–1776. Fu, X.Y., Zhang, J.J. (1993). Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74, 1135–1145. Fujimoto, M., Naka, T., Nakagawa, R., Kawazoe, Y., Morita, Y., Tateishi, A., et al. (2000). Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice. J Immunol 165, 1799–1806. Greenhalgh, C.J., Hilton, D.J. (2001). Negative regulation of cytokine signaling. J Leukoc Biol 70, 348–356. Greenhalgh, C.J., Metcalf, D., Thaus, A.L., Corbin, J.E., Uren, R., Morgan, P.O., et al. (2002). Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 277, 40181–40184.
BIN
LIU
AND
KE
SHUAI
Hilton, D.J., Richardson, R.T., Alexander, W.S., Viney, E.M., Willson, T.A., Sprigg, N.S., et al. (1998). Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95, 114–119. Horvath, C.M., Wen, Z., Darnell, J.E., Jr. (1995). A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 9, 984–994. Igaz, P., Toth, S., Falus, A. (2001). Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm Res 50, 435–441. Imada, K., Bloom, E.T., Nakajima, H., Horvath-Arcidiacono, J.A., Udy, G.B., Davey, H.W., et al. (1998). Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 188, 2067–2074. Imada, K., Leonard, W.J. (2000). The Jak-STAT pathway. Mol Immunol 37, 1–11. Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G., et al. (2001). CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349–354. Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W.G., Jr., Conaway, R.C., et al. (1998). The Elongin BC complex interacts with the conserved SOCSbox motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12, 3872–3881. Kaplan, M.H., Schindler, U., Smiley, S.T., Grusby, M.J. (1996). Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4, 313–319. Kaplan, M.H., Sun, Y.L., Hoey, T., Grusby, M.J. (1996). Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382, 174–177. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., et al. (2000). Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549–560. Karaghiosoff, M., Steinborn, R., Kovarik, P., Kriegshauser, G., Baccarini, M., Donabauer, B., et al. (2003). Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4, 471–477. Kawazoe, Y., Naka, T., Fujimoto, M., Kohzaki, H., Morita, Y., Narazaki, M., et al. (2001). Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 193, 263–269. Kile, B.T., Alexander, W.S. (2001). The suppressors of cytokine signalling (SOCS) Cell Mol Life Sci 58, 1627–1635. Kile, B.T., Schulman, B.A., Alexander, W.S., Nicola, N.A., Martin, H.M., Hilton, D.J. (2002). The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 27, 235–241. Kinjyo, I., Hanada, T., Inagaki-Ohara, K., Mori, H., Aki, D., Ohishi, M., et al. (2002). SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17, 583–591. Kishihara, K., Penninger, J., Wallace, V.A., Kundig, T.M., Kawai, K., Wakeham, A., et al. (1993). Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatasedeficient mice. Cell 74, 143–156. Klingmuller, U., Lorenz, U., Cantley, L.C., Neel, B.G., Lodish, H.F. (1995). Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80, 729–738. Kobayashi, M., Kweon, M.N., Kuwata, H., Schreiber, R.D., Kiyono, H., Takeda, K., et al. (2003). Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 111, 1297–1308. Krebs, D.L., Metcalf, D., Merson, T.D., Voss, A.K., Thomas, T., Zhang, J.G., et al. (2004). Development of hydrocephalus in mice lacking SOCS7. Proc Natl Acad Sci USA 101, 15446–15451. Krebs, D.L., Uren, R.T., Metcalf, D., Rakar, S., Zhang, J.G., Starr, R., et al. (2002). SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol. 22, 4567–4578. Kuperman, D., Schofield, B., Wills-Karp, M., Grusby, M.J. (1998). Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected
7. C Y T O K I N E - A C T I VAT E D
JAK-STAT
SIGNALING
from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 187, 939–948. Lang, R., Pauleau, A.L., Parganas, E., Takahashi, Y., Mages, J., Ihle, J.N., et al. (2003). SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4, 546–550. Lee, C.K., Raz, R., Gimeno, R., Gertner, R., Wistinghausen, B., Takeshita, K., et al. (2002). STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17, 63–72. Leonard, W.J., Spolski, R. (2005). Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5, 688–698. Levy, D.E., Darnell, J.E. (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3, 651–662. Levy, D.E., Lee, C.K. (2002). What does Stat3 do? J Clin Invest 109, 1143–1148. Li, L., Gronning, L.M., Anderson, P.O., Li, S., Edvardsen, K., Johnston, J., et al. (2004). Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem. 279, 34107–34114. Li, S., Chen, S., Xu, X., Sundstedt, A., Paulsson, K.M., Anderson, P., et al. (2000). Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med. 191, 985–994. Liao, J., Fu, Y., and Shuai, K. (2000). Distinct roles of the NH2- and COOHterminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT)1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction. Proc Natl Acad Sci USA 97, 5267–5272. Liu, B., Gross, M., ten Hoeve, J., and Shuai, K. (2001). A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proc Natl Acad Sci USA 98, 3203–3207. Liu, B., Liao, J., Rao, X., Kushner, S.A., Chung, C.D., Chang, D.D., et al. (1998). Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 95, 10626–10631. Liu, B., Mink, S., Wong, K.A., Stein, N., Getman, C., Dempsey, P.W., et al. (2004). PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 5, 891–898. Liu, B., Yang, R., Wong, K.A., Getman, C., Stein, N., Teitell, M.A., Cheng, G., Wu, H., and Shuai, K. (2005). Negative regulation of NF-κB signaling by PIAS1. Mol Cell Biol 25, 1113–1123. Liu, X., Robinson, G.W., Wagner, K.U., Garrett, L., Wynshaw-Boris, A., and Hennighausen, L. (1997). Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11, 179–186. Marine, J.C., McKay, C., Wang, D., Topham, D.J., Parganas, E., Nakajima, H., et al. (1999). SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98, 617–627. Marine, J.C., Topham, D.J., McKay, C., Wang, D., Parganas, E., Stravopodis, D., et al. (1999). SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98, 609–616. Matsumoto, A., Seki, Y., Kubo, M., Ohtsuka, S., Suzuki, A., Hayashi, I., et al. (1999). Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 19, 6396–6407. Meraz, M.A., White, J.M., Sheehan, K.C., Bach, E.A., Rodig, S.J., Dighe, A.S., et al. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431–442. Metcalf, D., Di Rago, L., Mifsud, S., Hartley, L., Alexander, W.S. (2000a). The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-γ and lacking the SOCS-1 gene. Proc Natl Acad Sci USA 97, 9174–9179. Metcalf, D., Greenhalgh, C.J., Viney, E., Willson, T.A., Starr, R., Nicola, N.A., et al. (2000b). Gigantism in mice lacking suppressor of cytokine signalling2. Nature 405, 1069–1073. Morita, Y., Naka, T., Kawazoe, Y., Fujimoto, M., Narazaki, M., Nakagawa, R., et al. (2000). Signals transducers and activators of transcription (STAT)induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor α-induced cell death in fibroblasts. Proc Natl Acad Sci USA 97, 5405–5410.
IN
THE
MOUSE
IMMUNE
SYSTEM
191
Muller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J.E., Jr., et al. (1993). Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-α and -γ signal transduction pathways. EMBO J 12, 4221–4228. Myers, M.P., Andersen, J.N., Cheng, A., Tremblay, M.L., Horvath, C.M., Parisien, J.P., et al. (2001). TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 276, 47771–47774. Naka, T., Matsumoto, T., Narazaki, M., Fujimoto, M., Morita, Y., Ohsawa, Y., et al. (1998). Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 95, 15577–15582. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., et al. (1997). Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924–929. Nakagawa, R., Naka, T., Tsutsui, H., Fujimoto, M., Kimura, A., Abe, T., et al. (2002). SOCS-1 participates in negative regulation of LPS responses. Immunity 17, 677–687. Nakajima, H., Liu, X.W., Wynshaw-Boris, A., Rosenthal, L.A., Imada, K., Finbloom, D.S., et al. (1997). An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor α chain induction. Immunity 7, 691–701. Neel, B.G. (1993). Structure and function of SH2-domain containing tyrosine phosphatases. Semin Cell Biol 4, 419–432. Neel, B.G., Tonks, N.K. (1997). Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 9, 193–204. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., Pfeffer, K. (1998). Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397–409. Nicholson, S.E., Willson, T.A., Farley, A., Starr, R., Zhang, J.G., Baca, M., et al. (1999). Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 18, 375–385. Nosaka, T., van Deursen, J.M., Tripp, R.A., Thierfelder, W.E., Witthuhn, B.A., McMickle, A.P., et al. (1995). Defective lymphoid development in mice lacking Jak3. Science 270, 800–802. Parganas, E., Wang, D., Stravopodis, D., Topham, D.J., Marine, J.C., Teglund, S., et al. (1998). Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385–395. Park, C., Li, S., Cha, E., Schindler, C. (2000). Immune response in Stat2 knockout mice. Immunity 13, 795–804. Park, S.Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., et al. (1995). Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3, 771–782. Penninger, J.M., Irie-Sasaki, J., Sasaki, T., Oliveira-dos-Santos, A.J. (2001). CD45: new jobs for an old acquaintance. Nat Immunol 2, 389–396. Qu, C.K., Nguyen, S., Chen, J., Feng, G.S. (2001). Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood 97, 911–914. Roberts, A.W., Robb, L., Rakar, S., Hartley, L., Cluse, L., Nicola, N.A., et al. (2001). Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 98, 9324–9329. Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur, C.D., et al. (1998). Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93, 373–383. Roth, W., Sustmann, C., Kieslinger, M., Gilmozzi, A., Irmer, D., Kremmer, E., et al. (2004). PIASy-deficient mice display modest defects in IFN and Wnt signaling. J Immunol 173, 6189–6199. Sano, S., Itami, S., Takeda, K., Tarutani, M., Yamaguchi, Y., Miura, H., et al. (1999). Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18, 4657–4668. Sano, S., Takahama, Y., Sugawara, T., Kosaka, H., Itami, S., Yoshikawa, K., et al. (2001). Stat3 in thymic epithelial cells is essential for postnatal maintenance of thymic architecture and thymocyte survival. Immunity 15, 261–273.
192 Santti, H., Mikkonen, L., Anand, A., Hirvonen-Santti, S., Toppari, J., Panhuysen, M., et al (2005). Disruption of the murine PIASx gene results in reduced testis weight. J Mol Endocrinol 34, 645–654. Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I., Yoshimura, A. (2000). CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275, 29338–29347. Schindler, C., Shuai, K., Prezioso, V.R., Darnell, J.E., Jr. (1992). Interferondependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257, 809–813. Schweizer, U., Gunnersen, J., Karch, C., Wiese, S., Holtmann, B., Takeda, K., et al. (2002). Conditional gene ablation of Stat3 reveals differential signaling requirements for survival of motoneurons during development and after nerve injury in the adult. J Cell Biol 156, 287–297. Seki, Y., Hayashi, K., Matsumoto, A., Seki, N., Tsukada, J., Ransom, J., et al. (2002). Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA 99, 13003–13008. Seki, Y., Inoue, H., Nagata, N., Hayashi, K., Fukuyama, S., Matsumoto, K., et al. (2003). SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med 9, 1047–1054. Shen, Y., Schlessinger, K., Zhu, X., Meffre, E., Quimby, F., Levy, D.E., et al. (2004). Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24, 407–419. Shimoda, K., Kato, K., Aoki, K., Matsuda, T., Miyamoto, A., Shibamori, M., et al. (2000). Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13, 561–571. Shimoda, K., van Deursen, J., Sangster, M.Y., Sarawar, S.R., Carson, R.T., Tripp, R.A., et al. (1996). Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380, 630–633. Shuai, K. (1999). The STAT family of proteins in cytokine signaling. Prog Biophys Mol Biol 71, 405–422. Shuai, K. (2000). Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19, 2638–2644. Shuai, K., Horvath, C.M., Huang, L.H., Qureshi, S.A., Cowburn, D., Darnell, J.E., Jr. (1994). Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76, 821–828. Shuai, K., Liao, J., Song, M.M. (1996). Enhancement of antiproliferative activity of γ interferon by the specific inhibition of tyrosine dephosphorylation of Stat1. Mol Cell Biol 16, 4932–4941. Shuai, K., Liu, B. (2003). Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3, 900–911. Shuai, K., Schindler, C., Prezioso, V.R., Darnell, J.E., Jr. (1992). Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258, 1808–1812. Shuai, K., Stark, G.R., Kerr, I.M., Darnell, J.E., Jr. (1993). A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science 261, 1744–1746. Shultz, L.D., Coman, D.R., Bailey, C.L., Beamer, W.G., Sidman, C.L. (1984). “Viable motheaten,” a new allele at the motheaten locus. I. Pathology. Am J Pathol 116, 179–192. Shultz, L.D., Rajan, T.V., Greiner, D.L. (1997). Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol 15, 302–307. Simoncic, P.D., Lee-Loy, A., Barber, D.L., Tremblay, M.L., McGlade, C.J. (2002). The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3. Curr Biol 12, 446–453. Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H., Schreiber, R.D. (1998). How cells respond to interferons. Annu Rev Biochem 67, 227–264. Starr, R., Metcalf, D., Elefanty, A.G., Brysha, M., Willson, T.A., Nicola, N.A., et al. (1998). Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 95, 14395–14399. Starr, R., Willson, T.A., Viney, E.M., Murray, L.J., Rayner, J.R., Jenkins, B.J., et al. (1997). A family of cytokine-inducible inhibitors of signalling. Nature 387, 917–921.
BIN
LIU
AND
KE
SHUAI
Takahashi, Y., Carpino, N., Cross, J.C., Torres, M., Parganas, E., Ihle, J.N. (2003). SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J 22, 372–384. Takeda, K., Clausen, B.E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., et al. (1999). Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39–49. Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., Akira, S. (1998). Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 161, 4652–4660. Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., et al. (1997). Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94, 3801–3804. Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., et al. (1996). Essential role of Stat6 in IL-4 signalling. Nature 380, 627–630. Teglund, S., McKay, C., Schuetz, E., van Deursen, J.M., Stravopodis, D., Wang, D., et al. (1998). Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93, 841–850. ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., et al. (2002). Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22, 5662–5668. Thierfelder, W.E., van Deursen, J.M., Yamamoto, K., Tripp, R.A., Sarawar, S.R., Carson, R.T., et al. (1996). Requirement for Stat4 in interleukin-12mediated responses of natural killer and T cells. Nature 382, 171–174. Thomis, D.C., Gurniak, C.B., Tivol, E., Sharpe, A.H., Berg, L.J. (1995). Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270, 794–797. Trop, S., De Sepulveda, P., Zuniga-Pflucker, J.C., Rottapel, R. (2001). Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes. Blood 97, 2269–2277. Udy, G.B., Towers, R.P., Snell, R.G., Wilkins, R.J., Park, S.H., Ram, P.A., et al. (1997). Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 94, 7239–7244. Urban, J.F., Jr., Noben-Trauth, N., Donaldson, D.D., Madden, K.B., Morris, S.C., Collins, M., et al. (1998). IL-13, IL-4Rα, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 8, 255–264. Varinou, L., Ramsauer, K., Karaghiosoff, M., Kolbe, T., Pfeffer, K., Muller, M., et al. (2003). Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-γ-dependent innate immunity. Immunity 19, 793–802. Wen, Z., Darnell, J.E., Jr. (1997). Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 25, 2062–2067. Wen, Z., Zhong, Z., Darnell, J.E., Jr. (1995). Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241–250. Wong, K.A., Kim, R., Christofk, H., Gao, J., Lawson, G., Wu, H. (2004). Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life. Mol Cell Biol 24, 5577–5586. Xu, X., Sun, Y.L., and Hoey, T. (1996). Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain [see comments]. Science 273, 794–797. Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., et al. (2003). IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4, 551–556. Yoo, J.Y., Huso, D.L., Nathans, D., Desiderio, S. (2002). Specific ablation of Stat3β distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell 108, 331–344. Yoshimura, A. (1998). The CIS family: negative regulators of JAK-STAT signaling. Cytokine Growth Factor Rev 9, 197–204.
7. C Y T O K I N E - A C T I VAT E D
JAK-STAT
SIGNALING
You, M., Yu, D.H., Feng, G.S. (1999). Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19, 2416–2424. You-Ten, K.E., Muise, E.S., Itie, A., Michaliszyn, E., Wagner, J., Jothy, S., et al. (1997). Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 186, 683–693.
IN
THE
MOUSE
IMMUNE
SYSTEM
193
Zabolotny, J.M., Bence-Hanulec, K.K., Stricker-Krongrad, A., Haj, F., Wang, Y., Minokoshi, Y., et al. (2002). PTP1B regulates leptin signal transduction in vivo. Dev Cell 2, 489–495. Zhang, J.G., Farley, A., Nicholson, S.E., Willson, T.A., Zugaro, L.M., Simpson, R.J., et al. (1999). The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 96, 2071–2076.
This page intentionally left blank
Chapter 8 Signal Transduction Events Regulating Integrin Function and T Cell Migration in the Mouse Lakshmi R. Nagarajan and Yoji Shimizu
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II. T Cell Receptor Signaling and Integrin Regulation . . . . . . . . . . . . . . . . . . . A. Mouse Knockout Models with Defects in TCR-Mediated Integrin Activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. ADAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Vav1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Rap1 and RapL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4. Itk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Phosphatidylinositol 3-Kinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III. T Cell Migration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Chemokine Receptor Signaling and T Cell Migration . . . . . . . . . . . . . . . . . A. Use of Knockout Models to Identify Intracellular Signaling Proteins Critical for T Cell Migration . . . . . . . . . . . . . . . . . . 1. DOCK2 and Rac GTPases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. PI 3-K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. RapL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4. Itk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Dok-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Integrin Signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VI. Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
196 196 199 199 199 199 200 200 201 202 202 202 202 203 203 203 203 204 204 204
Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
195
196
LAKSHMI R. NAGARAJAN AND YOJI SHIMIZU
I.
INTRODUCTION
Efficient immune surveillance of pathogens requires continuous trafficking of naïve T lymphocytes through secondary lymphoid tissues via the blood and lymphatic systems. Once in secondary lymphoid organs, naïve T cells survey the environment for dendritic cells displaying immunogenic peptides derived from foreign pathogens. These dendritic cells acquire antigen either while resident in lymphoid organs or before their migration from infected nonlymphoid tissue. Successful activation of a naïve T cell by antigen-laden dendritic cells involves engagement of the antigen-specific T cell receptor (TCR) complex, which generates an array of intracellular signals that leads to clonal expansion and the generation of effector functions such as cytotoxicity and cytokine production (Catron et al. 2004). Unlike naïve T cells, these effector T cells have the ability to exit secondary lymphoid tissue and migrate into nonlymphoid tissue. Some T cells ultimately differentiate into long-lived memory T cells that reside in both lymphoid and nonlymphoid tissue, ready to rapidly respond if the pathogen is encountered at a later time. The integrin family of adhesion receptors participates in T cell–mediated immune responses by mediating adhesive interactions to other cells and to extracellular matrix proteins that are critical for T cell migration and T cell recognition of antigen (Hynes 2002; Pribila et al. 2004). Integrins mediate efficient T cell adhesion to endothelial cells, which is essential for steadystate trafficking of naïve T cells into secondary lymphoid organs, as well as the migration of effector T cells into inflammatory sites. The lymphocyte function-associated antigen-1 (LFA-1) integrin, in particular, is critical for efficient T cell interaction with antigen-presenting cells and defines the outer ring of the immunological synapse (Huppa and Davis 2003). In addition, β1 integrins promote the interaction of T cells with extracellular matrix proteins found in the tissue extracellular environment. The functional activity of integrin receptors is regulated by intracellular signaling events generated by antigen receptors and chemokine receptors (Pribila et al. 2004), so that T lymphocytes cycle appropriately between adhesive and nonadhesive states suitable for different extracellular environments and conditions. Upon engagement with appropriate cell surface or extracellular matrix ligands, integrins also transduce signals critical for lymphocyte functional responses. Thus, intracellular signaling events play an essential role in integrin-dependent adhesive events critical for T lymphocyte function. Many of the early advances in our understanding of integrin function in the immune system came from in vitro approaches that allowed investigators to isolate and analyze specific integrin-ligand interactions. Such approaches, often utilizing human cells, were used to identify integrins and their ligands, as well as to define the contribution of integrins to cell-cell interactions in which multiple receptors play nonredundant roles. A particularly notable example is the use of parallel plate flow chamber systems to define the unique contribution of
integrins, selectins, and chemokines in the multistep cascade of adhesive events that occurs when lymphocytes interact with endothelium under conditions of vascular shear flow. In vitro approaches have also been critical in identifying intracellular signaling events that regulate integrin functional activity (Pribila and Shimizu 2003). In recent years, the physiological significance of integrins and integrin regulation has been tested with the use of various transgenic and knockout mouse models. In this chapter we highlight the mouse models that have provided key insights into integrin function and T cell migration (Table 8-1).
II.
T CELL RECEPTOR SIGNALING AND INTEGRIN REGULATION
Integrins expressed on resting T cells are typically unable to mediate strong adhesion to cells or extracellular matrix proteins. However, TCR activation results within minutes in a transient increase in integrin functional activity that does not require new protein synthesis. Thus, antigen-dependent stimulation of the TCR results in enhanced LFA-1-dependent interactions of T cells with antigen-presenting cells, allowing for more efficient transmission of critical signals between the T cell and the antigen-presenting cell. Integrins respond to activation signals initiated by the TCR (and other receptors, such as chemokine receptors) via two distinct mechanisms that probably work together to result in increased overall adhesive strength (Kinashi 2005). Structural studies have clearly demonstrated that integrins can alter their conformation and that these conformations have different ligand-binding affinities (Kinashi 2005). In addition to direct assessment of integrin affinity states using soluble integrin ligands, in many of these studies anti-integrin antibodies that recognize unique epitopes associated with specific integrin conformational states have been used. Almost all of these antibodies are specific for human integrins. The lack of availability of similar antibodies for mouse integrins has limited the analysis of the physiological relevance of changes in integrin conformation in response to T cell activation in the mouse. A second mechanism of integrin regulation involves activation-induced changes in the membrane distribution of integrins that result in clustering that can be detected by microscopic techniques. Integrin clustering involves transient changes in the attachment of integrins to the cytoskeleton (Kinashi 2005; Kucik et al. 1996). Engagement of ligand by integrins can promote integrin clustering (Kim et al. 2004), but clustering of some integrins can be observed before or in the absence of integrin ligand engagement (Medeiros et al. 2005). Integrin affinity modulation and clustering are both dependent on the association of integrin cytoplasmic tails with intracellular signaling proteins (Kinashi 2005). Although TCR signaling has been proposed to induce increased LFA-1 function primarily via integrin clustering (Stewart et al. 1996), a cooperative role
197
8 . S I G N A L T R A N S D U C T I O N E V E N T S R E G U L AT I N G I N T E G R I N F U N C T I O N
TABLE 8-1
MOUSE TRANSGENIC AND KNOCKOUT MODELS OF INTRACELLULAR SIGNALING PROTEINS CRITICAL FOR INTEGRIN FUNCTION AND/OR T CELL MIGRATION Model
Type of Molecule
Adhesion and Migration Phenotype
ADAP−/−
Adapter protein
●
●
●
VASP−/−
Cytoskeletal protein
●
Vav1−/−
Rac GEF, adapter protein
●
●
●
●
Rac1 L61 mutant transgenic RhoA V14 mutant transgenic Rap1A V12 mutant transgenic Rap1A E63 mutant transgenic
GTPase
●
GTPase
●
GTPase
●
GTPase
●
●
●
RapL−/−
Rap1A effector
● ●
●
●
SPA-1−/−
Rap1A GAP
●
●
Rap1GAP1 transgenic
Rap1A GAP
●
●
●
C3G−/−
Rap1A GEF
● ●
Cbl-b−/−
E3 ubiquitin ligase
●
●
Impaired integrin-mediated adhesion of T cells after TCR stimulation Impaired integrin clustering on T cells after TCR stimulation Impaired T cell proliferation Enhanced thrombin-induced increases in integrin-mediated binding of fibrinogen by platelets Impaired integrin-mediated adhesion of T cells after TCR stimulation Impaired antigen-dependent conjugate formation Impaired integrin clustering on T cells after TCR stimulation Impaired actin polymerization after TCR stimulation Enhanced basal adhesion of thymocytes to fibronectin Enhanced basal adhesion of thymocytes to fibronectin Enhanced basal adhesion of thymocytes to β1 and β2 integrin ligands Enhanced basal adhesion of thymocytes to ICAM-1 Reduced T cell proliferation and IL-2 production Increased fraction of regulatory T cells Reduced lymph node cellularity Impaired homing of T and B cells to lymph nodes and spleen Impaired lymphocyte adhesion to integrin ligands following chemokine stimulation Impaired dendritic cell adhesion and migration Elevated and persistent Rap1A activation in T cells after anti-CD3 stimulation Development of a spectrum of myeloid disorders characteristic of human chronic myelogenous leukemia Impaired antigen-dependent conjugate formation Impaired activation of Rap1 after CTLA-4 ligation Enhanced T cell proliferation and IL-2 production Embryonic lethal Defective adhesion, cell spreading, and Rap1 activation of C3G−/− fibroblasts Increased adhesion to ICAM-1, LFA-1 clustering, and Rap1 activation after TCR stimulation Enhanced interaction between Crk-L and the Rap1 GEF C3G
Reference Griffiths et al. 2001 Peterson et al. 2001
Hauser et al. 1999 Ardouin et al. 2003 Krawczyk et al. 2002
Gomez et al. 2001 Corre et al. 2001 Sebzda et al. 2002 Li et al. 2005
Katagiri, Ohnishi, et al. 2004
Ishida, Kometani, et al. 2003; Ishida, Yang, et al. 2003
Dillon et al. 2005
Ohba et al. 2001
Zhang et al. 2003
Continued
198
LAKSHMI R. NAGARAJAN AND YOJI SHIMIZU
TABLE 8-1
MOUSE TRANSGENIC AND KNOCKOUT MODELS OF INTRACELLULAR SIGNALING PROTEINS CRITICAL FOR INTEGRIN FUNCTION AND/OR T CELL MIGRATION—cont’d Model
Type of Molecule
Adhesion and Migration Phenotype
Itk−/−, Itk−/− Rlk−/−
Tyrosine kinases
●
●
●
●
● ●
p110δD910A/D910A
Lipid kinase
●
●
●
mev/mev(inactive SHP-1)
Phosphatase
●
●
●
DOCK2−/−
Adapter protein
● ●
●
●
●
Rac2−/− p110γ−/−
GTPase Lipid kinase
● ●
●
●
● ●
SHIP−/−
Phosphatase
●
●
PTEN+/−
Phosphatase
●
PTEN−/−
Phosphatase
●
Dok-1−/− Hck−/−, Fgr−/−
Adapter protein Tyrosine kinases
●
Syk−/−
Tyrosine kinase
●
SLP-76−/−
Adapter protein
●
●
●
●
Impaired antigen-dependent conjugate formation Impaired adhesion of T cells to ICAM-2 after anti-CD3 stimulation Impaired actin polymerization after TCR stimulation Impaired membrane recruitment of Vav1 and impaired activation of WASp after TCR stimulation Impaired T cell chemotaxis in vitro Decreased T cell homing to lymph nodes Defective adhesion and migration of mast cells after stem cell factor stimulation Normal adhesion of T cells to fibronectin and ICAM-1 after TCR stimulation Reduced migration of B cells to CXCL13 and reduced B cell homing to Peyer’s patches and splenic white pulp cords Impaired integrin-dependent adhesion and spreading of macrophages Elevated levels of PI (3,4,5)P3 and membrane-associated PI 3-K activity Enhanced T cell chemotaxis to CXCL12 in vitro Defective T and B cell chemotaxis in vitro Reduced number of T and B cells in secondary lymphoid tissue Loss of marginal zone B cells and lymphoid follicle atrophy Loss of chemokine-induced activation of Rac and actin polymerization Impaired integrin-mediated adhesion of B cells, but not T cells, after chemokine stimulation Impaired T cell chemotaxis in vitro Impaired in vitro migration of neutrophils and macrophages in response to chemoattractants Impaired migration of neutrophils and macrophages into inflammatory sites in vivo Altered F-actin localization in migrating neutrophils Modest reduction in T cell chemotaxis in vitro Impaired dendritic cell migration in vitro and in vivo Enhanced migration of thymocytes, B cells, and hematopoietic precursors to CXCL12 in vitro Enhanced calcium mobilization and actin polymerization in response to CXCL12 Increased responsiveness of B cells to CXCL12-induced chemotaxis Impaired B cell migration to CXCL12 and CXCL13 Enhanced T cell chemotaxis to CXCL12 in vitro Impaired integrin-mediated degranulation, oxidative burst, and cell spreading of neutrophils Impaired integrin-mediated spreading of macrophages Impaired integrin-mediated degranulation, oxidative burst and cell spreading of neutrophils Profound block in T cell development Impaired integrin-mediated degranulation, oxidative burst, and spreading of neutrophils
Reference Finkelstein et al. 2005; Fischer et al. 2004; Labno et al. 2003; Takesono et al. 2004
Ali et al. 2004; Okkenhaug et al. 2002
Kim, Qu, et al. 1999; Roach et al. 1998
Fukui et al. 2001; Nombela-Arrieta et al. 2004
Croker et al. 2002 Del Prete et al. 2004; Hannigan et al. 2002; Hirsch et al. 2000; Li et al. 2000; Nombela-Arrieta et al. 2004; Reif et al. 2004; Sasaki et al. 2000
Kim, Hangoc, et al. 1999
Fox et al. 2002 Anzelon et al. 2003 Okabe et al. 2004 Lowell et al. 1996; Mocsai et al. 1999; Suen et al. 1999 Mócsai et al. 2002 Clements et al. 1998; Pivniouk et al. 1998; Newbrough et al. 2003
8 . S I G N A L T R A N S D U C T I O N E V E N T S R E G U L AT I N G I N T E G R I N F U N C T I O N
for both LFA-1 affinity modulation and clustering has recently been proposed (Kim et al. 2004). Chemokine stimulation results in detectable changes in both LFA-1 clustering and conformation (Constantin et al. 2000). The proximal signaling events triggered by TCR stimulation have been extensively characterized and involve 1) src family tyrosine kinase-mediated phosphorylation of tyrosine residues in the immunoreceptor tyrosine-based activation motifs (ITAMs) in CD3 subunit cytoplasmic domains, 2) ITAMdependent association of the tyrosine kinase ZAP-70 and subsequent src family tyrosine kinase–mediated phosphorylation of ZAP-70, resulting in enhanced ZAP-70 tyrosine kinase activity, 3) ZAP-70-mediated tyrosine phosphorylation of two key substrates, the adapter proteins LAT (linker for T cell activation) and SLP-76 (SH2 domain containing protein of 76 kDa), and 4) the formation of LAT-nucleated protein-protein interactions critical for initiation of downstream signaling responses, such as calcium mobilization, that result in changes in gene transcription in the nucleus. The essential role that these early signaling events play in TCR function suggests that these signaling proteins will also play a central role in TCR-mediated activation of integrin function. Although studies with human T cells have in fact demonstrated that ZAP-70 and LAT are critical for TCR signaling to integrins, the inability of T cells to develop in the absence of these molecules (and others, such as SLP-76) has made it impossible to study integrin regulation in these knockout models (Clements et al. 1998; Negishi et al. 1995; Pivnioud et al. 1998; Zhang et al. 1999). Although the block in T cell development is not as profound in Lck-deficient mice (Molina et al. 1992), an extensive analysis of integrin function in these mice has not been conducted. Integrin function has also not been extensively analyzed in mice lacking Fyn, the other major src family tyrosine kinase expressed in T cells, even though these mice do not have major defects in T cell development (Appleby et al. 1992). The ability of Lck and Fyn to play compensatory roles when the other kinase is limiting may complicate such analyses, as there is a complete block in thymic development in mice lacking both Lck and Fyn (Groves et al. 1996; Van Oers et al. 1996).
A.
Mouse Knockout Models with Defects in TCR-Mediated Integrin Activation
1.
ADAP
Adhesion and degranulation-promoting adapter protein (ADAP) is an intracellular adapter protein that becomes tyrosine phosphorylated and associates with the SLP-76 adapter protein after TCR stimulation. An analysis of mice lacking ADAP demonstrated that TCR stimulation of ADAP-deficient T cells results in impaired increases in β2 and β1 integrin–mediated adhesion to purified ligands, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and fibronectin (Peterson et al. 2001;
199
Griffiths et al. 2001). This defect in TCR-mediated integrin activation is also associated with impaired integrin clustering after TCR stimulation (Peterson et al. 2001; Griffiths et al. 2001), suggesting a role for ADAP in regulating the interaction of integrins with the cytoskeleton. ADAP-deficient T cells also exhibit defects in TCR-mediated proliferation and cytokine production, even though key early signaling responses, including calcium mobilization and ERK activation, are not impaired. In addition to SLP-76, ADAP also interacts with other proteins, including Fyn, SKAP-55, and members of the Ena-VASP family of actin regulatory proteins. A SKAP-55 mouse knockout model has not as yet been reported, although in vitro studies using overexpression and RNA interference approaches suggested that loss of SKAP-55 may also impair TCR signaling to integrins (Jo et al. 2005; Wang et al. 2003). The role of Ena-VASP proteins in integrin regulation in T cells has also not been investigated using transgenic or knockout technology, although platelets from mice lacking expression of VASP exhibit enhanced, rather than reduced, integrin-dependent binding to fibrinogen after thrombin stimulation (Hauser et al. 1999). 2.
Vav1
Vav1 is a guanine nucleotide exchange factor (GEF) for the Rac1 and Rac2 small GTPases, and its multidomain structure allows it to function as an adapter molecule as well. Together with Wiskott-Aldrich syndrome protein (WASp), Vav1 plays an important role in inducing actin cytoskeleton reorganization, TCR clustering, and immunological synapse formation after TCR stimulation. T cells from Vav1 knockout mice demonstrate impaired integrin-dependent adhesion and integrin-dependent conjugate formation with antigen-presenting cells (Ardouin et al. 2003; Krawczyk et al. 2002). In contrast to ADAP-deficient T cells, Vav1-deficient T cells also exhibit defects in TCRmediated actin polymerization. The mechanism by which Vav1 controls integrin activation is unclear, but it appears to be independent of WASp, as WASp-deficient T cells do not exhibit defects in TCR-mediated increases in integrin-dependent adhesion or integrin clustering (Krawczyk et al. 2002). The enhanced basal integrin-dependent adhesion of thymocytes isolated from transgenic mice expressing a constitutively active form of Rac1 to fibronectin (Gomez et al. 2001) suggests that Vav1 may regulate integrin function via its role as a GEF for Rac1. Similar results were reported for thymocytes from transgenic mice expressing a constitutively active form of RhoA (Corre et al. 2001), consistent with the ability of Rho family GTPases to modify the actin cytoskeleton. 3.
Rap1 and RapL
Numerous studies using dominant-negative and constitutively active forms of the Rap1 GTPase have demonstrated that this member of the Ras family of small GTPases plays an important role in regulating both basal and activation-dependent integrin function in T lymphocytes (Bos et al. 2003). Development of
200 transgenic and knockout models in which Rap1 activity has been altered have confirmed these in vitro findings and further expanded our understanding of Rap1 and its role in regulating integrin function. Similar to transgenic mice expressing constitutively active Rac1 or RhoA, thymocytes from transgenic mice expressing constitutively active Rap1 (G12V) also have enhanced basal adhesion to β1 and β2 integrin ligands (Sebzda et al. 2002). Thymocytes from transgenic mice expressing a different active Rap1 construct (E63) also showed elevated LFA-1-dependent adhesion (Li et al. 2005). Despite elevated LFA-1 function, there are impaired T cell activation responses in Rap1 E63 transgenic mice that are associated with an increased number of regulatory T cells (Li et al. 2005). RapL is a recently identified effector of Rap1 that binds to active Rap1 as well as to the cytoplasmic domain of the β2 integrin (Katagiri et al. 2003). As described in further detail below, loss of RapL in mice results in impaired lymphocyte and dendritic cell migration (Katagiri, Ohnishi, et al. 2004). Although integrin function after TCR stimulation of RapL-deficient T cells was not analyzed in this study, in vitro studies predict impaired integrin function in the absence of RapL expression in mice. Other mouse models have focused on effects of loss of expression of proteins that modulate Rap1 activity. SPA-1 is a Rap1-specific GTPase activating protein (GAP), and naïve T cells from SPA-1-deficient mice exhibit elevated and persistent activation of Rap1 after stimulation of the TCR with anti-CD3 antibodies (Ishida, Yang, et al. 2003). Although T cell development is normal, SPA-1-deficient mice have an impaired recall response to antigen. In addition, a population of unresponsive CD44hi memory-like T cells develops in these mice as they age. These T cells have elevated levels of active Rap1, but impaired extracellular signal-regulated kinase (ERK) activation in response to anti-CD3 stimulation. This biochemical phenotype is consistent with the initial identification of Rap1 as an antagonist of Ras signaling and thus a potential factor critical in inducing T cell anergy. The relevance of these findings in SPA-1 knockout mice to potential perturbations in integrin function is currently unclear. However, it is interesting to note that SPA-1−/− mice also develop myeloid disorders characteristic of chronic myelogenous leukemia (Ishida, Kometani, et al. 2003), a disease that is associated with altered β1 integrin function and abnormal association of integrins with the cytoskeleton (Bhatia et al. 1999). Expression of the Rap1 GAP Rap1GAP1 in transgenic mice impairs Rap1 activation and integrin function in T cells, but these T cells exhibit enhanced proliferation and interleukin (IL)-2 production (Dillon et al. 2005). This study also demonstrated an ability of the inhibitory receptor cytotoxic T lymphocyte antigen-4 (CTLA-4) to activate Rap1, and CTLA-4 function was reduced in transgenic T cells expressing Rap1GAP1 (Dillon et al. 2005). Thus, this transgenic model is consistent with other mouse models, suggesting that Rap1 positively regulates integrin function but may negatively regulate other activation responses of T cells. One GEF that regulates Rap1 activity in T cells is C3G. Although C3G knockout mice die before embryonic day 7.5,
LAKSHMI R. NAGARAJAN AND YOJI SHIMIZU
fibroblast cell lines have been made from embryos rescued by expression of a human C3G transgene flanked by loxP recombination sites. When these cell lines were infected with Cre-expressing viruses, the resulting C3G-deficient cell lines exhibited defective adhesion, cell spreading, and Rap1 activation (Ohba et al. 2001). Mice with a conditional loss of C3G specifically in T cells have not as yet been developed. TCR stimulation of T cells from mice lacking the E3 ubiquitin ligase Cbl-b results in enhanced LFA-1 clustering and T cell adhesion to ICAM-1, as well as elevated levels of Rap1 activity (Zhang et al. 2003). In the absence of Cbl-b, the interaction between the adapter protein Crk-L and C3G is enhanced, suggesting that the association of Cbl-b and Crk-L serves to negatively regulate C3G-dependent Rap1 activation in T cells. 4.
Itk
TCR stimulation results in the association of the Tec family tyrosine kinase Itk to the LAT signaling complex, where it can modulate the activity of phospholipase C-γ1 (PLC-γ1). Consequently, T cells from Itk-deficient mice exhibit impaired PLC-γ1 tyrosine phosphorylation and calcium mobilization in response to TCR stimulation. Recent studies have also shown that Itk regulates actin cytoskeletal reorganization and integrindependent adhesion after TCR stimulation (Finkelstein and Schwartzberg 2004). T cells from Itk-deficient mice exhibit impaired integrin-dependent adhesion to purified integrin ligands after anti-CD3 stimulation (Finkelstein et al. 2005), as well as impaired antigen-dependent conjugate formation mediated by the LFA-1 integrin (Labno et al. 2003). T cells also express the Tec family tyrosine kinase Rlk and loss of Rlk together with Itk enhances the defect in TCR-mediated calcium mobilization observed in Itk−/− T cells. However, the defect in integrin function is comparable in Itk−/− T cells and Rlk−/−Itk−/− T cells (Finkelstein et al. 2005; Labno et al. 2003). Itk-deficient T cells also exhibit severe defects in actin polymerization upon interaction with antigen-pulsed antigen-presenting cells or anti-TCR antibody–coated latex beads. These defects in actin polymerization are associated with impaired recruitment of Vav1 to the contact site, as well as impaired activation of WASp (Labno et al. 2003). Thus, defects in TCR-mediated integrin activation in Itk-deficient T cells are consistent with a requirement for Itk in effective actin polymerization after T cell activation. The ability of Itk to regulate both PLC-γ1 activation and calcium mobilization may also be critical to the integrin defects observed in Itk knockout mice, as both PLC-γ1 and calcium have been implicated in TCR signaling to integrins using human T cell systems (Katagiri, Shimonaka, et al. 2004; Stewart et al. 1998). 5.
Phosphatidylinositol 3-Kinase
TCR-mediated integrin activation can be blocked by pharmacological inhibitors of phosphatidylinositol 3-kinase (PI 3-K), a family of lipid kinases that participates in intracellular signaling by phosphorylating the D-3 position of the inositol
8 . S I G N A L T R A N S D U C T I O N E V E N T S R E G U L AT I N G I N T E G R I N F U N C T I O N
ring of phosphatidylinositol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-trisphosphate [PI (3,4,5)P3]. Analysis of PI 3-K and its role in integrin regulation in mice has been complicated by the heterodimeric structure of PI 3-K, the presence of multiple isoforms of both subunits, the embryonic lethality of some knockouts, and changes in expression of PI 3-K subunits when one subunit is deleted in the mouse germline (Okkenhaug and Vanhaesebroeck 2003). Defects in TCR signaling have been reported in mice in which the p110δ subunit of PI 3-K has been inactivated by a point mutation that renders it catalytically inactive (Okkenhaug et al. 2002). Although p110δ-mutant mast cells exhibit defective integrin-dependent adhesion to fibronectin after stem cell factor stimulation (Ali et al. 2004), there are no defects in the adhesion of p110δ-mutant T cells to fibronectin or ICAM-1 after TCR stimulation (Okkenhaug et al. 2002). In contrast, integrin-dependent adhesion and spreading of macrophages is elevated in moth-eaten mice, which lack src homology 2 domain phosphatase-1 (SHP-1) enzymatic activity (Roach et al. 1998). Loss of SHP-1 activity is also associated with elevated levels of PI (3,4,5)P3 and membrane-associated PI 3-K activity, suggesting a role for SHP-1 in negative regulation of PI 3-K-dependent integrin function in macrophages.
III.
T CELL MIGRATION
A series of sequential events that are required for a lymphocyte to interact with endothelial cells and successfully leave the bloodstream have been identified in in vitro systems. In this adhesion cascade, initial tethering or rolling of lymphocytes along the endothelial surface is typically mediated by selectins or, in some cases, by α4 integrins. Subsequent triggering of G protein–coupled receptors by chemokines or chemoattractants “presented” on the endothelial cell surface transiently activates integrins, resulting in stable, shear-resistant attachment of lymphocytes to the endothelial surface. Integrins also participate in the transmigration process, in which lymphocytes move between adjacent endothelial cells as they exit the bloodstream and enter the surrounding tissue. Although the specific selectins, chemokine receptors, and integrins that mediate T cell migration are dependent on the differentiation and activation state of the T cell, as well as the activation state of the endothelial cells, intravitral microscopic studies have confirmed that this adhesion paradigm is operative in vivo under a variety of steady state and inflammatory conditions. For naïve T cells, L-selectin, the CCR7 chemokine receptor, and LFA-1 play particularly critical roles in mediating the migration of naïve T cells out of the bloodstream into lymph nodes. Knockout mouse models have been particularly informative in elucidating the role of these molecules in steadystate trafficking of naïve T cells into lymph nodes. Mice lacking expression of L-selectin or CCR7 exhibit drastic reductions in lymph node cellularity due to impaired ability of naïve T cells lacking expression of these molecules to
201
migrate into lymph nodes (Arbones et al. 1994; Forster et al. 1999). Similar defects in lymph node cellularity and naïve T cell trafficking into lymph nodes are also observed in mice lacking expression of the CCR7 chemokine receptor ligand, CCL21 (SLC) (Gunn et al. 1999). Analysis of mice lacking CCR7 or CCL21 also demonstrate a critical role for these molecules in trafficking of dendritic cells from nonlymphoid tissue into lymph nodes (Forster et al. 1999; Gunn et al. 1999). Mice lacking LFA-1 also have reduced lymph node cellularity and exhibit defects in naïve T cell trafficking into lymph nodes (Berlin-Rufenach et al. 1999). However, some residual trafficking of LFA-1-deficient T cells into lymph nodes is observed, consistent with some contribution of α4 integrins in naïve T cell migration into lymph nodes (Berlin-Rufenach et al. 1999). JAM-A (JAM-1), a molecule expressed in the tight junctions of endothelial cells as well as on dendritic cells, has been proposed to play a role in leukocyte transmigration, either via homophilic interactions or via interaction with the LFA-1 integrin (Ostermann et al. 2002). Recent studies have revealed that dendritic cells isolated from JAM-A knockout mice have increased migration to lymph nodes that is associated with enhanced contact hypersensitivity responses (Cera et al. 2004). Thus, these mice have revealed a novel negative regulatory role for JAM-A in dendritic cell migration. The migration of effector T cells into inflammatory sites can be mediated by a number of different chemokine receptors, chemokines, and chemoattractants and is dependent in large part on the nature of the inflammatory stimulus and where in the body it is occurring. Coupled with the large number of chemokine receptors and the ability of multiple chemokine receptors to recognize more than one chemokine, the issue of functional redundancy highlights the value of analyzing chemokine receptor knockout mouse models (Power 2003). For example, analysis of T cells lacking the CCR4 receptor, which is expressed by skin memory T cells, demonstrated that CCR4-independent migration is mediated by the CCR10 chemokine receptor interacting with the chemokine CCL27 (Reiss et al. 2001). Recent studies with knockout mice have also revealed that the interaction of the BLT1 chemoattractant receptor with the lipid mediator leukotriene B4 plays a critical role in mediating the migration of effector CD4 and CD8 T cells into inflammatory sites by regulating chemotaxis and shearresistant adhesion to endothelial cells under shear flow conditions (Goodarzi et al. 2003; Ott et al. 2003; Tager et al. 2003). Integrin knockout models have also provided new insights into effector T cell migration and function. The αEβ7 integrin is expressed on intraepithelial lymphocytes (IELs) and binds to E-cadherin expressed on epithelial cells. Mice lacking αE integrin expression show a dramatic reduction in the number of intestinal and vaginal IELs, as well as a reduced number of lamina propria T cells (Schön et al. 1999). Effector T cells also express the α1β1 integrin, which binds to the extracellular matrix protein collagen. Mice lacking α1 integrin expression exhibit attenuated immune responses in several different inflammatory disease models (De Fougerolles et al. 2000;
202
LAKSHMI R. NAGARAJAN AND YOJI SHIMIZU
Krieglstein et al. 2002; Ray et al. 2004). Because α1β1 integrin has not been implicated in mediating T cell adhesion to endothelial cells, it seems likely that α1β1 integrin expression on effector T cells may be critical for T cell retention in nonlymphoid tissue, which is rich in collagen. Knockout models have also been informative in defining the molecular requirements for the movement of lymphocytes out of tissue. Sphingosine-1-phosphate is produced by sphingosine kinase–mediated phosphorylation of sphingosine, a lipid that is generated de novo or by breakdown of membrane sphingolipids such as sphingomyelin. The receptor for sphingosine-1-phosphate (S1P1) is a recently identified Gαi protein–coupled receptor that is expressed on naïve T and B cells, as well as mature thymocytes. Initial evidence that S1P1 is critical for lymphocyte egress from the thymus and secondary lymphoid organs was obtained using FTY720, a small molecular agonist that sequesters S1P1. Although S1P1 knockout mice have an embryonic lethal phenotype, analysis of S1P1-deficient fetal liver chimeras or mice carrying Lox-P flanked S1P1 alleles and thymically expressed cre-recombinase revealed that S1P1 expression in T cells is essential for egress from the thymus (Matloubian et al. 2004). These studies have also documented an essential role for S1P1 in egress of T and B lymphocytes from secondary lymphoid organs.
IV.
CHEMOKINE RECEPTOR SIGNALING AND T CELL MIGRATION
As discussed above, signaling initiated by G protein–coupled chemokine receptors results in increased integrin functional activity. In addition, leukocyte migration in response to chemokines and other chemoattractants involves the acquisition of a polarized morphology, characterized by Rac-dependent actin polymerization at the leading edge that drives extension of the pseudopod. The leading edge of migrating cells also contains an increased accumulation of chemokine receptors and lipid products generated by PI 3-K. A large number of signaling intermediates are known to be activated in response to chemokine stimulation, including mobilization of intracellular calcium and activation of PI 3-K, PLC, protein kinase C, and ERK, as well as activation of small GTPases such as Rac and Rap1. Mouse knockout models have been informative in linking perturbations in chemokine receptor signaling with changes in cellular responses critical for effective cell migration, such as integrin activation and actin polymerization.
A.
Use of Knockout Models to Identify Intracellular Signaling Proteins Critical for T Cell Migration
A number of knockout models have been identified in which defects in T cell migration have been reported. Typically, these
studies involve testing the migration of knockout T cells in response to various chemokines using in vitro assays with transwell chambers, as well as assessing the ability of knockout T cells to rapidly enter lymph nodes after adoptive transfer into syngeneic recipients. Although these studies have identified a number of signaling intermediates critical for effective T cell migration in response to chemokines, the mechanism by which these molecules regulate the migration process remains less well defined at present. 1.
DOCK2 and Rac GTPases
DOCK2 is a member of the CDM family of scaffolding proteins that regulates activation of the small GTPase Rac. Analysis of DOCK2−/− mice demonstrated that chemokineinduced activation of Rac and actin polymerization in T and B cells is dependent on DOCK2 expression (Fukui et al. 2001). Consequently, DOCK2−/− T and B cells exhibit defective migration in response to appropriate chemokines, and DOCK2- deficient mice have reduced numbers of T and B cells in secondary lymphoid tissue, a loss of marginal zone B cells and lymphoid follicle atrophy. Thus, the DOCK2 knockout model provided evidence that the formation of actin-rich lamellipodial extensions via Rac activation is critical for lymphocyte migration in response to chemokines. Consistent with these findings, Rac2-deficient T cells also exhibit in vitro defects in T cell migration and actin polymerization in response to chemoattractants (Croker et al. 2002). DOCK2 also regulates chemokine- mediated integrin activation, as the adhesion of DOCK2-deficient B cells to integrin ligands is impaired after CXCL13 stimulation (Nombela-Arrieta et al. 2004). Surprisingly, chemokine-induced integrin activation is normal in DOCK2-deficient T cells, suggesting lymphocytespecific differences in the regulation of chemokine receptor signaling to integrins. 2.
PI 3-K
Numerous studies with PI 3-K inhibitors have indicated that PI 3-K plays a central role in leukocyte migration. The analysis of mouse knockout models has revealed unexpected complexity in the role that different PI 3-K isoforms play in this process in different cell types. The p110γ isoform of PI 3-K is activated specifically by G protein–coupled receptors, and therefore it was not surprising to find that neutrophils and macrophages isolated from p110γ−/− mice exhibit defects in migration in response to various chemoattractants in vitro and impaired migration into inflammatory sites (Hirsch et al. 2000; Li et al. 2000; Sasaki et al. 2000). In addition, p110γ−/− neutrophils exhibit altered intracellular localization of F-actin at the leading edge in response to chemoattractant stimulation (Hannigan et al. 2002). Whereas T cell migration in response to chemokines in vitro and in vivo is also inhibited by PI 3-K inhibitors, p110γ−/− T cells exhibit only modest defects in migration both in vitro
8 . S I G N A L T R A N S D U C T I O N E V E N T S R E G U L AT I N G I N T E G R I N F U N C T I O N
and in vivo (Nombela-Arrieta et al. 2004; Reif et al. 2004). Chemotactic responses of p110γ-deficient B cells are also normal (Reif et al. 2004). In contrast, there is impaired in vitro chemotaxis and in vivo homing to Peyer’s patches and spleen of B cells isolated from mice expressing a catalytically inactive mutant form of the p110δ subunit (Reif et al. 2004; Okkenhaug et al. 2002). Finally, although the chemotactic response of naïve T cells to the CCR7 ligands CCL21 and CCL19 is only modestly reduced in the absence of p110γ expression, the migration of p110γ−/− dendritic cells in response to these same chemokines is significantly impaired (Del Prete et al. 2004). Although PI 3-K inhibitors have been used to demonstrate a role for PI 3-K in regulating chemokine-mediated integrin clustering events (Constantin et al. 2000), the status of integrin membrane localization on T cells isolated from these various PI 3-K knockout models has not as yet been analyzed. Phosphatases that antagonize PI 3-K function have also been shown to modulate T cell migration. SH2-containing inositol-5′-phosphatase (SHIP) hydrolyzes the 5′ phosphate of the PI 3-K lipid product PI (3,4,5)P3. Thymocytes, B cells, and hematopoietic progenitor cells isolated from SHIP−/− mice exhibit enhanced migration in response to CXCL12 (SDF-1) in vitro, as well as enhanced chemokine-mediated calcium mobilization and actin polymerization (Kim, Hangoc, et al. 1999). The phosphoinositide-3-phosphatase and tensin homolog (PTEN) also antagonizes PI 3-K function by dephosphorylating the 3′ position of PI (3,4,5)P3 and phosphatidylinositol 3,4-bisphosphate. Whereas one report documented increased migration of B cells isolated from PTEN heterozygous mice to CXCL12 in vitro (Fox et al. 2002), another study using B cells from mice with a conditional deletion of PTEN demonstrated decreased migration and enhanced Rac activation of PTEN−/− B cells in response to CXCL12 and CXCL13 (Anzelon et al. 2003). Finally, the migration of several hematopoietic cell types, including T cells, in response to CXCL12 is enhanced in viable moth-eaten mice, which lack SHP-1 enzymatic activity (Kim, Qu, et al. 1999). Actin polymerization and ERK activation induced by CXCL12 stimulation are also elevated in moth-eaten mice. The mechanism by which SHP-1 regulates chemokine receptor signaling events is not clear, although the finding of elevated levels of PI 3-K lipid products in macrophages from moth-eaten mice (Roach et al. 1998) is consistent with a role for PI 3-K in chemokine-dependent chemotaxis. Alternatively, SHP-1 may affect tyrosine phosphorylation events critical to regulating the actin cytoskeleton (see below). 3.
RapL
Similar to what has been observed with TCR stimulation, chemokine stimulation of T cells also activates the Rap1 GTPase. Mice lacking expression of the Rap1 effector RapL have dramatically reduced cell numbers in lymph nodes (Katagiri, Ohnishi, et al. 2004). In addition, T cells and B cells isolated from RapL−/− mice have impaired migration to lymph
203
nodes and spleen when transferred into wild-type recipient mice. Consistent with in vitro studies, RapL−/− lymphocytes exhibit impaired adhesion to integrin ligands after chemokine stimulation. This suggests that the primary function of chemokinemediated activation of Rap1 is to regulate integrin functional activity during lymphocyte migration. Analysis of RapL knockout mice also revealed a function for RapL in dendritic cell adhesion and migration (Katagiri, Ohnishi, et al. 2004). 4.
Itk
In addition to Rap1, the tyrosine kinase Itk is also activated by both TCR signaling and chemokine receptor signaling (Fischer et al. 2004; Takesono et al. 2004). In vitro migration of Itk-deficient T cells in response to CXCL12 is reduced compared with that in wild-type T cells. In addition, there is an impaired ability of T cells isolated from Itk/Rlk-deficient mice to traffic into lymph nodes in vivo (Takesono et al. 2004). Thus, in contrast to integrin activation induced by the TCR, migratory responses of T cells appear to be dependent on both Itk and, to some extent, Rlk. Itk may participate in regulating both integrin activation and actin polymerization events, as Itk−/− T cells exhibit defects in T cell adhesion to fibronectin and actin polymerization after CXCL12 stimulation (Fischer et al. 2004). Impaired actin polymerization induced by chemokine stimulation of Itk−/− T cells is also consistent with a role for Itk in regulating chemokine-mediated activation of Rac (Takesono et al. 2004). 5.
Dok-1
Dok-1 (downstream of tyrosine kinase) is a 62-kDa adapter protein that associates with Ras GTPase-activating protein (RasGAP) that becomes tyrosine phosphorylated after stimulation with a number of cytokines, including platelet-derived growth factor and vascular endothelial growth factor. Stimulation of human T cells with CXCL12 also results in tyrosine phosphorylation of Dok-1 (Okabe et al. 2004). Consistent with proposed negative regulatory functions for Dok-1, T cells isolated from Dok-1−/− mice exhibit enhanced migration in response to CXCL12 in vitro (Okabe et al. 2004).
V.
INTEGRIN SIGNALING
Upon ligand engagement, integrins generate additional intracellular signals that can modulate cell function. Despite extensive in vitro studies characterizing integrin signaling in T cells and other cell types (Perez et al. 2003), mouse knockout models have not been extensively used to study integrin signaling in T cells. One recent study used adoptive transfer approaches with CD18−/− (β2 integrin) T cells expressing a transgenic TCR to demonstrate a role for LFA-1 in optimal
204
LAKSHMI R. NAGARAJAN AND YOJI SHIMIZU
priming of CD4 T cells in vivo (Kandula and Abraham 2004). Although these results are consistent with a role for LFA-1 in generating signals necessary for optimal T cell activation in vivo, the impaired response of CD18−/− T cells in vivo may also be due to a lack of effective LFA-1-dependent adhesion between T cells and antigen-presenting cells. Mouse knockout models have been most informative in delineating integrin signaling pathways in neutrophils and macrophages, where integrin function does not require “activation” induced via signaling from other receptors. Integrin-mediated degranulation, oxidative burst, and cell spreading are impaired in neutrophils lacking expression of the myeloid src family tyrosine kinases Hck and Fgr (Lowell et al. 1996; Mócsai et al. 1999), the Syk tyrosine kinase (Mócsai et al. 2002), or the SLP-76 adapter protein (Newbrough et al. 2003). Impaired integrin signaling is also observed in macrophages isolated from Hck/Fgr double knockout mice (Suen et al. 1999). These mouse models have been instrumental in defining key intermediates involved in integrin-mediated signaling in these cell types.
VI.
FUTURE DIRECTIONS
Transgenic and knockout mice have proven instrumental in advancing our understanding of integrin function and T cell migration. In addition to identifying novel functions for proteins in regulating T cell adhesion and migration, these mouse models have allowed investigators to assess the physiological significance of perturbing signaling pathways that regulate T cell adhesion and migration. These functional responses, such as the movement of lymphocytes into tissue sites, are not easily studied in vitro. Furthermore, the availability of TCR transgenic mice provides opportunities for assessing the impact of modulating these adhesive and migratory events on antigen-specific immune responses in vivo. However, there are some limitations to the use of mouse models that need to be considered. The critical role that many signaling proteins play in developmental processes makes it impossible to use conventional knockout models to study the role that these proteins play in mature lymphocytes. Alternative approaches, such as conditional or tissue-specific knockouts, are needed to study these molecules. In addition, redundant functions for signaling proteins may confound phenotypic changes in knockout mice, and in some cases it has been necessary to simultaneously delete genes encoding for two or more molecules that are capable of compensating for each other. Future advances in our understanding of T cell integrin function and migration will undoubtedly continue to utilize the mouse as a model system. The continued use of these proven approaches, together with new technologies such as RNA interference, will expand the utility of these models. A better understanding of these important cellular events in the context of physiological immune responses
will be critical to the development of novel therapeutic strategies targeting adhesion molecules and their modulators.
VII.
SUMMARY
Integrin adhesion receptors facilitate the movement of bloodborne cells into lymphoid and nonlymphoid tissue during both steady-state and inflammatory conditions. In addition, integrins promote the stable interaction of T lymphocytes with antigenpresenting cells that are necessary for optimal adaptive immune responses. Signal transduction initiated by antigen and chemokine receptors regulates the functional activity of integrin receptors to promote appropriate periods of strong adhesion during lymphocyte migration and antigen recognition. Recent advances in this area of immunological research have come from the identification of transgenic and knockout mouse models with defects in integrin function and/or T cell migration. These mouse models provide powerful new tools for elucidating the mechanisms by which integrin function and T cell migration are regulated. In addition, these models provide unique opportunities for examining the function of integrin-dependent responses in the context of physiological immune responses that can be initiated, manipulated, and monitored in mice.
REFERENCES Ali, K., Bilancio, A., Thomas, M., Pearce, W., Gilfillan, A.M., Tkaczyk, C., et al. (2004). Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 431, 1007–1011. Anzelon, A.N., Wu, H., Rickert, R.C. (2003). Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol 4, 287–294. Appleby, M.W., Gross, J.A., Cooke, M.P., Levin, S.D., Qian, X., Perlmutter, R.M. (1992). Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell 70, 751–763. Arbones, M.L., Ord, D.C., Ley, K., Ratech, H., Maynard-Curry, C., Otten, G., et al. (1994). Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1, 247–260. Ardouin, L., Bracke, M., Mathiot, A., Pagakis, S.N., Norton, T., Hogg, N., et al. (2003). Vav1 transduces TCR signals required for LFA-1 function and cell polarization at the immunological synapse. Eur J Immunol 33, 790–797. Berlin-Rufenach, C., Otto, F., Mathies, M., Westermann, J., Owen, M.J., Hamann, A., et al. (1999). Lymphocyte migration in lymphocyte functionassociated antigen (LFA)-1-deficient mice. J Exp Med 189, 1467–1478. Bhatia, R., Munthe, H.A., Verfaillie, C.M. (1999). Role of abnormal integrincytoskeletal interactions in impaired β1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol 27, 1384–1396. Bos, J.L., De Bruyn, K., Enserink, J., Kuiperij, B., Rangarajan, S., Rehmann, H., et al. (2003). The role of Rap1 in integrin-mediated cell adhesion. Biochem Soc Trans 31, 83–86. Catron, D.M., Itano, A.A., Pape, K.A., Mueller, D.L., Jenkins, M.K. (2004). Visualizing the first 50 Hr of the primary immune response to a soluble antigen. Immunity 21, 341–347. Cera, M.R., Del Prete, A., Vecchi, A., Corada, M., Martin-Padura, I., Motoike, T., et al. (2004). Increased DC trafficking to lymph nodes and contact
8 . S I G N A L T R A N S D U C T I O N E V E N T S R E G U L AT I N G I N T E G R I N F U N C T I O N
hypersensitivity in junctional adhesion molecule-A-deficient mice. J Clin Invest 114, 729–738. Clements, J.L., Yang, B., Ross-Barta, S.E., Eliason, S.L., Hrstka, R.F., Williamson, R.A., et al. (1998). Requirement for the leukocyte-specific adapter protein SLP-76 for normal T-cell development. Science 281, 416–419. Constantin, G., Majeed, M., Giagulli, C., Piccio, L., Kim, J.Y., Butcher, E.C., et al. (2000). Chemokines trigger immediate β2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13, 759–769. Corre, I., Gomez, M., Vielkind, S., Cantrell, D.A. (2001). Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. J Exp Med 194, 903–913. Croker, B.A., Handman, E., Hayball, J.D., Baldwin, T.M., Voigt, V., Cluse, L.A., et al. (2002). Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in TH1 responses. Immunol Cell Biol 80, 231–240. De Fougerolles, A.R., Sprague, A.G., Nickerson-Nutter, C.L., Chi-Rosso, G., Rennert, P.D., Gardner, H., et al. (2000). Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis. J Clin Invest 105, 721–729. Del Prete, A., Vermi, W., Dander, E., Otero, K., Barberis, L., Luini, W., et al. (2004). Defective dendritic cell migration and activation of adaptive immunity in PI3Kγ-deficient mice. EMBO J 23, 3505–3515. Dillon, T.J., Carey, K.D., Wetzel, S.A., Parker, D.C., Stork, P.J. (2005). Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol Cell Biol 25, 4117–4128. Finkelstein, L.D., Schwartzberg, P.L. (2004). Tec kinases: shaping T-cell activation through actin. Trends Cell Biol 14, 443–451. Finkelstein, L.D., Shimizu, Y., and Schwartzberg, P.L. (2005). Tec kinases regulate T cell receptor-mediated recruitment of signaling molecules and integrin-dependent cell adhesion. J Immunol 175, 5923–5930. Fischer, A.M., Mercer, J.C., Iyer, A., Ragin, M.J., and August, A. (2004). Regulation of CXC chemokine receptor 4-mediated migration by the Tec family tyrosine kinase ITK. J Biol Chem 279, 29816–29820. Forster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Muller, I., Wolf, E., et al. (1999). CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23–33. Fox, J.A., Ung, K., Tanlimco, S.G., Jirik, F.R. (2002). Disruption of a single Pten allele augments the chemotactic response of B lymphocytes to stromal cell-derived factor-1. J Immunol 169, 49–54. Fukui, Y., Hashimoto, O., Sanui, T., Oono, T., Koga, H., Abe, M., et al. (2001). Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412, 826–831. Gomez, M., Kioussis, D., Cantrell, D.A. (2001). The GTPase Rac-1 controls cell fate in the thymus by diverting thymocytes from positive to negative selection. Immunity 15, 703–713. Goodarzi, K., Goodarzi, M., Tager, A.M., Luster, A.D., Von Andrian, U.H. (2003). Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 4, 965–973. Griffiths, E.K., Krawczyk, C., Kong, Y.Y., Raab, M., Hyduk, S.J., Bouchard, D., et al. (2001). Positive regulation of T cell activation and integrin adhesion by the adapter Fyb/Slap. Science 293, 2260–2263. Groves, T., Smiley, P., Cooke, M.P., Forbush, K., Perlmutter, R.M., Guidos, C.J. (1996). Fyn can partially substitute for Lck in T lymphocyte development. Immunity 5, 417–428. Gunn, M.D., Kyuwa, S., Tam, C., Kakiuchi, T., Matsuzawa, A., Williams, L.T., et al. (1999). Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 189, 451–460. Hannigan, M., Zhan, L.J., Li, Z., Ai, Y.X., Wu, D.Q., Huang, C.K. (2002). Neutrophils lacking phosphoinositide 3-kinase γ show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc Natl Acad Sci USA 99, 3603–3608.
205
Hauser, W., Knobeloch, K.P., Eigenthaler, M., Gambaryan, S., Krenn, V., Geiger, J., et al. (1999). Megakaryocyte hyperplasia and enhanced agonistinduced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA 96, 8120–8125. Hirsch, E., Katanaev, V.L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., et al. (2000). Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 287, 1049–1053. Huppa, J.B., Davis, M.M. (2003). T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 3, 973–983. Hynes, R.O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687. Ishida, D., Kometani, K., Yang, H., Kakugawa, K., Masuda, K., Iwai, K., et al. (2003). Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 4, 55–65. Ishida, D., Yang, H.L., Masuda, K., Uesugi, K., Kawamoto, H., Hattori, M., et al. (2003). Antigen-driven T cell anergy and defective memory T cell response via deregulated Rap1 activation in SPA-1-deficient mice. Proc Natl Acad Sci USA 100, 10919–10924. Jo, E.K., Wang, H., Rudd, C.E. (2005). An essential role for SKAP-55 in LFA1 clustering on T cells that cannot be substituted by SKAP-55R. J Exp Med 201, 1733–1739. Kandula, S., Abraham, C. (2004). LFA-1 on CD4+ T cells is required for optimal antigen-dependent activation in vivo. J Immunol 173, 4443–4451. Katagiri, K., Maeda, A., Shimonaka, M., and Kinashi, T. (2003). RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat Immunol 4, 741–748. Katagiri, K., Ohnishi, N., Kabashima, K., Iyoda, T., Takeda, N., Shinkai, Y., et al. (2004). Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking. Nat Immunol 5, 1045–1051. Katagiri, K., Shimonaka, M., and Kinashi, T. (2004). Rap1-mediated lymphocyte function-associated antigen-1 activation by the T cell antigen receptor is dependent on phospholipase C-γ1. J Biol Chem 279, 11875–11881. Kim, C.H., Hangoc, G., Cooper, S., Helgason, C.D., Yew, S., Humphries, R.K., et al. (1999). Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest 104, 1751–1759. Kim, C.H., Qu, C.K., Hangoc, G., Cooper, S., Anzai, N., Feng, G.S., et al. (1999). Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J Exp Med 190, 681–690. Kim, M., Carman, C.V., Yang, W., Salas, A., Springer, T.A. (2004). The primacy of affinity over clustering in regulation of adhesiveness of the integrin αLβ2. J Cell Biol 167, 1241–1253. Kinashi, T. (2005). Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol 5, 546–559. Krawczyk, C., Oliveira-dos-Santos, A., Sasaki, T., Griffiths, E., Ohashi, P.S., Snapper, S., et al. (2002). Vav1 controls integrin clustering and MHC/peptidespecific cell adhesion to antigen-presenting cells. Immunity 16, 331–343. Krieglstein, C.F., Cerwinka, W.H., Sprague, A.G., Laroux, F.S., Grisham, M.B., Koteliansky, V.E., et al. (2002). Collagen-binding integrin α1β1 regulates intestinal inflammation in experimental colitis. J Clin Invest 110, 1773–1782. Kucik, D.F., Dustin, M.L., Miller, J.M., Brown, E.J. (1996). Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes. J Clin Invest 97, 2139–2144. Labno, C.M., Lewis, C.M., You, D.Q., Leung, D.W., Takesono, A., Kamberos, N., et al. (2003). Itk functions to control actin polymerization at the immune synapse through localized activation of Cdc42 and WASP. Curr Biol 13, 1619–1624. Li, L., Greenwald, R.J., Lafuente, E.M., Tzachanis, D., Berezovskaya, A., Freeman, G.J., et al. (2005). Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol 175, 3133–3139. Li, Z., Jiang, H., Xie, W., Zhang, Z., Smrcka, A.V., Wu, D. (2000). Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287, 1046–1049.
206 Lowell, C.A., Fumagalli, L., Berton, G. (1996). Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions. J Cell Biol 133, 895–910. Matloubian, M., Lo, C.G., Cinamon, G., Lesneski, M.J., Xu, Y., Brinkmann, V., et al. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355–360. Medeiros, R.B., Dickey, D.M., Chung, H., Quale, A.C., Nagarajan, L.R., Billadeau, D.D., et al. (2005). Protein kinase D1 and the β1 integrin cytoplasmic domain control β1 integrin function via regulation of Rap1 activation and membrane localization. Immunity 23, 213–226. Mócsai, A., Ligeti, E., Lowell, C.A., Berton, G. (1999). Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 162, 1120–1126. Mócsai, A., Zhou, M.J., Meng, F.Y., Tybulewicz, V.L., Lowell, C.A. (2002). Syk is required for integrin signaling in neutrophils. Immunity 16, 547–558. Molina, T.J., Kishihara, K., Siderovski, D.P., van Ewijk, W., Narendran, A., Timms, E., et al. (1992). Profound block in thymocyte development in mice lacking p56lck. Nature 357, 161–164. Negishi, I., Motoyama, N., Nakayama, K., Senju, S., Hatakeyama, S., Zhang, Q., et al. (1995). Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature 376, 435–437. Newbrough, S.A., Mócsai, A., Clemens, R.A., Wu, J.N., Silverman, M.A., Singer, A.L., et al. (2003). SLP-76 regulates Fcγ receptor and integrin signaling in neutrophils. Immunity 19, 759–769. Nombela-Arrieta, C., Lacalle, R.A., Montoya, M.C., Kunisaki, Y., Megías, D., Marqués, M., et al. (2004). Differential requirements for DOCK2 and phosphoinositide-3-kinase γ during T and B lymphocyte homing. Immunity 21, 429–441. Ohba, Y., Ikuta, K., Ogura, A., Matsuda, J., Mochizuki, N., Nagashima, K., et al. (2001). Requirement for C3G-dependent Rap1 activation for cell adhesion and embryogenesis. EMBO J 20, 3333–3341. Okabe, S., Fukuda, S., Kim, Y.J., Niki, M., Pelus, L.M., Ohyashiki, K., et al. (2004). Stromal cell-derived factor-1α/CXCL12 induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. Blood 105, 474–490. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., et al. (2002). Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297, 1031–1034. Okkenhaug, K., Vanhaesebroeck, B. (2003). PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3, 317–330. Ostermann, G., Weber, K.S., Zernecke, A., Schroder, A., Weber, C. (2002). JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol 3, 151–158. Ott, V.L., Cambier, J.C., Kappler, J., Marrack, P., Swanson, B.J. (2003). Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 4, 974–981. Perez, O.D., Mitchell, D., Jager, G.C., South, S., Murriel, C., McBride, J., et al. (2003). Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat Immunol 4, 1083–1092. Peterson, E.J., Woods, M.L., Dmowski, S.A., Derimanov, G., Jordan, M.S., Wu, J.N., et al. (2001). Coupling of the TCR to integrin activation by SLAP130/Fyb. Science 293, 2263–2265. Pivniouk, V., Tsitsikov, E., Swinton, P., Rathbun, G., Alt, F.W., Geha, R.S. (1998). Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76. Cell 94, 229–238. Power, C.A. (2003). Knock out models to dissect chemokine receptor function in vivo. J Immunol Methods 273, 73–82.
LAKSHMI R. NAGARAJAN AND YOJI SHIMIZU
Pribila, J.T., Quale, A.C., Mueller, K.M., Shimizu, Y. (2004). Integrins and T cell-mediated immunity. Annu Rev Immunol 22, 157–180. Pribila, J.T., Shimizu, Y. (2003). Signal transduction events regulating integrin function and T cell migration: new functions and complexity. Immunol Res 27, 107–128. Ray, S.J., Franki, S.N., Pierce, R.H., Dimitrova, S., Koteliansky, V., Sprague, A.G., et al. (2004). The collagen binding α1β1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity 20, 167–179. Reif, K., Okkenhaug, R., Sasaki, T., Penninger, J.M., Vanhaesebroeck, B., Cyster, J.G. (2004). Cutting edge: Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing. J Immunol 173, 2236–2240. Reiss, Y., Proudfoot, A.E., Power, C.A., Campbell, J.J., Butcher, E.C. (2001). CC chemokine receptor (CCR) 4 and the CCR10 ligand cutaneous T cellattracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 194, 1541–1547. Roach, T.I., Slater, S.E., White, L.S., Zhang, X.L., Majerus, P.W., Brown, E.J., et al. (1998). The protein tyrosine phosphatase SHP-1 regulates integrinmediated adhesion of macrophages. Curr Biol 8, 1035–1038. Sasaki, T., Irie-Sasaki, J., Jones, R.G., Oliveira, D.S., Stanford, W.L., Bolon, B., et al. (2000). Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040–1046. Schön, M.P., Arya, A., Murphy, E.A., Adams, C.M., Strauch, U.G., Agace, W.W., et al. (1999). Mucosal T lymphocyte numbers are selectively reduced in integrin αE (CD103)-deficient mice. J Immunol 162, 6641–6649. Sebzda, E., Bracke, M., Tugal, T., Hogg, N., Cantrell, D.A. (2002). Rap1A positively regulates T cells via integrin activation rather than inhibiting lymphocyte signaling. Nat Immunol 3, 251–258. Stewart, M.P., Caba~ nas, C., Hogg, N. (1996). T cell adhesion to intercellular adhesion molecule-1 (ICAM-1) is controlled by cell spreading and the activation of integrin LFA-1. J Immunol 156, 1810–1817. Stewart, M.P., McDowall, A., Hogg, N. (1998). LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain. J Cell Biol 140, 699–707. Suen, P.W., Ilic, D., Caveggion, E., Berton, G., Damsky, C.H., Lowell, C.A. (1999). Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. J Cell Sci 112, 4067–4078. Tager, A.M., Bromley, S.K., Medoff, B.D., Islam, S.A., Bercury, S.D., Friedrich, E.B., et al. (2003). Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 4, 982–990. Takesono, A., Horai, R., Mandai, M., Dombroski, D., Schwartzberg, P.L. (2004). Requirement for Tec kinases in chemokine-induced migration and activation of Cdc42 and Rac. Curr Biol 14, 917–922. Van Oers, N.S.C., Lowin-Kropf, B., Finlay, D., Connolly, K., Weiss, A. (1996). αβ T cell development is abolished in mice lacking both Lck and Fyn protein tyrosine kinases. Immunity 5, 429–436. Wang, H., Moon, E.Y., Azouz, A., Wu, X., Smith, A., Schneider, H., et al. (2003). SKAP-55 regulates integrin adhesion and formation of T cell-APC conjugates. Nat Immunol 4, 366–374. Zhang, W., Shao, Y., Fang, D., Huang, J., Jeon, M.S., Liu, Y.C. (2003). Negative regulation of T cell antigen receptor-mediated Crk-L-C3G signaling and cell adhesion by Cbl-b. J Biol Chem 278, 23978–23983. Zhang, W.G., Sommers, C.L., Burshtyn, D.N., Stebbins, C.C., DeJarnette, J.B., Trible, R.P., et al. (1999). Essential role of LAT in T cell development. Immunity 10, 323–332.
Chapter 9 Mouse Models of Negative Selection Troy A. Baldwin, Timothy K. Starr, and Kristin A. Hogquist
I.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Overview of Thymic Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . II. Positive and Negative Selection—Who and Where? . . . . . . . . . . . . . . . . . . III. Models for Central Tolerance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Anti-CD3/Peptide Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Endogenous Antigen Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. TCR Transgenics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Vβ Transgenics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Endogenous Superantigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Mediators of Negative Selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. The T Cell Receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Costimulatory Molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Signal Transducers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. ERK/JNK/p38 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Grb2/RasGRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. MINK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. Transcription Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Nuclear Factor-κB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. AIRE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Nur77 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E. Molecules Involved in Apoptosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Death Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Mitochondria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
208 208 208 209 209 209 209 209 213 213 215 215 215 216 216 216 216 216 216 217 217 217 217 218 218
Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
207
208
TROY
I.
A.
BALDWIN,
TIMOTHY
INTRODUCTION
T lymphocytes play a critical role in adaptive immunity to pathogens. Their ability to function properly in this role, while not causing an immune reaction to host tissues, reflects cellular properties that are established as they develop in the thymus. For this reason, the thymus has long been studied by immunologists, and many mouse models that facilitate these analyses exist. In this chapter, we discuss the utility and limitations of transgenic and gene-deficient mouse strains to model thymic processes, specifically negative selection.
K.
STARR,
Overview of Thymic Development
Thymocytes are derived from bone marrow progenitors that migrate via the blood to the thymus. The thymus is composed of two distinct areas, the outer cortex and inner medulla. Development of thymocytes proceeds through a well-defined series of intermediates culminating with exit from the thymus and entry into the periphery (Starr et al. 2003). The most immature thymocytes enter the thymus at the cortical-medullary junction and do not express either coreceptor CD4 or CD8 and are thus called “double negative” (DN). After entering the thymus, DN thymocytes begin to traffic outward toward the capsule and continue to develop. Progression within the DN compartment is broken down further into four steps (DN1–DN4) identified by the dynamic expression of CD44 and CD25. At the DN3 stage, rearrangement of the T cell receptor (TCR) β locus occurs, and, if it is successful, the TCRβ chain pairs with a pre-TCRα chain, traffics to the cell surface, and initiates the process of β-selection. An assembly-dependent signaling complex induces a burst of proliferation, initiates rearrangement at the TCRα locus, and sends survival signals to DN3 thymocytes (Michie and Zuniga-Pflucker 2002). After completion of β-selection, expression of CD4 and CD8 is induced, resulting in a “double-positive” (DP) thymocyte. At this stage a mature αβ-TCR is expressed, and the DP thymocyte enters the cortex and begins a return journey toward the medulla. All subsequent selection events are mediated by the clonal αβ-TCR. The selection process is necessary for the further development of those DP thymocytes that express a “useful” TCR (positive selection) and the elimination of those cells that express an overtly self-reactive TCR (negative selection). Negative selection provides the basis for the phenomenon of central tolerance. Recently, the clinical importance of central tolerance has been directly demonstrated by the loss of a critical transcription factor, the autoimmune regulator (AIRE), which results in an inherited autoimmune syndrome in both mouse and man (Venanzi et al. 2004). One of the long-standing questions in developmental immunology is how engagement of the same TCR by different ligands can lead to dramatically different fates—life or death. The answer appears to be tied to the affinity of the TCR for
KRISTIN
A.
HOGQUIST
self-peptide major histocompatability complexes (MHCs) (Alam et al. 1996). The affinity paradigm proposes that if the TCR interacts with self-peptide MHCs with a high affinity, a program of death ensues. If, however, the TCR interacts with self-peptide MHCs with a low to moderate affinity, the cell will receive survival signals and continue development to either the CD4 single-positive (CD4SP) or CD8 single-positive (CD8SP) lineage. Although this appealingly simple model can explain much of the data, other factors have been demonstrated to play a significant role in these selection processes.
II. A.
AND
POSITIVE AND NEGATIVE
SELECTION—WHO AND WHERE? The cell type expressing the self-peptide MHC probably plays an important role in the decision of the DP thymocyte to live or die. As was stated previously, the thymus is divided into two principal regions, the cortex and the medulla. The cortex comprises mostly cortical thymic epithelial cells (cTECs), fibroblasts, and DP thymocytes, whereas the medulla comprises medullary thymic epithelial cells (mTECs) and medullary dendritic cells (mDCs). These different compartments and the cell types residing within them are necessary for all the selection events, yet they play different roles in the selection process. As the DP thymocyte travels through the cortex toward the medulla, it first encounters cTECs. By restricting expression of MHC class II or I to cTEC using a keratin 14 (K14) promoter in class II- or I-deficient mice, respectively, positive selection was restored (Capone et al. 2001; Laufer et al. 1996). Interestingly, negative selection was impaired, resulting in self-reactivity in the periphery, implying the importance of the medulla for central tolerance. Other evidence also suggests that deletion occurs in the medulla. For example, when deletion of superantigen reactive thymocytes in MHC-sufficient or -deficient animals was compared, apoptotic cells were detected in the medulla of MHC-sufficient animals (Surh and Sprent 1994). Additionally, when MHC expression was restricted to the DC compartment, and thus the medulla (Shortman et al. 1998), by the CD11c promoter, deletion was observed (Brocker et al. 1997; Cannarile et al. 2004). Furthermore, ligation of CD40 has been demonstrated to be essential for clonal deletion by endogenous superantigen (Foy et al. 1995). Stimulation of CD40 upregulated the expression of B7 exclusively in the medulla. Therefore, the medulla and more specifically the medullary DCs are thought to be prominent in mediating deletion. Finally, AIRE expression is restricted to medullary TECs (Zuklys et al. 2000), and either direct presentation by mTECs or cross-presentation by mDCs of high-affinity ligand is sufficient to induce deletion (Gallegos and Bevan 2004). Overall, one can generalize that positive selection occurs in the cortex and is mediated by cTECs, whereas negative selection is restricted to the medulla. Interestingly, CCR7 is thought to be important for the directed
9. MOUSE
MODELS
OF
NEGATIVE
migration of thymocytes to the medulla, but the Takahama group showed that neither CCR7 expression on the thymocyte nor CCL19 or 21 expression in the medulla was required for thymocytes to be deleted or to exit the thymus (Ueno et al. 2004). These studies, however, were not conducted in mixed bone marrow chimeras with a normal thymic architecture, and thus it remains possible that CCR7 does play a role in directing the progenitor to the medulla for deletion.
III.
209
SELECTION
MODELS FOR CENTRAL TOLERANCE
Over the past 15–20 years, there have been numerous models used to study negative selection in the mouse. Early work focused on examination of deletion in two principle models, the first model being superantigen-mediated deletion in wild-type mice and the second being deletion in TCR transgenic mice. Interestingly, these two models produced different conclusions regarding the developmental stage of deletion. These discrepancies have made it difficult to map the molecular factors/ pathways controlling deletion. In describing the different models, we will attempt to point out strengths and weaknesses of each model and how these might affect results obtained with the different models.
(non–antigen-specific) DP thymocytes were deleted (Martin and Bevan 1997). DP thymocytes are particularly sensitive to apoptosis before positive selection, so it is these cells that are lost. These findings highlight the major drawbacks to using injection of antiTCR or peptide as a model for studying negative selection. To overcome some of the limitations of the aforementioned models, researchers have used fetal thymic organ culture (FTOC) or reaggregate thymic organ culture as an alternative. These model systems use an intact fetal lobe or empty thymic lobe seeded with thymocytes. With these models many different TCR stimuli can be used; costimulation is provided by physiological thymic APCs, and mature T cells are not present to respond to the stimulus. In general, this is a better alternative than the in vitro systems, but is somewhat difficult to carry out (Anderson and Jenkinson, 1998).
B.
Endogenous self-antigen expression is utilized in many models. These are powerful in vivo model systems, and selfreactive cells are tracked either by use of a TCR transgene, peptide/MHC tetramers, or Vβ antibodies in the case of endogenous superantigens. 1.
A.
Anti-CD3/Peptide Models
There are a number of models of negative selection in which bulk thymocyte populations are stimulated in vitro or in vivo with antibodies to CD3 or in the case of TCR transgenics, MHC-binding peptides. The in vitro models have the advantage of being cost and time effective. They are also extremely easy to manipulate by changing the amount of TCR stimulation or the costimulation molecule engaged. However, in most cases the TCR stimulus is artificial, and if antigen-presenting cells (APCs) are used, often they are not thymically derived. The biggest drawback to these in vitro models is that the assay is not conducted in the context of an intact thymus, and the threedimensional architecture of the thymus appears to be important for appropriate selection (van Ewijk 1991). In conclusion, although the in vitro systems are easy to use, the physiological relevance of the models is highly questionable. The in vivo administration of anti-CD3 or peptide has the benefit that negative selection occurs in an intact thymus; however, this alone may not be sufficiently physiologic. For example, in these cases, deletion occurs early in development at the DP stage, which is now recognized to be a nonspecific consequence of peripheral T cell activation due to the production of glucocorticoids and cytokines (Brewer et al. 2002; Martin and Bevan 1997; Zhan et al. 2003). In fact, when mature antigenspecific T cells were adoptively transferred into a wild-type host and activated by peptide injection, the host-derived
Endogenous Antigen Models
TCR Transgenics
As an alternative to the artificial injection of anti CD3 or peptide, negative selection to endogenous self-antigens can be modeled in TCR transgenics (Table 9-1). In many of these models, deletion occurs either at the DP or cortical stage, whereas in other models, deletion occurs at the SP or medullary stage. Clearly, where the self-antigen is expressed can contribute to this difference; however, this location does not seem to explain all of the data. It has been proposed that TCR affinity dictates the stage of deletion (Sant’Angelo and Janeway 2002), because DP cells have a lower level of TCR and are presumed to be less sensitive. However, direct tests of this hypothesis revealed that DP cells are as sensitive as mature cells (Davey et al. 1998). An additional factor to consider regarding TCR transgenics is their elevated, premature TCR expression in DN cells. Recently, this early TCR expression was demonstrated to have an impact on negative selection in the HY TCR model such that when the TCR was expressed at the physiological DP stage, deletion occurred late in development (Baldwin et al. 2005). Therefore, although TCR transgenics provide a powerful means to model negative selection, deletion occurs at an early stage, which is nonphysiological, in many models and again can lead to confounding information about molecular mechanisms. 2.
Vβ Transgenics
One means to avoid the overwhelming monoclonality and problematic early α chain expression of TCR transgenics is to
TABLE 9-1
210
TCR TRANSGENIC MODELS Model of Negative Selection
Name
Reference
2C
McGargill et al. 2002; Sha et al. 1998 Auphan et al. 1994 Morahan et al. 1991
BM3.3 F3
MHC Class
TCR Transgenes
Positive Selection Background
I
Vα3/Vβ8
H-2b
I I
?/? Vα8/Vβ11
H-2k H-2bm1
Antigen
NP transgenic
I
H-2k, H-2kxd
N15
Ghendler et al. 1997
I
Vα8/Vβ5.2
H-2b (Kb)
NOD.AI4, AI4 OT-1
Choisy-Rossi et al. 2004
I
Vα8/Vβ2
I
Vα2/Vβ5
P14
Gallegos and Bevan 2004; McGargill et al. 2000 Pircher et al. 1989
H-2g7 (NOD) (Kd) H-2b (Kb)
I
Vα2/Vβ8.1
H-2b (Db)
P1ACTL
Sarma et al. 1999
I
Vα8/Vβ1
H-2d (Ld)
Lymphocytic choriomeningitis virus (LCMV) GP33 P1A 35–43
QM11
Suzuki et al. 1994
I
Vα10/Vβ4
H-2q
I-Ak alloreactive
RT1 ST40 ST42 T1
Yokosuka et al. 2002
Doucey et al. 2003
I I I I
Vα42/Vβ8.1 Va16/Vb1 Va16/Vb1 Vα?/Vβ?
H-2d (Dd) H-2b (Db) H-2b (Db) H-2b
TG-B 6C5
Geiger et al. 1992 Sullivan et al. 2002
I Ib
Vα5/Vβ8 Vα3.2/Vβ5.1
H-2k (Kk) H-2b or H-2d (Qa-1b) H-2b (H-2M3)
HIV-1 gp160 Adenovirus E1a 234–243 Adenovirus E1a 234–243 Plasmodium berghei circumsporozoite Ag SV40 large T antigen Human insulin B chain
Vα4.2/Vβ8.1
Ib
Vα10.2/Vβ5.2
1H3.1
II
Vα1/Vβ6
Viret and Janeway 2000
H-2b or H-2d (H2-M3) H-2b (I-Ab)
Listeria monocytogenes AttM f-MFFINILTL L. monocytogenes LemA protein Peptide from I-Ea chain
B6.H2g7 RIP-OVA, K14OVAp K14-OVA, Act-OVA Neonatal (chronic) LCMV infection P1A (no deletion)
I-E+/Mtv 6/9+ strains Mlsa
Eµmb-P1A Strains expressing I-Ak
RIP-SV40
I-Ab/Ea peptide
HOGQUIST
Ib
Vesicular stomatitis virus 52–59 Uncharacterized β cell antigen Chicken ovalbumin (OVA) 257–264
A.
C10.4 Berg et al. 1999 TCRtrans+ D7 Chiu et al. 1999
H-2Kb expressing strains
KRISTIN
Schonrich et al. 1991
Male mice
AND
Kb5.C20, Des
H-2b (Db)
K14-male antigen transgenic
STARR,
I
Male mice
I-E+/ Mtv8/9/11
K.
H-2b (Db)
Baldwin et al. 2005
Vα17/Vβ 8.2 Vα17/Vβ 8.2 ?/?
B6 H-2Kb expressing strains
TIMOTHY
I
Ld
A.
H-2b (Db)
Alloantigen
BALDWIN,
Influenza nucleoprotein 366–374 Mouse male antigen SMCY 738–764 Mouse male antigen SMCY 738–764 H-2Kb alloantigen
Vα4/Vβ11
Superantigen
TROY
“SIY” peptide K14 promoter Kb transgenics RIP-Kb
I
HY (B6.2.12) HYcd4
Transgenic Antigen
Ld alloantigen (synthetic peptide SIYRYYGL H-2Kb) H-2Kb/PBM1 alloantigen Kb alloantigen
Mamalaki et al. 1993; Wack et al. 1996 Kisielow et al. 1988
F5
Endogenous Antigen
3.L2
Haribhai et al. 2003; Kersh et al. 1998 Haribhai et al. 2003; Zhang et al. 2003 Schmidt et al. 1997
II
Vα18/Vβ8.3
H-2k (I-Ek)
II
Vα3/Vβ8.2
H-2k (I-Ak)
II
Vα4.1/Vβ11
H-2g7 (I-Ag7)
Bogen et al. 1993 Girgis et al. 1999 Lanoue et al. 1997; Jordan et al. 2001; Reed et al. 2003; Sarukhan et al. 1998 Zal et al. 1994
II II II
Vα1, Vβ8.2 Vα11, Vβ3 Vα4/Vβ8.2
H-2d (I-Ed) H-2a (I-Ek) H-2d (I-Ed)
II
Vα11.1/Vβ8.3
H-2a (I-Ek) (C5a negative)
Complement protein C5 107–121
ABLE ABM or 3BBM74
Reiner et al. 1998 Backstrom et al. 1998
II II
Vα8.2/Vβ4 Vα2/Vβ8
H-2d (I-Ad) H-2b
Leishmania major LACK I-Abm12
AND
Liu et al. 1997; Oehen et al. 1996; Vasquez et al. 1992
II
Vα11/Vβ3
I-Ek or I-Ab (I-Ek or I-Ab)
MCC 88–103/PCC 88–104
B5 BDC2.5
Granucci et al. 1996 Katz et al. 1993
II II
Vα4/Vβ14 Vα1/Vβ4
H-2d (I-Ad) H-2g7 NOD
IgG2ab 435–451 Uncharacterized islet cell antigen
D011.10
II
Vα?/Vβ8.2
H-2d (I-Ad)
Chicken ovalbumin 323–339
D10, D10.G4.1
Fremont et al. 1996; Ignatowicz, Kappler, Marrack, 1996; Ignatowicz, Kappler, Parker, et al. 1996; Kawahata et al. 2002; Liu et al. 1996; Vella et al. 1996; Sant’Angelo and Janeway 2002
II
Vα2/Vβ8.2
H-2k (I-Ak)
Chicken conalbumin 134–146
Dep
Klein et al. 1998
II
Vα11.2/Vβ5.1
H-2b (I-Ab)
Ea6 G2, 2.102 G286, B16.3 KB
Viret et al. 2000 Hsu et al. 1995
II II
H-2b (I-Ab) H-2k (I-Ek)
Tarbell et al. 2002
II
Vα23.1/Vβ6 endogeno us α/Vβ1 Vα4.5/Vβ1
He et al. 2002
II
Vα10/Vβ8
(I-As)
Human reactive C protein (hCRP) 89–101 I-Eα-chain 52–66 Mouse hemoglobin d allele 64–76 Mouse glutamic acid decarboxylase 65 286–300 Human collagen IV α2 chain 675–686
3A9 4.1, NY4.1 4B2A1 5C.C7 6.5, HA, TS1
A18, C5
Pigeon cytochrome c (PCC) 81–104 Human hemoglobin (Hbb) d allele 64–76 Hen egg lysozyme (HEL) 46–61 Uncharacterized β cell antigen MOPC315 IgG2 91–101 PCC/MCC 88–104 Influenza hemaglutinin (HA) 111–119
PCC transgenic 1) 2) 1) 2)
Mls-2a and Mls-3a
Hbbd Tg tet HEL/Hbd Tg HEL Tg tet HEL/Hbd Tg
NOD β cell antigen MOPC315 BCR Tg MX-MCC-Hel Tg Igk-HA, RIP-HA, SV40-HA, Pev-HA, β-myo HA CBA mouse strain (C5a+) B6.bm12
1) Kb-PCC transgenic 2) I-Ek MCC peptide transgenic
I-As
Ld-nOVA transgenic
I-Ab
SELECTION
H-2a (I-Ek)
NEGATIVE
Vα?/Vβ3
OF
II
MODELS
Berg et al. 1989
9. MOUSE
2B4
NOD, no overt deletion seen
H-2 b, q, d, f, r, and u hCRP Tg I-Eαd transgenic Hbbd+ strains NOD
211
Continued
212
TABLE 9-1
TCR TRANSGENIC MODELS—cont’d Model of Negative Selection
Bovine pancreas RNAse alloreactive to H-2g7 41–61
Huseby et al. 2001
II
Vα2/Vβ8
H-2u (I-Au)
Goverman et al. 1993 II Lafaille et al. 1994 II Gallegos and Bevan 2004 II
Vα2.3/Vβ8.2 Vα?/Vβ8 Vα2/Vβ5
H-2u (I-Au) H-2u (I-Au) H-2b (I-Ab)
Sep SM1 Smarta
Klein et al. 1998 McSorley et al. 2002 Oxenius et al. 1998
II II II
Vα4/Vβ8.3 Vα10/Vβ2 Vα2.3/Vβ8.3
H-2b (I-Ab) H-2b (I-Ab) H-2b (I-Ab)
Murine myelin basic protein (MBP) 121–150 Murine MBP 1–11 Murine MBP 1–11 Chicken ovalbumin protein 323–339 hCRP 80–94 Salmonella flagellin 427–441 LCMV GP 61–80
TCli
Wong et al. 2000
II
Vα18/Vβ6
H-2b (I-Ab)
TCRHNT TEa
Scott et al. 1994
II
Vα?/Vβ8
H-2d (I-Ad)
Grubinet al. 1997
II
Vα2/Vβ6
H-2b (I-Ab)
Human invariant chain CLIP fragment 81–104 Influenza virus hemagglutinin 126–138 Murine I-Ea-chain 52–68
DN (CD1) SP (CD1)
Cheng et al. 1996 Cheng et al. 1996
Vα4.4/Vβ9 Vα4.4/Vβ9
H-2d H-2d
Probable alloreactivity to CD1 Probable alloreactivity to CD1
MBP, 121-150 MBP, 172.1 MBP, 19G OT-II
Eα-glucose-6phosphate isomerase peptide transgenic Endogenous MBP
RIP-OVA hCRP Tg Neonatal LCMV infection
Alloantigen NOD
Strains expressing I-Ea
AND
H-2k (I-Ak)
Superantigen
STARR,
Vα4/Vβ6
Transgenic Antigen
K.
II
Endogenous Antigen
TIMOTHY
Kouskoff et al. 1996; Shih et al. 2004
KRN, R28
Antigen
BALDWIN,
Positive Selection Background
A.
TCR Transgenes
Reference
TROY
MHC Class
Name
KRISTIN A. HOGQUIST
9. MOUSE
MODELS
OF
NEGATIVE
use mice expressing only the β chain of a particular TCR. Such mice have a diverse repertoire, but in many cases, the antigenspecific precursors are detectable with tools such as peptide/MHC tetramers (Baldwin et al. 1999) or by knowing which Vα chains give reactivity (Holman et al. 2003; Mikszta et al. 1999). This is an excellent model for some questions. One drawback, however, is that the level of TCR expressed on DP cells usually precludes their analysis with tetramers, so studying the stage and biochemical mechanism of negative selection is difficult with this model. 3.
213
SELECTION
Endogenous Superantigens
Arguably the most physiological model of negative selection to date is endogenous superantigen deletion in wild-type mice, which was in fact the first way that negative selection was modeled experimentally (Kappler et al. 1987). TCRVβ+ DP cells were present, but mature SP thymocytes were absent, suggesting that deletion occurred after positive selection, as cells transitioned to the SP stage. Studies by Surh and Sprent (1994) demonstrated that in MHC+ mice, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)+ cells were present in the medulla, whereas in MHC− mice, those cells were absent, confirming a late deletion mechanism. This model has a number of benefits, including the use of nontransgenic mice and endogenous antigen presentation. This mechanism of deletion occurs most efficiently in I-E+ strains. However, the strains most commonly used for gene targeting are C57BL/6 and 129, which are I-E−; thus, extensive breeding is required to test the role of various genes using this model. Another drawback is that the interaction of MHC-superantigen and TCR is quite different from the interaction of TCR with peptide-MHC, possibly resulting in differential signal transduction.
In summary, we assert that the most physiological models of negative selection in mice are those that display late deletion mediated by an endogenous peptide antigen in a Vβ or TCR transgenic mouse.
IV.
MEDIATORS OF NEGATIVE SELECTION
Two nonmutually exclusive paradigms have emerged in the field of positive and negative selection, the “affinity” model and the “unique costimulus” model. The affinity model postulates that the affinity of the clonally expressed TCR for self-peptide–MHC complexes is responsible for inducing either positive or negative selection (Starr et al. 2003), whereas the unique costimulus model suggests that ligation of an additional costimulatory receptor is required for deletion but not for positive selection (Amsen and Kruisbeek 1998). Probably both are true. One can envision a situation in which a high-affinity ligand but not a low-affinity ligand can induce the expression of a costimulatory receptor on the DP thymocyte and that ligation of this costimulatory receptor in the medulla is necessary to complete negative selection. In either case, it remains unclear how TCR and/or coreceptor engagement leads to apoptosis. Additionally, a great deal of controversy surrounds some molecules that have been shown to be important for deletion in certain systems but not others, perhaps due to the plethora of models used and their inherent differences. Because positive selection is thought to precede negative selection, many of the proximal signaling molecules downstream of the TCR are required for both positive and negative selection. In this chapter we focus exclusively on the pathways and molecules uniquely involved in negative selection. Table 9-2 provides an overview of the molecules
TABLE 9-2
MOLECULES INVOLVED IN NEGATIVE SELECTION Family
Molecule Affected
Modulation
Model
Effect
Reference
TCR
TCRζ
ITAM deletion
TCRβ TCRα CD3γ
FG loop deletion α-CPM deletion CD3γ ∆-ITAM knockin CD40L−/−
HY Exogenous superantigen N15 peptide injection OT-I FTOC F5 CD3γ ∆-ITAM knockin in vitro HY Endogenous superantigen AND/H-2a
Impaired Impaired Impaired None None
Shores et al. 1997 Shores et al. 1997 Sasada et al. 2002 Werlen et al. 2000 Haks et al. 2002
None Impaired
Page et al. 1998 Foy et al. 1995
Impaired
Foy et al. 1995
Endogenous superantigen Exogenous superantigen P1ACTL Endogenous superantigen
Impaired
Buhlmann et al. 2003
None Impaired Impaired
Buhlmann et al. 2003 Gao et al. 2002 Gao et al. 2002
Costimulator
CD40L-CD40
B7-1/B7-2-CD28
B7-1/B7-2−/−
Perinatal Ab. blockade
Continued
214
TROY
A.
BALDWIN,
TIMOTHY
K.
STARR,
AND
KRISTIN
A.
HOGQUIST
TABLE 9-2
MOLECULES INVOLVED IN NEGATIVE SELECTION—cont’d Family
Molecule Affected
Modulation
Model
Effect
Reference
Death receptor
Fas
Fas−/− (lpr)
Superantigen
None Impaired Impaired Impaired (high dose)
Kotzin et al. 1988 Dautigny et al. 1999 Page et al. 1998 Kishimoto et al. 1998
Impaired (high dose)
Kishimoto et al. 1998
Impaired Impaired Impaired (low Ag dose)
Castro et al. 1996 Castro et al. 1996 Schmitz et al. 2003
FasL blockade
Signal transducers
TNFR1 TNFR2 TRAIL DR3
TNFR1−/− TNFR2−/− TRAIL−/− DR3−/−
FADD-dependent death receptors Erk
Dominant-negative FADD Tg Dominant negative MEK Tg Dominant negative JNK1 Tg JNK 2−/− SB203580 inhibitor Grb2+/-
JNK1 JNK2 p38 Grb2
Transcription factors
MINK
MINK RNA interference
NF-κB
Retroviral overexpression of IκBNS AIRE−/− Dominant negative Nur77 Tg Apaf-1−/−
AIRE Nur77 Apoptosis
Apaf-1 Caspases
Bcl-2
Caspase 3−/− Caspase 8−/− Caspase 9−/− zVAD
Baculovirus p35 Tg EµBcl-2 Tg lckpr Bcl-2 Tg
Bak/Bax
Bak/Bax−/−
Bim
Bim−/−
HY Exogenous superantigen (neonates) Peptide injection of D011.10 (neonates) Anti-CD3 in vivo Peptide injection of D011.10 VSV8 peptide treated N15 FTOC Endogenous superantigen Endogenous superantigen Endogenous superantigen Endogenous superantigen HY Superantigen HY HY
None None None None Impaired None None None
Pfeffer et al. 1993 Erickson et al. 1994 Cretney et al. 2003 Wang et al. 2001 Wang et al. 2001 Newtonet al. 1998 Newton et al. 1998 Alberola-Ila et al. 1995
Peptide-injected AND Tg
Impaired
Rincon et al. 1998
Anti-CD3 injection in vivo Inhibitor-treated HY FTOC HY Anti-CD3 injection in vivo Endogenous superantigen HY Peptide injection of OT-II Anti-CD3 treatment of retrovirally infected RTOC 3A9 insHEL Tg NP-injected F5 Exogenous superantigen HY HY FTOC Anti-CD3/CD28 in vitro Anti-CD3 in vitro Anti-CD3/CD28 in vitro OT-I in vitro peptide
Impaired Impaired Impaired Impaired Impaired Impaired Impaired Enhanced
Sabapathy et al. 2001 Sugawara et al. 1998 Gong et al. 2001 Gong et al. 2001 McCarty et al. 2005 McCarty et al. 2005 McCarty et al. 2005 Fiorini et al. 2002
Impaired Impaired None None Impaired None None Impaired None Impaired
HY Peptide injection of F5 Endogenous superantigen HY Endogenous superantigen HY Anti-CD3 in vitro Endogenous superantigen Exogenous superantigen FTOC Peptide injection of OT-II HY
None Impaired None None Impaired Impaired Impaired Impaired Impaired
Liston et al. 2003 Calnan et al. 1995 Calnan et al. 1995 Hara et al. 2002 Matsuki et al. 2002 Kuida et al. 1996 Salmena et al. 2003 Kuida et al. 1998 Doerfler et al. 2000 McGargill, Hogquist 1999 Doerfler et al. 2000 Izquierdo et al. 1999 Sentman et al. 1991 Tao et al. 1994 Strasser et al. 1991 Strasser et al. 1994 Rathmell et al. 2002 Rathmell et al. 2002 Bouillet et al. 2002
Impaired Impaired
Bouillet et al. 2002 Bouillet et al. 2002
9. MOUSE
MODELS
OF
NEGATIVE
demonstrated to play a role in negative selection and the models used to test their role.
A.
The T Cell Receptor
The central player in clonal deletion is the TCR complex. Ligation of the TCR by high-affinity antigen and subsequent signal transduction are required for negative selection. The TCR complex is composed of disulfide-linked TCRα and β chains and noncovalently associated CD3γ/ε, CD3δ/ε, and TCRζ/ζ dimers. Deletion of a segment of the TCRβ chain (the FG loop), which may be involved in the association of CD3ε with the TCR, blocked negative selection in VSV8 peptide–injected N15 TCR transgenic mice (Sasada et al. 2002). In support of a role for TCRβ in mediating apoptosis, deletion of the TCRβ transmembrane and cytoplasmic domains impaired the ability of peripheral T cells to undergo activationinduced cell death after antigen stimulation (Teixeiro et al. 2004). The effect of this deletion on negative selection in the thymus has yet to be investigated. In contrast, a mutation in the TCRα chain (α-CPM), which results in a failure to recruit CD3δ upon TCR ligation, had no effect on negative selection in FTOC (Werlen et al. 2000). Based on this evidence, one could speculate that TCRβ plays an important role in signal transduction, leading to negative selection. The CD3/TCRζ complex contains a total of 10 signal transducing immunoreceptor tyrosine-based activation motifs (ITAMs). These motifs have been mutated in an attempt to decipher whether individual CD3 chains provide unique signals for negative selection or whether deletion is dependent on the “amount” of signal (i.e., number of ITAMs). Work by Shores et al. (1997) suggested that a reduction in the number of TCRζ ITAMs (one instead of three) resulted in impaired negative selection. This was observed in both early (HY male) and late (superantigen) models of deletion. On the other hand, when CD3γ lacked an ITAM, positive selection was impaired, but using an in vitro model, negative selection was not (Haks et al. 2002). Additionally, the CD3ε ITAM was not required for positive selection, whereas negative selection was not directly tested (Sommers et al. 2000). Therefore, there does appear to be a requirement for a minimal number of ITAMs, but the molecular organization of the TCR/CD3 complex also appears to be critical for negative selection. These findings suggest that the “quality” of signal received by the thymocyte plays a key role in negative selection, supporting the affinity model of deletion.
B.
215
SELECTION
Costimulatory Molecules
The role of costimulatory molecules in negative selection has been controversial. Some of the most compelling evidence for the role of costimulatory molecules in negative selection
involves the requirement for CD40-CD40 ligand (CD40L) and B7/CD28 interactions. With use of antibody blockade or CD40L-deficient mice, deletion was attenuated when CD40 on thymic APCs was not ligated (Foy et al. 1995). Interestingly, CD40L acts in a non–cell-autonomous fashion such that when both CD40L-expressing and CD40L-deficient thymocytes are present in the thymus, both populations are equally susceptible to deletion (Williams et al. 2002). These data suggest that ligation of CD40 on thymic APCs results in the upregulation or induction of a costimulatory molecule on the APCs required for deletion and supports a “unique costimulus” model for deletion. However, the requirement for CD40-CD40L interactions in negative selection has been demonstrated in late models of deletion, whereas most early models of deletion show no such requirement (Page et al. 1998). One of the molecules shown to be regulated by the CD40-CD40L interaction is B7-2 (Foy et al. 1995). A number of early studies showed either a limited or no role for CD28/B7 interactions in negative selection; however, recent experiments using B7-1/B7-2 double knockouts have demonstrated impaired endogenous superantigen-mediated deletion (Buhlmann et al. 2003). Furthermore, perinatal blockade of B7-1 and B7-2 leads to a decrease in negative selection and an increase in pathogenic T cells in both transgenic and superantigen models (Gao et al. 2002). Other costimulatory molecules such as CD43 and CD5 have, in some circumstances, been shown to affect deletion. In most cases the effect is subtle. However, when ligated with antibodies in combination with anti-CD28, their effect is much more pronounced in in vitro assays (Li and Page 2001). Because no single costimulatory molecule appears essential for deletion in all models, there is some speculation that signal transduction through these receptors is redundant or that high-affinity receptors do not require costimulation for deletion. Further work needs to be done to address this issue. Based on the data regarding the role of various cell surface receptors, it is likely that affinity plays a key role in determining the fate of the DP progenitor, but it is also likely that a second costimulatory signal provided by a medullary APC is also required. We hypothesize that induction of the costimulatory receptor on the progenitor is a consequence of a high-affinity TCR stimulus whereas expression of the costimulatory ligand on the APC may be mediated by CD40-CD40L interactions. Therefore, we favor a combination of both the affinity and unique costimulus models in negative selection.
C.
Signal Transducers
For the progenitor to undergo death, signal transduction pathways emanating from the TCR and perhaps other cell surface receptors must be initiated. For the most part, the pathways involved in clonal deletion are incompletely understood. However, a few key signal transducing molecules and pathways important in negative selection have been identified.
216 1.
TROY
A.
BALDWIN,
TIMOTHY
Grb2/RasGRP
The canonical MAPK signaling pathway is initiated by the activation of the small GTPase, Ras, by a guanine nucleotide exchange factor (GEF). In a number of cell types, Ras activation is mediated through the adaptor Grb2 binding to the GEF, Sos. Haplo-insufficiency at the Grb2 locus does not impair positive selection (Gong et al. 2001), as Ras activation during positive selection has been shown to be dependent on the presence of another GEF, namely RasGRP (Dower et al. 2000). Interestingly, haplo-insufficiency at the Grb2 locus did impair negative selection in both the HY and anti-CD3 injection negative selection models (Gong et al. 2001). This haploinsufficiency at the Grb2 locus did not affect MAPK activation, but did impair JNK and p38 activation, indirectly supporting a role for these molecules in negative selection. Therefore, thymocytes may have evolved different mechanisms for differential activation of the MAPKs in positive versus negative selection. 3.
MINK
The MAP4K, MINK, was recently identified as a molecule induced in DP thymocytes, and “knockdown” of MINK expression by RNA interference did not affect positive selection but dramatically inhibited clonal deletion (McCarty et al. 2005). This impairment in negative selection was observed in superantigen, peptide injection, and the HY models of deletion. MINK was demonstrated to interact with Nck, which has been shown to associate with the TCR through CD3ε. MINK was also demonstrated to be required for phosphorylation of JNK and subsequent induction of Bim (another molecule necessary for deletion that will be discussed later). MINK knockdown had no effect on ERK activation (McCarty et al. 2005). Therefore, MINK may be a direct link from the TCR leading to deletion. It will be interesting to determine whether the affinity of the TCR differentially regulates MINK and what the other players in this pathway are.
STARR,
D.
ERK/JNK/p38
The mitogen-activated protein kinase (MAPK) pathways have received considerable attention in both positive and negative selection. The extracellular signal-regulated kinase (ERK) pathway, although required for positive selection appears to be dispensable for negative selection (Alberola-Ila et al. 1995). There is evidence for a role of the c-Jun NH2-terminal kinase (JNK) and p38 pathways in negative selection. DN JNK1expressing (Rincon et al. 1998) or JNK2-deficient thymocytes (Sabapathy et al. 2001) were partially impaired in apoptosis, and treatment of thymocytes with a p38 inhibitor (SB203580) also interfered with negative selection (Sugawara et al. 1998). However, these findings have yet to be confirmed in more physiologic models of negative selection. 2.
K.
AND
KRISTIN
A.
HOGQUIST
Transcription Factors
Differential changes in gene expression are thought to be important factors influencing the decision of the progenitor to live or die. Therefore, the identification of specific transcription factors that are necessary or important for negative selection has been intensely investigated. To this point, only a few such transcription factors have been identified. 1.
Nuclear Factor-κB
The nuclear factor (NF)-κB transcription factor family is involved in many immune cell processes including development and survival. A novel inhibitor of NF-κB, IκBNS, was identified as a transcript specifically induced in DP thymocytes after peptide injection of N15 TCR transgenic mice (Fiorini et al. 2002). Retroviral overexpression of IκBNS resulted in increased thymic negative selection in FTOC treated with anti-CD3. Therefore, by inhibiting NF-κB, DP thymocytes were more sensitive to this type of stimuli. Other evidence for the role of NF-κB in negative selection exists; however, NF-κB is such an important factor for numerous processes and cell types, it is difficult to separate its requirement in other processes with those in negative selection. 2.
AIRE
Mutations in the AIRE gene result in a severe, multiorgan autoimmune syndrome in both mouse and man (Anderson et al. 2002; Bjorses et al. 1998). This autoimmunity was shown to be a result of defective negative selection in the thymus (Liston et al. 2003). AIRE is critical for the antigen presentation of tissuespecific antigens (TSA) such as insulin, thyroglobulin, and others (Anderson et al. 2002). Interestingly, AIRE-dependent presentation of TSAs occurs within a subset of medullary epithelial cells, further supporting the role of the medulla as the primary site of negative selection (Derbinski et al. 2001). AIRE contains a DNA-binding domain and thus has been postulated to be a transcription factor, driving transcription of these TSAs in the thymus (Pitkanen et al. 2000). Additionally, AIRE possesses an E3 ubiquitin-ligase activity, implicating a role for AIRE in antigen presentation by directing proteins to the proteosome as opposed to simply providing TSA transcripts (Uchida et al. 2004). In fact, work by the Matsumoto group demonstrated transcription of fodrin in AIRE-deficient mice, yet antigen presentation of fodrin was still impaired in this situation, resulting in autoimmunity highlighting the importance of the E3 ubiquitin-ligase activity in deletion (Kuroda et al. 2005). It will be of great interest to determine other transcription factors responsible for TSA expression in the absence of AIRE and the role of the E3 ubiquitin-ligase activity of AIRE.
9. MOUSE
3.
MODELS
OF
NEGATIVE
Nur77
Another transcription factor identified through a genetic screen for transcripts induced during apoptosis in T cell hybridomas was Nur77 (Liu et al. 1994). Nur77 is a member of the orphan steroid receptor transcription factor family. Nur77 is highly upregulated after TCR stimulation in DP thymocytes (Liu et al. 1994), and expression of a dominant negative form of Nur77 prevented negative selection in NP peptide–injected F5 TCR transgenic mice but not superantigen-mediated deletion (Calnan et al. 1995). Interestingly, Nur77-deficient thymocytes still undergo deletion (Lee et al. 1995), but it is thought that the Nur77 family member NOR1 can compensate for the loss of Nur77 in this situation (Cheng et al. 1997). Interestingly, in analysis of genes induced by Nur77 overexpression, two novel genes were identified. One gene, NDG1 (Nur77 downstream gene 1), induced apoptosis when expressed in 293 cells, but was blocked by the caspase 1 and 8 inhibitor, CrmA (Cheng et al. 1997). It will be of interest to identify other genes regulated by Nur77 in hopes of identifying factors involved in negative selection.
E.
Molecules Involved in Apoptosis
Although there is a considerable amount of information on the pathways leading to apoptosis in many cell types and a lot of effort has gone into understanding how apoptosis is mediated by negative selection, a clear paradigm has not yet emerged. There are two general pathways leading to death, one involving death receptor signaling (type I), and one not (type II). There are commonalities between these pathways, such as caspase activation and disruption of the mitochondria, but there are differences as well, including the mechanism of caspase activation. 1.
217
SELECTION
Death Receptors
Death receptor expression and ligation in peripheral T cells results in apoptosis through activation of caspases. Caspases can be recruited to death receptors through the association with death domain–containing adaptor proteins, such as Fas-associated death domain (FADD), and subsequently activated by proteolytic cleavage. For the most part, death receptor ligation does not appear to be required for negative selection. Deficiency of tumor necrosis factor receptor (TNFR) 1 (Pfeffer et al. 1993), TNFR2 (Erickson et al. 1994), death-inducing receptor-3 (Wang et al. 2001), and TNF-related apoptosis-inducing ligand (TRAIL) (Cretney et al. 2003) has little or no impact on negative selection. However, the role of Fas in negative selection is somewhat controversial. Early work in Fas-deficient mice demonstrated no impact on endogenous superantigen-mediated deletion (Kotzin et al. 1988), whereas in more recent experiments,
Fas does appear to play some role in negative selection (Castro et al. 1996; Kishimoto et al. 1998; Page et al. 1998; Schmitz et al. 2003). In some instances, ligation of Fas can augment deletion at high antigen concentrations (Kishimoto et al. 1998), whereas in others, Fas appears to have an affect at low antigen doses (Schmitz et al. 2003). Perhaps the most compelling evidence against the involvement of death receptors that utilize the adaptor protein FADD was obtained when expression of a dominant negative version of FADD had no effect on negative selection in numerous models (Newton et al. 1998). It will be of interest to determine whether other TNFR family members play a role in deletion. Recent gene array experiments from the Goodnow group indicated that in negative selection conditions, members of the TNFR superfamily including OX40 and 4-1BB were upregulated (Liston et al. 2004). It is possible that one of these receptors may be important for negative selection. 2.
Mitochondria
Mitochondria have been shown to play a critical role in apoptosis in all cell types. After initiation of the apoptotic program, there is a loss of outer mitochondrial membrane integrity and release of mitochondrial constituents into the cytosol, including cytochrome c. Cytochrome c then binds to caspase 9 and apoptotic protease activating factor-1 (apaf-1) to form the apoptosome and activates downstream caspases, ultimately leading to apoptosis. There is conflicting evidence for the role of apaf-1 in negative selection (Hara et al. 2002; Matsuki et al. 2002), and most individual caspases (3, 8, and 9) seem not to be required for negative selection (Kuida et al. 1996, 1998; Salmena et al. 2003). The use of broad-spectrum caspase inhibitors such as baculovirus p35 and zVADfmk in a number of different models (Doerfler et al. 2000; Izquierdo et al. 1999; Villunger et al. 2004) generally did not have an effect on negative selection. Therefore, the role for caspases in negative selection remains an open question. On the other hand, there is ample evidence for a role for bcl-2 family members in negative selection. The early approaches using transgenic overexpression of bcl-2 led to conflicting results. Two individual Bcl-2 transgenic mice were constructed and in one transgenic mouse, negative selection was unaffected in superantigen and HY models (Sentman et al. 1991; Tao et al. 1994), whereas using the same models of negative selection, the other Bcl-2 transgenic mouse showed impaired deletion (Strasser et al. 1991, 1994). The reason for this difference is currently unknown; however, one could postulate that differences in Bcl-2 expression levels due to copy number, integration site, or promoter strength may be the cause. In Bim-deficient animals, negative selection is highly impaired in a number of different models including exogenous superantigen-mediated deletion and in the HY system (Bouillet et al. 2002; Villunger et al. 2004). Bax and Bak are likewise required (Rathmell et al. 2002). Bim, Bax, and Bak
218
TROY
A.
BALDWIN,
TIMOTHY
are also required for death of DP thymocytes via pathways outside of the antigen receptor (such as glucocorticoids and irradiation) suggesting that they are generally important in regulating life and death in DP thymocytes (Bouillet et al. 1999; Rathmell et al. 2002). It is unclear at this point how the TCR regulates these bcl-2 family members, and further research is needed to address this crucial point.
V.
CONCLUSIONS
Clonal deletion is a fundamental process necessary to maintain tolerance to self-antigens. As demonstrated by the occurrence of multiorgan autoimmunity in the face of impaired negative selection to tissue-specific antigens in AIRE-deficient mice or humans, understanding the factors controlling deletion is of great importance. When one is using mice as a model system to study negative selection, it is critical to choose an appropriate model as data concerning the role of a molecule in negative selection from one model are not always the same as those in another model. Given that the medulla is replete with potent antigen-presenting cells, late deletion models appear to be the most physiological. Further work examining the molecular pathways leading to deletion, specifically those involved in delivering the apoptotic signal, is greatly needed at this juncture.
REFERENCES Alam, S.M., Travers, P.J., Wung, J.L., Nasholds, W., Redpath, S., Jameson, S.C., et al. (1996). T-cell-receptor affinity and thymocyte positive selection. Nature 381, 616–620. Alberola-Ila, J., Forbush, K.A., Seger, R., Krebs, E.G., Perlmutter, R.M. (1995). Selective requirement for MAP kinase activation in thymocyte differentiation. Nature 373, 620–623. Amsen, D., Kruisbeek, A.M. (1998). Thymocyte selection: not by TCR alone. Immunol Rev 165, 209–229. Anderson, G., Jenkinson, E.J. (1998). Use of explant technology in the study of in vitro immune responses. J Immunol Methods 216, 155–163. Anderson, M.S., Venanzi, E.S., Klein, L., Chen, Z., Berzins, S.P., Turley, S.J., et al. (2002). Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395–1401. Auphan, N., Curnow, J., Guimezanes, A., Langlet, C., Malissen, B., Mellor, A., et al. (1994). The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR). and influences negative selection in TCR-transgenic mice. Eur J Immunol 24, 1572–1577. Backstrom, B.T., Muller, U., Hausmann, B., Palmer, E. (1998). Positive selection through a motif in the αβ T cell receptor. Science 281, 835–838. Baldwin, K.K., Trenchak, B.P., Altman, J.D., Davis, M.M. (1999). Negative selection of T cells occurs throughout thymic development. J Immunol 163, 689–698. Baldwin, T.A., Sandau, M.M., Jameson, S.C., Hogquist, K.A. (2005). The timing of TCR α expression critically influences T cell development and selection. J Exp Med 202, 111–121. Berg, L.J., Pullen, A.M., Fazekas de St Groth, B., Mathis, D., Benoist, C., Davis, M.M. (1989). Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell 58, 1035–1046.
K.
STARR,
AND
KRISTIN
A.
HOGQUIST
Berg, R.E., Princiotta, M.F., Irion, S., Moticka, J.A., Dahl, K.R., Staerz, U.D. (1999). Positive selection of an H2-M3 restricted T cell receptor. Immunity 11, 33–43. Bjorses, P., Aaltonen, J., Horelli-Kuitunen, N., Yaspo, M.L., Peltonen, L. (1998). Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet 7, 1547–1553. Bogen, B., Dembic, Z., Weiss, S. (1993). Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J 12, 357–363. Bouillet, P., Metcalf, D., Huang, D.C., Tarlinton, D.M., Kay, T.W., Kontgen, F., et al.. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735–1738. Bouillet, P., Purton, J.F., Godfrey, D.I., Zhang, L.C., Coultas, L., Puthalakath, H., et al. (2002). BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415, 922–926. Brewer, J.A., Kanagawa, O., Sleckman, B.P., Muglia, L.J. (2002). Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J Immunol 169, 1837–1843. Brocker, T., Riedinger, M., Karjalainen, K. (1997). Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 185, 541–550. Buhlmann, J.E., Elkin, S.K., Sharpe, A.H. (2003). A role for the B7-1/B7-2: CD28/CTLA-4 pathway during negative selection. J Immunol 170, 5421–5428. Calnan, B.J., Szychowski, S., Chan, F.K., Cado, D., Winoto, A. (1995). A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigeninduced negative selection. Immunity 3, 273–282. Cannarile, M.A., Decanis, N., van Meerwijk, J.P., Brocker, T. (2004). The role of dendritic cells in selection of classical and nonclassical CD8+ T cells in vivo. J Immunol 173, 4799–4805. Capone, M., Romagnoli, P., Beermann, F., MacDonald, H.R., van Meerwijk, J.P. (2001). Dissociation of thymic positive and negative selection in transgenic mice expressing major histocompatibility complex class I molecules exclusively on thymic cortical epithelial cells. Blood 97, 1336–1342. Castro, J.E., Listman, J.A., Jacobson, B.A., Wang, Y., Lopez, P.A., Ju, S., et al. (1996). Fas modulation of apoptosis during negative selection of thymocytes. Immunity 5, 617–627. Cheng, L., Dejbakhsh-Jones, S., Liblau, R., Zeng, D., Strober, S. (1996). Different patterns of TCR transgene expression in single-positive and double-negative T cells: evidence for separate pathways of T cell maturation. J Immunol 156, 3591–3601. Cheng, L.E., Chan, F.K., Cado, D., Winoto, A. (1997). Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. EMBO J 16, 1865–1875. Chiu, N.M., Chun, T., Fay, M., Mandal, M., and Wang, C.R. (1999). The majority of H2-M3 is retained intracellularly in a peptide-receptive state and traffics to the cell surface in the presence of N-formylated peptides. J Exp Med 190, 423–434. Choisy-Rossi, C.M., Holl, T.M., Pierce, M.A., Chapman, H.D., Serreze, D.V. (2004). Enhanced pathogenicity of diabetogenic T cells escaping a non-MHC gene-controlled near death experience. J Immunol 173, 3791–3800. Cretney, E., Uldrich, A.P., Berzins, S.P., Strasser, A., Godfrey, D.I., Smyth, M.J. (2003). Normal thymocyte negative selection in TRAIL-deficient mice. J Exp Med 198, 491–496. Dautigny, N., Le Campion, A., Lucas, B. (1999). Timing and casting for actors of thymic negative selection. J Immunol 162, 1294–1302. Davey, G.M., Schober, S.L., Endrizzi, B.T., Dutcher, A.K., Jameson, S.C., Hogquist, K.A. (1998). Preselection thymocytes are more sensitive to T cell receptor stimulation than mature T cells. J Exp Med 188, 1867–1874. Derbinski, J., Schulte, A., Kyewski, B., Klein, L. (2001). Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2, 1032–1039.
9. MOUSE
MODELS
OF
NEGATIVE
SELECTION
Doerfler, P., Forbush, K.A., Perlmutter, R.M. (2000). Caspase enzyme activity is not essential for apoptosis during thymocyte development. J Immunol 164, 4071–4079. Doucey, M.A., Goffin, L., Naeher, D., Michielin, O., Baumgartner, P., Guillaume, P., et al. (2003). CD3δ establishes a functional link between the T cell receptor and CD8. J Biol Chem 278, 3257–3264. Dower, N.A., Stang, S.L., Bottorff, D.A., Ebinu, J.O., Dickie, P., Ostergaard, H.L., et al. (2000). RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol 1, 317–321. Erickson, S.L., de Sauvage, F.J., Kikly, K., Carver-Moore, K., Pitts-Meek, S., Gillett, N., et al. (1994). Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372, 560–563. Fiorini, E., Schmitz, I., Marissen, W.E., Osborn, S.L., Touma, M., Sasada, T., et al. (2002). Peptide-induced negative selection of thymocytes activates transcription of an NF-κB inhibitor. Mol Cell 9, 637–648. Foy, T.M., Page, D.M., Waldschmidt, T.J., Schoneveld, A., Laman, J.D., Masters, S.R., et al. (1995). An essential role for gp39, the ligand for CD40, in thymic selection. J Exp Med 182, 1377–1388. Fremont, D.H., Hendrickson, W.A., Marrack, P., Kappler, J. (1996). Structures of an MHC class II molecule with covalently bound single peptides. Science 272, 1001–1004. Gallegos, A.M., Bevan, M.J. (2004). Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med 200, 1039–1049. Gao, J.X., Zhang, H., Bai, X.F., Wen, J., Zheng, X., Liu, J., et al. (2002). Perinatal blockade of b7-1 and b7-2 inhibits clonal deletion of highly pathogenic autoreactive T cells. J Exp Med 195, 959–971. Geiger, T., Gooding, L.R., Flavell, R.A. (1992). T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci USA 89, 2985–2989. Ghendler, Y., Hussey, R.E., Witte, T., Mizoguchi, E., Clayton, L.K., Bhan, A.K., et al. (1997). Double-positive T cell receptor (high). thymocytes are resistant to peptide/major histocompatibility complex ligand-induced negative selection. Eur J Immunol 27, 2279–2289. Girgis, L., Davis, M.M., Fazakas de St Groth, B. (1999). The avidity spectrum of T cell receptor interactions accounts for T cell anergy in a double transgenic model. J Exp Med 189, 265–278. Gong, Q., Cheng, A.M., Akk, A.M., Alberola-Ila, J., Gong, G., Pawson, T., et al. (2001). Disruption of T cell signaling networks and development by Grb2 haploid insufficiency. Nat Immunol 2, 29–36. Goverman, J., Woods, A., Larson, L., Weiner, L.P., Hood, L., Zaller, D.M. (1993). Transgenic mice that express a myelin basic proteinspecific T cell receptor develop spontaneous autoimmunity. Cell 72, 551–560. Granucci, F., Rescigno, M., Marconi, G., Foti, M., Ricciardi-Castagnoli, P. (1996). Ig-specific T cell receptor-transgenic T cells are not deleted in the thymus and are functional in vivo. J Exp Med 183, 203–213. Grubin, C.E., Kovats, S., deRoos, P., Rudensky, A.Y. (1997). Deficient positive selection of CD4 T cells in mice displaying altered repertoires of MHC class II-bound self-peptides. Immunity 7, 197–208. Haks, M.C., Pepin, E., van den Brakel, J.H., Smeele, S.A., Belkowski, S.M., Kessels, H.W., et al. (2002). Contributions of the T cell receptor-associated CD3γ-ITAM to thymocyte selection. J Exp Med 196, 1–13. Hara, H., Takeda, A., Takeuchi, M., Wakeham, A.C., Itie, A., Sasaki, M., et al. (2002). The apoptotic protease-activating factor 1-mediated pathway of apoptosis is dispensable for negative selection of thymocytes. J Immunol 168, 2288–2295. Haribhai, D., Engle, D., Meyer, M., Donermeyer, D., White, J.M., Williams, C.B. (2003). A threshold for central T cell tolerance to an inducible serum protein. J Immunol 170, 3007–3014. He, X., Janeway, C.A., Jr., Levine, M., Robinson, E., Preston-Hurlburt, P., Viret, C., et al. (2002). Dual receptor T cells extend the immune repertoire for foreign antigens. Nat Immunol 3, 127–134.
219 Holman, P.O., Walsh, E.R., Hogquist, K.A. (2003). The central tolerance response to male antigen in normal mice is deletion and not receptor editing. J Immunol 171, 4048–4053. Hsu, B.L., Evavold, B.D., Allen, P.M. (1995). Modulation of T cell development by an endogenous altered peptide ligand. J Exp Med 181, 805–810. Huseby, E.S., Sather, B., Huseby, P.G., Goverman, J. (2001). Age-dependent T cell tolerance and autoimmunity to myelin basic protein. Immunity 14, 471–481. Ignatowicz, L., Kappler, J., Marrack, P. (1996). The repertoire of T cells shaped by a single MHC/peptide ligand. Cell 84, 521–529. Ignatowicz, L., Kappler, J., Parker, D.C., Marrack, P. (1996). The responses of mature T cells are not necessarily antagonized by their positively selecting peptide. J Immunol 157, 1827–1831. Izquierdo, M., Grandien, A., Criado, L.M., Robles, S., Leonardo, E., Albar, J.P., et al. (1999). Blocked negative selection of developing T cells in mice expressing the baculovirus p35 caspase inhibitor. EMBO J 18, 156–166. Jordan, M.S., Boesteanu, A., Reed, A.J., Petrone, A.L., Holenbeck, A.E., Lerman, M.A., et al. (2001). Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2, 301–306. Kappler, J.W., Roehm, N., Marrack, P. (1987). T cell tolerance by clonal elimination in the thymus. Cell 49, 273–280. Katz, J.D., Wang, B., Haskins, K., Benoist, C., Mathis, D. (1993). Following a diabetogenic T cell from genesis through pathogenesis. Cell 74, 1089–1100. Kawahata, K., Misaki, Y., Yamauchi, M., Tsunekawa, S., Setoguchi, K., et al. (2002). Generation of CD4+CD25+ regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression. J Immunol 168, 4399–4405. Kersh, G.J., Donermeyer, D.L., Frederick, K.E., White, J.M., Hsu, B.L., Allen, P.M. (1998). TCR transgenic mice in which usage of transgenic α- and β-chains is highly dependent on the level of selecting ligand. J Immunol 161, 585–593. Kishimoto, H., Surh, C.D., Sprent, J. (1998). A role for Fas in negative selection of thymocytes in vivo. J Exp Med 187, 1427–1438. Kisielow, P., Bluthmann, H., Staerz, U.D., Steinmetz, M., von Boehmer, H. (1988). Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 333, 742–746. Klein, L., Klein, T., Ruther, U., Kyewski, B. (1998). CD4 T cell tolerance to human C-reactive protein, an inducible serum protein, is mediated by medullary thymic epithelium. J Exp Med 188, 5–16. Kotzin, B.L., Babcock, S.K., Herron, L.R. (1988). Deletion of potentially selfreactive T cell receptor specificities in L3T4-, Lyt-2-T cells of lpr mice. J Exp Med 168, 2221–2229. Kouskoff, V., Korganow, A.S., Duchatelle, V., Degott, C., Benoist, C., Mathis, D. (1996). Organ-specific disease provoked by systemic autoimmunity. Cell 87, 811–822. Kuida, K., Haydar, T.F., Kuan, C.Y., Gu, Y., Taya, C., Karasuyama, H., et al. (1998). Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94, 325–337. Kuida, K., Zheng, T.S., Na, S., Kuan, C., Yang, D., Karasuyama, H., et al. (1996). Decreased apoptosis in the brain and premature lethality in CPP32deficient mice. Nature 384, 368–372. Kuroda, N., Mitani, T., Takeda, N., Ishimaru, N., Arakaki, R., Hayashi, Y., et al. (2005). Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol 174, 1862–1870. Lafaille, J.J., Nagashima, K., Katsuki, M., Tonegawa, S. (1994). High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 78, 399–408. Lanoue, A., Bona, C., von Boehmer, H., Sarukhan, A. (1997). Conditions that induce tolerance in mature CD4+ T cells. J Exp Med 185, 405–414. Laufer, T.M., DeKoning, J., Markowitz, J.S., Lo, D., Glimcher, L.H. (1996). Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature 383, 81–85.
220
TROY
A.
BALDWIN,
TIMOTHY
Lee, S.L., Wesselschmidt, R.L., Linette, G.P., Kanagawa, O., Russell, J.H., Milbrandt, J. (1995). Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science 269, 532–535. Li, R., Page, D.M. (2001). Requirement for a complex array of costimulators in the negative selection of autoreactive thymocytes in vivo. J Immunol 166, 6050–6056. Liston, A., Lesage, S., Gray, D.H., O’Reilly, L.A., Strasser, A., Fahrer, A.M., et al. (2004). Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity 21, 817–830. Liston, A., Lesage, S., Wilson, J., Peltonen, L., Goodnow, C.C. (2003). Aire regulates negative selection of organ-specific T cells. Nat Immunol 4, 350–354. Liu, C.P., Kappler, J.W., Marrack, P. (1996). Thymocytes can become mature T cells without passing through the CD4+ CD8+, double-positive stage. J Exp Med 184, 1619–1630. Liu, C.P., Parker, D., Kappler, J., Marrack, P. (1997). Selection of antigenspecific T cells by a single IEk peptide combination. J Exp Med 186, 1441–1450. Liu, Z.G., Smith, S.W., McLaughlin, K.A., Schwartz, L.M., Osborne, B.A. (1994). Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 367, 281–284. Mamalaki, C., Elliott, J., Norton, T., Yannoutsos, N., Townsend, A.R., Chandler, P., et al. (1993). Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev Immunol 3, 159–174. Martin, S., Bevan, M.J. (1997). Antigen-specific and nonspecific deletion of immature cortical thymocytes caused by antigen injection. Eur J Immunol 27, 2726–2736. Matsuki, Y., Zhang, H.G., Hsu, H.C., Yang, P.A., Zhou, T., Dodd, C.H., et al. (2002). Different role of Apaf-1 in positive selection, negative selection and death by neglect in foetal thymic organ culture. Scand J Immunol 56, 174–184. McCarty, N., Paust, S., Ikizawa, K., Dan, I., Li, X., Cantor, H. (2005). Signaling by the kinase MINK is essential in the negative selection of autoreactive thymocytes. Nat Immunol 6, 65–72. McGargill, M.A., Derbinski, J.M., Hogquist, K.A. (2000). Receptor editing in developing T cells. Nat Immunol 1, 336–341. McGargill, M.A., Hogquist, K.A. (1999). Antigen-induced coreceptor downregulation on thymocytes is not a result of apoptosis. J Immunol 162, 1237–1245. McGargill, M.A., Mayerova, D., Stefanski, H.E., Koehn, B., Parke, E.A., Jameson, S.C., et al. (2002). A spontaneous CD8 T cell-dependent autoimmune disease to an antigen expressed under the human keratin 14 promoter. J Immunol 169, 2141–2147. McSorley, S.J., Asch, S., Costalonga, M., Reinhardt, R.L., Jenkins, M.K. (2002). Tracking Salmonella-specific CD4 T cells in vivo reveals a local mucosal response to a disseminated infection. Immunity 16, 365–377. Michie, A.M., Zuniga-Pflucker, J.C. (2002). Regulation of thymocyte differentiation: pre-TCR signals and β-selection. Semin Immunol 14, 311–323. Mikszta, J.A., McHeyzer-Williams, L.J., McHeyzer-Williams, M.G. (1999). Antigen-driven selection of TCR in vivo: related TCR α-chains pair with diverse TCR β-chains. J Immunol 163, 5978–5988. Morahan, G., Hoffmann, M.W., Miller, J.F. (1991). A nondeletional mechanism of peripheral tolerance in T-cell receptor transgenic mice. Proc Natl Acad Sci USA 88, 11421–11425. Newton, K., Harris, A.W., Bath, M.L., Smith, K.G., Strasser, A. (1998). A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 17, 706–718. Oehen, S., Feng, L., Xia, Y., Surh, C.D., Hedrick, S.M. (1996). Antigen compartmentation and T helper cell tolerance induction. J Exp Med 183, 2617–2626. Oxenius, A., Bachmann, M.F., Zinkernagel, R.M., Hengartner, H. (1998). Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol 28, 390–400.
K.
STARR,
AND
KRISTIN
A.
HOGQUIST
Page, D.M., Roberts, E.M., Peschon, J.J., Hedrick, S.M. (1998). TNF receptordeficient mice reveal striking differences between several models of thymocyte negative selection. J Immunol 160, 120–133. Pfeffer, K., Matsuyama, T., Kundig, T.M., Wakeham, A., Kishihara, K., Shahinian, A., et al. (1993). Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73, 457–467. Pircher, H., Burki, K., Lang, R., Hengartner, H., Zinkernagel, R.M. (1989). Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342, 559–561. Pitkanen, J., Doucas, V., Sternsdorf, T., Nakajima, T., Aratani, S., Jensen, K., et al. (2000). The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein. J Biol Chem 275, 16802–16809. Rathmell, J.C., Lindsten, T., Zong, W.X., Cinalli, R.M., Thompson, C.B. (2002). Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 3, 932–939. Reed, A.J., Noorchashm, H., Rostami, S.Y., Zarrabi, Y., Perate, A.R., Jeganathan, A.N., et al. (2003). Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation. J Immunol 171, 6502–6509. Reiner, S.L., Fowell, D.J., Moskowitz, N.H., Swier, K., Brown, D.R., Brown, C.R., et al. (1998). Control of Leishmania major by a monoclonal αβ T cell repertoire. J Immunol 160, 884–889. Rincon, M., Whitmarsh, A., Yang, D.D., Weiss, L., Derijard, B., Jayaraj, P., et al. (1998). The JNK pathway regulates the in vivo deletion of immature CD4+CD8+ thymocytes. J Exp Med 188, 1817–1830. Sabapathy, K., Kallunki, T., David, J.P., Graef, I., Karin, M., Wagner, E.F. (2001). c-Jun NH2-terminal kinase (JNK). 1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J Exp Med 193, 317–328. Salmena, L., Lemmers, B., Hakem, A., Matysiak-Zablocki, E., Murakami, K., Au, P.Y., et al. (2003). Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev 17, 883–895. Sant’Angelo, D.B., Janeway, C.A., Jr. (2002). Negative selection of thymocytes expressing the D10 TCR. Proc Natl Acad Sci USA 99, 6931–6936. Sarma, S., Guo, Y., Guilloux, Y., Lee, C., Bai, X.F., Liu, Y. (1999). Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J Exp Med 189, 811–820. Sarukhan, A., Garcia, C., Lanoue, A., von Boehmer, H. (1998). Allelic inclusion of T cell receptor α genes poses an autoimmune hazard due to low-level expression of autospecific receptors. Immunity 8, 563–570. Sasada, T., Touma, M., Chang, H.C., Clayton, L.K., Wang, J.H., Reinherz, E.L. (2002). Involvement of the TCR Cβ FG loop in thymic selection and T cell function. J Exp Med 195, 1419–1431. Schmidt, D., Verdaguer, J., Averill, N., Santamaria, P. (1997). A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. J Exp Med 186, 1059–1075. Schmitz, I., Clayton, L.K., Reinherz, E.L. (2003). Gene expression analysis of thymocyte selection in vivo. Int Immunol 15, 1237–1248. Schonrich, G., Kalinke, U., Momburg, F., Malissen, M., Schmitt-Verhulst, A.M., Malissen, B., et al. (1991). Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 65, 293–304. Scott, B., Liblau, R., Degermann, S., Marconi, L.A., Ogata, L., Caton, A.J., et al. (1994). A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1, 73–83. Sentman, C.L., Shutter, J.R., Hockenbery, D., Kanagawa, O., Korsmeyer, S.J. (1991). bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67, 879–888. Sha, W.C., Nelson, C.A., Newberry, R.D., Kranz, D.M., Russell, J.H., Loh, D.Y. (1988). Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature 336, 73–76.
9. MOUSE
MODELS
OF
NEGATIVE
SELECTION
Shih, F.F., Mandik-Nayak, L., Wipke, B.T., Allen, P.M. (2004). Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells. J Exp Med 199, 323–335. Shores, E.W., Tran, T., Grinberg, A., Sommers, C.L., Shen, H., Love, P.E. (1997). Role of the multiple T cell receptor (TCR)-ζ chain signaling motifs in selection of the T cell repertoire. J Exp Med 185, 893–900. Shortman, K., Vremec, D., Corcoran, L.M., Georgopoulos, K., Lucas, K., Wu, L. (1998). The linkage between T-cell and dendritic cell development in the mouse thymus. Immunol Rev 165, 39–46. Sommers, C.L., Dejarnette, J.B., Huang, K., Lee, J., El-Khoury, D., Shores, E.W., Love, P.E. (2000). Function of CD3 ε-mediated signals in T cell development. J Exp Med 192, 913–919. Starr, T.K., Jameson, S.C., Hogquist, K.A. (2003). Positive and negative selection of T cells. Annu Rev Immunol 21, 139–176. Strasser, A., Harris, A.W., Cory, S. (1991). bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67, 889–899. Strasser, A., Harris, A.W., von Boehmer, H., Cory, S. (1994). Positive and negative selection of T cells in T-cell receptor transgenic mice expressing a bcl-2 transgene. Proc Natl Acad Sci USA 91, 1376–1380. Sugawara, T., Moriguchi, T., Nishida, E., Takahama, Y. (1998). Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity 9, 565–574. Sullivan, B.A., Kraj, P., Weber, D.A., Ignatowicz, L., Jensen, P.E. (2002). Positive selection of a Qa-1-restricted T cell receptor with specificity for insulin. Immunity 17, 95–105. Surh, C.D., Sprent, J. (1994). T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372, 100–103. Suzuki, H., Eshima, K., Takagaki, Y., Hanaoka, S., Katsuki, M., Yokoyama, M., et al. (1994). Origin of a T cell clone with a mismatched combination of MHC restriction and coreceptor expression. J Immunol 153, 4496–4507. Tao, W., Teh, S.J., Melhado, I., Jirik, F., Korsmeyer, S.J., Teh, H.S. (1994). The T cell receptor repertoire of CD4–8+ thymocytes is altered by overexpression of the BCL-2 protooncogene in the thymus. J Exp Med 179, 145–153. Tarbell, K.V., Lee, M., Ranheim, E., Chao, C.C., Sanna, M., Kim, S.K., et al. (2002). CD4+ T cells from glutamic acid decarboxylase (GAD) 65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer. J Exp Med 196, 481–492. Teixeiro, E., Daniels, M.A., Hausmann, B., Schrum, A.G., Naeher, D., Luescher, I., et al. (2004). T cell division and death are segregated by mutation of TCRβ chain constant domains. Immunity 21, 515–526. Uchida, D., Hatakeyama, S., Matsushima, A., Han, H., Ishido, S., Hotta, H., et al. (2004). AIRE functions as an E3 ubiquitin ligase. J Exp Med 199, 167–172. Ueno, T., Saito, F., Gray, D.H., Kuse, S., Hieshima, K., Nakano, H., et al. (2004). CCR7 signals are essential for cortex-medulla migration of developing thymocytes. J Exp Med 200, 493–505. van Ewijk, W. (1991). T-cell differentiation is influenced by thymic microenvironments. Annu Rev Immunol 9, 591–615. Vasquez, N.J., Kaye, J., Hedrick, S.M. (1992). In vivo and in vitro clonal deletion of double-positive thymocytes. J Exp Med 175, 1307–1316.
221 Vella, A.T., Scherer, M.T., Schultz, L., Kappler, J.W., Marrack, P. (1996). B cells are not essential for peripheral T-cell tolerance. Proc Natl Acad Sci USA 93, 951–955. Venanzi, E.S., Benoist, C., Mathis, D. (2004). Good riddance: thymocyte clonal deletion prevents autoimmunity. Curr Opin Immunol 16, 197–202. Villunger, A., Marsden, V.S., Zhan, Y., Erlacher, M., Lew, A.M., Bouillet, P., et al. (2004). Negative selection of semimature CD4+8−HSA+ thymocytes requires the BH3-only protein Bim but is independent of death receptor signaling. Proc Natl Acad Sci USA 101, 7052–7057. Viret, C., He, X., Janeway, C.A., Jr. (2000). On the self-referential nature of naive MHC class II-restricted T cells. J Immunol 165, 6183–6192. Viret, C., Janeway, C.A., Jr. (2000). Functional and phenotypic evidence for presentation of Eα52–68 structurally related self-peptide(s) in I-Eα-deficient mice. J Immunol 164, 4627–4634. Wack, A., Ladyman, H.M., Williams, O., Roderick, K., Ritter, M.A., Kioussis, D. (1996). Direct visualization of thymocyte apoptosis in neglect, acute and steady-state negative selection. Int Immunol 8, 1537–1548. Wang, E.C., Thern, A., Denzel, A., Kitson, J., Farrow, S.N., Owen, M.J. (2001). DR3 regulates negative selection during thymocyte development. Mol Cell Biol 21, 3451–3461. Werlen, G., Hausmann, B., Palmer, E. (2000). A motif in the αβ T-cell receptor controls positive selection by modulating ERK activity. Nature 406, 422–426. Williams, J.A., Sharrow, S.O., Adams, A.J., Hodes, R.J. (2002). CD40 ligand functions non-cell autonomously to promote deletion of self-reactive thymocytes. J Immunol 168, 2759–2765. Wong, P., Goldrath, A.W., Rudensky, A.Y. (2000). Competition for specific intrathymic ligands limits positive selection in a TCR transgenic model of CD4+ T cell development. J Immunol 164, 6252–6259. Yokosuka, T., Takase, K., Suzuki, M., Nakagawa, Y., Taki, S., Takahashi, H., et al. (2002). Predominant role of T cell receptor (TCR)-α chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. J Exp Med 195, 991–1001. Zal, T., Volkmann, A., Stockinger, B. (1994). Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 180, 2089–2099. Zhan, Y., Purton, J.F., Godfrey, D.I., Cole, T.J., Heath, W.R., Lew, A.M. (2003). Without peripheral interference, thymic deletion is mediated in a cohort of double-positive cells without classical activation. Proc Natl Acad Sci USA 100, 1197–1202. Zhang, M., Vacchio, M.S., Vistica, B.P., Lesage, S., Egwuagu, C.E., Yu, C.R., et al. (2003). T cell tolerance to a neo-self antigen expressed by thymic epithelial cells: the soluble form is more effective than the membrane-bound form. J Immunol 170, 3954–3962. Zuklys, S., Balciunaite, G., Agarwal, A., Fasler-Kan, E., Palmer, E., Hollander, G.A. (2000). Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmunepolyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Immunol 165, 1976–1983.
This page intentionally left blank
Chapter 10 Peripheral Tolerance of T Cells in the Mouse Vigo Heissmeyer, Bogdan Tanasa, and Anjana Rao
I. II. III. IV. V. VI.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The Mouse as a Model System for the Study of Autoimmune Disease . . . Scope of This Chapter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The Context of Antigen Recognition Determines T Cell Activation . . . . . Processes Involved in T Cell Activation . . . . . . . . . . . . . . . . . . . . . . . . . . . T Cell Receptor Signal Transduction Leading to Productive T Cell Activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII. Control of T Cell–Mediated Autoimmunity through Central Tolerance . . . VIII. TCR Stimulation in the Absence of Costimulation: Induction of Peripheral T Cell Tolerance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IX. Contributions from T Cell Homeostasis and T Cell Apoptosis . . . . . . . . . . X. Negative Regulation of T Cell Activation . . . . . . . . . . . . . . . . . . . . . . . . . . A. Humoral Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Negative Costimulatory Molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. E3 Ubiquitin Ligases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. Adaptor Molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E. Phosphatases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . XI. Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I.
INTRODUCTION
One of the most crucial evolutionary advances made by higher vertebrates has been to create an adaptive immune system that protects against foreign substances and invading organisms. Unfortunately, the newly acquired effectiveness in
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
223 224 224 224 233 234 234 235 236 236 236 237 237 238 238 238 239
blocking potential pathogens has also brought about a propensity to autoimmune self-destruction. The likelihood of developing autoimmunity has arisen as a consequence of the new mode of “adaptive” antigen recognition, in which lymphocytes in the immune system can recognize millions of possible chemical target structures in specific molecular, cellular, and humoral contexts.
Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
223
224
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
Inappropriate recognition of host antigens by T cells in the periphery is a relatively common feature of peripheral T cells, which are positively selected in the thymus for having productively rearranged their T cell antigen receptor (TCR) genes so as to yield receptors with some degree of cross-reactivity to the particular antigens and major histocompatibility complex (MHC) molecules that are present in the host. Concomitant negative selection in the thymus filters out T cells that have strong autoreactivity, but negative selection by itself is not completely effective for eliminating self-reactive T cell clones. As a result, a plethora of cellular programs and molecular mechanisms have coevolved with the adaptive immune system to deal with self-reactive lymphocytes and silence their autoreactivity. In healthy individuals, these mechanisms operate synergistically and redundantly to ensure that self-reactivity is minimized and that immune and inflammatory responses are ended as promptly as is consistent with effective clearance of pathogens.
II.
THE MOUSE AS A MODEL SYSTEM FOR THE STUDY OF AUTOIMMUNE DISEASE
Study of the underlying mechanisms of peripheral tolerance has been an area of intensive research, since knowledge of how to modulate immune function is invaluable for the treatment of autoimmune disease and the avoidance of transplant rejection. The use of the laboratory mouse has been critical in this endeavor. Initially, immunologists used mice to recapitulate human autoimmune diseases and to establish a causal relationship between the antigen, the reactive immune cell type, and the development of the autoimmune phenotype. Later, T cells capable of transferring or attenuating autoimmune disease were cloned, either from mouse strains that are genetically prone to develop autoimmune disease or from mice that were immunized deliberately with antigens capable of inducing an autoimmune attack on a specific tissue (e.g., myelin basic protein, pancreatic β-cell antigens, and collagen or other joint antigens in mouse models of autoimmune demyelinating diseases, autoimmune diabetes, and autoimmune arthritis, respectively). The molecular cloning of rearranged T cell receptor genes from these T cell clones allowed the subsequent generation of TCR-transgenic mice, which have been invaluable as a means of manipulating at will the development of autoimmune disease, especially in adoptive transfer models. These mice are also a source of homogeneous T cell populations, which can be stimulated with a defined antigen in vitro to assess their biochemical responses to antigen and other signaling inputs. Finally, current advances in gene targeting in mice, combined with emerging results from genome-wide screens in which mice treated with mutagenic substances are evaluated for autoimmune phenotypes, have provided investigators with a growing list of molecules whose mutation or loss of function alters the susceptibility of a mouse strain to develop autoimmune disease.
III.
SCOPE OF THIS CHAPTER
In this chapter we attempt to provide a comprehensive list of gene products that have been implicated as negative regulators of autoimmunity in T cells, as judged by the fact that mice deficient in or mutant for the gene in question present either with frank autoimmunity or show increased susceptibility to developing autoimmunity in experimental models of autoimmune disease (Table 10-1). Given space constraints, we regret that we cannot include a discussion of the many known autoimmune loci, which are genomic regions linked to specific autoimmune diseases that in general contain large numbers of candidate genes. The focus of this chapter will be on the biological mechanisms intrinsic to T cells that are involved in preventing autoimmunity and not on the pathological differences in the autoimmune phenotypes that arise after autoreactive T cells start to attack host tissue. We have excluded genes whose genomic deletion is associated with autoimmune disease in mice, but whose products are not expressed in T cells; or genes whose deletion gives rise to an autoimmune phenotype that is not T cell autonomous. In the following sections, we will summarize established and potential molecular mechanisms that contribute to peripheral T cell tolerance, briefly discussing possible mechanisms through which selected gene products that are thought to be involved in T cell tolerance or otherwise may act to prevent autoimmunity.
IV.
THE CONTEXT OF ANTIGEN RECOGNITION DETERMINES T CELL ACTIVATION
T lymphocytes bind with their antigen receptors only to antigens that are presented on a matching MHC molecule. The specific recognition of antigen that leads to T cell activation occurs during an extended period of time, during which the T cell forms close membrane contacts with specialized cell types known as antigen-presenting cells. These close contacts occur in the context of a macromolecular structure known as the immunological synapse, which is suited for intense information exchange between the T cell and the antigen-presenting cell (Krogsgaard et al. 2003). Antigen is presented particularly effectively by a well-characterized subtype of antigen-presenting cells known as dendritic cells, which mature in a specific humoral milieu established by cells of the innate immune system that produce proinflammatory cytokines in response to infection by pathogens (Germain 2004). T cell activation therefore results from an encounter with an antigen-loaded antigen-presenting cell and is not simply a function of interaction strength and local concentration of the TCR and complexes of antigen-MHC. Rather, the T cell sums inputs from multiple interactions that occur within the immunological synapse, between surface receptors (TCR, integrins, and costimulatory receptors) on the T cell and their ligands on the
225
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES Molecule Name [aliases] [gene name description]
Molecular Function
Mouse Knockout Phenotype
AIRE [autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)]
Probable transcriptional regulator protein that binds to DNA as dimer and tetramer, highly expressed in thymus stromal cells, contains SAND and PHD domains. It is localized to speckled domains in the nucleus and shows colocalization with the cytoskeletal filaments. The PHD domain of AIRE mediates E3 ubiquitin ligase activity.
AKT1 [PKB] [thymoma viral proto-oncogene 1]
A serine/threonine-protein kinase, widely expressed, contains a PH domain. A mediator of survival factors and a regulator of cell cycle, AKT1 activation occurs through PI3K.
BCL2L11 [Bim] [Bcl-2-like 11 (apoptosis facilitator)]
A member of the BCL-2 family, acts as an apoptosis activator. Contains a BH3 domain and forms heterodimers with other members of the BCL-2 family, including BCL2 and BCL-XL. Expressed in lymphoid lineage; it is sequestered to the microtubular dynein motor complex.
BHLHB2 [Stra13] [basic helix-loop-helix (bHLH) domain containing, class B2]
Contains a bHLH domain and may function as a transcription factor. Able to heterodimerize with E47/TCFE2A, associates with UBC9 that targets the molecules for proteolysis by the ubiquitindependent proteasome pathway.
1. The Aire−/− thymic medullary epithelial cells showed a specific reduction in ectopic transcription of genes encoding peripheral antigens. Aire−/− mice exhibited multiorgan autoimmunity and an increased level of autoantibodies, with a similar pattern of organ distribution (Anderson et al. 2002). 2. Aire-deficient mice developed Sjögren’s syndrome– like pathological changes in the exocrine organs, and these were associated with autoimmunity against a ubiquitous protein, α-fodrin, whose gene expression was retained in the Aire-deficient thymus (Kuroda et al. 2005). 3. Mutations in human AIRE are responsible for autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) (The Finnish-German APECED Consortium, 1997). 4. Deficiency of Aire expression is observed in severe immunodeficiencies with autoimmune manifestations. In Omenn syndrome patients, hypomorphic mutations in RAG1 and RAG2 genes impair the process of VDJ recombination, leading to the generation of T cells with a highly restricted receptor repertoire that infiltrate the skin, the gut, the liver, and the spleen (Cavadini et al. 2005). 1. In transgenic mice expressing myristoylated Akt (mAkt), a constitutively active form of AKT, T cells were less dependent on CD28 costimulation, grow rapidly, and secrete IL-2 and IFN-γ in the absence of CD28 ligation. mAkt-transgenic T lymphocytes resist death-by-neglect and accumulate memory T and B cells. Many aged mAkt-transgenic mice developed autoimmunity with immunoglobulin deposits on kidney glomeruli and displayed increased incidence of lymphoma (Rathmell et al. 2003). 1. In Bim−/− mice, the numbers of both the CD4-8-pro-T cells and the mature T cells CD4+ or CD8+ are elevated. The absence of Bim augmented survival of the resting T and B cells and protected the cells against apoptosis induced by cytokine withdrawal. With age, Bim deficiency led to progressive lymphadenopathy, autoimmune glomerulonephritis, and vasculitis. The number of plasma cells was dramatically increased and immunoglobulin (Ig) G autoantibodies reached very high concentrations (Bouillet et al. 1999). 2. TCR ligation upregulated Bim expression and promoted interaction of BIM with BCL-XL, inhibiting its survival function. Thymocytes lacking Bim are refractory to apoptosis induced by TCR-CD3 stimulation. In transgenic mice expressing autoreactive TCRs that cause widespread clonal deletion, Bim deficiency severely impaired thymocyte killing (Bouillet et al. 2002). 1. T cell development is normal in Stra13−/− mice. Stra13 deficiency affect clonal expansion, differentiation, and AICD. Ineffective deletion of activated T and B cells leads to lymphoid hyperplasia and Stra13−/− mice develop autoimmune disease characterized by circulating autoantibodies, infiltration in multiple organs, and Continued
226
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
CBLB [Casitas B-lineage lymphoma b]
Molecular Function
A signal transduction protein, contains an EFhand-like calcium-binding domain and a a RING-type zinc finger that mediates the binding to an E2 ubiquitin–conjugating enzyme.
Mouse Knockout Phenotype
1.
2.
CD274 [B7-H1; PD-L1] [CD274 antigen]
PDCD1 [PD-1] [programmed cell death 1]
CD276 [B7H3] [CD276 antigen]
CTLA-4 [CD152] [cytotoxic T lymphocyte–associated protein 4]
PD-L1, a type I membrane protein, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-CD1-independent manner. Contains Ig-like C2-type and V-type domains
1.
PD-CD1, a type I membrane protein, a possible inducer of apoptosis. Belongs to the immunoglobulin superfamily, contains an Ig-like V-type domain. Interaction between PD-CD1 and PD-L1 inhibits T cell proliferation and cytokine production. A type I membrane protein, serves as a negative regulator of T cell activation and function.
3.
A type I membrane protein, contains 1 Ig-like V-type domain and transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal.
2.
1.
1.
2.
E2F2 [E2F transcription factor 2]
A member of the E2F family of transcription factors; acts cooperatively with DP family members and regulates the genes involved in cell cycle regulation or in DNA replication. E2F2 binds specifically to RB1 protein, in a cell cycle–dependent manner.
1.
deposition of immune complex in glomeruli. The phenotype of Stra13−/− mice is similar of that of IL2-and IL-2 receptor-deficient mice, which show normal T cell development but impaired expansion and apoptosis after lymphocyte activation (Sun et al. 2001). Resting Cblb−/− lymphocytes display increased proliferation and IL-2 production upon TCR stimulation, with minimal requirement for CD28 costimulation. Cblb−/− mice develop spontaneous autoimmunity characterized by infiltration of activated T and B lymphocytes into multiple organs, organ damage, and autoantibody production (Bachmaier et al. 2000). Thymic positive and negative selections of T cells in Cblb−/− mice are normal. Mice deficient in Cblb are highly susceptible to experimental autoimmune encephalomyelitis (Chiang et al. 2000). T cell responses, including cytokine production, were enhanced in Pdl1−/− mice. Pdl1−/− mice develop an autoimmune-like phenotype, which is delayed in onset compared with Ctla4−/− mice (Latchman et al. 2004). Pdcd1−/− mice die prematurely on a BALB/c background, but not on a C57BL/6 background. Pdcd1-deficient BALB/c mice develop dilated cardiomyopathy that leads to heart failure and exhibit high-titer autoantibodies (Nishimura et al. 2001). C57BL/6-Pdcd1−/− mice spontaneously developed lupus-like glomerulonephritis and destructive arthritis as they age. The onset and severity of both glomerulonephritis and arthritis in B6-Pdcd1−/− mice is accelerated by the additional lymphoproliferation (lpr) mutation (Nishimura et al. 1999). B7H3 negatively regulates T helper (Th) 1 responses. B7h3-deficient mice developed experimental autoimmune encephalomyelitis and severe airway inflammation and accumulated increased concentrations of autoantibodies. T helper cells differentiate toward a Th1 rather than a Th2 phenotype (Suh et al. 2003). Ctla4-deficient T cells proliferated strongly and spontaneously after TCR stimulation, and they were sensitive to FAS-mediated apoptosis. Lymph nodes and spleens of Ctla4−/− mice, but also liver, heart, lung, and pancreas tissue, were infiltrated with activated T cells. The concentration of serum immunoglobulins was elevated (Waterhouse et al. 1995). Ctla4-deficient mice develop lymphoproliferative disease with multiorgan infiltration and tissue destruction, with particularly severe myocarditis and pancreatitis (Tivol et al. 1995). In E2f2-deficient mice, thymic negative selection is intact, and T cells show an enhanced proliferation but normal sensitivity to FAS-triggered apoptosis and/or IL-2 withdrawal. Autoreactive effector/memory T lymphocytes accumulate and appear to be responsible for causing late-onset autoimmune features, represented by widespread inflammatory infiltrates, antinuclear antibodies, and glomerular deposition of immune complexes (Murga et al. 2001).
227
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
Molecular Function
FAS [CD95; TNFR6] [Fas (TNF receptor superfamily member)]
FAS, type I membrane protein, contains a death domain involved in the binding of Fas associated death domain (FADD). FADD recruits caspase-8 to the activated receptor, and the resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation, which initiates the subsequent cascade of caspases mediating apoptosis.
FASL [CD95L; TNFSF6; CD178] [Fas ligand (TNF superfamily, member 6)]
FASL, type II membrane protein, belongs to the TNF family. Homotrimer, binds to FAS.
FOXJ1 [FKHL13] [forkhead box J1]
Contains one forkhead DNA-binding domain.
FOXO3A [FKHRL1] [forkhead box O3a]
Contains one forkhead DNA-binding domain. May trigger apoptosis by inducing the expression of genes that are critical for cell death.
FOXP3 [JM2; scurfin] [forkhead box P3]
Contains 1 fork-head DNA-binding domain.
GADD45A [Ddit1] [growth arrest and DNA-damage-inducible 45 α]
Belongs to the GADD45 family binds to proliferating cell nuclear antigen (PCNA), interacts with cell division protein kinase (CDK) complexes; stimulates DNA excision repair and inhibits entry of cells into S phase.
Mouse Knockout Phenotype 2. T cells lacking E2f1 and E2f2 proliferate more extensively in response to antigenic stimulation. E2f1/E2f2-null mutant mice are predisposed to the development of tumors and exhibit signs of autoimmunity (Zhu et al. 2001). 1. Mice carrying the lpr mutation have defects in the Fas gene. The lpr mice develop lymphadenopathy and suffer from a systemic lupus erythematosus–like autoimmune disease (Watanabe-Fukunaga et al. 1992). 2. Fas-null mice show a massive proliferation of lymphocytes and a substantial liver hyperplasia (Adachi et al. 1995). 3. Autoimmune lymphoproliferative syndrome (ALPS) type IA, characterized by nonmalignant lymphadenopathy, autoimmunity, and expanded populations of CD4−CD8− lymphocytes, is caused by mutation in the human Fas gene (Fisher et al. 1995; Rieux-Laucat et al. 1995). 4. An autosomal recessive mutation generalized lymphoproliferative disease (gld) determines the development of massive lymphoid hyperplasia with antinuclear antibodies and hypergammaglobulinemia, a pattern that resembles the phenotype induced by the lpr mutation (Roths et al. 1984). 5. Fasl−/− mice exhibited splenomegaly and lymphadenopathy, multiple organ infiltration, and autoimmune disease (Karray et al. 2004). 6. ALPS type IB is caused by mutation in the human Fasl gene (Wu et al. 1996). 1. Foxj1−/− mice die in utero because of hydrocephalus and/or heterotaxy. Foxj1−/− chimeras displayed evidence of systemic autoimmune inflammation, including T cell infiltrates of the salivary glands, liver, lung, and kidney. Naïve Foxj1−/− T cells produced elevated quantities of IL-2 and IFN-γ after TCR stimulation and Foxj1−/− Th cells demonstrated increased NF-kB1 activation (Lin, Spoor, et al. 2004). 1. Foxo3a-deficient mice were generated using the gene trap targeting strategy. Foxo3a deficiency leads to spontaneous lymphoproliferation and the inflammation of the salivary gland, lung, and kidney. No apoptotic defects were observed. Helper T cells were hyperactivated hyperproliferated, and produced large amounts of cytokines. NF-kB1 activity in Foxo3a-deficient mice was elevated (Lin, Hron, et al. 2004). 1. Scurfy is an X-linked recessive mouse mutant characterized by CD4+ T cell hyperproliferation, extensive multiorgan infiltration, and elevation of numerous cytokines. The gene defective in sf mice is Foxp3 (Brunkow et al. 2001). 2. FOXP3 is specifically expressed in CD4+CD25+ regulatory T cells, and it is required for their development. Foxp3-null mice develop a lethal autoimmune syndrome (Fontenot et al. 2003). 1. Gadd45a−/− T cells hyperproliferate after TCR stimulation. Gadd45a−/− mice develop an autoimmune disease that is similar to human systemic lupus erythematosus, with high titers of autoantibodies, hematological disorders, and autoimmune glomerulonephritis. The development of autoimmunity was accelerated in mice deficient in both Gadd45a and Cdkn1a (p21) (Salvador et al. 2002). Continued
228
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
Molecular Function
Mouse Knockout Phenotype
GPR132 [G2a] [G protein–coupled receptor 132]
Integral membrane protein, belongs to the G protein-coupled receptor 1 family, receptor for lysophosphatidylcholine. Induced by DNA-damaging agents and may serve as a mechanism for T and B cells to slow their proliferation and repair damaged DNA to ensure proper replication.
ICOS [inducible T cell costimulator]
Type I membrane protein, contains 1 immunoglobulin-like V-type domain, expressed on activated T cells and resting memory T cells. Homodimer, enhances proliferation, secretion of lymphokines, and effective help for antibody secretion by B cells. Does not increase the production of IL-2, but induces IL-10 expression. Prevents the apoptosis of preactivated T cells and plays a critical role in CD40-mediated class switching of Ig isotypes. Belongs to the α/β interferon family. Monomer, has antiviral, antibacterial, and anticancer activities.
1. Gpr132-deficient T cells are hyperresponsive to TCR stimulation and exhibit enhanced proliferation. Old Gpr132−/− mice develop lymphoid hyperplasia that is associated with abnormal expansion of both T and B lymphocytes, multiple organ infiltration, glomerular deposition of immune complexes, antinuclear autoantibodies, and a progressive wasting syndrome (Le et al. 2001). 1. T cell activation and proliferation are defective in Icos-deficient mice. Icos−/− T cells fail to produce IL-2, IL-4, or IL-13. Icos−/− mice showed enhanced susceptibility to experimental autoimmune encephalomyelitis (Dong et al. 2001).
IFNB1 [interferon-β1, fibroblast]
IL-2 [interleukin 2]
Belongs to the IL-2 family and produced by T cells in response to antigenic or mitogenic stimulation. The expression of this gene in mature thymocytes is monoallelic. Required for T cell proliferation.
IL-2RA [CD25] [interleukin 2 receptor, α chain]
The IL-2RA and IL-2RB chains, together with the common γ chain IL-2RG, constitute the high-affinity IL-2 receptor. Homodimeric α chains IL-2RA result in low-affinity receptor, whereas homodimeric IL-2RB chains produce a medium-affinity receptor. Type I membrane protein, contains two Sushi domains.
1. Ifnb1−/− mice are susceptible to experimental autoimmune encephalitis and develop severe and chronic neurological symptoms with extensive central nervous system inflammation and demyelination. T cells proliferate normally, but have increased effector functions, as measured by IFN-γ and IL-4 production (Teige et al. 2003). 2. The IFN-RI/CD118 deficiency leads to lymphoproliferative syndrome and autoantibody production. The IFN-RII/CD119 deficiency protected MRL/lpr mice from the development of autoimmuneassociated lymphadenopathy, autoantibodies, and autoimmune renal disease. Mice deficient for both IFN-RI and IFN-RII developed an autoimmune phenotype intermediate between that of wild-type and IFN-RII-deficient animals (Hron and Peng 2004). 1. T cell development in Il2−/− mice is normal. The number of activated T and B cells is elevated, as well as the serum immunoglobulin levels. The null mutants develop adult onset autoimmune disease, with death due to hemolytic anemia. Survivors develop an inflammatory bowel disease with anti-colon antibodies (Sadlack et al. 1993). 2. Il2−/− mice on a BALB/c background develop a lymphoproliferative syndrome with autoantibodies and of various specificities hemolytic anemia and die within 1 month of age (Sadlack et al. 1995). 3. Il2−/− mice on a C3H background, after immunization with myosin, develop severe myocarditis with high titers of autoantibodies (Grassl et al. 1997). 1. The development of T and B cells in Il2ra−/− is normal. Activation-induced cell death is impaired, T and B cells expand, and adult mice develop enlargement of secondary lymphoid organs. Older Il2ra-deficient mice develop autoimmune disorders, including hemolytic anemia and inflammatory bowel disease (Willerford et al. 1995).
229
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
Molecular Function
Mouse Knockout Phenotype
IL-2RB [CD122] [interleukin 2 receptor, β chain]
The intermediate- and high-affinity forms of the receptor are involved in transduction of mitogenic signals from IL-2 and in receptor-mediated endocytosis. Type I membrane protein, contains one fibronectin type III domain.
IL-10 [CSIF] [interleukin 10]
Homodimer, belongs to the IL10 family. Inhibits the synthesis of a number of cytokines, including IFN-γ, IL-2, IL-3, and TNF produced by activated macrophages and by helper T cells.
ITCH [itchy]
A E3 ubiquitin-protein ligase, contains one HECT-type E3 ubiquitin-protein ligase domain.
LAT [linker for activation of T cells]
Type III membrane protein, involved in TCR signal transduction pathway. Tyrosine phosphorylation by ZAP-70 leads to the recruitment of multiple signaling molecules.
MGAT5 [GlcNAc-TV] [mannoside acetylglucosaminyl transferase 5]
Type II membrane protein, on Golgi apparatus; glycosyltransferase is involved in the synthesis of protein-bound and lipid-bound oligosaccharides.
1. In Il2rb−/− mice, T cells are spontaneously activated, and B cells differentiate into plasma cells and produce high serum concentrations of IgG1 and IgE. Autoantibodies cause hemolytic anemia, and animals died after about 12 weeks (Suzuki et al. 1995). 2. Transgenic thymic expression of the Il2rb in Il2rbdeficient mice prevents autoimmunity and restores the normal production of B lymphocytes (Malek et al. 2000). 3. Autoimmunity and imbalanced T cell homeostasis were prevented by the adoptive transfer of normal CD4+CD25+ T cells to Il2rb−/− mice (Malek et al. 2002). 1. In Il10-deficient mice, lymphocyte development and antibody responses are normal, but growth is retarded and the mice are anemic and suffer from chronic enterocolitis. Mutants kept under specific pathogen-free conditions develop only a local inflammation limited to the proximal colon (Kuhn et al. 1993). 1. An inversion in Itch is responsible for the immunological phenotype of the non–agouti-lethal 18H mice. On the JU/Ct background, the mice develop an inflammatory intestinal disease. On the C57BL/6J background, they develop a lethal disease characterized by chronic inflammation of the lung, stomach, and skin, resulting in scarring due to constant itching and the hyperplasia of lymphoid cells (Perry et al. 1998). 2. Itch−/− T cells show an activated phenotype and enhanced proliferation, with hyperproduction of IL4 and IL5 after stimulation and increased serum concentrations of IgG1 and IgE. Itch deficiency leads to immune and inflammatory disorders and constant itching of the skin (Fang et al. 2002). 1. In Lat−/− deficient mice, B cell populations are normal, but T cell development is blocked at the CD4−CD8− stage (Zhang et al. 1999). 2. The phenotype of distal four tyrosines knockin mice was identical to the phenotype of Lat−/− mice: Thymocyte development was arrested at the CD4−CD8− stage, and no mature T cells were detected (Sommers et al. 2001). 3. Mice homozygous for a single tyrosine mutation in Lat developed a polyclonal lymphoproliferative syndrome and signs of autoimmune disease: elevated serum concentrations of IgG1, IgE, and IgM and nuclear autoantibodies. IL2 production and T cell apoptosis were affected (Sommers et al. 2002). 4. Mice homozygous for a single tyrosine mutation in Lat showed hampered T cell development but accumulated polyclonal T cells having a Th2 phenotype. Th2 differentiation leads to eosinophilia and maturation of plasma cells secreting IgE and IgG1 (Aguado et al. 2002). 1. Mgat5−/− mice showed an autoimmune-mediated glomerulonephritis, increased susceptibility to experimental autoimmune encephalomyelitis, and enhanced delayed-type hypersensitivity. Mgat5 deficiency lowers the T cell activation threshold by promoting TCR clustering (Demetriou et al. 2001). Continued
230
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
Molecular Function
NFAT1 [Nfatc2; Nfatp] [nuclear factor of activated T cells, cytoplasmic, calcineurindependent 2]
Cytoplasmic for the phosphorylated form and nuclear after activation that is controlled by calcineurin-mediated dephosphorylation. Rapid nuclear exit of NFAT is thought to be one mechanism by which cells distinguish between sustained and transient calcium signals.
PIK3CD [p110δ] [phosphatidylinositol 3-kinase catalytic δ polypeptide]
Contains a PI3/PI4 kinase domain, belongs to the PI3/PI4 kinase family; expressed predominantly in leukocytes, involved in signaling pathways regulating cell growth.
PIK3R1 [p50α; p55α; p85α] [phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1]
PI3K phosphorylates the inositol ring of phosphatidylinositol at the 3′ position. The enzyme comprises a 110-kDa catalytic subunit and a regulatory subunit of either 85, 55, or 50 kDa. Acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Belongs to the PI3K p85 subunit family, one SH3 domain and one SH2 domain. The protein encoded this gene is a PIP3 and contains one tensin domain and one tyrosine protein phosphatase domain. A tumor suppressor that is mutated in a large number of cancers. Defects in PTEN are a cause of Cowden disease, Lhermitte-Duclos disease, Bannayan -Zonana syndrome, and Proteus syndrome.
PTEN [TEP1; MMAC1] [phosphatase and tensin homolog]
Mouse Knockout Phenotype 2. Mgat5−/− mice produce more IFN-γ and less IL-4 compared with wild-type cells (Morgan et al. 2004). 1. Nfat1−/− mice showed increased primary responses to Leishmania major. Accumulation of eosinophils and increased levels of IgE were observed in an in vivo model of allergic inflammation in Nfat1−/− mice (Xanthoudakis et al. 1996). 2. Nfat1−/− mice have splenomegaly with hyperproliferation of both B and T cells. Early IL-4 expression in Nfat1−/− mice is impaired, but production of IL-4 at later time points as well as Th2 differentiation is increased. IL-2 and IFN-γ are minimally affected. The mice display defects in Cd40l and Fasl transcription (Hodge et al. 1996). 3. Nfat1 deficiency leads to the accumulation of activated T cells, enhanced T cell responses after secondary stimulation, and defects in the termination of immune responses. Nfat1−/− T cells do not show defects in FAS-mediated apoptosis (Schuh et al. 1998). 4. Nfat1/Nfat2−/− T cells were deficient in cytokine production and cytolytic activity. Doubly deficient B cells were hyperactivated, serum IgG1 and IgE were elevated, and multiple organs were infiltrated (Peng et al. 2001). 5. The Nfat1−/− Nfat4−/− T cells showed increased proliferation and differentiate into Th2 cells. Nfat1/Nfat4 deficiency lowers the activation threshold and makes CD28 ligation dispensable (Rengarajan et al. 2002). 1. Pik3cd was inactivated by point mutation instead of deletion to prevent changes in the expression levels of the other PI3K catalytic and regulatory subunits. Thymocyte development was normal and Pik3cdD910A/D910A homozygous mice did not exhibit anatomical or behavioral abnormalities. B and T cell responses were impaired and the Pik3cdD910A/D910A mice developed an inflammatory bowel disease (Okkenhaug et al. 2002). 1. The transgenic mice expressing an active form of PI3K (p65, a truncation mutant of p85) showed prolonged CD4+ T cell survival and developed an infiltrating lymphoproliferative disorder and kidney autoimmune disease, with increased numbers of memory T lymphocytes and anti-double-stranded (ds) DNA antibodies. The signs were similar to those developed by heterozygous Pten+/− mice. p65 Tg p53−/− mice develop T cell lymphomas (Borlado et al. 2000). 1. Pten+/− mutants develop an autoimmune disorder with glomerulopathy, hypergammaglobulinemia, and autoantibodies reacting against nuclear antigens. FAS-mediated apoptosis was impaired in Pten+/− mice, and T cells showed increased proliferation upon activation. The features were similar to those observed in Fas-deficient mutants (Di Cristofano et al. 1999). 2. In Ptenflox/− mice, the negative selection is diminished, T cells are spontaneously activated, hyperproliferate, secrete increased levels of cytokines, and resist apoptosis. The mice display hypergammaglobulinemia
231
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
Molecular Function
PTPN22 [PEP; Ptpn8] [protein tyrosine phosphatase, nonreceptor type 22 (lymphoid)]
PEP is a cytoplasmic phosphatase expressed exclusively in hematopoietic cells and associates with C-terminal c-Src kinase (CSK) to inhibit TCR signaling through dephosphorylation of LCK.
PTPN6 [SHP1; moth-eaten] [protein tyrosine phosphatase, nonreceptor type 6]
Belongs to the protein tyrosine phosphatase family, a regulator of tyrosine protein kinase CSK in T cells.
PTPRC [CD45 ] [protein tyrosine phosphatase, receptor type C]
Type I membrane protein, belongs to protein tyrosine phosphatase family. Expression is restricted to the hematopoietic cells, required for T cell activation through TCR.
RasGRP1 [RAS guanyl-releasing protein 1]
A member of a family of genes characterized by the presence of a Ras superfamily guanine nucleotide exchange factor (GEF) domain. Contains an EF-hand motif.
RC3H1 [Roquin] [RING CCCH (C3H) domains 1]
Contains RING-type zinc finger and C3H1-type zinc finger domains. Acts as an ubiquitin ligase that regulates ubiquitin-dependent control of AU-rich mRNA. Represses ICOS function and plays a central role in the prevention of production of autoantibodies by repressing follicular helper T cells and germinal centers.
Mouse Knockout Phenotype and elevated levels of autoantibodies (Suzuki et al. 2001). 3. Mice heterozygous for both Pten and Ship developed lymphoproliferation, hypergammaglobulinemia with high autoantibody titers, and renal disease. The pathological changes were more severe than those in Pten+/− mice (Moody et al. 2003). 1. Ptpn22 deficiency had minimal effects on naïve T cell activation, but the effector and memory T cells demonstrated increased expansion and function. Germinal centers develop spontaneously in the spleen and Peyer’s patches, and the serum levels of IgG1, IgG2, and IgE were elevated (Hasegawa et al. 2004). 2. 1858T, a functional polymorphism in Ptpn22, which encodes the amino-acid substitution R620W, affects the interaction with CSK and confers susceptibilities to rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, and Graves disease (Siminovitch, 2004). 1. Mice with the recessive moth-eaten (me) or the viable moth-eaten (mev) mutations develop a severe autoimmune and immunodeficiency syndrome (Tsui et al. 1993). 2. Sequence analyses revealed that both the me and mev mutations are point mutations that result in aberrant splicing of the Shp1 transcript (Shultz et al. 1993). 1. In Cd45−/− mice, thymocyte development is inhibited at two distinct stages: CD4−CD8− to CD4+ CD8+ transition and double-positive into single-positive transition. Apoptosis is impaired in response to TCR signals, but it can be induced normally in Cd45-null thymocytes by non-TCR-mediated signals (Byth et al. 1996). 2. A single point mutation E613R inactivates the inhibitory wedge of CD45 and causes polyclonal lymphocyte activation, leading to lymphoproliferation and severe lupus nephritis with anti-dsDNA antibodies. Both homozygous and heterozygous mice develop the autoimmune pathological changes (Majeti et al. 2000). 1. The thymi of Rasgrp-null mutant mice are deficient in mature, single-positive thymocytes (Dower et al. 2000). 2. A mutation in Rasgrp1 that prevented translation seems to be responsible for an autoimmune lymphoproliferative syndrome similar to systemic lupus erythematosus. Rasgrp1lag T cells spontaneously adopted a memory phenotype, were skewed toward IL-4 production and became resistant to activation-induced cell death. Autoantibodies were detected in older mice (Layer et al. 2003). 1. The sanroque mutation was generated by ethylnitrosourea mutagenesis, disrupts Roquin, a repressor of ICOS, and leads to excessive production of IL-21 by T cells. The san/san mice develop signs of systemic lupus erythematosus: glomerulonephritis with deposition of immune complexes, autoantibodies against dsDNA, hepatitis, anemia, and autoimmune thrombocytopenia. It is believed that the failure to repress autoimmunity Continued
232
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
SH2D2A [Lad; TSAd] [SH2 domain protein 2A]
Molecular Function
Contains one SH2 domain, a T cell–specific adapter protein involved in the control of T cell activation, upregulated substantially after T cell activation.
Mouse Knockout Phenotype
1.
2.
STAT4 [signal transducer and activator of transcription 4]
Belong to the transcription factor STAT family. STAT4 and STAT6 contain one SH2 domain and carry out a dual function: signal transduction and activation of transcription.
1.
STAT6 [signal transducer and activator of transcription 6]
STAT6 is involved in IL-4 signaling.
Sts-1 [Cbl-interacting protein Sts-1] and Sts-2 [Ubash3a] [ubiquitin associated and SH3 domain containing type A]
Sts-1 contains one SH3 domain, an ubiquitin-associated (UBA) domain, and a domain with similarities to the catalytic motif of phosphoglycerate mutase. Sts-2/Ubash3a contains one SH3 domain and one UBA domain.
1.
TGFB1 [transforming growth factor β1]
Belongs to the TGFB family. Controls proliferation and differentiation. Defects in TGFB1 are the cause of Camurati-Engelmann disease. TGFB1, TGFB2, and TGFB3 function through the same receptor signaling systems.
1.
2.
TRAF6 [TNF receptor–associated factor 6]
Contains RING-type zinc finger and TRAF-type zinc finger domains. Adapter protein and signal transducer, homotrimer.
2.
1.
2.
ZAP-70 [Srk] [ζ chain (TCR)–associated protein kinase]
Belongs to the Tyr protein kinase family, SYK/ZAP-70 subfamily. Contains two SH2 domains.
1.
in the sanroque strain does not correspond to defects in any of the known tolerance mechanisms (Vinuesa et al. 2005). Sh2d2a-deficienct mice develop glomerulonephritis, autoantibodies against single-stranded DNA and dsDNA, and hypergammaglobulinemia and accumulate large numbers of activated T and B cells in spleen. The autoimmune phenotype in Sh2d2a−/− mice is associated with defective T cell death (Drappa et al. 2003). In Sh2d2a−/− mice, T cell proliferation and production of IL2 and IFNG, but not IL4, were defective (Rajagopal et al. 1999). Stat4-deficient NZM mice develop nephritis in the absence of high levels of autoantibodies and in the presence of reduced levels of IFN-γ. In contrast, Stat6-deficient NZM mice exhibit a significant reduction in the incidence of the kidney disease despite the presence of high levels of autoantibodies (Jacob et al. 2003). Stat4 deficiency leads to an increase in type 2 cytokine responses and to a decrease in type 1 cytokine production. Stat6 deficiency or anti-IL-4 antibody treatment decreases type 2 cytokine responses and ameliorates the kidney disease (Singh et al. 2003). Sts2−/− mice did not succumb to any unusual pathological condition. Sts1/2−/− T cells are hyperresponsive to TCR stimulation, with a marked increase in cytokine production. Double knockout mice are susceptible to experimental autoimmune encephalomyelitis, but triple knockout mice, lacking both Sts proteins and Cblb, developed the disease comparable in incidence and severity with Sts1/2−/− mice (Carpino et al. 2004). Tgfb1−/− mice succumb to a wasting syndrome accompanied by multifocal inflammation and tissue necrosis that leads to organ failure and death (Shull et al. 1992). Tgfb1−/− mice develop a rapid wasting syndrome and die by 4 weeks of age. Pathological examination of Tgfb1−/− mice revealed massive infiltration of lymphocytes and macrophages in many organs and primarily in heart and lungs (Kulkarni et al. 1993). Traf6−/− mice die prematurely. In Traf6−/− chimeras, T cell development is normal, and T cells are polarized toward a Th2 phenotype. The mice exhibit cachexia, scaling, and itching and develop a progressive lethal inflammatory disease associated with massive organ infiltration. Complementation of Rag2-deficient mice with Traf6-deficient lymphocytes leads to the development of a similar inflammatory disease (Chiffoleau et al. 2003). Autoimmunity was induced by grafting Traf6−/− fetal thymic stroma into athymic nude mice. The number of regulatory T cells was dramatically reduced in the Traf6−/− thymus (Akiyama et al. 2005). Zap70−/− mice had neither CD4 nor CD8 single-positive T cells, but expression of wild-type human ZAP-70 reconstituted both CD4 and CD8 single-positive populations (Negishi et al. 1995).
233
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
TABLE 10-1
GENES WHOSE KNOCKOUTS IN MICE DISPLAY HYPERPROLIFERATIVE SYNDROMES, MANIFESTATIONS OF AUTOIMMUNITY, AND/OR AUTOIMMUNE DISEASES—cont’d Molecule Name [aliases] [gene name description]
Molecular Function
Mouse Knockout Phenotype 2. Spontaneous point mutation in the SH2 domain of ZAP-70 causes chronic autoimmune arthritis in mice that resembles human rheumatoid arthritis. Alterations of the ZAP-70 activity changes the thresholds of thymic selection and leads to the positive selection of otherwise negatively selected autoimmune T cells (Sakaguchi et al. 2003).
The molecules were selected based on the phenotype ontology descriptions (Smith et al. 2005) in the Mouse Genome Database (Eppig et al. 2005), which are associated with the defined criteria for autoimmunity (Rose and Bona 1993; Witebsky et al. 1957). The molecular functions are given based on biochemical characterizations and functional studies, and the information is available in the UCSC Genome Browser Database (Karolchik et al. 2003), NCBI Gene (Maglott et al. 2005), and Swiss-Prot/Uniprot (Bairoch et al. 2005). References are given for the descriptions of the autoimmune phenotype of the knockout or knockin mouse.
antigen-presenting cell, and then makes an integrated response. The response may be further influenced by simultaneous contact with regulatory T cells or through auto- or paracrine stimulation with pro- or anti-inflammatory cytokines. Finally, transduction of the signal that emanates from a single TCR-antigen–MHC complex is subject to regulation through negative factors that attenuate the signal and positive regulators that amplify it. The amplitude of these modulations and the kinetics with which they come into play with respect to antigen encounter are influenced by the prior activation history of the T cells, either determining the response threshold before the antigen encounter or altering the overall duration of the antigen response by influencing the kinetics of negative feedback mechanisms that curtail the activating response. Thus, the overall output response of a T cell to an activating stimulus reflects the history of the cell’s previous encounters with antigen, cytokines, surface receptors on antigen-presenting cells, and other environmental inputs which, together with intrinsic genetic influences, establish the gene expression profile within the T cell at the instant of primary or secondary antigenic stimulation. Over time, changes in gene expression measure the persistence of antigen and thereby allow opposing responses in situations of acute versus chronic stimulation.
V.
PROCESSES INVOLVED IN T CELL ACTIVATION
The use of very focused biological, biophysical, or biochemical methods to describe complex processes such as T cell activation results in an inevitable reductionism. However, the enormous medical importance of T cell activation has inspired many different ways of examining and evaluating this process in all its complexity, and these efforts will eventually provide
us with a molecular picture that approaches reality. Before we try to connect the T cell receptor with intracellular signaling cascades that culminate in the nucleus, with the objective of identifying the critical players, it seems appropriate to emphasize the complex and dynamic nature of T cell activation. It is possible that the molecular mechanisms that prevent inappropriate activation do not simply block signal transduction but dynamically downmodulate responses. On the microscopic level, antigen recognition by T cells leads to cellular changes such as the acquisition of cellular polarity. The stimulated T cells also show clustering of T cell receptors (capping) in the membrane of the contact zone. Inside the cell, a reorientation of the microtubule organizing center occurs, which now allows for directed endo- and exocytosis from and into the membrane patch that forms the contact to the antigenpresenting cell (Kupfer and Kupfer 2003). The cytoskeleton becomes rearranged, providing an adjusted structure in which cytoskeleton-associated signal transduction and transport can influence signaling and cellular processes. In parallel, the immunological synapse that forms at the contact surface of the T cell with the antigen-presenting cell adopts a typical structure, with a central area containing T cell receptor molecules bound to the MHC-antigen complex, and a peripheral ring in which the integrin lymphocyte function–associated antigen-1 (LFA-1) is bound to intercellular adhesion molecules. This structure is itself a result of signal transduction and is usually stable over prolonged periods of time, a property correlated with productive T cell activation (Bromley et al. 2001). Biochemistry provides another view: rapidly after TCR crosslinking, a burst of tyrosine phosphorylation can be detected. Phosphorylation not only activates downstream enzymes such as phospholipase C-γ (PLC-γ) and Vav, but also allows phosphorylation-dependent interactions so that multiprotein complexes form and provide physical interactions for efficient enzyme-substrate
234
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
interaction (Singer and Koretzky 2002). Fusion of lipid rafts occurs after triggering of the T cell receptor, and the subsequent changes in local membrane composition bring in a large number and variety of signaling molecules, which either bind to specific lipids/phospholipids or interact with molecules that constitutively or transiently associate with the rafts. The catalytic activity of enzymes such as phospholipase C locally produces second messenger molecules that amplify the signal, because their rapid diffusion generates a concentration gradient and activate signal transduction molecules along the way. Inactivation of genes encoding signaling proteins in the mouse has validated many biochemical findings, previously generated in cell lines by studying changes in protein-protein interactions, protein modifications, or protein localization during T cell activation. However, it has often been difficult to assign a given protein a specific position in the signal transduction cascade by gene ablation alone, either because the entire pathway is inactivated or because of compensation by redundant members of a multigene family. Nevertheless, targeted gene disruption and genome-wide mutagenesis strategies have led to many unexpected findings and have in many instances brought about a readjusted view. The large number of molecules, many assembled in multiprotein complexes, and the different cell membrane and cytoskeletal processes that participate in T cell activation, allow differential modulation of the preexisting, T cell–intrinsic gene expression pattern, skewing transduction of the signal so that several very different outcomes can be generated. In particular, T cell stimulation can lead under different conditions to effector cytokine production, cell growth and proliferation, cell differentiation, activation-induced cell death (AICD), or a state of functional unresponsiveness known as anergy.
VI.
T CELL RECEPTOR SIGNAL TRANSDUCTION
LEADING TO PRODUCTIVE T CELL ACTIVATION In a very simplified view of T cell activation, the signal starts with the recognition of antigen-MHC complexes by the T cell receptor, which then allows Src-family kinases to phosphorylate the LAT adaptor protein. Phosphorylated LAT is bound by ZAP-70, and this triggers activation of PLC-γ1, a critical enzyme that catalyzes hydrolysis of phosphatidylinositol 4,5bisphosphate to diacylglycerol and inositol 1,4,5-trisphosphate (IP3), two very important second messengers. IP3 binds to the IP3 receptor and triggers Ca2+ release from intracellular endoplasmic reticulum (ER) stores. By an unknown mechanism, the now-emptied ER stores couple to the opening of Ca2+ channels of unknown identity in the plasma membrane, inducing a strong rise in intracellular Ca2+. The elevation of intracellular Ca2+ activates the phosphatase calcineurin, which dephosphorylates the transcription factor NFAT in the cytoplasm and allows it to enter the nucleus and activate transcription. The other second messenger, diacylglycerol, is a
lipid that attracts signaling proteins containing C1 domains to the plasma membrane. Among these are proteins such as protein kinase (PK) Cθ and RasGRP, key signaling molecules that trigger the activation of Ras/mitogen-activated protein kinase (MAPK)/c-Jun NH2-terminal kinase (JNK) and inhibitor of nuclear factor (NF)-κB (IκB)-kinases. These signaling cascades culminate in nuclear activation of AP-1 (activator protein-1) and NF-κB transcription factors (Wange 2000). Together, transcriptional activation of NFAT, AP-1, and NF-κB is required to productively induce T cell proliferation and induce expression of effector cytokines such as IL-2, IFN-γ, and tumor necrosis factor (TNF)-α. Although TCR stimulation alone is able to activate all three transcription factors NFAT, AP-1, and NF-κB, the latter two transcription factors, AP-1 and NF-κB, are more potently activated through coengagement of CD28/B7 (Acuto and Michel 2003). The cis-regulatory regions of cytokine genes (i.e., IL-2 and IFN-γ) often contain composite sites that are bound by an NFAT-AP1 complex with much higher affinity than by NFAT or AP-1 individually; this ensures strong gene expression only if CD28 is triggered in combination with the TCR. TCR stimulation also leads to increased phosphoinositide 3-kinase (PI3K) activity, which is potentiated if CD28 is engaged as well. Ligation of CD28 leads to tyrosine phosphorylation in its cytoplasmic tail, which can then be bound by the p85 SH2 (Src homology) domain of PI3K. PI3K activity phosphorylates phosphatidylinositol 4-5-bisphosphate at the 3′ position and produces another important second messenger, phosphatidyl inositol 3,4,5-trisphosphate (PIP3). PIP3 allows membrane localization and activation of PH domain-containing proteins such as Vav, a GTP/GDP exchange factor for the small GTPases, Rac, and Cdc42, which couples TCR/CD28 stimulation to cytoskeletal rearrangement. Another very well-studied outcome of PI3K signaling is activation of the PH domain–containing kinase, Akt/PKB. Akt has been shown to critically regulate T cell survival through activation of the transcription factor NF-κB, leading to the induction of Bcl-XL (Kane and Weiss 2003).
VII.
CONTROL OF T CELL–MEDIATED
AUTOIMMUNITY THROUGH CENTRAL TOLERANCE T lymphocytes that mature in the thymus are subject to positive and negative selection. These processes have been described in detail in chapter 9 and will therefore not be discussed here. In brief, thymocytes are positively selected for their ability to cross-react to self-antigen, as a measure of having a productively rearranged T cell receptor. However if the thymocyte displays a strong reaction against self-antigens, death is induced, and the T cell with the self-reactive TCR is clonally deleted (negative selection).
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
Mutations in two categories of genes that influence negative selection can lead equivalently to an autoimmune phenotype. Gene inactivation of the putative transcriptional regulator AIRE results in flagrant autoimmune disease in mice. The aire-deficient mouse shows a phenotype very similar to the disease found in human patients with APECED, who also have mutations in the AIRE gene. AIRE appears to de-repress transcription of tissuespecific self-antigens in the medulla of the thymus, enabling the thymocytes to experience the full repertoire of antigens in the periphery and providing the molecular basis for negative selection (Anderson et al. 2002, 2005; Liston, Gray, et al. 2004). Surprisingly, however, point mutations in signaling proteins that participate in TCR signal transduction (i.e., LAT, RasGRP, and ZAP-70), which create hypomorphic alleles, also evoke an autoimmune phenotype in the mouse. As demonstrated for the knockin Y136F mutation in LAT, a decreased ability of LAT to couple to PLC-γ1 activation leads to a partial block in T cell development, but the T cells that enter the periphery display autoreactivity and cause autoimmune disease (Aguado et al. 2002; Sommers et al. 2002). The underlying mechanism of such autoimmunity can be seen as a shift in the threshold for positive and negative selection, as observed for point mutations in both LAT and ZAP-70 (Sakaguchi et al. 2003; Sommers et al. 2005). A possible interpretation for the observed autoimmune phenotype of these mutant mice could be that only those T cells that have high affinity for self are positively selected, since these compensate for compromised signaling. Among the positively selected T cells, incomplete negative selection due to overall reduced responsiveness or due to the absence of specific selfepitopes in the thymus will allow escape of self-reactive T cells to the periphery and create autoimmune potential. The mechanisms of cell death during negative selection are not entirely clear. One step, however, appears to be the induction of proapoptotic proteins, among them the BH3 domain-containing protein Bim. Gene deficiency for Bim leads to decreased sensitivity of double-positive thymocytes as well as mature T cells to apoptotic stimuli such as ionomycin and cytokine deprivation. Older Bim-deficient mice display accumulation of single-positive T cells and the development of autoimmune disease (Bouillet et al. 1999). The inefficient deletion of self-reactive T cells that was observed in the autoimmune diabetes-prone NOD mouse strain (Kishimoto and Sprent 2001) is associated with reduced upregulation of Bim in CD4-positive T cells that recognize selfantigen in the thymus (Liston, Lesage, et al. 2004).
VIII.
TCR STIMULATION IN THE ABSENCE OF
COSTIMULATION: INDUCTION OF PERIPHERAL T CELL TOLERANCE Although peptide-MHC recognition by the T cell receptor is the central component in T cell activation, its impact on T cell
235
cytokine production and proliferation is greatly enhanced through costimulation. Conversely, strong cross-linking of the TCR in vitro without CD28 stimulation induces a state of unresponsiveness termed anergy. In this cell intrinsic unresponsiveness the T cell stays alive but fails to respond with IL-2 production and proliferation to optimal stimulation through its TCR and costimulatory receptors. It seems that a partial stimulus induces the anergic state since altered peptide ligands can also induce unresponsiveness in the presence of costimulation (Schwartz 2003). The in vivo correlate of an anergizing condition can be produced when TCR-transgenic T cells are adoptively transferred into a host that presents the recognized antigen (Schwartz 2003), in this case initial T cell activation that soon converts into an unresponsive state of the T cells occurs. Partial stimulation in vivo could also be provided by quiescent DCs that have not received stimulation through innate immune pathways (i.e., Toll-like receptors), and have not upregulated expression of B7.1 and B7.2 molecules that are the ligands for the costimulatory receptor CD28 (Medzhitov 2001). On the transcriptional level, stimulation of the TCR in the absence of costimulation is associated with efficient calcium mobilization, which induces nuclear translocation of NFAT. In the absence of costimulation, however, the TCR signal does not sufficiently activate AP-1 and NF-κB. In fact, NFAT transcription in the absence of AP-1 induces anergy-associated genes, consistent with induction of anergy through the Ca2+ ionophore ionomycin and the observed inability of T cells to produce IL-2 in response to TCR stimulation when they have been transduced to ectopically express constitutively active NFAT (Macian et al. 2002). Targeted deletion of NFAT family members has shown that NFAT expression in lymphocytes is required for activation and full effector function (Hodge et al. 1996; Ranger, Hodge, et al. 1998). It has also been observed that NFAT1 or NFAT1 and 4 deficiency triggers hyperactivation of T cells (Ranger, Oukka, et al. 1998; Rengarajan et al. 2002; Xanthoudakis et al. 1996) and in combined knockouts (NFAT 1 and 2 or NFAT1 and 4) the development of autoimmune disease (Peng et al. 2001; Ranger, Oukka, et al. 1998). Peripheral T cell tolerance is not only mediated through cell-intrinsic unresponsiveness, but also contains a dominant suppressive component mediated by regulatory T cells (Treg). These cells can be considered as a separate CD4+CD25+ T helper lineage, characterized by high FoxP3 expression and suppressor function (Hori et al. 2003). FoxP3 deficiency in the naturally occurring scurfy mouse mutant prevents the development of regulatory T cells, leading to an autoimmune phenotype in mice that resembles human immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, also caused by mutations in FoxP3 (Fontenot et al. 2003). It is clear that development of Treg cells requires T cell receptor–dependent recognition of antigen. Moreover Tregs that naturally develop in the thymus can also be induced in the periphery (Apostolou and von Boehmer 2004). It is tempting to suggest that T cell tolerance utilizes acute mechanisms such as
236
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
clonal deletion in the thymus and T cell intrinsic unresponsiveness to cope with self-antigen recognition but that there is also a connection of T cell activation to the developmental process that generates regulatory T cells. Indeed, antigen recognition is known to be needed for Treg development, both in the thymus and also in an adaptive process in the periphery (Apostolou and von Boehmer 2004; Jordan et al. 2001).
IX.
CONTRIBUTIONS FROM T CELL
HOMEOSTASIS AND T CELL APOPTOSIS The importance of T cell homeostasis to prevent autoimmune disease is best illustrated by the behavior of T cells during experimental or disease- or stress-induced lymphopenia. Under lymphopenic conditions, T cells engage in compensatory proliferation in an attempt to fill up the empty lymphoid compartment and this proliferation then allows self-reactive T cells to expand in the periphery and cause autoimmune disease, with IL-21 as one factor that may trigger the homeostatic expansion (King et al. 2004). Indeed, many experimental autoimmune disease models make use of the lymphopenia-induced proliferation and activation of self-reactive T cells that occurs when small numbers of T cells are injected into immune-compromised (e.g., RAG-deficient) hosts. Under these conditions, the expanding T cells very effectively cause autoimmune diseases, for example, inflammatory bowel disease. Normal immune responses also bring about enormous expansion of effector T cells, but after elimination of the pathogen it is essential that the population of T lymphocytes is induced to contract massively. This contraction is achieved through AICD, in which T cells are killed in a Fas ligand (FasL)-dependent fashion. FasL expression in T cells may be regulated through activation-associated increases in levels of the transcription factor Stra13. T cells from Stra13 knockout mice showed reduced cytokine and FasL induction and reduced AICD, and older mice developed autoimmunity with accumulation of T and B cells in the periphery as well as multiorgan infiltration (Sun et al. 2001). FasL/CD95 ligation effectively induces death in T cells that contain a low ratio of antiapoptotic (Bcl-2 and Bcl-XL) to proapoptotic (Bim, Bid, and Bax) factors (for review, see Krueger et al. 2003). The antiapoptotic factors Bcl-2 and Bcl-XL are induced either as a result of costimulationinduced NF-κB activation or, in the case of memory T cells, in response to stimulation with cytokines that promote cell survival. NF-κB activation in T cells appears to be regulated through the kinase activity of Akt/PKB, which in turn depends on membrane levels of PIP3 (Kane and Weiss 2003); in fact, hypermorphic Akt alleles caused NF-κB activation, Bcl-XL expression, and increased T lymphocyte survival (Jones et al. 2000) as well as the development of autoimmune disease with immunoglobulin deposits on kidney glomeruli (Rathmell et al. 2003).
Notably, various genetic manipulations of the Akt pathway, which either introduce an activator or inactivate an inhibitor of upstream or downstream Akt signaling, lead to induction of autoimmune disease. Thus, transgenic expression of a constitutively active PI3K p85 deletion mutant (p65), as well as targeted disruption of genes encoding the PIP3 phosphatases PTEN and SHIP (SH2-containing inositol-5′-phosphatase), results in upregulation of PIP3 levels and consequent Akt activation, and both manipulations are associated with increased survival of lymphocytes, appearance of T lymphomas, and the development of autoimmune disease (Borlado et al. 2000; Di Cristofano et al. 1999; Moody et al. 2003; Suzuki et al. 2001). Similarly, downstream of Akt, targeted deletions of Foxj and Foxo3 have implicated these transcription factors as negative regulators of NF-κB, with one mode of inhibition being a role in the basal expression of IκBβ or IκBβ and IκBε (Lin, Hron, et al. 2004; Lin, Spoor, et al. 2004). Balanced T cell homeostasis is especially important in the CD4+CD25+ subset of regulatory T cells to prevent autoimmune disease. These cells critically depend on the CD28-B7 interaction (Lohr et al. 2003; Salomon et al. 2000) as well as on IL-2 that is produced by effector T cells, since neutralization or IL-2 deficiency leads to autoimmune disease owing to reduced numbers of regulatory T cells (Setoguchi et al. 2005).
X.
NEGATIVE REGULATION OF T CELL ACTIVATION
Our overall understanding of negative signaling in T cells is much more limited than our understanding of positive signaling. Negative regulators have been identified mostly through analysis of knockout mice that displayed exaggerated responses to T cell stimulation, with respect to proliferation or cytokine production. Negative regulation has been described at many levels of T cell biology. These include humoral factors, costimulatory molecules, adaptor molecules, E3 ubiquitin ligases, phosphatases, and transcription factors.
A.
Humoral Factors
Humoral factors, especially the anti-inflammatory cytokines IL-10 and transforming growth factor-β (TGFβ), are well known to influence the responsiveness of T cells. Both cytokines can inhibit T cell responses, both directly and through their effects on the functions of antigen-presenting cells. IL-10 and TGFβ are particularly effective in preventing the development of colitis and CD8 T cell–mediated inflammation, respectively. Additionally, IL-10 is implicated in the function and TGFβ in the induction of regulatory T cells (von Boehmer 2005).
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
B.
Negative Costimulatory Molecules
Negative costimulatory molecules of the CD28 family include CTLA-4 and PD-1. CTLA-4 deficiency causes severe lymphoproliferative and autoimmune disease (Tivol et al. 1995). CTLA-4 is expressed on activated T cells and shows trafficking to the immunological synapse upon TCR stimulation, in a manner that depends on the strength of the activating stimulus (Egen and Allison 2002). In vivo findings also demonstrate that CTLA-4 levels on T cells tune the threshold of activation (Eggena et al. 2004): ovalbumin (OVA)-specific T cells in a CTLA-4-deficient background, when injected into lymphopenic hosts, caused autoimmune destruction of the target organ (β islets expressing OVA from a rat insulin promoter), whereas self-reactive T cells from wild-type mice in the same experimental setting needed to be primed with antigen and adjuvants. CTLA-4 has been proposed to mediate inhibition through competition with CD28 for B7 binding (Collins et al. 2002; Linsley et al. 1994), thereby reducing costimulation and elevating the signal threshold of activated T cells. In addition, CTLA-4 might also itself transduce signals, either to the inside of the same cell by activating Rap1 and thereby inducing LFA-1 clustering and adhesion (Schneider et al. 2005) or to other cells via B7 ligation. In fact, it was recently shown that T cells from B7-deficient mice were not sensitive to suppression by regulatory T cells (Paust et al. 2004). Suppression could be restored by transduction of constructs expressing full-length B7 molecules but not by B7 molecules that lack the cytoplasmic tail, even though both types of B7 molecules were equally costimulatory if transduced into antigen-presenting cells (Paust et al. 2004). The PD-1/PD-L1 system is another very important costimulatory pathway that prevents autoimmunity. PD-1 negatively regulates T cell activation and counteracts CD28-dependent IL-2 production; however, PD-1 effects on proliferation can be reversed through increased CD28 ligation or exogenous IL-2 (Carter et al. 2002). PD-1 ligation inhibited expression of the Bcl-XL gene, possibly by recruiting SHP proteins (Src homology 2 domain phosphatase) (Chemnitz et al. 2004). PD1-deficient mice develop different autoimmune diseases depending on the strain background, exhibiting arthritis and a lupus-like phenotype on the C57BL/6 background but dilated cardiomyopathy on the BALB/c background, the latter associated with and likely induced by antibodies against cardiac troponin I (Nishimura et al. 1999, 2001; Okazaki et al. 2003). PD-1 or PD-L1 blockade precipitated autoimmune diabetes in NOD mice, consistent with a general role of PD-1 in autoimmune diseases (Ansari et al. 2003).
C.
E3 Ubiquitin Ligases
Polyubiquitination has been recognized for a long time as a way for cells to flag cytoplasmic and nuclear proteins for degradation mediated by the proteasome. However, during the
237
last few years there has been an enormous increase in our understanding of how ubiquitin regulates cellular processes. Specifically, we now know that the cellular pathway influenced by formation of branched ubiquitin chains depends on the specific lysine residue in ubiquitin that is used for this purpose: branched-chain formation using lysine 48 of ubiquitin targets proteins for proteasome-mediated degradation, whereas branched-chain formation using lysine 63 activates the IκB kinase (IKK) signaling cascade. Moreover, it is now established that mono- and di-ubiquitination regulate the sorting of membrane proteins to the endosomal-lysosomal compartment, stemming from findings that mono- and di-ubiquitin can serve as protein-protein interaction motifs for ubiquitin-binding domains. In other recently investigated functions, mono- and di-ubiquitination have been shown to serve as activating histone modifications and also appear to play a role in DNA-repair. It is therefore not surprising that a rather large number of E3 ubiquitin ligases are involved in the regulation of T cell responses. T cell unresponsiveness has been shown to be a result of unproductive activation of T cells through their T cell receptor in the absence of costimulation (Schwartz 2003). Such signaling triggers the induction of many anergy-associated genes, which are upregulated primarily through activation of the Ca2+/calcineurin/NFAT signaling pathway (Macian et al. 2002), and impose a cell-intrinsic unresponsiveness due to defects in proximal TCR signal transduction (Schwartz 2003). As a result of reduced signal transduction, the formation of the immunological synapse becomes destabilized (Heissmeyer et al. 2004) in a characteristic pattern of disintegration of the LFA-1 ring, that can also be observed if T cells are stimulated with altered peptide ligands (Sumen et al. 2004). Among the anergy-associated genes are those encoding the E3 ligases Cbl-b, Itch, and Grail (Anandasabapathy et al. 2003; Heissmeyer et al. 2004). These E3 ligases are not only upregulated at the transcriptional level but Itch and the structurally related E3 ligase Nedd4 also display membrane relocalization to lipid rafts after anergy induction. Furthermore, Itch is able to ubiquitinate PLC-γ1 after coexpression, PKCθ is mono-ubiquitinated after anergy induction, and both molecules appear at reduced levels in anergic T cells during restimulation. These findings suggest that during restimulation of an anergized T cell, E3 ligases target signaling proteins for degradation via the endosomal/lysosomal degradation pathway (Heissmeyer et al. 2004). Resistance of Itch and Cbl-b-deficient T cells to anergy induction was demonstrated by evaluating their proliferation; furthermore, reduced effectiveness of anergy induction was observed in Cbl-b-deficient T cells as measured by synapse stability and Ca2+ mobilization (Heissmeyer et al. 2004; Jeon et al. 2004). Targeted disruption of either cbl-b or itch genes is associated with an autoimmune phenotype in mice (Bachmaier et al. 2000; Chiang et al. 2000; Fang et al. 2002; Perry et al. 1998). Recently, another E3 ubiquitin ligase, Roquin, was identified in a genome-wide mouse mutagenesis screen. Roquin activity is required to inhibit the development of an autoimmune
238
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
phenotype akin to systemic lupus erythematosus in mice (Vinuesa et al. 2005). Roquin function appears critical in a specific subset of T cells called follicular helper T cells that provide T cell help to B cells (Vinuesa et al. 2005). Decreased Roquin activity, traced to a point mutation in the roquin gene, resulted in increased levels of the costimulatory ICOS molecule in follicular helper T cells. It is possible that this increase in the levels of ICOS and other factors whose expression might be restrained by Roquin, enables autoreactive follicular helper T cells, which recognize self antigens in the absence of costimulation to differentiate and provide help to B cells, thereby triggering autoantibody production.
D.
Adaptor Molecules
Combined inactivation of the related adapter molecules T cell receptor signaling (Sts)-1 and Sts-2 in mice results in an autoimmune phenotype, implying a negative role for these molecules in TCR signal transduction. The same proteins have a role in signal transduction through the epidermal growth factor (EGF) receptor, by binding the adaptor-type E3 ubiquitin ligase Cbl and regulating the ubiquitination-dependent endosomal/lysosomal degradation of the EGF receptor. Sts-1 and Sts-2 have ubiquitinassociated domains as well as an SH3 domain, and as demonstrated using T cells from double Sts-1, Sts-2-deficient mice, they destabilize ubiquitinated forms of ZAP-70 in T cells and inhibit ZAP-70 activity through a mechanism that is not yet understood (Carpino et al. 2004). Cbl and Cbl-b, the presumed binding partners of Sts-1 and Sts-2 in T cells, cooperate in activation-induced downregulation of the TCR (Naramura et al. 2002), suggesting that one way to prevent autoimmunity is to terminate TCR signal transduction by targeting the TCR itself for degradation. In this context, it was recently shown that OVAreactive T cells, when adoptively transferred into a host that systemically presented this soluble antigen, did not cause disease in a host that contains B cells since the T cells became anergized in vivo; this effect on T cell function correlated with dramatic downregulation of the TCR in a B cell– and antigen-dependent fashion (Knoechel et al. 2005). Further analysis is required to understand the importance of TCR downregulation in T cell anergy and tolerance and to identify the molecules involved. One other family of adaptor proteins has shown a pronounced link to autoimmunity. The protein T cell specific adaptor (TSAd) contains an SH2 domain, four conserved tyrosines that can be phosphorylated by protein tyrosine kinases, and two proline stretches, providing multiple interaction surfaces to interact with phosphorylated SH2 motifs or SH2 and SH3 domains in other proteins (Marti et al. 2005). Gene ablation of TSAd leads to spontaneous development of a lupus-like autoimmune disease apparent in older mice, as well as much higher susceptibility to immunization-induced lupus in young Tsad-deficient mice (Drappa et al. 2003). The molecular pathway in which TSAd deficiency is required to prevent autoimmunity is not yet
clear, but it has been proposed that positive regulation of TCRtriggered IL-2 expression and apoptosis induction through the mitochondrial pathway might be most important (Drappa et al. 2003; Marti et al. 2005).
E.
Phosphatases
The genetic linkage of the ptpn22 gene to human autoimmune disease provides compelling evidence for the involvement of the tyrosine phosphatase (PTP) N22 in diabetes, rheumatoid arthritis, systemic lupus erythematosus, and Graves thyroiditis (for review, see Siminovitch 2004). In mice, PTPN22−/− T cells display increased positive selection and no defects in negative selection or AICD but rather an overall increased signaling by T cells with higher levels of Ca2+-flux, prolonged Lck activation, and increased proliferation (Hasegawa et al. 2004). In fact, mice deficient for this phosphatase show increased numbers of effector T cells in the periphery, elevated IgG1, IgG2, and IgE levels and spontaneous germinal center formation in the spleen and Peyer’s patches that depended on T cell help. Surprisingly, and different from the situation in humans, neither young nor old PTPN22−/− mice develop overt autoimmune symptoms (Hasegawa et al. 2004). Not only phosphorylated proteins but also phospholipids are targets of phosphatases that inhibit the development of autoimmunity. The control of cellular PIP3 levels by the phosphatases PTEN and SHIP, two phosphatases that dephosphorylate the 3′ and the 5′ position of PIP3, respectively, has been shown to prevent autoimmunity (Moody et al. 2003), and both PTEN and SHIP are important regulators of T cell apoptosis and homeostasis (see earlier).
XI.
CONCLUDING REMARKS
Gene targeting in mice, inactivating single genomic loci at a time, has elucidated a predominant role for T cells in various autoimmune diseases. Mice carrying such mutations develop fatal systemic or organ-specific damage, the symptoms of which correlate well with many detrimental human autoimmune diseases. Genetic linkage analysis of human patients points to a complex multigenic basis for many autoimmune syndromes, and the associated genes or genetic regions show considerable overlap with genes linked to autoimmunity in mice. Although our knowledge of general “autoimmune factors” is limited at present, some of the genes identified could have diagnostic and therapeutic potential. Experimental access to cells and tissues in mice has allowed investigators to study perturbations in processes such as thymic selection, T cell homeostasis, differentiation, or activation that have been shown to result in autoimmunity, and critical molecules and pathways of signal transduction have been identified.
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
The constantly growing list of genes that participate in T cell signaling and autoimmune disease indicates that our understanding of these processes is at an early stage and still incomplete. Although there is evidence from the clinic that the onset of autoimmune disease shows a crucial environmental influence, the critical factors have not been identified experimentally. Also, how infection shapes the immune system and thereby determines the type or severity of autoimmune disease an individual will develop, is not understood. Progress in all of these areas is needed to discover treatments for autoimmunity that target critical points in the disease and alleviate a patient’s burden with minimal side effects.
REFERENCES Acuto, O., Michel, F. (2003). CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 3, 939–951. Adachi, M., Suematsu, S., Kondo, T., Ogasawara, J., Tanaka, T., Yoshida, N., et al. (1995). Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 11, 294–300. Aguado, E., Richelme, S., Nunez-Cruz, S., Miazek, A., Mura, A.M., Richelme, M., et al. (2002). Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science 296, 2036–2040. Akiyama, T., Maeda, S., Yamane, S., Ogino, K., Kasai, M., Kajiura, F., et al. (2005). Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science 308, 248–251. Anandasabapathy, N., Ford, G.S., Bloom, D., Holness, C., Paragas, V., Seroogy, C., et al. (2003). GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18, 535–547. Anderson, M.S., Venanzi, E.S., Chen, Z., Berzins, S.P., Benoist, C., Mathis, D. (2005). The cellular mechanism of Aire control of T cell tolerance. Immunity 23, 227–239. Anderson, M.S., Venanzi, E.S., Klein, L., Chen, Z., Berzins, S.P., Turley, S.J., et al. (2002). Projection of an immunological self shadow within the thymus by the Aire protein. Science 298, 1395–1401. Ansari, M.J., Salama, A.D., Chitnis, T., Smith, R.N., Yagita, H., Akiba, H., et al. (2003). The programmed death-1 (PD-1). pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198, 63–69. Apostolou, I., von Boehmer, H. (2004). In vivo instruction of suppressor commitment in naive T cells. J Exp Med 199, 1401–1408. Bachmaier, K., Krawczyk, C., Kozieradzki, I., Kong, Y.Y., Sasaki, T., Oliveirados-Santos, A., et al. (2000). Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211–216. Bairoch, A., Apweiler, R., Wu, C.H., Barker, W.C., Boeckmann, B., Ferro, S., et al. (2005). The Universal Protein Resource (UniProt). Nucleic Acids Res 33, D154–D159. Borlado, L.R., Redondo, C., Alvarez, B., Jimenez, C., Criado, L.M., Flores, J., et al. (2000). Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 14, 895–903. Bouillet, P., Metcalf, D., Huang, D.C., Tarlinton, D.M., Kay, T.W., Kontgen, F., et al. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735–1738. Bouillet, P., Purton, J.F., Godfrey, D.I., Zhang, L.C., Coultas, L., Puthalakath, H., et al. (2002). BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415, 922–926. Bromley, S.K., Burack, W.R., Johnson, K.G., Somersalo, K., Sims, T.N., Sumen, C., et al. (2001). The immunological synapse. Annu Rev Immunol 19, 375–396.
239
Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B., Yasayko, S.A., et al. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27, 68–73. Byth, K.F., Conroy, L.A., Howlett, S., Smith, A.J., May, J., Alexander, D.R., et al. (1996). CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. J Exp Med 183, 1707–1718. Carpino, N., Turner, S., Mekala, D., Takahashi, Y., Zang, H., Geiger, T.L., et al. (2004). Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. Immunity 20, 37–46. Carter, L., Fouser, L.A., Jussif, J., Fitz, L., Deng, B., Wood, C.R., et al. (2002). PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol 32, 634–643. Cavadini, P., Vermi, W., Facchetti, F., Fontana, S., Nagafuchi, S., Mazzolari, E., et al. (2005). AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest 115, 728–732. Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H., Riley, J.L. (2004). SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173, 945–954. Chiffoleau, E., Kobayashi, T., Walsh, M.C., King, C.G., Walsh, P.T., Hancock, W.W., et al. (2003). TNF receptor-associated factor 6 deficiency during hemopoiesis induces Th2-polarized inflammatory disease. J Immunol 171, 5751–5759. Chiang, Y.J., Kole, H.K., Brown, K., Naramura, M., Fukuhara, S., Hu, R.J., et al. (2000). Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403, 216–220. Collins, A.V., Brodie, D.W., Gilbert, R.J., Iaboni, A., Manso-Sancho, R., Walse, B., et al. (2002). The interaction properties of costimulatory molecules revisited. Immunity 17, 201–210. Demetriou, M., Granovsky, M., Quaggin, S., Dennis, J.W. (2001). Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409, 733–739. Di Cristofano, A., Kotsi, P., Peng, Y.F., Cordon-Cardo, C., Elkon, K.B., Pandolfi, P.P. (1999). Impaired Fas response and autoimmunity in Pten+/− mice. Science 285, 2122–2125. Dong, C., Juedes, A.E., Temann, U.A., Shresta, S., Allison, J.P., Ruddle, N.H., et al. (2001). ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409, 97–101. Dower, N.A., Stang, S.L., Bottorff, D.A., Ebinu, J.O., Dickie, P., Ostergaard, H.L., et al. (2000). RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol 1, 317–321. Drappa, J., Kamen, L.A., Chan, E., Georgiev, M., Ashany, D., Marti, F., et al. (2003). Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice. J Exp Med 198, 809–821. Egen, J.G., Allison, J.P. (2002). Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16, 23–35. Eggena, M.P., Walker, L.S., Nagabhushanam, V., Barron, L., Chodos, A., Abbas, A.K. (2004). Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J Exp Med 199, 1725–1730. Eppig, J.T., Bult, C.J., Kadin, J.A., Richardson, J.E., Blake, J.A., Anagnostopoulos, A., et al. (2005). The Mouse Genome Database (MGD): from genes to mice—a community resource for mouse biology. Nucleic Acids Res 33, D471–D475. Fang, D., Elly, C., Gao, B., Fang, N., Altman, Y., Joazeiro, C., et al. (2002). Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat Immunol 3, 281–287. Fisher, G.H., Rosenberg, F.J., Straus, S.E., Dale, J.K., Middleton, L.A., Lin, A.Y., et al. (1995). Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935–946. Fontenot, J.D., Gavin, M.A., Rudensky, A.Y. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330–336.
240
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
Germain, G.N. (2004). An innately interesting decade of research in immunology. Nat Med 10, 1307–1320. Grassl, G., Pummerer, C.L., Horak, I., Neu, N. (1997). Induction of autoimmune myocarditis in interleukin-2-deficient mice. Circulation 95, 1773–1776. Hasegawa, K., Martin, F., Huang, G., Tumas, D., Diehl, L., Chan, A.C. (2004). PEST domain-enriched tyrosine phosphatase (PEP). regulation of effector/ memory T cells. Science 303, 685–689. Heissmeyer, V., Macian, F., Im, S.H., Varma, R., Feske, S., Venuprasad, K., et al. (2004). Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 5, 255–265. Hodge, M.R., Ranger, A.M., Charles de la Brousse, F., Hoey, T., Grusby, M.J., Glimcher, L.H. (1996). Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice. Immunity 4, 397–405. Hori, S., Nomura, T., Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061. Hron, J.D., Peng, S.L. (2004). Type I IFN protects against murine lupus. J Immunol 173, 2134–2142. Jacob, C.O., Zang, S., Li, L., Ciobanu, V., Quismorio, F., Mizutani, A., et al. (2003). Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol 171, 1564–1571. Jeon, M.S., Atfield, A., Venuprasad, K., Krawczyk, C., Sarao, R., Elly, C., et al. (2004). Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21, 167–177. Jones, R.G., Parsons, M., Bonnard, M., Chan, V.S., Yeh, W.C., Woodgett, J.R., et al. (2000). Protein kinase B regulates T lymphocyte survival, nuclear factor κB activation, and Bcl-XL levels in vivo. J Exp Med 191, 1721–1734. Jordan, M.S., Boesteanu, A., Reed, A.J., Petrone, A.L., Holenbeck, A.E., Lerman, M.A., et al. (2001). Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2, 301–306. Kane, L.P., Weiss, A. (2003), The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol Rev 192, 7–20. Karolchik, D., Baertsch, R., Diekhans, M., Furey, T.S., Hinrichs, A., Lu, Y.T., et al. (2003). The UCSC Genome Browser Database. Nucleic Acids Res 31, 51–54. Karray, S., Kress, C., Cuvellier, S., Hue-Beauvais, C., Damotte, D., Babinet, C., et al. (2004). Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 172, 2118–2125. King, C., Ilic, A., Koelsch, K., Sarvetnick, N. (2004). Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117, 265–277. Kishimoto, H., Sprent, J. (2001). A defect in central tolerance in NOD mice. Nat Immunol 2, 1025–1031. Knoechel, B., Lohr, J., Kahn, E., Abbas, A.K. (2005). The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J Immunol 175, 21–26. Krogsgaard, M., Huppa, J.B., Purbhoo, M.A., Davis, M.M. (2003). Linking molecular and cellular events in T-cell activation and synapse formation. Semin Immunol 15, 307–315. Krueger, A., Fas, S.C., Baumann, S., Krammer, P.H. (2003). The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 193, 58–69. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., Muller, W. (1993). Interleukin10-deficient mice develop chronic enterocolitis. Cell 75, 263–274. Kulkarni, A.B., Huh, C.G., Becker, D., Geiser, A., Lyght, M., Flanders, K.C., et al. (1993). Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90, 770–774. Kupfer A., Kupfer H. (2003). Imaging immune cell interactions and functions: SMACs and the immunological synapse. Semin Immunol 15, 295–300. Kuroda, N., Mitani, T., Takeda, N., Ishimaru, N., Arakaki, R., Hayashi, Y., et al. (2005). Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol 174, 1862–1870. Latchman, Y.E., Liang, S.C., Wu, Y., Chernova, T., Sobel, R.A., Klemm, M., et al (2004). PD-L1-deficient mice show that PD-L1 on T cells, antigenpresenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 101, 10691–10696.
Layer, K., Lin, G., Nencioni, A., Hu, W., Schmucker, A., Antov, A.N., et al. (2003). Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity 19, 243–255. Le, L.Q., Kabarowski, J.H., Weng, Z., Satterthwaite, A.B., Harvill, E.T., et al. (2001). Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 14, 561–571. Lin, L., Hron, J.D., Peng, S.L. (2004). Regulation of NF-κB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity 21, 203–213. Lin, L., Spoor, M.S., Gerth, A.J., Brody, S.L., Peng, S.L. (2004). Modulation of Th1 activation and inflammation by the NF-κB repressor Foxj1. Science 303, 1017–1020. Linsley, P.S., Greene, J.L., Brady, W., Bajorath, J., Ledbetter, J.A., Peach, R. (1994). Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793–801. Liston, A., Gray, D.H., Lesage, S., Fletcher, A.L., Wilson, J., Webster, K.E., et al. (2004). Gene dosage—limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med 200, 1015–1026. Liston, A., Lesage, S., Gray, D.H., O’Reilly, L.A., Strasser, A., Fahrer, A.M., et al. (2004). Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity 21, 817–830. Lohr, J., Knoechel, B., Jiang, S., Sharpe, A.H., Abbas, A.K. (2003). The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 4, 664–669. Macian, F., Garcia-Cozar, F., Im, S.H., Horton, H.F., Byrne, M.C., Rao, A. (2002). Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109, 719–731. Maglott, D., Ostell, J., Pruitt, K.D., Tatusova, T. (2005). Entrez Gene: genecentered information at NCBI. Nucleic Acids Res 33, D54–D58. Majeti, R., Xu, Z., Parslow, T.G., Olson, J.L., Daikh, D.I., Killeen, N., Weiss, A. (2000). An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103, 1059–1070. Malek, T.R., Porter, B.O., Codias, E.K., Scibelli, P., Yu, A. (2000). Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J Immunol 164, 2905–2914. Malek, T.R., Yu, A., Vincek, V., Scibelli, P., Kong, L. (2002). CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice: implications for the nonredundant function of IL-2. Immunity 17, 167–178. Marti, F., Lapinski, P.E., King, P.D. (2005). The emerging role of the T cell-specific adaptor (TSAd) protein as an autoimmune disease-regulator in mouse and man. Immunol Lett 97, 165–170. Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nat Rev Immunol 1, 135–145. Moody, J.L., Pereira, C.G., Magil, A., Fritzler, M.J., Jirik, F.R. (2003). Loss of a single allele of SHIP exacerbates the immunopathology of Pten heterozygous mice. Genes Immunol 4, 60–66. Morgan, R., Gao, G., Pawling, J., Dennis, J.W., Demetriou, M., Li, B. (2004). N-Acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol 173, 7200–7208. Murga, M., Fernandez-Capetillo, O., Field, S.J., Moreno, B., Borlado, L.R., Fujiwara, Y., et al. (2001). Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 15, 959–970. Naramura, M., Jang, I.K., Kole, H., Huang, F., Haines, D., Gu, H. (2002). c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol 3, 1192–1199. Negishi, I., Motoyama, N., Nakayama, K., Nakayama, K., Senju, S., Hatakeyama, S., et al. (1995). Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature 376, 435–438. Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T. (1999). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151.
10. PERIPHERAL TOLERANCE OF T CELLS IN THE MOUSE
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319–322. Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., et al. (2003). Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9, 1477–1483. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., et al. (2002). Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297, 1031–1034. Palacios, E.H., Weiss, A. (2004). Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23, 7990–8000. Paust, S., Lu, L., McCarty, N., Cantor, H. (2004). Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA 101, 10398–10403. Peng, S.L., Gerth, A.J., Ranger, A.M., Glimcher, L.H. (2001). NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 14, 13–20. Perry, W.L., Hustad, C.M., Swing, D.A., O’Sullivan, T.N., Jenkins, N.A., Copeland, N.G. (1998). The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat Genet 18, 143–146. Rajagopal, K., Sommers, C.L., Decker, D.C., Mitchell, E.O., Korthauer, U., Sperling, A.I., et al. (1999). RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation. J Exp Med 190, 1657–1668. Ranger, A.M., Hodge, M.R., Gravallese, E.M., Oukka, M., Davidson, L., Alt, F.W., et al. (1998). Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc. Immunity 8, 125–134. Ranger, A.M., Oukka, M., Rengarajan, J., Glimcher, L.H. (1998). Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 9, 627–635. Rathmell, J.C., Elstrom, R.L., Cinalli, R.M., Thompson, C.B. (2003). Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur J Immunol 33, 2223–2232. Rengarajan, J., Tang, B., Glimcher, L.H. (2002). NFATc2 and NFATc3 regulate TH2 differentiation and modulate TCR-responsiveness of naïve TH cells. Nat Immunol 3, 48–54. Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fischer, A., et al. (1995). Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347–1349. Rose, N.R., Bona, C. (1993). Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today 14, 426–430. Roths, J.B., Murphy, E.D., Eicher, E.M. (1984). A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159, 1–20. Sadlack, B., Lohler, J., Schorle, H., Klebb, G., Haber, H., Sickel, E., et al. (1995). Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25, 3053–3059. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., Horak, I. (1993). Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253–261. Sakaguchi, N., Takahashi, T., Hata, H., Nomura, T., Tagami, T., Yamazaki, S., et al. (2003). Altered thymic T-cell selection due to a mutation of the ZAP70 gene causes autoimmune arthritis in mice. Nature 426, 454–460. Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., et al. (2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431–440. Salvador, J.M., Hollander, M.C., Nguyen, A.T., Kopp, J.B., Barisoni, L., Moore, J.K., et al. (2002). Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16, 499–508. Schneider, H., Valk, E., da Rocha Dias, S., Wei, B., Rudd, C.E. (2005). CTLA4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function. Proc Natl Acad Sci USA 102, 12861–12866.
241
Schuh, K., Kneitz, B., Heyer, J., Bommhardt, U., Jankevics, E., BerberichSiebelt, F., et al. (1998). Retarded thymic involution and massive germinal center formation in NF-ATp-deficient mice. Eur J Immunol 28, 2456–2466. Schwartz, R.H. (2003). T cell anergy. Annu Rev Immunol 21, 305–334. Setoguchi, R., Hori, S., Takahashi, T., Sakaguchi, S. (2005). Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201, 723–735. Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., et al. (1992). Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693–699. Shultz, L.D., Schweitzer, P.A., Rajan, T.V., Yi, T., Ihle, J.N., Matthews, R.J., et al. (1993). Mutations at the murine moth-eaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73, 1445–1454. Siminovitch, K.A. (2004). PTPN22 and autoimmune disease. Nat Genet 36, 1248–1249. Singer, A.L., Koretzky, G.A. (2002). Control of T cell function by positive and negative regulators. Science, 296, 1639–1640. Singh, R.R., Saxena, V., Zang, S., Li, L., Finkelman, F.D., Witte, D.P., Jacob, C.O. (2003). Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 170, 4818–4825. Smith, C.L., Goldsmith, C.A., Eppig, J.T. (2005). The Mammalian Phenotype Ontology as a tool for annotating, analyzing and comparing phenotypic information. Genome Biol 6, R7. Sommers, C.L., Lee, J., Steiner, K.L., Gurson, J.M., Depersis, C.L., El-Khoury, D., et al. (2005). Mutation of the phospholipase C-γ1-binding site of LAT affects both positive and negative thymocyte selection. J Exp Med 201, 1125–1134. Sommers, C.L., Menon, R.K., Grinberg, A., Zhang, W., Samelson, L.E., Love, P.E. (2001). Knock-in mutation of the distal four tyrosines of linker for activation of T cells blocks murine T cell development. J Exp Med 194, 135–142. Sommers, C.L., Park, C.S., Lee, J., Feng, C., Fuller, C.L., Grinberg, A., et al. (2002). A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science 296, 2040–2043. Suh, W.K., Gajewska, B.U., Okada, H., Gronski, M.A., Bertram, E.M., Dawicki, W., et al. (2003). The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 4, 899–906. Sumen, C., Dustin, M.L., Davis, M.M. (2004). T cell receptor antagonism interferes with MHC clustering and integrin patterning during immunological synapse formation. J Cell Biol 166, 579–590. Sun, H., Lu, B., Li, R.Q., Flavell, R.A., Taneja, R. (2001). Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nat Immunol 2, 1040–1047. Suzuki, H., Kundig, T.M., Furlonger, C., Wakeham, A., Timms, E., Matsuyama, T., et al. (1995). Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268, 1472–1476. Suzuki, A., Yamaguchi, M.T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., et al. (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523–534. Teige, I., Treschow, A., Teige, A., Mattsson, R., Navikas, V., Leanderson, T., et al. (2003). IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 170, 4776–4784. The Finnish-German APECED Consortium. Autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy: an autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. (1997). Nat Genet 17, 399–403. Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A., Sharpe, A.H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541–547. Tsui, H.W., Siminovitch, K.A., de Souza, L., Tsui, F.W. (1993). Moth-eaten and viable moth-eaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 4, 124–129.
242
V I G O H E I S S M E Y E R , B O G D A N TA N A S A , A N D A N J A N A R A O
Vinuesa, C.G., Cook, M.C., Angelucci, C., Athanasopoulos, V., Rui, L., Hill, K.M., et al. (2005). A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435, 452–458. von Boehmer, H. (2005). Mechanisms of suppression by suppressor T cells. Nat Immunol 6, 338–344. Wange, R.L. (2000). LAT, the linker for activation of T cells: a bridge between T cell-specific and general signaling pathways. Sci STKE 63, RE1. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., Nagata, S. (1992). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314–317. Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., et al. (1995). Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985–988. Willerford, D.M., Chen, J., Ferry, J.A., Davidson, L., Ma, A., Alt, F.W. (1995). Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521–530.
Witebsky, E., Rose, N.R., Terplan, K., Paine, J.R., Egan, R.W. (1957). Chronic thyroiditis and autoimmunization. JAMA 164, 1439–1447. Wu, J., Wilson, J., He, J., Xiang, L., Schur, P.H., Mountz, J.D. (1996). Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98, 1107–1113. Xanthoudakis, S., Viola, J.P., Shaw, K.T., Luo, C., Wallace, J.D., Bozza, P.T., et al. (1996). An enhanced immune response in mice lacking the transcription factor NFAT1. Science 272, 892–895. Zhang, W., Sommers, C.L., Burshtyn, D.N., Stebbins, C.C., DeJarnette, J.B., Trible, R.P., et al. (1999). Essential role of LAT in T cell development. Immunity 10, 323–332. Zhu, J.W., Field, S.J., Gore, L., Thompson, M., Yang, H., Fujiwara, Y., et al. (2001). E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol 21, 8547–8564.
Chapter 11 The Genetics of Mouse Models of Systemic Lupus Srividya Subramanian and Edward K. Wakeland
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II. Models of Murine Lupus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III. Spontaneous Lupus Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. MRL.lpr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. BXSB.yaa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. [NZW × NZB]F1: Insights into MHC and Non-MHC Susceptibility Loci . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. NZM2410 and the Congenic Derivatives . . . . . . . . . . . . . . . . . . . . . . . E. Congenic Dissection of NZM2410 . . . . . . . . . . . . . . . . . . . . . . . . . . . . F. Epistatic Interactions in the Development of Pathogenic Autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G. Epistatic Interactions in the Suppression of Pathogenic Autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Insights into Lupus, Pathways, and Epistasis from Genetically Manipulated Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Antigen and Immune Complex Clearance . . . . . . . . . . . . . . . . . . . . . . . B. Regulation of Proliferation and Apoptosis . . . . . . . . . . . . . . . . . . . . . . . C. Lymphocyte Signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I.
INTRODUCTION
The prototype of systemic autoimmune disorders, systemic lupus erythematosus (SLE), is characterized by a loss in immunological tolerance to a variety of ubiquitous self-antigens, such as chromatin, double-stranded (ds) DNA, ribonucleoproteins, and complement. A variety of immunological aberrations THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
243 244 244 244 246 247 249 249 250 251 251 252 253 254 255 256
ultimately culminate in the different pathogenic processes of SLE, which can include glomerulonephritis (GN), nondeforming arthritis, pericarditis, vasculitis, pleuritis, and serosititis (Wakeland et al. 2001). These immune irregularities have been postulated to be a consequence of changes in the activation thresholds and functions of immune cells, variations in the cytokine milieu produced, alterations in the clearance of apoptotic Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
243
244
SRIVIDYA
and necrotic debris by phagocytotic cells, and modulations in antigen presentation capacities (reviewed in Banchereau et al. 2004; Carroll 1998; Hoffman 2004; Lipsky 2001). Whereas the factors involved in the initiation of SLE are poorly understood, numerous researchers have clearly demonstrated that genetic predisposition is the major element dictating lupus susceptibility. SLE has all the features of a complex, polygenic trait, including a requirement for multiple genes, incomplete penetrance, and genetic heterogeneity (Vyse and Kotzin 1998; Wandstrat and Wakeland 2001). An understanding of the genetic basis of lupus susceptibility is further complicated by emerging evidence indicating that the predisposing causal variants are common alleles that per se are nondeleterious, as most clearly exemplified by the human leukocyte antigen (HLA) polymorphisms associated with autoimmunity (Rioux and Abbas 2005). This makes conclusive identification of the causal polymorphisms difficult, as they are relatively frequent within the population, and their phenotypic consequences are subtle. If the predisposing allelic variations are commonly found in the general population, how then do they elicit systemic autoimmunity? It is postulated that different combinations of polymorphic genes, due to their specific genetic interactions, termed epistasis, can lead to imbalances in immune regulation/function that potentiate the development and progression of autoimmunity (Subramanian and Wakeland 2005).
II.
MODELS OF MURINE LUPUS
The overall complexity of the genetics of human SLE susceptibility has led many investigators to turn to murine lupus models. These studies are greatly facilitated by the availability of both spontaneous and engineered mouse strains that develop lupus. These murine models share many of the immunological and pathological abnormalities observed in human patients with lupus, including a loss in tolerance to nuclear antigens and consequent high titers of serum autoantibodies (autoAbs), as well as the development of immune complex–mediated GN. Spontaneous models are particularly useful as they represent genomes, which through different breeding strategies, contain enough susceptibility genes so that their “autoimmune potential” is maximized, and the animals develop overt disease. Linkage analysis has been a powerful tool in the identification of predisposing loci in these spontaneous lupus models, as summarized in Table 11-1. However, the 95% confidence intervals obtained for these loci often contain hundreds of potential candidate genes, making functional identification of the causal gene challenging and providing little insight into the contributions of individual loci to the disease process. Consequently, congenic dissection of these strains has proven to be invaluable. This involves introgressing the susceptibility locus of interest onto a non-autoimmune prone background, such as C57Bl/6J (B6), and assessing the clinical and immunological phenotypes
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
mediated by the locus in isolation. Importantly, these congenic lines can then be used to generate recombinants for fine mapping of the susceptibility locus. A major caveat to this approach is that the phenotype mediated by the locus in isolation must be reasonably robust. An alternative strategy is to move corresponding resistance loci onto the autoimmune background and assess for disease amelioration. Lupus-like phenotypes have also been observed in mice in which genetic ablation and transgenic overexpression of genes has been performed. In addition, by introgressing these genetic modifications onto autoimmune-prone spontaneous strains, insight has been gained into the requirements for certain molecules in disease initiation and pathogenesis. Both the spontaneous and engineered models provide tools with which to better identify genes contributing to underlying genetic susceptibility and shed light onto how abnormalities in various pathways may contribute to the overall disease process (Jorgensen et al. 2004; Vyse and Kotzin 1998; Wakeland et al. 2001).
III.
SPONTANEOUS LUPUS MODELS
A.
MRL.lpr
The lpr mutation was originally discovered during the derivation of the MRL/MpJ strain, and on this background resulted in hypergammaglobulinemia, anti-dsDNA autoAbs, profound lymphadenopathy and splenomegaly, and immune complex (IC)-mediated GN. MRL.lpr mice were also characterized by the emergence of an unusual CD4−CD8−CD3+B220+ T cell population. It was later discovered that lpr encodes for the apoptosis-signaling receptor Fas antigen and that the mutation results in premature termination of Fas transcription (Watanabe-Fukunaga et al.1992). The mechanism by which lack of Fas-mediated signaling results in autoimmunity is postulated to be due to the emergence of self-reactive T and B cells that would normally undergo apoptosis during thymic, bone marrow (BM), and peripheral selection events (Rioux and Abbas 2005; Vyse and Kotzin 1998). However, the effect of the lpr mutation is highly genome dependent, as evidenced by the varying degrees of autoimmunity seen when it is introgressed onto non-autoimmune strains, such as B6, C3H, and AKR. This illustrates the necessity for epistatic interactions between lpr and the rest of the genome for full disease expression (Kelley and Roths 1985). Furthermore, Fas-intact MRL mice develop a late-onset autoimmunity, culminating in 50% mortality by 18 months, suggesting that lpr is an accelerating factor, as opposed to a causal mutation (Watson et al. 1992). Consistent with this result, CD4+ T cells from Fas-intact MRL mice have an intrinsic hyperresponsive phenotype after engagement with high- and low-affinity peptide-MHC complexes and a lower threshold for CD3-mediated activation. Thus, the
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
245
LUPUS
TABLE 11-1
MAJOR SPONTANEOUS LUPUS MODELS AND LOCI LINKED TO AUTOIMMUNE PHENOTYPES Autoimmune Mouse Strain
Linked Loci
Chromosome (peak QTL cM)
Associated Phenotype(s) GN GN SM, LA, dsDNA SM, LA, dsDNA SM, LA, dsDNA SM, LA, GN dsDNA dsDNA SM, ANA, GN dsDNA SM, ANA, GN GN ANA, GN
MRL.lpr
Lrdm1 Lrdm2 Lmb1 Lmb2 Lmb3 Lmb4
BXSB.yaa
Bxs1 Bxs2 Bxs3 Bxs4 Nba1 Nba2
7 (6.0) 12 (35.0) 4 (57.5) 5 (41.0) 7 (28.0) 10 (41.0) 2 11 1 (32.8) 1 (61.3) 1 (100.0) 1 (7.7) 4 (75.0) 1 (95.0)
Nba3
7 (42.6)
ANA, GN
Lbw1 Lbw2 Lbw5 Lbw6 Lbw7 Sle1a Sle1b
17 (19.1) 4 (42.6) 7 (23.0) 18 (47.0) 1 (90.0) 1 (88.0) 1 (89.5)
ANA, GN SM, GN GN GN SM, ANA ANA SM, ANA
Sel1c Sleld Sle2a Sle2b Sle3
1 (106.3) 1 4 (33.0) 4 (42.6) 7 (16.0)
ANA GN SM, dsDNA, GN SM, dsDNA, GN SM, ANA, GN
Sle5
7 (0.0)
dsDNA, ANA
Sles1
17 (19.0)
Sles2 Sles3
4 (58.0) 3 (35.0)
SM, ANA, dsDNA, GN (suppressed) ANA (suppressed) ANA (suppressed)
[NZB × NZW]F1
NZM2410
Postulated Gene(s)
Ifi202
SLAM/Cd2 family Cr2
References Vidal et al. 1998 Vidal et al. 1998 Watson et al. 1992 Watson et al. 1992 Watson et al. 1992 Watson et al. 1992 Gu et al. 1998 Gu et al. 1998 Haywood et al. 2004 Haywood et al. 2004 Haywood et al. 2004 Haywood et al 2004 Drake et al. 1994 Drake et al. 1994; Rozzo et al. 2001 Drake et al. 1994; Vyse, Drake, et al. 1996 Kono et al. 1994 Kono et al. 1994 Kono et al. 1994 Kono et al. 1994 Kono et al. 1994 Morel et al. 2001 Morel et al. 2001; Wandstrat et al. 2004 Morel et al. 2001 Morel et al. 2001 Xu et al. 2005 Xu et al. 2005 Mohan, Morel, et al. 1999; Morel et al. 1994; Morel, Mohan, et al. 1999 Mohan, Morel, et al. 1999; Morel, Mohan, et al. 1999 Morel, Tian, et al. 1999; Subramanian et al. 2005 Morel, Tian, et al. 1999 Morel, Tian, et al. 1999
Listed are the various loci identified in the different spontaneous lupus models discussed in the text, their chromosomal positions in centimorgans (cM) (based on the Mouse Genome Informatics database, if available), the various phenotypes associated with the loci, and postulated causal genes. ANA, antinuclear autoantibodies; dsDNA, anti-dsDNA IgG; GN, glomerulonephritis; LA, lymphadenopathy; SM, splenomegaly.
phenotypic variations of the Fas mutation may be a consequence of strain-specific differences in the intrinsic responsiveness of the T cell compartment (Vratsanos et al. 2001; Zielinski et al. 2005). Further insights into mechanisms leading to autoimmunity in the MRL.lpr strain come from studies investigating how genetic ablation of various molecules potentiates or ameliorates disease. The absence of molecules such as interferon (IFN)-RI, the C3 inhibitory factor decay-accelerating factor (DAF), interleukin (IL)-10, and the costimulatory molecule CD80, have been to shown to exacerbate various aspects of disease (Hron and Peng 2004; Liang et al. 1999; Miwa et al. 2002; Yin et al. 2002).
In contrast, deficiency in a variety of molecules involved in immune functions, such as interferon receptor II (IFN-RII), colony-stimulation factor (CSF), leukocyte function-associated antigen-1 (LFA-1), Nuclear-factor E2–related factor (NrF2), terminal deoxynucleotidyl transferase (Tdt), IL-2, IL-12p40, Factor B, CD28, CD86, and IFN-γ receptor (IFNγR), were observed to confer a protective effect on specific disease phenotypes (Hron and Peng 2004; Kevil et al. 2004; Kikawada et al. 2003; Lenda et al. 2004; Liang et al. 1999; Morito et al. 2004; Robey et al. 2004; Schwarting et al. 1998; Tada et al. 1999; Watanabe et al. 2000; Xiao et al. 2003).
246
SRIVIDYA
It must be kept in mind that in many of these studies, the deficiencies were studied on mixed genetic backgrounds, which can significantly influence the magnitude of disease phenotypes. This situation was seen in the case of interleukin-18 receptor (IL-18R), where, in contrast to a previous report on a less homogenous genetic background, deficiency of the IL18R, and consequently IL-18-mediated signaling, was found to have no effect on disease development (Lin and Peng 2005). Deficiency of the common Fcγ receptor (FcγR) chain was also shown to have no impact on disease development (Matsumoto et al. 2003). Linkage analyses have been performed on the MRL.lpr strain to identify loci contributing to the strain-specific effects of the lpr mutation described above. By using [MRL.lpr × Cast/Ei]F1 × MRL.lpr backcross animals, MRL-derived loci on chromosomes 7 and 12 (Lrdm1–2) were identified as contributing to renal disease (Watson et al. 1992). Another cross utilizing [MRL.lpr × B6.lpr]F2 intercross progeny identified four loci with significant linkage to lymphadenopathy and/or splenomegaly on chromosomes 4, 5, 7, and 10, termed Lmb1–4, respectively. Lmb1–3 were also associated with antidsDNA autoAbs, whereas Lmb4 was associated with GN (Vidal et al. 1998). An analysis of [MRL.lpr × BALB/c]F2 mice revealed linkage for anti-dsDNA autoAbs with chromosomes 2 and 11 (Gu et al. 1998). Other linkage studies have been performed to identify loci involved in the development of arthritis and collagen disease in the MRL.lpr strain, which has also been used as a model of polyarteritis, rheumatoid arthritis, Sjögren’s syndrome, and autoimmune lymphoproliferative syndrome (Kamogawa et al. 1999, 2002; Nakatsuru et al. 1999; Nishihara et al. 1999). The specific identities of any of these genes have not yet been determined.
B.
BXSB.yaa
The BXSB.yaa strain is a recombinant inbred strain derived from B6 and SB/Le. Because of the presence of the as-yet unidentified Y chromosome autoimmune accelerator (yaa) locus, male mice from this strain spontaneously develop humoral autoimmunity to a plethora of self-antigens and lupus nephritis, ultimately culminating in 100% mortality by 6 months of age. Analyses of different consomic strains, carrying the BXSB-derived Y chromosome have revealed that the ability of yaa to mediate severe autoimmunity is, like that of lpr, highly dependent on interactions between it and other susceptibility loci from the autosomal genome (Hudgins et al. 1985). Moreover, the addition of yaa to a variety of F1 crosses, in which the progeny are normally non-autoimmune, such as [New Zealand white (NZW) × B6]F1 and [New Zealand black (NZB) × B6]F1 crosses, can lead to the development of significant systemic autoimmunity (Hudgins et al. 1985; Kikuchi et al. 2005; Santiago et al. 1998). Importantly, yaa on the B6
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
background does not lead to fulminant autoimmunity, and it has been postulated that the capacity of yaa to promote autoimmunity is dependent on the ability of the autosomal background to promote the spontaneous development of autoantibodies (Merino et al. 1994). The course of disease in BXSB.yaa males is highly similar to that seen in other murine lupus models. In addition to clinical features, such as GN and the emergence of immunoglobulin (Ig) G autoAbs specific for different self-antigens, the animals develop with age a profoundly activated immune system and hypercellularity of the spleen and lymph nodes (LNs). This is characterized by dramatic increases in the percentage of CD4+ T cells having effector memory (CD62L−CD45RBloCD44hi) and activated (CD25+) phenotypes. The CD4+ cells have been shown to be refractive to both anti-CD3 and phorbol myristic acid/ionomycin-induced proliferation in vitro, yet produced increased amounts of IFN-γ and IL-4 and decreased IL-2 in response to both of these stimuli (Chu et al. 1994). Notably, decreased IL-2 production is also a feature of human lupus T cells (Chowdhury et al. 2005; Crispin and Alcocer-Varela 1998; Juang et al. 2005). These changes in the functional responses of CD4 T cells are also characteristic of replicative senescence. Treatment with cytotoxic T lymphocyte-associated Ag (CTLA-4) Ig was shown to prevent different CD4 cell surface and functional phenotypes and reduced both GN and anti-chromatin autoAbs, presumably via negative regulation of T cells. Cessation of treatment, however, restored the CD4 effector memory phenotype (Chu et al. 1996). BXSB.yaa mice lacking the cyclin-dependent kinase inhibitor p21 showed increased survival and a reduction in GN scores, anti-chromatin IgG, and hypergammaglobulinemia. CD4 cells were reduced in overall number and had a less activated phenotype. Importantly, these CD4s made less IFN-γ, and more of the CD4+CD44hi cells were undergoing apoptosis, had incorporated bromodeoxyuridine, and were in the G1 versus G0 phase of the cell cycle (Lawson et al. 2004). Hence, it may be that preventing the accrual of these CD4 cells can ameliorate some of the more pathogenic phenotypes and ameliorate morbidity. There are numerous B cell–associated differences in BXSB.yaa mice as well, some of which appear to be specifically associated with the yaa locus and are independent of the development of systemic autoimmunity. Resting splenic B cells from both BXSB.yaa and B6.yaa mice were shown to proliferate more in response to a variety of different stimuli. These data suggested that yaa acts downstream of initial signaling events and is not Ca2+ or PKC dependent. Because this difference in B cell responsiveness was seen in both BXSB.yaa and B6.yaa, it indicated that such a change is not sufficient for the development of autoimmunity. In contrast, similar experiments performed with purified T cells from young B6.yaa mice showed no differences in proliferative responses to various stimuli. This increased B cell responsiveness was not amplified with age, and by 5 months, similar to the CD4 T cells, BXSB.yaa B cells showed reduced proliferative responses,
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
which were also mitigated in BXSB.yaa|p21-mice (DesJardin et al. 1996, Lawson et al. 2004). The ultimate goal of identifying the causal gene within a susceptibility locus is unusually confounded in the case of yaa. In most murine positional cloning efforts naturally occurring meiotic recombination events and subsequent phenotypic characterizations are used to narrow the locus to a susceptibility interval amenable for causal gene identification. This is not possible for Y chromosome–located genes, and investigators have used other approaches to help elucidate the nature of the yaa gene. Mixed BM chimeric experiments have demonstrated that only yaa- bearing B cells produce autoantibodies and that the presence of yaa- bearing T cells is not sufficient to make nonyaa- bearing B cells make autoantibodies (Merino et al. 1991). Further studies using both mixed BM chimeric experiments and BXSB.yaa/TCRα−/− mice implicated CD4 T cells as being necessary for severe disease but demonstrated that these cells do not need to express yaa to mediate severe disease (Fossati et al. 1995; Lawson et al. 2001). These data indicate that although CD4 T cells are necessary, only the B cells actually need to functionally express yaa for disease development to occur in this lupus model. Despite the difficulties associated with identifying yaa, a variety of linkage studies have been conducted to determine the positions of autosomal genes that interact with yaa to mediate lupus. Analyses of [NZW × B6.yaa]F1 × B6 males, to identify dominant NZW contributions, revealed a major dominant locus contributing to severe GN and anti-dsDNA IgG susceptibility on chromosome 7. Interestingly, whereas there was no significant linkage of either of these phenotypes to chromosome 17 by itself, there appeared to be interactions between the chromosome 7 locus and chromosome 17, such that heterozygotes at chromosome 7 and B6 homozygotes at chromosome 17 had the highest titers. Somewhat surprisingly, no significant linkage for these phenotypes was obtained with chromosome 1 (Santiago et al. 1998). In a similar study of [NZB × B6.yaa]F1 × B6 backcross males NZB-contributed GN susceptibility was mapped to chromosomes 1 and 13 but not to chromosomes 7 and 17. Interestingly, anti-DNA and anti-chromatin IgG mapped to an NZB contribution on chromosome 1 but to B6 homozygosity at chromosome 17 (Kikuchi et al. 2005). Congenic analyses of various autosomal yaa-interacting loci, identified via such linkage studies, have revealed some interesting findings. The chromosome 1 Bxs1–4 loci, originally identified in [BXSB.yaa × B10]F1 reciprocal backcrosses, were moved in various combinations onto the B10.yaa background. Bxs1 appeared to have an impact on kidney pathological changes in the absence of significant antinuclear autoantibody (ANA) production, Bxs2 specifically contributed to antidsDNA IgG, whereas the most centromeric locus, Bxs4, appeared to interact with Bxs1 to mediate moderate GN. It is evident, however, that the major BXSB-derived locus on
LUPUS
247
chromosome 1 is Bxs3, which can interact with yaa on the B10 background to recapitulate most, if not all, of the phenotypes observed in BXSB.yaa (Haywood et al. 2004). Interestingly, Bxs3 corresponds to the same genomic interval as the NZBand NZM2410-derived loci Nba2 and Sle1, respectively, both of which can also interact with yaa on the non-autoimmune B6 background to generate systemic autoimmunity (Croker et al. 2003; Kikuchi et al. 2005; Morel et al. 2000). A limitation in the interpretation of the above-described studies is that none of the Bxs chromosome 1 loci have been studied in the absence of yaa on the B10 background. Given the importance of epistatic interactions in the development of various lupus phenotypes, it would be informative to assess the component phenotypes of individual loci. Similar studies with the NZB-derived chromosome 1 and 7 loci, Nba2 and Nba5, respectively, demonstrated that both these loci can interact with yaa on the B6 background as well, in both cases resulting in increased 15-month mortality and severe GN. Only B6.Nba2|yaa mice showed increased anti-DNA and antichromatin IgG relative to both female controls and B6.yaa (Kikuchi et al. 2005). C.
[NZW × NZB]F1: Insights into MHC and Non-MHC Susceptibility Loci
One of the most well-characterized models of murine lupus is the F1 hybrid of the NZB and NZW inbred mouse strains (BWF1). These mice develop progressive, severe GN, and high levels of antinuclear antigen–specific IgG autoAbs, similar to both BXSB.yaa and MRL.lpr, but unlike those models, no single gene mutation is necessary for full disease expression. Interestingly, neither parental strain develops severe lupus phenotypes, although each is associated with a late-onset mild autoimmunity, illustrating the importance of genetic interactions in the F1 genome for full expression of lupus phenotypes (Morel and Wakeland 1998). As observed in the other spontaneous lupus models, a variety of immunological abnormalities are observed in BWF1 mice. B cells from young BWF1 mice demonstrate elevated expression of costimulatory molecules ex vivo and show increased IgM secretion, proliferation, and expression of costimulatory molecules after both cytokine and CD40 cross-linking stimulation in vitro (Wither, Roy, et al. 2000). Furthermore, using different IgM Tg systems, it was found that whereas BWF1 mice had intact central B cell tolerance, the frequency of anti-dsDNA IgG–producing follicular B cells was increased, even in the setting of a very restricted B cell repertoire, suggesting significant alterations in the peripheral selection mechanisms in these mice (Wellmann, Letz, et al. 2001; Wellman, Werner, et al. 2001). Ectopic expression of CXCL13, a B lymphocyte chemoattractant, has been observed in myeloid dendritic cells in the thymus, kidney, and lungs of BWF1 mice, as well as impaired and aberrant B1 trafficking
248
SRIVIDYA
(Ishikawa et al. 2001; Ito et al. 2004; Sato et al. 2004). Treatment of BWF1 mice with CTLA-4 Ig was shown to decrease the expansion of autoreactive B cells, inhibit the Ig class switch, and decrease numbers of activated CD4+ T cells, although this effect was not permanent (Mihara et al. 2000). Numerous linkage studies with a variety of different crosses have been undertaken to identify susceptibility loci in the BWF1 murine lupus model. In most of these studies the concentration has been on assessing NZB contributions to disease. As recently reviewed, loci associated with suggestive or significant linkage have been implicated on >14 of the autosomal chromosomes (Jorgensen et al. 2004). Consistent linkages have been observed with distal chromosome 1, mid-distal chromosome 4, chromosome 7, and the MHC region of chromosome 17, as described below. Backcross analyses of [BWF1 × NZW]F1 progeny revealed a strong linkage on chromosome 4, termed Nba1 (New Zealand Black autoimmunity) (Drake et al. 1994; Vyse, Drake, et al. 1996). This interval was also implicated in an independent backcross study of similar design and in an analysis of [SWR × NZB]F1 × NZB backcross progeny (Hirose et al. 1994; Xie et al. 2001). Linkage studies of BWF2 intercross progeny also identified a chromosome 4 locus, designated Lbw2 (Lupus-NZB × NZW), as being involved in mortality, GN, and splenomegaly but not anti-chromatin autoAbs. Genome-wide linkage studies with two different non-autoimmune, H2z congenic strains, revealed that whereas chromosome 4 was linked to nephritis in [BALB.H2z × NZB]F1 × NZB backcross progeny, it was not when B6.H2z was used instead of BALB.H2z (Rozzo et al. 1996). This latter study illustrates the impact genetic interactions with loci from the non-autoimmune strain can have in such crosses. Linkage to anti-chromatin autoAbs and nephritis was also seen on chromosome 4 in a study of [B6 × NZB]F2 mice (Tucker et al. 2000). Like chromosome 4, chromosome 1 has been implicated in a number of different experimental crosses. An NZB-derived locus, designated Nba2, has been mapped in [NZB × SM/J]F1 × NZW, [B6.H2z × NZB]F1 × NZB, and [BALB.H2z × NZB]F1 × NZB backcross and [B6 × NZB]F2 progeny as contributing to nephritis, hypergammaglobulinemia, autoAbs, and polyclonal B cell activation phenotypes (Drake, Rozzo, Vyse, et al. 1995; Rozzo et al. 1996; Vyse et al. 1997; Wither, Patterson, et al. 2000). Lbw7, an NZB-derived locus on chromosome 1 contributing to anti-chromatin autoAbs, was mapped in BWF2 intercross progeny in the same region as Nba2 (Kono et al. 1994). Evidence for NZW contributions to IgG autoAb production on chromosome 1 has also been revealed using [BALB/c × NZW]F1 × NZW backcross progeny (Vyse, Morel, et al. 1996). Mice made congenic for the NZB-derived Nba2 interval on the B6 background, (B6.Nba2), broke tolerance to chromatin, and had increased percentages of CD69+ B cells and increased in vitro IgM secretion (Atencio et al. 2004; Rozzo et al. 2001). The causal gene has been postulated to be Ifi202, an IFNinducible gene showing differential expression, identified via
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
microarray analyses. Sequencing of the promoter region of Ifi202 revealed eight different promoter polymorphisms between B6 and NZB, and the one at position 95 correlates with known expression differences between mouse strains. However, the congenic interval introgressed in the study was >30 cM in length and contained >100 genes, making it impossible to definitively conclude that Ifi202 is the causal gene within Nba2 (Rozzo et al. 2001). The third non-MHC region consistently implicated in multiple studies is chromosome 7. In BWF2 intercross progeny, the chromosome 7 locus Lbw5 was linked more strongly with heterozygosity than with NZB or NZW homozygosity, and similar results were observed in BWF1 × NZB backcross progeny as well (Kono et al. 1994; Vyse et al. 1999). A dominant NZB chromosome 7 contribution, Nba3, was identified as contributing to nephritis and autoAbs in [NZB × SM/J] F1 × NZW and [BWF1 × NZW] backcross progeny, respectively (Drake, Rozzo, Vyse, et al. 1995; Vyse, Drake, et al. 1996). Linkage of the murine MHC on chromosome 17 with lupus susceptibility, similar to the observation in human studies, has proved to be very complicated and background specific. Studies of the BWF1 model, which has a heterozygous MHC genotype, have implicated separate strong contributions from both H2d (NZB) and H2z (NZW). Analysis of BWF2 intercross progeny identified Lbw1 on chromosome 17, where H2dz heterozygosity conferred increased risk for mortality, GN, and anti-chromatin antibodies (Abs) (Kono et al. 1994). Linkage of various lupus phenotypes to MHC heterozygosity has also been observed in BWF1 × NZW, BWF1 × NZB, and [BALB/c × NZW]F1 × NZW backcross progeny (Hirose et al. 1994; Vyse, Drake, et al. 1996; Vyse, Morel, et al. 1996; Vyse et al. 1999). In contrast to chromosome 4, [B6.H2z × NZB]F1 × NZB backcross progeny showed linkage to the MHC, but when BALB.H2z was used, this association was not observed, again illustrating the importance of non-MHC background loci in these two crosses (Rozzo et al. 1996). In addition, B6 MHC contributions were observed in linkage studies of [B6 × NZB]F2 progeny, in which maximum susceptibility was observed for H2b/b (Tucker et al. 2000). No MHC effect was observed in [NZB × SM/J] F1 × NZW backcross progeny, indicating that H2zd and H2zv confer equal risk (Drake, Rozzo, Hirschfeld, et al. 1995). To evaluate the risk conferred by the class II IEz in the development of lupus, linkage analysis comparing [B6.H2z × NZB]F1 × NZB and [B6.IEz × NZB]F1 × NZB backcross progeny was undertaken. In the latter cross, B6 mice express transgenic Class II IEz, but have no other H2z contributions. Interestingly, no linkage was observed with transgenic class II IEz expression and lupus nephritis development, although the previously observed MHC association was again seen in the control [B6.H2z × NZB]F1 × NZB backcross progeny (Vyse et al. 1998). A similar lack of association was observed when C57BL/10 (B10) mice expressed a transgene for class II IAz (Rozzo et al. 1999). This suggests that class II IAz and IEz are
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
not the culprit genes within the MHC and that mixed haplotype effects cannot explain the increased susceptibility observed in BWF1 mice, as has been long postulated (Drake et al. 1994; Morel et al. 1994; Rozzo et al. 1996; Vyse, Drake, et al. 1996; Vyse, Morel, et al. 1996; Zhang et al. 2004).
D.
NZM2410 and the Congenic Derivatives
The major difficulty associated with studying the BWF1 model of lupus, the spontaneous model most reminiscent of human lupus in terms of both disease phenotypes and underlying genetic complexity, is the fact that the hybrid genome is required for disease expression. This prevents the full utilization of the genetic uniformity found in inbred strains to study this complex trait. Fortuitously, a series of 27 inbred strains, termed the New Zealand Mixed (NZM) strains, were derived from [NZB × NZW]F1 × NZW backcross progeny and show varying degrees of susceptibility to SLE. The NZM2410 (NZM) strain is one of the most severely affected BWF1 derivatives and spontaneously develops autoAbs by 4–6 months and lupus nephritis by 6 months. Linkage analyses of [NZM × B6]F1 × NZM (BC1) progeny were performed to map recessive NZM loci linked to GN and anti-dsDNA IgG production. Three NZM loci were found to be linked to GN susceptibility: Sle1, Sle2, and Sle3 on chromosomes 1, 4, and 7 respectively. Heterozygosity at a locus on chromosome 17, initially termed Sle4, was found to be associated with GN. This study also demonstrated that the incidence of disease correlated with the number of susceptibility loci that had segregated in the BC1 progeny according to a threshold liability model, the first such demonstration in an animal model of autoimmunity (Morel et al. 1994). Subsequently, a [NZM × B6]F1 intercross was performed to identify dominant NZM genes contributing to GN and humoral autoimmunity, the effects of which would have been masked in the original BC1 study. The age of GN onset in these F2 animals was more delayed than that in the BC1 progeny, consistent with the recessive inheritance of loci contributing to this phenotype. This study again identified linkage for Sle1 and Sle3, as well as a new locus on chromosome 7 termed Sle5, but not for Sle2 and Sle4 (Morel, Mohan, et al. 1999). To study the component phenotype of these loci, each was introgressed onto the B6 background and studied as a B6.Sle strain.
E.
Congenic Dissection of NZM2410
B6.Sle1 mice were found to develop a progressive loss in tolerance, such that by 9–12 months, they made high titers of anti-chromatin IgG, as well as some degree of anti-dsDNA IgG autoAbs, but did not develop GN (Mohan et al. 1998; Morel et al. 1997; Subramanian et al. 2005). In addition, the mice
LUPUS
249
developed mild splenomegaly and an age-associated increase in activated splenic B and T cells. Despite this intrinsic activation phenotype, B and T cells were shown to have normal in vitro proliferative responses to different stimuli and in vivo IgM and IgG responses to T-dependent antigens. Furthermore, lymphocytes from B6.Sle1 mice had comparable rates of spontaneous and receptor-engagement induced apoptosis (Mohan et al. 1998; Morel et al. 1997). Mixed BM chimera experiments revealed that Sle1 is expressed in a BM-derived population and that the ability of a B cell to produce anti-chromatin autoantibodies and express an increased activation status is contingent on the B cell expressing Sle1 (Sobel et al. 1999). Subsequent experiments, using B6.Sle1|TCRα−/− and B6.Sle1|µMT mice, revealed that conventional T cells were not required for the increased levels of total, anti-chromatin, and anti-ssDNA IgM or for the manifestation of cell surface B cell activation phenotypes but were necessary for the generation of high-tittered IgG autoantibodies. In the absence of B cells, there were still increased percentages of activated CD4 T cells, suggesting that Sle1 is expressed functionally at the level of both the B and T cell (Sobel, Satoh, et al. 2002). Fine mapping of the Sle1 locus revealed that it is actually a cluster of functionally related subloci termed Sle1a–1d. All of these loci, with the exception of Sle1d, are associated with varying degrees of humoral autoimmunity, with B6.Sle1b mice recapitulating most of the phenotypes observed for the entire locus, making it the most potent of the subloci (Morel et al. 2001). It has been proposed that the causal gene for the Sle1c locus is the complement receptor Cr2/Cr1, as the allele from Sle1c has a novel glycosylation site that results in lowered functional responses to low and intermediate stimuli (Boackle et al. 2001). Fine mapping and subsequent sequencing of the Sle1b interval linked extensive functional polymorphisms in the SLAM/CD2 family of genes with the autoimmune phenotypes of B6.Sle1b (Wandstrat et al. 2004). Each family member is expressed in a specific set of immune cell lineages, and their expression can be altered by different stimuli, including antigen and Toll-like receptor triggering, as well as cytokines. Studies have demonstrated that this family can affect numerous immune functions, including macrophage, natural killer cell and T cell activation, cell-cell interactions, cytokine secretion, and cytotoxicity (Mooney et al. 2004; Wang et al. 2004). Altogether, these data strongly indicate that the SLAM/CD2 family has the ability to modulate immune responses in a highly flexible fashion and hence may function as “fine-tuners” of the immune response (reviewed in Veillette and Latour 2003). It was also shown that the Sle1b SLAM/CD2 family haplotype is the more prevalent version in both non-autoimmune and autoimmune-prone laboratory mouse strains and that only in the context of the B6 genome does this haplotype elicit autoimmunity, indicative of epistatic interactions (Wandstrat et al. 2004).
250
SRIVIDYA
Characterization of the NZW-derived Sle3/5 locus initially revealed primarily T cell phenotypes including elevated CD4/CD8 ratios and increased CD4 T cell activation phenotypes and proliferative responses but reduced activation-induced cell death (AICD). With age, splenic B cells showed increased expression of activation markers and produced anti-chromatin autoAbs. Unlike B6.Sle1, there was no evidence for splenomegaly in aged mice, but the spleens showed an agedependent change in splenic architecture. Despite the low-grade IgG humoral autoimmune response, these mice had a GN penetrance of ~20% (Mohan, Yu, et al. 1999). Mixed BM chimera experiments revealed that, like Sle1, Sle3/5 needed to be expressed in a BM-derived, radiationsensitive population. Interestingly however, non-Sle3/5 bearing T and B cells can express the phenotypes associated with this locus, such as elevated CD4/CD8 ratios and the production of anti-chromatin Abs, provided they develop in the presence of Sle3/5-bearing BM. This finding suggested that Sle3/5 is expressed in a non-B cell APC population or that Sle3/5 T cells have both autocrine and paracrine effects (Sobel, Morel, et al. 2002), which was subsequently shown to be a consequence of hyperstimulatory dendritic cells and macrophages that had more activated phenotypes and were less apoptotic, more pro-inflammatory, and better costimulators (Zhu et al. 2005). In contrast to Sle1 and Sle3/5, the phenotypes associated with the chromosome 4 locus, Sle2, were very B cell specific. There was no evidence of splenomegaly, lymphadenopathy, or changes in T cell percentages, activation status, or functional response. The B cells, however, were larger, had elevated activation marker expression, secreted increased levels of IgM, and were more responsive to different stimuli in vitro. Both T-independent and T-dependent IgM in vivo responses were heightened, whereas there was no change in the secondary IgG response, consistent with Sle2 not affecting the T cell compartment (Mohan et al. 1997). Starting at an early age, there was an increase in the peritoneal cavity B1a population in B6.Sle2 mice, with a concomitant decrease in the conventional B2 population, which was also seen in the spleen at an older age. This B1a expansion was independent of the housing conditions of the mice and was recently shown to be CD5 independent (Mohan et al. 1997; Xu et al. 2004). Mixed fetal liver chimeras, the early source of the B1a population, further revealed that Sle2 must be expressed in the B cell for this B1a expansion to occur (Xu et al. 2004). Congenic dissection hence allowed the complex, polygenic lupus phenotypes characteristic of the NZM2410 strain to be broken down and “assigned” to a specific chromosome interval. Characterization of the various B6 congenic lines revealed a variety of phenotypes, many of which are indicative of an overall heightened responsiveness to stimuli. This finding suggests that a more self-reactive immune system may be a consequence of the fact that the different immune cell populations bearing these susceptibility alleles are more prone to respond.
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
The above studies also clearly demonstrate that in isolation on the B6 background, none of these susceptibility loci are sufficient to mediate systemic autoimmunity. On the basis of the original modeling analysis, which demonstrated that disease liability increased as a function of the number of susceptibility alleles present, it was predicted that combining these loci would reconstitute the severe lupus phenotypes associated with NZM2410 (Morel et al. 1994). To test this hypothesis, a series of bi- and tricongenic lines were created to assess the role of their different genetic interactions in the development of disease, as detailed below. F.
Epistatic Interactions in the Development of Pathogenic Autoimmunity
The combination of Sle1 and Sle3/5 on the B6 background resulted in significant humoral and pathogenic autoimmunity, much greater than what would be predicted by the phenotypes of these loci in isolation. By 9–12 months of age, these mice had significant mortality, 75% penetrance of GN, severe splenomegaly, and increased reactivity to a spectrum of chromatin components, as well as increased numbers of glomerular basement membrane–binding Abs. There were also increased percentages of both B and T cells expressing activation and effector-phenotype markers in the spleen (Mohan, Morel, et al. 1999). In contrast, B6.Sle1|Sle2 mice had a slight increase in mortality (18%) with a low penetrance of proliferative GN, but like B6.Sle1|Sle3/5 mice had spleen weights comparable to those of NZM2410. In addition, the level of humoral autoimmunity was not very high in this bicongenic line and was similar to that seen in B6.Sle1 (Morel et al. 2000). These data indicate that the degree of epistatic interaction between Sle1 and Sle3/5 is greater than that seen between Sle1 and Sle2. It is tempting to speculate that this finding may be due to the fact that both loci in the former combination have effects on both T and B cells, whereas this is not true for Sle2 in the latter combination. Interestingly, the combination of Sle2 and Sle3 on the B6 background does not result in phenotypes significantly different from the parental congenics, suggesting that these loci do not interact in a multiplicative fashion. The kidneys from this particular bicongenic combination, however, display numerous hyaline deposits and mesangial lesions. These types of kidney pathological changes are not observed in the parental congenic strains and are almost indistinguishable from those seen in NZW (Morel et al. 2000). Although Sle1 and Sle3/5 are sufficient to mediate a high degree of fatal lupus nephritis on the B6 background, the combined effects of these loci does not fully recapitulate the severity and kinetics of disease observed in NZM2410. The combination of Sle1, Sle2, and Sle3/5 on the B6 background, however, results in fully penetrant lupus nephritis. The degree of proliferative lesions, splenomegaly, and 5-month anti-dsDNA IgG autoantibodies was in fact higher than that seen in NZM2410
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
(Morel et al. 2000). In addition, B6.Sle1|Sle2|Sle3/5, like NZM2410, accumulated long-lived splenic plasma cells that do not migrate normally in response to CXCL12, with a corresponding absence of BM plasma cells (Erickson et al. 2003). These data demonstrate that this combination of NZM2410 loci, originally identified via linkage analyses, fulfills the genetic equivalent of Koch’s postulates, as they are sufficient to reconstitute the development of fatal lupus nephritis on the non-autoimmune B6 background. Sle1, Sle2, and Sle3/5 were also individually combined on the B6 background with the BXSB-derived Y chromosome locus, yaa, to test the degree of epistatic interactions between this amplifying locus and the NZM2410-derived lupus susceptibility loci. Interestingly, only Sle1 interacts epistatically with yaa, culminating in fatal lupus nephritis and immunological characteristics similar to those with BXSB.yaa, whereas yaa combined with either Sle2 or Sle3/5 does not result in phenotypes that are significantly different from those observed by these loci in isolation (Croker et al. 2003; Morel et al. 2000). What stands out from these different studies is the necessity for the break in tolerance to chromatin, mediated by Sle1, for the development of pathogenic and systemic autoimmunity. Only the bicongenic combinations in which Sle1 is present (Sle1|Sle2, Sle1|Sle3/5 and Sle1|yaa) resulted in significant potentiation of autoimmunity, indicating that the breach in immune tolerance to chromatin mediated by Sle1 is key to the initiation of fatal autoimmunity in these models. G.
Epistatic Interactions in the Suppression of Pathogenic Autoimmunity
The importance of epistatic interactions in the development of autoimmunity is clearly exemplified by the amplified phenotypes elicited when different susceptibility loci are combined. The demonstration that Sle1, Sle2, and Sle3|5 are necessary and sufficient on the B6 background to reconstitute the fatal autoimmunity seen in NZM2410, while validating the results of the original linkage analysis, also begets an important question. Because Sle1, Sle3/5, and part of Sle2 are derived from the non-autoimmune NZW parent of NZM2410, why does the NZW strain not develop penetrant and fatal lupus nephritis? A genome wide analysis of [B6.Sle1 × NZW]F1 × NZW backcross progeny was conducted to identify putative, recessive epistatic suppressive modifiers. These analyses revealed four recessive Sles (SLE suppressor) loci: Sles1, Sles2, Sles3, and Sles4 on chromosomes 17, 4, 3, and 9, respectively, where B6/NZW heterozygosity was associated with increased susceptibility. Multivariate analysis of disease penetrance as a function of suppressive alleles supported the hypothesis that the cumulative effects of these four loci accounted for the lack of autoimmunity in NZW (Morel, Tian, et al. 1999).
LUPUS
251
The described linkage analyses identified the chromosome 17 locus, Sles1, as the strongest of the four suppressive modifier loci. Introgression of Sles1 onto B6.Sle1, B6.Sle2, and B6.Sle3/5 was performed, via marker-assisted selection, to test its ability to modulate the various phenotypes associated with each of the single congenics. Interestingly, Sles1 was able to completely suppress the anti-chromatin IgG autoAbs and increased B cell CD86 expression of Sle1, yet had no effect on the increased peritoneal cavity B1a/B2 ratio and anti-dsDNA IgG phenotypes of Sle2 and Sle3/5, respectively (Morel, Tian, et al. 1999). This result is consistent with the nature of the original linkage analysis, which was designed to identify suppressive modifiers in the context of Sle1 homozygosity. Impressively, when B6.Sle1|Sles1 is crossed to NZW, instead of the severe GN, high autoAb titers, and splenomegaly seen in [B6.Sle1 × NZW]F1 progeny, the mice have no autoimmune phenotypes (Morel, Tian, et al. 1999). These data indicate that homozygosity at Sles1 is sufficient to suppress the autoimmunity elicited by homozygosity at Sle1 in this particular lupus model and that Sles1 interacts specifically with Sle1. It is important to note, however, that in the BC1 progeny, a percentage of the mice that are NZW homozygous at Sles1 still develop fatal GN, again illustrating the importance of additional epistatic interactions in the modulation of these phenotypes. Furthermore, the lack of anti-dsDNA IgG suppression in the B6.Sle3/5|Sles1 bicongenic would indicate that Sles1 is not a global suppressor of humoral autoimmunity. Recently, fine mapping of Sles1 with truncated congenic intervals localized it to a ~956 kilobase segment of mouse chromosome 17, and classic genetic complementation tests suggested that the non-autoimmune 129/SvJ strain possesses a Sles1 allele complementary to NZW, as evidenced by the complete lack of autoimmunity in [129 × B6.Sle1|Sles1]F1 crosses (Subramanian et al. 2005).
IV.
INSIGHTS INTO LUPUS, PATHWAYS, AND EPISTASIS FROM GENETICALLY MANIPULATED MODELS
The ability to manipulate the mouse genome provides powerful tools with which to understand the functions of genes classically either via transgenic overexpression or genetic ablation. Such systems have provided tremendous insight into the requirements for the expression of different molecules in the development and functional responses of the various lineages and subsets of the immune system. The utility of such models in the analysis of SLE susceptibility would be expected to be more limited, as the causal mutations for such a complex genetic trait are predicted to be minor polymorphisms resulting in slightly altered function, rather than complete ablation or aberrantly high overexpression (Subramanian and Wakeland 2005).
252
SRIVIDYA
However, such knockouts and transgenics can provide insight into the requirement for certain molecules, such as cytokines, in the development of various phenotypes when introgressed onto spontaneously autoimmune strains, as has been reviewed in the previous sections. Interestingly, and somewhat surprisingly, a number of strains with targeted deletions of different molecules that are involved in a variety of cellular functions upon aging develop lupus-like phenotypes, such as GN and autoantibody production (Morel 2004). Although many reflect a legitimate alteration of the pathways leading to autoimmunity, recent work has demonstrated that in many cases these late-onset autoimmune phenotypes may be a consequence of epistatic interactions between the 129 genome, derived from the ES cell in which the targeted deletion was made, and that of B6, the strain that many of knockouts are bred onto. Further proof of this theory comes from the fact that the SLE phenotypes oftentimes disappear when moved onto pure backgrounds. In the next section, the various genes implicated by either knockout or transgenic technologies as influencing the development of systemic autoimmunity are organized according to pathways relevant to their function. Any evidence for the background genome having an impacting on the autoimmune effects is discussed as well. In addition, Table 11-2 provides information regarding their murine and human chromosomal locations, the strain of origin of the ES cell used (for knockouts), the background genome used, and any modulations in phenotypes observed when the genes are studied on different backgrounds.
A.
Antigen and Immune Complex Clearance
The components of the complement pathway play important roles in both the clearance of ICs and the determination of activation thresholds in lymphocytes. Hence, it has been postulated that complement deficiencies lead to an autoreactive B cell repertoire, perhaps due to altered peripheral tolerance (Carroll 1998). Although deficiencies in the early components of complement, C1q and C4, act in an almost monogenic fashion to mediate SLE in humans, the data from murine studies is less definitive and much more dependent on background genome effects (Manderson et al. 2004). The effects of c1q deficiency have been investigated on the B6/129 F2 and the pure 129, B6, and MRL (Fas intact) backgrounds, and these studies provide clear examples of background genome effects. On both the pure B6 and 129 backgrounds, c1q deficiency does not lead to either autoAb production or GN (Botto et al. 1998; Mitchell et al. 2002). However, c1q− B6/129 F2 mice developed both autoAbs (54%) and severe GN (25%), significantly higher than that seen in B6, 129, and wild-type (WT) B6/129 F2 controls. However, of the WT B6/129 F2 controls, 33% developed IgG autoAbs and 4% developed GN, both of which were not observed in the
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
parental B6 and 129 strains, clearly demonstrating the epistatic interactions occurring between these two genomes (Botto et al. 1998). On the autoimmune-prone MRL background, c1q deficiency led to increased mortality, GN, autoAb production, larger spleen weights, monocytosis, and increased B and T cell activation phenotypes, with a concomitant increase in plasma cells (Mitchell et al. 2002; Trendelenburg et al. 2004). These data illustrate that the lack of c1q serves to amplify an existing predisposition to autoimmunity. In the case of C4 deficiency, although the severity of the phenotypes varies, on all backgrounds some autoimmune phenotypes are present relative to appropriate controls. Compared with WT B6/129 F2 controls, C4−/− mice had ICmediated GN, elevated autoAb titers, splenomegaly, increased numbers of activated B and T cells, and increased CD11b+ percentages (Chen et al. 2000). When the effects of C4 deficiency on the B6, B6/129 F2, and [B6X129] F1 × BALB/c backgrounds were examined separately, in all cases, relative to WT controls, the C4-deficient mice had increased anti-dsDNA autoAbs (Paul et al. 2002). Serum amyloid P component (SAP) has been shown to bind, in a Ca2+-dependent manner, chromatin on the surface blebs of apoptotic cells and in nuclear debris (Casciola-Rosen et al. 1996; Cocca et al. 2002; Korb and Ahearn 1997; Nauta et al. 2002; Navratil et al. 2001). These functional data suggest that SAP could play an important role in efficient removal of key SLE self-antigens. The results of the targeted disruption of the Apcs gene, which encodes for SAP, are very similar to that seen for C1q: highly background-specific effects on lupus phenotypes. The first study examining Apcs−/− mice on the B6/129 F2 background, showed an increase in anti-chromatin and antidsDNA autoAbs and GN relative to WT F2 controls (Bickerstaff et al. 1999). A follow-up study examining the lack of SAP on the pure B6 and 129 backgrounds demonstrated that although on the B6 background Apcs−/− mice had increased autoAbs and increased incidence of GN (75%), there was no “lupus” phenotype on the 129 background. Furthermore, transgenic expression of human SAP did not prevent the development of the SLE phenotypes on the B6 background, suggesting that the mutation per se may not be causal (Gillmore et al. 2004). A second study examining the lack of SAP on B6/129 F2 progeny demonstrated that in WT F2 mice, if the chromosome 1 interval was fixed as 129 and compared with Apcs−/− mice of the same background, there were no differences in the antichromatin autoAbs between the two groups (Bygrave et al. 2004). These data clearly indicate that the chromosome 1 segment derived from 129 has the potential to mediate loss in tolerance to chromatin on the appropriate background, independent of the effects of targeted deletion of SAP. This finding was further supported by the break in tolerance to chromatin seen in two independently derived 129 chromosome 1 congenic lines on the B6 background (Bygrave et al. 2004; Wandstrat et al. 2004). As previously mentioned, this 129 interval includes
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
253
LUPUS
TABLE 11-2
SUBSET OF GENES IMPLICATED IN LUPUS SUSCEPTIBILITY THROUGH KNOCKOUT AND TRANSGENIC STRATEGIES Gene*
Protein
Mouse Chromosome†
Human Chromosome (Cytoband)
ES Cell‡
Ptprc Tnfsf6 Frcgr2b
CD45 FasL FcRII
1 (138.0) 1 (161.8) 1 (171.0)
1q31.3 1q24.3 1q23.3
129 — 129
Apcs
SAP
1 (173.0)
1q23.2
129
Rasgrp1 Bcl2l11 Mertk Sh2d2a Lyn E2f2 C1qa
RASgrp1 Bim C-mer TSAd E2F2 C1q
2(117.1) 2 (127.9) 2 (128.4) 3 (88.3) 4 (3.6) 4 (134.6) 4 (135.4)
15q14 2q13 2q13 1q23.1 8q12.1 1p36.12 1p36.12
129 129 129 129 129 129
Gadd45a Bhlhb2 Tnfrsf13b Prkcd
GADD45a Stra13 TACI PKCδ
6 (67.1) 6 (109.1) 11 (60.7) 14 (26.6)
1p31.2 3p26.1 17p11.2 3p21.1
129 129 129 129
Background Genome§
Autoimmune Phenotypes¶
129/B6 C3H/HeJ 129/B6 BALB/c (N12) B6 (N12) 129/B6 129 (N6) B6 (N6) 129/B6 129/B6 B6 (N10) B6 (N10) 129/B6
GN, autoAbs AutoAbs None None GN, autoAbs GN, autoAbs None GN, autoAbs GN, autoAbs GN, autoAbs AutoAbs GN, autoAbs GN, autoAbs GN, autoAbs GN, autoAbs None None GN, autoAbs GN, autoAbs GN, autoAbs GN, autoAbs GN, autoAbs
129/B6 B6 (N12) 129 (N12) MRL/+ (N12) 129/B6 129/B6 129/B6 129/B6
Listed by murine chromosomal locations are the various genes discussed in the text that have been implicated in lupus susceptibility through transgenic or knockout methods. *Genetically ablated or overexpressed genes. †Chromosomal positions of genes that were knocked out and enhancer/promoter-type used in transgenics. ‡Strain of ES cell line. —, spontaneous mutation; not applicable. §Background genome. (strain A/strain B): [strain A × strain B]F2; N(x): number of backcross generations if known. ¶Autoimmune phenotypes: none, GN, or autoAbs.
the same SLAM/CD2 family haplotype as that seen in Sle1b, demonstrating the functional equivalency of this region from both strains in mediating a humoral autoimmune phenotype. Intriguingly, the second F2 study demonstrated that in both WT and knockout F2 mice, a B6 interval on chromosome 17, encompassing the Sles1 region, had suggestive association with increased GN susceptibility (Bygrave et al. 2004). The facts that 129 and B6 share the same MHC haplotype (in particular, class II alleles) and that 129 mice are non-autoimmune despite an autoimmune-promoting SLAM/CD2 family haplotype provides further evidence that, like NZW, a suppressive modifier allele may be harbored within the 129 MHC region. Two other molecules for which roles in “antigen clearance” have been postulated to explain the lupus phenotypes seen in their absence are the nuclease DNase I and the membrane tyrosine kinase c-mer. DNase I is a nuclease expressed at sites of high cell turnover such as the gastrointestinal tract, skin, and hematopoietic system, and DnaseI-deficient B6/129 F2 mice developed higher levels of autoAbs than those observed in WT controls, whereas the incidence of GN was not significantly increased (Napirei et al. 2000). The effects of this mutation on
a pure background have not been reported. The membrane tyrosine kinase c-mer regulates macrophage cytokine profiles and indirectly binds phosphatidyl serine. On the B6 background, c-mer−/−mice had decreased in vitro and in vivo phagocytosis of apoptotic cells, increased titers of autoAbs of various specificities, and increased tumor necrosis factor (TNF)-α production (Cohen et al. 2002). This increase in proinflammatory cytokine production coupled with impaired apoptotic clearance may be responsible for the increased humoral autoimmune phenotype.
B.
Regulation of Proliferation and Apoptosis
Gadd45α (growth arrest and DNA damage-inducible) has roles in various cellular processes including cell growth and apoptosis, is regulated by the tumor suppressor gene p53, and is expressed in many tissues, including resting T cells. It also interacts with the cyclin-dependent kinase, p21, which is involved in the inhibition of cell cycle progression (Salvador et al. 2002, 2005). Targeted deletion of Gadd45α and p21, both on the B6/129 F2 background, revealed similar phenotypes
254
SRIVIDYA
including increased mortality, GN, and autoAb production, and these effects were exacerbated in the absence of both genes. Both knockouts had increased T cell numbers, but their responses to various T cell stimuli differed. Whereas Gadd45α−/− mice had increased proliferative responses to T cell receptor (TCR) stimulation in terms of both kinetics and magnitude, p21-mice had increased responses only to IL-2, and both phenotypes were seen in the double knockout. These data indicate that p21 and Gadd45α act to negatively regulate cytokineinduced and TCR-mediated T cell proliferation, respectively. Notably, they both normally act via inhibition of cell cycle progression, but not by increasing apoptosis. Neither targeted deletion affects the B cell compartment (Balomenos et al. 2000; Salvador et al. 2002). The protein tyrosine phosphatase Pten has been shown to play a role in proliferation, differentiation, and apoptosis. In the absence of Pten activity, there is increased activation of the survival-promoting factor protein kinase B (PKB/Akt) due to increased phosphatidylinositol 3-kinase (PI3K) activity. Although Pten-is an embryonic lethal mutation, it has been demonstrated that Pten haploinsufficiency on the B6/129 F2 background led to a severe lymphoproliferative disorder with increased mortality, IC-mediated GN, and increased autoAbs. These mice also had an expansion of splenic CD4 T cells and increased peripheral B and T cell activation and Fas expression, with impaired AICD and responsiveness to Fas stimulation (Di Cristofano et al. 1999). Furthermore, Pten deletion, specifically in either B or T cells, resulted in autoAb production, hypergammaglobulinemia, hyperproliferation, and resistance to apoptosis. Interestingly, lymphocyte-specific Pten deletion was not reported to result in increased GN (Suzuki et al. 2001, 2003). Consistent with the idea that increased cell survival mediated by the PI3K/Akt axis can increase susceptibility to autoimmunity was the demonstration that T cell—specific expression of a constitutively active form of PI3K led to IC-mediated GN, autoAbs, and an expansion of the CD4 compartment. These T cells developed an effector memory phenotype and in vitro display increased survival and decreased cell death (Borlado et al. 2000). More recently, in vivo inhibition of PI3Kγ was shown to increase survival in the MRL.lpr mouse strain (Barber et al. 2005). Protein kinase Cd (PKCd) has been shown to be involved in apoptosis and the inhibition of cell differentiation and growth, and PKCd deficiency on the B6/129 F2 background led to GN and autoAb production. Pkcd−/−mice had an expansion in their peripheral B cell population, and B cells in vitro displayed increased proliferative potential and IL-6 production (Miyamoto et al. 2002). Similarly, genetic ablation of a member of the E2F family, E2F2, involved in regulation of the cell cycle, differentiation, and apoptosis, resulted in GN, splenomegaly, and serum autoAbs on the B6/129 F2 background. T cells from E2f−/− mice showed increased proliferation in vivo and in vitro, with no change in responses to apoptotic stimuli. A matter of some concern regarding the studies on
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
the E2f−/− mice is the fact that the authors reported WT F2 spleen weights in excess of 650 mg by 8–12 weeks of age, making interpretation of “splenomegaly” a difficult issue (Murga et al. 2001). Members of the Bcl2 family of molecules have also been implicated in dysregulation of apoptotic processes in lupus. Transgenic overexpression of the cell survival–promoting Bcl2 in B cells led to IC-mediated GN and serum autoAbs, with B cell accumulation in the BM and periphery. Interestingly, these B cells had a quiescent phenotype indicative of increased survival but not proliferation (Strasser et al. 1991). Similarly, the absence of Bim, a proapoptotic member of the Bcl2 family, on the B6/129 F2 background, resulted in GN, splenomegaly, and autoAbs, with elevated numbers of both B and T cells (Bouillet et al. 1999).
C.
Lymphocyte Signaling
Early indications that aberrations in proximal signaling molecules can influence the development of autoimmunity came from studies of mice deficient in the Src family protein tyrosine kinase (PTK) Lyn. Despite a significant reduction in peripheral B cells and impairment in B cell receptor (BCR)–mediated signaling, Lyn−/− mice developed GN, splenomegaly, IgG autoAbs, and increased total IgM and numbers of plasma cells (Hibbs et al. 1995; Nishizumi et al. 1995). Additional deletion of another Src family PTK, Fyn, resulted in decreased survival, presumably due to the increased kidney disease seen in the double knockout (Yu et al. 2001). For the receptor protein tyrosine phosphatase CD45, targeted knockin of a mutation that prevents negative regulation of CD45 signaling, led to IC-mediated GN, splenomegaly, and serum autoAbs in an allele dose-dependent fashion, with concomitant activation of both B and T cells (Majeti et al. 2000). These data suggest that the lack of the inhibitory functions normally mediated by these molecules can result in the development of systemic autoimmunity on the appropriate genetic background. The impact of deficiency in the inhibitory Fcγ receptor, FcγRIIb, on the development of autoimmunity, has a highly background-dependent effect. On the mixed B6/129 F2 and on the pure BALB/c backgrounds, FcγrIIb−/− mice did not develop autoimmunity. However, on a pure B6 background FcγRIIb deficiency led to mortality, GN, splenomegaly, and autoAb production, as well as an activated lymphocyte population. In fact, with the exception of mortality and GN, B6.FcgrIIb−/− mice had phenotypes almost identical to that seen for B6.Sle1b (Bolland and Ravetch 2000). The FcγR gene cluster is just proximal to the SLAM/CD2 family on chromosome 1, and 129 shares the same haplotype as that seen in Sle1b (Wandstrat et al. 2004). It is hence tempting to speculate that the increased mortality and GN seen in B6.FcgrIIb−/− mice is a consequence of the lack of the inhibitory FcγRIIb in the context of the
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
predisposition to humoral autoimmunity conferred by the SLAM/CD2 haplotype. The importance of expression levels of FcγRIIb in maintaining peripheral tolerance, however, was revealed in a recent report. In these studies, it was shown that a modest increase in the levels of FcγRIIb on B cells, using retroviral transduction, ameliorated the pathogenic and humoral phenotypes seen in NZM2410, BXSB.yaa, and B6.FcgrIIb−/− mice (McGaha et al. 2005). Deficiencies in molecules that function downstream of initial signal transduction events have also been implicated in predisposition to lupus-like autoimmunity. Mice that lack the T cell adaptor molecule (TSAd), which is expressed in thymocytes and activated T cells, and mice deficient in the transcriptional repressor Stra13, normally induced upon naïve T cell activation, both developed with age IC-mediated GN, splenomegaly, and autoAb production. In addition, both knockouts showed increased T and B cell activation phenotypes and impaired AICD, IL-2, and IFN-γ induction in activated T cells (Drappa et al. 2003; Sun et al. 2001). T cells from young Stra13−/− mice were also shown to have impaired proliferative and cytokine responses in vitro and in vivo (Sun et al. 2001). Mice with a spontaneous deficiency in the Ras guanidine nucleotide exchange factor, Rasgrp1, which normally serves to activate Ras after TCR stimulation, also developed the characteristic lupus phenotypes of GN, splenomegaly, and autoAbs. Interestingly, Rasgrp−/−mice were shown to have impaired thymic development that prevented selection of low-affinity TCRs, yet showed an accumulation of splenic effector memory CD4 T cells with reduced numbers of CD8 T cells. This finding is in accordance with data showing that low-affinity TCRs are highly dependent on Rasgrp1 signals for positive selection and suggests that in its absence only high-affinity TCRs undergo positive selection (Layer et al. 2003). The phenotypes of Rasgrp−/− mice are, in fact, very similar to those seen for knockin mice with a point mutation in LAT (Y136F) that disrupts PLCγ activation upon TCR signaling (Aguado et al. 2002; Sommers et al. 2002). Recently, members of the TNF superfamily of ligands and receptors have also emerged as modulators of systemic autoimmunity. Transgenic overexpression of BLyS, a potent B cell–activating cytokine, both in a ubiquitous and in a B cell–specific manner, resulted in the characteristic murine lupus phenotypes of GN, splenomegaly, and autoAb production. Although there were no gross changes in B cell development, there was increased in vivo B cell numbers and in vitro B cell viability in BLyS transgenic mice (Gross et al. 2000; Khare et al. 2000). Consistent with the idea that overexpression of BLyS and consequent B cell activation can result in murine lupus phenotypes, deficiency in the inhibitory receptor for BLyS-mediated signaling, TACI, expressed on B cells and CD4 T cells, resulted in murine lupus. In addition to decreased survival, GN, splenomegaly, and autoAbs, TACI−/− mice had increased B cell percentages and in vitro proliferative responses and Ig secretion
255
LUPUS
(Seshasayee et al. 2003). These studies again emphasize the importance of appropriate inhibition of signaling in the prevention of autoimmunity. Studies have also provided evidence for the idea that subtle modulations in the expression of key signaling molecules can facilitate the development of systemic autoimmunity. CD19 is a BCR coreceptor that undergoes rapid tyrosine phosphorylation upon BCR engagement, allowing it to interact with a variety of downstream signaling molecules. A transgenic line that overexpresses CD19 by just 20% was shown to develop humoral autoimmunity in the absence of GN, with titers of IgG autoAbs comparable to that seen in a line overexpressing two times the normal levels of CD19. Significantly, this small increase in CD19 expression did not result in detectable alterations in phosphorylation patterns of downstream signaling molecules or any changes in B cell numbers or percentages (Sato et al. 2000).
V.
CONCLUSIONS
The various murine lupus models have provided great insight into the many immune irregularities underlying lupus, and, cumulatively, the data suggest a multistep genetic pathway for the development of systemic autoimmunity, as illustrated in Fig. 11-1. This model postulates that a key step for the initiation and development of pathogenic autoimmunity is mediated by loci such as the Sle1a–c subloci, all of which cause a loss in tolerance to chromatin and are associated with minimal pathogenicity. It is believed that these loci modulate immune cell interactions, antigen clearance, and response to antigen. These effects can be considered to be similar to the phenotype of seropositivity seen in first-degree relatives of SLE probands. Genes such as Sle2, Sle3/5, lpr, and yaa amplify and interact with the pathways modulated by the “first-step” genes, via unknown mechanisms, resulting in the development of pathogenic autoimmunity. It may be postulated that the genes encoded by these loci could contribute to overall immune responsiveness and these particular allelic variants result in slightly dysregulated immune function on a non-autoimmune-prone background. The final class of susceptibility genes, such as Sle1d, Sle6, IFNα, and FcγrIIb, are believed to potentiate end-organ damage, via a variety of mechanisms such as a modification of effector functions, an increase in inflammatory processes, or an alteration of end-organ susceptibility. This last class of genes may be responsible for the wide diversity in clinical end-organ pathogenesis seen in human lupus patients. This lupus model provides a framework with which to interpret the genetic interactions that progressively increase disease pathogenesis in mouse model systems. The remaining questions focus on the identification of the specific disease alleles and the characterization of the molecular mechanisms responsible for driving disease. Although identification of the disease-causing genes still
256
SRIVIDYA
Susceptible Individuals Pathway 1 Chronic lymphocytic activation
Sle1b, Sle1c, Roquim
Sles1, Sles2, Sles3
Anti-nuclear Autoantibodies 2-4% of population ANA positive Familial aggregation
Pathway 2 Disruption of immune regulation
Sle2, Sle3, Fas Yaa, Lyn - SHP- 1
Sles1
Pathogenic Autoimmunity Familial aggregation
Pathway 3 End-organ targeting
FcRIIb, Sle1d, IFNα nephritis
neurologic disorders
arthritis
vasculitis
Fig. 11-1 Model pathway demonstrating the interactions of potentiating and suppressive genes leading to systemic autoimmunity. We postulate that genes involved in mediating susceptibility to SLE have an impact on one or more of the three pathways shown in the figure. The epistatic interactions between these loci, which can be potentiating or suppressive, culminate in the development of systemic autoimmunity. Adapted from Wakeland et al. 2001.
remains a challenge, advances in technology and the persistent efforts of many investigators are beginning to break down the major obstacles of positional cloning strategies. As disease alleles are identified in mouse models of systemic autoimmunity, this new information will undoubtedly increase our understanding of disease progression in humans. REFERENCES Aguado, E., Richelme, S., Nunez-Cruz, S., Miazek, A., Mura, A.M., Richelme, M., et al. (2002). Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science 296, 2036–2040. Atencio, S., Amano, H., Izui, S., Kotzin, B.L. (2004). Separation of the New Zealand Black genetic contribution to lupus from New Zealand Black determined expansions of marginal zone B and B1a cells. J Immunol 172, 4159–4166. Balomenos, D., Martin-Caballero, J., Garcia, M.I., Prieto, I., Flores, J.M., Serrano, M., et al. (2000). The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 6, 171–176. Banchereau, J., Pascual, V., Palucka, A.K. (2004). Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20, 539–550. Barber, D.F., Bartolome, A., Hernandez, C., Flores, J.M., Redondo, C., FernandezArias, C., et al. (2005). PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11, 933–935. Bickerstaff, M.C., Botto, M., Hutchinson, W.L., Herbert, J., Tennent, G.A., Bybee, A., et al. (1999). Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5, 694–697. Boackle, S.A., Holers, V.M., Chen, X., Szakonyi, G., Karp, D.R., Wakeland, E.K., et al. (2001). Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15, 775–785. Bolland, S., Ravetch, J.V. (2000). Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277–285.
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
Borlado, L.R., Redondo, C., Alvarez, B., Jimenez, C., Criado, L.M., Flores, J., et al. (2000). Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 14, 895–903. Botto, M., Dell’Agnola, C., Bygrave, A.E., Thompson, E.M., Cook, H.T., Petry, F., et al. (1998). Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19, 56–59. Bouillet, P., Metcalf, D., Huang, D.C., Tarlinton, D.M., Kay, T.W., Kontgen, F., et al. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735–1738. Bygrave, A.E., Rose, K.L., Cortes-Hernandez, J., Warren, J., Rigby, R.J., Cook, H.T., et al. (2004). Spontaneous autoimmunity in 129 and C57BL/6 mice–implications for autoimmunity described in gene-targeted mice. PLoS Biol 2, E243. Carroll, M.C. (1998). The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 16, 545–568. Casciola-Rosen, L., Rosen, A., Petri, M., Schlissel, M. (1996). Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 93, 1624–1629. Chen, Z., Koralov, S.B., Kelsoe, G. (2000). Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J Exp Med 192, 1339–1352. Chowdhury, B., Tsokos, C.G., Krishnan, S., Robertson, J., Fisher, C.U., Warke, R.G., et al. (2005). Decreased stability and translation of T cell receptor ζ mRNA with an alternatively spliced 3’-untranslated region contribute to ζ chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem 280, 18959–18966. Chu, E.B., Ernst, D.N., Hobbs, M.V., Weigle, W.O. (1994). Maturational changes in CD4+ cell subsets and lymphokine production in BXSB mice. J Immunol 152, 4129–4138. Chu, E.B., Hobbs, M.V., Wilson, C.B., Romball, C.G., Linsley, P.S., Weigle, W.O. (1996). Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J Immunol 156, 1262–1268. Cocca, B.A., Cline, A.M., Radic, M.Z. (2002). Blebs and apoptotic bodies are B cell autoantigens. J Immunol 169, 159–166. Cohen, P.L., Caricchio, R., Abraham, V., Camenisch, T.D., Jennette, J.C., Roubey, R.A., et al. (2002). Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 196, 135–140. Crispin, J.C., Alcocer-Varela, J. (1998). Interleukin-2 and systemic lupus erythematosus—fifteen years later. Lupus 7, 214–222. Croker, B.P., Gilkeson, G., Morel, L. (2003). Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. Genes Immun 4, 575–585. DesJardin, L.E., Butfiloski, E.J., Sobel, E.S., Schiffenbauer, J. (1996). Hyperproliferation of BXSB B cells is linked to the Yaa allele. Clin Immunol Immunopathol 81, 145–152. Di Cristofano, A., Kotsi, P., Peng, Y.F., Cordon-Cardo, C., Elkon, K.B., Pandolfi, P.P. (1999). Impaired Fas response and autoimmunity in Pten+/− mice. Science 285, 2122–2125. Drake, C.G., Babcock, S.K., Palmer, E., Kotzin, B.L. (1994). Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB × NZW)F1 mice. Proc Natl Acad Sci USA 91, 4062–4066. Drake, C.G., Rozzo, S.J., Hirschfeld, H.F., Smarnworawong, N.P., Palmer, E., Kotzin, B.L. (1995). Analysis of the New Zealand Black contribution to lupus-like renal disease: multiple genes that operate in a threshold manner. J Immunol 154, 2441–2447. Drake, C.G., Rozzo, S.J., Vyse, T.J., Palmer, E., Kotzin, B.L. (1995). Genetic contributions to lupus-like disease in (NZB × NZW)F1 mice. Immunol Rev 144, 51–74.
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
Drappa, J., Kamen, L.A., Chan, E., Georgiev, M., Ashany, D., Marti, F., et al. (2003). Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice. J Exp Med 198, 809–821. Erickson, L.D., Lin, L.L., Duan, B., Morel, L., Noelle, R.J. (2003). A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci USA 100, 12905–12910. Fossati, L., Sobel, E.S., Iwamoto, M., Cohen, P.L., Eisenberg, R.A., Izui, S. (1995). The Yaa gene-mediated acceleration of murine lupus: Yaa-T cells from non-autoimmune mice collaborate with Yaa+ B cells to produce lupus autoantibodies in vivo. Eur J Immunol 25, 3412–3417. Gillmore, J.D., Hutchinson, W.L., Herbert, J., Bybee, A., Mitchell, D.A., Hasserjian, R.P., et al. (2004). Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? Immunology 112, 255–264. Gross, J.A., Johnston, J., Mudri, S., Enselman, R., Dillon, S.R., Madden, K., et al. (2000). TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995–999. Gu, L., Weinreb, A., Wang, X.P., Zack, D.J., Qiao, J.H., Weisbart, R., et al. (1998). Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus. J Immunol 161, 6999–7006. Haywood, M.E., Rogers, N.J., Rose, S.J., Boyle, J., McDermott, A., Rankin, J.M., et al. (2004). Dissection of BXSB lupus phenotype using mice congenic for chromosome 1 demonstrates that separate intervals direct different aspects of disease. J Immunol 173, 4277–4285. Hibbs, M.L., Tarlinton, D.M., Armes, J., Grail, D., Hodgson, G., Maglitto, R., et al. (1995). Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83, 301–311. Hirose, S., Tsurui, H., Nishimura, H., Jiang, Y., Shirai, T. (1994). Mapping of a gene for hypergammaglobulinemia to the distal region on chromosome 4 in NZB mice and its contribution to systemic lupus erythematosus in (NZB × NZW)F1 mice. Int Immunol 6, 1857–1864. Hoffman, R.W. (2004). T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 113, 4–13. Hron, J.D., Peng, S.L. (2004). Type I IFN protects against murine lupus. J Immunol 173, 2134–2142. Hudgins, C.C., Steinberg, R.T., Klinman, D.M., Reeves, M.J., Steinberg, A.D. (1985). Studies of consomic mice bearing the Y chromosome of the BXSB mouse. J Immunol 134, 3849–3854. Ishikawa, S., Sato, T., Abe, M., Nagai, S., Onai, N., Yoneyama, H., et al. (2001). Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 193, 1393–1402. Ito, T., Ishikawa, S., Sato, T., Akadegawa, K., Yurino, H., Kitabatake, M., et al. (2004). Defective B1 cell homing to the peritoneal cavity and preferential recruitment of B1 cells in the target organs in a murine model for systemic lupus erythematosus. J Immunol 172, 3628–3634. Jorgensen, T.N., Gubbels, M.R., Kotzin, B.L. (2004). New insights into disease pathogenesis from mouse lupus genetics. Curr Opin Immunol 16, 787–793. Juang, Y.T., Wang, Y., Solomou, E.E., Li, Y., Mawrin, C., Tenbrock, K., et al. (2005). Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 115, 996–1005. Kamogawa, J., Terada, M., Mizuki, S., Nishihara, M., Yamamoto, H., Mori, S., et al. (2002). Arthritis in MRL/lpr mice is under the control of multiple gene loci with an allelic combination derived from the original inbred strains. Arthritis Rheum 46, 1067–1074. Kamogawa, J., Terada, M., Nishihara, M., Mizuki, S., Mori, S., Nakatsuru, S., et al. (1999). Susceptibility loci to autoimmune arthritis in MRL/lpr mice. Nihon Rinsho Meneki Gakkai Kaishi 22, 487–490. Kelley, V.E., Roths, J.B. (1985). Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol 37, 220–229.
LUPUS
257
Kevil, C.G., Hicks, M.J., He, X., Zhang, J., Ballantyne, C.M., Raman, C., et al. (2004). Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Faslpr mice from autoimmune disease. Am J Pathol 165, 609–616. Khare, S.D., Sarosi, I., Xia, X.Z., McCabe, S., Miner, K., Solovyev, I., et al. (2000). Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97, 3370–3375. Kikawada, E., Lenda, D.M., Kelley, V.R. (2003). IL-12 deficiency in MRLFaslpr mice delays nephritis and intrarenal IFN-γ expression, and diminishes systemic pathology. J Immunol 170, 3915–3925. Kikuchi, S., Fossati-Jimack, L., Moll, T., Amano, H., Amano, E., Ida, A., et al. (2005). Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis. J Immunol 174, 1111–1117. Kono, D.H., Burlingame, R.W., Owens, D.G., Kuramochi, A., Balderas, R.S., Balomenos, D., et al. (1994). Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 91, 10168–10172. Korb, L.C., Ahearn, J.M. (1997). C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 158, 4525–4528. Lawson, B.R., Baccala, R., Song, J., Croft, M., Kono, D.H., Theofilopoulos, A.N. (2004). Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1). promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J Exp Med 199, 547–557. Lawson, B.R., Koundouris, S.I., Barnhouse, M., Dummer, W., Baccala, R., Kono, D.H., et al. (2001). The role of αβ+ T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus. J Immunol 167, 2354–2360. Layer, K., Lin, G., Nencioni, A., Hu, W., Schmucker, A., Antov, A.N., et al. (2003). Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity 19, 243–255. Lenda, D.M., Stanley, E.R., Kelley, V.R. (2004). Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Faslpr mice. J Immunol 173, 4744–4754. Liang, B., Gee, R.J., Kashgarian, M.J., Sharpe, A.H., Mamula, M.J. (1999). B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies. J Immunol 163, 2322–2329. Lin, L., Peng, S.L. (2005). Interleukin-18 receptor signaling is not required for autoantibody production and end-organ disease in murine lupus. Arthritis Rheum 52, 984–986. Lipsky, P.E. (2001). Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2, 764–766. Majeti, R., Xu, Z., Parslow, T.G., Olson, J.L., Daikh, D.I., Killeen, N., et al. (2000). An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103, 1059–1070. Manderson, A.P., Botto, M., Walport, M.J. (2004). The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22, 431–456. Matsumoto, K., Watanabe, N., Akikusa, B., Kurasawa, K., Matsumura, R., Saito, Y., et al. (2003). Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum 48, 486–494. McGaha, T.L., Sorrentino, B., Ravetch, J.V. (2005). Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590–593. Merino, R., Fossati, L., Lacour, M., Izui, S. (1991). Selective autoantibody production by Yaa+ B cells in autoimmune Yaa+-Yaa-bone marrow chimeric mice. J Exp Med 174, 1023–1029. Merino, R., Iwamoto, M., Gershwin, M.E., Izui, S. (1994). The Yaa gene abrogates the major histocompatibility complex association of murine lupus in (NZB × BXSB)F1 hybrid mice. J Clin Invest 94, 521–525. Mihara, M., Tan, I., Chuzhin, Y., Reddy, B., Budhai, L., Holzer, A., et al. (2000). CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 106, 91–101.
258
SRIVIDYA
Mitchell, D.A., Pickering, M.C., Warren, J., Fossati-Jimack, L., Cortes-Hernandez, J., Cook, H.T., et al. (2002). C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 168, 2538–2543. Miwa, T., Maldonado, M.A., Zhou, L., Sun, X., Luo, H.Y., Cai, D., et al. (2002). Deletion of decay-accelerating factor (CD55). exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 161, 1077–1086. Miyamoto, A., Nakayama, K., Imaki, H., Hirose, S., Jiang, Y., Abe, M., et al. (2002). Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature 416, 865–869. Mohan, C., Alas, E., Morel, L., Yang, P., Wakeland, E.K. (1998). Genetic dissection of SLE pathogenesis: Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 101, 1362–1372. Mohan, C., Morel, L., Yang, P., Wakeland, E.K. (1997). Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 159, 454–465. Mohan, C., Morel, L., Yang, P., Watanabe, H., Croker, B., Gilkeson, G., et al. (1999). Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest 103, 1685–1695. Mohan, C., Yu, Y., Morel, L., Yang, P., Wakeland, E.K. (1999). Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 162, 6492–6502. Mooney, J.M., Klem, J., Wulfing, C., Mijares, L.A., Schwartzberg, P.L., Bennett, M., et al. (2004). The murine NK receptor 2B4 (CD244). exhibits inhibitory function independent of signaling lymphocytic activation molecule-associated protein expression. J Immunol 173, 3953–3961. Morel, L. (2004). Mouse models of human autoimmune diseases: essential tools that require the proper controls. PLoS Biol 2, E241. Morel, L., Blenman, K.R., Croker, B.P., Wakeland, E.K. (2001). The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci USA 98, 1787–1792. Morel, L., Croker, B.P., Blenman, K.R., Mohan, C., Huang, G., Gilkeson, G., et al. (2000). Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci USA 97, 6670–6675. Morel, L., Mohan, C., Yu, Y., Croker, B.P., Tian, N., Deng, A., et al. (1997). Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 158, 6019–6028. Morel, L., Mohan, C., Yu, Y., Schiffenbauer, J., Rudofsky, U.H., Tian, N., et al. (1999). Multiplex inheritance of component phenotypes in a murine model of lupus. Mamm Genome 10, 176–181. Morel, L., Rudofsky, U.H., Longmate, J.A., Schiffenbauer, J., Wakeland, E.K. (1994). Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1, 219–229. Morel, L., Tian, X.H., Croker, B.P., Wakeland, E.K. (1999). Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity 11, 131–139. Morel, L., Wakeland, E.K. (1998). Susceptibility to lupus nephritis in the NZB/W model system. Curr Opin Immunol 10, 718–725. Morito, N., Yoh, K., Hirayama, A., Itoh, K., Nose, M., Koyama, A., et al. (2004). NrF2 deficiency improves autoimmune nephritis caused by the fas mutation lpr. Kidney Int 65, 1703–1713. Murga, M., Fernandez-Capetillo, O., Field, S.J., Moreno, B., Borlado, L.R., Fujiwara, Y., et al. (2001). Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 15, 959–970. Nakatsuru, S., Terada, M., Nishihara, M., Kamogawa, J., Miyazaki, T., Qu, W.M., et al. (1999). Genetic dissection of the complex pathological manifestations of collagen disease in MRL/lpr mice. Pathol Int 49, 974–982. Napirei, M., Karsunky, H., Zevnik, B., Stephan, H., Mannherz, H.G., Moroy, T. (2000). Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25, 177–181.
SUBRAMANIAN
AND
EDWARD
K.
WAKELAND
Nauta, A.J., Trouw, L.A., Daha, M.R., Tijsma, O., Nieuwland, R., Schwaeble, W.J., et al. (2002). Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 32, 1726–1736. Navratil, J.S., Watkins, S.C., Wisnieski, J.J., Ahearn, J.M. (2001). The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 166, 3231–3239. Nishihara, M., Terada, M., Kamogawa, J., Ohashi, Y., Mori, S., Nakatsuru, S., et al. (1999). Genetic basis of autoimmune sialadenitis in MRL/lpr lupusprone mice: additive and hierarchical properties of polygenic inheritance. Arthritis Rheum 42, 2616–2623. Nishizumi, H., Taniuchi, I., Yamanashi, Y., Kitamura, D., Ilic, D., Mori, S., et al. (1995). Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 3, 549–560. Paul, E., Pozdnyakova, O.O., Mitchell, E., Carroll, M.C. (2002). Anti-DNA autoreactivity in C4-deficient mice. Eur J Immunol 32, 2672–2679. Rioux, J.D., Abbas, A.K. (2005). Paths to understanding the genetic basis of autoimmune disease. Nature 435, 584–589. Robey, I.F., Peterson, M., Horwitz, M.S., Kono, D.H., Stratmann, T., Theofilopoulos, A.N., et al. (2004). Terminal deoxynucleotidyltransferase deficiency decreases autoimmune disease in diabetes-prone nonobese diabetic mice and lupus-prone MRL-Faslpr mice. J Immunol 172, 4624–4629. Rozzo, S.J., Allard, J.D., Choubey, D., Vyse, T.J., Izui, S., Peltz, G., et al. (2001). Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 15, 435–443. Rozzo, S.J., Vyse, T.J., David, C.S., Palmer, E., Izui, S., Kotzin, B.L. (1999). Analysis of MHC class II genes in the susceptibility to lupus in New Zealand mice. J Immunol 162, 2623–2630. Rozzo, S.J., Vyse, T.J., Drake, C.G., Kotzin, B.L. (1996). Effect of genetic background on the contribution of New Zealand Black loci to autoimmune lupus nephritis. Proc Natl Acad Sci USA 93, 15164–15168. Salvador, J.M., Hollander, M.C., Nguyen, A.T., Kopp, J.B., Barisoni, L., Moore, J.K., et al. (2002). Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16, 499–508. Salvador, J.M., Mittelstadt, P.R., Belova, G.I., Fornace, A.J., Jr., Ashwell, J.D. (2005). The autoimmune suppressor Gadd45α inhibits the T cell alternative p38 activation pathway. Nat Immunol 6, 396–402. Santiago, M.L., Mary, C., Parzy, D., Jacquet, C., Montagutelli, X., Parkhouse, R.M., et al. (1998). Linkage of a major quantitative trait locus to Yaa gene-induced lupus-like nephritis in (NZW × C57BL/6)F1 mice. Eur J Immunol 28, 4257–4267. Sato, S., Hasegawa, M., Fujimoto, M., Tedder, T.F., Takehara, K. (2000). Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165, 6635–6643. Sato, T., Ishikawa, S., Akadegawa, K., Ito, T., Yurino, H., Kitabatake, M., et al. (2004). Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur J Immunol 34, 3346–3358. Schwarting, A., Wada, T., Kinoshita, K., Tesch, G., Kelley, V.R. (1998). IFN-γ receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Faslpr mice. J Immunol 161, 494–503. Seshasayee, D., Valdez, P., Yan, M., Dixit, V.M., Tumas, D., Grewal, I.S. (2003). Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18, 279–288. Sobel, E.S., Mohan, C., Morel, L., Schiffenbauer, J., Wakeland, E.K. (1999). Genetic dissection of SLE pathogenesis: adoptive transfer of Sle1 mediates the loss of tolerance by bone marrow-derived B cells. J Immunol 162, 2415–2421. Sobel, E.S., Morel, L., Baert, R., Mohan, C., Schiffenbauer, J., Wakeland, E.K. (2002). Genetic dissection of systemic lupus erythematosus pathogenesis: evidence for functional expression of Sle3/5 by non-T cells. J Immunol 169, 4025–4032. Sobel, E.S., Satoh, M., Chen, Y., Wakeland, E.K., Morel, L. (2002). The major murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal functions of both B and T cells. J Immunol 169, 2694–2700.
11. THE
GENETICS
OF
MOUSE
MODELS
OF
SYSTEMIC
Sommers, C.L., Park, C.S., Lee, J., Feng, C., Fuller, C.L., Grinberg, A., et al. (2002). A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science 296, 2040–2043. Strasser, A., Whittingham, S., Vaux, D.L., Bath, M.L., Adams, J.M., Cory, S., Harris, A.W. (1991). Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88, 8661–8665. Subramanian, S., Wakeland, E.K. (2005). The importance of epistatic interactions in the development of autoimmunity. In The Genetics of Autoimmunity, pp. 76–93. Wiley, Chichester, UK. Subramanian, S., Yim, Y.S., Liu, K., Tus, K., Zhou, X.J., Wakeland, E.K. (2005). Epistatic suppression of systemic lupus erythematosus: fine-mapping of Sles1 to less than 1 Mb. J Immunol 175, 1062–1072. Sun, H., Lu, B., Li, R.Q., Flavell, R.A., Taneja, R. (2001). Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nat Immunol 2, 1040–1047. Suzuki, A., Kaisho, T., Ohishi, M., Tsukio-Yamaguchi, M., Tsubata, T., Koni, P.A., et al. (2003). Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 197, 657–667. Suzuki, A., Yamaguchi, M.T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., et al. (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523–534. Tada, Y., Nagasawa, K., Ho, A., Morito, F., Koarada, S., Ushiyama, O., et al. (1999). Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. J Immunol 163, 3153–3159. Trendelenburg, M., Manderson, A.P., Fossati-Jimack, L., Walport, M.J., Botto, M. (2004). Monocytosis and accelerated activation of lymphocytes in C1q-deficient autoimmune-prone mice. Immunology 113, 80–88. Tucker, R.M., Vyse, T.J., Rozzo, S., Roark, C.L., Izui, S., Kotzin, B.L. (2000). Genetic control of glycoprotein 70 autoantigen production and its influence on immune complex levels and nephritis in murine lupus. J Immunol 165, 1665–1672. Veillette, A., Latour, S. (2003). The SLAM family of immune-cell receptors. Curr Opin Immunol 15, 277–285. Vidal, S., Kono, D.H., Theofilopoulos, A.N. (1998). Loci predisposing to autoimmunity in MRL-Faslpr and C57BL/6-Faslpr mice. J Clin Invest 101, 696–702. Vratsanos, G.S., Jung, S., Park, Y.M., Craft, J. (2001). CD4+ T cells from lupusprone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J Exp Med 193, 329–337. Vyse, T.J., Drake, C.G., Rozzo, S.J., Roper, E., Izui, S., Kotzin, B.L. (1996). Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J Clin Invest 98, 1762–1772. Vyse, T.J., Halterman, R.K., Rozzo, S.J., Izui, S., Kotzin, B.L. (1999). Control of separate pathogenic autoantibody responses marks MHC gene contributions to murine lupus. Proc Natl Acad Sci USA 96, 8098–8103. Vyse, T.J., Kotzin, B.L. (1998). Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 16, 261–292. Vyse, T.J., Morel, L., Tanner, F.J., Wakeland, E.K., Kotzin, B.L. (1996). Backcross analysis of genes linked to autoantibody production in New Zealand White mice. J Immunol 157, 2719–2727. Vyse, T.J., Rozzo, S.J., Drake, C.G., Appel, V.B., Lemeur, M., Izui, S., et al. (1998). Contributions of Eaz and Ebz MHC genes to lupus susceptibility in New Zealand mice. J Immunol 160, 2757–2766. Vyse, T.J., Rozzo, S.J., Drake, C.G., Izui, S., Kotzin, B.L. (1997). Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand Black mice. J Immunol 158, 5566–5574. Wakeland, E.K., Liu, K., Graham, R.R., Behrens, T.W. (2001). Delineating the genetic basis of systemic lupus erythematosus. Immunity 15, 397–408. Wandstrat, A., Wakeland, E. (2001). The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2, 802–809.
LUPUS
259
Wandstrat, A.E., Nguyen, C., Limaye, N., Chan, A.Y., Subramanian, S., Tian, X.H., et al. (2004). Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 21, 769–780. Wang, N., Satoskar, A., Faubion, W., Howie, D., Okamoto, S., Feske, S., et al. (2004). The cell surface receptor SLAM controls T cell and macrophage functions. J Exp Med 199, 1255–1264. Watanabe, H., Garnier, G., Circolo, A., Wetsel, R.A., Ruiz, P., Holers, V.M., et al. (2000). Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164, 786–794. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., Nagata, S. (1992). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314–317. Watson, M.L., Rao, J.K., Gilkeson, G.S., Ruiz, P., Eicher, E.M., Pisetsky, D.S., Matsuzawa, A., et al. (1992). Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 176, 1645–1656. Wellmann, U., Letz, M., Schneider, A., Amann, K., Winkler, T.H. (2001). An Ig µ-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB × NZW)F1 mice. Int Immunol 13, 1461–1469. Wellmann, U., Werner, A., Winkler, T.H. (2001). Altered selection processes of B lymphocytes in autoimmune NZB/W mice, despite intact central tolerance against DNA. Eur J Immunol 31, 2800–2810. Wither, J.E., Paterson, A.D., Vukusic, B. (2000). Genetic dissection of B cell traits in New Zealand Black mice: the expanded population of B cells expressing up-regulated costimulatory molecules shows linkage to Nba2. Eur J Immunol 30, 356–365. Wither, J.E., Roy, V., Brennan, L.A. (2000). Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB × NZW)F1 mice. Clin Immunol 94, 51–63. Xiao, S., Sung, S.S., Fu, S.M., Ju, S.T. (2003). Combining Fas mutation with interleukin-2 deficiency prevents colitis and lupus: implicating interleukin-2 for autoreactive T cell expansion and Fas ligand for colon epithelial cell death. J Biol Chem 278, 52730–52738. Xie, S., Chang, S., Yang, P., Jacob, C., Kaliyaperumal, A., Datta, S.K., et al. (2001). Genetic contributions of nonautoimmune SWR mice toward lupus nephritis. J Immunol 167, 7141–7149. Xu, Z., Butfiloski, E.J., Sobel, E.S., Morel, L. (2004). Mechanisms of peritoneal B-1a cells accumulation induced by murine lupus susceptibility locus Sle2. J Immunol 173, 6050–6058. Xu, Z., Duan, B., Croker, B.P., Wakeland, E.K., Morel, L. (2005). Genetic dissection of the murine lupus susceptibility locus Sle2: contributions to increased peritoneal B-1a cells and lupus nephritis map to different loci. J Immunol 175, 936–943. Yin, Z., Bahtiyar, G., Zhang, N., Liu, L., Zhu, P., Robert, M.E., et al. (2002). IL-10 regulates murine lupus. J Immunol 169, 2148–2155. Yu, C.C., Yen, T.S., Lowell, C.A., DeFranco, A.L. (2001). Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr Biol 11, 34–38. Zhang, D., Fujio, K., Jiang, Y., Zhao, J., Tada, N., Sudo, K., et al. (2004). Dissection of the role of MHC class II A and E genes in autoimmune susceptibility in murine lupus models with intragenic recombination. Proc Natl Acad Sci USA 101, 13838–13843. Zhu, J., Liu, X., Xie, C., Yan, M., Yu, Y., Sobel, E.S., et al. (2005). T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest 115, 1869–1878. Zielinski, C.E., Jacob, S.N., Bouzahzah, F., Ehrlich, B.E., Craft, J. (2005). Naive CD4+ T cells from lupus-prone Fas-intact MRL mice display TCRmediated hyperproliferation due to intrinsic threshold defects in activation. J Immunol 174, 5100–5109.
This page intentionally left blank
Chapter 12 Inhibitory Receptors and Autoimmunity in the Mouse Menna R. Clatworthy and Kenneth G.C. Smith
I. II.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Inhibitory Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. IgG Fc Receptors—The Archetypal Activatory and Inhibitory Receptor Pair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III. Inhibitory Receptors and Autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . A. FcγRIIb and Autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Genetic Linkage Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. FcγRIIb Polymorphisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. FcγRIIb-Deficient Mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4. FcγRIIb and B Cell Tolerance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Inhibitory Receptors and B Cell Activation Thresholds . . . . . . . . . . . . 1. CD22 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. PD-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Inhibitory NK Receptors for MHC Class I . . . . . . . . . . . . . . . . . . . . . . 1. KIRs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Ly49 Natural Killer Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. T Cell Inhibitory Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. CTLA-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. BTLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Inhibitory Receptor Pathways and Autoimmunity . . . . . . . . . . . . . . . . . . . . A. Lyn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. SHP-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. SHIP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
262 262 263 264 264 264 265 265 265 267 267 267 268 268 268 268 268 269 269 269 269 270 270 271
Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
261
262
MENNA
I.
INTRODUCTION
The role of the immune system is to recognize and eliminate invading microorganisms. It has evolved a number of complex mechanisms to achieve this goal, which center on an ability to distinguish between self and non-self and to limit autoreactivity. Critical to its function is the capacity to rapidly mount a potentially lethal response to pathogens but yet to limit and terminate the relevant pathways when they are no longer required. Thus, the immune system has evolved activatory mechanisms that facilitate a rapid response that are counterbalanced by inhibitory pathways. Loss of inhibitory signaling pathways is associated with both autoreactivity and excessive inflammatory responses, emphasizing their critical role.
II.
INHIBITORY RECEPTORS
Paired activatory and inhibitory receptors have been identified on most cells of the immune system (Table 12-1). In B cells inhibitory receptors, including FcγRIIb, CD22, and CD72, downregulate B cell receptor (BCR)–triggered activation (Pritchard and Smith 2003). In addition, inhibitory motif–containing Fc receptor homologs (FcRHs) have been identified in B cells, although their role in inhibitory signaling remains to be characterized (Davis et al. 2001; Ehrhardt et al. 2003). Natural killer (NK) cells have major histocompatability (MHC)–recognizing receptors, such as killer cell immunoglobulin (Ig)-like receptors (KIRs) and lectin-like Ly49 receptors, which mediate the capacity of NK cells to preferentially kill targets lacking MHC class I (Chiesa et al. 2005). In T cells
R.
CLATWORTHY
AND
KENNETH
G.C.
SMITH
three inhibitory receptors that inhibit immune activation after binding to B7 family members, namely cytotoxic T lymphocyte–associated antigen-4 (CTLA-4), programmed death-1 (PD-1), and B and T lymphocyte attenuator (BTLA) have been identified (Chen 2004). The best-characterized activatoryinhibitory receptor pair is that of the activatory and inhibitory Fc receptors (FcRs) (Ravetch and Bolland 2001). The generation of the inhibitory Fc receptor (FcγRIIb)–deficient mouse nearly a decade ago has allowed the detailed characterization of inhibitory signaling pathways and the definition of several general paradigms for the class of inhibitory receptors as a whole; therefore, much of this chapter will focus on FcγRIIb. Two broad classes of inhibitory receptor exist—most are of the immunoglobulin superfamily whereas the remainder are lectin-like molecules. They share a number of structural and functional similarities and can be identified by a consensus amino acid sequence, the immunoreceptor tyrosine-based inhibitory motif (ITIM). Each inhibitory receptor contains one or more ITIMs within its cytoplasmic domain. The ITIM consists of a prototype six amino acid sequence, (Ile/Val/Leu/Ser)-X-Tyr-X-X-(Leu/Val), where X denotes any amino acid (Muta et al. 1994). Inhibitory receptors function to attenuate signals generated by activatory receptors, often those containing immunoreceptor tyrosine-based activation motifs (ITAMs) within their cytoplasmic domains, and mediate this function upon clustering with their activatory counterpart on the cell surface (Daeron, Malbec, et al. 1995). Ligation of the inhibitory receptor with an ITAM-containing activatory receptor results in phosphorylation of the tyrosine residue within the ITIM, often by a Src family kinase (Malbec et al. 1998). This allows binding and activation of phosphatases containing an Src homology 2 (SH2) domain. Two classes of SH2-containing inhibitory phosphatases have been identified; the tyrosine
TABLE 12–1
INHIBITORY RECEPTORS Inhibitory Receptor
Activatory Counterpart
Expression Pattern
Phenotype in Knockout Mouse
FcγRIIb CD22
FcγRI, III, IV FcεR, BCR BCR
B cells, macrophages, dendritic cells, mast cells, activated neutrophils B cells
PD-1
TCR, BCR
T cells, B cells, myeloid cells
CD72
BCR
B cells
PIR-B CD5 CTLA-4
BCR BCR CD28
B cells B1 cells T cells
BTLA KIRs Ly49 CD94/NK
TCR
Th1 cells, B cells NK cells NK cells NK cells/ T cells
Spontaneous SLE-like disease on C57BL/6 background Hyperactive B cells, development of autoantibodies, but no overt autoimmune disease Development of SLE-like disease and autoimmune dilatory cardiomyopathy Hyperactive B cells, no autoantibodies or autoimmune disease Hyperactive B cells, enhanced graft versus host disease Hyperactive B cells and autoantibodies Rapid infiltration of organs with T cells, autoimmunity No obvious spontaneous disease — — —
Ly49/DAP10
12. INHIBITORY
RECEPTORS
AND
AUTOIMMUNITY
phosphatases SHP-1 and SHP-2, and the phosphoinositol phosphatases SHIP1 and SHIP2 (Tamir et al. 2000). These classes have separate downstream signaling pathways through which they modulate cellular inhibition. In general, each class interacts with the ITIMs of different inhibitory receptors, but each inhibitory receptor appears to act predominantly through one class of phosphatase. A.
IgG Fc Receptors—The Archetypal Activatory and Inhibitory Receptor Pair
FcγRs are widely distributed cell surface molecules that recognize the Fc portion of IgG (Daeron 1997). There are three activatory FcγRs in mice, FcγRI (CD64), FcγRIII (CD16), and the recently described FcγRIV (CD16-2) (Nimmerjahn et al. 2005), which are multichain receptors made up of a ligandbinding FcR α subunit associated with one or two signal transduction subunits that contain ITAMs (Fig. 12-1). In humans, but not in mice, there is another FcγR activatory receptor, FcγRIIa, which is a single-chain receptor with an ITAM in its cytoplasmic domain. The inhibitory receptor FcγRIIb is a single-chain low-affinity IgG receptor and is found on B cells, monocytes, macrophages, activated neutrophils, and mast cells. Activatory
Inhibitory
Activatory
FcγRIIb
FcγRIII
FcγRI
s-s
+
s-s
+
+
−
+
+ +
γ chain
α chains
ε−γ chain+
Key Ig-like domain
+ ITIM
− ITIM
Fig. 12-1 Murine activatory and inhibitory FcγRs. FcγRs are members of the Ig superfamily, with variable numbers of disulfide-bonded immunoglobulin domains extracellularly. FcγRI and FcγRIII are activatory and are associated ITAM-containing accessory molecules such as γ chains. FcγRIIb is an inhibitory receptor containing a cytoplasmic ITIM.
IN
THE
MOUSE
263
It is a 40-kDa protein that consists of two extracellular Ig-like domains, a transmembrane domain, and a cytoplasmic domain that contains one ITIM (Latour et al. 1996) (Fig. 12-1). It binds to multivalent soluble antigen as immune complexes or to cell membranes. FcγRIIb is encoded by a single gene (Fcgr2b) on chromosome 1 in both humans (1q23–24) and mice (1 92.3) (Hogarth et al. 1991). Control of FcγRIIb transcription lies in two methylated regions in the promoter and in the intron between the two exons coding for the leader peptide (intron 3) (Bonnerot et al. 1992). Sequence analysis of the 5′-untranslated region (UTR) of the mouse FcγRIIb gene indicated the presence of regulatory elements including three binding sites for the transcription factor Sp1, an activator protein-4 (AP-4) binding site, and a tandem glucocorticoid response element upstream of the transcription initiation site. In addition, sites of methylation that regulate gene expression were also located at the 5′ end of the mouse FcγRIIb gene (Bonnerot et al. 1988; Hogarth et al. 1991). Several isoforms of the receptor are found on different cell types; in B cells FcγRIIb1 contains an intracytoplasmic motif that prevents its internalization whereas in myeloid cells FcγRIIb2 can mediate phagocytosis (Latour et al. 1996) FcγRIIb, when signaling through its cytoplasmic ITIM, functions to inhibit activatory signals generated through adjacent ITAM-containing activatory receptors (Muta et al. 1994). It has been shown in vitro to be capable of inhibiting ITAM signals from activatory Fc receptors, the BCR and the T cell receptor (TCR) (Daeron, Latour, et al. 1995; Muta et al. 1994). Coligation of FcγRIIb to the activatory receptor leads to tyrosine phosphorylation of the ITIM by the tyrosine kinase Lyn (Malbec et al. 1998). Once phosphorylated, FcγRIIb recruits the cytoplasmic phosphatase SHIP through its SH2 domain and activates it by phosphorylation(Ono et al. 1996). SHIP then inhibits ITAM activation signaling by dephosphorylation of phosphatidylinositol triphosphate (PIP3), which is the product of receptor activation (Ono et al. 1996). This leads to disassociation of Btk and phospholipase Cγ (PLCγ) from the activatory complex at the cell membrane, producing blockade of Ca2+ flux through the capacitancecoupled channel and inhibition of calcium dependent signaling (Bolland et al. 1998). Calcium-dependent processes such as degranulation, phagocytosis, antibody-dependent cellmediated cytotoxicity, and cytokine release are all blocked (Fig. 12-2). SHIP has a role in prevention of proliferation in B cells, but the precise mechanism remains uncertain. By dephosphorylation of PIP3, SHIP can prevent recruitment of the survival factor Akt (Liu et al. 1999). It also functions to recruit p62dok to the membrane where it is activated by Lyn to downregulate mitogen-activated protein (MAP) kinase activity (Yamanashi et al. 2000). These two FcγRIIb-mediated inhibitory effects on Ca2+-dependent signaling and prevention of proliferation appear to be independent, since FcγRIIb in dok-deficient B cells is unable to arrest BCR-mediated
264
MENNA
R.
CLATWORTHY
AND
KENNETH
G.C.
SMITH
Co-crosslinking by IgG immune complexes
FcγRIIb
FcγRIII Ag
Ag
Ag
PIP2 PIP2
+
+ PO4
Syk
PIP3
PO4
PO4 PO4
PLC-γ2
Btk
1
PI3K
Btk DAG
Lyn
- PO
4
PO4
IP3
PO4
SHIP
1
MAPK Ca2+ activation mobilization
Lyn
2
p62 dok
Fig. 12-2 Inhibitory FcγRIIb signaling. Cross-linking of FcγRIIb to the activatory FcγR (or the BCR) by immune complexes containing IgG leads to tyrosine phosphorylation of the ITIM by the kinase Lyn. This allows recruitment of the phosphatase SHIP, which mediates inhibition of activation by 1) blockade of Ca2+ flux and calcium-dependent signaling by dephosphorylation of PIP3 by SHIP and subsequent disassociation of Btk and PLCγ and 2) recruitment of p62dok to the membrane where it is activated by Lyn to downregulate MAP kinase (MAPK) activity. Ag, antigen; PIP2, phosphatidylinositol bisphosphate; DAG, diacylglycerol; IP3, inositol 3-phosphate.
proliferation while retaining its ability to inhibit a Ca2+ response. An additional regulatory function of FcγRIIb in the B cell is the induction of apoptosis on co-aggregation of the receptor without BCR signaling. In this circumstance an apoptotic signal is generated through Btk and Jnk, which is abrogated by the recruitment of SHIP that occurs on cross-linking with the BCR (Pearse et al. 1999).
III.
INHIBITORY RECEPTORS AND
A.
FcγRIIb and Autoimmunity
Three lines of evidence implicate defective FcγRIIb function in the pathogenesis of autoimmunity: • Genetic linkage studies in polygenic mouse models of autoimmune diseases, such as systemic lupus erythematosus (SLE). • A naturally occurring murine FcγRIIb polymorphism is associated with autoimmunity. • FcγRIIb-deficient mice have an increased susceptibility to both inducible and spontaneous autoimmune diseases.
AUTOIMMUNITY As mentioned previously, one of the central features of the immune system is that potentially lethal responses are directed against pathogens whereas the host itself is spared. Inhibitory receptors play a critical role in maintaining self-tolerance, and an absence or dysfunction of these receptors can lead to a variety of autoimmune diseases.
1.
Genetic Linkage Studies
Genetic studies of polygenic murine autoimmune diseases implicate FcγRIIb in pathogenesis. Seven independent linkage studies in murine models of autoimmune disease have identified a susceptibility locus that contains Fcgrb2 (Wakeland et al. 2001). It should be emphasized that the region at the distal end
12. INHIBITORY
RECEPTORS
AND
AUTOIMMUNITY
of chromosome 1 containing Fcgr2 also contains a large number of other candidate genes, for example, Cr2 (Boackle et al. 2001). The situation is made more complex because it is now clear that contributions to disease pathogenesis are made by at least three independent subdivisions of this locus that have been identified by congenic studies (Morel et al. 2001). 2.
FcγRIIb Polymorphisms
The earliest murine FcγRIIb polymorphism described was that of the Ly-17 alloantigenic system (Hibbs et al. 1985). The mouse Ly-17 locus has two alleles, Ly-17a and Ly-17b, encoding the Ly17.1 and Ly17.2 antigens, respectively. Ly-17 polymorphisms have been defined in a number of strains of inbred mice. Although all autoimmune strains examined in this study were of the Ly-17.1 allotype (BXSB, MRL/lpr, NZB, and NZW), so were a number of non-autoimmune-prone strains (C3H/HeJ, SM/J, SJL/J, and WySnJ); therefore, it is unlikely that this polymorphism contributes to a predisposition to autoimmunity (Slingsby et al. 1997). More recently, four further polymorphic sites were identified in the gene encoding FcγRIIb: two in the third intron and two in the promoter (Jiang et al. 2000; Pritchard et al. 2000) (Fig. 12-3). The 13-base pair deletion within the promoter, 110 base pairs upstream from the start site, is found in most autoimmune-prone inbred strains including NZB, BXSB, MRL, and NOD and is associated with reduced surface expression of the receptor on macrophages (Pritchard et al. 2000) and activated B cells (Jiang et al. 2000). The polymorphism and associated reduction in FcγRIIb expression in inbred strains correlated with increased antibody titers after immunization (Jiang et al. 2000) and with macrophage hyperactivity as evidenced by enhanced calcium fluxes and phagocytosis (Pritchard et al. 2000). Furthermore, a luciferase reporter assay indicated that the deletion was associated with reduced transcriptional activity, probably due to reduced binding of the transcription factor AP-4 as shown by Southwestern analysis (Xiu et al. 2002). Interestingly, C57BL/6 mice congenic for a region containing the promoter deletion also show downregulation of FcγRIIb in germinal center B cells and higher levels of antibody after immunization. These studies are highly suggestive that this promoter polymorphism contributes to immune hyperactivity and a predisposition to autoimmunity. 3.
FcγRIIb-Deficient Mice
Some of the most compelling evidence for the involvement of FcγRIIb in autoimmunity has been produced by studying the FcγRIIb knockout mouse. FcγRIIb-deficient mice on a 129/SvC57BL/6 background have augmented humoral responses after immunization with both T-dependent and -independent antigens but do not develop autoantibodies spontaneously (Takai et al. 1996). FcγRIIb deficiency renders normally resistant strains of mice susceptible to a number of antibody- or immune complex–dependent induced models of autoimmunity, including
IN
THE
MOUSE
265
collagen-induced arthritis (CIA), Goodpasture’s syndrome, and immune complex–mediated alveolitis. The CIA model is antibody-dependent arthritis and occurs after immunization with bovine type II collagen. H2q haplotype mice (e.g., DBA/1) are susceptible to this disease but H2b (e.g., C57BL/6 and 129) are resistant. Deficiency in FcγRIIb renders H2b mice as susceptible to disease as H2q mice (Yuasa et al. 1999). Enhanced arthritis in FcγRIIb-deficient BALB/c mice after the administration of anticollagen antibodies and cytokines has also been reported (Kagari et al. 2003). In CIA, signaling through FcγRIIb appears to inhibit the degradation of aggregan and collagen by matrix metalloproteases, causing inhibition of severe cartilage destruction (Blom et al. 2003). In the model of Goodpasture’s syndrome,FcγRIIbdeficient mice develop pulmonary hemorrhage and crescentic glomerulonephritis in response to immunization with bovine type IV collagen, whereas no control animals developed disease (Nakamura et al. 2000). Similarly, in cryoglobulin-associated membranoproliferative glomerulonephritis induced by overexpression of thymic stromal lymphopoietin, deletion of FcγRIIb caused a massive influx of macrophages and increased cellular proliferation, aggravating disease progression (Muhlfeld et al. 2003). Mice deficient in FcγRIIb also develop alveolar inflammation in response to subthreshold concentration of immune complexes (Clynes et al. 1999). This inflammation is characterized by the influx of neutrophils into the lungs and by heightened tumor necrosis factor-α secretion by macrophages. FcγRIIb knockout mice also have an enhanced susceptibility to a murine model of multiple sclerosis, myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. By contrast, γ chain–deficient mice were protected from disease (Abdul-Majid et al. 2002). In addition, FcγRIIb−/− mice derived on a 129/Sv/C57BL/6 background backcrossed for 10 generations onto a C57BL/6 background develop hypergammaglobulinemia, autoantibodies (to antigens such as chromatin and doublestranded [dsDNA]), and an immune complex-mediated autoimmune disease resembling SLE (Bolland and Ravetch 2000). This is characterized by an immune complex–mediated glomerulonephritis, renal failure, and a reduced life expectancy. Transfer studies show that the disease is fully transferable and dependent on B cells. FcγRIIb−/− myeloid cells are not necessary for disease development in this system (Bolland and Ravetch 2000), but a role for them in determining severity has not been excluded. The differences seen between the knockouts on different backgrounds are postulated to be produced by differences in strain-specific epistatic modifiers of autoimmunity. Finally, even mice heterozygous for deletions in FcγRIIb exhibit only a modest reduction in protein expression but have a predisposition to autoimmunity (Bolland et al. 2002). 4.
FcγRIIb and B Cell Tolerance
The work outlined above in the FcγRIIb knockout mouse has left little doubt that abnormalities of this inhibitory receptor can contribute to the development of autoimmunity, but the precise
266
MENNA
R.
CLATWORTHY
AND
KENNETH
G.C.
SMITH
Ly-17 polymorphisms 116 161 166 AA: Ly-17.1 Pro Gln Thr Ly-17.2 Leu Leu Pro
258 Ile Ser
Intron 3
Promoter 1 2
4
3
5
6
EC1 EC2
Nucleotide: -123 -> -111 -100->-98 Polymorphic region 1+2 X
-
7
8
TM
IC1
9
10
IC2 IC3
4133->4136 4921-4944 Region 3
Region 4
X X
X
-
-
-
NZB, BXSB, MRL, NOD NZW, SJL, SWR BALB/c, C57BL/6, DBA
FcγRIIb regulatory region polymorphisms
Key
Intron
Coding region
Untranslated region
Unmethylated region
Fig. 12-3 Murine FcγRIIb polymorphisms. The Ly-17 antigenic system consists of three single-nucleotide polymorphisms (SNPs) within the area of the gene encoding the second extracellular domain and a further SNP in exon 8, encoding the intracytoplasmic domain. The second group of polymorphisms are deletions within regulatory regions in the promotor region and in intron 3. Autoimmune-prone inbred strains of mice (such as NZB, BXSB, MRL, and NOD) have deletions in polymorphic regions 1, 2, and 3. The 13-base pair deletion in region 1 is associated with reduced gene transcription, probably due to disruption of the binding site for the transcription factor AP-4.
mechanism remains a subject of intense investigation. However, it seems that FcγRIIb plays a role in the development or maintenance of self-tolerance. It is now widely accepted that despite a number of developmental checkpoints (central tolerance), self-reactive cells do escape into the periphery (Bouneaud et al. 2000). In addition, mechanisms that enhance antibody diversity, such as somatic hypermutation, can generate potentially autoreactive antigen receptors in the adult (Marion et al. 2003). Thus, checkpoints operate in the periphery and are critical for maintaining tolerance to self-antigens that only appear after maturity. Inhibitory signaling is a critical feature of peripheral tolerance, providing a means for establishing thresholds of activation and for deletion of autoreactive cells. FcγRIIb is the only Fc receptor expressed by B cells, and its expression is required for the maintenance of tolerance (Bolland and Ravetch 2000). As mentioned previously, C57BL/6 FcγRIIb-deficient mice develop lupus-like autoimmunity, including a fulminant glomerulonephritis (Bolland and Ravetch 2000). Studies of bone marrow transfer into recombinase-activating gene (RAG)-deficient mice suggest that FcγRIIb deficiency in the B cell compartment is most likely responsible for the loss of tolerance seen in these mice. Furthermore, several autoimmune-prone inbred strains of
mice such as NZB, NOD, and BXSB have also been shown to have reduced FcγRIIb expression in germinal centers (Jiang et al. 2000). These results suggest that the absolute level of FcγRIIb expressed on B cells may regulate the ability of these cells to maintain tolerance and that relatively small changes may allow the persistence and expansion of autoimmune cells. Further support for this concept has been provided by studies in which B cell FcγRIIb expression was normalized by retroviral transduction of bone marrow cells from NZB, BXSB, and FcγRIIb-deficient mice (McGaha et al. 2005). Mice were irradiated, and bone marrow was reconstituted with autologous marrow transduced with FcγRIIb-expressing retrovirus. These mice exhibit reduced levels of antinuclear antibodies and antibodies to DNA and chromatin, reduced renal immune complex deposition, and improved survival compared with mice with control transfected bone marrow. The only caveat to these observations is that although FcγRIIb upregulation after retroviral transduction was seen in 40% of B cells, 20% of immature thymocytes and 10% of macrophages also showed increased expression, so the role of the inhibitory receptor in restoring tolerance may be related to expression on these other cell types. The precise mechanism by which FcγRIIb contributes to the maintenance of peripheral tolerance is still unclear, but there is
12. INHIBITORY
RECEPTORS
AND
AUTOIMMUNITY
evidence to suggest that it may alter receptor editing and control the expansion of autoreactive plasma cells (Fukuyama et al. 2005). It has also been suggested that FcγRIIb serves to differentiate between high-affinity cognate antigen binding and low-affinity (and hence potentially cross-reactive) specificities in the germinal center. Antigen in the germinal center is retained in the form of immune complexes bound to follicular dendritic cells, and hence B cell stimulation can occur either through FcγRIIb stimulation alone, resulting in apoptosis, or through FcγRIIb and the BCR, producing survival (Pearse et al. 1999). In addition to its controlling role in peripheral tolerance, FcγRIIb may also play a role in central B cell tolerance (Brauweiler and Cambier 2004). FcγRIIb is expressed on pre-B cells, and aggregation (in the absence of B cell aggregation) can induce cell death and inhibit migration (Brauweiler and Cambier 2004). However, if the pre-B cell receptor is cross-linked, then FcγRIIb can inhibit apoptosis (Kato et al. 2002). B.
Inhibitory Receptors and B Cell Activation Thresholds
Upon antigen binding to the BCR, B cell activation thresholds are determined by the net effects of positive and negative regulatory molecules. A number of inhibitory receptors have been identified on B cells, including FcγRIIb, CD22, PD-1, CD72, CD5, CD66a, leukocyte-associated Ig-like receptor-1 (LAIR-1), paired Ig-like receptor-B (PIR-B), and Ig-like transcript (ILT-2). Some of these will be discussed in detail but overall, mice deficient in these molecules have hyperactive B cells and are prone to autoimmunity. 1.
CD22
CD22 is a B cell–specific surface glycoprotein of the Ig superfamily in the sialoadhesin subclass (O’Keefe et al. 1996). It is made up of seven extracellular Ig-like domains, a transmembrane region, and an intracytoplasmic tail that contains six highly conserved tyrosine residues, three of which are within ITIMs (Smith and Fearon 1999). The ligand for CD22 is Siaα2,6Galβ1-4GlcNAc, a glycosylated sialic acid residue expressed at high levels on lymphocytes and inflamed endothelial cells (Hanasaki et al. 1994). CD22 is constitutively associated with the BCR and is phosphorylated on stimulation through it by the tyrosine kinase Lyn. Lyn also controls the basal levels of CD22 phosphorylation and SHP-1 association (Smith et al. 1998). Phosphorylation of the ITIMs within the cytoplasmic tail of CD22 allows association with and phosphorylation of SHP-1. Ligation of CD22 to the BCR and subsequent SHP-1 activation inhibits B cell activation by inhibiting the MAP kinases extracellular signal-regulated kinase-2 (ERK2), c-Jun NH2-terminal kinase (JNK), and p38
IN
THE
MOUSE
267
and dephosphorylating molecules involved in the early events of BCR-mediated activation (Smith and Fearon 1999). Coligation of CD22 to the BCR reduces B cell activation while sequestering it away from the BCR, as would occur if CD22 bound to its ligand on adjacent cells, results in B cell hyperactivity. Thus, the interaction of CD22 with its ligand may promote B cell activation in appropriate lymphoid environments. Alternatively, increased levels of ligand on inflamed endothelium would recruit CD22 and make B cell activation by inflamed self less likely (Neuberger et al. 1999). CD22-deficient mice have an expanded B1 cell population and increased serum IgM levels. They also have B cells that are hyper-responsive to stimulation via their BCR (O’Keefe et al. 1996). With age they develop high-affinity, isotype-switched autoantibodies to dsDNA, myeloperoxidase, and cardiolipin, although not overt autoimmune disease (O’Keefe et al. 1999). Heterozygous CD22 knockout mice have a reduced but significant autoimmune phenotype and mice heterozygous for CD22, Lyn, and SHP-1 show reduced B cell tolerance in the HEL-antiHEL transgenic system (Cornall et al. 1998). These data imply that even a partial defect in CD22 function may contribute to the development of autoimmune disease. Mice deficient in other molecules involved in the inhibitory pathway, such as Lyn and SHP-1, also display B cell hyperresponsiveness and autoimmune disease (Hibbs et al. 1995). The CD22 gene has been shown to lie within a susceptibility locus for the development of lupus in the NZBW/F1 and related NZM2410 models of lupus (the relevant locus in the NZM2410 being of NZW origin (Kono et al. 1994; Morel et al. 1994, 1997). This region has also been linked to the development of glucose intolerance in the NOD mouse (Ghosh et al. 1993) and to experimental allergic encephalomyelitis (EAE) (Butterfield et al. 1999). A number of autoimmuneprone strains of mice, including the NZW mouse, express the CD22a or CD22c alleles, which are associated with abnormal processing of CD22 mRNA leading to heterogeneous 5′-UTRs and truncated exon-4 coding sequence (Mary et al. 2000). This defect is associated with reduced surface expression of CD22 on resting B cells and reduced ability of lipopolysaccharideactivated B cells to upregulate CD22. Heterozygous expression of CD22a with the Y chromosome–linked autoimmune accelerator Yaa promoted autoantibody production, supporting a link between this CD22 allele and autoimmune disease. 2.
PD-1
PD-1 is a 55-kDa transmembrane protein of the Ig superfamily and is expressed on resting B cells, T cells, and macrophages (Agata et al. 1996). It is composed of a single extracellular Iglike domain and a transmembrane domain and has two tyrosine residues in its cytoplasmic tail, one of which forms part of an ITIM (Nishimura and Honjo 2001). Two PD-1 ligands have been identified; These are membrane
268
MENNA
proteins of the Ig superfamily expressed constitutively on dendritic cells and on heart, lung, thymus, and kidney (Freeman et al. 2000; Latchman et al. 2001). In vitro studies on a B cell lymphoma line using a chimeric molecule with an FcγRIIb extracellular domain and a PD-1 cytoplasmic domain have shown that ligation of the PD-1 cytoplasmic domain to the BCR can inhibit signaling through it (Okazaki et al. 2001). Mice lacking PD-1 have defects in T cell selection and in the maintenance of peripheral T cell tolerance. Splenic B cells from these mice have enhanced responses to anti-IgM stimulation in vitro and an enhanced IgG3 response to T-independent antigen. On a C57BL/6 background, PD-1-deficient mice develop autoantibodies, an immune complex–mediated glomerulonephritis (similar to that seen in human SLE), and a deforming arthritis resembling rheumatoid arthritis (Nishimura et al. 1999). When the C57BL/6 PD-1 knockouts were crossed onto the lpr/lpr mouse, they developed high titers of anti-dsDNA autoantibodies and accelerated glomerulonephritis and arthritis. BALB/c PD-1−/− mice develop dilated cardiomyopathy, with IgG deposition on the myocardium associated with the development of isotype switched autoantibodies to a cardiac myocyte–specific protein (Nishimura et al. 2001). PD-1−/− mice were protected from disease and the development of autoantibodies on the RAG2−/− background, and disease could successfully be transferred to these mice with spleen or bone marrow cells from diseased mice. Therefore, lymphoid cells appear to be crucial in the development of autoimmune disease in PD-1-deficient mice. Although defective PD-1 on myeloid cells may not be critical to transfer of disease, this result does not rule out an additional role for myeloid cells in the disease process. More recent studies have also implicated PD-1 in the development of glucose intolerance in the NOD mouse (Ansari et al. 2003) and in the progression of EAE in a murine model (Salama et al. 2003). A polymorphism of PD-1 has now been identified in humans. An intronic SNP in PD-1 (also called PDCD1) is associated with the development of SLE in Europeans (found in 12% of affected individuals versus 5% of control subjects). The SNP alters a binding site for the runt-related transcription factor 1 (RUNX1) located in an intronic enhancer leading to aberrant regulation of PD-1 expression, and perhaps a release of autoreactive cells from inhibitory restraint (Prokunina et al. 2002).
C.
Inhibitory NK Receptors for MHC Class I
One critical characteristic of the immune system is its ability to distinguish self from non-self. This is illustrated by the capacity of NK cells to preferentially target cells lacking MHC class I. NK cell–mediated surveillance for class I expression is mediated by three classes of NK inhibitory receptors that
R.
CLATWORTHY
AND
KENNETH
G.C.
SMITH
functionally dominate triggering signals induced by activatory receptors: the KIRs, the Ly49 receptors, and the heterodimeric CD94-NKG2A-B receptor, which recognizes nonclassic MHC class I molecules (Chiesa et al. 2005). All three classes of NK inhibitory receptors have one or more ITIMs in their cytoplasmic domain. 1.
KIRs
In humans, NK cell receptors are encoded by KIR genes. They were initially though to be absent in mice, but a number of murine KIR genes have now been identified (Hoelsbrekken et al. 2003). After MHC recognition, downstream events include recruitment of SHP-1 and the subsequent inhibition of Vav1. Vav1 plays a central role in the regulation of actin-dependent changes during cytotoxic lymphocyte activation (Stebbins et al. 2003). 2.
Ly49 Natural Killer Receptors
Mouse NK receptors are encoded by the C-type lectin Ly49 multigene family that maps onto chromosome 6, in a region termed the NK gene complex (NKC). The genes encoded within the NKC display allelic polymorphism, which in conjunction with alternative mRNA splicing results in expanding of the Ly49 repertoire. It is possible that at least 23 Ly49 members exist, of which 13 are inhibitory (Ortaldo and Young 2005). Ly49 receptors are expressed at the cell surface as transmembrane disulfide-bonded homodimeric type II transmembrane proteins, each composed of a C-type lectin domain connected to the cell membrane by an α-helical stalk. Inhibitory Ly49 NK cell receptors contain an ITIM in their cytoplasmic domain, which recruits SHP-1 on ITIM phosphorylation (Nakamura et al. 1997). Activatory Ly49 receptors are associated noncovalently with the ITAM-containing adaptor protein DAP-12. The inhibitory receptors dominate, and studies indicate that NK cells require two activatory signals (e.g., activatory Ly49 receptor engagement and treatment with interleukin-12) to overcome the overriding inhibitory receptor–mediated blockade (Ortaldo and Young 2003). These receptors are likely to be important in the immune response to viruses and in tumor immunity, but as yet there are no data on their role in autoimmunity.
D.
T Cell Inhibitory Receptors
On T cells, three receptors have been noted to inhibit T cell activation after binding to B7 family members: CTLA-4, PD-1 (discussed above), and BTLA. 1.
CTLA-4
CTLA-4 is the most extensively characterized of the T cell inhibitory receptors. Whereas CD28 recognition of B7-1 (CD80) and B7-2 (CD86) on antigen-presenting cells (APCs)
12. INHIBITORY
RECEPTORS
AND
AUTOIMMUNITY
provides effective costimulation for T cells recognizing antigen via their TCRs, recognition of B7 by CTLA-4 markedly inhibits T cell activation (Taylor et al. 2004). CTLA-4-deficient mice show polyclonal T cell proliferation and a lymphoproliferative disorder that culminates in early mortality (Tivol et al. 1995; Waterhouse et al. 1995). The mechanism of CTLA-4-mediated inhibition is unclear, but this receptor does not contain a classical ITIM in its cytoplasmic domain. It may act by competing for B7 binding, thus preventing the association of activation-mediating molecules such as CD28. More recently some data suggest a more complex mechanism in which CTLA-4 modulates tryptophan catabolism in APCs (Fallarino et al. 2003; Grohmann et al. 2002). The ligation of APC B7 by CTLA-4 triggers interferon (IFN)-γ production, which in turn promotes the synthesis of an enzyme that catabolizes tryptophan (indoleamine 2, 3-dioxygenase [IDO]). Tryptophan is an essential constituent of all proteins and is also required for the function of two biochemical pathways, the generation of 5-hydroxytryptophan, and the IDO-catalyzed formation of a series of biologically active metabolites referred to as the kynurenines. By mechanisms that are as yet unclear, activation of IDO and/or production of kynurenines can regulate T cell proliferation and survival and promote an immunomodulatory rather than a stimulatory phenotype (Grohmann, Fallarino, Puccetti, et al. 2003). Dendritic cells from autoimmune-prone NOD mice exhibit a defect in IFN-γ-induced IDO activity and thus fail to develop a tolerizing phenotype (Grohmann, Fallarino, Bianchi, et al. 2003). In humans and in the NOD mouse, a CTLA-4 polymorphism that gives rise to alternatively spliced, soluble forms of CTLA-4 and has been mapped to susceptibility regions for a variety of autoimmune diseases including Graves’ disease, autoimmune hypothyroidism, and type 1 diabetes in humans has been identified (Ueda et al. 2003). 2.
BTLA
BTLA is an Ig domain–containing transmembrane receptor that has two ITIMs in its cytoplasmic tail, both of which can recruit SHP-1 and SHP-2 (Gavrieli et al. 2003; Watanabe et al. 2003). BTLA is expressed only on activated B cells and on developing T helper (Th) 1 and Th2 cells. It is subsequently lost from fully developed Th2 cells but is retained by Th1 cells. Binding of its putative ligand B7-H4 inhibits TCR-induced cytokine production and cell cycle progression. Furthermore, administration of the fusion protein for the putative ligand (B7H4-Ig) inhibits antigen-specific T cell responses in vivo (Sica et al. 2003). In the BTLA knockout mouse T cells show increased proliferation in response to antigen. B cells are also hyperactive and BTLA-deficient mice have increased levels of antigen-specific IgG titers after T-dependent immunization. These mice are also susceptible to peptide antigen-induced EAE (Watanabe et al. 2003).
IN
IV.
THE
269
MOUSE
INHIBITORY RECEPTOR PATHWAYS AND AUTOIMMUNITY
Inhibitory receptors are subserved by remarkably similar signaling pathways. Mice with deficiencies or abnormalities in these downstream signaling molecules also have a predisposition to autoimmunity, providing further evidence of the importance of these pathways in the pathogenesis of autoimmune disease.
A.
Lyn
Lyn is a Src family kinase that phosphorylates ITIMs in both the SHIP- and SHP-1–mediated inhibitory receptor pathways. Lyn is expressed in many hemopoietic cells, but much of the work to date has focused on its function in B cells (Burkhardt et al. 1991; Takata et al. 1994). A significant proportion of Lyn molecules are constitutively associated with the BCR, and it becomes rapidly activated on BCR cross-linking. Lyn is involved in both the activation and inhibition of the B cell. Cross-linking of the BCR in Lyndeficient mice leads to delayed and reduced phosphorylation of Syk and several other substrates within the activatory pathway. However, there is sufficient phosphorylation by other Src kinase family members to generate a B cell response (Takata et al. 1994). The nonredundant role of Lyn appears to be inhibitory, however, because the B cells of Lyndeficient mice are hyper-responsive to BCR cross-linking (Smith et al. 1998). B cells in lyn−/− mice show exaggerated proliferative responses after BCR cross-linking (Wang et al. 1996) and have increased numbers of peripheral mature B cells and elevated serum IgM and IgA levels. B cells from Lyn-deficient anti-HEL transgenic mice show a delay in the initial antigen–induced Ca2+ flux, but overall Ca2+ flux was increased (Cornall et al. 1998). This suggests that Lyn may be involved in the initiation of intracellular Ca2+ release but overall has an inhibitory effect upon it. The Lyn knockout mice develop isotype switched autoantibodies, lymphadenopathy, splenomegaly, and immune complex–mediated glomerulonephritis similar to that seen in SLE (Hibbs et al. 1995). Lyn-deficient mice develop worse disease than do mice deficient in single inhibitory receptors, presumably because Lyn deficiency interrupts the function of multiple inhibitory receptors.
B.
SHP-1
SHP-1 is the protein tyrosine phosphatase most widely utilized in the inhibitory receptor signaling pathways. It contains two amino-terminal SH2 domains, a phosphatase domain, and
270
MENNA
two conserved carboxyl-terminal tyrosine residues (Tamir et al. 2000). SHP-2 has an additional carboxyl-terminal domain that may allow interaction with SH3-containing proteins (Hof et al. 1998). Although both molecules are activated after binding through their amino-terminal SH2 domains to phosphorylated ITIMs, they appear to bind with different affinities (Barford and Neel 1998; Vely et al. 1997). These differences in structure and binding affinities appear to confer significant differences in the signaling functions of the two molecules. SHP-1 is a broadly inhibitory molecule and plays the predominant role of the two in regulation through ITIMs, although increasingly evidence suggests that SHP-2 may have an additional activatory role (Huyer and Alexander 1999). Clearly these molecules have an important role in regulation of a normal immune system that is due, at least in part, to their recruitment by inhibitory receptors. Consistent with its role in mediating inhibitory receptor function, SHP-1 deficiency results in the development of spontaneous autoimmune disease. However, the situation is complicated because this is not the only group of receptors it subserves. SHP-1 also associates with BCRs, FcRs, growth factor, complement, and cytokine receptors (Bolland and Ravetch 1999). Despite these complicating factors, much of the knockout phenotype is consistent with SHP-1 having a predominant role in the inhibitory receptor pathways. The “moth-eaten” (me) and “moth-eaten viable” (mev) mice are naturally occurring SHP-1 mutants (Greiner et al. 1986). The me mutation completely stops production of SHP-1, whereas the mev mutation is a single base pair deletion that disrupts an mRNA splice site, leading to production of aberrant SHP-1 protein with 10–20% of normal activity (Tsui et al. 1993). The me and mev mice have a broadly similar phenotype, although it is milder in the mev. These mice have reduced numbers of B cells but a higher proportion of B1 cells. The mice have B cells that are hyper-responsive to BCR stimulation, have raised levels of serum immunoglobulin, and develop autoantibodies (Sidman et al. 1986). Both strains develop severe autoimmune disease with immune complex deposition in skin, lung, and kidney, patchy alopecia, splenomegaly, and inflamed paws. The lifespan of a homozygous me mouse is 3 weeks whereas that of a homozygous mev mouse is 9 weeks (Shultz et al. 1984). The double mutant mev and RAG-1−/− mice develop the full phenotype but do not develop autoantibodies. Thus, SHP-1 deficiency produces such severe immune dysregulation that B cells do not appear to be necessary for the development of disease, although their contribution is demonstrated by the fact its phenotype is altered in their absence (Yu et al. 1996). The severity of the disease that is seen in SHP-1–deficient mice is clearly worse than that seen in mice with deficiencies of individual inhibitory receptors. This is most likely due to the effects of disruption of multiple inhibitory receptor pathways, although the fact that SHP-1 has functions in addition to mediating inhibitory receptor suppression should be kept in mind. In a number of genetic studies of mouse models of disease, susceptibility loci that contain SHP-1 have been identified,
R.
CLATWORTHY
AND
KENNETH
G.C.
SMITH
although a role for them in disease pathogenesis has not been proven (Mary et al. 2000; McIndoe et al. 1999).
C.
SHIP
SHIP is an SH2-containing inositol phosphatase related to SHIP-2, and they share a conserved N-terminal SH2 catalytic domain. In the B cell, SHIP acts predominantly on the FcγRIIb signaling pathway. In humans, it occurs in a number of isoforms, the most common of which is 145 kDa in size. The molecule is highly conserved between humans and mice (96% homology) and is widely expressed in myeloid and lymphoid lineages (Huber et al. 1999). SHIP acts to dephosphorylate PIP3 and inositol-1,3,4,5-tetra phosphate, and because PIP3 is produced by the action of phosphoinositide 3-kinase (PI3K) on phosphatidylinositol bisphosphate, in so doing it serves to counteract PI3K activity (Damen et al. 1996). Through this mechanism activation of SHIP leads to reduced BCR-mediated phosphoinositide hydrolysis and Ca2+ mobilization (Brauweiler et al. 2000). The pattern of B cell abnormalities seen in SHIP-deficient mice is consistent with this inhibitory role in B cell signaling. Splenic B cells have an activated phenotype with lower surface levels of IgM and higher levels of IgD and are hyper-responsive to BCR-mediated stimulation measured by the activation markers CD69 and CD86 (Helgason et al. 1998). SHIP-deficient B cells also demonstrate prolonged Ca2+ influx and enhanced proliferation in vitro in response to BCR stimulation, which was associated with increased phosphorylation of MAP kinase and Akt and also with increased cell cycling and survival (Helgason et al. 2000; Liu et al. 1998). SHIP-deficient mice also have elevated serum immunoglobulin levels with enhanced IgG responses to thymus-independent (TI) antigen (Helgason et al. 2000). However, the mice do not develop autoantibodies or B cell–mediated autoimmune disease. They die prematurely (50% mortality by 10–12 weeks) with consolidation of the lungs brought about by myeloid cell infiltration (Helgason et al. 1998). Thus, mice deficient in these three signaling molecules develop autoimmune disease, emphasizing the important role inhibitory pathways play in the maintenance of tolerance.
V.
CONCLUSION
The innate and adaptive immune systems utilize a range of inhibitory receptors, which control the strength and duration of an immune response. They facilitate the development of a measured response and play an important role in preventing autoreactivity. An increasing number of immune inhibitory receptors have been identified in mice and humans. The generation of mice deficient in both inhibitory receptors and molecules downstream in inhibitory pathways has provided
12. INHIBITORY
RECEPTORS
AND
AUTOIMMUNITY
compelling evidence that inhibitory mechanism are critical for the prevention of autoimmunity. A better understanding of these pathways will also allow the development of therapeutic agents that might modify inhibition and prevent or reduce autoimmune diseases.
REFERENCES Abdul-Majid, K.B., Stefferl, A., Bourquin, C., Lassmann, H., Linington, C., Olsson, T., et al. (2002). Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand J Immunol 55, 70–81. Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H., et al. (1996). Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8, 765–772. Ansari, M.J., Salama, A.D., Chitnis, T., Smith, R.N., Yagita, H., Akiba, H., et al. (2003). The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198, 63–69. Barford, D., Neel, B.G. (1998). Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 6, 249–254. Blom, A.B., van Lent, P.L., Holthuysen, A.E., Jacobs, C., van den Berg, W.B. (2003). Skewed balance in basal expression and regulation of activating v inhibitory Fcγ receptors in macrophages of collagen induced arthritis sensitive mice. Ann Rheum Dis 62, 465–471. Boackle, S.A., Holers, V.M., Chen, X., Szakonyi, G., Karp, D.R., Wakeland, E.K., et al. (2001). Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15, 775–785. Bolland, S., Pearse, R.N., Kurosaki, T., Ravetch, J.V. (1998). SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 8, 509–516. Bolland, S., Ravetch, J.V. (1999). Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 72, 149–177. Bolland, S., Ravetch, J.V. (2000). Spontaneous autoimmune disease in FcγRIIBdeficient mice results from strain-specific epistasis. Immunity 13, 277–285. Bolland, S., Yim, Y.S., Tus, K., Wakeland, E.K., Ravetch, J.V. (2002). Genetic modifiers of systemic lupus erythematosus in FcγRIIB−/− mice. J Exp Med 195, 1167–1174. Bonnerot, C., Choukroun, V., Marloie, M.A., Fridman, W.H. (1992). Two distinct regions of the mouse βFcγR gene control its transcription. Immunobiology 185, 222–234. Bonnerot, C., Daeron, M., Varin, N., Amigorena, S., Hogarth, P.M., Even, J., et al. (1988). Methylation in the 5’ region of the murine βFcγR gene regulates the expression of Fcγ receptor II. J Immunol 141, 1026–1033. Bouneaud, C., Kourilsky, P., Bousso, P. (2000). Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13, 829–840. Brauweiler, A.M., Cambier, J.C. (2004). Autonomous SHIP-dependent FcγR signaling in pre-B cells leads to inhibition of cell migration and induction of cell death. Immunol Lett 92, 75–81. Brauweiler, A.M., Tamir, I., Cambier, J.C. (2000). Bilevel control of B-cell activation by the inositol 5-phosphatase SHIP. Immunol Rev 176, 69–74. Burkhardt, A.L., Brunswick, M., Bolen, J.B., Mond, J.J. (1991). Antiimmunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases. Proc Natl Acad Sci USA 88, 7410–7414. Butterfield, R.J., Blankenhorn, E.P., Roper, R.J., Zachary, J.F., Doerge, R.W., Sudweeks, J., et al. (1999). Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nonrelapsing EAE are immunogenetically distinct. J Immunol 162, 3096–3102. Chen, L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4, 336–347.
IN
THE
MOUSE
271
Chiesa, S., Tomasello, E., Vivier, E., Vely, F. (2005). Coordination of activating and inhibitory signals in natural killer cells. Mol Immunol 42, 477–484. Clynes, R., Maizes, J.S., Guinamard, R., Ono, M., Takai, T., Ravetch, J.V. (1999). Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 189, 179–185. Cornall, R.J., Cyster, J.G., Hibbs, M.L., Dunn, A.R., Otipoby, K.L., Clark, E.A., et al. (1998). Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8, 497–508. Daeron, M. (1997). Fc receptor biology. Annu Rev Immunol 15, 203–234. Daeron, M., Latour, S., Malbec, O., Espinosa, E., Pina, P., Pasmans, S., et al. (1995). The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3, 635–646. Daeron, M., Malbec, O., Latour, S., Espinosa, E., Pina, P., Fridman, W.H. (1995). Regulation of tyrosine-containing activation motif-dependent cell signalling by FcγRII. Immunol Lett 44, 119–123. Damen, J.E., Liu, L., Rosten, P., Humphries, R.K., Jefferson, A.B., Majerus, P.W., Krystal, G. (1996). The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA 93, 1689–1693. Davis, R.S., Wang, Y.H., Kubagawa, H., Cooper, M.D. (2001). Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA 98, 9772–9777. Ehrhardt, G.R., Davis, R.S., Hsu, J.T., Leu, C.M., Ehrhardt, A., Cooper, M.D. (2003). The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci USA 100, 13489–13494. Fallarino, F., Grohmann, U., Hwang, K.W., Orabona, C., Vacca, C., Bianchi, R., et al. (2003). Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4, 1206–1212. Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192, 1027–1034. Fukuyama, H., Nimmerjahn, F., Ravetch, J.V. (2005). The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 6, 99–106. Gavrieli, M., Watanabe, N., Loftin, S.K., Murphy, T.L., Murphy, K.M. (2003). Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 312, 1236–1243. Ghosh, S., Palmer, S.M., Rodrigues, N.R., Cordell, H.J., Hearne, C.M., Cornall, R.J., et al. (1993). Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nat Genet 4, 404–409. Greiner, D.L., Goldschneider, I., Komschlies, K.L., Medlock, E.S., Bollum, F.J., Schultz, L. (1986). Defective lymphopoiesis in bone marrow of motheaten (me/me) and viable motheaten (mev/mev) mutant mice. I. Analysis of development of prothymocytes, early B lineage cells, and terminal deoxynucleotidyl transferase-positive cells. J Exp Med 164, 1129–1144. Grohmann, U., Fallarino, F., Bianchi, R., Orabona, C., Vacca, C., Fioretti, M.C., et al. (2003). A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 198, 153–160. Grohmann, U., Fallarino, F., Puccetti, P. (2003). Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24, 242–248. Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., et al. (2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3, 1097–1101. Hanasaki, K., Varki, A., Stamenkovic, I., Bevilacqua, M.P. (1994). Cytokineinduced β-galactoside α-2,6-sialyltransferase in human endothelial cells mediates α 2,6-sialylation of adhesion molecules and CD22 ligands. J Biol Chem 269, 10637–10643.
272
MENNA
Helgason, C.D., Damen, J.E., Rosten, P., Grewal, R., Sorensen, P., Chappel, S.M., et al. (1998). Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 12, 1610–1620. Helgason, C.D., Kalberer, C.P., Damen, J.E., Chappel, S.M., Pineault, N., Krystal, G., et al. (2000). A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of B lymphocytes in SHIP−/− mice. J Exp Med 191, 781–794. Hibbs, M.L., Hogarth, P.M., McKenzie, I.F. (1985). The mouse Ly-17 locus identifies a polymorphism of the Fc receptor. Immunogenetics 22, 335–348. Hibbs, M.L., Tarlinton, D.M., Armes, J., Grail, D., Hodgson, G., Maglitto, R., et al. (1995). Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83, 301–311. Hoelsbrekken, S.E., Nylenna, O., Saether, P.C., Slettedal, I.O., Ryan, J.C., Fossum, S., et al. (2003). Cutting edge: Molecular cloning of a killer cell Ig-like receptor in the mouse and rat. J Immunol 170, 2259–2263. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M.J., Shoelson, S.E. (1998). Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441–450. Hogarth, P.M., Witort, E., Hulett, M.D., Bonnerot, C., Even, J., Fridman, W.H., et al. (1991). Structure of the mouse βFcγ receptor II gene. J Immunol 146, 369–376. Huber, M., Helgason, C.D., Damen, J.E., Scheid, M., Duronio, V., Liu, L., et al. (1999). The role of SHIP in growth factor induced signalling. Prog Biophys Mol Biol 71, 423–434. Huyer, G., Alexander, D.R. (1999). Immune signalling: SHP-2 docks at multiple ports. Curr Biol 9, R129–R132. Jiang, Y., Hirose, S., Abe, M., Sanokawa-Akakura, R., Ohtsuji, M., Mi, X., et al. (2000). Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 51, 429–435. Kagari, T., Tanaka, D., Doi, H., Shimozato, T. (2003). Essential role of Fcγ receptors in anti-type II collagen antibody-induced arthritis. J Immunol 170, 4318–4324. Kato, I., Takai, T., Kudo, A. (2002). The pre-B cell receptor signaling for apoptosis is negatively regulated by FcγRIIB. J Immunol 168, 629–634. Kono, D.H., Burlingame, R.W., Owens, D.G., Kuramochi, A., Balderas, R.S., Balomenos, D., Theofilopoulos, A.N. (1994). Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 91, 10168–10172. Latchman, Y., Wood, C.R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., et al. (2001). PD-L2 is a second ligand for PD-I and inhibits T cell activation. Nat Immunol 2, 261–268. Latour, S., Fridman, W.H., Daeron, M. (1996). Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human FcγRIIB1. J Immunol 157, 189–197. Liu, Q., Oliveira-Dos-Santos, A.J., Mariathasan, S., Bouchard, D., Jones, J., Sarao, R., et al. (1998). The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. J Exp Med 188, 1333–1342. Liu, Q., Sasaki, T., Kozieradzki, I., Wakeham, A., Itie, A., Dumont, D.J., et al. (1999). SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev 13, 786–791. Malbec, O., Fong, D.C., Turner, M., Tybulewicz, V.L., Cambier, J.C., Fridman, W.H., et al. (1998). Fcε receptor I-associated lyn-dependent phosphorylation of Fcγ receptor IIB during negative regulation of mast cell activation. J Immunol 160, 1647–1658. Marion, T.N., Krishnan, M.R., Steeves, M.A., Desai, D.D. (2003). Affinity maturation and autoimmunity to DNA. Curr Dir Autoimmun 6, 123–153. Mary, C., Laporte, C., Parzy, D., Santiago, M.L., Stefani, F., Lajaunias, F., et al. (2000). Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 165, 2987–2996. McGaha, T.L., Sorrentino, B., Ravetch, J.V. (2005). Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590–593.
R.
CLATWORTHY
AND
KENNETH
G.C.
SMITH
McIndoe, R.A., Bohlman, B., Chi, E., Schuster, E., Lindhardt, M., Hood, L. (1999). Localization of non-Mhc collagen-induced arthritis susceptibility loci in DBA/1j mice. Proc Natl Acad Sci USA 96, 2210–2214. Morel, L., Blenman, K.R., Croker, B.P., Wakeland, E.K. (2001). The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci USA 98, 1787–1792. Morel, L., Mohan, C., Yu, Y., Croker, B.P., Tian, N., Deng, A., et al. (1997). Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 158, 6019–6028. Morel, L., Rudofsky, U.H., Longmate, J.A., Schiffenbauer, J., Wakeland, E.K. (1994). Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1, 219–229. Muhlfeld, A.S., Segerer, S., Hudkins, K., Carling, M.D., Wen, M., Farr, A.G., et al. (2003). Deletion of the Fcγ receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am J Pathol 163, 1127–1136. Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M.C., Ravetch, J.V. (1994). A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling. Nature 369, 340. Nakamura, A., Yuasa, T., Ujike, A., Ono, M., Nukiwa, T., Ravetch, J.V., et al. (2000). Fcγ receptor IIB-deficient mice develop Goodpasture’s syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med 191, 899–906. Nakamura, M.C., Niemi, E.C., Fisher, M.J., Shultz, L.D., Seaman, W.E., Ryan, J.C. (1997). Mouse Ly-49A interrupts early signaling events in natural killer cell cytotoxicity and functionally associates with the SHP-1 tyrosine phosphatase. J Exp Med 185, 673–684. Neuberger, M.S., Lanoue, A., Ehrenstein, M.R., Batista, F.D., Sale, J.E., Williams, G.T. (1999). Antibody diversification and selection in the mature B-cell compartment. Cold Spring Harb Symp Quant Biol 64, 211–216. Nimmerjahn, F., Bruhns, P., Horiushi, K., Ravetch, J.V. (2005). FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41–51. Nishimura, H., Honjo, T. (2001). PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22, 265–268. Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T. (1999). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151. Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319–322. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., Honjo, T. (2001). PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98, 13866–13871. O’Keefe, T.L., Williams, G.T., Batista, F.D., Neuberger, M.S. (1999). Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189, 1307–1313. O’Keefe, T.L., Williams, G.T., Davies, S.L., Neuberger, M.S. (1996). Hyperresponsive B cells in CD22-deficient mice. Science 274, 798–801. Ono, M., Bolland, S., Tempst, P., Ravetch, J.V. (1996). Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB. Nature 383, 263–266. Ortaldo, J.R., Young, H.A. (2003). Expression of IFN-γ upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. J Immunol 170, 1763–1769. Ortaldo, J.R., Young, H.A. (2005). Mouse Ly49 NK receptors: balancing activation and inhibition. Mol Immunol 42, 445–450. Pearse, R.N., Kawabe, T., Bolland, S., Guinamard, R., Kurosaki, T., Ravetch, J.V. (1999). SHIP recruitment attenuates FcγRIIB-induced B cell apoptosis. Immunity 10, 753–760. Pritchard, N.R., Cutler, A.J., Uribe, S., Chadban, S.J., Morley, B.J., Smith, K.G.C. (2000). Autoimmune-prone mice share a promoter haplotype
12. INHIBITORY
RECEPTORS
AND
AUTOIMMUNITY
associated with reduced expression and function of the Fc receptor FcγRII. Curr Biol 10, 227–230. Pritchard, N.R., Smith, K.G.C. (2003). B cell inhibitory receptors and autoimmunity. Immunology 108, 263–273. Prokunina, L., Castillejo-Lopez, C., Oberg, F., Gunnarsson, I., Berg, L., Magnusson, V., et al. (2002). A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32, 666–669. Ravetch, J.V., Bolland, S. (2001). IgG Fc receptors. Annu Rev Immunol 19, 275–290. Salama, A.D., Chitnis, T., Imitola, J., Ansari, M.J., Akiba, H., Tushima, F., et al. (2003). Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 198, 71–78. Shultz, L.D., Coman, D.R., Bailey, C.L., Beamer, W.G., Sidman, C.L. (1984). “Viable motheaten,” a new allele at the motheaten locus. I. Pathology. Am J Pathol 116, 179–192. Sica, G.L., Choi, I.H., Zhu, G., Tamada, K., Wang, S.D., Tamura, H., et al. (2003). B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849–861. Sidman, C.L., Shultz, L.D., Hardy, R.R., Hayakawa, K., Herzenberg, L.A. (1986). Production of immunoglobulin isotypes by Ly-1+ B cells in viable motheaten and normal mice. Science 232, 1423–1425. Slingsby, J.H., Hogarth, M.B., Walport, M.J., Morley, B.J. (1997). Polymorphism in the Ly-17 alloantigenic system of the mouse FcgRII gene. Immunogenetics 46, 361–362. Smith, K.G.C., Fearon, D.T. (1999). Receptor modulators of BCR signalling—CD19/22. Curr Top Microbiol Immunol 245, 195–212. Smith, K.G.C., Tarlinton, D.M., Doody, G.M., Hibbs, M.L., Fearon, D.T. (1998). Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med 187, 807–811. Stebbins, C.C., Watzl, C., Billadeau, D.D., Leibson, P.J., Burshtyn, D.N., Long, E.O. (2003). Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 23, 6291–6299. Takai, T., Ono, M., Hikida, M., Ohmori, H., Ravetch, J.V. (1996). Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379, 346–349. Takata, M., Sabe, H., Hata, A., Inazu, T., Homma, Y., Nukada, T., et al. (1994). Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 13, 1341–1349. Tamir, I., Dal Porto, J.M., Cambier, J.C. (2000). Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction. Curr Opin Immunol 12, 307–315.
IN
THE
MOUSE
273
Taylor, P.A., Lees, C.J., Fournier, S., Allison, J.P., Sharpe, A.H., Blazar, B.R. (2004). B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions. J Immunol 172, 34–39. Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A., Sharpe, A.H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541–547. Tsui, H.W., Siminovitch, K.A., de Souza, L., Tsui, F.W. (1993). Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 4, 124–129. Ueda, H., Howson, J.M., Esposito, L., Heward, J., Snook, H., Chamberlain, G., et al. (2003). Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506–511. Vely, F., Olivero, S., Olcese, L., Moretta, A., Damen, J.E., Liu, L., et al. (1997). Differential association of phosphatases with hematopoietic co-receptors bearing immunoreceptor tyrosine-based inhibition motifs. Eur J Immunol 27, 1994–2000. Wakeland, E.K., Liu, K., Graham, R.R., Behrens, T.W. (2001). Delineating the genetic basis of systemic lupus erythematosus. Immunity 15, 397–408. Wang, J., Koizumi, T., Watanabe, T. (1996). Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 184, 831–838. Watanabe, N., Gavrieli, M., Sedy, J.R., Yang, J., Fallarino, F., Loftin, S.K., et al. (2003). BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4, 670–679. Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., Thompson, C.B., et al. (1995). Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985–988. Xiu, Y., Nakamura, K., Abe, M., Li, N., Wen, X.S., Jiang, Y., et al (2002). Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. J Immunol 169, 4340–4346. Yamanashi, Y., Tamura, T., Kanamori, T., Yamane, H., Nariuchi, H., Yamamoto, T., et al. (2000). Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. Genes Dev 14, 11–16. Yu, C.C., Tsui, H.W., Ngan, B.Y., Shulman, M.J., Wu, G.E., Tsui, F.W. (1996). B and T cells are not required for the viable motheaten phenotype. J Exp Med 183, 371–380. Yuasa, T., Kubo, S., Yoshino, T., Ujike, A., Matsumura, K., Ono, M., et al. (1999). Deletion of Fcγ receptor IIB renders H-2b mice susceptible to collagen-induced arthritis. J Exp Med 189, 187–194.
This page intentionally left blank
Chapter 13 Mouse Models of Immunodeficiency B. Anne Croy, James P. Di Santo, Marcus Manz, and Richard B. Bankert
I. II.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Commonly Used Natural (Spontaneous) Mutant Models and Their Hybrids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. The Athymic “Nude” Mouse (Genotype Foxn1nu; Forkhead Box N1; Chromosome 11, cM 45.0) . . . . . . . . . . . . . . . . . . . . . . . . . . B. SCID Mice (Genotype Prkdcscid; Protein Kinase, DNA Activated, Catalytic Polypeptide; Chromosome 16 cM 9.2) . . . . . . . . . . . . . . . . . C. Nonobese Diabetic Strains (Genotype Idd#; Insulin-Dependent Diabetes Susceptibility Genes; Multiple Chromosomes) . . . . . . . . . . . D. NOD-scid (NOD-Prkdc) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III. Commonly Used, Genetically Engineered Immune-Deficient Strains and Their Hybrids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Rag1 or Rag2 Gene Deleted (T and B Cell–Deficient; Chromosome 2, cM 56.0) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Common Cytokine Chain γ Null (T and NK Cell–Deficient; Il2rg; Interleukin 2 Receptor γ; X Chromosome) and Related Cytokine Signaling-Deficient Strains . . . . . . . . . . . . . . . . . . . . . . . . . . C. Alymphoid Mice (T, B, and NK Cell–Deficient) . . . . . . . . . . . . . . . . . D. Lymphotoxin and Lymphotoxin Receptor Null Mutants (Lta, Chromosome 17 cM 19.059; Ltb, Chromosome 17 cM 19.061; Ltbr, Chromosome 6 cM 60.4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E. Complement Cascade Disrupted Strains . . . . . . . . . . . . . . . . . . . . . . . . F. Gene Overexpression Resulting in Impaired Immune Responsiveness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Point Mutagenesis to Create Immunologically Deficient and Immune-Modified Mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Specialized Allogeneic and Xenogeneic Transplantation Applications Using Immune-Deficient Hosts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Analysis of Mouse Lymphohematopoietic Cell Lineage Differentiation B. Analyses of Differentiation of Human Lymphohematopoietic Cell Lineages . . . . . . . . . . . . . . . . . . . . . . . . . . C. Analyses of Therapeutic Strategies for Cancer Patients . . . . . . . . . . . . D. Analyses of the Maternal-Fetal Interface . . . . . . . . . . . . . . . . . . . . . . . . VI. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
276 277 277 278 278 278 278 278
279 279
279 280 280 280 281 281 281 283 284 284 285 Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
275
276
B.
ANNE
I.
C R O Y,
JAMES
P.
DI
SANTO,
INTRODUCTION
There are many types of genetically immune-deficient mice. Immune-deficient mice include spontaneously mutant (Joliat and Shultz 2001) and genetically engineered deleted or transgenic and mutagen exposed lines (Nelms and Goodnow 2001; Schorle et al. 1991; Ziljstra et al. 1989). The numbers of immunedeficient lines and strains available for research continue to increase through intercrossing of established lines and by new genetic engineering and mutagenesis (Maurer et al. 2002; Nelms and Goodnow 2001). Murine immune deficits, like those in humans, range from very mild to complete absence of multiple immune cell lineages (Fischer et al. 1997). Genetic loss of one or more lymphocyte lineage or its significant impairment creates an absolute requirement for specialized husbandry to provide a barrier to microbiological agents that would compromise the health of these animals. Most modern animal facilities have barrier areas. It is ideal that mice with even mild immune deficiencies be housed under barrier conditions and regularly monitored for disease through post-mortem histopathological analysis. Post-mortem examinations of immune-deficient mice will have unusual findings (Ward et al. 2000). These will be specific for genotype, and it is helpful for the investigator to advise the pathologist of anticipated findings that are “normal” for the strain being examined. Findings may include missing organs [i.e., thymus (Pantelouris 1968) or lymph nodes (Rennert et al. 1996; Kim et al. 2000)], unusually sized organs (the spleen is small in some strains and dramatically enlarged in others (Nilsson and Bertoncello 1994) and modified microscopic architecture (e.g., absence of nasal-associated lymphoid tissue (Ying et al. 2005), absence of Peyer’s patches (Rennert et al. 1996), or great reductions in bone marrow cavity space (Tagaya et al. 2000), or more subtle distortion of subregions within a lymphoid structure (Junt et al. 2002). Serological surveillance requires use of immune-competent sentinels because seroconversion due to pathogen exposure does not occur in most severely immune-compromised mice.
MARCUS
MANZ,
AND
RICHARD
B.
BANKERT
Immune deficiencies encompass not only the lymphocyte lineages but all other immune cell types such as granulocytes, macrophages, and dendritic cells (Guleria and Pollard 2001). Expression of immune deficiency may result from alterations in properties intrinsic to immune cells themselves, such as absence of a cytokine receptor (di Santo 2000) or downstream receptor signaling molecule (Kaplan et al. 1998) or may result from changes extrinsic to the immune cell. The latter would include a reduction or absence in cytokine support (Guleria and Pollard 2001; Kennedy et al. 2000; Leonard 2001; Ranson et al. 2003) or altered hormone-mediated effects (Thurmond et al. 2000). Often, when a series of distinct deletions is made in a common pathway, the resulting animals are similar. For example, deletion of the common cytokine receptor chain γ (γc), blocks signaling by interleukin (IL)-15 and several additional cytokines. The resulting mice are similar to those in which IL-15 is deleted as well as those in which Jak3 (Janus-family tyrosine kinase-3) is deleted. Jak3 is a downstream transcription factor from the IL-15 receptor (Fischer et al. 1997). The vast range of immune deficits and the large number and continuing development of new mutant lines make it impractical to discuss murine immune-deficient models briefly but comprehensively. For example, in 1996, mice deleted for the proinflammatory cytokine tumor necrosis factor-α (TNF-α) were reported (Pasparakis et al. 1996). Today (mid-2006), strain panels are being reported in which TNF-α deletion occurs only in T cells, only in B cells, and only in macrophages (Grivennikov et al. 2005). Use of the panel permits identification of critical, nonredundant functions of TNF-α in promotion of pathogenesis and health. Readers will find the most up-to-date information in electronic databases. Of particular interest is the Wellcome Trust (UK) Library of Immune Variants. Table 13-1 provides current Web addresses for governmentally supported consortia providing mouse genomic and phenomic information. It is essential to assess immune parameters in phenotyping of all new strains. Deletions of a number of molecules not primarily associated with the immune system have resulted in major immune deficiencies. Examples are the severe natural killer (NK) cell deficit in mice deleted for the vitamin D
TABLE 13-1
DATABASES PROVIDING ACCESS TO ESTABLISHED AND EMERGING IMMUNE-DEFICIENT MICE Name of Database
Address
Wellcome Trust (UK) Library of Immune Variants Comparative Resources Medicine Directory Canadian Mutant Mouse Resource European Mutant Mouse Archive MRC Mammalian Genetics Unit, Harwell Riken BioResource Center Australian Phenomics Facility Mouse Genome Informatics International Mouse Strain Resource
http://www.apf.edu.au/resources/wt/data.shtml http://www.ncrr.nih.gov/ncrrprog/cmpdir/RODENT.asp http://www.cmmr.ca/index.html http://www.emma.rn.cnr.it http://www.mgu.har.mrc.ac.uk http://www.brc.riken.jp/lab/animal/en http://www.apf.edu.au/index.shtml http://www.informatics.jax.org http://www.jax.org/resources/mouse_resources.html
13. MOUSE
MODELS
OF
IMMUNODEFICIENCY
upregulated protein 1 (Lee et al. 2005) and the resistance to induction of autoimmune disease in mice deleted for an amine oxidase known as vascular adhesion protein-1 (Stolen et al. 2005). In this chapter we will focus on commonly used, severely immune-deficient strains that have been cornerstones for studying the immune system via genetic functional deletion. It should be noted that a single gene may be mutated in multiple ways at a single point or, because of its length, at different points (Gauen et al. 1994). Alterations at key residues within the one gene may affect the immune system differentially, causing immune hypersensitivity, autoimmunity, or immune deficiency. Investigations of these types of variations and defining the phenotypes of newly induced mutations in genes that affect the immune system represent a major effort in current studies of the mouse immune system (Nelms and Goodnow 2001). The common immune-deficient strains are most often used to define the steps in lymphohematopoietic cell differentiation and its regulation (Traggiai et al. 2004; Vosshenrich et al. 2005) and to define susceptibility, development, progression, pathogenesis, and therapy of infectious diseases (Mercer et al. 2001) and tumors (Dore et al. 1987; Hess et al. 2003). The success of many of these studies has depended upon adoptive cell transfer and the ability of immune-deficient mice to support not only syngeneic cells but also allogeneic and xenogenic cells and tissues. The “humanized” immune-deficient mouse has been and continues to be of unique value in providing new models to approach experimental therapeutic manipulations. Examples of these applications conclude our chapter.
II.
COMMONLY USED NATURAL (SPONTANEOUS) MUTANT MODELS AND THEIR HYBRIDS
A.
The Athymic “Nude” Mouse (Genotype Foxn1nu; Forkhead Box N1; Chromosome 11, cM 45.0)
In 1968, a spontaneous mouse mutation presenting as hairless and designated nu/nu was reported to be athymic (Pantelouris 1968). Nude mice do not develop thymus-derived T cells, but they retain functional extrathymic T cell differentiation pathways and low levels of T cells. Distribution of this mutant and its commercial development triggered research with immune-deficient mice and fueled the development of new types of caging and husbandry procedures now taken as routine for successful work with immune-deficient rodents (Committee on Immunologically Compromised Rodents 1989). Nude mice accept a wide range of xenografts (Manning et al. 1973), but they are best known as hosts for murine or xenogeneic tumor transplants. Because some types of transplanted tumors metastasize in patterns similar to those seen in in situ disease, tumor-transplanted nude mice have been extensively used to
277 investigate antioncogenic therapies. At the beginning of April 2005, PubMed held ~30,000 publications on nude mice with >21,000 related to tumor biology. The nude mutation, now formally designated Foxn1nu/Foxn1nu, blocks normal development of epithelium (Brissette et al. 1996; Lee et al. 1999; Nehls et al. 1994) by alteration of a wingedhelix/forkhead transcription factor. This gives the characteristic hairless state with twisted toenails. In normal mice at fetal gestation day 10–11, the aortic arches bud off the epithelial anlage of the thymus. This does not happen in the Foxn1nu/Foxn1nu nude mouse. Development of most T cells requires transit through the thymus, where maturation and clonal deletion occur. Thus, T cell deficiency is the major immune defect in nude mice. Because T cells provide cytokine help in B cell differentiation and activation, reduced B cell function is seen in these mice. Nude mice have highly activated NK cells that can be undesirable for some research applications (Clark et al. 1981). The residual mucosally associated T cells, activated innate immunity, and B cell responsiveness make nude mice less susceptible to microbial challenge than immune-deficient mice lacking more than a one lineage (Bonnez et al. 1993; Croy and Percy 1993). Nude mice have elevated rates of some types of spontaneous tumors compared with their heterozygote littermates or wild-type mice, but these do not usually restrict experiments (Dore et al. 1987). By backcrossing, a number of other spontaneous mutants have been combined with nude. One of these, “beige/nude/Xid,” is a mouse homozygously deleted for three spontaneous immune deficiency genes, each impairing a separate lymphocyte lineage. Beige/nude/Xid was the first pan-lymphocyte-impaired strain and it served as a forerunner to alymphoid strains now available. Beige (Lystbg) reduces NK cell lytic but not cytokine functions, nude (Foxn1nu) removes thymus-derived T cells, and Xid, X-linked Bruton agammaglobulinemia tyrosine kinase (Btkxid), greatly reduces the number of B cells (Brandt et al. 1981; Cancro et al. 2001). Beige/nude/Xid was the first strain routinely successful for study of engrafted normal human lymphohematopoietic stem cells (Kamel-Reid and Dick 1988). The most recently defined T cell subset is a minor population referred to as “regulatory” T cells (Treg). These cells are mostly CD25+ (IL-2 receptor α chain) CD4+CD8−, appear lineage committed by the forkhead transcription factor FOXP3 and function in promotion of self-tolerance, i.e., suppression (Fontenot and Rudensky 2005). Treg arise in the thymus and require signals from T cell receptors during their differentiation. This was established by studies in which Treg failed to develop when major histocompatability complex (MHC) class I-restricted T cell receptor transgenic mice were crossed to Rag null mice who are unable to construct T cell receptors (see Section III.A later). Autoimmune diseases arise in the absence of functional Treg. Mice deleted in IL-2, its receptor chains, FOXP3, the glucocorticoid-inducible tumor necrosis factor receptor (GITR), CD80, CD86 and the spontaneous mutant scurfy have been valuable in establishing Treg as a separate functional lineage (Fontenot et al. 2005; Stephens et al. 2004; von Boehmer 2005).
278 B.
B.
ANNE
C R O Y,
JAMES
P.
DI
SANTO,
SCID Mice (Genotype Prkdcscid; Protein Kinase,
MARCUS
C.
MANZ,
AND
RICHARD
B.
BANKERT
Nonobese Diabetic Strains (Genotype Idd#;
DNA Activated, Catalytic Polypeptide;
Insulin-Dependent Diabetes Susceptibility
Chromosome 16 cM 9.2)
Genes; Multiple Chromosomes)
Reduced plasma immunoglobulin is indicative of compromise to the B cell lineage. The SCID mutation (scid/scid, severe combined immune deficiency older nomenclature; formally Prkdc gene and Prkdcscid genotype) was found as spontaneous agammaglobulinemia in an immunoglobulin genotyping experiment conducted in barrier-raised C.B-17 mice and was first reported in 1983 (Bosma et al. 1983). At the time of writing of the chapter, PubMed included >8000 citations for the “SCID mouse.” If the search term is “SCID or RAG and mouse” citations number just over 12,000. C.B-17-scid mice are mutated in the DNA-dependent protein kinase necessary for joining nonhomologous ends of double-stranded DNA. These ends are created by recombinase activating gene (RAG) products during somatic rearrangement of immunoglobulin molecules (B cell receptors) and T cell receptors. Thus, SCID and the RAG1 null and RAG2 null mice subsequently created (Mombaerts et al. 1992; Shinkai et al. 1992) lack both T and B cell lineages. These three T and B cell-deficient strains can be used interchangeably for many applications. Because C.B-17-scid mice have reduced ability to repair DNA, they have been found to be very sensitive to irradiation compared with other strains, including RAG1 null and RAG2 null (Essers et al. 2000). They also frequently develop very large primary thymic lymphomas that can almost fill the thoracic cavity (Martina et al. 2003). This results in wasting and can lead to death, although humane euthanasia is strongly recommended once wasting is observed. Thymomas are not usually seen in animals younger than 16 weeks of age unless they have been irradiated or subjected to other DNA-damaging events. Another feature of the C.B-17-scid mouse is the development of “leakiness” with age (Bosma and Carroll 1991). This refers to detection of low concentrations of antibodies in plasma or serum as the mice age. The amounts of antibody never reach the concentrations seen in immune-competent animals, and the antibodies are of very limited specificity (i.e., oligoclonal) (Gibson et al. 1989). For some applications, endogenous antibodies may complicate experimental interpretation. It should be noted that maternal immunoglobulins will pass to the pups during lactation (Broen and Cafruny 1993) if the dam is leaky or immune competent (i.e., heterozygote mother or wild-type mother receiving C.B-17-scid conceptuses by embryo transfer). Thus, serological testing for immunoglobulin should not be undertaken during the first 2 weeks after weaning of C.B-17-scid pups because falsepositive results may be found. If the lactating mother is immunoglobulin negative, testing can be undertaken at weaning. Genotype, but not leakiness, can be determined by DNA analysis.
Many autoimmune mouse strains have been bred from the original lines referred to as nonobese diabetic (NOD). A series of polygeneic interactions accounts for the phenotype. Many of these genes have been mapped and are called insulin-dependent diabetes susceptibility genes (Leiter 1997). The NOD model of type 1 juvenile diabetes has a generalized dysregulation of the immune system that contributes to inflammation and destruction of pancreatic islets. The immunological problems in NOD mice include deficits in antigen presentation, T cell regulation, NK cell function, cytokine production, and the absence of the complement protein C5 (Serreze and Leiter 1988). The NOD mouse has been backcrossed to create further immune deficiencies and cytokine deficiencies.
D.
NOD-scid (NOD-Prkdc)
The multiple defects in innate immunity known in NOD mice and the T and B cell defects in adaptive immunity of C.B-17-scid mice led to crossing of the strains and development of the NOD-scid strain reported in 1995 (Shultz et al. 1995). The NOD-scid mouse does not display diabetes but retains the cytokine aberrations of the NOD strain as well as defects in NK cell lysis, macrophage lipopolysaccharide response, and complement C5 (Greiner et al. 1998; Shultz et al. 1995). NOD-scid mice show hypocellularity of their bone marrow and a mild macrocytic anemia with normal hematocrits (i.e., reduced erythrocyte numbers with an increased mean cell volume). Only 10% of NOD-scid mice show immunoglobulin “leakiness,” but there is an elevated rate of thymic lymphoma. The NOD-scid mouse has been widely used as a host for human hematopoietic cells since 1996, when it was reported to accept 5- to 10-fold more human hematopoietic cells than the other immune-deficient mice available at that time (Greiner et al. 1998).
III.
COMMONLY USED, GENETICALLY
ENGINEERED IMMUNE-DEFICIENT STRAINS AND THEIR HYBRIDS A. Rag1 or Rag2 Gene Deleted (T and B Cell–Deficient; Chromosome 2, cM 56.0) Gene ablation technology has produced many immunedeficient mutations. Mice deleted in either Rag1 or Rag2 lack
13. MOUSE
MODELS
OF
adaptive immunity and present a phenotype resembling C. B-17-scid. Rag1 and Rag2 are located next to each other in the mouse genome and in the genomes of all jawed vertebrates that have been investigated (Litman et al. 1999). The RAG1 and RAG2 proteins are only coexpressed in B and T lymphocytes. In these cells, RAG1 and RAG2 form a complex that participates at the earliest steps of somatic gene rearrangement for B cell receptors (immunoglobulin molecules) and T cell receptors by recognizing specific signal sequences and cleaving the DNA. In later stages of rearrangement, the RAG1/RAG2 complex interacts with additional proteins to conduct repair of the nicked DNA and provide a functionally rearranged receptor gene (Fugmann et al. 2000). Thus, loss of function of either Rag1 or Rag2 is sufficient to produce a mouse lacking both T and B cells (Mombaerts et al. 1992; Shinkai et al. 1992). Lymphoid organs in Rag1- or Rag2-deleted mice are small, and these strains do not show the leakiness of oligoclonal lymphocyte rearrangement seen in C.B-17-scid mice.
B.
279
IMMUNODEFICIENCY
Common Cytokine Chain γ Null
(T and NK Cell–Deficient; Il2rg; Interleukin 2
C.
Alymphoid Mice (T, B, and NK Cell–Deficient)
γc null mice provided a starting point for generating viable, nonleaky, alymphoid (i.e., B, T and NK cell–deficient) mouse strains. The complete NK cell deficiency in γc null mice was crossed to the completely B and T cell–deficient RAG null strains to create double mutants. RAG/γc double knockout mice are viable, breed normally, and have a normal lifespan when maintained in protected, specific pathogen–free conditions. In comparison with the RAG null or γc null single mutants, RAG/γc doubly null mice are more susceptible to infections (bacterial, fungal, or viral) and are less efficient in rejecting tumors. The more severe immune deficiency of RAG/γc doubly null mice also extends to their inability to reject allogeneic or xenogeneic tissues. RAG/γc doubly null mice fail to reject H-2 mismatched tissues and accept rat and human xenografts of normal tissue. This last feature of RAG/γc doubly null mice has provided the greatest opportunities to date for creation of human/mouse tissue chimeras that are useful for the study of human physiology as well as pathological conditions (see Section V). NOD/RAG/γc triple null mice capitalize on the same feature (Hiramatsu et al. 2003; Ishikawa et al. 2005; Ito et al. 2002).
Receptor γ; X Chromosome) and Related Cytokine Signaling-Deficient Strains D. Cytokines are soluble proteins that act in autocrine or paracrine fashions to play important roles in hematopoiesis in general and lymphopoiesis in particular. A group of cytokines that includes IL-2, -4, -7, -9, -15, and -21, use a shared signaling component—γc (Vosshenrich and di Santo 2001). These cytokines are essential for normal lymphocyte development and function. Humans deficient in γc manifest X-linked severe combined immunodeficiency disease (SCIDX1), a lethal condition (if untreated) that is characterized by cellular and humoral immunodeficiencies due to the absence of T cells and NK cells. Mice deficient in γc are likewise immune deficient, having reduced (but not absent) T cell development and a complete block in NK cell generation. γc null mice, unlike SCIDX1 patients, have reduced numbers of B cells. The immunophenotype of γc deficiency is copied in mice and humans that are deficient in JAK3 tyrosine kinase, which physically and functionally associates with γc-dependent signaling pathways (Fischer et al. 1997). The immune defects in γc null mice result from the additive effects of inhibiting individual γc-dependent cytokine pathways. Thus, IL-7 deficiency reduces B and T cell development in mice and IL-15 deficiency blocks NK development. γc null mice therefore manifest the sum total of abnormalities found in IL-2, -4, -7, -9, -15, and -21 deficient mice, which further underlines the specificity of individual γc-dependent pathways and functions in vivo (di Santo 2000).
Lymphotoxin and Lymphotoxin Receptor
Null Mutants (Lta, Chromosome 17 cM 19.059; Ltb, Chromosome 17 cM 19.061; Ltbr, Chromosome 6 cM 60.4) A series of mice deleted in lymphotoxin (LT) family members has been important in defining development and organization of murine secondary lymphoid tissue, i.e., lymph nodes, spleen, and intestinal Peyer’s patches (Cupedo and Mebius 2005; Rennert et al. 1996). LTα and LTβ are members of the TNF superfamily. LTα is lymphocyte restricted and secreted as a homotrimer and binds to either of the TNF receptors, TNF-R55 or TNF-R75. LTβ is a surface molecule that only forms heterotrimers which include LTα. These heterotrimers bind to a unique LTβ receptor (LTβR), not to the TNFR (Rennert et al. 1996). Deletion of Lta-generated mice lacking lymph nodes and Peyer’s patches and having disorganized splenic architecture (Detogni et al. 1994; Fu et al. 1997), whereas deletion of TNF (formally Tnfsf1a) generated mice lacking only Peyer’s patches (Matsumoto, Fu, et al. 1997). Deletion of Ltb provided mice with no peripheral lymph nodes or Peyer’s patches but retention of mesenteric and cervical lymph node development. Deletion of Ltbr gave mice without any lymph nodes (Fu and Chaplin 1999). Functional immune deficits accompanied these changes in secondary lymphoid tissues.
280
B.
ANNE
C R O Y,
JAMES
P.
DI
SANTO,
From these initial observations, understanding of murine lymph node development has rapidly advanced (Cupedo and Mebius 2005). Three components that are coordinately involved in establishing the environment for attracting and retaining circulating hematopoietic cells are characterized. These are “lymphoid tissue inducer” cells, stromal organizer cells, and induction of expression of adhesion and vascular addressin molecules. It appears that the various lymph nodes in the body depend upon slightly different signaling events. This fact represents the beginning in understanding the mechanisms for tissue and organ-specific immune monitoring and organ-specific immune responsiveness.
E.
Complement Cascade Disrupted Strains
Complement proteins were among the first described proteins of the immune system. They are found in plasma, extravascular fluids, and cell membranes. The complement system comprises >20 proteins that become activated to provide humoral immunity. Antigen-antibody complexes mediate classical complement activation; the alternative pathway is triggered in antibody-independent interactions, for example, by endotoxin. Complement activation is a proteolyic process that produces cleaved proteins that serve as ligands for receptors carried by polymorphonuclear leukocytes, eosinophils, macrophages, mast cells, and other cell types. This makes the complement system particularly important in host resistance to microbial infection. Genetic complement deficiencies are well characterized in both humans (Colten 1992) and in mice. Mouse genome informatics currently lists ~40 genes associated with complement, including its receptors and inhibitors. A number of immune-deficient strains are available that lack specific components of the complement system (Coxon et al. 1996; Fischer et al. 1996; Matsumoto, Fukuda, et al. 1997; Xu et al. 2000). Mice deleted in the negative complement regulatory protein Crry are of particular interest because of embryo lethality. Investigations of this genotype found that the onset of fetal loss occurred after gestation day 9.5 and was associated with complement activation. In normal mice, CRRY is expressed by gestation day 7.5 on trophoblast cells committed to placental differentiation. In Crry null mice, complement deposits onto the surface of the placenta, leading to extreme implantation site inflammation and fetal death. Only the alternate and not the classic complement activation pathway contributes to this breeding disruption that was subsequently associated with a block to placental angiogenesis (Mao et al. 2003; Xu et al. 2000).
F.
Gene Overexpression Resulting in Impaired Immune Responsiveness
Gene deletion and loss of function mutations are not the only strategies for producing immune-deficient mice. Some immune
MARCUS
MANZ,
AND
RICHARD
B.
BANKERT
defects are created in mice with generalized, organ-specific, or lymphocyte subset-specific forced overexpression of molecules (Araujo et al. 2003; Fehniger et al. 2001; Kondo et al. 1997; Temann et al. 2002). It is becoming routine to contrast deletion and overexpression mutations for complete examination of immune effects of key gene products. Overexpression of genes associated with apoptosis induction or cell survival, such as Fas, Bcl2, Bcl-xL (formally Bcl2l1), and Xiap (formally Birc4) disturbs immune homeostasis and leads to specific immune impairments that accompany overactivity in other components of the immune system (Chuang et al. 2002; Conte et al. 2001; Van Parijs et al. 1998). Overexpression of cytokine genes, such as Il15, can result in chronic inflammation that leads to overproduction of some lymphocyte subsets with relative deficits in others. Il15 overexpressing mice rapidly develop a fatal leukemia (Fehniger et al. 2001).
IV.
POINT MUTAGENESIS TO
CREATE IMMUNOLOGICALLY DEFICIENT AND IMMUNE-MODIFIED MICE Because of the importance of the mouse as a genetic model for most mammalian physiological and pathological processes and the availability of the full genome, an international effort has been organized to identify the functions of all mouse genes using a process of chemical mutagenesis. One of the thrusts in this initiative is to discover new, immunologically variant strains (Nelms and Goodnow 2001). The mutagen N-ethylN-nitrosourea (ENU) is used in this phenotype-driven rather than genotype-driven search for new strains. Usually male mice are mutagenized and then are screened and bred and have their sperm cryopreserved. Generation 2 mice are intercrossed, and generation 3 animals are investigated using 10 generation 3 animals per mutagenized founder. The immune phenotype screen includes humoral immunity and autoimmunity. Sera are collected at 8 weeks of age, followed by immunization with an immunoglobulin-coupled hapten to induce IgG1 and a killed bacterium to induce IgG2a. Fifteen days later, the primary antibody response is measured and is indicative of polarized Th2 versus Th1 responses. A second round of immunization is undertaken 4 weeks after the primary immunization using the immunoglobulin-coupled hapten and a T cell–independent antigen (NP-Ficoll). Sera are collected for evaluation after 7 more days. The antibody titers provide assessment of affinity maturation and humoral memory. Sera are also screened for antinuclear antibodies. According to the Web site for the Wellcome Trust (UK) Library of Immune Variants (http://www.apf.edu.au/resources/wt/data.shtml) “extended immune phenotypes that include hematological cytopenia,” a reflection of immune deficiency, have been obtained. Currently listed as ENU5WT45 is a mouse without B cells.
13. MOUSE
MODELS
OF
ENU4AT92 and ENU4AT13 are lymphopenic, whereas a number of strains show low IgG or low responses to NP-Ficoll. ENU4AT37 has a killing defect. Mice generated in the ENU mutagenesis and phenome screening programs are available to investigators internationally. This rapidly changing resource site should be consulted by investigators requiring up-to-date information for protocol design.
V.
281
IMMUNODEFICIENCY
SPECIALIZED ALLOGENEIC AND
XENOGENEIC TRANSPLANTATION APPLICATIONS USING IMMUNE-DEFICIENT HOSTS A. Analysis of Mouse Lymphohematopoietic Cell Lineage Differentiation Like all hematopoietic lineages, lymphocytes derive from hematopoietic stem cells (often called HSCs) that are produced during embryonic, fetal, and adult life. One extremely useful approach to study hematopoietic development has been the use of murine hematopoietic stem cell chimeras, whereby HSCs are transferred into appropriately conditioned recipients. The transferred hematopoietic stem cells are subsequently capable of long-term reconstitution of all differentiated blood cell types (white blood cells, red blood cells, platelets, etc.) in the recipient animal. Several aspects of the host-conditioning regimen influence the success of hematopoietic stem cell engraftment. These include the availability of environmental niches (or stem cell “space”) as well as immunological tolerance of the host since hematopoietic stem cells can be rejected by host T or NK cells. Alymphoid RAG/γc null mice have proven to be the recipients of choice for hematopoietic stem cell transfer because these hosts have normal radiation sensitivity (Mazurier et al. 1999) unlike C.B-17-scid mice that are highly radiation sensitive (Fulop and Phillips 1990) and due to their complete deficiency in alloreactive lymphocytes, especially NK cells (Colucci et al. 1999). Direct comparisons of RAG null versus RAG/γc null show that the latter are superior hosts for allogeneic hematopoietic stem cells and especially those from embryos (Colucci et al. 2000; Cumano et al. 2001). Because recipient RAG/γc null mice are completely alymphoid, all lymphocytes present after hematopoietic stem cell transfer are, by definition, donor-derived. The recent derivation of RAG/γc null mice bearing different H-2 alleles (H-2b, H-2d, or H-2k; Traggiai et al. 2004) and hematopoietic marker allotypes (CD45.1 or CD45.2) provides an additional means to unambiguously distinguish the origins of nonlymphoid, but hematopoietic-derived, cells after transfer of HSC into RAG/γc null recipients.
B.
Analyses of Differentiation of Human Lymphohematopoietic Cell Lineages
For ethical and practical reasons, most research on human cells and tissues has been restricted to in vitro assays that have brief time courses and lack the major components and complexity of a living organism. With the increasing availability of immunodeficient mice that have reduced capacities for rejection of xenogenic grafts, it has become possible to develop in vivo models to study aspects of normal human lymphohematopoiesis. In these models, human hematopoietic cells and tissues and/or hematopoietic stem and progenitor cells are transplanted into immunodeficient recipients. Human cells and subcellular components can then be detected in the xenogenic hosts, simply by using human-specific markers for fluorescenceactivated cell sorting, enzyme-linked immunosorbent assay, polymerase chain reaction, immunostaining, or in situ hybridization. Within the last two decades, tremendous progress has been made in shaping xenogenic human to mouse transplantation models to more and more faithfully resemble the human lymphohematopoietic system. Table 13-2 summarizes selected publications on human to mouse xenotransplantation models. In pioneering work during the late 1980s, three groups initiated the broad use of mice as recipients for normal human hematopoietic cells: Mosier et al. (1988) transferred human peripheral blood leukocytes into severe combined immunodeficient mice (hu-PBL-SCID mice), McCune et al. (1988; McCune 1996) transplanted human fetal liver hematopoietic cells, fetal bone, fetal thymus, and fetal lymph nodes into C.B-17-scid mice (SCID-hu mice), and Kamel-Reid and Dick (1988) engrafted beige/nude/X-linked immunodeficient mice with human bone marrow cells. Both hu-PBL-SCID mice that maintain B and T cells over a limited time and SCID-hu mice that support de novo differentiation of B and T cells are used to study some aspects of adaptive immune responses, for example, in viral infections such as human immunodeficiency virus (HIV) (Mosier 2000). However, these models are associated with substantial limitations. Hu-PBL-SCID mice produce human recall, but rarely primary immune responses (Delham et al. 1998; Lapenta et al. 2003; Mosier 2000; Mosier et al. 1988; Sandhu et al. 1994), and activation of transferred human xenoreactive T cells can cause graft-versus-host disease (Pflumio et al. 1993; Tary-Lehmann et al. 1994). SCID-hu mice require multiple fetal tissues and are labor and cost intensive, and primary human immune responses to vaccinations are only detectable upon transplantation of additional nonhematopoietic human tissues such as skin (Carballido et al. 2000). To study human hematopoietic stem cells and early hematopoiesis, models were improved (for review see Greiner et al. 1998). Initial studies with both beige/nude/X-linked immunodeficient as well as C.B-17scid mice showed rather low levels of hematopoietic engraftment. This, however, changed dramatically once nonobese diabetic-scid (NOD-scid) mice were generated. NODscid mice display additional defects in the innate immune system
282
B.
ANNE
C R O Y,
JAMES
P.
DI
SANTO,
MARCUS
MANZ,
AND
RICHARD
B.
BANKERT
TABLE 13-2
SELECTED PUBLICATIONS ON HUMAN TO MOUSE XENOTRANSPLANTATION MODELS Cell/Tissue Source for Transplantation
Route of Transplantation
Type of Human Cell Engraftment
i.p. Surgery
B, Ig, T, myelomonocytic B, Ig, T, myelomonocytic
Adult Adult
PBMNC FL, FTh, FLN, FBone, Fskin BM CB, BM, PB
i.v. i.v.
Myelomonocytic B, myelomonocytic
NOD-scid/β2m−/−
Adult
CB, BM, PB
i.v.
B, myelomonocytic
NOD-scid anti-IL-2Rβ NOD-scid β2m−/− NOD-scid
Adult Newborn Adult
CB CB CB
i.v. i.v., i.p., i.h. i.v.
NOD-scid/γc (NOG)
Adult
CB
i.v.
Rag2−/−gγc−/− (huAIS-RG) NOD-scid/γc−/− (complete) NOD-scid/γc−/− (complete) Rag2−/−gγc−/− (huAIS-RG)
Newborn
CB
i.h.
Adult
PB +/-IL-7
i.v.
Newborn
CB CD34+
i.v.
Newborn
FL
i.p.
B, T, myelomonocytic B, T, myelomonocytic B, myelomonocytic, DC, IPC B, Ig, T, NK, myelomonocytic B, Ig, T, myelomonocyte, DC, IPC B, Ig, T, NK, myelomonocytic, IPD B, Ig, T, myelomic, DC, IPC, mouse FDC B, T, myelomonocytic, onocytic, erythrocytes, megakaryocytes
Recipient Mouse
Recipient Age
SCID (hu-PBL-SCID) SCID (SCID-hu)
Adult Adult
Bnx NOD-scid
Reference Moiser et al. 1988 Carballido et al. 2000; McCune 1996; McCune et al. 1988 Kamel-Reid and Dick 1988 Greiner et al. 1998; Lowry et al. 1996; Pflumio et al. 1996 Glimm et al. 2001; Kollet et al. 2000 Kerre et al. 2002 Ishikawa et al. 2002 Cravens et al. 2005; Palucka et al. 2003 Hiramatsu et al. 2003; Ito et al. 2002; Yahata et al. 2002 Gimeno et al. 2004; Schotte et al. 2003 Shultz et al. 2005 Traggiai et al. 2004 Ishikawa et al. 2005
PBMNC, peripheral blood mononucleated cells; i.p., intraperitoneal; i.v., intravenous; i.h., intrahepatic; B, B cells; Ig, human immunoglobulins; T, T cells; myelomonocytic, myelomonocytic cells; FL, fetal liver; FTh, fetal thymus; FLN, fetal lymph node; FSkin, fetal skin; Bnx, beige/nude/X-linked immunodeficiency; BM, bone marrow; CB, cord blood; PB, peripheral blood; IL-2Rβ, interleukin-2 receptor β; DC, dendritic cells, IPC, natural interferon type I–producing cells, NK, NK cells; FDC, follicular dendritic cells.
(complement, macrophage, and NK cell deficiency as described earlier in this chapter) that promote about 1 log-fold better human stem and progenitor cell engraftment levels than C.B-17scid mice (i.e., human cells in some animals were found to account for up to 80% of all nucleated cells in hematopoietic tissues). Since then, NOD-scid mice have become the standard human to mouse xenotransplantation model for researchers studying early human hematopoiesis (Greiner et al. 1998; Hogan et al. 1997; Lowry et al. 1996; Pflumio et al. 1996; Wang et al. 1997). Upon human stem and progenitor transfer, NOD-scid mice maintain donor stem cells for a limited time (up to about 1/2 year) and develop B cells as well as some myelomonocytic cells. In addition, development of dendritic cells and natural type I interferon-producing cells was recently reported (Cravens et al., 2005; Palucka et al. 2003). However, no significant human T cell development occurs in engrafted NOD-scid mice, and B cells do not mature to immunoglobulin-secreting plasma cells, probably because of the lack of T cell help. Thus, human lymphohematopoietic reconstitution remained incomplete and stem and progenitor cell transplanted NOD-scid mice were not suitable models to study all aspects of human lymphohematopoietic reconstitution and function.
Most recently, relevant T cell development and consecutive B cell maturation to immunoglobulin-secreting cells was observed, when residual mouse NK cells were eliminated, and incoming human stem and progenitor cells (isolated from fetal liver, cord blood, bone marrow, and peripheral blood as cytokine mobilized stem and progenitor cells) were given an environment highly supportive for immune system development (Glimm et al. 2001; Kollet et al. 2000). NK cell elimination was achieved by either antibody-induced depletion (anti-IL-2 receptor β chain; Kerre et al. 2002) or by genetic deletion of the signaling part or of the complete common cytokine receptor chain γ, a receptor component essential for NK cell development. The most supportive environmental conditions were achieved by transplanting cells into newborn Rag2 null/γc null or NOD-scid/γc null mice of specific H-2 backgrounds, ready to expand their immune system, or by adding human IL-7 to adult transplanted NOD-scid/γc null animals (Gimeno et al. 2004; Hiramatsu et al. 2003; Ishikawa et al. 2002, 2005; Ito et al. 2002; Schotte et al. 2003; Shultz et al. 2005; Traggiai et al. 2004; Yahata et al. 2002) (Table 13-2). In mice in which human B cells, T cells, NK cells, myelomonocytic cells, dendritic cells, natural interferon-producing cells, and even some human erythrocytes and megakaryocytes develop, human
13. MOUSE
MODELS
OF
IMMUNODEFICIENCY
cells form primary and secondary lymphoid organ structures and even induce some mouse lymphoid tissue development, as shown by the formation of mouse follicular dendritic cells, probably induced by lymphotoxin α expression on human B cells. This implies substantial conservation and cross-reactivity of some important elements of the lymphohematopoietic system across species barriers. The availability of these “complete” human immune system reconstituted animals will certainly improve research on human immune system–specific viruses such as HIV and Epstein-Barr virus (EBV), may be useful for the generation of human monoclonal antibodies, and will probably allow “preclinical” testing of vaccinations or substances that specifically target the human lymphohematopoietic system. However, although NOD-scid mice and now NOG (NOD-scid/γc null) and huAIS-RG mice (human adaptive immune system RAG/γc null) provide powerful models to study aspects of human lymphohematopoietic cell development and function, they are still probably far from perfect. In terms of human T cell selection in the thymus and MHC restriction in a mouse, it might be useful to transgenically express human MHC on nonhematopoietic cells, such as thymic stroma, in future models. In terms of “parking” human hematopoietic stem cells for maintenance, it may become useful to provide human cytokines and chemokines or additional human nonhematopoietic cell support. In this way, further improvements will be made to produce models that even more faithfully resemble the development and function of the human lymphohematopoietic-system.
C.
Analyses of Therapeutic Strategies for Cancer Patients
The ability to engraft human tumors, human immunocompetent cells, and nondisrupted tumor biopsy tissues has been successfully exploited to evaluate a wide variety of therapeutic approaches to cancer (Bankert et al. 2001). The simplest and most widely utilized version of these mouse models uses single cell suspensions of human tumor cell lines implanted orthotopically or ectopically into nude (Foxn1nu/Foxn1nu or Prkdcscid) or other immunodeficient mice. Both conventional as well as novel chemotherapeutic agents have been evaluated (Guilbaud et al. 1997; Hua and Pero 1997; Jounaidi and Waxman 2000; Kamishohara et al. 1996; Kuo et al. 1993; Nielson et al. 1999; Sharma et al. 1997; Silver and Piver 1999; Tanaka et al. 1994; Tang et al. 1998; Teicher et al. 1997). The ectopic route, in which tumors are implanted subcutaneously, is the most common application because it is possible to assess drug effects upon the tumor by periodically measuring changes in xenograft volume (usually by use of calipers) after administration of test agents systemically or by direct tumor inoculation. In addition to chemotherapeutic drugs that have direct effects upon tumors, agents that act indirectly upon tumors have been
283 successfully evaluated in SCID mouse-human tumor models. For example, monoclonal antibodies specific for endothelial cells have been used to inhibit angiogenesis and shown to inhibit the progression of human breast tumor xenografts (Brooks et al. 1995). The orthotopic route, in which tumors are implanted into the organ in which the tumor originated, are more physiologically relevant for studying therapeutic effects upon tumor progression and metastases. This approach is less frequently utilized because of the difficulty in monitoring tumor growth over time. To overcome this limitation, tumor cells have been transfected with marker genes (i.e., prostate-specific antigen), and their progression has been monitored by quantifying the level of the tumor marker protein in sera from the tumor-bearing mice (Conway et al. 2000). With this approach the effects of antibody-directed cytotoxic drug-loaded immunoliposomes upon the growth and metastasis of human lung tumor xenografts established orthotopically in the lungs of C.B-17-scid mice were successfully monitored. Several other orthotopic human tumor xenograft models have been developed and used successfully for evaluation of different therapeutic strategies (Boehle et al. 2000; Mohammad et al. 1998). Co-engraftment of human tumors and human immunocompetent cells into immunodeficient mice has been used to evaluate immune-based cancer therapies. These more complex models pose several pitfalls and challenges including the complications of graft-versus-host disease, host-versus-graft disease, and the spontaneous development of EBV-positive human B cell lymphomas that can rapidly kill the host mouse. These limitations and their possible solutions are discussed further in Bankert et al. (2001). One of the earliest successful uses of the co-engraftment model demonstrated that human cytotoxic T cells were able to suppress the growth and spontaneous metastases of human melanomas and that exogenous IL-2 enhanced this cytotoxic T lymphocyte (CTL)–mediated antitumor immunity (Sabzevari and Reisfeld 1993). Additional researchers have used co-engraftment of tumors and effector cells to confirm the efficacy of both allogeneic (Conlon et al. 1996; de Kroon et al. 1997; Riedle et al. 1998) and autologous (Stenholm et al. 1998) tumor-specific CTL or lymphokine activated killer cells (Takahashi et al. 1993) to suppress the growth of human tumors. Novel strategies designed to enhance the delivery of effector cells to tumors, that is, bispecific antibodies (Bohlen et al. 1997; Cochlovius et al. 1999; Manzke et al. 1997; Weiner et al. 1993), enhance the function and duration of effector cells with targeted cytokine delivery (Becker et al. 1996; Dolman et al. 1998; Gillies et al. 1998), or modulate coregulatory molecules (Chen et al. 1995; Foy et al. 1998; Hirano et al. 1999; Kim et al. 1998; Lazarus et al. 1999; Murphy et al. 1999; Parney et al. 1997; Sabel et al. 2000) have been successfully evaluated in C.B-17-scid mice co-engrafted with human tumors and human immunocompetent effector lymphocytes. A relatively simple and effective approach for demonstrating the presence of tumor-specific T cells in the peripheral blood
284
B.
ANNE
C R O Y,
JAMES
P.
DI
SANTO,
leukocytes (PBLs) of tumor-bearing patients is to mix varying numbers of the patient’s PBLs with the patient’s own dissociated tumor cells and then inject the mixed cell suspensions subcutaneously into C.B-17-scid mice. Effector T cells inhibit the development and growth of the tumor xenograft in a titratable, dose-dependent manner (Egilmez et al. 2002). This model is called the SCID/Winn assay because of its analogy to the original Winn model designed to evaluate murine effector cells (Winn 1960). The dissociated tumor cell models discussed above are limited by the absence of a human tumor microenvironment. The microenvironment is a major contributor to tumor progression or arrest, and it is therefore likely to significantly affect responsiveness to therapy. By surgically implanting intact (i.e., not disrupted) small pieces of human tumor biopsy samples into C.B-17-scid mice, xenografts can be established in which the tissue architecture, including tumor-associated leukocytes, endothelial cells, pericytes, tumor cells, and other stromal cells, is functionally preserved (Sugiyama et al. 2001; Williams et al. 1996). This xenograft model established the fact that delivery of exogenous IL-12 into the tumor microenvironment mobilizes human tumor-associated leukocytes to kill tumors in situ by indirect mechanisms that are dependent upon human interferon-γ (Broderick et al. 2005; Hess et al. 2003). Future human-SCID mouse chimeric models for evaluating cancer immunotherapies will probably focus upon engraftment of nondisrupted patient tumor tissue to establish xenografts that retain an intact microenvironment. Investigators should standardize their routes, doses, and schedules of the inoculation of human tissues and the administration of therapeutic agents (e.g., drugs, cytokines, effector cells, and antibodies). This standardization would make it possible to compare results from one laboratory to another more reliably. Ultimately it will be necessary to determine how closely the responses to therapy in xenograft models reflect the responses that are observed in human patients.
D.
Analyses of the Maternal-Fetal Interface
The observation that pregnancies occur normally in most lines of immune-deficient mice has been important in focusing investigations to strains in which pregnancy fails, such as the Crry gene deleted embryo (see Section III.G above) (Xu et al. 2000), to elucidate critical components in the maternal-fetal relationship. A transient influx of NK cells or NK-like cells occurs early in gestation in all species studied to date (Stewart 1998). These cells achieve extremely high numbers in mice, rats, and humans. Histological investigation of various lymphocyte-depleted strains was instrumental in defining the lineage of these pregnancy-associated lymphocytes whereas adoptive cell transfers to pregnant alymphoid hosts has advanced understanding of their biology and in their promotion of placenta-associated angiogenesis (Croy et al. 2003). In the absence of uterine
MARCUS
MANZ,
AND
RICHARD
B.
BANKERT
NK cells, the midgestational structural changes that enlarge the capacity of placental arteries do not occur (Croy et al. 2003). The use of immune-deficient animals in cross-breeding and embryo transfer studies was critical in establishing roles for indoleamine-2,3-dioxygenase in T cell tolerance of the fetus (Mellor et al. 2002; Munn et al. 1998) and in regulatory T cell function at the fetal-maternal interface (Aluvihare et al. 2004; Zenclussen et al. 2005). The mouse is among the species that, like humans, have invasive hemochorial placentae. This, plus the limited access to the human implantation site and the descriptive/correlative nature of the data human uterine samples provide, makes the genetically modified mouse one of the best tools for developing insights into the constantly changing relationships and structures in implantation sites. The ability of alymphoid mice to provide in vivo support for differentiation of early human trophoblast explants (Poehlmann et al. 2004) and for their uterine arteries to undergo the quantifiable, pregnancy-associated vascular changes when exposed to human proteins (Croy et al. 2003), suggest that humanized mouse models addressing the physiology and pathology of human pregnancy can be developed. The mice we have discussed and the transplantation studies we have briefly reviewed are simply examples that illustrate the wide range of immune-deficient lines available and their value in contributing new information on specific research questions. There are numerous additional research areas in which studies using immune-deficient mice have provided seminal understanding. One of these is the arena of infectious diseases (Mercer et al. 2001). By cross-breeding, transfer of embryos or lymphocytes, and/or tissue grafting, powerful novel in vivo models can be created that will continue to advance understanding of processes that promote health and disease.
VI.
SUMMARY
Genetically defined immune-deficient mice are important research tools. Their study has provided deep insights into the differentiation, functions, and regulatory relationships of the immune system. Types of immune-deficient mice range from those with complete absences of multiple immune cell lineages to others with mild alterations. Success in use of immunedeficient mice requires specialized attention to husbandry that will maintain their environment free from microbial contaminants. Under these conditions, most immune-deficient stains are fertile and long lived. Immune-deficient strain development is ongoing with the use of gene-targeting manipulations in embryos, cross-breeding, and mutagenesis. Immune-deficient mice have found special applications as recipients of transplanted murine or xenogenic cells and tissues. They support more complex interactions than most in vitro models and provide an in vivo environment for studies of disease pathogenesis and treatment. in this chapter we have highlighted key features of the major,
13. MOUSE
MODELS
OF
IMMUNODEFICIENCY
historically significant immune deficient strains that have been widely used and provided comparative information to help readers optimize their selection of an immune-deficient strain.
REFERENCES Aluvihare, V.R., Kallikourdis, M., Betz, A.G. (2004). Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5, 266–271. Araujo, J.A., Meng, L., Tward, A.D., Hancock, W.W., Zhai, Y., Lee, A., et al. (2003). Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. J Immunol 171, 1572–1580. Bankert, R.B., Egilmez, N.K., Hess, S.D. (2001). Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22, 386–393. Becker, J.C., Pancook, J.D., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A. (1996). Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 93, 2702–2707. Boehle, A.S., Dohrmann, P., Leuschner, I., Kalthoff, H., Henne-Bruns, D. (2000). An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice. Ann Thorac Surg 69, 1010–1015. Bohlen, H., Manzke, O., Titzer, S., Lorenzen, J., Kube, D., Engert, A., et al. (1997). Prevention of Epstein-Barr virus-induced human B-cell lymphoma in sever combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Cancer Res 57, 1704–1709. Bonnez, W., Rose, R.C., Darin, C., Borkhuis, C., Jensen, K.L.D., Reichman, R.C. (1993). Propagation of human papillomavirus type-II in human xenografts using the severe combined immunodeficiency (SCID). mouse and comparison to the nude-mouse model. Virology 197, 455–458. Bosma, G.C., Custer, R.P., Bosma, M.J. (1983). A severe combined immunodeficiency mutation in the mouse. Nature 301, 527–530. Bosma, M.J., Carroll, A.M. (1991). The SCID mouse mutant—definition, characterization, and potential uses. Annu Rev Immunol 9, 323–350. Brandt, E.J., Swank, R.T., Novak, E.K. (1981). The murine Chediak-Higashi mutation and other murine pigmentation mutations. In Immunological Defects in Laboratory Animals, M.E. Gershwin, B. Merchant, eds., pp. 99–117. Plenum Publishing Corp., New York. Brissette, J.L., Li, L., Kamimura, J., Lee, D., Dotto, G.P. (1996). The product of the mouse nude locus, Whn, regulates the balance between epithelial cell growth and differentiation. Genes Dev 10, 2212–2221. Broderick, L., Yokota, S.J., Reineke, J., Mathiowitz, E., Stewart, C.C., Barcos, M., et al. (2005). Human CD4+ effector memory T-cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-γ, and eradicate tumor cells. J Immunol 174, 898–906. Broen, J.J., Cafruny, W.A. (1993). Immunoglobulin transfer from immunereconstituted SCID mice to nursing neonates: blood distribution of antibody and association with perinatal virus protection. Reg Immunol 5, 44–52. Brooks, P.C., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F.H., Cheresh, D.A. (1995). Anti-integrin αVβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96, 2833–2840. Cancro, M.P., Sah, A.P., Levy, S.L., Allman, D.M., Schmidt, M.R., Woodland, R.T. (2001). xid mice reveal the interplay of homeostasis and Bruton’s tyrosine kinase-mediated selection at multiple stages of B cell development. Int Immunol 13, 1501–1514. Carballido, J.M., Namikawa, R., Carballido-Perrig, N., Antonenko, S., Roncarolo, M.G., de Vries, J.E. (2000). Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice. Nat Med 6, 103–106. Chen, F.A., Williams, S.S., Fanslow, W.C., Bankert, R.B. (1995). Human antibody response in human peripheral blood leukocytes/severe combined
285 immunodeficient chimeric model is dependent upon B and T cell cosimulation via CD40/CD40 ligand. J Immunol 155, 2833–2840. Chuang, P.I., Morefield, S., Liu, C.Y., Chen, S., Harlan, J.M., Willerford, D.M. (2002). Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1. Blood 99, 3350–3359. Clark, E.A., Shultz, L.D., Pollack, S.B. (1981). Mutations in mice that influence natural killer (NK). cell activity. Immunogenetics 12, 601–613. Cochlovius, B., Perschl, A., Adema, G.J., Zoller, M. (1999). Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanomaspecific cytotoxic T cells by bi-specific antibody fragments. Int J Cancer 81, 486–493. Colten, H.R. (1992). Complement deficiencies. Annu Rev Immunol 10, 809–834. Colucci, F., Guy-Grand, D., Wilson, A., Turner, M., Schweighoffer, E., Tybulewicz, V.L.J., et al. (2000). A new look at Syk in αβ and γδ T cell development using chimeric mice with a low competitive hematopoietic environment. J Immunol 164, 5140–5145. Colucci, F., Soudais, C., Rosmaraki, E., Vanes, L., Tybulewicz, V.L.J., di Santo, J.P. (1999). Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation. J Immunol 162, 2761–2765. Committee on Immunologically Compromised Rodents. (1989). Immunodeficient Rodents: A Guide to their Immunobiology, Husbandry, and Use. National Academy Press, Washington, DC. Conlon, K.C., Anver, M.R., Longo, D.L., Ortaldo, J.R., Murphy, W.J. (1996). Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts. J Immunother 19, 317–323. Conte, D., Liston, P., Wong, J.W., Wright, K.E., Korneluk, R.G. (2001). Thymocyte-targeted overexpression of xiap transgene disrupts T lymphoid apoptosis and maturation. Proc Natl Acad Sci USA 98, 5049–5054. Conway, T.F., Sabel, M.S., Sugano, M., Frelinger, J.G., Egilmez, N.K., Chen, F.A., et al. (2000). Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum. J Immunol Methods 233, 57–65. Coxon, A., Rieu, P., Barkalow, F.J., Askari, S., Sharpe, A.H., vonAndrian, U.H., et al. (1996). A novel role for the β2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 5, 653–666. Cravens, P.D., Melkus, M.W., Padgett-Thomas, A., Islas-Ohlmayer, M., Martin, M.D., Garcia, J.V. (2005). Development and activation of human dendritic cells in vivo in a xenograft model of human hematopoiesis. Stem Cells 23, 264–278. Croy, B.A., Esadeg, S., Chantakru, S., van den Heuvel, M., Paffaro, V.A., Jr., He, H., et al. (2003). Update on pathways regulating the activation of uterine natural killer cells, their interactions with decidual spiral arteries and homing of their precursors to the uterus. J Reprod Immunol 59, 175–191. Croy, B.A., Percy, D.H. (1993). Viral hepatitis in scid mice. Lab Anim Sci 43, 193–194. Cumano, A., Ferraz, J.C., Klaine, M., di Santo, J.P., Godin, I. (2001). Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, provide long-term multilineage reconstitution. Immunity 15, 477–485. Cupedo, T., Mebius, R.E. (2005). Cellular interactions in lymph node development. J Immunol 174, 21–25. de Kroon, J.F., van Bergen, C.A., de Paus, R.A., Kluin-Nelemans, H.C., Willemze, R., Falkenburg, J.H. (1997). Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID). mice but show diminished function. J Immunother 20, 101–110. Delhem, N., Hadida, F., Gorochov, G., Carpentier, F., de Cavel, J.P., Andreani, J.F., et al. (1998). Primary TH1 cell immunization against HIVgp160 in SCID-hu mice coengrafted with peripheral blood lymphocytes and skin. J Immunol 161, 2060–2069. Detogni, P., Goellner, J., Ruddle, N.H., Streeter, P.R., Fick, A., Mariathasan, S., et al. (1994). Abnormal-development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 703–707.
286
B.
ANNE
C R O Y,
JAMES
P.
DI
SANTO,
di Santo, J.P. (2000). Severe combined immunodeficiency caused by defects in common cytokine receptor γc signaling pathways. Immunol Allergy Clin North Am 20, 19-+. Dolman, C.S., Mueller, B.M., Lode, H.N., Xiang, R., Gillies, S.D., Reisfeld, R.A. (1998). Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin Cancer Res 4, 2551–2557. Dore, J.F., Bailly, M., Bertrand, S. (1987). Metastases of human tumors in experimental animals. Anticancer Res 7, 997–1003. Egilmez, N.K., Hess, S.D., Chen, F.A., Takita, H., Conway, T.F., Bankert, R.B. (2002). Human CD4+ effector T cells mediate indirect interleukin-12-and interferon-γ-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 62, 2611–2617. Essers, J., van Steeg, H., de Wit, J., Swagemakers, S.M.A., Vermeij, M., Hoeijmakers, J.H.J., et al. (2000). Homologous and non-homologous recombination differentially affect DNA damage repair in mice. EMBO J 19, 1703–1710. Fehniger, T.A., Suzuki, K., Pannappan, A., VanDeusen, J.B., Cooper, M.A., Florea, S.M., et al. (2001). Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 193, 219–231. Fischer, A., Cavazzana-Calvo, M., de Saint Basile, G., de Villartay, J.P., di Santo, J.P. (1997). Naturally occurring primary deficiencies of the immune system. Annu Rev Immunol 15, 93–124. Fischer, M.B., Ma, M.H., Goerg, S., Zhou, X.N., Xia, J.R., Finco, O., et al. (1996). Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 157, 549–556. Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., Rudensky, A.Y. (2005). Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 22, 329–342. Fontenot, J.D., Rudensky, A.Y. (2005). A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6, 331–337. Foy, T.M., McIlraith, M., Masters, S.R., Dunn, J.J., Rossini, A.A., Shultz, L.D., et al. (1998). Blockade of CD40-CD154 interferes with human T cell engraftment in scid mice. Cell Transplant 7, 25–35. Fu, Y.X., Chaplin, D. (1999). Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 17, 399–433. Fu, Y.X., Molina, H., Matsumoto, M., Huang, G.M., Min, J.J., Chaplin, D.D. (1997). Lymphotoxin-α (LTα). supports development of splenic follicular structure that is required for IgG responses. J Exp Med 185, 2111–2120. Fugmann, S.D., Lee, A.I., Shockett, P.E., Villey, I.J., Schatz, D.G. (2000). The rag proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 18, 495–527. Fulop, G.M., Phillips, R.A. (1990). The scid mutation in mice causes a general defect in DNA-repair. Nature 347, 479–482. Gauen, L.K., Zhu, Y., Letourneur, F., Hu, O., Bolen, J.B., Matis, L.A., Klausner, R.D., Shaw, A.S. (1994). Interactions of p59fyn and ZAP-70 with T-cell receptor activation motifs: defining the nature of a signalling motiif. Mol Cell Biol 14, 3729–3741. Gibson, D.M., Bosma, G.C., Bosma, M.J. (1989). Limited clonal diversity of serum immunoglobulin in leaky scid mice. Curr Top Microbiol Immunol 152, 125–136. Gillies, S.D., Lan, Y., Wesolowski, J.S., Qian, X.Q., Reisfeld, R.A., Holden, S., et al. (1998). Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol 160, 6195–6203. Gimeno, R., Weijer, K., Voordouw, A., Uittenbogaart, C.H., Legrand, N., Alves, N.L., et al. (2004). Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2−/− γc−/− mice: functional inactivation of p53 in developing T cells. Blood 104, 3886–3893. Glimm, H., Eisterer, W., Lee, K., Cashman, J., Holyoake, T.L., Nicolini, F., et al. (2001). Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin-null mice. J Clin Invest 107, 199–206.
MARCUS
MANZ,
AND
RICHARD
B.
BANKERT
Greiner, D.L., Hesselton, R.A., Shultz, L.D. (1998). SCID mouse models of human stem cell engraftment. Stem Cells 16, 166–177. Grivennikov, S.I., Tumanov, A.V., Liepinsh, D.J., Kruglov, A.A., Marakusha, B.I., Shakhov, A.N., et al. (2005). Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22, 93–104. Guilbaud, N., KrausBerthier, L., SaintDizier, D., Rouillon, M.H., Jan, M., Burbridge, M., et al. (1997). Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Anti-Cancer Drugs 8, 276–282. Guleria, I., Pollard, J.W. (2001). Aberrant macrophage and neutrophil population dynamics and impaired Th1 response to Listeria monocytogenes in colony-stimulating factor 1-deficient mice. Infect Immun 69, 1795–1807. Hess, S.D., Egilmez, N.K., Bailey, N., Anderson, T.M., Mathiowitz, E., Bernstein, S.H., et al. (2003). Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J Immunol 170, 400–412. Hiramatsu, H., Nishikomori, R., Heike, T., Ito, M., Kobayashi, K., Katamura, K., et al. (2003). Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood 102, 873–880. Hirano, A., Longo, D.L., Taub, D.D., Ferris, D.K., Young, L.S., Eliopoulos, A.G., et al. (1999). Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93, 2999–3007. Hogan, C.J., Shpall, E.J., McNulty, O., McNiece, I., Dick, J.E., Shultz, L.D., et al. (1997). Engraftment and development of human CD34+-enriched cells from umbilical cord blood in, NOD/LtSz-scid/scid mice. Blood 90, 85–96. Hua, J., Pero, R.W. (1997). Toxicity, antitumor and chemosensitizing effect of 3-chloroprocainaminde. Acta Oncol 36, 811–816. Ishikawa, F., Livingston, A.G., Wingard, J.R., Nishikawa, S.I., Ogawa, M. (2002). An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/β2-microglobulinnull mice. Exp Hematol 30, 488–494. Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T., Yoshimoto, G., et al. (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice. Blood 106, 1565–1573. Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., et al. (2002). NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175–3182. Joliat, M.J., Shultz, L.D. (2001). The molecular bases of spontaneous immunological mutations in the mouse and their homologous human diseases. Clin Immunol 101, 113–129. Jounaidi, Y., Waxman, D.J. (2000). Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 60, 3761–3769. Junt, T., Nakano, H., Dumrese, T., Kakiuchi, T., Odermatt, B., Zinkernagel, R.M., et al. (2002). Antiviral immune responses in the absence of organized lymphoid T cell zones in plt/plt mice. J Immunol 168, 6032–6040. Kamel-Reid, S., Dick, J.E. (1988). Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 242, 1706–1709. Kamishohara, M., Kawai, H., Sakai, T., Uchida, T., Tsuruo, T., Otake, N. (1996). Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Cancer Chemother Pharmacol 38, 495–498. Kaplan, M.H., Wurster, A.L., Grusby, M.J. (1998). A signal transducer and activator of transcription (Stat). 4-independent pathway for the development of T helper type 1 cells. J Exp Med 188, 1191–1196. Kennedy, M.K., Glaccum, M., Brown, S.N., Butz, E.A., Viney, J.L., Embers, M., et al. (2000). Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191, 771–780. Kerre, T.C.C., De Smet, G., De Smedt, M., Zippelius, A., Pittet, M.J., Langerak, A.W., et al. (2002). Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34+ cells. Blood 99, 1620–1626.
13. MOUSE
MODELS
OF
IMMUNODEFICIENCY
Kim, D., Mebius, R.E., MacMicking, J.D., Jung, S., Cupedo, T., Castellanos, Y., et al. (2000). Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 192, 1467–1478. Kim, K.M., Min, H.Y., Jung, S.H., Lee, T.H., Kim, J.G., Kang, C.Y. (1998). Characterization of an immunosuppressive anti-CD40 ligand monoclonal antibody. Hybridoma 17, 463–470. Kollet, O., Peled, A., Byk, T., Ben Hur, H., Greiner, D., Shultz, L., et al. (2000). β2 microglobulin-deficient (B2mnull). NOD/SCID mice are excellent recipients for studying human stem cell function. Blood 95, 3102–3105. Kondo, M., Akashi, K., Domen, J., Sugamura, K., Weissman, I.L. (1997). Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common γ chain-deficient mice. Immunity 7, 155–162. Kuo, T.H., Kubota, T., Nishibori, H., Watanabe, M., Furukawa, T., Kase, S., et al. (1993). Experimental cancer-chemotherapy using a liver metastatic model of human colon cancer transplanted into the spleen of severe combined immunodeficient mice. J Surg Oncol 52, 92–96. Lapenta, C., Santini, S.M., Logozzi, M., Spada, M., Andreotti, M., Di Pucchio, T., et al. (2003). Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-α. J Exp Med 198, 187–196. Lazarus, A.H., Crow, A.R., Freedman, J., Blanchette, V., Hannach, B. (1999). Inhibition of a secondary human alloimmune response via the soluble active component of CD154 (CD40L). in severe combined immune-deficient mice engrafted with human lymphocytes. Transfusion 39, 818–823. Lee, D., Prowse, D.M., Brissette, J.L. (1999). Association between mouse nude gene expression and the initiation of epithelial terminal differentiation. Dev Biol 208, 362–374. Lee, K.N., Kang, H.S., Jeon, J.H., Kim, E.M., Yoon, S.R., Song, H., et al. (2005). VDUP1 is required for the development of natural killer cells. Immunity 22, 195–208. Leiter, E.H. (1997). The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Protoc Immunol 4, 15.9.1–15.9.23. Leonard, W.J. (2001). Cytokines and immunodeficiency diseases. Nat Rev Immunol 1, 200–206. Litman, G.W., Anderson, M.K., Rast, J.P. (1999). Evolution of antigen binding receptors. Annu Rev Immunol 17, 109–147. Lowry, P.A., Shultz, L.D., Greiner, D.L., Hesselton R.M., Kittler, E.L., Tiarks, C.Y., et al. (1996). Improved engraftment of human cord blood stem cells in NOD/LtSz-scid/scid mice after irradiation or multiple-day injections into unirradiated recipients. Biol Blood Marrow Transplant 2, 15–23. Manning, D.D., Reed, N.D., Shaffer, C.F. (1973). Maintenance of skin xenografts of widely divergent phylogenetic origin on congenitally athymic (nude) mice. J Exp Med 138, 488–494. Manzke, O., Titzer, S., Tesch, H., Diehl, V., Bohlen, H. (1997). CD3 × CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma. Cancer Immunol Immunother 45, 198–202. Mao, D.L., Wu, X.B., Deppong, C., Friend, L.D., Dolecki, G., Nelson, D.M., Molina, H. (2003). Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity 19, 813–822. Martina, C., Wayne, J., Bell, A., Chang, Y. (2003). In vivo ligation of CD3 on neonatal scid thymocytes blocks gamma-irradiation-induced TCRP rearrangements and thymic lymphomagenesis. Immunol Lett 85, 279–286. Matsumoto, M., Fu, Y.X., Molina, H., Huang, G.M., Kim, J.H., Thomas, D.A., et al. (1997). Distinct roles of lymphotoxin α and the type I tumor necrosis factor (TNF). receptor in the establishment of follicular dendritic cells from non-bone marrow-derived cells. J Exp Med 186, 1997–2004. Matsumoto, M., Fukuda, W., Circolo, A., Goellner, J., Straussschoenberger, J., Wang, X.F., et al. (1997). Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci USA 94, 8720–8725. Maurer, M., Kobsar, I., Berghoff, M., Schmid, C.D., Carenini, S., Martini, R (2002). Role of immune cells in animal models for inherited neuropathies: facts and visions. J Anat 200, 405–414.
287 Mazurier, F., Fontanellas, A., Salesse, S., Taine, L., Landriau, S., Moreau-Gaudry, F., et al. (1999). A novel immunodeficient mouse model— RAG2 × common cytokine receptor γ chain double mutants—requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J Interferon Cytokine Res 19, 533–541. McCune, J.M. (1996). Development and applications of the SCID-hu mouse model. Semin Immunol 8, 187–196. McCune, J.M., Namikawa, R., Kaneshima, H., Shultz, L.D., Lieberman, M., Weissman, I.L. (1988). The Scid-Hu mouse—murine model for the analysis of human hematolymphoid differentiation and function. Science 241, 1632–1639. Mellor, A.L., Chandler, P., Lee, G.K., Johnson, T., Keskin, D.B., Lee, J., et al. (2002). Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol 57, 143–150. Mercer, D.F., Schiller, D.E., Elliott, J.F., Douglas, D.N., Hao, C., Rinfret, A., et al. (2001). Hepatitis C viral replication in mice with chimeric human livers. Nat Med 7, 927–933. Mohammad, R.M., Al Katib, A., Pettit, G.R., Vaitkevicius, V.K., Joshi, U., Adsay, V., et al. (1998). An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. Clin Cancer Res 4, 887–894. Mombaerts, P., Iacomini, J., Johnson, R.S., Herrup, K., Tonegawa, S., Papaioannou, V. (1992). RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877. Mosier, D.E. (2000). Human xenograft models for virus infection. Virology 271, 215–219. Mosier, D.E., Gulizia, R.J., Baird, S.M., Wilson, D.B. (1988). Transfer of a functional human immune-system to mice with severe combined immunodeficiency. Nature 335, 256–259. Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., et al. (1998). Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191–1193. Murphy, W.J., Funakoshi, S., Fanslow, W.C., Rager, H.C., Taub, D.D., Longo, D.L. (1999). CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL-SCID chimeras. Clin Immunol 90, 22–27. Nehls, M., Pfeifer, D., Schorpp, M., Hedrich, H., Boehm, T. (1994). New member of the winged-helix protein family disruped in mouse and rat nude mutations. Nature 372, 103–107. Nelms, K.A., Goodnow, C.C. (2001). Genome-wide ENU mutagenesis to reveal immune regulators. Immunity 15, 409–418. Nielson, L.L., Shi, B., Hajian, G., Yaremko, B., Lipari, P., Ferrari, E., et al. (1999). Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus). in preclinical cancer models. Cancer Res 59, 5896–5901. Nilsson, S.K., Bertoncello, I. (1994). The development and establishment of hematopoiesis in fetal and newborn osteopetrotic (Op/Op). mice. Dev Biol 164, 456–462. Palucka, A.K., Gatlin, J., Blanck, J.P., Melkus, M.W., Clayton, S., Ueno, H., et al. (2003). Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood 102, 3302–3310. Pantelouris, E.M. (1968). Absence of thymus in a mouse mutant. Nature 217, 370–371. Parney, I.F., Petruk, K.C., Zhang, C.S., FarrJones, M., Sykes, D.B., Chang, L.J. (1997). Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 8, 1073–1085. Pasparakis, M., Alexopoulou, L., Episkopou, V., Kollias, G. (1996). Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184, 1397–1411. Pflumio, F., Izac, B., Katz, A., Shultz, L.D., Vainchenker, W., Coulombel, L. (1996). Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and
288
B.
ANNE
C R O Y,
JAMES
P.
DI
SANTO,
nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. Blood 88, 3731–3740. Pflumio, F., Lapidot, T., Murdoch, B., Patterson, B., Dick, J.E. (1993). Engraftment of human lymphoid-cells into newborn Scid mice leads to graftversus-host disease. Int Immunol 5, 1509–1522. Poehlmann, T., Bashar, S., Markert, U., Caniggia, I., Han, V., Croy, B.A., et al. (2004). Letter to the editors. Placenta 35, 357–358. Ranson, T., Vosshenrich, C.A.J., Corcuff, E., Richard, O., Laloux, V., Lehuen, A., et al. (2003). IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc Natl Acad Sci U S A 100, 2663–2668. Rennert, P.D., Browning, J.L., Mebius, R., Mackay, F., Hochman, P.S. (1996). Surface lymphotoxin α/β complex is required for the development of peripheral lymphoid organs. J Exp Med 184, 1999–2006. Riedle, S., Rosel, M., Zoller, M. (1998). In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice. Int J Cancer 75, 908–918. Sabel, M.S., Conway, T.F., Chen, F.A., Bankert, R.B. (2000). Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB). block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. J Immunother 23, 362–368. Sabzevari, H., Reisfeld, R.A. (1993). Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res 53, 4933–4937. Sandhu, J., Shpitz, B., Gallinger, S., Hozumi, N. (1994). Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J Immunol 152, 3806–3813. Schorle, H., Holtschke, T., Hunig, T., Schimpl, A., Horak, I. (1991). Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352, 621–624. Schotte, R., Rissoan, M.C., Bendriss-Vermare, N., Bridon, J.M., Duhen, T., Weijer, K., et al. (2003). The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development. Blood 101, 1015–1023. Serreze, D.V., Leiter, E.H. (1988). Defective activation of T-suppressor cellfunction in nonobese diabetic mice—potential relation to cytokine deficiencies. J Immunol 140, 3801–3807. Sharma, R., Adam, E., Schumacher, U. (1997). The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br J Cancer 76, 1011–1016. Shinkai, U., Rathburn, G., Lam K-P, Oltz, E.M., Stewart, V., Mendleson, M., et al. (1992). RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855–867. Shultz, L.D., Lyons, B.L., Burzenski, L.M., Gott, B., Chen, X.H., Chaleff, S., et al. (2005). Human lymphoid and myeloid cell development in NOD/LtSzscid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174, 6477–6489. Shultz, L.D., Schweitzer, P.A., Christianson, S.W., Gott, B., Schweitzer, I.B., Tennent, B., et al. (1995). Multiple defects in innate and adaptive immunological function in NOD/LtSz-scid mice. J Immunol 154, 180–191. Silver, D.F., Piver, M.S. (1999). Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 73, 280–284. Stenholm, A.C.O., Kirkin, A.F., Zeuthen, J. (1998). In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: a SCID mouse model. Int J Cancer 77, 476–480. Stephens, G.L., McHugh, R.S., Whitters, M.J., Young, D.A., Luxenberg, D., Carreno, B.M., et al. (2004). Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 173, 5008–5020. Stewart, I.J. (1998). Granulated metrial gland cells in ‘minor’ species. J Reprod Immunol 40, 129–146. Stolen, C.M., Marttila-Ichihara, F., Koskinen, K., Yegutkin, G.G., Turja, R., Bono, P., et al. (2005). Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 22, 105–115.
MARCUS
MANZ,
AND
RICHARD
B.
BANKERT
Sugiyama, Y., Kato, M., Chen, F.A., Williams, S.S., Kawaguchi, Y., Miya, K., et al. (2001). Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J Immunother 24, 37–45. Tagaya, H., Kunisada, T., Yamazaki, H., Yamane, T., Tokuhisa, T., Wagner, E.F., et al. (2000). Intramedullary and extramedullary B lymphopoiesis in osteopetrotic mice. Blood 95, 3363–3370. Takahashi, H., Nakada, T., Puisieux, I. (1993). Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259, 1460–1463. Tanaka, Y., Wu, A.Y.S, Ikekawa, N., Iseki, K., Kawai, M., Kobayashi, Y. (1994). Inhibition of HT-29 human colon-cancer growth under the renal capsule of severe combined immunodeficient mice by an analog of 1,25-dihydroxyvitamin D-3, DD-003. Cancer Res 54, 5148–5153. Tang, D.G., Li, L., Zhu, Z., Joshi, B., Johnson, C.R., Marnett, L.J., et al. (1998). BMD188, a novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases. Pathol Oncol Res 4, 179–190. Tary-Lehmann, M., Lehmann, P.V., Schols, D., Roncarolo, M.G., Saxon, A. (1994). Anti-SCID mouse reactivity shapes the human CD4+ T-cell repertoire in Hu-PBL-SCID chimeras. J Exp Med 180, 1817–1827. Teicher, B.A., Kakeji, Y., Ara, G., Herbst, R.S., Northey, D. (1997). Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 11, 453–461. Temann, U.A., Ray, P., Flavell, R.A. (2002). Pulmonary overexpression of IL9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest 109, 29–39. Thurmond, T.S., Murante, F.G., Staples, J.E., Silverstone, A.E., Korach, K.S., Gasiewicz, T.A. (2000). Role of estrogen receptor α in hematopoietic stem cell development and B lymphocyte maturation in the male mouse. Endocrinology 141, 2309–2318. Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.C., Lanzavecchia, A., et al. (2004). Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304, 104–107. Van Parijs, L., Biuckians, A., Abbas, A.K. (1998). Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 160, 2065–2071. von Boehmer, H. (2005). Mechanisms of suppression by suppressor T cells. Nat Immunol 6, 338–345. Vosshenrich, C.A.J., di Santo, J.P. (2001). Cytokines: IL-21 joins the γc-dependent network? Curr Biol 11, R175-R177. Vosshenrich, C.A.J., Ranson, T., Samson, S.I., Corcuff, E., Colucci, F., Rosmaraki, E.E., et al. (2005). Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol 174, 1213–1221. Wang, J.C.Y., Doedens, M., Dick, J.E. (1997). Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89, 3919–3924. Ward, J.M., Mahler, J.F., Maronpot, R.R., Sundberg, J.P., Frederickson, R.M.E. (2000). Pathology of Genetically Engineered Mice. Iowa State University Press: Ames. Weiner, L.M., Holmes, M., Adams, G.P., Lacreta, F., Watts, P., Depalazzo, I.G. (1993). A human tumor xenograft model of therapy with a bispecific monoclonal-antibody targeting C-Erbb-2 and Cd16. Cancer Res 53, 94–100. Williams, S.S., Chen, F.A., Kida, H., Yokota, S., Miya, K., Kato, M., et al. (1996). Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J Immunol 156, 1908–1915. Winn, H.J. (1960). Immune mechanisms in homotransplantations. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 84, 228–239.
13. MOUSE
MODELS
OF
IMMUNODEFICIENCY
Xu, C.G., Mao, D.L., Holers, V.M., Palanca, B., Cheng, A.M., Molina, H. (2000). A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 287, 498–501. Yahata, T., Ando, K., Nakamura, Y., Ueyama, Y., Shimamura, K., Tamaoki, N., et al. (2002). Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice. J Immunol 169, 204–209. Ying, X.Y., Chan, K., Shenoy, P., Hill, M., Ruddle, N.H. (2005). Lymphotoxin plays a crucial role in the development and function of nasal-associated lymphoid tissue through regulation of chemokines and peripheral node addressin. Am J Pathol 166, 135–146.
289 Zenclussen, A.C., Gerlof, K., Zenclussen, M.L., Sollwedel, A., Bertoja, A.Z., Ritter, T., et al. (2005). Abnormal T-cell reactivity against paternal antigens in spontaneous abortion—adoptive transfer of pregnancy-induced CD4+ CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 166, 811–822. Ziljstra, M., Li, E., Sajjadi, F., Subramani, S., Jaenisch, R. (1989). Germ-line transmission of a disrupted β2-microglobulin gene produced by homologous recombination in embryonic stem cells. Nature 342, 435–438.
This page intentionally left blank
Chapter 14 Mouse Models to Study the Pathogenesis of Allergic Asthma Chad E. Green, Nicholas J. Kenyon, Scott I. Simon, and Fu-Tong Liu
I. II. III. IV. V.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mouse Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IgE and Mast Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Trafficking of Eosinophils Involving Cytokines, Chemokines, Selectins, and Integrins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Role of Cytokines and Chemokines . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Selectins and Their Sialylated Ligands . . . . . . . . . . . . . . . . . . . . . . . . . C. Leukocyte Integrins and Their Ligands . . . . . . . . . . . . . . . . . . . . . . . . . VI. Contribution of Eosinophils to AHR and Airway Remodeling . . . . . . . . . . VII. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VIII. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I.
INTRODUCTION
Allergic asthma is a chronic inflammatory disease of the airways characterized by airway inflammation, reversible bronchoconstriction, and airway hyperresponsiveness (AHR). Recent advancements have led to the identification of a number of cellular and molecular components that contribute to airway inflammation. T cells play a central role in this process and cytokines produced by T helper (Th) 2 cells contribute to the initiation of the inflammatory response. As with other adaptive immune responses, dendritic cells are responsible for antigen presentation to T cells and are now recognized as sentinel cells THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
291 292 293 294 295 295 296 296 297 297 298 298
in the immune and inflammatory response in the lung. Patients with allergic asthma often have elevated IgE levels against environmental allergens and thus IgE levels specific to the allergens are believed to contribute to the asthmatic phenotype. Mast cells are important effector cells, and the peptide and lipid mediators as well as cytokines that they secrete contribute to the inflammatory response. Cytokines and chemokines combined with mast cell–released mediators lead to the upregulation of adhesion molecules on the vascular endothelium and the recruitment to the airways of inflammatory cells, in particular, eosinophils, the most notable inflammatory component of allergic asthma. Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
291
292
CHAD
E.
GREEN,
NICHOLAS
J.
The bronchial epithelium itself is an active participant. Not only is it a target of the mediators and cytokines mentioned above, but also it produces substances that directly or indirectly contribute to or amplify the asthmatic response. Some of the effector cells and molecules described above contribute to AHR. They are probably also associated with the asthmatic phenotype of a progressive loss of lung function over time, a process attributed to dysregulated remodeling of the airways, which is characterized by thickening of the airway wall and increased collagen. The development of allergic asthma and the progression of the disease therefore involve complex interactive processes that require both molecular and mechanical coordination between regulatory and effector cells. Studies of human materials have gradually unraveled many of the pathological processes described above. However, this approach lacks the detailed examination of the time course of morphological changes occurring in airways and the potential for genetic manipulation of the cell phenotype. In this respect, animal models provide an opportunity for a more thorough evaluation of the mechanisms underlying the development of asthma. The most common animal model is the mouse; this model has many attributes including wellestablished technologies for generating transgenic mice, well-defined physiology, short breeding periods, and ease of maintenance. Indeed this model has afforded valuable insights into the hierarchy of events culminating in asthma progression. The purpose of this chapter is to provide an overview of the mouse model as well as the molecular and cellular mechanisms linking T-cell and mast cell activation with the recruitment of eosinophils to the airways and development of AHR.
II.
MOUSE MODELS
In general, mice are immunized systemically with an antigen and subsequently challenged with the same antigen through the airways. Wide variations exist in the protocols used to sensitize and challenge the mice with regard to dosage of the antigen, the number of times the antigen is administered, and timing (as described in articles cited in the following sections). In most studies, mice are immunized intraperitoneally with an antigen adsorbed on alum as adjuvant. In the majority of cases the antigen used is ovalbumin (OVA). One immunization is usually sufficient for sensitizing the mice (Mayr et al. 2002), although two immunizations 2 weeks apart are commonly used (Zhang et al. 1997). In selected cases, immunization is performed with a soluble antigen without adjuvant; however multiple immunizations are required to sensitize the mice sufficiently (Hessel et al. 1995; Mayr et al. 2002; Williams and Galli 2000). The airway antigen challenge is typically performed 14 days after the immunization, either by exposing the mice to the aerosolized antigen once a day for several consecutive days or giving the antigen intranasally a number of times (Mayr et al. 2002; Zhang et al. 1997). The aerosol is generated in a Plexiglas
KENYON,
SCOTT
I.
SIMON,
AND
FU-TONG
LIU
chamber connected to a nebulizer. More recently, a chronic asthma model with structural changes characteristic of airway remodeling has been developed. In this model, sensitized mice are exposed to aerosolized antigen daily or several times a week for weeks (Kenyon et al. 2003; Kumar and Foster 2002; Tanaka et al. 2001). The OVA mouse model is invariably associated with airway eosinophilia developed after the airway antigen challenge. Bronchoalveolar lavage fluid from the mice contains a large number of eosinophils as well as elevated levels of different Th2 cytokines. The model also exhibits AHR and reversible airflow obstruction, two cardinal features of human allergic asthma. Mice demonstrate increased AHR in response to methacholine compared with mice exposed to filtered air (Hamelmann et al. 1997; Kenyon et al. 2003; Temelkovski et al. 1998). Furthermore, when these methacholine-exposed mice are subsequently allowed to breathe filtered air or are treated with a bronchodilator, airflow obstruction is ameliorated and airway resistance decreases to baseline levels. Measurement of AHR in mice exposed to OVA is done by several techniques and this topic has been reviewed thoroughly (Bates and Irvin 2003). The least invasive technique and one of the most popular involves monitoring anesthetized, unrestrained mice in a whole body plethysmograph. Plethysmograph pressure changes are measured and analyzed with changes in the respiratory pattern. OVA-exposed mice treated with nebulized methacholine develop rapid, shallow breathing; changes in the resulting pressure waveform may reflect changes in the caliber of the airways. The calculated output, enhanced pause (Penh), is a dimensionless value and the interpretation of Penh remains a point of contention (Lundblad et al. 2002). Several factors are difficult to control when measuring Penh, including changes in gas temperature and humidity with respiration. Still, Penh measurements have been correlated with changes in lung mechanics (e.g., increased lung resistance) by more formal methods in several studies (Hemelmann et al. 1997b). We believe that unrestrained plethysmography is useful for screening larger groups of mice, particularly when testing potential therapeutic inhibitors (Kenyon et al. 2003). This technique can limit the usage of animals in such trials. Any promising results in these screening trials should be repeated with measurements of lung mechanics by more formal methods (e.g., Kenyon and Last 2005; Zhang et al. 1997; Zuberi et al. 2004). The most well-studied and accepted measurements of lung mechanics in mice are respiratory system impedance, resistance, and compliance, which are measured before and after exposure to methacholine. For these measurements, mice are deeply anesthetized, often paralyzed, and mechanically ventilated through a tracheotomy cannula. A single pressure transducer is needed to determine impedance, and pressure and flow transducers are needed to calculate respiratory system resistance and compliance. Impedance is determined by measuring the change in pressure at the tracheotomy tube, while the mouse is ventilated at a constant flow rate on a volume-cycled mode. The more
14. MOUSE
MODELS
TO
STUDY
THE
PATHOGENESIS
conventional technique for determining compliance and resistance requires independent measurements of pressure and flow. Generally, the pressure transducer is in-line with the ventilator, whereas the flow transducer is connected to the sealed mouse plethysmograph. Dynamic compliance, for example, is calculated by dividing the change in volume, derived from the flow-time signal, over the change in pressure. Measurement of lung, rather than respiratory system, resistance requires eliminating the contribution of the chest wall by opening the mouse chest cavity. However, in the deeply anesthetized and paralyzed mouse, the chest wall and diaphragmatic contributions to total respiratory system resistance are probably minimal. Changes in dynamic compliance and resistance in response to methacholine probably reflect changes in the airways. Methacholine is the most commonly used bronchoconstrictive agent in experiments designed to quantify AHR. It can be nebulized through the ventilator for anesthetized mice and nebulized into a mixing chamber for freely roaming mice. Although nebulized administration is most popular, intravenous methacholine is preferred by some investigators and the doses range from 3000 µg/kg in various studies. Significant strain variation exists in the doses of methacholine required to promote AHR, and this has been well described (Reinhard et al. 2002). In general, no comparisons can be made between the severity of AHR in mice and human asthma based on the doses of methacholine given. On the basis of differences between the mouse and human lung, there is frequent discussion that the OVA mouse model is not a model of asthma. This is true; the OVA mouse model is a model of allergic airway inflammation and AHR. Mice do not experience the wheezing episodes that characterize persistent asthma. Several important anatomical differences between human and mice lungs must be considered when one makes
OF
ALLERGIC
ASTHMA
comparisons between the OVA mouse model and human asthma. Such differences include a relatively large airways diameter in mice, an increased airway/lung parenchyma ratio in mice, and a single lobe in the left lung (Bates and Irvin et al. 2003). The sum of these anatomical differences appear to result in less resistance to airflow in the airways of mice as a percentage of total lung resistance compared with the airways of humans. Whether this can explain why mice do not wheeze is not known. Other important differences include the presence of an inflammatory alveolitis and the absence of airway thickening and fibrosis in mice exposed to OVA for 1 week. In the chronic asthma model, in which mice are exposed to aerosolized OVA for 4–8 weeks, the animals do develop airway remodeling, and this may reflect human asthma better (Kenyon et al. 2003; Temelkovski et al. 1998). In addition, mice are obligate nose breathers, and measurements of respiratory function in unrestrained mice must factor in the contribution of the upper airways. Thus, as with any case of using an animal model to understand human disease, interpretation of the mechanisms underlying asthma are preliminary until confirmed in humans.
III.
CYTOKINES
A body of evidence implicates a role for cytokines in allergic airway inflammation and AHR. A mainstay of the data comes from transgenic and gene knockout mice, whereas others are from mice given recombinant proteins or neutralizing antibodies. Unless otherwise stated, the cited studies involved mice sensitized with OVA and challenged by the same antigen through the airways. This section focuses on interleukin (IL)-4, IL-5, IL-12, and IL-13 and the relevant studies on other cytokines are listed in Table 14-1.
TABLE 14-1
PHENOTYPE OF TRANSGENIC MICE OVEREXPRESSING OR DEFICIENT IN A CYTOKINE Cytokines IL-4 IL-4 IL-5 IL-5 IL-9 IL-10 IL-10 IL-10 IL-11 IL-12 IL-13 IL-15 IL-18
Transgenic (tg) or Knockout (ko)
Airway Eosinophilia
ko ko ko ko tg ko ko ko tg ko ko tg ko
↓ ↓ ↓ ↓ ↑ ↓ ↑ ↔ ↓ ↓ ↓ ↓ ↑
293
AHR ↓ ↓ ↑ ↑ ↓ ↔
References Brusselle et al. 1994; Hogan et al. 1997 Hamelmann et al. 2000 Mould et al. 1997; Wang et al. 1998 Foster et al., 1996; Hamelmann et al. 2000 McLane et al. 1998 Yang et al. 2000 Tournoy et al. 2000 Mäkelä et al. 2000 Wang et al. 2000 Wang et al. 2001 Wang et al. 2000; Webb et al. 2000 Whittaker et al. 2002 Campbell et al. 2000
↑, ↓, and ↔ indicate that the response is higher than, lower than, and comparable with that of wild-type mice, respectively.
294
CHAD
E.
GREEN,
NICHOLAS
J.
IL-4 and IL-13 are major Th2 cytokines known to play an important role in the allergic response, including the production of immunoglobulin (Ig) E. IL-5 is another Th2 cytokine that regulates eosinophil development. A number of groups have shown that IL-4−/− mice developed substantially fewer eosinophils in the airways compared with wild-type mice (Brusselle et al. 1994; Hogan et al. 1997). These mice also mounted reduced AHR when challenged with methacholine (Hamelmann et al. 2000). The role of IL-4 has also been shown by experiments in which mice were given in vitro generated antigen-specific Th2 cells and then exposed to nebulized antigen. It was found that Th2 cells from IL-4−/− mice did not accumulate in the lung, suggesting that endogenous IL-4 in Th2 cells contributes to cell recruitment to the lung (Cohn et al. 1997). These authors subsequently found that although mice receiving Th2 cells from wild-type mice developed airway eosinophilia and AHR, those receiving cells from IL-4−/− mice exhibited markedly reduced airway eosinophilia. However, there was no difference in AHR (Cohn et al. 1997). Thus, it was concluded that IL-4 production by Th2 cells is critical for the accumulation of eosinophils into the airways but not essential for the induction of AHR. Another report emphasized the finding that IL-4−/− mice still developed airway eosinophilia, albeit at reduced levels, and AHR comparable to those in wild-type mice (Hogan et al. 1998). Only when these mice were treated with anti-IL-5 mAb before the airway antigen challenge was airway eosinophilia and AHR abolished (Hogan et al. 1997). However, in another study, IL-4−/− mice pretreated with anti-IL-5 monoclonal antibody (mAb) still developed AHR, although airway inflammation was substantially reduced (Hogan et al. 1998). Finally, by using a chronic asthma model and IL-4−/− mice, it was concluded that IL-4 is responsible for allergen-induced airway remodeling (Komai et al. 2003). A number of reports showed that airway eosinophilia was diminished in IL-5−/− mice (Foster et al. 1996; Hamelmann et al. 2000; Mould et al. 1997; Wang et al. 1998). It was also demonstrated that delivery of vectors expressing IL-5 restored the response (Foster et al. 1996; Wang et al. 1998). These findings, together with reports demonstrating that airway eosinophilia is diminished by treatment of the mice by anti-IL-5 monoclonal antibody, convincingly established the essential role of IL-5 in development of airway eosinophilia. Some of these studies also demonstrated the role of IL-5 in the development of AHR. However, such a role as well as the issue of whether eosinophils contribute to AHR remains unresolved (see section VI for more discussion). Finally, in a study using IL-5 receptor–deficient mice, IL-5 transgenic mice, and antiIL-5 antibody, convincing evidence was provided that IL-5 is an important contributor of airway remodeling (Tanaka et al. 2004). Another group reached the same conclusion by using IL-5−/− mice (Cho et al. 2004). Inhibition of IL-13 by neutralizing antibody results in reduction of airway eosinophilia and AHR (Grünig et al. 1998;
KENYON,
SCOTT
I.
SIMON,
AND
FU-TONG
LIU
Wills-Karp et al. 1998). Subsequently, it was shown that compared with wild-type animals, IL-13−/− mice exhibited diminished accumulation of eosinophils in the airways; however, AHR was still present (Kumar et al. 2002; Webb et al. 2000). An important role of IL-13 was further supported by studying transfer of OVA-specific CD4+ T cells that were wild type or deficient in IL-13 to nonsensitized mice that were then challenged with nebulized OVA. This model clearly demonstrates that T cell– derived IL-13 plays a key role in regulating airway eosinophilia and AHR (Mattes et al. 2001). Additional studies showed that the contribution of IL-13 to the airway response does not overlap with that of IL-4. Thus, the reduced airway inflammation in IL-13−/− mice could be further reduced by treatment with antibody to IL-4 (Webb et al. 2000). Moreover, mice in which both IL-4 and IL-13 were depleted displayed a marked reduction in airway eosinophilia and AHR to an extent greater than in those deficient in either one of the cytokines (Webb et al. 2000). Finally, results from studies of IL-13−/− mice demonstrated that IL-13 plays an important role in airway remodeling in a chronic asthma model (Kumar et al. 2002). IL-12 is a primary Th1 cytokine and contributes significantly to eosinophil recruitment, as IL-12−/− mice exhibited substantially reduced airway eosinophilia (Wang et al. 2001). A number of researchers demonstrated that mouse recombinant IL-12 administered to mice systemically at the time of immunization or during airway antigen challenge abolished the airway eosinophilia and AHR (Gavett et al. 1995; Kips et al. 1996; Riezman et al. 1997). Delivery of IL-12 locally into the airway is more effective than systemic IL-12 in inhibiting AHR (Sur et al. 2000). The mechanism of IL-12 action may be secondary to its role in increasing interferon (IFN)-γ and decreasing IL-4 and IL-5 expression (Gavett et al. 1995). It was also reported that the effects of IL-12 were partially inhibited by anti-IFN-γ mAb and that administration of IL-12 during daily aerosol exposure significantly inhibited eosinophilia in both IFN-γ−/− mice and wild-type controls (Gavett et al. 1995; Brusselle et al. 1997). With an adenovirus-mediated gene transfer approach, the conclusion in another study was that IL-12-mediated inhibition of airway eosinophilia was mainly IFN-γ independent (Stampfli et al. 1999). Finally, using IL-10-deficient mice, it was shown that inhibition of the airway response by IL-12 is independent of IL-10 (Tournoy et al. 2001).
IV.
IgE AND MAST CELLS
IgE-activated mast cells are a primary source of inflammatory cytokines, chemokines, and lipid mediators during the progression of asthma. It is known that asthma can result from sensitization to various allergens and IgE specific to these allergens are present in individuals with asthma. The importance of IgE and IgE-dependent mast cell activation in human asthma is underlined by the close association between asthma and serum
14. MOUSE
MODELS
TO
STUDY
THE
PATHOGENESIS
IgE levels, as well as skin-test reactivity to allergens (Milgrom et al. 1999). The most convincing evidence for the role of IgE is provided by clinical trials on anti-IgE therapy. This therapy is based on a monoclonal antibody that binds IgE and inhibits its binding to IgE receptors. The therapy causes a dramatic reduction in the IgE level (Casale et al. 1997; Corne et al. 1997; MacGlashan et al. 1997) and the efficacy of this therapy has been established in multiple clinical trials (reviewed in Bousquet et al. 2005; Brownell and Casale 2004; Bush 2002; Holgate et al. 2004). In mice, it has been reported that germinal centers containing IgE- and IgG-producing plasma cell are formed in the parenchyma of inflamed lungs after airway antigen challenge (Chvatchko et al. 1996). Zuberi et al. (2000) showed that IgE secreted locally in a mouse model of asthma can capture the antigen presented to the airways, and the immune complexes are able to augment the allergic airway response in an Fc ε receptor I (FcεRI)-dependent manner. Thus, IgE present in airway secretions may facilitate antigen-mediated allergic airway inflammation. However, allergic airway inflammation and AHR can be elicited in mice in the absence of IgE (Hamelmann et al. 1999; Mehlhop et al. 1997) or all classes of immunoglobulins (Corry et al. 1998). In addition, both IL-4−/− and CD40−/−mice mount airway responses to antigen challenge even though antigenspecific IgE is not detectable in the sera (Brusselle et al. 1994; Hogan et al. 1997). Furthermore, administration of IL-12 to actively immunized mice during the daily airway antigen exposure abolished airway eosinophilia and AHR but did not influence the production of antigen-specific IgE (Bursselle et al. 1997). The results suggest that allergic airway disease can occur via pathways that operate independently of allergen-specific IgE. In view of the demonstrated clinical efficacy of anti-IgE therapy on human asthma, it is of interest to know the effect of neutralizing anti-IgE antibody in mouse models of asthma. In this regard, there is a report that anti-IgE antibody is able to inhibit eosinophilic infiltration induced by airway antigen challenge (Coyle et al. 1996). However, results of another study show that the effect of anti-IgE treatment is dependent on the method used to sensitize the mice. In mice sensitized to dust mite allergen in conjunction with human respiratory syncytial virus infection, anti-IgE treatment was effective in reducing the airway inflammatory response. However, the same treatment had no effect in mice sensitized to the same antigen in the absence of concomitant viral infection (Tumas et al. 2001). These studies illustrate well the fact that for mouse models of asthma to be useful for preclinical testing of drugs, protocols tailored for the purpose may need to be developed. The role of IgE is also revealed by studying mice deficient in its receptor, FcεRI. In general, FcεRI-deficient (FcεRI−/−) mice exhibited reduced airway responses only under experimental conditions in which immunization or antigen challenge is suboptimal. We found that FcεRI−/− mice developed reduced airway eosinophilic inflammation compared to wild-type mice, when
OF
ALLERGIC
ASTHMA
295
they were sensitized with OVA in the absence of adjuvant and then challenged with OVA through the airways. OVA-sensitized FcεRI−/− mice also showed reduced airway inflammation when they were challenged with OVA intranasally, but not when they were challenged with nebulized OVA (Mayr et al. 2002). The role of mast cells in allergic airway inflammation and bronchial reactivity has been investigated using W/Wv mast cell–deficient mice, which demonstrate attenuated eosinophil airway inflammation (Kung et al. 1995; Ogawa et al. 1999) and a lack of IgE-induced pulmonary responsiveness to cholinergic stimulation (Martin et al. 1993). However, in a number of studies mast cell participation in allergic airway inflammation and AHR was not revealed (Brusselle et al. 1994; Nagai et al. 1996; Takeda et al. 1997). More recently, Kobayashi et al. (2000) used W/Wv mice sensitized and challenged by suboptimal amounts of OVA and found reduced AHR compared with that in normal congenic mice. However, the mice developed AHR that was comparable to that in normal mice when they were more highly sensitized by using either a higher dose of the antigen or an increased number of immunizations. Likewise, Williams and Galli (2000) noted that W/Wv mice developed significantly reduced responses when the mice were immunized with OVA in the absence of adjuvant and then challenged with OVA intranasally. In contrast, W/Wv mice that were sensitized with OVA in alum and then challenged with aerosolized OVA exhibited airway responses similar to those in unsensitized mice. Thus, it appears the role of mast cells in development of AHR is dependent on the protocols used to induce airway responses. Hence, AHR can be induced by different mechanisms, and only certain protocols enlist mechanisms that involve IgE-mediated mast cell activation.
V.
TRAFFICKING OF EOSINOPHILS INVOLVING CYTOKINES, CHEMOKINES, SELECTINS, AND INTEGRINS A.
Role of Cytokines and Chemokines
Inflammatory responses are typically initiated when cytokines and chemokines trigger selectin-mediated adhesion of leukocytes to the vascular endothelium. The principal function of the cytokines and chemokines are to 1) induce expression of adhesion molecules on the luminal surface of vascular endothelium, 2) signal increased release of eosinophils from the bone marrow, and 3) chemoattract circulating eosinophils to the inflamed airways. Allergen-challenged T cells produce Th2 cytokines that combine to elicit numerous responses from adjacent epithelial cells including release of chemokines that function as attractants for eosinophils. The most abundant chemoattractants are IL-8 (or the murine homolog KC), RANTES (regulated on activation, normal T-cell expressed and
296
CHAD
E.
GREEN,
NICHOLAS
J.
secreted), MCP-1 (monocyte chemoattractant protein-1), MIP1α (macrophage inflammatory protein-1α), and eotaxin (Erger et al. 1995; Li et al. 1999; Kameyoshi et al. 1992; Ponath et al. 1996). Some of these chemokines also mediate eosinophil adhesion to inflamed airway endothelium (Gonzalo et al. 1996; Holgate et al. 1997; Lamkhioued et al. 1997; McNulty et al. 1999). In most cases, these chemokines signal cell arrest of eosinophils on endothelium through activation of the β1- and β2-integrins (Burke-Gaffney et al. 1996; Walsh et al. 1991). Data from both asthmatic patient and mouse models suggest that expression of CXC and CC chemokines may serve to coordinate the eosinophil recruitment. In particular, eotaxin-1 and eotaxin-2 are CC chemokines that specifically activate and chemoattract eosinophils through binding to CCR3 (Ponath et al. 1996; Ravensberg et al. 2005). Eotaxin-1 may be expressed very early in asthma, providing a primary activator of arrest and transmigration of eosinophils. In this regard, IL-13-induced eosinophil recruitment to the lung is inhibited in eotaxin−/− mice (Pope et al. 2001). Moreover, antigen-induced eosinophil recruitment to the airways is decreased in eotaxin-1−/− mice (Rothenberg et al. 1997) and inhibited by antibody to eotaxin (Kim et al. 2001). However, another study showed that eotaxin-1−/− mice developed airway eosinophilia and AHR after airway antigen challenge, indicating that this chemokine is not essential for the development of antigen-induced airway responses in mice (Tomkinson et al. 2001). A subsequent study also using eotaxin-1−/− mice showed that this chemokine is required for the acute but not chronic allergic airway response in mice sensitized to and then challenged by the fungus Aspergillus fumigatus (Schuh et al. 2002). The roles of a number of chemokine receptors in the allergic airway response have been studied by using mice deficient in respective receptors, as listed in Table 14-2.
TABLE 14-2
PHENOTYPE OF MICE DEFICIENT IN A CHEMOKINE AND CHEMOKINE RECEPTOR Chemokine/Chemokine Receptor Eotaxin-1 Eotaxin-1 Eotaxin-1 Eotaxin-2 Eotaxin-1/2 CCR2 CCR2 CCR3 CCR4 CCR6 CCR8
Airway Eosinophilia ↓ ↔ ↓ ↓ ↓↓ ↑ ↔ ↓↓ ↓ ↓ ↔
AHR ↔
↑ ↔ ↓ ↓
References Rothenberg et al. 1997 Tomkinson et al. 2001 Pope et al. 2005 Pope et al. 2005 Pope et al. 2005 Kim et al. 2001 MacLean et al. 2000 Pope et al. 2005 Schuh et al. 2002 Lukacs et al. 2001 Chung et al. 2003
↑, ↓, ↓↓, and ↔ indicate the response is higher than, lower than, substantially lower than, and comparable with that of wild-type mice, respectively. Eotaxin-1/2 represents mice deficient in both eotaxin-1 and -2.
KENYON,
SCOTT
I.
SIMON,
AND
FU-TONG
LIU
With expression of adhesion molecules and release of chemoattractants, the bronchial postcapillary endothelium is primed for leukocyte infiltration. The process of eosinophil recruitment to inflamed vasculature is characterized as a multistep continuum of receptor-ligand binding events (Springer 1994; Wardlaw 1999). The initial phase of capture and rolling is dependent upon low-affinity interactions between opposing selectin molecules on leukocytes and inflamed endothelium. Subsequent firm adhesion and migration requires higher affinity binding between leukocyte integrins and endothelial intercellular adhesion molecules. Although structurally diverse, these adhesion receptors function sequentially and synergistically in mediating leukocyte arrest under the constant shear force of blood.
B.
Selectins and Their Sialylated Ligands
The pattern of upregulated expression of chemokines, selectins, and their fucosylated and sialyl Lewisx ligands begins to explain the sequence by which eosinophils are recruited during asthma. Eosinophils express P-selectin glycoprotein ligand 1 (PSGL-1), the most widely expressed selectin ligand that is recognized by endothelial P-selectin and E-selectin, as well as L-selectin on leukocytes. PSGL-1 is essential for optimal eosinophil tethering and subsequent diapedesis into the airway of asthmatic mice (Borchers et al. 2001). The role of P-selectin in eosinophil recruitment to the airways is demonstrated by the lack of eosinophil tethering and accumulation in P-selectin−/− mice after airway antigen challenge (Broide et al. 1998). The essential role of both P-selectin and E-selectin in allergen-induced airway eosinophilia and AHR was similarly established using mice lacking either or both of these selectins (Lukacs et al. 2002). L-selectin is, on the other hand, not required for recruitment into the airways, as no decrease in eosinophil infiltration into the lung was evident in OVA challenged Lselectin−/− mice relative to wild-type mice (Fiscus et al. 2001).
C.
Leukocyte Integrins and Their Ligands
Within minutes of tethering and rolling via selectins, leukocytes arrest on inflamed endothelium through engagement of integrins. Of the integrins, eosinophils utilize the β2-integrins (CD18), specifically LFA-1 (lymphocyte function–associated Ag, αLβ2, CD11a/CD18) and Mac-1 (αMβ2, CD11b/CD18), in mediating adhesion. Eosinophils also use VLA-4 (very late antigen-4, α4β1, CD49d/CD29), which participates in cell rolling and arrest through binding primarily to vascular cell adhesion molecule-1 (VCAM-1). VLA-4 also binds with high affinity to the CS-1 region of fibronectin that is positioned outside of the more common RGD binding motif (Elices et al. 1990). The primary ligand for the β2-integrins on inflamed endothelium is intercellular adhesion molecule-1 (ICAM-1)
14. MOUSE
MODELS
TO
STUDY
THE
PATHOGENESIS
(Diamond et al. 1990; Dustin and Springer, 1988). Collectively, sequential and cooperative engagement of endothelial cell adhesion molecules by the β1- and β2-integrins contributes to slow rolling and ultimately firm arrest of eosinophils on inflamed endothelium (Dunne et al. 2002). Mouse models have helped establish these adhesive interactions. Thus, intraperitoneal injection of anti-ICAM-1 reduced infiltration of eosinophils into the lung of OVA challenged mice by >70% (Chin et al. 1997). Systemic administration of anti-VCAM-1 significantly reduced eosinophil infiltration to the lung in OVA challenged mice (Borchers et al. 2001; Chin et al. 1997). Similarly, small molecule antagonists of VCAM-1 have been shown to inhibit airway eosinophilia in this model (Kudlacz et al. 2002). Therefore, evidence suggests that there is cooperation between the β1- and β2-integrins in recruitment of eosinophils to the lung.
VI.
CONTRIBUTION OF EOSINOPHILS TO AHR AND AIRWAY REMODELING
In mouse models of asthma, both development of airway eosinophilia and AHR are observed. Although the relationship between the two has been extensively investigated, the contribution of eosinophils to AHR remains to be completed resolved. Transgenic mice constitutively expressing IL-5 in the lung epithelium showed a large number of eosinophils in the peribronchial areas. In addition, these animals displayed AHR to methacholine even in the absence of airway antigen challenge (Lee et al. 1997). The results seem to support the contribution of eosinophils to AHR. However, in another study IL-5 transgenic mice did not show AHR, despite the presence of eosinophils in the lungs (Hisada et al. 1999). Results obtained from studying IL-5-deficient mice or mice treated with anti-IL-5 mAbs are also controversial, and some of the studies have already been described in the section on cytokines. For example, studies by Nagai et al. (1996) and Corry et al. (1996) showed that the anti-IL-5 antibody treatment inhibited airway eosinophilia but not AHR. Kobayashi et al. (2000) also described markedly inhibited airway eosinophilia without a concomitant reduction in AHR in mice treated with anti-IL-5 antibody. However, it has been shown that anti-IL-5 mAb prevented the development of AHR (Hamelmann et al. 1997a), and there are studies showing that IL-5−/− mice develop neither eosinophilia nor AHR (Foster et al. 1996), supporting an association between these two processes. Furthermore, it has been observed that repeated intranasal administration of IL-5 to mice resulted in eosinophil infiltration into the airways followed by development of AHR (Van Oosterhout et al. 1995), which also supports the relationship between these two responses. A number of studies suggested that the contribution of eosinophils to the development of AHR in mice might be
OF
ALLERGIC
ASTHMA
297
masked by coexisting pathways that operate independently of eosinophils. First, whereas in IL-4−/− mice, AHR persisted after treatment with anti-IL-5 mAb that caused a diminished eosinophil response, AHR was abolished when the mice were treated also by anti-CD4+ mAb (Hogan et al. 1998). Second, whereas anti-IL-5 treatment did not reduce AHR significantly in wild-type mice, the same treatment inhibited AHR in IL-13−/− mice (Webb et al. 2000). Third, anti-IL-5 treatment caused a substantial reduction in AHR in FcεRI−/− mice but not in wildtype mice (Mayr et al. 2002). Thus, pathways dependent on CD4+ T cells, IL-13, and IgE-mediated mast cell activation, respectively, may mask the contribution of eosinophils to the development of AHR. In the absence of one of these pathways, a positive correlation between eosinophilia and AHR can be more easily demonstrated. In the third case, the results also suggest that there is a synergy between mast cells and eosinophils in the induction of AHR. It is possible that mast cells and eosinophils secrete different mediators that may activate bronchial smooth muscle through distinct pathways and these pathways cooperate synergistically in inducing heightened bronchial responsiveness. As mentioned in the section on cytokines, various studies have demonstrated the role of IL-5 in development of airway remodeling, which indirectly support the role of eosinophils in this process. Importantly, a direct role for eosinophils as effector cells in airway remodeling has been established by experiments in which the eosinophil lineage was ablated (Humbles et al. 2004).
VII.
CONCLUSIONS
The use of transgenic mice together with the use of specific neutralizing antibody or small molecule antagonists has enabled the discovery of cytokines, chemokines, adhesion molecules, and cell types responsible for development and progression of airway inflammation and AHR. In this role, mouse asthma models have provided tremendous insight into the mechanisms regulating human disease. Ongoing research indicates that asthma is a complex disease involving T cells, mast cells, macrophages, epithelial cells, and endothelial cells. These cells produce and respond to cytokines, chemokines, and small molecule mediators that ultimately result in AHR and recruitment of eosinophils to the bronchial airways through specific interactions between adhesion molecules. However, for a number of different molecules, variable and sometimes contradictory results were obtained from different research groups and thus the roles of these molecules in the airway response in mice remain to be elucidated. Studies also show that the role of a given molecule and cell sometimes depends on the protocol used to induce the airway response. In addition, the conclusions achieved with mouse models remain to be tested in humans before they can be accepted as applicable to human asthma.
298
CHAD
E.
GREEN,
NICHOLAS
J.
Nevertheless, mouse models will continue to be useful for elucidation of the pathogenesis of human asthma. They will also be valuable for discovering or validating molecules and cells as targets for treatment for asthma as well as for testing agonists/antagonists directed at these molecules and cells.
VIII.
SUMMARY
Allergic asthma is a disease of the airways characterized by reversible bronchial obstruction and airway hyperresponsiveness associated with allergic inflammation. Discovery of the individual molecular and cellular components of asthma has depended heavily on animal models that mimic human disease. In this regard, these models have enabled description of a complex sequence of events involving T cells, B cells, dendritic cells, mast cells, macrophages, eosinophils, epithelial cells, and endothelial cells. Differential responses of these various cell types to triggers of asthma results in a hierarchy of cytokine, chemokine, and mediator release, leading to homing and activation of immune and inflammatory cells in the pulmonary vasculature and culminating in allergic inflammation. Some of these cells and molecules are also responsible for development of airway hyperresponsiveness. Mouse models have been particularly valuable, especially in conjunction with the use of genetically engineered animals with heightened expression or deficiency of certain gene products. In this chapter, we discussed briefly various methodological aspects of mouse models and then reviewed some of the critical components in progression of asthma for which the models have provided insights, including 1) cytokine release, 2) mast cell activation and degranulation, and 3) homing of eosinophils.
REFERENCES Bates, J.H., Irvin, C.G. (2003). Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 94, 1297–1306. Borchers, M.T., Crosby, J., Farmer, S., Sypek, J., Ansay, T., Lee, N.A., et al. (2001). Blockade of CD49d inhibits allergic airway pathologies independent of effects on leukocyte recruitment. Am J Physiol 280, L813–L821. Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., et al. (2005). The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60, 302–308. Broide, D.H., Sullivan, S., Gifford, T., Sriramarao, P. (1998). Inhibition of pulmonary eosinophilia in P-selectin- and ICAM-1-deficient mice. Am J Respir Cell Mol Biol 18, 218–225. Brownell, J., Casale, T.B. (2004). Anti-IgE therapy. Immunol Allergy Clin North Am 24, 551–568. Brusselle, G.G., Kips, J.C., Peleman, R.A., Joos, G.F., Devos, R.R., Tavernier, J.H., and Pauwels, R.A. (1997). Role of IFN-γ in the inhibition of the allergic airway inflammation caused by IL-12. Am J Respir Cell Mol Biol 17, 767–771. Brusselle, G.G., Kips, J.C., Tavernier, J.H., van der Heyden, J.G., Cuvelier, C.A., Pauwels, R.A., and Bluethmann, H. (1994). Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 24, 73–80.
KENYON,
SCOTT
I.
SIMON,
AND
FU-TONG
LIU
Burke-Gaffney, A., Hellewell, P.G. (1996). Eotaxin stimulates eosinophil adhesion to human lung microvascular endothelial cells. Biochem Biophys Res Commun 227, 35–40. Bush, R.K. (2002). The use of anti-IgE in the treatment of allergic asthma. Med Clin North Am 86, 1113–1129. Campbell, E., Kunkel, S.L., Strieter, R.M., Lukacs, N.W. (2000). Differential roles of IL-18 in allergic airway disease: induction of eotaxin by resident cell populations exacerbates eosinophil accumulation. J Immunol 164, 1096–1102. Casale, T.B., Bernstein, I.L., Busse, W.W., LaForce, C.F., Tinkelman, D.G., Stoltz, R.R., et al. (1997). Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100, 110–121. Chin, J.E., Hatfield, C.A., Winterrowd, G.E., Brashler, J.R., Vonderfecht, S.L., Fidler, S.F., et al. (1997). Airway recruitment of leukocytes in mice is dependent on alpha4-integrins and vascular cell adhesion molecule-1. Am J Physiol 272, L219–L229. Cho, J.Y., Miller, M., Baek, K.J., Han, J.W., Nayar, J., Lee, S.Y., et al. (2004). Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 113, 551–560. Chung, C.D., Kuo, F., Kumer, J., Motani, A.S., Lawrence, C.E., Henderson, W.R., Jr., Venkataraman, C. (2003). CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J Immunol 170, 581–587. Chvatchko, Y., Kosco Vilbois, M.H., Herren, S., Lefort, J., Bonnefoy, J.Y. (1996). Germinal center formation and local immunoglobulin E (IgE) production in the lung after an airway antigenic challenge. J Exp Med 184, 2353–2360. Cohn, L., Homer, R.J., Marinov, A., Rankin, J., Bottomly, K. (1997). Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med 186, 1737–1747. Corne, J., Djukanovic, R., Thomas, L., Warner, J., Botta, L., Grandordy, B., et al. (1997). The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 99, 879–887. Corry, D.B., Folkesson, H.G., Warnock, M.L., Erle, D.J., Matthay, M.A., Wiener-Kronish, J.P., et al. (1996). Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 183, 109–117. Corry, D.B., Grunig, G., Hadeiba, H., Kurup, V.P., Warnock, M.L., Sheppard, D., et al. (1998). Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. Mol Med 4, 344–355. Coyle, A.J., Wagner, K., Bertrand, C., Tsuyuki, S., Bews, J., Heusser, C. (1996). Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: Inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 183, 1303–1310. Diamond, M.S., Staunton, D.E., de Fougerolles, A.R., Stacker, S.A., Garcia-Aguilar, J., Hibbs, M.L., Springer, T.A. (1990). ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 111, 3129–3139. Dunne, J.L., Ballantyne, C.M., Beaudet, A.L., Ley, K. (2002). Control of leukocyte rolling velocity in TNF-α-induced inflammation by LFA-1 and Mac-1. Blood 99, 336–341. Dustin, M.L., Springer, T.A. (1988). Lymphocyte function-associated antigen1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 107, 321–331. Elices, M.J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M.E., et al. (1990). VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60, 577–584. Erger, R.A., Casale, T.B. (1995). Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am J Physiol 268, L117–L122. Fiscus, L.C., Van Herpen, J., Steeber, D.A., Tedder, T.F., Tang, M.L. (2001). L-Selectin is required for the development of airway hyperresponsiveness but
14. MOUSE
MODELS
TO
STUDY
THE
PATHOGENESIS
not airway inflammation in a murine model of asthma. J Allergy Clin Immunol 107, 1019–1024. Foster, P.S., Hogan, S.P., Ramsay, A.J., Matthaei, K.I., Young, I.G. (1996). Interleukin 5 deficiency abolishes eosinophilia, airways hyperractivity, and lung damage in a mouse asthma model. J Exp Med 183, 195–201. Gavett, S.H., O’Hearn, D.J., Li, X.M., Huang, S.K., Finkelman, F.D., Wills-Karp, M. (1995). Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 182, 1527–1536. Gonzalo, J.A., Lloyd, C.M., Kremer, L., Finger, E., Martinez-A, C., Siegelman, M.H., et al. (1996). Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 98, 2332–2345. Grünig, G., Warnock, M., Wakil, A.E., Venkayya, R., Brombacher, F., Rennick, D.M., et al. (1998). Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261–2263. Hamelmann, E., Cieslewicz, G., Schwarze, J., Ishizuka, T., Joetham, A., Heusser, C., et al. (1999). Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 160, 934–941. Hamelmann, E., Oshiba, A., Loader, J., Larsen, G.L., Gleich, G., Lee, J., et al. (1997a). Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am J Respir Crit Care Med 155, 819–825. Hamelmann, E., Schwarze, J., Takeda, K., Oshiba, A., Larsen, G.L., Irvin, C.G., et al. (1997b). Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156, 766–775. Hamelmann, E., Takeda, K., Haczku, A., Cieslewicz, G., Shultz, L., Hamid, Q., et al. (2000). Interleukin (IL)-5 but not immunoglobulin E reconstitutes airway inflammation and airway hyperresponsiveness in IL-4-deficient mice. Am J Respir Cell Mol Biol 23, 327–334. Hessel, E.M., Van Oosterhout, A.J., Hofstra, C.L., De Bie, J.J., Garssen, J., Van Loveren, H., et al. (1995). Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice. Eur J Pharmacol 293, 401–412. Hisada, T., Hellewell, P.G., Teixeira, M.M., Malm, M.G., Salmon, M., Huang, T.J., et al. (1999). α4-Integrin-dependent eotaxin induction of bronchial hyperresponsiveness and eosinophil migration in interleukin-5 transgenic mice. Am J Respir Cell Mol Biol 20, 992–1000. Hogan, S.P., Matthaei, K.I., Young, J.M., Koskinen, A., Young, I.G., Foster, P.S. (1998). A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol 161, 1501–1509. Hogan, S.P., Mould, A., Kikutani, H., Ramsay, A.J., Foster, P.S. (1997). Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergenspecific immunoglobulins. J Clin Invest 99, 1329–1339. Holgate, S.T., Bodey, K.S., Janezic, A., Frew, A.J., Kaplan, A.P., Teran, L.M. (1997). Release of RANTES, MIP-1α, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med 156, 1377–1383. Holgate, S.T., Chuchalin, A.G., Hebert, J., Lotvall, J., Persson, G.B., Chung, K.F., et al. (2004). Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34, 632–638. Humbles, A.A., Lloyd, C.M., McMillan, S.J., Friend, D.S., Xanthou, G., McKenna, E.E., et al. (2004). A critical role for eosinophils in allergic airways remodeling. Science 305, 1776–1779. Ishimitsu, R., Nishimura, H., Yajima, T., Watase, T., Kawauchi, H., Yoshikai, Y. (2001). Overexpression of IL-15 in vivo enhances Tc1 response, which inhibits allergic inflammation in a murine model of asthma. J Immunol 166, 1991–2001. Kameyoshi, Y., Dorschner, A., Mallet, A.I., Christophers, E., Schroder, J.M. (1992). Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176, 587–592.
OF
ALLERGIC
ASTHMA
299
Kenyon, N.J., Last, J.A. (2005). Reversible and irreversible airway inflammation and fibrosis in mice exposed to inhaled ovalbumin. Inflamm Res 54, 57–65. Kenyon, N.J., Ward, R.W., Last, J.A. (2003). Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol 186, 90–100. Kenyon, N.J., Ward, R.W., McGrew, G., Last, J.A. (2003). TGF-β1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax 58, 772–777. Kim, J., Merry, A.C., Nemzek, J.A., Bolgos, G.L., Siddiqui, J., Remick, D.G. (2001). Eotaxin represents the principal eosinophil chemoattractant in a novel murine asthma model induced by house dust containing cockroach allergens. J Immunol 167, 2808–2815. Kim, Y., Sung, S.-s. Kuziel, W.A., Feldman, S., Fu, S.M., Rose, C.E., Jr. (2001). Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). J Immunol 166, 5183–5192. Kips, J.C., Brusselle, G.J., Joos, G.F., Peleman, R.A., Tavernier, J.H., Devos, R.R., Pauwels, R.A. (1996). Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med 153, 535–539. Kobayashi, T., Miura, T., Haba, T., Sato, M., Serizawa, I., Nagai, H., Ishizaka, K. (2000). An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol 164, 3855–3861. Komai, M., Tanaka, H., Masuda, T., Nagao, K., Ishizaki, M., Sawada, M., Nagai, H. (2003). Role of Th2 responses in the development of allergeninduced airway remodelling in a murine model of allergic asthma. Br J Pharmacol 138, 912–920. Kudlacz, E., Whitney, C., Andresen, C., Duplantier, A., Beckius, G., Chupak, L., et al. (2002). Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule α4β1 antagonists. J Pharmacol Exp Ther 301, 747–752. Kumar, R.K., Foster, P.S. (2002). Modeling allergic asthma in mice: pitfalls and opportunities. Am J Respir Cell Mol Biol 27, 267–272. Kumar, R.K., Herbert, C., Yang, M., Koskinen, A.M., McKenzie, A.N., Foster, P.S. (2002). Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy 32, 1104–1111. Kung, T.T., Stelts, D.M., Zurcher, J.A., Adams, G.K., Egan, R.W., Kreutner, W., et al. (1995). Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 13, 360–365. Lamkhioued, B., Renzi, P.M., Abi-Younes, S., Garcia-Zepada, E.A., Allakhverdi, Z., Ghaffar, O., et al. (1997). Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 159, 4593–4601. Lee, J.J., McGarry, M.P., Farmer, S.C., Denzler, K.L., Larson, K.A., Carrigan, P.E., et al. (1997). Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 185, 2143–2156. Li, L., Xia, Y., Nguyen, A., Lai, Y.H., Feng, L., Mosmann, T.R., et al. (1999). Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 162, 2477–2487. Lukacs, N.W., John, A., Berlin, A., Bullard, D.C., Knibbs, R., Stoolman, L.M. (2002). E- and P-selectins are essential for the development of cockroach allergen-induced airway responses. J Immunol 169, 2120–2125. Lukacs, N.W., Prosser, D.M., Wiekowski, M., Lira, S.A., Cook, D.N. (2001). Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J Exp Med 194, 551–555. Lundblad, L.K., Irvin, C.G., Adler, A., Bates, J.H. (2002). A reevaluation of the validity of unrestrained plethysmography in mice. J Appl Physiol 93, 1198–1207. MacGlashan, D.W., Jr., Bochner, B.S., Adelman, D.C., Jardieu, P.M., Togias, A., McKenzie-White, J., et al. (1997). Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158, 1438–1445. MacLean, J.A., De Sanctis, G.T., Ackerman, K.G., Drazen, J.M., Sauty, A., DeHaan, E., et al. (2000). CC chemokine receptor-2 is not essential for the
300
CHAD
E.
GREEN,
NICHOLAS
J.
development of antigen-induced pulmonary eosinophilia and airway hyperresponsiveness. J Immunol 165, 6568–6575. Mäkelä, M.J., Kanehiro, A., Borish, L., Dakhama, A., Loader, J., Joetham, A., et al. (2000). IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc Natl Acad Sci USA 97, 6007–6012. Martin, T.R., Takeishi, T., Katz, H.R., Austen, K.F., Drazen, J.M., Galli, S.J. (1993). Mast cell activation enhances airway responsiveness to methacholine in the mouse. J Clin Invest 91, 1176–1182. Mattes, J., Yang, M., Siqueira, A., Clark, K., MacKenzie, J., McKenzie, A.N., et al. (2001). IL-13 induces airways hyperreactivity independently of the IL-4R α chain in the allergic lung. J Immunol 167, 1683–1692. Mayr, S.I., Zuberi, R.I., Zhang, M., de Sousa-Hitzler, J., Ngo, K., Kuwabara, Y., et al. (2002). IgE-dependent mast cell activation potentiates airway responses in murine asthma models. J Immunol 169, 2061–2068. McLane, M.P., Haczku, A., Van de Rijn, M., Weiss, C., Ferrante, V., MacDonald, D., et al. (1998). Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am J Respir Cell Mol Biol 19, 713–720. McNulty, C.A., Symon, F.A., Wardlaw, A.J. (1999). Characterization of the integrin and activation steps mediating human eosinophil and neutrophil adhesion to chronically inflamed airway endothelium. Am J Respir Cell Mol Biol 20, 1251–1259. Mehlhop, P.D., Van de Rijn, M., Goldberg, A.B., Brewer, J.P., Kurup, V.P., Martin, T.R., et al. (1997). Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA 94, 1344–1349. Milgrom, H., Jr., Fick, R.B., Su, J.Q., Reimann, J.D., Bush, R.K., Watrous, M.L., et al. (1999). Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341, 1966–1973. Mould, A.W., Matthaei, K.I., Young, I.G., Foster, P.S. (1997). Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 99, 1064–1071. Nagai, H., Yamaguchi, S., Maeda, Y., Tanaka, H. (1996). Role of mast cells, eosinophils and IL-5 in the development of airway hyperresponsiveness in sensitized mice. Clin Exp Allergy 26, 642–647. Ogawa, K., Kaminuma, O., Kikkawa, H., Kameda, R., Ikezawa, K., Suko, M., et al. (1999). Primary role of CD4+ T cells and supplemental role of mast cells in allergic pulmonary eosinophilia. Int Arch Allergy Immunol 120 (Suppl. 1), 15–18. Ponath, P.D., Qin, S., Ringler, D.J., Clark-Lewis, I., Wang, J., Kassam, N., et al. (1996). Cloning of the human eosinophil chemoattractant, eotaxin: expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 97, 604–612. Pope, S.M., Brandt, E.B., Mishra, A., Hogan, S.P., Zimmermann, N., Matthaei, K.I., et al. (2001). IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 108, 594–601. Pope, S.M., Zimmermann, N., Stringer, K.F., Karow, M.L., Rothenberg, M.E. (2005). The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol 175, 5341–5350. Ravensberg, A.J., Ricciardolo, F.L., van Schadewijk, A., Rabe, K.F., Sterk, P.J., Hiemstra, P.S., et al. (2005). Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol 115, 779–785. Reinhard, C., Eder, G., Fuchs, H., Ziesenis, A., Heyder, J., Schulz, H. (2002). Inbred strain variation in lung function. Mamm Genome 13, 429–437. Riezman, H., Woodman, P.G., Van Meer, G., Marsh, M. (1997). Molecular mechanisms of endocytosis. Cell 91, 731–738. Rothenberg, M.E., MacLean, J.A., Pearlman, E., Luster, A.D., Leder, P. (1997). Targeted disruption of the chemokine eotaxin partially reduces antigeninduced tissue eosinophilia. J Exp Med 185, 785–790. Schuh, J.M., Blease, K., Kunkel, S.L., Hogaboam, C.M. (2002). Eotaxin/CCL11 is involved in acute, but not chronic, allergic airway responses to Aspergillus fumigatus. Am J Physiol 283, L198–L204.
KENYON,
SCOTT
I.
SIMON,
AND
FU-TONG
LIU
Schuh, J.M., Power, C.A., Proudfoot, A.E., Kunkel, S.L., Lukacs, N.W., Hogaboam, C.M. (2002). Airway hyperresponsiveness, but not airway remodeling, is attenuated during chronic pulmonary allergic responses to Aspergillus in CCR4−/− mice. FASEB J 16, 1313–1315. Springer, T.A. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301–314. Stampfli, M.R., Scott Neigh, G., Wiley, R.E., Cwiartka, M., Ritz, S.A., Hitt, M.M., et al. (1999). Regulation of allergic mucosal sensitization by interleukin-12 gene transfer to the airway. Am J Respir Cell Mol Biol 21, 317–326. Sur, S., Choudhury, B.K., Lam, J.S., Bouchard, P., Wild, J.S., Sur, N., et al. (2000). Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs. Exp Lung Res 26, 457–476. Takeda, K., Hamelmann, E., Joetham, A., Shultz, L.D., Larsen, G.L., Irvin, C.G., et al. (1997). Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 186, 449–454. Tanaka, H., Komai, M., Nagao, K., Ishizaki, M., Kajiwara, D., Takatsu, K., et al. (2004). Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol 31, 62–68. Tanaka, H., Masuda, T., Tokuoka, S., Komai, M., Nagao, K., Takahashi, Y., et al. (2001). The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. Inflamm Res 50, 616–624. Temelkovski, J., Hogan, S.P., Shepherd, D.P., Foster, P.S., Kumar, R.K. (1998). An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 53, 849–856. Tomkinson, A., Duez, C., Cieslewicz, G., Gelfand, E.W. (2001). Eotaxin-1-deficient mice develop airway eosinophilia and airway hyperresponsiveness. Int Arch Allergy Immunol 126, 119–125. Tournoy, K.G., Kips, J.C., Pauwels, R.A. (2000). Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness. Clin Exp Allergy 30, 775–783. Tournoy, K.G., Kips, J.C., Pauwels, R.A. (2001). Counterbalancing of TH2-driven allergic airway inflammation by IL-12 does not require IL-10. J Allergy Clin Immunol 107, 483–491. Tumas, D.B., Chan, B., Werther, W., Wrin, T., Vennari, J., Desjardin, N., et al. (2001). Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization. J Allergy Clin Immunol 107, 1025–1033. Van Oosterhout, A.J., Fattah, D., Van Ark, I., Hofman, G., Buckley, T.L., Nijkamp, F.P. (1995). Eosinophil infiltration precedes development of airway hyperreactivity and mucosal exudation after intranasal administration of interleukin-5 to mice. J Allergy Clin Immunol 96, 104–112. Walsh, G.M., Mermod, J.J., Hartnell, A., Kay, A.B., Wardlaw, A.J. (1991). Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is α4β1 (very late antigen-4) dependent. J Immunol 146, 3419–3423. Wang, J., Homer, R.J., Hong, L., Cohn, L., Lee, C.G., Jung, S., et al. (2000). IL-11 selectively inhibits aeroallergen-induced pulmonary eosinophilia and Th2 cytokine production. J Immunol 165, 2222–2231. Wang, J., Palmer, K., Lotvall, J., Milan, S., X.-Lei, F., Matthael, K.I., et al. (1998). Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 102, 1132–1141. Wang, S., Fan, Y., Han, X., Yang, J., Bilenki, L., Yang, X. (2001). IL-12-dependent vascular cell adhesion molecule-1 expression contributes to airway eosinophilic inflammation in a mouse model of asthma-like reaction. J Immunol 166, 2741–2749. Wardlaw, A.J. (1999). Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol 104, 917–926. Webb, D.C., McKenzie, A.N., Koskinen, A.M., Yang, M., Mattes, J., Foster, P.S. (2000). Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 165, 108–113. Whittaker, L., Niu, N., Temann, U.A., Stoddard, A., Flavell, R.A., Ray, A., et al. (2002). Interleukin-13 mediates a fundamental pathway for airway epithelial
14. MOUSE
MODELS
TO
STUDY
THE
PATHOGENESIS
mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 27, 593–602. Williams, C.M., Galli, S.J. (2000). Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 192, 455–462. Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T.Y., Karp, C.L., et al. (1998). Interleukin-13, central mediator of allergic asthma. Science 282, 2258–2261. Yang, X., Wang, S., Fan, Y., Han, X. (2000). IL-10 deficiency prevents IL-5 overproduction and eosinophilic inflammation in a murine model of asthmalike reaction. Eur J Immunol 30, 382–391.
OF
ALLERGIC
ASTHMA
301
Zhang, Y., Lamm, W.J.E., Albert, R.K., Chi, E.Y., Henderson, W.R., Jr., Lewis, D.B. (1997). Influence of the route of allergen administration and genetic background on the murine allergic pulmonary response. Am J Respir Crit Care Med 155, 661–669. Zuberi, R.I., Apgar, J.R., Chen, S.S., Liu, F.T. (2000). Role for IgE in airway secretions: IgE immune complexes are more potent inducers than antigen of airway inflammation in a murine model. J Immunol 164, 2667–2673. Zuberi, R.I., Hsu, D.K., Kalayci, O., Chen, H.Y., Sheldon, H.K., Yu, L., et al. (2004). Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol 165, 2045–2053.
This page intentionally left blank
Chapter 15 The Mouse Trap: How Well Do Mice Model Human Immunology? Christopher C.W. Hughes and Javier Mestas
I. Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II. Immune System–Related Genetic Disorders . . . . . . . . . . . . . . . . . . . . . . . . III. Response to Viral Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Response to Mycobacterium tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . V. Response to Helminth Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VI. Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis . . . . VII. Delayed-Type Hypersensitivity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VIII. Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IX. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I.
OVERVIEW
Huge advances have been made in the understanding of human immune responses through the study of mice. However, therein lies a trap: mice have proved to be such good models that it is now tempting to assume that what is true in mice—in vivo veritas—is necessarily true in human. As we describe below, the differences between human and mouse immunology are significant and numerous. Although recent sequencing efforts reveal only 300 or so genes that are unique to mouse or human (Waterston et al. 2002), it should not be forgotten that the two species diverged around 75 million years ago, differ hugely in both size and lifespan, and have evolved in quite different ecological niches in which widely different pathogenic challenges need to be met. THE MOUSE IN BIOMEDICAL RESEARCH, 2ND EDITION
303 307 307 308 308 308 309 309 309 310 310
Notably, humans are about 3000 times larger than mice and have a correspondingly larger number of cells, the result of perhaps 105 more mitoses (Rangarajan and Weinberg 2003). Added to this, humans live 30–50 times longer, resulting in a greatly increased potential for generating cells bearing mutations predisposing to cancer. As such, it might be predicted that changes in immune surveillance may have evolved to combat this risk. Most, if not all, of the differences we have noted between mouse and human immunology (Table 15-1) have probably become fixed during the 75 million years since our divergence because they provide some selective advantage. In all likelihood these adaptations are in response to new pathological challenges from microorganisms, which have very short generation times and often have high mutation rates (McDade and Worthman 1999). Such rapid changes in microorganisms have Copyright © 2007, 1980, Elsevier Inc. All rights reserved.
303
304
CHRISTOPHER
C . W.
HUGHES
AND
J AV I E R
MESTAS
TABLE 15-1
SUMMARY OF SOME KNOWN IMMUNOLOGICAL DIFFERENCES BETWEEN MOUSE AND HUMAN
Hematopoiesis in spleen Presence of BALT Neutrophils in peripheral blood Lymphocytes in peripheral blood Hematopoietic stem cells CD34− MSC expression of CXCR5 CD34− MSC expression of CCR2 TLR2 expression on PBLs TLR3 TLR9
TLR10 Expression of IRAK splice variants Response to endotoxin Sialic acid Neu5GC expression CD33 Leukocyte defensins Paneth cell defensins Paneth cell defensins iNOS in macrophages Murine macrophage NO CD4 on macrophage Predominant T cells in skin and mucosa γ/δ T cells respond to phospho-antigens CD1 genes NK inhibitory receptors for MHC I NKG2D ligands
Mouse
Human
Active into adulthood Significant 10–25%
Ends before birth Largely absent in healthy tissue 50–70%
Pabst and Gehrke 1990 Doeing et al. 2003
75–90%
30–50%
Doeing et al. 2003
c-kithigh, flt-3− Absent
c-kitlow, flt-3+ Present
Sitnicka et al. 2003 von Luttichau et al. 2005
Present
Absent
von Luttichau et al. 2005
Low (induced on many cells including T cells) Expressed on DCs, macrophages; induced by LPS Expressed on all myeloid cells, plasmacytoid DCs and B cells
Constitutive (but not on T cells)
Binds lipopeptides
Rehli 2002
Expressed by DC; no LPS induction Expressed only on B cells, plasmacytoid DCs and neutrophils Widely expressed IRAK1b, IRAK1c
Binds dsRNA
Heinz, Haehnel et al. 2003; Rehli 2002 Lund et al. 2003; Trevani et al. 2003
Pseudogene All IRAK2 variants, IRAK1s, IRAK1b Requires high dose; no physiological response Widespread Expressed on granulocytes
Low dose induces fever, tachycardia Absent Expressed on monocytes
Toll receptor regulation
Rao et al. 2005 Copeland et al. 2005
Binds pathogens Binds sialic acids
Yes
Kaufmann 1996
CD1d 8–18 Ly49 (except Ly49D and H), 2 KIR H-60, Rae1β
CD1a,b,c,d 9–14 KIR, 1 LY49
Dutronc and Porcelli 2002 Lanier 1998; Parham 2005
MIC A, MIC B, ULBP Expressed by all
Low Absent
High Present
FcγRIIA, C Serum IgA
Absent Mostly polymeric
Present Mostly monomeric
Ig classes
IgA, IgD, IgE, IgG1, IgG2a,* IgG2b, IgG3, IgM Shorter, less diverse IgMhi B cells in periphery
IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, IgM Longer, more diverse No peripheral B cells
Normal pre-B and immature B Leaky block at pro-B to pre-B transition
Blocks pro-B to pre-B transition Blocks pro-B to pre-B transition
Neutrophils
Varki 2001 Brinkman-Van der Linden et al. 2003 Risso 2000 Cunliffe et al. 2001; Ghosh et al. 2002 Ouellette and Selsted 1996 Schneemann et al. 1993 Weinberg 1998 Crocker et al. 1987 Elbe et al. 1996
Present Stored as pro-form; processed by trypsin Two Absent Induced by IFN-α/β Present α/β TCRs
Only on activated and memory
Btk deficiency λ5 deficiency
Binds CpG
References
Absent Processed by MMP7; stored preprocessed At least 20 Present Induced by IFN-γ and LPS Absent γ/δ TCRs (dendritic epidermal T cells) No
NKG2D expression on αβ CD8+ T cells fMLP receptor affinity FcαRI
Ig CDR-H3 region BLNK deficiency
Notes
NK activating receptors Costimulatory naïve human T
Raulet 2003 Maasho et al. 2005 Gao and Murphy 1993 Monteiro and Van De Winkel 2003 Daeron 1997 Monteiro and Van De Winkel 2003 Martin and Lew 1998 Zemlin et al. 2003 Minegishi et al. 1999; Pappu et al. 1999 Conley et al. 2000 Conley et al. 2000
15. THE
MOUSE
TRAP:
HOW
WELL
DO
MICE
MODEL
HUMAN
305
IMMUNOLOGY?
TABLE 15-1
SUMMARY OF SOME KNOWN IMMUNOLOGICAL DIFFERENCES BETWEEN MOUSE AND HUMAN—cont’d
Osteopontin expression in lymph node CD38 expression on B cells B cell CD5 and CD23 expression IL-13 effect on B cells Thy1 expression
Mouse
Human
Absent on follicular DCs
Widespread including follicular DCs High on GC B cells and plasma cells Coexpression
Low on GC B cells, off in plasma cells Mutually exclusive None Thymocytes, peripheral T cells
Notes
Li et al. 2005 Gordon et al. 2001 Gordon et al. 2001
Induces switch to IgE Absent from all T cells, expressed on neurons Loss of T and NK cells, but B cell numbers normal Phenocopies γc deficiency Only blocks T cell development
Snapper and Finkelman 1999 Tokugawa et al. 1997
Effect of γc deficiency
Loss of T, NK, and B cells
Effect of Jak3 deficiency Effect of IL-7R deficiency
Phenocopies γc deficiency Blocks T and B cell development
ZAP70 deficiency
No CD4+ or CD8+ T cells
Caspase 8 deficiency
Embryonic lethal
No CD8+ T cells but many nonfunctional CD4+ Viable, immunodeficiency
Caspase 10 IFN-α promotes Th1 differentiation Induction of IL-12R β2
Absent No
Present Yes
IFN-γ
IFN-α/β but not IFN-γ
Th expression of IL-10 IL-4 and IFN-γ expression by cultured Th cells CD26 expression on T cells
Th2 Either/or
Th1 and Th2 Sometimes both
CD4 CD8 DN thymocytes
CD4+ and CD8+ thymocytes, memory T Widespread, including T cells
Complement R
On 80% of CD4+, 50% of CD8+ Cyclin D2, no cyclin D3
D3→ rapid response?
CD46 expression CD28 expression on T cells Cyclin D in resting CD8+ memory T cells ICOS deficiency
Only on spermatozoa and testes germ cells On 100% of CD4+ and CD8+ Cyclin D3 Normal B cell numbers and function, normal IgM levels
B cells immature and severely reduced in number, low IgM
B7-H3 effects on T cells
Inhibits activation
Promotes activation
ICAM3
Absent
Present
P-selectin promoter GlyCAM MHC II expression on T cells
Activated by TNF and LPS Present Absent
Unresponsive to inflammation Absent Present
MUC1 on T cells
Absent
Present
Granulysin CXCR1
Absent Absent
Present Present
IL-8, NAP-2, ITAC, MCP-4, HCC-1, HCC-2, MPIF-1, PARC, eotaxin-2/3 MRP-1/2, lungkine, MCP-5
Absent
Present
Present
Absent
Protective in EAE
Exacerbates MS
IFN-γ effects in demyelinating disease
References
Related to syk level?
Mutant stat2 in mice
Fischer et al. 1997; Leonard 1999 Buckley 1999 Peschon et al. 1994; Roifman et al. 2000 Chu et al. 1999; Elder et al. 2001 Chun et al. 2002; Tibbetts et al. 2003 Tibbetts et al. 2003 Farrar et al. 2000 Rogge et al. 1997; Szabo et al. 1997 Del Prete et al. 1993
Ohnuma et al. 2005 Kemper et al. 2005 Lenschow et al. 1996
Possibly age-related Grimbacher et al. 2003; McAdam et al. 2001; Tafuri et al. 2001 Chapoval et al. 2001; Suh et al. 2003 DC-SIGN ligand Geijtenbeek et al. 2000; van Kooyk and Geijtenbeek 2002 Pan et al. 1998 Crommie and Rosen 1995 Barnaba et al. 1994; Lombardi et al. 1996; Denton et al. 1999; Taams et al. 1999 Regulates Correa et al. 2003 migration? In CTL Flynn and Chan 2001; Olson and Ley 2002; Zlotnik and Yoshie 2000 Chemokines Olson and Ley 2002; Zlotnik and Yoshie 2000 Chemokines
Olson and Ley 2002; Zlotnik and Yoshie 2000 Heremans et al., 1996; Lublin et al. 1993; Panitch et al. 1987 Continued
306
CHRISTOPHER
C . W.
HUGHES
AND
J AV I E R
MESTAS
TABLE 15-1
SUMMARY OF SOME KNOWN IMMUNOLOGICAL DIFFERENCES BETWEEN MOUSE AND HUMAN—cont’d Mouse
Human
Notes
Protective in EAE
Exacerbates MS
Exacerbates EAE
Protects in MS
Neutrophil-rich
Lymphocyte-rich
Constitutive MHC II on ECs ECs present antigen to CD4+ T cells
Absent No
Present Yes
CD58 (LFA-3) T cell dependence on CD2-ligand interactions CD2-ligand interaction CD40 on ECs
Absent Low
Present High
Selmaj et al. 1991; van Oosten et al. 1996 Loss of Treg in mu. Kohm et al. 2003; Bielekova et al. 2004 Crowle 1975; Dumonde et al 1982 Choo et al. 1997 Memory T only Mestas and Hughes 2001; Murphy et al. 1999; Pober et al. 2001 CD2 ligand van der Merwe 1999 van der Merwe 1999
Lower affinity, with CD48 Absent
Higher affinity, with CD58 Present
Vascularized grafts tolerogenic? Success with microchimerism inducing graft tolerance CD24 or CD25 mAbs induce tolerance Passenger leukocytes
Yes
No
High
Low (experiments in nonhuman primates) No
TNF effects in demyelinating disease IL-2 mAb effects in demyelinating disease DTH lesions
High-dose IL-2 for anticancer treatment
Yes Account for graft immunogenicity Clears B16 melanoma
Do not account for graft immunogenicity Little to no benefit
References
van der Merwe 1999 Ensminger et al. 2003; Karmann et al. 1995 Sykes 2001 Monaco 2003 Sachs 2003 Wood 2003 Parkinson et al. 1990; Sparano et al. 1993
BALT, bronchus-associated lymphoid tissue; MSC, mesenchymal stem cell; TLR, toll-like receptor; DC, dendritic cell; LPS, lipopolysaccharide; ds, doublestranded; PBL, peripheral blood lymphocytes; IRAK, IL-1 receptor kinase; MMP, matrix metalloproteinase; iNOS, inducible nitric oxide synthase; NO, nitric oxide; fMLP, formyl-methionyl-leucyl-phenylalanine; GC, germinal center; DN, double negative; ICAM, intercellular adhesion molecule; NCP, neutrophilactivating peptide; ITAC, interferon-inducible T cell α chemoattractant; MCP, monocyte chemoattractant protein; HCC, hemofiltrate CC chemokine; MPIF, myeloid progenitor inhibitory factor; PARC, pulmonary and activation-regulated chemokine; MRP, multidrug resistance protein; LFA, leukocyte (lymphocyte) function-associated antigen. *Absent in C57BL/6, /10, SJL, and NOD mice, which have IgG2c.
driven rapid evolution of mammalian major histocompatability (MHC) molecules, and consequently, natural killer (NK) cell inhibitory receptors (Martin et al. 2002; Pabst and Gehrke 1990; Parham 2005). By assuming that what is true in mice is also true in human we run the risk of overlooking aspects of human immunology that do not occur or cannot be modeled in the mouse. Included in this subset are differences that may preclude a successful preclinical trial in mice becoming a successful clinical trial in human. The literature is littered with examples of therapies that work well in mice but fail to provide similar efficacy in humans (Monaco 2003; Oehler and Bicknell 2000; Panitch, Hirsch et al. 1987; Shepherd and Sridhar 2003; Sykes 2001; van Oosten et al. 1996; Wood 2003). When the ultimate goal of research in mice is to improve human health, then efforts to identify ways we respond differently to immunological challenges will surely help avoid undue early focus on therapies that are destined to be unsuccessful in the clinic.
So, why do we focus so much immunological research on the mouse? The simple answer is that, in comparison, doing these experiments in people is very hard. Humans are outbred and do not live in controlled environments; obtaining institutional review board approvals is time-consuming and costly; and the ethics of placebo-controlled trials are still being debated. Some of these issues were recently reviewed (Steinman and Mellman 2004). Several groups, including our own, have used SCID mice engrafted with various components of the human immune system, including purified T cells, and these models have proven to be a useful intermediate between mouse studies and clinical trials (Bankert et al. 2001; Davis and Stanley 2003; Murray et al. 1994; Sultan et al. 1997). However, there are dangers in these models, too, as some cell-cell interactions do not cross species barriers. For example, human T cells do not efficiently cross mouse endothelium (Murray et al. 1994). We recently published a detailed discussion of the immunological differences between the species (Mestas and Hughes 2004),
15. THE
MOUSE
TRAP:
HOW
WELL
DO
MICE
MODEL
and these are summarized with updates in Table 15-1. In this chapter, we will focus on specific disease processes that are known to differ between mice and humans.
II.
IMMUNE SYSTEM–RELATED GENETIC DISORDERS
Important differences have been noted between patients with mutations in BLNK (SLP-65) and mice having targeted mutations in this gene. BLNK is an adapter protein that is rapidly phosphorylated by Syk after cross-linking of the B cell antigen receptor. It then serves as a scaffold for downstream signaling components such as Grb2, Vav, Nck, and phospholipase C-γ. A naturally occurring mutation in the human BLNK protein has been identified that results in a splicing defect preventing protein expression. In this patient there was a block in the pro-B to pre-B transition, resulting in a complete absence of B cells in the periphery. In contrast, although B cell development in mice lacking BLNK was also blocked at the pro-B to pre-B transition, there were low numbers of IgM+ B cells in the periphery; however, no mature IgMloIgDhi B cells were observed (Pappu et al. 1999). These findings suggest a more severe block in human B cell development than in mouse in response to defects in BLNK (Minegishi et al. 1999). Btk is a tyrosine kinase associated with B cell receptor (BCR) signaling, and both human X-linked agammaglobulinemia (XLA) and mouse X-linked immunodeficiency are associated with defects in this gene (Satterthwaite and Witte 2000). Mutation of Btk in human XLA results in a severe block in B cell development at the pre-B cell stage. In contrast, deletion of the gene in mice results in normal numbers of pre-B and immature cells and ~50% of the normal number of mature B cells. In addition, these mice have near normal concentrations of IgG1, IgG2a, and IgG2b, although levels of IgG3 and IgM are low (Conley et al. 2000). Importantly, when mice have been generated with mutations identical to those seen in human disease, these differences persisted (Buckley 1999; Thomas et al. 1993). Similarly discrepant phenotypes are seen in mice and humans lacking a functional λ5 gene. λ5 is the light chain component of the pre-BCR and in λ5-deficient patients there is again an almost complete block in B cell differentiation at the pro-B to pre-B cell stage (Conley et al. 2000). In stark contrast, mice that lack λ5 also have a block at this stage but it is “leaky,” such that mature mice have 10–20% of the normal number of B cells and antibody responses occur normally. Overall, the data suggest that B cell development is more tightly regulated in human than in mouse. Human and mouse X-linked severe combined immunodeficiency disease (SCID) is the result of mutations in the gene for the cytokine receptor common γ chain, γc. Several cytokine receptors, including those for interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15, share this signaling component. Perhaps not surprisingly,
HUMAN
IMMUNOLOGY?
307
deletion or mutation of this gene, which is on the X chromosome, results in severe immunological defects. Interestingly, these differ between human and mouse X-linked SCID (Fischer et al. 1997; Leonard 1999). Numerous mutations have been identified in the human γc gene that inhibit function, and in most of these cases the result is a dramatic decrease in the number of T cells and NK cells. B cell development, however, is normal, although function is impaired, probably because of the lack of T cell help. In marked contrast, B cell numbers are greatly diminished in γc-null mice. Given that IL-7 receptor deficiency in mouse blocks both T and B cell development (Peschon et al. 1994) but only blocks T cell development in humans (Roifman et al. 2000), it is likely that B cell development in humans is independent of IL-7. The major signal transducer for γc is JAK3 (Janus tyrosine kinase-3) and mutation of this gene phenocopies the γc mutation in both mouse and human, that is, a lack of T and NK cells in human with the addition of a severe B cell defect in mice (Buckley 1999). Interesting differences have also been noted in ZAP70deficient mice and humans. ZAP70 is essential for T cell receptor (TCR) signaling in both development and activation and compromised signaling results in SCID. In humans the defect results in normal numbers of CD4+ T cells and the absence of CD8+ T cells. The CD4+ T cells are, however, nonfunctional. In contrast, an identical mutation introduced into the mouse ZAP70 results in a block in differentiation of both T cell subsets at the double-positive stage (Elder et al. 2001). It has been suggested that the “leakiness” of the human mutant is due to incomplete downregulation of the protein tyrosine kinase Syk in human thymocytes, compared with mouse thymocytes (Chu et al. 1999). To become fully activated T cells require both a primary, antigen-dependent signal and a second, antigen-independent or costimulatory signal. Costimulation is provided by antigenpresenting cells (APCs) expressing ligands for costimulatory receptors on the T cells. Inducible T cell costimulator (ICOS) is an important costimulatory molecule and a human ICOS deficiency was recently reported (Grimbacher et al. 2003). Whereas in mouse the loss of ICOS does not affect either the number of mature B cells, their maturation status, or their secretion of IgM (McAdam et al. 2001; Tafuri et al. 2001), the loss of ICOS in human resulted in a severe reduction in B cell number, maturation status, and secretion of IgM (Grimbacher et al. 2003).
III.
RESPONSE TO VIRAL INFECTIONS
Human cytomegalovirus (HCMV) infection has been widely modeled in mice using mouse cytomegalovirus (MCMV), and despite earlier reports to the contrary MCMV can indeed establish latent infections in mice, similar to those from HCMV in human (Reddehase et al. 2002). Using different strains of mice a susceptibility locus (cmv1) was identified and later shown to encode the Ly49 family of proteins (Webb et al. 2002). There are some 8–18
308
CHRISTOPHER
members of the family, and most are expressed on NK and NK T cells, in which the majority act as NK inhibitory receptors for MHC I molecules (Parham 2005). Apart from a related gene with a different function, the Ly49 family is absent in human, which uses the KIR family as NK inhibitory receptors (Lanier 1998; Parham 2005). KIR proteins are highly diverged from the Ly49 family and have immunoglobulin rather than C-type lectin domains in their extracellular domain; however, similarly to Ly49, they also recognize MHC class I. Ly49H is an activating receptor implicated in the pathogenesis of MCMV infection and binds an MHC-like protein encoded by MCMV (Arase et al. 2002). The NKG2D receptor appears to play an analogous role in human (Raulet 2003) and is important for control of viral replication. The ligands for mouse and human NKG2D differ: in human, NKG2D binds the polymorphic MHC class I–like molecules MHC class I chain related A antigen (MIC A) and MHC class I chain related B antigen (MIC B) and the UL16 binding protein (ULBP) family, whereas in mouse NKG2D binds to H-60 and Rae1β. NKG2D is more widely expressed in human than in mouse and in human acts also as a T cell costimulator (Maasho et al. 2005). The significance of these differences to cytomegalovirus infection and to NK biology in general have not been determined. There has been considerable interest in generating mouse models of human immunodeficiency virus (HIV) infection. Currently the best model utilizes SCID mice transplanted with human peripheral blood mononuclear cells or fetal liver and fetal thymus. These models have proven to be a necessary complication as mouse macrophages, in contrast to human macrophages, do not express CD4 (Crocker et al. 1987). As a consequence, the infection of macrophages by HIV in the early phase of disease is not easily modeled in mice. Recently, transgenic mice have been generated that express human CD4 and CCR5. The T cells of these mice are infectible with R5-tropic HIV-1 strains, although the virus does not replicate (Unutmaz et al. 1998).
IV.
RESPONSE TO MYCOBACTERIUM TUBERCULOSIS
The CD1 family of molecules along with γ/δ T cells have been implicated in the pathogenesis of tuberculosis (TB) (Flynn and Chan 2001; Kaufmann 2001); however, there are significant differences between mouse and human responses. Mouse epidermis contains a large fraction of cells bearing a Vγ5-Vδ1 TCR, and these are known as dendritic epidermal T cells (DETCs). DETCs represent the predominant T cell in mouse skin, whereas cells bearing α/β receptors predominate in human skin and are found mostly in the dermis. Indeed, a cell with DETC characteristics has not been identified in human (Elbe et al. 1996). The differing expression of CD1 genes between mice and humans may turn out to affect activation of both α/β and γ/δ T cells in TB, as both subsets can recognize a variety of antigens presented by CD1 molecules.
C . W.
HUGHES
AND
J AV I E R
MESTAS
However, only human γ/δ T cells are thought to recognize antigen presented by CD1 molecules, in particular CD1b in human (Dutronc and Porcelli 2002). Interestingly, of the five CD1 molecules found in human (designated CD1a, b, c, d, and e), only CD1d is expressed in mice (Dutronc and Porcelli 2002). Some other differences in mouse models of M. tuberculosis infection include the limited role of reactive nitrogen intermediates in human and the absence in mice of granulysin, a potent killer of mycobacteria that along with perforin is present in human cytotoxic lymphocyte granules (Flynn and Chan 2001).
V.
RESPONSE TO HELMINTH INFECTIONS
The existence of polarized T cell populations was first demonstrated by Mossman et al. (1986) and since then has become a guiding principle for T cell activation. Although polarization is relatively easy to observe in mice, the paradigm has never been as clear-cut in the human system. For example, in mice IL-10 is considered to be a Th2 cytokine, whereas in human both Th1 and Th2 cells can make IL-10 (Del Prete et al. 1993). In mice T cells make either IL-4 or interferon (IFN)-γ when polarized, whereas it is relatively easy to induce human T cells to make both cytokines in culture. Epidemiological data suggest that a Th2 response involving eosinophils and IgE may be key to combating schistosomiasis infection in humans (Hagan 1993), whereas in mice effector cell activation by IFN-γ, a Th1 response, is essential for clearance of the parasite (Pearce and Sher 1991).
VI.
MULTIPLE SCLEROSIS AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
Demyelinating diseases provide a fine example of both differences and similarities between mouse and human immunology. Multiple sclerosis (MS) is a multifactorial disease that appears to have a large autoimmune component (Pedotti et al. 2003). Experimental autoimmune (allergic) encephalomyelitis (EAE) is a widely used model for MS that mimics the demyelination seen in central and peripheral nerves in MS. Several studies have indicated that IFN-γ is protective in EAE as neutralizing antibodies exacerbate disease, potentially by blocking induction/activation of suppressor activity (Lublin et al. 1993; Heremans et al. 1996). It was surprising, therefore that clinical trials were not successful; indeed they were stopped because treatment with IFN-γ was found to exacerbate disease (Panitch et al. 1987). A similar, but opposite conundrum has arisen with anti-IL-2 receptor (CD25) therapy. A humanized anti-CD25 monoclonal antibody (mAb) was recently shown to reduce by >75% the appearance of new MS lesions and to promote a significant improvement in clinical outcome (Bielekova et al. 2004). In sharp contrast, anti-CD25 treatment of mice with EAE led to
15. THE
MOUSE
TRAP:
HOW
WELL
DO
MICE
MODEL
exacerbation of disease (Kohm et al. 2003), probably because of a decline in CD4+CD25+ T regulatory (Treg) cells (Furtado et al. 2002). Interestingly, only a subset of human Treg cells have the CD4+CD25+ phenotype seen in mice (Mills 2004). A third example of the failure of mouse models to accurately predict the efficacy of MS treatments in humans comes from the tumor necrosis factor (TNF) field. Anti-TNF antibodies have been shown to be highly effective in abrogating autoimmune demyelination in EAE mice (Selmaj et al. 1991); however when transferred to the clinic, neutralizing mAbs to TNF led to enhanced lesions detectable by magnetic resonance imaging and an increase in cerebrospinal fluid leukocyte count and immunoglobulin (Ig) G index (van Oosten et al. 1996). On the plus side, however, studies in mice suggested that blocking of the VLA-4 (very late antigen-4, α4β1 integrin)-VCAM-1 (vascular cell adhesion molecule-1) interaction might help in MS (Yednock et al. 1992), and this blockade has indeed been carried through successfully into human trials (Miller et al. 2003).
VII.
HUMAN
IMMUNOLOGY?
309
once they reach a draining lymph node and upregulate costimulators such as CD80 and CD86. A teleological argument can be made for the need to present antigen locally in human but not necessarily in mouse. It has been estimated that once a cell enters the lymphatics in human, it takes approximately 24 hours to return to the circulation if it is not retained in a node (Freitas 1999). On the basis of the higher cardiac output of mice as a proportion of their total blood volume compared with humans (5–10 ml/min, 2 ml total volume in mouse; 5 L/min, 5 L total volume in human), it is reasonable to suppose that the return of lymph is at least as fast in mouse as it is in human. Then it becomes a matter of scale. We calculate that an antigen traveling from toe to an inguinal lymph node in the groin should take ~12 hours in human and 20 minutes in mice. As the human DTH response begins ~4 hours after secondary antigen challenge, we propose that triggering of recall responses may occur by different mechanisms in mouse and human, involving draining of antigen to lymph nodes in mice, compared with local antigen presentation, possibly by ECs, in human.
DELAYED-TYPE HYPERSENSITIVITY VIII.
An interesting difference exists in the appearance of delayedtype hypersensitivity (DTH) reactions in mice and human. In human, ~4 hours after antigen challenge neutrophils can be seen forming a “cuff” around the venules. This is followed by a dramatic influx of mononuclear cells, such that by 24–48 hours the lesion is mostly mononuclear with a mix of T cells and macrophages (Dumonde et al. 1982). Paradoxically, in mice in which peripheral blood has a relative paucity of neutrophils compared with human blood (Table 15-1), the DTH response tends to be more neutrophil rich (Crowle 1975). In some cases, however, the response may be neutrophil rich at 24 hours but then evolves to a mononuclear-rich infiltrate by 48 hours. In addition, elicitation of murine DTH requires much higher concentrations of antigen than in human, and lesions cannot be assessed by the degree of redness and induration; rather, DTH in mouse skin is usually measured by swelling of the footpad or pinna of the ear. There is now considerable evidence that human endothelial cells (ECs) can present antigen to resting memory CD4+ and CD8+ T cells (Mestas and Hughes 2001; Murphy et al. 1999; Pober et al. 2001), whereas in mouse CD8+ T cells can be activated by ECs (Kreisel et al. 2002), but CD4+ T cells cannot (Kreisel et al. 2002). As CD4+ T cell–mediated activation of macrophages is thought to drive human DTH responses the suggestion has arisen that EC may be one of the local APCs that trigger the recall, CD4+ T cell–dependent, phase of DTH in human. It is not clear in mice whether the recall phase involves local antigen presentation or whether antigen is carried to the lymph node by Langerhans cells that then present the antigen to T cells in the node. There is good evidence that Langerhans cells express low levels of costimulators and are poor APCs (Geissmann et al. 2002), only becoming fully functional APCs
TRANSPLANTATION
The antigen presenting ability of human ECs may have significant consequences for transplantation. For example, in many rodent models vascularized grafts are tolerizing, whereas such grafts are rapidly rejected in human (Sykes 2001). Numerous studies have shown that purging mouse tissues of CD45+ cells before transplantation dramatically extends the life of the graft, sometimes even inducing tolerance. In sharp contrast, purging human tissues of CD45+ cells provided no benefit as the grafts were still rapidly rejected (Wood 2003). In addition, the establishment of microchimerism in mouse has been quite successful in inducing tolerance, whereas this has not been the case in human (Monaco 2003). The implication of these findings is that there are major differences between mouse and human in their responses to grafted tissue, and that there are cells in human grafts that are CD45– and are able to trigger host T cell activation. Taken together, these studies provide compelling evidence that human ECs can act as APCs to CD4+ T cells whereas mouse ECs cannot.
IX.
SUMMARY
These studies highlight how caution is required when results from mouse studies are extrapolated to the clinic. In many cases not only do successful mouse therapies fail to work in the clinic, they actually have opposite effects in patients, leading to exacerbation of disease. Although the mouse will continue to be an important preclinical model system, it is a dangerous trap to fall into if one believes that what is true in mouse must be true in human.
310
CHRISTOPHER
ACKNOWLEDGMENTS Because of space limitations, we have in many cases cited reviews rather than the primary literature, and we offer our apologies to those authors we have been unable to acknowledge directly. We thank the following people for helpful suggestions: Jeffrey Bender, Mark Boothby, Alfred Bothwell, Michael Cahalan, David Camerini, Paolo Casali, George Chandy, Cheong Chang, Nick Crispe, Olja Finn, Bruce Freedman, David Fruman, Geoff Kansas, Mitch Kronenberg, Tom Lane, Klaus Ley, Ruslan Medzhitov, Andre Ouellette, Peter Parham, Howard Petrie, Jordan Pober, Bruce Rosengard, Markus Schneemann, Michael Selsted, Carl Ware, Marian Waterman, Arthur Weiss, and Miriam Wittmann. We acknowledge the Journal of Immunology for allowing us to use parts of our previously published review in this chapter. This work was supported by a grant from the National Institutes of Health (RO1 AI40710).
REFERENCES Arase, H., Mocarski, E.S., Campbell, A.E., Hill, A.B., Lanier. L.L. (2002). Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296, 1323–1326. Bankert, R.B., Egilmez, N.K., Hess, S.D. (2001). Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22, 386–393. Barnaba, V., Watts, C., de Boer, M., Lane, P., Lanzavecchia, A. (1994). Professional presentation of antigen by activated human T cells. Eur J Immunol 24, 71–75. Bielekova, B., Richert, N., Howard, T., Blevins, B., Markovic-Plese, S., McCartin, J., et al. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc Natl Acad Sci USA 101, 8705–8708. Brinkman-Van der Linden, E.C., Angata, T., Reynolds, S.A., Powell, L.D., Hedrick, S.M., Varki, A. (2003). CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol 23, 4199–4206. Buckley, R.H. (1999). Primary immunodeficiency diseases, in Fundamental Immunology, W.E. Paul, ed., pp. 1427–1453. Lippincott-Raven, Philadelphia. Chapoval, A.I., Ni, J., Lau, J.S., Wilcox, R.A., Flies, D.B., Liu, D., et al. (2001). B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol 2, 269–274. Choo, J.K., Seebach, J.D., Nickeleit, V., Shimizu, A., Lei, H., Sachs, D.H., Madser, J.D. (1997). Species differences in the expression of major histocompatibility complex class II antigens on coronary artery endothelium: implications for cell-mediated xenoreactivity. Transplantation 64, 1315–1322. Chu, D.H., van Oers, N.S., Malissen, M., Harris, J., Elder, M., Weiss, A. (1999). Pre-T cell receptor signals are responsible for the down-regulation of Syk protein tyrosine kinase expression. J Immunol 163, 2610–2620. Chun, H.J., Zheng, L., Ahmad, M., Wang, J., Speirs, C.K., Siegel, R.M., et al. (2002). Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419, 395–399. Conley, M.E., Rohrer, J., Rapalus, L., Boylin, E.C., Minegishi, Y. (2000). Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse. Immunol Rev 178, 75–90.
C . W.
HUGHES
AND
J AV I E R
MESTAS
Copeland, S., Warren, H.S., Lowry, S.F., Calvano, S.E., Remick, D. (2005). Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 12, 60–67. Correa, I., Plunkett, T., Vlad, A., Mungul, A., Candelora-Kettel, J., Burchell, J.M., et al. (2003). Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology 108, 32–41. Crocker, P.R., Jefferies, W.A., Clark, S.J., Chung, L.P., Gordon, S. (1987). Species heterogeneity in macrophage expression of the CD4 antigen. J Exp Med 166, 613–618. Crommie, D., Rosen, S.D. (1995). Biosynthesis of GlyCAM-1, a mucin-like ligand for L-selectin. J Biol Chem 270, 22614–22624. Crowle, A.J. (1975). Delayed hypersensitivity in the mouse. Adv Immunol 20, 197–264. Cunliffe, R.N., Rose, F.R., Keyte, J., Abberley, L., Chan, W.C., Mahida, Y.R. (2001). Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 48, 176–185. Daeron, M. (1997). Fc receptor biology. Annu Rev Immunol 15, 203–234. Davis, P.H., Stanley, S.L., Jr. (2003). Breaking the species barrier: use of SCID mouse-human chimeras for the study of human infectious diseases. Cell Microbiol 5, 849–860. Del Prete, G., De Carli, M., Almerigogna, F., Giudizi, M.G., Biagiotti, R., Romagnani, S. (1993). Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150, 353–360. Denton, M.D., Geehan, C.S., Alexander, S.I., Sayegh, M.H., Briscoe, D.M. (1999). Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4+ T cell alloactivation. J Exp Med 190, 555–566. Doeing, D.C., Borowicz, J.L., Drockett, E.T. (2003). Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 3, 3. Dumonde, D.C., Pulley, M.S., Paradinas, F.J., Southcott, B.M., O’Connell, D., Robinson, M.R., et al. (1982). Histological features of skin reactions to human lymphoid cell line lymphokine in patients with advanced cancer. J Pathol 138, 289–308. Dutronc, Y., Porcelli, S.A. (2002). The CD1 family and T cell recognition of lipid antigens. Tissue Antigens 60, 337–353. Elbe, A., Foster, C.A., Stingl, G. (1996). T-cell receptor αβ and γδ T cells in rat and human skin—are they equivalent? Semin Immunol 8, 341–349. Elder, M.E., Skoda-Smith, S., Kadlecek, T.A., Wang, F., Wu, J., Weiss, A. (2001). Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. J Immunol 166, 656–661. Ensminger, S.M., Spriewald, B.M., Fischlein T., Weyand, M., Morris, P.J., Wood, K.J. (2003). Mouse endothelial CD40 expression does not play a role during the development of transplant arteriosclerosis. Endothelium 10, 111–117. Farrar, J.D., Smith, J.D., Murphy, T.L., Leung, S., Stark, G.r., Murphy, K.M. (2000). Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol 1, 65–69. Fischer, A., Cavazzana-Calvo, M., De Saint Basile, G., DeVillartay, J.P., DiSanto, J.P., Hivroz, C., et al. (1997). Naturally occurring primary deficiencies of the immune system. Annu Rev Immunol 15, 93–124. Flynn, J.L., Chan, J. (2001). Immunology of tuberculosis. Annu Rev Immunol 19, 93–129. Freitas, R. (1999). Lymphatic system, in Nanomedicine, Vol. I: Basic Capabilities. Landes Bioscience, Georgetown, TX. Furtado, G.C., Curotto de Lafaille, M.A., Kutchukhidze, N., Lafaille, J.J. (2002). Interleukin 2 signaling is required for CD4+ regulatory T cell function. J Exp Med 196, 851–857. Gao, J.L., Murphy, P.M. (1993). Species and subtype variants of the N-formyl peptide chemotactic receptor reveal multiple important functional domains. J Biol Chem 268, 25395–25401. Geijtenbeek, T.B., Torensma, R., van Vliet, S.J., van Duijnhoven, G.C., Adema, G.J., van Kooyk, Y., et al. (2000). Identification of DC-SIGN, a novel
15. THE
MOUSE
TRAP:
HOW
WELL
DO
MICE
MODEL
dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100, 575–585. Geissmann, F., Dieu-Nosjean, M.C., Dezutter, C., Valladeau, J., Kaval., S., Leborqne, M., et al. (2002). Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 196, 417–430. Ghosh, D., Porter, E., Shen, B., Lee, S.K., Wilk, D., Drazba, J., et al. (2002). Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 3, 583–590. Gordon, C.J., Grafton, G., Wood, P.M., Larche, M., Armitage, R.J. (2001). Modelling the human immune response: can mice be trusted? [Commentary]. Curr Opin Pharmacol 1, 431–435. Grimbacher, B., Hutloff, A., Schlesier, M., Glocker, E., Warnatz, K., Drager, R., et al. (2003). Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 4, 261–268. Hagan, P. (1993). IgE and protective immunity to helminth infections. Parasite Immunol 15, 1–4. Heinz, S., Haehnel, V., Karaghiosoff, M., Schwarzfischer, L., Muller, M., Krause, S.W., et al. (2003). Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 278, 21502–21509. Heremans, H., Dillen C., Groenen M., Martens, E., Biliau, A. (1996). Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-γ. Eur J Immunol 26, 2393–2398. Karmann, K., Hughes, C.C., Schechner, J., Fanslow, W.C., Pober, J.S. (1995). CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 92, 4342–4346. Kaufmann, S.H. (1996). γδ and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA 93, 2272–2279. Kaufmann, S.H. (2001). How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 1, 20–30. Kemper, C., Verbsky, J.W., Price, J.D., Atkinson, J.P. (2005). T-cell stimulation and regulation: with complements from CD46. Immunol Res 32, 31–44. Kohm, A.P., Carpentier, P.A., Miller, S.D. (2003). Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells. Novartis Found Symp 252, 45–52; discussion 52–4, 106–14. Kreisel, D., Krupnick, A.S., Balsara, K.R., Riha, M., Gelman, A.E., Popma, S.H., et al. (2002). Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol 169, 6154–6161. Lanier, L.L. (1998). NK cell receptors. Annu Rev Immunol 16, 359–393. Lenschow, D.J., Walunas, T.L., Bluestone, J.A. (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol 14, 233–258. Leonard, W.J. (1999). Type I cytokines and interferons and their receptors, in Fundamental Immunology, W.E. Paul, ed., pp. 741–774. Lippincott-Raven, Philadelphia. Li, Q., Lifson, J.D., Duan, L., Schacker, T.W., Reilly, C., Carlis, J., et al. (2005). Potential roles of follicular dendritic cell-associated osteopontin in lymphoid follicle pathology and repair and in B cell regulation in HIV-1 and SIV infection. J Infect Dis 192, 1269–1276. Lombardi, G., Hargreaves, R., Sidhu, S., Imami, N., Lightstone, L., Fuller-Espie, S., et al. (1996). Antigen presentation by T cells inhibits IL-2 production and induces IL-4 release due to altered cognate signals. J Immunol 156, 2769–2775. Lublin, F.D., Knobler, R.L., Kalman, B., Goldhaber, M., Marini, J., Perrault, M., et al. (1993). Monoclonal anti-γ interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 16, 267–274. Lund, J., Sato, A., Akira, S., Medzhitov, R., Iwasaki, A. (2003). Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 198, 513–520. Maasho, K., Opoku-Anane, J., Marusina, A.I., Coligan, J.E., Borrego, F. (2005). NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 174, 4480–4484. Martin, A.M., Kulski, J.K., Witt, C., Pontarotti, P., Christiansen, F.T. (2002). Leukocyte Ig-like receptor complex (LRC) in mice and men. Trends Immunol 23, 81–88.
HUMAN
IMMUNOLOGY?
311
Martin, R.M., Lew, A.M. (1998). Is IgG2a a good Th1 marker in mice? Immunol Today 19, 49. McAdam, A.J., Greenwald, R.J., Levin, M.A., Chernova, T., Malenkovich, N., Ling, V., et al. (2001). ICOS is critical for CD40-mediated antibody class switching. Nature 409, 102–105. McDade, T.W., Worthman, C.M. (1999). Evolutionary process and the ecology of human immune function. Am J Human Biol 11, 705–717. Mestas, J., Hughes, C.C. (2001). Endothelial cell costimulation of T cell activation through CD58-CD2 interactions involves lipid raft aggregation. J Immunol 167, 4378–4385. Mestas, J., Hughes, C.C. (2004). Of mice and not men: differences between mouse and human immunology. J Immunol 172, 2731–2738. Miller, D.H., Khan, O.A., Sheremata, W.A., Blumhardt, L.D., Rice, G.P., Libonati, M.A., et al. (2003). A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348, 15–23. Mills, K.H. (2004). Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4, 841–855. Minegishi, Y., Rohrer, J., Coustan-Smith, E., Lederman, H.M., Pappu, R., Campana, D., et al. (1999). An essential role for BLNK in human B cell development. Science 286, 1954–1957. Monaco, A.P. (2003). Chimerism in organ transplantation: conflicting experiments and clinical observations. Transplantation 75(9 Suppl), 13S–16S. Monteiro, R.C., Van De Winkel, J.G. (2003). IgA Fc receptors. Annu Rev Immunol 21, 177–204. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., Coffman, R.L. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136, 2348–2357. Murphy, L.L., Mazanet, M.M., Taylor, A.C., Mestas, J., Hugher, C.C. (1999). Single-cell analysis of costimulation by B cells, endothelial cells, and fibroblasts demonstrates heterogeneity in responses of CD4+ memory T cells. Cell Immunol 194, 150–161. Murray, A.G., Petzelbauer, P., Hughes, C.C., Costa, J., Askenase, P., Pober, J.S. (1994). Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proc Natl Acad Sci USA 91, 9146–9150. Oehler, M.K., Bicknell, R. (2000). The promise of anti-angiogenic cancer therapy. Br J Cancer 82, 749–752. Ohnuma, K., Yamochi, Y., Uchiyama, M., Nishibashi, K., Iwatat, S., Hosono, O., et al. (2005). CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol Cell Biol 25, 7743–7757. Olson, T.S., Ley, K. (2002). Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol 283, R7–R28. Ouellette, A.J., Selsted, M.E. (1996). Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J 10, 1280–1289. Pabst, R., Gehrke, I. (1990). Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Am J Respir Cell Mol Biol 3, 131–135. Pan, J., Xia, L., McEver, R.P. (1998). Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells. J Biol Chem 273, 10058–10067. Panitch, H.S., Hirsch, R.L., Haley, A.S., Johnson, K.P. (1987). Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1, 893–895. Pappu, R., Cheng, A.M., Li, B., Gong, Q., Chiu, C., Griffin, N., et al. (1999). Requirement for B cell linker protein (BLNK) in B cell development. Science 286, 1949–1954. Parham, P. (2005). MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5, 201–214. Parkinson, D.R., Fisher, R.I., Rayner, A.A., Paietta, E., Margolin, K.A., Weiss, G.R., et al. (1990). Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8, 1630–1636.
312
CHRISTOPHER
Pearce, E.J., Sher, A. (1991). Functional dichotomy in the CD4+ T cell response to Schistosoma mansoni. Exp Parasitol 73, 110–116. Pedotti, R., De Voss, Steinman, J.J., L., Galli, S.J. (2003). Involvement of both ‘allergic’ and ‘autoimmune’ mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol 24, 479–484. Peschon, J.J., Morrissey, P.J., Grabstein, K.H., Ramsdell, R.J., Marakovsky, E., Gliniak, B.C., et al. (1994). Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180, 1955–1960. Pober, J.S., Kluger, M.S., Schechner, J.S. (2001). Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin. Ann NY Acad Sci 941, 12–25. Rangarajan, A., Weinberg, R.A. (2003). Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3, 952–959. Rao, N., Nguyen, S., Ngo, K., Fung-Leung, W.P. (2005). A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling. Mol Cell Biol 25, 6521–6532. Raulet, D.H. (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3, 781–790. Reddehase, M.J., Podlech, J., Grzimek, N.K. (2002). Mouse models of cytomegalovirus latency: overview. J Clin Virol 25 (Suppl 2), S23–S36. Rehli, M. (2002). Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23, 375–378. Risso, A. (2000). Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leuk Biol 68, 785–792. Rogge, L., Barberis-Maino, L., Biffi M., Passini N., Presky, D.H., Gubler, U, et al. (1997). Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185, 825–831. Roifman, C.M., Zhang, J., Chitayzt D., Sharfe, N. (2000). A partial deficiency of interleukin-7Rα is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 96, 2803–2807. Sachs, D.H. (2003). Tolerance: of mice and men. J Clin Invest 111, 1819–1821. Satterthwaite, A.B., Witte, O.N. (2000). The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 175, 120–127. Schneemann, M., Schoedon, G., Hofer, S., Blau, N., Guerrero, L., Schaffner, A. (1993). Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 167, 1358–1363. Selmaj, K., Raine, C.S., Cross, A.H. (1991). Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30, 694–700. Shepherd, F.A., Sridhar, S.S. (2003). Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 41 (Suppl 1): S63–S72. Sitnicka, E., Buza-Vidas, N., Larsson, S., Nygren, J.M., Liuba, K., Jacobson, S.E. (2003). Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 102, 881–886. Snapper, C.M., Finkelman, F.D. (1999). Immunoglobulin class switching, in Fundamental Immunology, W.E. Paul, Ed., pp. 831–861. Lippincott-Raven, Philadelphia. Sparano, J.A., Fisher, R.I., Sunderland, M., Margolin, K., Ernest, M.L., Sznol, M., et al. (1993). Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa2a in patients with advanced melanoma. J Clin Oncol 11, 1969–1977. Steinman, R.M., Mellman, I. (2004). Immunotherapy: bewitched, bothered, and bewildered no more. Science 305, 197–200. Suh, W.K., Gajewska, B.U., Okada, H., Gronski, M.A., Bertram, E.M., Dawicki, W., et al. (2003). The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 4, 899–906. Sultan, P., Schechner, J.S., McNiff, J.M., Hochman, P.S., Hughes, C.C., Lorber, M.I., et al. (1997). Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol 15, 759–762.
C . W.
HUGHES
AND
J AV I E R
MESTAS
Sykes, M. (2001). Mixed chimerism and transplant tolerance. Immunity 14, 417–424. Szabo, S.J., Dighe, A.S., Gubler, U., Murphy, K.M. (1997). Regulation of the interleukin (IL)-12R β2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 185, 817–824. Taams, L.S., van Eden, W., Wauben M.H. (1999). Antigen presentation by T cells versus professional antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T cell-APC interactions. Eur J Immunol 29, 1543–1550. Tafuri, A., Shahinian, A., Bladt F., Yoshinaga, S.K., Jordana, M., Wakeham, A., et al. (2001). ICOS is essential for effective T-helper-cell responses. Nature 409, 105–109. Thomas, J.D., Sideras, P., Smith, C.I., Vorechovsky, I., Chapman, V., Paul, W.E. (1993). Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355–358. Tibbetts, M.D., Zheng, L., Lenardo, M.J. (2003). The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 4, 404–409. Tokugawa, Y., Koyama, M., Silver, J. (1997). A molecular basis for species differences in Thy-1 expression patterns. Mol Immunol 34, 1263–1272. Trevani, A.S., Chorny, A, Salamone, G., Vermeulen, M., Gamberale, R., Schettini, J., et al. (2003). Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 33, 3164–3174. Unutmaz, D., KewalRamani, V.N., Littman, D.R. (1998). G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models. Semin Immunol 10, 225–236. van der Merwe, P.A. (1999). A subtle role for CD2 in T cell antigen recognition. J Exp Med 190, 1371–1374. van Kooyk, Y., Geijtenbeek, T.B. (2002). A novel adhesion pathway that regulates dendritic cell trafficking and T cell interactions. Immunol Rev 186, 47–56. van Oosten, B.W., Barkhof, F., Truyen, L., Boringa, J.B., Bertelsmann, F.W., von Blomberg, B.M., et al. (1996). Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531–1534. Varki, A. (2001). Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol Suppl 33, 54–69. Von Luttichau, I.V., Notohamiprodjo, M., Wechselberger, A., Peters, C., Henger, A., Seliger, C., et al. (2005). Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 14, 329–336. Waterston, R.H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J.F., Agarwal, P., et al. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520–562. Webb, J.R., Lee, S.H., Vidal, S.M. (2002). Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match. Genes Immun 3, 250–262. Weinberg, J.B. (1998). Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med 4, 557–591. Wood, K.J. (2003). Passenger leukocytes and microchimerism: what role in tolerance induction? Transplantation 75(9 Suppl), 17S–20S. Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L., Karin, N. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356, 63–66. Zemlin, M., Klinger, M., Link, J., Zemlin, C., Bauer, K., Engler, J.A., et al. (2003). Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 334, 733–749. Zlotnik, A., Yoshie, O. (2000). Chemokines: a new classification system and their role in immunity. Immunity 12, 121–127.
Index A Activation-induced cytidine deaminase, 95, 156–157, 161–162 Adaptive immune system activation of, 87 cells of, 38–48 description of, 3, 109–110 T cells in, 144–145, 208 Adaptor molecules, 238 Adaptor protein-1, 3 Adhesion and degranulation-promoting adapter protein, 199 Aire, 68 Airway eosinophilia, 294 Airway hyperresponsiveness cytokines in, 293–294 description of, 291–292 eosinophils’ role in, 297 methacholine uses, 293 Airway remodeling, 297 Allergic asthma bronchial epithelium in, 292 cytokines in, 293–294 description of, 291 development of, 292 lung measurements, 292–293 mast cells in, 295 mouse models of, 292–293 summary of, 298 Alymphoid mice, 279 Anaphylatoxins description of, 7 receptors for, 11, 13 Antibody anti-CD11c, 139 classes of, 22–23 complementarity-determining regions, 21 diversity of, 155–157 Fab fragment, 21 H chains, 21 structure of, 21–22 subclasses of, 22–23 Antibody-dependent cellular cytotoxicity, 5, 171 Antibody-forming B cells, 146 Anti-CD3/peptide central tolerance models, 209 Anti-CD11c antibodies, 139 Antigen processing, 18–20 Antigen-antibody complexes, 280 Antigen-binding complex, 24–25
Antigen-presenting cells, 35, 268–269, 309 Antigen-specific cells, 59 Antiintegrin antibodies, 196 AP-1, 234 APECED, 235 ApoB48, 161 Apoptosis death receptors’ role in, 217 mitochondria’s role in, 217–218 regulation of, 253–254 T cell, 236 Athymic nude mice, 277 Autoimmune diseases mouse as model system for studying, 221 natural killer cells and, 173 systemic lupus erythematosus. See Systemic lupus erythematosus Autoimmune regulator, 68, 208, 216 Autoimmunity FCγRIIB and, 264–267 pathogenic, 250–251 T cell–mediated, 234–235
B B cell(s) activation of, 25, 267–268 affinity maturation of, 88 antibody-forming, 146 B-1 cells, 46, 81–82, 86 description of, 7, 43–44 development of, 44–48, 59–60, 307 effector, 91 extrafollicular differentiation of, 92–93 extrinsic signals, 82–83 follicular, 82, 85–86 germinal center differentiation of, 94 selection of, 95–96 homeostasis of, 82–85 intrinsic defects, 61 intrinsic signals, 83–85 maturation of, 45, 282 memory, 91 migration of description of, 47, 76–77 to lymphoid follicles, 78–82 negative selection of, 84–85 ontogeny of, 60–61 plasma cell differentiation from, 91 positive selection of, 84–85
B cell(s) (continued) precursors of, 61 resting splenic, 246 signaling of, 81 signals of, 87 survival of, 82 T cells and, 62, 91–96 tolerance of, 48, 61, 265–266 transitional, 85 turnover of, 82 B cell receptor BAFF and, 85 coreceptors, 24 description of, 23, 43 diversity of, 45 membrane Ig, 83 NF-κB activation via, 84 signaling of, 27–28 B cell stimulating factor-1, 30 B lineage cells, 60 B lymphocyte attenuator, 262 B-1 cells, 46, 81–82, 86 B-2 cells, 45–46 B7-1, 26–28, 268 B7-2, 26–28, 268 B220, 142–143 BAFF B cell receptor and, 85 description of, 82 marginal zone B cells affected by, 86 BAFF-R, 82–83, 85 Bapx1, 76 Basophils, 35 Bat1, 127 Bcl-6, 93, 94 Blimp-1, 93 BLNK, 307 Bone marrow anatomy of, 59–60 cellular organization of, 60–62 dendritic cells from, 140, 148–149 hematopoietic stem cells in, 33 hypertrophy of, 60 natural killer cell development, 37 structure of, 60 thymocytes from, 208 Brd2, 123 Bronchial-associated lymphoid tissue, 69 Btk, 307 BTLA, 269 BXSB.yaa mice, 246–247
313
314
INDEX
C C1, 8 c1q deficiency, 252 C3aR, 11 C3G, 200 C3H/HeJ mice, 110 C4 deficiency, 252 C4A, 124 C4B, 124 C4, 124 C5aR, 11 C5L2, 13 C5 convertase, 8 C57BL/10ScCr mice, 110 Cancer, 283–284 CARMA1, 84 Caspase recruitment domains, 114 C.B-17-scid mice, 278 CCL21, 201 CD1, 20–21, 141 CD3, 24 CD4, 26 CD4+ T cells, 39–40 CD8, 26 CD8+ T cells description of, 39–40 effector, 90 CD11b, 170 CD11b, 33 CD16, 175 CD19, 24, 84 CD21, 94 CD22, 83, 267 CD25, 42, 308–309 CD27, 93 CD35, 94 CD40, 28–29 CD40 ligand, 28–29, 94, 142 CD43, 170 CD45, 84, 254 Cd45, 189 CD49b, 170 CD62L, 90 CD70, 93 CD72, 83 CD74, 19 CD80, 245 CD86, 94, 142 CD91, 141 CD94/NKG2, 174 CD94/NKG2 receptors, 15 CD103, 43 CD122, 170 CD154, 29 CD206, 13 CD244, 175 Central supramolecular activation cluster, 89 Central tolerance models of, 209 T cell–mediated autoimmunity control through, 234–235 Centroblast B cells, 162 Centroblasts, 93
Centrocytes description of, 95 somatic hypermutation of, 94–96 terminal differentiation of, 96 cFLIPL, 95 CH12F3-2, 157 Chemokine(s) dendritic cell migration regulated by, 143–144 description of, 29, 31, 34, 47, 64 in inflammatory responses, 295 in lymphoid organogenesis, 75 natural killer cell production of, 171–172 from radiation-resistant stroma, 93 transcription of, 75 Chemokine receptors description of, 29, 64 signaling of, 202–204 CIITA, 93 Ciliary neurotrophic factor receptor, 41 Cis transgenic mice, 188 c-Kit, 35 Class II-associated invariant chain peptide, 19 Class switch recombination description of, 157 mismatch repair proteins involved in, 164 Clonal deletion, 215, 218 Clonal expansion, 68 Cluster of differentiation, 32 Collectins, 14 Complement protein 3, 8 Complement proteins, 280 Complement receptors characteristics of, 10 CR1, 10–11 CR2, 10–11 CR3, 11 CR4, 11 Complement system activation of, 8 functions of, 8 lectin pathway of, 8 overview of, 8–10 pentraxin pathway of, 8 Complementarity-determining regions, 21 Cortical epithelial cells, 63, 65 Cortical thymic epithelial cells, 208 Costimulatory molecules, 215 CR1, 10–11 CR2, 10–11, 24 Cr2, 11 CR3, 11 CR4, 11 Crry, 280 Cryptopatches, 69 CTLA-4, 237, 268–269 C-type lectin, 36 C-type lectin receptors, 13–14 C-type lectin-like glycoprotein, 175 CXCL13, 75, 78 CXCR5, 78 Cytochrome c, 217
Cytokine(s) in airway hyperresponsiveness, 293–294 description of, 29, 279 in inflammatory responses, 295 natural killer cell production of, 171–172 receptors for, 30–31 suppressors of cytokine signaling, 180–181 Cytokine-activated JAK-STAT pathway, 180–181 Cytokine-like factor-1, 41 Cytomegalovirus human, 307–308 mouse human cytomegalovirus modeled using, 307–308 natural killer cells, 172–173 Cytoplasmic receptors, 114 Cytosolic pathway, 18 Cytotoxic T cell-associated antigen 4, 26, 200 Cytotoxic T lymphocytes, 171, 283
D 33D1, 139 Death receptors, 214, 217 DEC-205, 139 Decay-accelerating factor, 245 Dectin-1, 14 ß-defensins, 32 Delayed-type hypersensitivity, 309 Delta-like 1, 63 Dendritic cells antigen handling by, 141–142 bone marrow, 140, 148–149 CD1 expression, 141 CD86 levels, 142 chemokine effects on, 143–144 definition of, 35 dendrites of, 141 dermal, 140 description of, 3 differentiation of, 36, 142 discovery of, 136 ex vivo studies of, 146–147 follicular, 71, 78, 140 functions of, 144–146 generation of, 139 granulocyte-macrophage colony-stimulating factor system for creation of, 139 in immature state, 142, 144–145 interleukin-12 production and, 144 interstitial, 36 intestinal, 146 isolation protocols for, 147–149 Langerhans cells and, 140 life span of, 141 lymphoid tissue distribution of, 139–140 major histocompatibility complex expression by, 138 in marginal zone, 78 maturation of, 142 migration of, 87, 143–144
315
INDEX
Dendritic cells (continued) monoclonal antibodies, 138 morphological properties of, 138, 141 mouse strains used to study, 136–138 myeloid, 112 natural killer cells and, 172 in nonlymphoid tissue, 140–141 phenotypic changes, 87 physical properties of, 138 plasmacytoid description of, 37, 76–77, 142–143 maturation of, 143 toll-like receptor signaling in, 114 spleen, 146–147 subsets of, 142–143 surface composition of, 138 T cell interactions with, 88–89, 145 in T cell regions, 139–140 in thymus, 139 tolerance mediated by, 145–146 turnover of, 141 Dendritic epidermal T cells, 308 Deoxyuridine, 95 Diacylglycerol, 234 DNA polymerases, 164 DNAX adapter protein-12, 174 DOCK2, 202 Dok-1, 203 Double negative thymocytes, 208 Double-stranded RNA, 112 Drosophila, 64–65
E E3 ubiquitin ligases, 237–238 Effector B cells, 91 Endo 180 receptor, 13 Endocytic pathway, 18 Endocytosis, 19 Endogenous antigen models, 209–213 Enhanced green fluorescent protein, 140 Eosinophil(s) in airway hyperresponsiveness, 297 description of, 33–34 inflammatory role of, 34 Eosinophilia, 294 Eotaxin-1, 296 Eotaxin-2, 296 Epidermal growth factor receptor, 238 Epidermal T cells, 308 Epithelial cells, 6 Epstein-Barr virus, 283 ERK/JNK/p38, 216 Erythropoietin receptor, 182 Experimental autoimmune encephalomyelitis, 308–309 Eya, 65
F Fab fragment, 21 Fas-associated death domain, 217 Fc receptors FCαRI, 8 FCγRI, 7 FCεRI, 7–8, 295
Fc receptors (continued) FCγRIIB autoimmunity and, 264–266 B cell tolerance, 265–266 description of, 6–7, 142, 254 genetic linkage studies, 264–265 mice deficient in, 265 polymorphisms, 265 signaling of, 263 FCγRIII, 7 FCγRIV, 7 homologs, 262 IgG, 263–264 Langerhans cell expression of, 140 neonatal, 6 overview of, 5 poly-Ig receptor, 5–6 transmembrane ligand-binding protein, 5 Fcgr2, 264–265 Fetal-maternal interface, 284 Fibroblast growth factor-7, 66 Fibroblast growth factor-10, 66 FLICE, 95 Follicle-associated epithelium, 69 Follicular dendritic cells B cell recruitment affected by, 93 description of, 71, 78, 140 Forkhead box N1, 277 Foxl1, 74 Foxn1nu, 277 Foxp3, 42 Foxp3+CD4+CD25+ Treg cells, 43 fsh, 123 FTY720, 202
G Gadd45α, 253–254 GATA-1, 34 Gene overexpression, 280 Gene targeting, 238 Genomic segmental polymorphism, 120 Germinal centers architecture of, 93 B cells differentiation of, 94 selection of, 95–96 IgE, 295 involution of, 96 kinetics of, 93 stromal support for, 93–94 Glucocorticoid-inducible tumor necrosis factor receptor, 277 Glycogen synthase kinase 3ß, 67 Glycolipids, 141 Glycosylphosphatidylinositol, 3, 110 Graft-versus-host disease, 283 Grb2/RasGRP, 216 GTPase activating protein, 200 Guanine nucleotide exchange factor, 199, 216
H H2-DM, 20 H2-DO, 20
H2-M4, 129 H2-Q region, 126–127 H2-T region, of Mhc, 127–128 Hassall’s corpuscles, 63 Helminth infections, 308 Helper T cells cytokines secreted by, 91–92 description of, 40–41, 89–90 Hematopoiesis, 60 Hematopoietic stem cells description of, 33, 60 T cell precursor derivation from, 63 Hereditary hemochromatosis, 121 Hoxa3, 64–65 Human ß-defensin-1, 32 Human killer cell immunoglobulin-like receptors, 170
I Immature dendritic cells, 144–145 Immune response, 87–88 Immune system adaptive cells of, 38–48 description of, 3 innate cells of, 32–38 description of, 3 ligands of, 3–15 receptors of, 3–15 Immunoglobulins IgA, 23 IgD, 23 IgE, 23, 294–295 IgG, 22–23, 263–264 IgG2b, 8, 22 IgM, 8, 23 membrane-anchored, 23 structure of, 43–44 Immunoreceptor tyrosine-based activation motifs, 83, 199, 215 Immunoreceptor tyrosine-based inhibitory motif, 6, 262 Immunoreceptor tyrosine-based switch motif, 28 Inducible costimulator, 28 Inducible costimulator ligand, 28 Inflammation eosinophils in, 34 modulation of, 7 Inflammatory responses, 295 Inhibitory receptors B cell activation thresholds and, 267–268 classes of, 262–263 description of, 262 natural killer cell receptors, 268 pathways of, 269–270 T cell, 268–269 Innate immune system activation of, 87 cells of, 32–38, 109 description of, 3
316
INDEX
Innate immune system (continued) ligands of, 3–15 receptors of, 3–15 Integrins clustering of, 196 description of, 196 knockout models, 201 leukocyte, 296–297 signaling, 203–204 T cell receptor-mediated activation defects, 199–201 Intercellular adhesion molecule-1, 81 Interferon-τ, 30–31, 172 Interferon regulatory factor-2, 143 Interferon regulatory factor-5, 114 Interleukin-1, 30 Interleukin-1 receptor-associated kinase, 113 Interleukin-2, 30, 170 Interleukin-2 receptor, 42 Interleukin-3, 30 Interleukin-4, 30, 43, 294 Interleukin-5, 30, 34, 297 Interleukin-6, 30, 93 Interleukin-7 deficiency of, 279 description of, 30, 74 Interleukin-8, 295 Interleukin-10, 30, 236 Interleukin-12, 30, 41, 144, 284, 294 Interleukin-13, 30, 294 Interleukin-15 deficiency of, 279 description of, 30, 173 Interleukin-17, 42 Interleukin-23, 41 Interstitial dendritic cells, 36 Intestinal crypts, 69 Isolated lymphoid follicles, 69 Itk, 200, 203
J J chains, 6 Jak1-deficient mice, 183 Jak2-deficient mice, 183 Jak3, 74 JAK3 tyrosine kinase, 279 Jak3-deficient mice, 183–184 JAK-STAT pathway cytokine-activated, 180–181 regulation of, 181–183 signaling of, 183–189 JAM-A, 201 Januse kinases, 180, 183–184
K Keratinocytes, 32 Killer cell immunoglobulin-like receptors, 262 Knockout mice integrin, 201 T cell migration, 197–198, 202 with T cell receptor-mediated integrin activation defects, 199–201
L Langerhans cells, 139–140, 309 Langerin, 14 Leucine-rich repeat motifs, 3, 110 Leukocyte(s) derivation of, 32–33 description of, 32–33 integrins, 296–297 peripheral blood, 283–284 Leukocyte receptor complex, 174 Lipopolysaccharides description of, 5 strains sensitive to, 110 L-selectin, 77 LTßR, 73 Ly-17, 265 Ly49 receptors, 14–15, 170, 175, 268 Lymph nodes B cell entry and exit from, 76–77 development of, 69–70 peripheral, 69 Lymphocyte(s) B. See B cell(s) lymphoid organ entry of, 77 natural killer cells, 37–38 recruitment of, 75 signaling of, 254–255 T. See T cell(s) Lymphocyte function-associated antigen-1, 176, 196, 233, 296 Lymphohematopoietic cell lineages, 281–283 Lymphoid enhancing factor, 67 Lymphoid follicles B cell migration to, 78–82 description of, 78 Lymphoid organs bone marrow. See Bone marrow location of, 59 molecular regulation of, 70–75 overview of, 59 primary, 59–68 secondary anatomy of, 68 B cell zones in, 78 cryptopatches, 69 dendritic cells, 143 formation of, 79–80 immune response function of, 68 location of, 69 lymphatic drainage to, 76 lymphocyte entry into, 77 microdomains in, 78–82 natural killer cells in, 171 overview of, 68–70 Peyer’s patches, 69 spleen. See Spleen thymus. See Thymus Lymphoid tissue-inducing cells description of, 73 development of, 73–74 LTα1ß2 induction on, 74 recruitment of, 74 Lymphotoxin, 279–280
Lymphotoxin receptor null mutants, 279–280 Lyn, 269
M M1, 128 M5, 129 M6, 129 M10, 128 Macrophage(s) characteristics of, 33 FCγRI expression on, 7 from TLR2-/- mice, 110 in granulomatous processes, 33 Macrophage inflammatory protein, 172 Macrophage inflammatory protein-1, 35 Macrophage inflammatory protein-1α, 296 Macrophage inflammatory protein-2, 14 Macrophage mannose receptor, 13 Macropinocytosis, 142 MAdCAM-1, 77 Major histocompatibility complex antigen processing, 18–20 CD1 genes, 20–21 dendritic cell expression of, 138 description of, 15 molecules class I, 15, 17–18, 308 class II, 17–18, 123 description of, 120 overview of, 119–120 receptors, 170 Marginal zone absence of, in neonatal period, 81 definition of, 78 macrophages, 14, 81 Mast cells in allergic asthma, 295 description of, 35 IgE-activated, 294–295 Maternal fetal interface, 284 mDC-SIGN, 14 Medullary epithelial cells, 63, 65, 67 Membrane attack complex, 8 Membrane-anchored immunoglobulin, 23, 83 Memory B cells, 91 Memory T cells, 90 Mesenchyme, 65 Methacholine, 293 Mhc class I region, 125–126, 130 class II molecules, 123, 130 class III region, 124–125, 130 comparative map of, 121–130 DM, 123 DO, 123 DP, 123 DQ, 123 DR, 123 H2-M region, 128 H2-M4, 129 H2-Q region, 126–127 H2-T region, 127–128
317
INDEX
Mhc (continued) M region, 129–130 M5, 129 M6, 129 non–class II molecules, 123 overview of, 119–120 polymorphism of, 120 regions of, 120 sequencing of, 120–121 ß2-Microglobulin, 15, 17 MINK, 216 Mismatch repair, 162–164 Mitochondria, 217–218 Mitogen-activated protein kinase kinase 6, 113 Mitogen-activated protein kinase pathways, 216 Mixed leukocyte reaction, 138 Monocyte(s), 33 Monocyte chemoattractant protein-1, 296 Mouse cytomegalovirus human cytomegalovirus modeled using, 307–308 natural killer cells, 172–173 Mouse genome project, 120 Mouse mammary tumor virus, 123 MRL.lpr mice, 244–246 mSIGNR2, 13–14 Mucosa-associated lymphoid tissue, 69 Mucosal epithelia, 32 Multiple sclerosis, 308–309 Murine activating receptor-1, 175 Mycobacterium tuberculosis, 308 MyD88, 113–114 Myeloid dendritic cells, 112 Myeloid differentiation factor 88, 3
N Nasal-associated lymphoid tissue, 69 Natural cytotoxicity receptors, 175 Natural killer cell(s) activating receptors, 174–175 activation of, 174–176 autoimmune diseases and, 173 cytokine and chemokine production by, 171–172 cytotoxicity functions of, 171 dendritic cells and, 172 description of, 37–38 development of, 170–171 discovery of, 169–170 function of, 171–174 inhibitory receptors, 174 interleukin-2 and, 171 major histocompatibility-recognizing receptors, 262 morphology of, 171 reproductive functions of, 173–174 summary of, 176 surface markers of, 171 tissue distribution of, 171 tumor immunity applications of, 172 uterine, 173, 284 viral immunity applications of, 172–173
Natural killer cell receptors description of, 14–15, 125 inhibitory, 268 Ly49, 268 Natural killer cell-committed precursors, 170 Natural killer T cells, 43 Negative costimulatory molecules, 237 Negative selection anti-CD3/peptide central tolerance models, 209 cell death mechanisms during, 235 costimulatory molecules in, 215 endogenous antigen models, 209–213 mediators of, 213–218 overview of, 208–209 signal transducers in, 215–216 T cell receptor in, 215 transcription factors in, 216–217 Neonatal Fc receptors, 6 Neutrophil(s) definition of, 33 functions of, 33 NHEJ, 164–165 NKG2D, 15, 173, 175 NKR-P1C, 175 Nod2, 114 NOD-scid mice, 278 Nuclear factor-κB B cell receptor activation of, 84 description of, 72, 216 T cell activation of, 236 Nude mice, athymic, 277 Nur77, 217 NZM2410 strain, 249–250 [NZW × NZB]F1 mice, 247–249
O Organogenesis LTßR ligation during, 73 signaling mutations effect on, 75 Ovalbumin, 237, 292
P p21, 254 Paired Ig-like receptor-B, 267 Pathogen-specific molecular patterns, 110 Pathogenic autoimmunity, 250–251 Pax1, 65 Pax9, 65 PD-1, 237, 267–268 PD-L1, 237 PD-L2, 28 Peptidoglycan, 110 Peripheral blood leukocytes, 283–284 Peripheral tolerance, 146, 266 Peyer’s patches B cell entry and exit from, 76–77 description of, 69 Phagocytes, 10 Phagocytosis, 19 Pheromones, 129 Phosphatases, 174, 238 Phosphatidylinositol 3-kinase, 200–203
Phosphoinositide 3-kinases, 234 Phospholipase C-τ, 233 Plasma cells, 91 Plasmablasts, 92–93 Plasmacytoid dendritic cells description of, 37, 76–77, 142–143 maturation of, 143 toll-like receptor signaling in, 114 Plethysmography, 292 Point mutagenesis, 280–281 Poly-Ig receptor, 5–6 Polyubiquitination, 237 Positive selection, 208–209 Pou5fl, 127 Prkdcscid, 278 Programmed death-1, 28 Protein inhibitor of activated STATs description of, 180–182 in vivo functions of, 188 Pias1-deficient mice, 188 Piasx-deficient mice, 189 Piasy-deficient mice, 188–189 Protein kinase Cd, 254 Protein tyrosine kinase, 254 Protein tyrosine phosphatases description of, 180, 189 in vivo functions of, 189 JAK-STAT pathway regulation by, 182–183, 189 Proteoglycans, 35 P-selectin glycoprotein ligand 1, 296 Ptp1b, 189 PU.1, 34
Q Qa2, 126
R Rac GTPases, 202 RAG-1, 48 Rag1, 278–279 rag-1/2, 61 RAG-2, 48 Rag2, 278–279 RAG/τc, 279 Rap1, 199–200 RapL, 199–200, 203 Rasgrp1, 255 Receptor activator of NF-κB ligand, 71 Receptor editing, 48 Receptor recombinase, 38 Recombination signal sequences, 38, 44 Regulatory T cells, 42 Replication protein A, 161 Reproduction, natural killer cells’ role in, 173–174 Respiratory system, 292 Retinoic acid inducible gene-I, 114 Retinoic acid–early inducible-1, 173 Ring3, 123 Roquin, 237–238 RT1-N, 128 Runt-related transcription factor 1, 268
318
INDEX
S S1P1, 202 Salmonella typhimurium, 112 Selectins, 296 Self-tolerance, 42–43 Serum amyloid P, 252 Severe combined immune deficiency description of, 183 mouse models, 278, 307 SH2-containing protein tyrosine phosphatase, 83 SHIP, 263–264, 270 Short consensus repeat units, 10 SHP-1, 263, 269–270 Shp1, 189 SHP-2, 28, 263 Shp2, 189 Six1, 65 SKAP-55, 199 Skin barrier function of, 32 cornification of, 32 functions of, 32 Sle1, 249–250 Sle2, 251 Sle3/5, 250–251 Slp, 124 SLP-76, 199 Socs5 transgenic mice, 188 Somatic hypermutation cytidine deamination in, 161 description of, 94–96, 156–157 mismatch repair proteins in, 164 proteins involved in, 158–160 SP-A, 14 SPA-1, 200 SP-D, 14 Specific intracellular adhesion molecule-3 grabbing non-integrin family, 13 Spi-B, 95 Spleen anatomy of, 77 dendritic cells, 147–148 description of, 69 development of, 75–76 red pulp of, 77 white pulp of, 77 STATs description of, 180–181 in vivo functions of, 185 Stat1-deficient mice, 184 Stat1S727A-mutant mice, 184 Stat2-deficient mice, 184 Stat3-deficient mice, 184, 186 Stat3S727A-mutant mice, 184, 186 Stat4-deficient mice, 186 Stat5a- and Stat5b-deficient mice, 186 Stat6-deficient mice, 186 Stem cell factor, 170 Stem cells, hematopoietic, 33 Sts-1, 238 Sts-2, 238 Superantigens, 213
Suppressors of cytokine signaling proteins Cis transgenic mice, 188 description of, 180–181 in vivo functions of, 187 Socs1-deficient mice, 186–187 Socs2-deficient mice, 188 Socs3-deficient mice, 187–188 Socs5 transgenic mice, 188 Surfactant proteins, 14 Syk kinases, 23 Syndecan-1, 93 Systemic lupus erythematosus antigen clearance, 252–253 description of, 251–254 immune complex clearance, 252–253 murine models of BXSB.yaa, 246–247 description of, 244 MRL.lpr, 244–246 NZM2410, 249–250 [NZW × NZB]F1, 247–249 summary of, 255–256 overview of, 243–244
T T cell(s) γδ, 39 activation of adaptor molecules, 238 antigen recognition and, 221, 233 description of, 88–90 E3 ubiquitin ligases, 237–238 humoral factors in, 236 negative costimulatory molecules, 237 negative regulation of, 236–239 phosphatases, 238 processes involved in, 233–234 adaptive immunity, 144–145, 208 anergic, 237 antigen receptor binding of, 224 antigen-specific, 68, 145 apoptosis of, 236 autoimmunity mediated by, 234–235 B cells and, 62, 91–96 CD4+, 39–40 CD8+, 39–40 dendritic cells and, 88–89, 145 dendritic epidermal, 308 development of, 38–39, 62, 282, 307 differentiation of, 88–90 effector, 201, 236 epidermal, 308 homeostasis of, 236 integrin expression on, 196 knockout models, 197–198, 202, 204 memory, 90 migration of description of, 47, 201–202 knockout models, 197–198, 202, 204 transgenic models, 197–198, 204 natural killer, 43 nuclear factor-κB activation in, 236 phenotypic differentiation of, 40–41
T cell(s) (continued) precursors of, 63 priming of, 89 regulatory, 42, 235, 277 response of, 145 self-reactive, 42 self-tolerance, 42–43 Th cells cytokines secreted by, 91–92 description of, 40–41, 89–90, 145 thymic, 39, 62 tolerance of, 235–236 transgenic models, 197–198, 204 T cell adaptor molecule, 255 T cell coreceptors, 25–26 T cell inhibitory receptors, 268–269 T cell receptor αß, 38 γδ rearrangement, 39 antigen-binding complex, 24–25 in clonal deletion, 215 description of, 24–25, 196 negative selection mediated by, 215 signal transduction, 234 signal-transducing complex, 25 signaling, 196–201 stimulation of, 235–236 transgenics, 209–212 V-D-J rearrangement, 38, 61 T cell specific adaptor, 238 T cell zone, 82 T1 cells, 85 T2 cells, 85 Tap 1/2, 123 TAPA, 24 Tapasin, 18, 125 Tbsp, 123 Tcptp, 189 Terminal deoxynucleotidyl transferase dUTP nick-end labeling cells, 213 TFH cells, 90 Th cells, 40–41, 89–90, 145, 291 Th17 cells, 41–42 Thymic epithelial cells cortical, 208 description of, 62, 67 origin of, 65 Thymic stromal lymphopoietin, 145 Thymocytes bone marrow, 208 description of, 64 double negative, 208 T cell-epithelium interactions during selection of, 67–68 from transgenic mice, 200 Thymus anatomy of, 62 cortical epithelial cells of, 63, 65 corticomedullary junction of, 63 dendritic cells in, 139 development of, 64–67, 208 epithelium of, 63 medullary epithelial cells of, 63, 65 mesenchyme of, 65
319
INDEX
Thymus (continued) structure of, 62–63 T cell development in, 62–64 Thymus-independent antigen, 270 Tissue-specific antigens, 216 TLR4, 110 Tnsf1a, 279 Tolerance B cell, 48, 61 dendritic cell mediation of, 145–146 peripheral, 146, 266 T cell, 42–43, 235–236 Toll/interleukin-1 receptor homology domain, 3, 110 Toll-like receptors characteristics of, 3 definition of, 110 description of, 110 innate responses via, 144 signaling pathway for, 113–114 TLR1, 3, 110–111 TLR2, 3, 110–111 TLR3, 5, 112 TLR4, 5, 110 TLR5, 5, 112 TLR6, 5, 110–111 TLR7, 5, 112, 114 TLR8, 5, 112 TLR9, 5, 112, 114 TLR10, 5
Toll-like receptors (continued) TLR11, 5, 112–113 types of, 3–5 Toxoplasma gondii, 112 Transcription factors, 216–217 Transferrin receptor, 8 Transforming growth factor-ß, 31, 236 Transgenic mice Cis, 188 cytokine expression, 293 Socs5, 188 suppressors of cytokine signaling, 186–187 T cell migration, 197–198 thymocytes from, 200 Transgenics T cell receptor, 209–212 Vß, 209, 213 Transplantation, 309 Transporter associated with antigen processing proteins, 18–19 Treg cells, 42, 235 TRIF-dependent pathway, 114 Tumor necrosis factor-α, 31 Tumor necrosis factor-ß, 31 Tumor necrosis factor immediate family, 75 Tumor necrosis factor receptors, 70–71, 217 Tumor necrosis factor-receptor superfamily description of, 70–71 signaling events, 71–72
Tumor necrosis factor-related apoptosis–inducing ligand, 171, 217 Tyk2-deficient mice, 184
U UL-16 binding protein–like transcript-1, 173 Uracil N-glycosylase, 161 Uterine natural killer cells, 173, 284
V Vß transgenics, 209, 213 Vascular cell adhesion molecule-1, 81, 296 Vav1, 199 V-D-J rearrangement, 38, 61, 155–156
W Wnt glycoproteins, 67
X Xiap, 280 X-linked immunodeficiency, 307
Z ZAP-70, 199, 234, 307
This page intentionally left blank
Cumulative Index A A strain development, 2:636–637 nonneoplastic conditions, 2:637 pathogen susceptibility, 2:638 phenotype, 2:637 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:637–638 AA4.1 antigen, 3:160 AAV. See Adeno-associated virus ABC transporters. See ATP-binding cassette transporters Abdomen anatomy of, 3:2 necropsy evaluations, 3:482 Abducens nerve, 3:7 Abductor digiti longus, 3:5 Abnormal behavior, 3:517–518 Absolute decreased red cell mass, 3:147 Absolute differential white blood cell count, 3:141 Absolute reticulocyte width, 3:141 Accelerated erythropoiesis, 3:161, 3:163 Accessorius nerve, 3:7 Accessory glands, 3:96 Acetylcholinesterase description of, 3:53 megakaryocyte precursors and, 3:154 Acetyl-coenzyme A carboxylase-beta, 1:313 Acidification, of drinking water, 3:418 Acinar cells, 3:64 Acini, 3:51 Actinobacillus muris. See Pasteurellaceae Activated partial thromboplastin time, 3:141, 3:157 Activation-induced cytidine deaminase, 4:95, 4:156–157, 4:161–162 Acyl CoA:cholesterol acyltransferase, 3:187 Adaptive immune system activation of, 4:87 cells of, 4:38–48 description of, 4:3, 4:109–110 T cells in, 4:144–145, 4:208 Adaptor molecules, 4:238
Adaptor protein-1, 4:3 Adductor, 3:6–7 Adeno-associated virus, gene transfer vectors, 1:272 Adenosine monophosphate-activated protein kinase, 3:183 Adenosine triphosphate-binding cassette transporter A1, 3:186, 3:549 Adenovirus description of, 3:391 gene transfer vectors, 1:271–272 genome and structure, 1:271–272 vaccine vector development, 1:275–276 Adhesion, of embryo, 3:102 Adhesion and degranulation-promoting adapter protein, 4:199 Adip2, 3:624 Adipocytes, 3:184 Adipogenesis inhibitory factor, 3:192 Adipokines description of, 3:184 measurement of, 3:185 Adiponectin functions of, 3:618 insulin and, 3:184 Adiposity, 3:128 Adiposity index, 3:627 Adrenal demedullation, 3:466 Adrenalectomy, 3:466 Adrenalitis, murine cytomegalovirus myocarditis model, 2:24 Adrenocorticotrophic hormone, 3:201 Advanced intercross lines breeding, 1:71 gene mapping, 1:128 nomenclature, 1:85, 1:87 Advanced recombinant inbred lines, gene mapping, 1:128 Affinity chromatography, 3:740 A/Fg mice, 3:180 Aflatoxins, 3:346–348 Afp, 3:208 Age-related pathology. See also specific organisms amyloidosis, 2:632–633 hematopoietic neoplasms, 2:633 Aging accelerated, 3:651–653 antagonistic pleiotropy theory of, 3:650 biomarkers of chronological age and, 3:654
Aging (continued) description of, 3:668 end stage, 3:653, 3:655–658 life span, 3:652–653 nonlethal, 3:654–655 pathology data and, 3:657–658 purpose of, 3:658 rate, 3:653–655 selection criteria, 3:654 state, 3:653–655 summary of, 3:658 uses of, 3:653 classification of, in mice, 3:644 definition of, 3:640 disease models of, 3:652–653 endocrine theory of, 3:664–665 evolutionary theory of, 3:650 free radical theory of, 3:661 hematopoietic stem cells, 3:666 metabolic theory of, 3:665 senescence vs., 3:640, 3:642–643 stem cell theory of, 3:665–666 Aging clocks detection of, 3:662–663 evidence of, 3:661 number of, 3:661–662 operational definition of, 3:662 research, 3:664 in segregating populations, 3:663 Aging mice erythrocytes in, 3:161 hematology of, 3:161–162 leukocytes in, 3:161–162 lymphocytes in, 3:162 vitamin requirements in, 3:368 Aging research advances in, 3:639 availability of aged mice, 3:647–648 mouse models for description of, 3:639 F1 hybrids, 3:646–648 4-way cross stocks, 3:647, 3:649 heterogeneous lines, 3:648 inbred strains, 3:645–646, 3:648 outbred stock, 3:648 overview of, 3:639 terminology associated with, 3:639–644 AgNOR staining, ribosomal DNA, 1:150 Agouti mouse, 3:620 Agouti-related peptide, 3:184, 3:620 Agriculture, house mice impact, 1:29–30
321
322 Agtpbplpcd, 3:678 A/He mice, 3:260 Ahr, 3:579 AI. See Artificial insemination Aibl, 3:624 AILs. See Advanced intercross lines Air class 100, 3:299 quality of, in ventilated cages, 3:295 Air exchange rate, 3:412 Air monitoring, 3:413 Aire, 4:68 Airway eosinophilia, 4:294 Airway hyperresponsiveness cytokines in, 4:293–294 description of, 3:59–60, 4:291–292 eosinophils’ role in, 4:297 methacholine uses, 4:293 Airway pressure, 3:56 Airway pressure time index, 3:56 Airway reactivity, 3:63 Airway remodeling, 4:297 Airway resistance, 3:63 Airway responsiveness, 3:59 Airway segments, 3:55 AKR mice cholesterol studies in, 3:65 development, 2:638 life span of, 3:651 phenotype, 2:638 production index for, 3:260 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:639 nonneoplastic conditions, 2:638–639 pathogen susceptibility, 2:639 related strains, 2:639 AKR/J mice diet for, 3:107 protein requirements, 3:332 Akt, prostate cancer signaling, 2:599–600 Alanine aminotransferase description of, 3:198 reference range for, 3:181 Alb1, 3:208 Albendazole, Giardia muris management, 2:521 Albumin description of, 3:206 reference range for, 3:181 Alcohol, 3:426 Aldolase, 3:200 Aldrin, 3:346 Alkaline phosphatase description of, 3:198 intestinal, 3:198 reference range for, 3:181 tissue nonspecific, 3:198 Allantoin, 3:73
CUMULATIVE
Alleles diversity of, in wild-derived mice, 3:650–651 inheritance modes, 1:57–59 naming, 1:91 overview, 1:56–57 in random bred colonies, 3:267 Allergic asthma bronchial epithelium in, 4:292 cytokines in, 4:293–294 description of, 4:291 development of, 4:292 lung measurements, 4:292–293 mast cells in, 4:295 mouse models of, 4:292–293 summary of, 4:298 Allometric scaling, 3:67 Alopecia, C3H mice, 2:644 Alpha-1-fetoprotein, 3:208 Altered Schaedler’s flora, 3:228–229 Alternative splicing. See Splice variants Alveolar duct, 3:51 Alveolar fluid transport, 3:61 Alveolar pressure, 3:52 Alymphoid mice, 4:279 Alzheimer’s disease, 3:683–685 Ambient temperature metabolism affected by, 3:68 water consumption affected by, 3:76 Amino acids arginine, 3:333 autoclaving effects on, 3:362 description of, 3:331–332 requirements for, 3:332–333 in urine, 3:72 4-Aminoantipyrine, 3:187 4-Amino-5-imidazolecarboxamide, 3:73 Ammonia, 3:293 Amnion, 1:190 Amoxicillin Clostridium perfringens infection management, 2:357 Helicobacter infection management, 2:428–429 Ampicillin Clostridium perfringens management, 2:357 Corynebacterium bovis management, 2:401 Ampulla coli, 3:15 Ampullary glands, 3:96 Amy-1, 3:200 Amy-2, 3:200 Amylase, 3:66, 3:200 Amylin, 3:183 Amyloid precursor protein, 3:683–684 Amyloidosis Balb/cJ mice, 2:641 C57BL mice, 2:649 definition, 2:672–673 features, 2:692–694 SJL/J mice, 2:654 A strain mice, 2:637 Swiss mice, 2:658–659 Amyotrophic lateral sclerosis, 3:678–679
INDEX
Anabolic phase, of estrous cycle, 3:100 Anagen phase, of hair growth, 3:706–707 Analgesics, 3:480–481 Analytes age effects on, 3:180 cyclic biorhythm effects on, 3:180 dietary effects on, 3:180 ELISA kits, 3:177–178 historical methods of measuring, 3:175 immunologic methods to detect, 3:175–176 in insulin resistance, 3:185 lipid metabolism, 3:188 Anaphylatoxins description of, 4:7 receptors for, 4:11, 4:13 Anatomy body regions, 3:2–3 cupula diaphragmatis, 3:14 digestive tract, 3:15 female genital organs, 3:20–21 heart, 3:8–11 kidneys, 3:17 liver, 3:16 lungs, 3:10–11 lymph nodes, 3:21–22 male genital organs, 3:18–19 mammary gland, 3:3 skeleton, 3:4 stomach, 3:16 thoracic cavity, 3:12 Androgen(s) definition of, 3:130 erythropoiesis stimulated by, 3:161 in estrogen production, 3:130 functions of, 3:202 testosterone. See Testosterone Androgen receptor, 3:130 Anemia of chronic disease, 3:148 Anesthesia cardiovascular effects of, 3:30–31 care after, 3:479–480 cryoanesthesia, 3:464–465 for echocardiography, 3:48 for ear tagging, 3:441 hypothermic, 3:464–465 for imaging, 3:492 inhalants, 3:463–464 injectable anesthetics, 3:461–463 ketamine combinations for, 3:462 local anesthetics, 3:461 methods of, 3:179 neuroleptanesthetics, 3:462 for orbital sinus bleeding, 3:455 pentobarbital, 3:462–463 postanesthetic care, 3:479–480 preanesthetic medications, 3:460–461 side effects of, 3:31 tribromoethanol, 3:461–462 Anesthesia machine, 3:464 Angelman syndrome, 3:568 Angiogenesis in cancer, 3:601 corneal growth factor-stimulated, 3:611 ocular, 3:599–601
CUMULATIVE
323
INDEX
Angiogenic inhibitors, 3:611 Angioplasty, 3:554 Angiopoietin-1, 3:599 Angiopoietin-2, 3:599 Angiotensin I, 3:70 Angiotensin II, 3:70–71 Angiotensin type 1 receptors, 3:38 Angiotensinogen, 3:70–71 Animal bite, management, 2:735 Animal caretakers, 3:387 Animal husbandry, 2:626, 3:660–661 Anisocytosis prevalence of, 3:143 red cell distribution width, 3:143 Anonymous DNA segments, nomenclature, 1:89–90 Ansa subclavia dextra et sinistra, 3:10 Anserine, 3:180 Antagonistic pleiotropy, 3:650 Anterior segment dysgenesis definition of, 3:597 genes involved in, 3:603 histologic findings, 3:604 Anterior vena cava, 3:27 Anthelmintics, in drinking water, 3:309 Antibacterial agents, 3:228 Antibiotic therapy. See specific antibiotics Antibiotic-infused drinking water, 3:309 Antibody anti-CD11c, 4:139 classes of, 4:22–23 complementarity-determining regions, 4:21 diversity of, 4:155–157 Fab fragment, 4:21 H chains, 4:21 mouse mouse hepatitis virus diagnostics, 2:161 mousepox virus prevention, 2:89 Sendai virus prevention, 2:298 structure of, 4:21–22 subclasses of, 4:22–23 Antibody-dependent cellular cytotoxicity, 4:5, 4:171 Antibody-forming B cells, 4:146 Antibody-production tests, 3:746–747 Anti-CD11c antibodies, 4:139 Anti-CD3/peptide central tolerance models, 4:209 Anticonvulsants, 3:566 Antidiuretic hormone, 3:70, 3:77 Antiepileptic drugs, 3:566, 3:571, 3:582, 3:586 Antigen processing, 4:18–20 Antigen sensitization, 3:62 Antigen-antibody complexes, 4:280 Antigen-binding complex, 4:24–25 Antigenic assays, 3:190–191 Antigen-presenting cells, 4:35, 4:268–269, 4:309 Antigen-specific cells, 4:59 Antiintegrin antibodies, 4:196 Antioxidants, 3:550–551 Antisepsis, 3:424
Antithrombin II, 3:553 Anucleate erythroid cells, 3:159 Anus, 3:3, 3:20 Anxiety, 3:517 Aorta abdominalis et vena cava caudalis, 3:14, 3:20 Aorta descendens, 3:18 Aorta-gonad-mesonephros, 3:160 Aortic aneurysm, 3:553 Aortic valve, 3:27 Aorticus lymph node, 3:22 AP-1, 4:234 Apafl, 3:675 APECED, 4:235 Apex ceci, 3:15 Apicomplexa, general features, 2:528–529 ApoB48, 4:161 Apocrine glands, 3:713 Apolipoproteins ApoA-I, 3:186 ApoA-II, 3:186 ApoA-IV, 3:186 ApoB-48, 3:186 ApoB100, 3:185–186 ApoC-I, 3:186 ApoC-II, 3:186 ApoC-III, 3:186 ApoC-IV, 3:186 ApoE, 1:309, 3:186, 3:538, 3:556, 3:683–684 definition of, 3:185 measurement of, 3:188 types of, 3:186 Apoptosis death receptors’ role in, 4:217 defects in, 3:674–675 dermal cells, 3:709 description of, 3:142 mitochondria’s role in, 4:217–218 mouse polyoma virus anti-apoptotic responses, 2:111–112 regulation of, 4:253–254 in retinal degeneration, 3:607 T cell, 4:236 Apposition, 3:102 Aquaporins, 3:61 Ar, 3:130 Arachidonic acid metabolites, 3:196–198 Arcus aortae, 3:9–11 Arcus costalis, 3:2 Arginine, 3:333, 3:370 Arginine vasopressin. See Vasopressin Aromatase, 3:130 Arsenic, 3:336, 3:345 Arteria axillaris dextra, 3:10–11 Arteria axillaris sinistra, 3:11 Arteria carotis communis dextra, 3:9–10 Arteria carotis communis sinistra, 3:9–11 Arteria cervicalis superficialis dextra, 3:9, 3:11 Arteria cervicalis superficialis dextra et sinistra, 3:10 Arteria cervicalis superficialis sinistra, 3:9 Arteria ductus deferentis sinistra, 3:19
Arteria et vena circumflexa ilium dextra, 3:17 Arteria et vena circumflexa ilium sinistra, 3:17 Arteria et vena ovarica dextra, 3:17 Arteria et vena ovarica sinistra, 3:17 Arteria et vena renalis dextra, 3:17 Arteria et vena renalis sinistra, 3:17 Arteria intercostalis suprema, 3:9 Arteria ovarica sinistra, 3:21 Arteria pulmonalis dextra et sinistra, 3:10–11 Arteria subclavia dextra, 3:9–10 Arteria subclavia sinistra, 3:9–10 Arteria testicularis sinistra, 3:19 Arteria thoracica interna dextra, 3:9, 3:11 Arteria thoracica interna sinistra, 3:9, 3:11 Arteria vertebralis dextra, 3:9–10 Arteria vertebralis sinistra, 3:9–11 Arteriae mesentericae caudales, 3:17 Arterial blood collection, 3:457–458 Arterial catheterization, 3:475 Arteritis features, 2:699 strain 129 mice, 2:635 Arthritis, 3:191 Artificial insemination, 1:212, 3:227 Arytenoids, 3:50 AS spermatogonia, 3:96 Ascorbic acid, 3:370 Aseptic hysterotomy, for germfree mice derivation, 3:226 Aseptic technique, 3:465–466 Ashing process, 3:336 Asp1, 3:579–580 Aspartate, 3:584 Aspartate aminotransferase description of, 3:198–199 reference range for, 3:181 Aspergillus spp., 3:348, 3:423 Aspiculuris spp. A. tetraptera diagnosis, 2:556 differentiation from Syphacia obvelata, 2:553 life cycle, 2:556 morphology, 2:555 research-confounding effects, 2:556 treatment, 2:556–559 description of, 3:398 Assays antigenic, 3:190–191 bioassays, 3:751 functional, 3:190 immunoassays. See Immunoassays Limulus amebocyte lysate, 3:742 mouse antibody production, 3:400 Assisted reproduction. See also Reproduction artificial insemination, 1:212, 3:227 in vitro fertilization principles, 1:212–213 rederivation, 1:220–221 intracytoplasmic sperm injection principles, 1:213–214
324 Assisted reproduction (continued) somatic nuclear transfer, 1:221–222 steps, 1:214 transgenic mouse preparation, 1:216 parthenogenesis, 1:214 Associated animal, 3:218 Association for Gnotobiotics, 3:232 Association of Official Analytical Chemists, 3:324 Asthma characteristics of, 3:61–62 murine models of, 3:61–63 Astrocytes, 3:599 Ataxia Friedreich’s, 3:682 spinocerebellar, 3:680–681 Ataxia-telangiectasia, 3:679–680 Ataxin-7, 3:681 Atherosclerosis accelerated, 3:539 analytes associated with, 3:188 aortic, 3:541 characteristics of, 3:186 cholesterol levels and, 3:537 clinical features of, 3:537 description of, 3:544 disorders associated with, 3:186 lesion quantification, 3:541–542 magnetic resonance imaging evaluations, 3:556 modifiers of antioxidants, 3:550–551 cell adhesion molecules, 3:545–546 chemokines, 3:545 cytokines, 3:545 estrogen replacement therapy, 3:551–552 foam cells, 3:546 genetic, 3:544–550 growth factors, 3:545 infectious agents, 3:552 inflammatory mediators, 3:545 matrix remodeling, 3:546 nongenetic, 3:550–552 mouse models of accelerated, 3:539 aortic aneurysm, 3:553 apoE-/-, 3:544 cardiovascular disease induction in, 3:553–554 characteristics of, 3:539 description of, 3:537–538 genetic modification, 3:538–540 heart failure, 3:553 LDLR-/-, 3:544 linked genes, 3:549–550 myocardial infarction, 3:553–554 restenosis, 3:554 plaque bone marrow transfer studies of, 3:549 characteristics of, 3:540–543 development of, 3:548 matrix metalloproteinase effects on, 3:548
CUMULATIVE
Atherosclerosis, murine cytomegalovirus myocarditis model, 2:24 Athymic nude mice, 4:277 Atipamezole, 3:461 ATP-binding cassette transporters, 1:310 Atresia, of follicles, 3:99 Atrial natriuretic factor promoter, 3:38 Atrioventricular valves, 3:27 Atropine, 3:461 Attenuation, 3:495–496 Auchense hairs, 3:696 Audiogenic seizures definition of, 3:578 description of, 3:292, 3:415 in epilepsy prone mice, 3:580–581 experimental epilepsy model use of, 3:578–581 Frings mice, 3:571 genetic studies of, 3:580 interstrain variability in, 3:578–579 long-term potentiation and, 3:579 monogenic, 3:571–573 neurochemical findings, 3:579–580 neuropathologic findings, 3:579 serotonin levels and, 3:580 sudden unexpected death in epilepsy and, 3:579 susceptibility to, 3:578–579 Auricula dexter, 3:9, 3:11 Auricula sinister, 3:9, 3:11 Autoantibodies, 3:191 Autoclaves data loggers used with, 3:421 decontamination uses of, 3:303 description of, 3:225 ethylene oxide used in, 3:422 gnotobiotic uses of, 3:225 maintenance of, 3:421 noise caused by, 3:415 placement of, 3:415 precautions when working with, 3:421 pressurization of, 3:421 Autoclaving of automatic watering systems, 3:420 of diet description of, 3:225, 3:304–305, 3:362 irradiation of diet vs., 3:366 moist heat, 3:362 nutrients affected by, 3:362–3:363 physical changes caused by, 3:363 toxicological risks with, 3:363 Autocrine hormones, 3:124 Autoimmune diseases description of, 3:191 mouse as model system for studying, 4:221 natural killer cells and, 4:173 systemic lupus erythematosus. See Systemic lupus erythematosus Autoimmune regulator, 4:68, 4:208, 4:216 Autoimmunity FCγRIIB and, 4:264–267 pathogenic, 4:250–251 T cell–mediated, 4:234–235
INDEX
Automated hematologic analyzers, 3:140, 3:142 Automatic watering systems chlorine added to, 3:308–309 cleaning of, 3:420 description of, 3:241, 3:285–286, 3:419–420 flush systems, 3:419–420 pressure in, 3:420 recirculating systems, 3:419–420 steam autoclaving of, 3:420 Avertin, 3:30–31 Axenic animal, 3:218 Axillaris accessorius lymph nodes, 3:21–22 Axillaris proprius lymph nodes, 3:21–22 Azaperone, 3:461 Azotemia, 3:207
B B7-1, 4:26–28, 4:268 B7-2, 4:26–28, 4:268 B220, 4:142–143 B cell(s) activation of, 4:25, 4:267–268 affinity maturation of, 4:88 antibody-forming, 4:146 B-1 cells, 4:46, 4:81–82, 4:86 description of, 3:162, 4:7, 4:43–44 development of, 4:44–48, 4:59–60, 4:307 effector, 4:91 extrafollicular differentiation of, 4:92–93 extrinsic signals, 4:82–83 follicular, 4:82, 4:85–86 germinal center differentiation of, 4:94 selection of, 4:95–96 germinal center differentiation, 4:94 homeostasis of, 4:82–85 intrinsic defects, 4:61 intrinsic signals, 4:83–85 lactate dehydrogenase-elevating virus response, 2:224 lymphocytic choriomeningitis virus persistence role, 2:200–201 maturation of, 4:45, 4:282 memory, 4:91 migration of description of, 4:47, 4:76–77 to lymphoid follicles, 4:78–82 mouse adenovirus type 1 response, 2:60 mouse hepatitis virus response, 2:155, 2:157 mousepox response, 2:82 murine cytomegalovirus immune response, 2:28–29 myocarditis role, 2:23 negative selection of, 4:84–85 ontogeny of, 4:60–61 plasma cell differentiation from, 4:91 positive selection of, 4:84–85 precursors of, 4:61 resting splenic, 4:246 Sendai virus response, 2:296 signaling of, 4:81
CUMULATIVE
325
INDEX
B cell(s) (continued) signals of, 4:87 survival of, 4:82 T cells and, 4:62, 4:91–96 tolerance of, 4:48, 4:61, 4:265–266 transitional, 4:85 turnover of, 4:82 B cell receptor BAFF and, 4:85 coreceptors, 4:24 description of, 4:23, 4:43 diversity of, 4:45 membrane Ig, 4:83 NF-kB activation via, 4:84 signaling of, 4:27–28 B cell stimulating factor-1, 4:30 B-1 cells, 4:46, 4:81–82, 4:86 B-2 cells, 4:45–46 B lineage cells, 4:60 B lymphocyte attenuator, 4:262 B6 mice, 3:53 B6;129 mouse phenotype, 2:655 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:655 nonneoplastic conditions, 2:655 BAC. See Bacterial artificial chromosome Bacillus thetaiotaomicron, 3:228 Bacitracin Clostridium difficile infection management, 2:360 Clostridium perfringens infection management, 2:357 Back, 3:2 Backward migration, 3:257 Bacteria. See also specific bacteria antibacterial agents for, 3:228 feces examination to identify, 3:230 in gastrointestinal tract, 3:227 irradiation resistance by, 3:364 microbiological quality control testing for, 3:742–743 thermal death of, 3:310 urease positive, 3:230 Bacterial artificial chromosome clones, 3:623–624 genome sequencing, 1:100–101, 1:107 BAFF B cell receptor and, 4:85 description of, 4:82 marginal zone B cells affected by, 4:86 BAFF-R, 4:82–83, 4:85 Bait stations, 3:429 BALB/c mice blood volume in, 3:138 erythrocyte life span in, 3:142 isoflurane anesthesia in, 3:463 phenotype, 2:639–640 production index for, 3:260 spontaneous diseases
BALB/c mice (continued) comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:641–642 nonneoplastic conditions, 2:640–641 pathogen susceptibility, 2:642–643 related strains, 2:643 urea nitrogen levels in, 3:207 BALB/cBY mice description of, 3:181, 3:666 phenotype, 2:639–640 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:641–642 nonneoplastic conditions, 2:640–641 pathogen susceptibility, 2:642–643 related strains, 2:643 Band neutrophils, 3:153 Bapx1, 4:76 Barbering, 3:388 Basal cells, 3:50, 3:712 Basal metabolic rate description of, 3:67 nonshivering thermogenesis and, 3:68 Basement membrane, 3:72 Basophils, 3:150, 4:35 Bat1, 4:127 Batch washers, 3:302, 3:310, 3:417 Bax, 3:675 B-cell attracting chemokine-1, 3:195 B6C3F1 mouse phenotype, 2:655–656 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:656–657 nonneoplastic conditions, 2:656 pathogen susceptibility, 2:657 Bcl-6, 4:93–94 Bcl-2, 3:675 Bcl-xL, 3:142 BDNF. See Brain-derived neurotrophic factor Bdnf, 3:708 Bedding. See also Nests ammonia production, 3:293 autoclaving of, 3:421 breeding colony, 3:240–241 cellulose products as, 3:306 certified, 3:306 contact, 3:240 contaminated, 3:280 corncob as, 3:306 disposal of, 3:280 hardwood, 3:306
Bedding (continued) materials used for, 3:306 microbiological status of, 3:423 selection of, 3:305–306 soiled, 3:277, 3:285, 3:401 storage of, 3:423 Bedding dispensers, 3:285 Bedding sentinel animals, 3:395 Bedding transfer, 3:394 Behavior abnormal, 3:517–518 continuous monitoring of, 3:516 description of, 3:238 domains of, 3:518–520 evoked, constrained, 3:516–517 factors that affect, 3:514–516 high throughput test batteries, 3:515 homeostatic functions of, 3:514–516 information sources, 3:515–516 measurement of, 3:516–518, 3:520–524 naturalistic observation of, 3:516 phenotypes, 1:247–249, 3:514–516, 3:519 quantitative traits, 3:517–518 subdomains of, 3:518–520 temperature effects on, 3:107 Behavior of the Laboratory Rat, The, 3:531 Behavioral test acclimatization to testing room, 3:529 accuracy of, 3:520–521 apparatus used in, 3:525–526, 3:529–531 automated scoring of, 3:526 behavior observations during, 3:529 “blind” testing, 3:528–529 cage enrichment effects, 3:525 in colony room, 3:527–529 conducting of, 3:526–530 development of, 3:518 disease control, 3:525 equipment used in, 3:525–526, 3:529–530 handling during, 3:529 information sources, 3:530–531 lab environment, 3:527 light-dark cycle effects, 3:524–525 local conditions that affect, 3:527 maturity effects, 3:524 Morris water maze, 3:518, 3:520 multiple, 3:520 order of, 3:527 planning of, 3:524–526 precision of, 3:521 protocol for, 3:527 recommendations for, 3:531 refinement of, 3:518 reliability of, 3:521–522 replicability of, 3:522 sample protocol, 3:528 scoring of, 3:526 transport of mice for, 3:529 validity of, 3:522–524 video tracking of, 3:526 Bel2, 3:674 Benzoylphenyl urea, 3:430 Bernard-Soulier syndrome, 3:155 Beta-carotene, 3:550 Beta-catenin, 3:699
326 Bfq1, 3:624 Bgeq2, 3:624 Biceps brachii, 3:5–6 Biceps femoris, 3:4, 3:6 Bile collection of, 3:454 daily production of, 3:454 description of, 3:65 Bile acid, 3:66, 3:206 Bile acid CoA ligase, 3:206 Bile acid-CoA:amino acid N-acyltransferase, 3:206 Bile duct cannulation of, 3:454 catheterization of, 3:478–479 Bilirubin clearance of, 3:205–206 conjugated, 3:205 description of, 3:65 reference range for, 3:181 unconjugated, 3:205 Bioassays, 3:751 Bioexclusion facilities, for breeding colony cage level, 3:246–247 cleaning of, 3:244 combined techniques, 3:247 conventional, 3:243 disinfection of, 3:244 group level, 3:245 room level, 3:243–245 water supply, 3:244–245 Biofilms, 3:285 Biologic assays, 3:178 Biological control, house mice, 1:46 Biological hazards, 3:280 Biological indicator, 3:421 Biological safety cabinets Class I, 3:300–301 Class II, 3:301, 3:313 Class III, 3:302 illustration of, 3:281–282 Biologicals accidental human exposure to, 3:733 bioassays of, 3:751 contamination of, 3:401–402, 3:733–734 Creutzfeldt-Jakob disease contamination, 3:734 definition of, 3:732 derivation of, 3:732–734 efficacy of, 3:751 history of, 3:732 impurities in, 3:750 modern production of, 3:732 mouse antibody production assay, 3:400 mycoplasma contamination, 3:734 polymerase chain reaction testing, 3:400 prions, 3:734 purity and potency of, 3:750–751 quality control of cell-substrate characterization, 3:749–750 microbiological. See Microbiological quality control nonmicrobiological, 3:749–751 out-of-specification results, 3:751–752
CUMULATIVE
Biologicals (continued) product purity and potency, 3:750–751 raw materials, 3:738 regulation of, 3:732–733 testing of, 3:400–401 transmissible agents in, 3:733 viral agents in, 3:400–401 Bioluminescence imaging, 3:506–507 Biomarkers, of aging chronological age and, 3:654 end stage, 3:653, 3:655–658 identification of, 3:174 life span, 3:652–653 nonlethal, 3:654–655 pathology data and, 3:657–658 purpose of, 3:658 rate, 3:653–655 selection criteria, 3:654 state, 3:653–655 summary of, 3:658, 3:668 uses of, 3:653 Biomedical research mammals used in, 3:173 mouse in, 3:173 Biopharmaceuticals, 3:732, 3:750 Biopsy, testicular, 3:470 Biotin, 3:341–342, 3:369 Bisphenol A, 3:294, 3:307, 3:417 Bite. See Animal bite Biuret method, 3:208 Bladder. See Urinary bladder Blastocele, 3:102 Blastocyst microinjection chimeric mouse generation, 1:218 principles, 1:216–218 Blattella germanica, 3:429 Blatticides, 3:430 Bleeding orbital sinus, 3:454–455 submandibular, 3:457–458 Bleeding time, 3:155, 3:157 Blimp-1, 4:93 “Blind” testing, 3:528–529 BLNK, 4:307 Blood handling of, 3:138–139 refrigerated, 3:139 volume of, 3:137–138 Blood collection arterial, 3:457–458 cardiac puncture, 3:455–456 caudal vena cava, 3:458 after decapitation, 3:458 description of, 3:137–139 dorsal pedal vein, 3:456 heart, 3:455–456 hemolysis concerns during, 3:182 jugular vein, 3:179, 3:456–457 lateral tail vein, 3:456–457 after limb amputation, 3:458 orbital sinus, 3:454–455 restraints for, 3:454 saphenous vein, 3:456 sites for, 3:179
INDEX
Blood collection (continued) submandibular vascular bundle, 3:457–458 techniques for, 3:454 Blood concentration, 3:201 Blood islands, 3:158–159 Blood pressure fluctuations in, 3:31–32 monitoring methods electrocardiography. See Electrocardiography indwelling fluid-filled catheters, 3:33–34 invasive, 3:33–36 noninvasive, 3:32–33 radiotelemetry, 3:34–35 tail-cuff measurements, 3:32–33, 3:555 tethering techniques, 3:33 transducer-tipped catheters, 3:35–36 Blood smears evaluation of, 3:140, 3:145 platelet appearance on, 3:155 preparation of, 3:139 reticulocyte count on, 3:145 Blood urea nitrogen, 3:207 B10.LP mice, 3:142 B-mode echocardiography, 3:45 Body fat, 3:630–631 Body plethysmography, 3:54 Body regions, 3:2–3 Body size, 3:524 Body temperature heart rate affected by, 3:37 maintenance of, during electrocardiography, 3:37 thermoneutrality zone, 3:67–68 Body weight aging and, 3:655 diet restriction effects on, 3:366–367 water intake based on, 3:75 Bomb calorimetry, 3:324 Bone characteristics of, 3:124 hormones that affect, 3:127–131 phytoestrogen effects on, 3:350 regulation of, 3:124 x-ray imaging of, 3:494–495 Bone cells, 3:125, 3:136 Bone marrow age-related changes in, 3:161 anatomy of, 4:59–60 cellular organization of, 4:60–62 cellularity of, 3:145 collection of, 3:139, 3:458 dendritic cells from, 4:140, 4:148–149 evaluation of, 3:140, 3:145 hematopoietic stem cells in, 4:33 hypertrophy of, 4:60 megakaryocytes in, 3:154 natural killer cell development, 4:37 smear of, 3:139–3:140 structure of, 4:60 thymocytes from, 4:208 transplantation of, lethal irradiation for, 3:453–454
CUMULATIVE
327
INDEX
Bone marrow transfer experiments, 3:549 Bone morphogenetic proteins BMP-4, 3:93 signaling in hair follicle morphogenesis, 3:701–702 in nail development, 3:714 in sebaceous gland development, 3:711 in volar pad development, 3:716–717 Bone remodeling cells involved in, 3:125 mechanism of, 3:126–127 Bone resorption, 3:130–131 Boric acid, 3:430 Boron, 3:336 Borrelia, 2:729 Bottles. See Watering systems, bottles Bovine spongiform encephalopathy, 3:749 Boyle’s law, 3:54 Brain, 3:7 Brain-derived growth factor, 3:677 Brain-derived neurotrophic factor, 1:283 Brd2, 4:123 Breathing patterns, 3:52–53 Breeders replacement of, 3:238 retirement of, 3:261 Breeding. See also Reproduction ages to begin, 3:239 breeder selection, 1:54 chemical mutagenesis screening dominant phenotypes, 1:235 modifying genes dominant modifiers, 1:238 recessive modifiers, 1:238–239, 1:241 recessive phenotypes, 1:235–236 region-specific recessive mutations, 1:236–237 chromosomal aberration considerations, 1:72–73 commercial, 3:237 complexity of, 3:237–238 conditional mutagenesis strain maintenance, 1:71–72 economic considerations, 3:237–238 environmental factors that affect, 1:55–56, 3:108 genetic fundamentals alleles, 1:56–57 inheritance modes, 1:57–59 lethality and sterility, 1:59–60 genetic monitoring. See Genetic monitoring house mice characteristics intensity, 1:37 season length, 1:35–36 mating systems for, 3:252 mosaic populations, 1:75 noncommercial, 3:237 olfactory stimuli effects on, 3:239 pheromone responses, 1:54 protein requirements for, 3:332 random breeding, 1:75 record keeping, 1:56 strategies, 1:61, 1:74
Breeding (continued) summary of, 3:267–268 troubleshooting, 1:56 Breeding colony. See also Breeding stocks animal identification, 3:265–266 bedding for, 3:240–241 commercial, 3:237 culling of animals, 3:265 diet for, 3:239–240 economic considerations, 3:237–238 evaluation of, 3:110 exclusionary status, 3:248 F1 hybrids, 3:258 facilities for. See Breeding facilities feed, 3:239–240 founder animals, 3:251–252 genetically modified mice, 3:258–259 health monitoring of, 3:248–249 health status of, 3:105 hybrid strains, 3:266–267 inbred, 3:253–254, 3:266–267 inclusionary status, 3:248 litter consolidation, 3:261 maintenance of, 3:104–105 management of, 3:262 microbiological status of, 3:247–248 mismatchings, 3:266–267 noncommercial, 3:237 nutritional requirements, 3:240 outbred, 3:254–258 overview of, 3:236–237 planning for, 3:250–251 production colony sectioning, 3:259 production index for, 3:259 productivity information, 3:251 pup inventories, 3:265 quality assurance program testing of bacterial agents, 3:397–398 enzyme-linked immunosorbent assay, 3:396 frequency of, 3:395 Helicobacter spp., 3:397 hemagglutination inhibition assays, 3:396 immunofluorescence antibody testing, 3:396 Mycoplasma arthritidis, 3:397 Mycoplasma pulmonis, 3:397 number of animals to be tested, 3:395 parasites, 3:397–398 Pasteurella pneumotropica, 3:397 serologic tests, 3:395–396 sick or deceased animals, 3:394 variations in results, 3:394–395 viral genetic material, 3:396–397 random bred, 3:267 records. See Breeding records retirement, 3:261 sampling program for, 3:248–249 sentinel animals co-housed with, 3:394 specific pathogen free status of, 3:247–248 structure of, 3:252–259 timed matings, 3:261–262 transgenic mice, 3:258–259
Breeding colony (continued) troubleshooting the performance of, 3:109–110 water for, 3:241 Breeding facilities bioexclusion cage level, 3:246–247 cleaning of, 3:244 combined techniques, 3:247 conventional, 3:243 disinfection of, 3:244 group level, 3:245 room level, 3:243–245 water supply, 3:244–245 caging, 3:242–243 costs of, 3:238 isolators. See Isolators microisolation caging, 3:247 overview of, 3:241–242 Breeding records cage-level, 3:262–263 description of, 3:104 pedigree card, 3:262–263 pedigree ledger, 3:263, 3:265 pedigree tree, 3:265 production report, 3:263–264 Breeding stocks. See also Breeding colony advanced intercross lines, 1:71 background effects, 1:64–65 coisogenic strains, 1:64 congenic strains, 1:66–69 conplastic strains, 1:70–71 consomic strains, 1:69–70 hybrids, 1:65–66 inbred strains, 1:62–63 outbred stocks, 1:73, 1:75 recombinant congenic strains, 1:71 recombinant inbred strains, 1:71 segregating backgrounds, 1:66 segregating inbred strains, 1:63–64 Breeding unit configuration of, 3:109 description of, 3:104 Bromodeoxyuridine, sister chromatid exchange detection, 1:149 Bronchial circulation, 3:51–52 Bronchial-associated lymphoid tissue, 4:69 Bronchioles, 3:50 Bronchoalveolar lavage, 3:483 Bronchoconstrictor agents, 3:63 Bronchopulmonary inflammation, 3:48 Bronchopulmonary lavage, 3:459 Bronchus principalis dexter et rami arteriae et venae pulmonalis, 3:13 Bronchus principalis sinister, 3:13 Bruce effect, pheromone response, 1:54 Bsbob, 3:624 Btk, 4:307 BTLA, 4:269 Buccinatorius, 3:5 Buffy coat, 3:140 Bulboglandularis, 3:19 Bulbourethral glands, 3:96 Bulbus olfactorius, 3:7 Burst forming unit-erythroid, 3:142
328
CUMULATIVE
Butorphanol, 3:462 Bwq5, 3:624 BXSB.yaa mice, 4:246–247
C C1, 4:8 C3, 3:190 C3 mice, 3:53 C3aR, 4:11 C4 deficiency, 4:252 C4A, 4:124 C4B, 4:124 C5, 3:190 C5aR, 4:11 C5L2, 4:13 11C, 3:503 C58, 2:651 C4, 4:124 C5 convertase, 4:8 CACNA1A, 3:572–573 Cacnal a, 3:676 CACNB4, 3:572–573 Cacng2, 3:574 Cadmium, 3:345 Caesarean section, 3:251, 3:404 CAF1 mice, 3:157 Cage ammonia monitoring in, 3:294 behavior monitoring in, 3:516 cleaning of, 3:415–416 decontamination of, 3:280 enrichment of, 3:239, 3:525 environmental enrichment, 3:314 filter top, 3:242, 3:246, 3:293 flooding of, 3:307 health monitoring program based on, 3:248 history of, 3:294 infectious disease monitoring in, 3:394 isolators. See Isolators lighting in, 3:413–414 mass air displacement units in, 3:299–302 metal, 3:417 open top, 3:242 plastic, 3:417 radionuclide decontamination, 3:281 records on, 3:262–263 room temperature in, 3:239 size of, 3:242–243 static microisolator, 3:294–295 sterilization of, 3:280–281 ventilated air quality concerns, 3:295 blowers, 3:298 considerations in using, 3:298 description of, 3:284 excessive ventilation, 3:297–298 individually, 3:295–299 intracage supply/intracage exhaust, 3:295–296 intracage supply/perimeter capture, 3:295–296 water bottles in, 3:286–3:290 Cage filters, 3:417–418
Cage sanitation area chemical storage in, 3:277 clean activity, 3:277 description of, 3:276–277 location of, 3:273–274 mechanical equipment in, 3:277 soiled activity, 3:277, 3:285 Cage wash area clean cage wash, 3:311 description of, 3:277–278 soiled cage wash, 3:311–312 Cage washers alkali residues, 3:417 batcher, 3:302, 3:310, 3:417 cumulative heat factor, 3:416 efficacy evaluations, 3:417 filter screens, 3:417 improper loading of, 3:416 objective of, 3:415 operation of, 3:416 performance recommendations for, 3:416 pressure gauges, 3:416 quality assurance program for, 3:416 spray nozzles, 3:417 temperature gauges, 3:416 tunnel washer, 3:302–303, 3:310, 3:415–416 types of, 3:415 Calcα, 3:129 Calcaneus et ossa tarsi, 3:4 Calcitonin, 3:129 Calcitonin gene-related peptide, 3:129 Calcium daily requirements for, 3:336 dystrophic calcinosis, 3:338 reference range for, 3:181 serum levels of, 3:207–208 Calcium channels, voltage-gated, 3:572–573 Calcium:phosphorus ratio, 3:338 Calodium hepaticum, 1:46 Caloric restriction, for epileptic seizures, 3:583 Calories calculation of daily requirements, 3:445 definition of, 3:324 Cancer, 4:283–284 Cannibalism, 3:109 Cannulation bile duct, 3:454 vascular, 3:452 Caput epididymidis, 3:19 Caput laterale musculi gastrocnemii, 3:4, 3:6 Caput mediale musculi gastrocnemii, 3:7 CAR. See Cocksackie-adenovirus receptor CAR bacillus. See Cilia-associated respiratory bacillus Cara1, 3:624 Carbohydrates digestion of, 3:66 metabolism of, 3:185 Carbon dioxide asphyxiation using, 3:481 description of, 3:293 euthanasia uses of, 3:481 narcosis caused by, 3:464
INDEX
Carbon monoxide delivery of, 3:61 diffusing capacity for, 3:55 Carboxypeptidase E, 3:621 Carcinogenic compounds, 3:367 Cardiac output, 3:42–43 Cardiac puncture, 3:455–456 Cardiomyocytes, 3:29 Cardiovascular disease antioxidants and, 3:550 in atherosclerotic mice, 3:553–554 estrogen replacement therapy and, 3:551–552 in humans, 3:536 mortality caused by, 3:536 phenotyping, 1:245–246 prevalence of, 3:536 risk factors for, 3:536 Cardiovascular phenotyping, 3:555–556 Cardiovascular system ex-vivo techniques, 3:29–30 functions of, 3:41 heart. See Heart in-vivo techniques anesthesia effects, 3:30–31 blood pressure. See Blood pressure cardiac output, 3:42–43 electrocardiography. See Electrocardiography exercise tolerance assessment, 3:40–42 heart rate, 3:39–40 noninvasive imaging, 3:43–48 isolated heart preparation, 3:29–30 magnetic resonance imaging evaluations, 3:501–502 overview of, 3:25–26 Cardioviruses. See Encephalomyocarditis virus; Theiler’s murine encephalomyelitis virus Caretakers, 3:387 CARMA1, 4:84 Carnosine, 3:180 Carotid artery catheterization, 3:476 Carp1, 3:624 Carpal pads, 3:715 Casein, 3:354 Caspase recruitment domains, 4:114 Caspase-3 apoptosis inhibitor, 3:610 CAST/Ei mice, 3:651 Catabolic phase, of estrous cycle, 3:100 Catagen phase, of hair growth, 3:706–708 Caterpillar pads, 3:715 Cathepsins description of, 3:126 K, 1:310 Catheter(s) advantages and disadvantages of, 3:33–34 indwelling fluid-filled, 3:33–34 intragastric, 3:446 over-the-needle, 3:474 transducer-tipped, 3:35–36 vascular, 3:474 Catheterization arteries, 3:475 bile duct, 3:478–479
CUMULATIVE
329
INDEX
Catheterization (continued) carotid artery, 3:476 catheters used in, 3:474 colonic, 3:478 duodenal, 3:478 femoral artery, 3:476–477 femoral vein, 3:476–477 gastric, 3:477–478 ileal, 3:478 indications for, 3:474 intrathecal, 3:479 jejunal, 3:478 jugular vein, 3:475 nonsurgical approach, 3:474 nonvascular, 3:477–479 portal vein, 3:476 renal artery, 3:477 tail vein, 3:475 urinary bladder, 3:479 Catnb, 2:599, 2:602–603 Cauda epididymidis, 3:19 Caudal abdomen, 3:2 Caudal vena cava blood collection, 3:458 CBA, 2:646–647 CBA/J mice blood volume in, 3:138 water intake in, 3:76 CBA/JPh mice, 3:142 CBA/N mice, 3:189 C-banding, 1:149–150, 1:156 C57BL mice development, 2:647 phenotype, 2:647 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:649–650 nonneoplastic conditions, 2:647–649 pathogen susceptibility, 2:650 related strains, 2:650–651 C57BL/6 mice age-related diseases in, 3:646 atherosclerosis models, 3:539 breeding colony, 3:262 corticosterone levels in, 3:201 hyaloid development in, 3:600 immunoglobulins in, 3:189 isoflurane anesthesia in, 3:463 leptin levels in, 3:185 pentobarbital effects, 3:463 production index for, 3:260 protein requirements, 3:332 reference ranges for, 3:181 retinal vascular development in, 3:600 serum protein profiles of, 3:174 testosterone in, 3:202 trabecular meshwork in, 3:602 urea nitrogen levels in, 3:207 C57BL/10 mice, 3:138 C57BL/129 mice, 3:185 C57BL/6J mice asthma models, 3:62
C57BL/6J mice (continued) breathing patterns in, 3:52 cholesterol studies in, 3:65 diet for, 3:107 kidneys in, 3:71 C57BL/10ScCr mice, 4:110 C.B-17-scid mice, 4:278 CCL21, 4:201 CCR5, 1:308 CD1, 4:20–21, 4:141 CD3, 4:24 CD4, 4:26 CD8, 4:26 CD11b, 4:170 CD16, 4:175 CD19, 4:24, 4:84 CD21, 4:94 CD22, 4:83, 4:267 CD25, 4:42, 4:308–309 CD27, 4:93 CD30L, 3:194 CD35, 4:94 CD40, 3:193, 4:28–29 CD40 ligand, 3:194, 4:28–29, 4:94, 4:142 CD43, 4:170 CD45, 4:84, 4:254 CD49b, 4:170 CD62L, 4:90 CD70, 4:93 CD72, 4:83 CD74, 4:19 CD80, 4:245 CD86, 4:94, 4:142 CD91, 4:141 CD94/NKG2, 4:174 CD103, 4:43 CD122, 4:170 CD154, 4:29 CD206, 4:13 CD244, 4:175 Cd45, 4:189 CD-1 mice cholesterol studies in, 3:65 isoflurane anesthesia in, 3:463 reference ranges for, 3:181 CD4+ T cells, 4:39–40 CD8+ T cells description of, 4:39–40 effector, 4:90 CD11b, 4:33 Cdh1, 3:699 CD94/NKG2 receptors, 4:15 Cecal volume, in germfree mice, 3:219, 3:227, 3:482 Ced4, 3:675 Cell adhesion molecules, 3:545–546 Cell bank, 3:738–739 Cell cycle, 3:675 Cell transplantation therapy, embryonic stem cell studies, 1:286 Cell-substrate characterization, 3:749–750 Cellular retinaldehyde binding protein, 3:607 Cellular senescence, 3:640 Cellulose, 3:306
Cenpb, 3:622 Central nervous system, 3:674 Central supramolecular activation cluster, 4:89 Central tolerance models of, 4:209 T cell–mediated autoimmunity control through, 4:234–235 Centroacinar cells, 3:64 Centroblast B cells, 4:162 Centroblasts, 4:93 Centrocytes description of, 4:95 somatic hypermutation of, 4:94–96 terminal differentiation of, 4:96 Centromere, fluorescent in situ hybridization, 1:153 Cerebellum, 3:7 Cerebrospinal fluid collection, 3:458 Certified diet, 3:353 Ceruloplasmin, 3:206, 3:208 Ceruminous glands, 3:711 Cervical collars, 3:448 Cervical dislocation, 3:481 Cervical vagotomy, 3:473 Cervicales profundi lymph nodes, 3:21 Cervicales superficiales lymph nodes, 3:21 Cervicalis profundus caudalis lymph node, 3:22 Cervix, 3:98–99 Cervix uteri, 3:20 CF1 mice, 3:106 cFLIPL, 4:95 CFTR. See Cystic fibrosis transmembrane conductance regulator C3G, 4:200 C3H mice description of, 3:260 development, 2:643 phenotype, 2:643 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:645–646 nonneoplastic conditions, 2:643–645 pathogen susceptibility, 2:646 related strains, 2:646–647 Chagas disease, 3:45 Channelopathies, 3:676–677 Charge coupled device, 3:506 Chemical mutagenesis breeding strategies dominant phenotypes, 1:235 modifying genes dominant modifiers, 1:238 recessive modifiers, 1:238–239, 1:241 recessive phenotypes, 1:235–236 region-specific recessive mutations, 1:236–237 chlorambucil, 1:230–231 classification, 1:229 cyclophosphamide, 1:232
330 Chemical mutagenesis (continued) diethyl sulfate, 1:232 embryonic stem cells applications, 1:253 mutagens ethylmethanesulfonate, 1:255 ethylnitrosourea, 1:255 ICR191, 1:255–256 trimethylpsoralen, 1:256 phenotyping, 1:256 principles, 1:253–255 ethylmethanesulfonate, 1:231 ethylnitrosourea advantages, 1:233 clinical relevance, 1:233 description of, 1:230 effectiveness measures, 1:235 gene mapping, 1:241 historical perspective, 1:232–233 principles, 1:109 resources, 1:110 genotyping denaturing high-performance liquid chromatography, 1:256–257 single-strand conformational polymorphism, 1:256 temperature gradient capillary electrophoresis, 1:257 methyl methanesulfonate, 1:231 phenotyping. See Phenotyping procarbazine, 1:229–230 screening programs, 1:233–234 strain selection, 1:233–235 trimethylenemelamine, 1:230 Chemical mutagenicity, 3:175 Chemically defined diet, 3:352–353 Chemiluminescent immunoassays, 3:176 Chemogenomics, 1:294–295 Chemokine(s) atherosclerosis affected by, 3:545 CCR1, 3:197 CCR2, 3:196–197 CCR3, 3:196–197 CCR4, 3:196–197 CCR5, 3:196–197 CCR6, 3:197 CCR7, 3:196–197 CCR8, 3:196–197 CCR9, 3:197 CCR10, 3:197 dendritic cell migration regulated by, 4:143–144 description of, 3:195–196, 4:29, 4:31, 4:34, 4:47, 4:64 function of, 3:197 homeostatic, 3:195 inflammatory, 3:195 in inflammatory responses, 4:295 in lymphoid organogenesis, 4:75 natural killer cell production of, 4:171–172 from radiation-resistant stroma, 4:93 transcription of, 4:75 Chemokine receptors CCR2, 3:544
CUMULATIVE
Chemokine receptors (continued) description of, 4:29, 4:64 signaling of, 4:202–204 Chemosterilants, 3:431 Chenodeoxycholic acid, 3:206 Chest, 3:2 CH12F3-2, 4:157 C3H/Fg mice, 3:180 C3H/HeJ mice, 3:52, 4:110 Chief cells, 3:64 Chilomastix bettencourti, 2:525 Chimeric mouse blastocyst microinjection, 1:216–218 morula aggregation, 1:218 Chitin, 3:430 Chlamydia muridarum culture, 2:333 developmental cycle, 2:331–332 genital infection course, 2:339–340 immune response, 2:341–342 pathologic response, 2:340–341 genome, 2:331 history of study, 2:326–328 metabolism, 2:332–333 morphology, 2:330–331 pathogenesis, 2:334–335 respiratory infection course, 2:335–336 immune response, 2:337–339 pathologic response, 2:336–337 strains, 2:333–334 structure, 2:331 taxonomy, 2:333 Chlamydia spp. C. pneumoniae description of, 3:552 history of study, 2:342–343 mouse infection studies, 2:330, 2:343–344 taxonomy, 2:333 C. psittaci, 2:330, 2:344 C. trachomatis history of study, 2:327–328 mouse infection studies, 2:329–330, 2:339–342 taxonomy, 2:333 Chloral hydrate, 3:31 α-Chloralose, 3:31 α-Chlordane, 3:346 τ-Chlordane, 3:346 Chloride daily requirements for, 3:336 measurement of, 3:207 reference range for, 3:181 Chlorinated drinking water, 3:308–309, 3:372, 3:418–419 Chlorine dioxide description of, 3:309, 3:426 isolator sterilization using, 3:224 microbicidal efficacy of, 3:309 in research facilities, 3:309–310 shelf life of, 3:310 Chlorpyriphos, 3:346 Cholecalciferol, 3:339, 3:342
INDEX
Cholecystokinin, 3:64 Cholesterol. See also Lipoprotein(s) atherosclerosis risks, 3:537. See also Atherosclerosis description of, 3:65 efflux of, 3:187 excess, 3:187 measurement of, 3:187–188 mouse levels of, 3:537 serum, 3:187–188 total plasma, 3:188 Cholesterol ester hydrolase, 3:187 Cholesterol ester transfer protein, 3:186, 3:538 Cholesterol esters, 3:537 Cholic acid, 3:206 Choline, 3:340, 3:342 Chorion, 1:190 Chromatin, 3:149 Chromatography, 3:740 Chromium, 3:336 Chromosomal aberrations breeding considerations, 1:72–73 nomenclature, 1:94–97, 1:154–155 Chromosomal sex, 3:92 Chromosome(s). See Meiotic chromosomes; Mitotic chromosomes Chronobiology, 3:108–109 Chylomicrons, 3:66, 3:185, 3:537 CIITA, 4:93 Cilia, 3:696–697 Cilia-associated respiratory bacillus clinical features, 2:455–456 control of, 2:459 culture, 2:455 description of, 3:391 diagnosis culture, 2:458 electron microscopy, 2:459 enzyme-linked immunosorbent assay, 2:458 histopathology, 2:458–459 immunohistochemistry, 2:459 polymerase chain reaction, 2:459 geographic distribution, 2:457 history of study, 2:454–455 host range, 2:457–458 pathogenesis, 2:456–457 pathology, 2:456 prevalence of, 2:458 prevention of, 2:459 properties, 2:455 strains, 2:455 transmission, 2:458 treatment, 2:459 Ciliary neurotrophic factor, 3:599 Ciliary neurotrophic factor receptor, 4:41 Ciliated cells, 3:50 Ciliated fimbria, 3:98 Circular paired mating system, 3:255 Circulating immune complexes, 3:191 Cis transgenic mice, 4:188 Citrobacter rodentium, 3:391 classification, 2:373 clinical features, 2:375–376
CUMULATIVE
331
INDEX
Citrobacter rodentium (continued) diagnosis, 2:376 epizootiology, 2:376 history of study, 2:373–374 pathogenesis, 2:374–375 properties, 2:374 treatment and control, 2:377 c-Kit, 4:35 c-kit, 3:142 C57L, 2:651 Clara cells, 3:51 Class 100 air, 3:299 Class II-associated invariant chain peptide, 4:19 Class switch recombination description of, 4:157 mismatch repair proteins involved in, 4:164 Clavicula, 3:4–6 Clean cage wash, 3:311 Cleidobrachialis, 3:5–6 Cleidocephalicus, 3:4–6 Cleidooccipitalis, 3:5 Clindamycin Clostridium difficile infection management, 2:359 Clostridium perfringens infection management, 2:357 Clinical chemistry changes in, 3:175 ELISA kits, 3:177–178 information sources, 3:179 instrumentation used in, 3:174 multiplex technology, 3:176–177 quality assurance, 3:182 sampling, 3:179–180 services available, 3:176 statistics, 3:182 techniques used in, 3:174 Clinical descriptive terms, 3:137 Clitoral glands, 3:711 Clitoris, 3:21 Clitoris et orificium urethrae externum, 3:3 Clitoris et seccio transversalis clitoridis, 3:20 Clock, mutation phenotyping, 1:247 Clonal deletion, 4:215, 4:218 Clonal expansion, 4:68 Cloning. See Somatic nuclear transfer Closed formula diet, 3:355 Clostridium spp. C. difficile clinical features, 2:358–359 control and prevention, 2:360 culture, 2:358 diagnosis, 2:359 epizootology, 2:359 history of study, 2:357–358 pathogenesis, 2:359 properties, 2:358 strains and antigenic relationships, 2:358 treatment, 2:359–360 C. perfringens clinical features, 2:356 control and prevention, 2:357
Clostridium spp. (continued) culture, 2:356 description of, 3:228 diagnosis, 2:357 epizootology, 2:357 history of study, 2:355 pathogenesis, 2:356–357 properties, 2:356 strains and antigenic relationships, 2:356 treatment, 2:357 C. piliforme clinical features, 2:351–353 control and prevention, 2:355 culture, 2:351 description of, 3:392 diagnosis, 2:353–355 epizootology, 2:353 history of study, 2:350 pathogenesis, 2:353 properties, 2:350 strains and antigenic relationships, 2:350 treatment, 2:355 Cluster of differentiation, 4:32 c-mpl, 3:142, 3:154 c-Myc, 3:712–713 Coagulase test, 3:742 Coagulation time prolongation, 3:158 Coat color, genetics and nomenclature, 2:628–630 Cobalamin, 3:341 Cobalt, 3:336 Cobblestone pads, 3:715 Cocaine amphetamine regulated transcript, 3:130 Coccygeus, 3:18 Coccygeus dorsalis, 3:7 Coccygeus ventralis, 3:7 Cockroaches, 3:429–430 Cocksackie-adenovirus receptor, 2:54 Coelomys, 1:14 Coenzyme Q10, 3:550 Coisogenic strains breeding, 1:64 nomenclature, 1:87 Cold adaptation, 1:31, 3:68–69 Collars cervical, 3:448 polyethylene restraint, 3:444 Collectins, 4:14 Collection procedures blood. See Blood collection bone marrow, 3:139 Colliculi caudales, 3:7 Colliculi rostrales, 3:7 Collimation, 3:502 Colobomas, 3:598 Colon ascendens, 3:15 Colon descendens, 3:15, 3:17 Colon transversum, 3:15 Colonic catheterization, 3:478 Colonization resistance, 3:228 Colony. See also Breeding stocks animal identification, 3:265–266
Colony (continued) bedding for, 3:240–241 commercial, 3:237 culling of animals, 3:265 diet for, 3:239–240 economic considerations, 3:237–238 evaluation of, 3:110 exclusionary status, 3:248 F1 hybrids, 3:258 facilities for. See Breeding facilities feed, 3:239–240 foundation. See Foundation colony founder animals, 3:251–252 genetically modified mice, 3:258–259 health monitoring of, 3:248–249 health status of, 3:105 hybrid strains, 3:266–267 inbred, 3:253–254, 3:266–267 inclusionary status, 3:248 litter consolidation, 3:261 maintenance of, 3:104–105 management of, 3:262 microbiological status of, 3:247–248 mismatchings, 3:266–267 noncommercial, 3:237 nutritional requirements, 3:240 outbred, 3:254–258 overview of, 3:236–237 planning for, 3:250–251 production colony sectioning, 3:259 production index for, 3:259 productivity information, 3:251 pup inventories, 3:265 quality assurance program testing of bacterial agents, 3:397–398 enzyme-linked immunosorbent assay, 3:396 frequency of, 3:395 Helicobacter spp., 3:397 hemagglutination inhibition assays, 3:396 immunofluorescence antibody testing, 3:396 Mycoplasma arthritidis, 3:397 Mycoplasma pulmonis, 3:397 number of animals to be tested, 3:395 parasites, 3:397–398 Pasteurella pneumotropica, 3:397 serologic tests, 3:395–396 sick or deceased animals, 3:394 variations in results, 3:394–395 viral genetic material, 3:396–397 random bred, 3:267 records. See Breeding records retirement, 3:261 sampling program for, 3:248–249 sentinel animals co-housed with, 3:394 specific pathogen free status of, 3:247–248 structure of, 3:252–259 timed matings, 3:261–262 transgenic mice, 3:258–259 troubleshooting the performance of, 3:109–110 water for, 3:241
332 Colony forming unit-erythroid cells, 3:142 Colony log, 3:263–3:264 Colony stimulating factor-1, 3:131 Color flow Doppler echocardiography, 3:46 Column chromatography, 3:740 Commensal impact, 1:28–29 Commercial breeding colonies, 3:237 Committee for Proprietary Medicinal Products, 1:298 Comparative genome analysis ancestral chromosome structure, 1:106–107 conserved noncoding sequences, 1:105–106 conserved synteny, 1:106 gene orthology, 1:105 genome size, 1:105 polymorphisms and haplotypes, 1:106 prospects, 1:111, 1:315 purposes, 1:104 repetitive sequences, 1:104 Comparative tumor biology. See Tumor pathology, in genetically engineered mice Competence, 3:698 Complement protein 3, 4:8 Complement proteins, 4:280 Complement receptor(s) characteristics of, 4:10 CR1, 4:10–11 CR2, 4:10–11 CR3, 4:11 CR4, 4:11 Complement receptor 1 related gene/protein Y, 3:190 Complement system activation of, 4:8 description of, 3:190–191 functions of, 4:8 lectin pathway of, 4:8 overview of, 4:8–10 pentraxin pathway of, 4:8 Complementarity-determining regions, 4:21 Complete blood count, 3:141 Complex Trait Consortium, 3:632 Compound A, 3:464 Computed tomography contrast-enhanced, 3:496 facilities for, 3:282–283 high-resolution x-ray, 3:43–44 single-photon emission, 3:43, 3:504, 3:509 x-ray, 3:43–44, 3:493–494 Conditional mutagenesis, 1:264–265 Conduction system, 3:27 Confidence limit, 1:143 Congenic strains analysis of, 3:628–629 breeding, 1:66–69 definition, 2:628 development of, 1:67–69, 3:173 gene mapping, 1:128–129 marker-assisted development, 1:69 nomenclature, 1:87
CUMULATIVE
Congenic strains (continued) production of, 3:629 recombinant, 1:71, 1:84, 3:629–630 Conjugated bilirubin, 3:205 Conjunctivitis, 2:484–485 Conplastic strains breeding, 1:70–71 nomenclature, 1:87, 1:89 Conservation, 1:30–31 Consomic strains breeding, 1:69–70 gene mapping, 1:129 nomenclature, 1:87 Constant volume-reheat, 3:288 Constrictor vulvae, 3:20 Construct validity, 3:653 Contact bedding, 3:240 Contaminants adventitious agents description of, 3:735–736 prevention of, 3:737–739 cell banks used to prevent, 3:738–739 chlorinated hydrocarbons, 3:346 contaminant removal or inactivation, 3:739–740 description of, 3:345 drinking water, 3:241 endogenous retroviruses, 3:736–737 heavy metals, 3:345–347 laboratory practices to prevent, 3:739 manufacturing practices to prevent, 3:739 maximum amounts of, 3:345–346 murine leukemia virus, 3:737 mycotoxins, 3:347–348 nitrosamines, 3:350–351 operator-induced, 3:739 organophosphates, 3:346 pesticides, 3:345, 3:347 phytoestrogens, 3:348–350 polycarbon biphenyls, 3:347 saponins, 3:351 sources of, 3:736 viruses, 3:739–740 Contrast, 3:491 Contrast agents computed tomography use of, 3:496 magnetic resonance imaging use of, 3:502 ultrasound use of, 3:497–498 uses of, 3:492 Conventional animal, 3:218 Copper, 3:336 Copulation plug, 3:101–102, 3:110, 3:261–262 Cor in pericardii, 3:12 Corncob bedding, 3:306 Corneal dystrophy, Balb/c mice, 2:640 Corneal growth factor-stimulated angiogenesis, 3:611 Corniculate cartilage, 3:50 Cornu uteri dextrum, 3:20–21 Cornu uteri sinistrum, 3:20–21 Coronary arteries anatomy of, 3:27–28 magnetic resonance imaging of, 3:45
INDEX
Coronary veins, 3:28 Coronavirus, 3:396 Corpora lutea, 3:101, 3:103 Corpus cavernosum clitoridis, 3:20 Corpus cavernosum penis, 3:96 Corpus ceci, 3:15 Corpus pancreatis, 3:14 Corpus ventriculi, 3:16 Cortex telencephali, 3:7 Cortical epithelial cells, 4:63, 4:65 Cortical thymic epithelial cells, 4:208 Corticosterone adrenocorticotrophic hormone affected by, 3:201 circulation of, 3:200–201 definition of, 3:200 reference ranges for, 3:181 Cortisol-binding globulin, 3:200 Corynebacterium spp. C. bovis clinical features, 2:400 culture, 2:399 description of, 3:220 diagnosis, 2:401 epizootiology, 2:400–401 properties, 2:399 strains, 2:399 treatment and control, 2:401–402 C. kutscheri clinical features, 2:402–403 culture, 2:402 diagnosis, 2:403–404 epizootiology, 2:403 properties, 2:402 strains, 2:402 treatment and control, 2:404 Costa ultima, 3:9 Costimulatory molecules, 4:215 Coumestrol, 3:349 Cowper’s glands, 3:96 COX. See Cyclooxygenase COX-2 inhibitors, 3:480 Cpe, 3:621 CPMP. See Committee for Proprietary Medicinal Products c1q deficiency, 4:252 CR1, 4:10–11 CR2, 4:10–11, 4:24 CR3, 4:11 CR4, 4:11 Cr2, 4:11 Cranial abdomen, 3:2 CRB1, 3:607 Crb1rd8 mice, 3:607 C-reactive protein, 3:190 Creatine kinase description of, 3:199–200 mitochondrial, 3:199 Creatinine, 3:181, 3:207 Creatinine/creatine ratio, 3:73 Creutzfeldt-Jakob disease, 3:734 Crhr2, 3:520 Cricoid cartilage, 3:50 Critical infection risks, 3:424
CUMULATIVE
333
INDEX
Cross-linkage mapping backcross, 1:120–124 backcross-intercross, 1:123 guidelines, 1:120 intercross, 1:122–124 ordering loci in multipoint crosses, 1:124 penetrance, expressivity, or modifier loci, 1:124–125 strain selection databases, 1:116 description of, 1:120 disequilibrium mapping, 1:127 marker types, 1:117–120 mutant genes, 1:116–117, 1:241 quantitative trait loci, 1:126–127 Cross-validation, 3:653 Crry, 4:280 Crumbs homolog 1 gene, 3:607 Cryoanesthesia, 3:464–465 Cryopreservation description of, 3:114 embryos, 1:218–219, 1:235 germplasm, 1:219 ovarian tissue, 1:219–220, 1:235 sperm, 1:235 “Cryptic” immunodeficiency, 3:389, 3:396 Cryptopatches, 4:69 Cryptosporidium muris cell biology, 2:539 clinical features, 2:539 diagnosis, 2:539 history of study, 2:538 life cycle, 2:538–539 prevention, 2:539–540 research implications, 2:540 treatment and control, 2:539–540 Crypts, 3:65–66, 3:98 Crypts of Lieberkuhn, 3:66 CSTB, 3:570 CTLA-4, 4:237, 4:268–269 C-type lectin, 4:36 C-type lectin receptors, 4:13–14 C-type lectin-like glycoprotein, 4:175 C-type particles, 3:737 64Cu, 3:503 Cuboidal epithelial cells, 3:97 Cumulative exposure hypothesis, 3:664 Cumulative heat factor, 3:416 Cumulus cells, 3:102 Cuneiform cartilage, 3:50 Cupula diaphragmatis, 3:9, 3:14 Current Protocols in Neuroscience, 3:531 Curvatura major, 3:16 Curvatura major ventriculi, 3:17 Curvatura minor, 3:16 Cutaneus trunci, 3:5–6 Cut-like 1 signaling, 3:702 CXCL3, 3:196 CXCL4, 3:196 CXCL6, 3:196 CXCL9, 3:196 CXCL10, 3:196 CXCL11, 3:196 CXCL12, 3:196 CXCL13, 4:75, 4:78
CXCR2, 3:195 CXCR3, 3:195, 3:197 CX3CR1, 3:197 CXCR4, 3:195, 3:197 CXCR5, 3:195, 3:197, 4:78 CXCR6, 3:195, 3:197 Cyanocobalamin, 3:341 Cyclic adenosine monophosphate, 3:125 Cyclic biorhythms, 3:180 Cyclin-dependent kinase 5, 3:576, 3:683 Cyclohexylamine, 3:362 Cyclooxygenase description of, 3:196 inhibitors of, 3:480 knockout mouse phenotypes, 1:313 Cyclophosphamide, 1:232 Cyp19a1, 3:130 Cyp1b1−/−, 3:604 CYPs. See Cytochrome P1:450 Cystatin B, 3:569–571 Cystic fibrosis transmembrane conductance regulator, 1:309 Cystocentesis, 3:460 Cytochrome c, 4:217 Cytochrome P450 CYP1A2 humanized mouse, 1:312 knockout mouse phenotype, 1:311–312 CYP2D6 knockout mouse phenotype, 1:312 CYP2E1 knockout mouse phenotype, 1:312 CYP3A4 humanized mouse, 1:312 pharmacokinetic studies in vitro versus in vivo, 1:313–314 Cytochrome-oxidase activity, 3:68 Cytogenetic analysis. See Meiotic chromosomes; Mitotic chromosomes Cytokine(s) in airway hyperresponsiveness, 4:293–294 atherosclerosis affected by, 3:545 description of, 4:29, 4:279 in inflammatory responses, 4:295 leukocytes affected by, 3:153 natural killer cell production of, 4:171–172 receptors for, 4:30–31 suppressors of cytokine signaling, 4:180–181 Cytokine-activated JAK-STAT pathway, 4:180–181 Cytokine-like factor-1, 4:41 Cytomegalovirus atherosclerosis and, 3:552 description of, 3:105, 3:391 human, 4:307–308 mouse. See Mouse cytomegalovirus Cytoplasmic receptors, 4:114 Cytosolic pathway, 4:18 Cytotoxic T cell-associated antigen 4, 4:26, 4:200 Cytotoxic T lymphocytes, 4:171, 4:283 Cytotoxic T-lymphocyte associated antigen-8, 3:193
D 33D1, 4:139 Daidzein, 3:348–349 Dam, foster, 3:112 DAPI banding, 1:149 Dark:light cycle behaviors affected by, 3:524–525 description of, 3:291, 3:414 mating during, 3:101 Data loggers, 3:421 DBA mice development, 2:651 phenotype, 2:651 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:651–652 nonneoplastic conditions, 2:651–652 pathogen susceptibility, 2:651–653 DBA/2 mice cholesterol studies in, 3:65 pentobarbital effects, 3:463 production index for, 3:260 DBA/2J mice adult onset glaucoma in, 3:610 audiogenic seizure susceptibility in, 3:579 diet for, 3:107 pigmentary glaucoma in, 3:605–606 protein requirements, 3:332 testosterone in, 3:202 water intake in, 3:76 DC. See Dendritic cell DDT, 3:346 Death receptors, 4:214, 4:217 DEC-205, 4:139 Decapitation blood collection after, 3:458 description of, 3:481–482 Decay-accelerating factor, 4:245 Decidual response, 3:102 Decontamination. See also Autoclaving; Disinfectants; Sterilization definition of, 3:424 monitoring of procedures for, 3:427 of cage, 3:280 of diet, 3:361–366 Dectin-1, 4:14 ß-defensins, 4:32 Defined flora, 3:227–229, 3:247 Defined flora animal, 3:218, 3:247 Definitive erythropoiesis, 3:135, 3:158 Definitive hematopoiesis, 3:160 Dehydration postoperative, 3:479 red cell mass affected by, 3:146 signs of, 3:146 Dehydroepiandrosterone, 3:371, 3:647, 3:667 Dehydroretinol, 3:339 Delayed-type hypersensitivity, 4:309 Deletion mapping, 1:130
334 Delta-like 1, 4:63 Deltoideus, 3:5 Demodex musculi clinical features, 2:568 diagnosis, 2:568 host range, 2:568 life cycle, 2:568 morphology, 2:568 pathobiology, 2:568 prevention and control, 2:568 treatment, 2:568 Denaturing high-performance liquid chromatography, 1:256–257 Dendritic cells antigen handling by, 4:141–142 bone marrow, 4:140, 4:148–149 CD1 expression, 4:141 CD86 levels, 4:142 chemokine effects on, 4:143–144 definition of, 4:35 dendrites of, 4:141 dermal, 4:140 description of, 4:3 differentiation of, 4:36, 4:142 discovery of, 4:136 ex vivo studies of, 4:146–147 follicular, 4:71, 4:78, 4:140 functions of, 4:144–146 generation of, 4:139 granulocyte-macrophage colony-stimulating factor system for creation of, 4:139 immature, 4:142, 4:144–145 interleukin-12 production and, 4:144 interstitial, 4:36 intestinal, 4:146 isolation protocols for, 4:147–149 Langerhans cells and, 4:140 life span of, 4:141 lymphocytic choriomeningitis virus persistence role, 2:199 lymphoid tissue distribution of, 4:139–140 major histocompatibility complex expression by, 4:138 in marginal zone, 4:78 maturation of, 4:142 migration of, 4:87, 4:143–144 monoclonal antibodies, 4:138 morphological properties of, 4:138, 4:141 mouse strains used to study, 4:136–138 murine cytomegalovirus immune response, 2:27 myeloid, 4:112 natural killer cells and, 4:172 in nonlymphoid tissue, 4:140–141 phenotypic changes, 4:87 physical properties of, 4:138 plasmacytoid description of, 4:37, 4:76–77, 4:142–143 maturation of, 4:143 toll-like receptor signaling in, 4:114 spleen, 4:146–147 subsets of, 4:142–143 surface composition of, 4:138
CUMULATIVE
Dendritic cells (continued) T cells and, 4:88–89, 4:139–140, 4:145 in thymus, 4:139 tolerance mediated by, 4:145–146 turnover of, 4:141 Dendritic epidermal T cells, 4:308 Dentatorubral and pallidoluysian atrophy, 3:681–682 Deoxycytidine, 3:73 Deoxynivalenol, 3:346, 3:348 Deoxyuridine, 4:95 Depolarization, 3:37 Depressor labii inferioris, 3:5 Dermal administration of drugs, 3:447–449 Dermal papilla, 3:694–695 Dermal sheath, 3:694 Dermatitis, 3:371 Dermatophytosis fungal diagnosis, 2:511 epidemiology, 2:510–511 history of study, 2:510 pathology, 2:511 taxonomy, 2:510 treatment and control, 2:511 ringworm in humans clinical signs, 2:731 reservoir and incidence, 2:730 transmission, 2:730 DES. See Diethyl sulfate Developmental degenerations amyotrophic lateral sclerosis, 3:678–679 ataxia-telangiectasia, 3:679–680 cell cycle failure, 3:675 channelopathies, 3:676–677 dentatorubral and pallidoluysian atrophy, 3:681–682 DNA double strand break repair, 3:675 Friedreich’s ataxia, 3:682 homeostasis failures, 3:675–677 Huntington’s disease, 3:680 inherited human, mouse models of, 3:678–685 motor neuron diseases, 3:678–679 nervous mouse, 3:678 Niemann-Pick type C disease, 3:677–678 patterning failure, 3:674 programmed cell death defects, 3:674–675 progressive motor neuronopathy, 3:677 Purkinje cell degeneration, 3:678 retina, 3:679 spinal and bulbar muscular atrophy, 3:681 spinal muscular atrophy, 3:678 spinocerebellar ataxia, 3:680–681 summary of, 3:685 triplet repeat disease models, 3:680–682 wobbler mouse, 3:677 Developmental glaucoma, 3:603 Dexamethasone, 3:131 Diabetes mellitus definition of, 3:183 future research, 3:631–632 maternal effects, 3:631 mouse models of chemically mutagenized, 3:625–626
INDEX
Diabetes mellitus (continued) congenic strain analysis, 3:628–629 diet-induced, 3:630–631 haplotype analysis, 3:627–628 knockout, 3:621–623 multigenic, 3:626–630 natural alleles, 3:626–630 recombinant congenic strain, 3:629–630 recombinant inbred strain, 3:629–630 spontaneous single gene mutations, 3:620–621 transgenic, 3:623–624 N-ethyl-N-nitrosourea studies, 3:625 non-insulin dependent, 3:618, 3:631 obesity and, 3:184–185 phenotype, 3:630 prevalence of, 3:618 diabetes mutation, 3:620 Diacylglycerol, 4:234 Diaphragm, 3:52 Diazepam, 3:461 Diazinon, 3:346 Dibromoacetaldehyde, 3:461 Dichlorvos-containing pellets, 3:399 Dieldrin, 3:346 Diestrus, 3:100–3:101 Diet. See also Feed; Nutrients; Water amino acid requirements, 3:332–333 analytes affected by, 3:180 autoclaving of description of, 3:225, 3:304–305, 3:362, 3:421–422 irradiation of diet vs., 3:366 moist heat, 3:362 nutrients affected by, 3:362–363 physical changes caused by, 3:363 toxicological risks with, 3:363 breeding colony, 3:239–240 calcium:phosphorus ratio, 3:338–339 certified, 3:353 chemically defined, 3:352–353 closed formula, 3:355 contaminants in chlorinated hydrocarbons, 3:346 description of, 3:345 heavy metals, 3:345–347 maximum amounts of, 3:345–346 mycotoxins, 3:347–348 nitrosamines, 3:350–351 organophosphates, 3:346 pesticides, 3:345, 3:347 phytoestrogens, 3:348–350 polycarbon biphenyls, 3:347 saponins, 3:351 decontamination of, 3:361–366 energy requirements correlated with, 3:325 ethylene oxide sterilization of, 3:362 expanded, 3:240 extruded description of, 3:353–354 hardness of, 3:356 manufacturing process of, 3:357 softening of, 3:357 fat content of, 3:335
CUMULATIVE
335
INDEX
Diet (continued) fenbendazole added to, 3:305, 3:353 fiber content of, 3:335 fixed-formula, 3:355 forms of, 3:353–355 gamma-irradiated, 3:305 gelled, 3:240 ground, 3:354 hardness of, 3:355–357 high-quality, 3:373 house mice, 1:28 humidity effects on, 3:361 importance of, 3:323 infectious diseases affected by, 3:369–371 irradiation of autoclaving of diet vs., 3:366 description of, 3:361, 3:363–364 dosages for, 3:364 factors that affect, 3:364 microorganisms affected by, 3:364–365 nutrient effects, 3:365–366 packaging, 3:364 process involved in, 3:364 reviews of, 3:364 laboratory testing of, 3:351 least-cost formula, 3:355 liquid, 3:354–355 meals, 3:353 medicated, 3:353 microbiological spoilage of, 3:360 mineral requirements, 3:336–337 moisture in, 3:360 natural-ingredient blending of, 3:358 description of, 3:239, 3:304–305, 3:351 extrusion of, 3:358–359 manufacturing of, 3:358–359 packaging of, 3:359 pelleting of, 3:358 phytoestrogens in, 3:349 raw materials used in, 3:358 storage of, 3:360, 3:423 nutrient composition of, 3:325 open formula, 3:355 packaging of, 3:359 pasteurization of, 3:361 pelleted autoclaving of, 3:356–357, 3:422 description of, 3:240, 3:353 hardness of, 3:355 illustration of, 3:445 manufacturing process of, 3:357 natural-ingredient diets, 3:358 quality of, 3:356 steam sterilization of, 3:422 summary of, 3:357 pest control issues, 3:361 protein. See Protein, dietary purified for carcinogenicity studies, 3:352 composition of, 3:351–352 description of, 3:337, 3:351–352 manufacturing of, 3:359 vitamin levels in, 3:342 semisolid, 3:445
Diet (continued) shelf life of, 3:305 sterilization of, 3:304–305, 3:361 storage of, 3:360–361 summary of, 3:372–373 temperature effects on, 3:360 ultrafiltered, 3:354 variable-formula, 3:355 Diet restriction body weight affected by, 3:366–367 carcinogenic compound sensitivity affected by, 3:367 dehydroepiandrosterone effects, 3:667 form of, 3:366 immunity effects of, 3:371 protein, 3:368 spontaneous tumors and, 3:366 stem cell aging and, 3:666 survival affected by, 3:366–367 tumor incidence affected by, 3:366–367 undernutrition vs., 3:367–368 vitamin requirements and, 3:368–369 Diethyl sulfate, 1:232 Diethylhydroxylamine, 3:667 Differential white blood cell count, 3:151 Diffusing capacity for carbon monoxide, 3:55 Diffusion capacity of lungs, 3:55, 3:61 Digastricus, 3:5, 3:8 Digestive system description of, 3:63 esophagus, 3:63–64 exocrine pancreas, 3:64 gallbladder, 3:64–65 intestine, 3:65–66 liver, 3:64–65 oral cavity, 3:63 stomach, 3:64 Digestive tract, 3:15 Digital pads, 3:715 Dihydrotestosterone 5a-, 3:93, 3:130 description of, 3:202 1,25-Dihydroxy vitamin D3, 3:129–130 2,3-Diphosphoglycerate, 3:161 Disease definition of, 3:642 senescence vs., 3:642–644, 3:668 Diseases, house mice, 1:43–45 Disinfectants. See also Decontamination; Sterilization alcohol, 3:426 chemical bases for, 3:425 chlorine dioxide, 3:426 cleaning before application of, 3:424 description of, 3:423–424 dilution of, 3:425 formaldehyde gas, 3:426 high-level, 3:424 infection risk and, 3:424 intermediate, 3:424 iodophors, 3:425 low level, 3:424 monitoring of, 3:425 peroxymonosulfate, 3:426
Disinfectants (continued) quats, 3:425 rotation of use, 3:425 selection of, 3:424–425 sodium hypochlorite, 3:426 training in use of, 3:425 vaporized hydrogen peroxide, 3:426 Disinfection definition of, 3:237, 3:424 of room level bioexclusion facilities, 3:244 ultraviolet, 3:307–308 Disulfaton, 3:346 Diuretics, 3:74 Diverticulum glandulae bulbourethralis, 3:18–19 Dixenic animal, 3:218 DLCO. See Diffusing capacity for carbon monoxide DNA double strand break repair, 3:675 DNA microarray drug target elucidation, 1:293–294 gene expression analysis, 1:108 limitations, 1:294 DNA polymerases, 4:164 DNA vaccine, gene transfer, 1:270 DNA-binding fluorochrome test, 3:743 DNA-PKc, 3:675 DNAX adapter protein-12, 4:174 DOCK2, 4:202 Dok-1, 4:203 Domains, mouse proteins, 1:103 Domestication, 3:75 Dominant allele, 1:57 Dopaminergic neurons, 3:574 Doppler echocardiography, 3:45–46 Doppler effect, 3:497 Dorsal pedal venipuncture, 3:456–457 Double negative thymocytes, 4:208 Double stranded ribonucleic acid, 3:195 Double-stranded RNA, 4:112 Drinking water acidification of, 3:308, 3:372, 3:418 additives in, 3:308 anthelmintics added to, 3:309 antibiotics added to, 3:309 automatic systems for, 3:241, 3:285–286 bisphenol A contamination, 3:307 chlorine added to, 3:308–309, 3:372, 3:418–419 contaminants in, 3:241 delivery of, 3:241, 3:286–3:290, 3:307. See also Watering systems drug administration in, 3:444–445 hydrochloric acid added to, 3:308, 3:418 irradiation of, 3:372 mechanical filtration of, 3:372 microorganisms in, 3:371 monitoring of, 3:420 municipal sources of, 3:241, 3:307 ozone treatment of, 3:372 processing of, 3:307–308 quality of, 3:371–372, 3:418 restriction of, 3:371 reverse osmosis of, 3:307, 3:372 steam sterilization of, 3:308
336 sterilization of, 3:225, 3:308 ultraviolet disinfection of, 3:307–308 variations in, 3:306–307 Drosophila, 1:4–5, 4:64–65 Drug administration considerations before, 3:444 in drinking water, 3:444–445 enteral methods of, 3:444–447 external jugular vein, 3:451–452 food supply for, 3:445 footpad injections, 3:453 intrabronchial, 3:449 intracranial, 3:452 intradermal, 3:449 intragastric, 3:445–447 intramuscular injection, 3:445, 3:450 intranasal, 3:449 intranodal, 3:452–453 intraosseous, 3:452 intraperitoneal, 3:445, 3:450–451 intrasplenic, 3:453 intrathecal injection, 3:447 intrathoracic, 3:451 intratracheal, 3:449 intravascular, 3:451–452 intravenous bolus, 3:445 intravenous slow infusion, 3:445 lateral tail vein, 3:451 neonatal, 3:453 oral, 3:445 parenteral methods of, 3:447–452 rectal, 3:446–447 retro-orbital, 3:452 subcutaneous description of, 3:445 injection, 3:449–450 osmotic pumps, 3:450 pellets, 3:450 topical, 3:447–449 vascular cannulation, 3:452 in water, 3:444–445 Drug development costs of, 3:174 regulation of, 3:174–175 Drug discovery classical approach, 1:293 drug targets classification, 1:307 elucidation chemogenomics, 1:294–295 DNA microarray, 1:293–294 phenotype-driven selection, 1:296 validation, 1:295–296 historical perspective, 1:296–297 mouse contributions, 1:296–297 pharmacogenetic traits in mice, 1:304 pharmacogenomic study prospects in mice, 1:314–315 preclinical testing mouse versus rat, 1:297–298 pharmacodynamic studies, 1:299–300 pharmacokinetic studies, 1:300 safety studies carcinogenicity, 1:302–303 genotoxicity, 1:302
CUMULATIVE
Drug discovery (continued) immunotoxicity, 1:304 local tolerance, 1:301–302 overview, 1:300–301 photo-safety, 1:303 reproduction toxicity, 1:302 toxicokinetics, 1:301 quantitative trait loci mapping of drug response genes, 1:305–306 regulatory agencies, 1:298–299 transgenic, knockout, and knockin mouse examples, 1:306–313 Dry heat sterilization, 3:362 Ductile cells, 3:64 Ductus deferens, 3:96 Ductus deferens dexter, 3:19 Ductus deferens sinister, 3:18 Ductus parotideus, 3:5 Duffy, 3:197 Duodenum anatomy of, 3:14, 3:16 catheterization of, 3:478 Duodenum ascendens, 3:15 Duplication-deficiency mapping, 1:130–131 Dynamic lung compliance, 3:56, 3:58, 3:60 Dyslipidemia, 3:539 Dystrophic calcinosis, 3:338 Dystrophin, 1:313
E E3 ubiquitin ligases, 4:237–238 Ear neural degeneration in, 3:679 punching of, 3:265, 3:441–3:442 tagging of, 3:441–3:442 Early transposon-related elements features, 2:276 insertional mutagenesis, 2:272 Eccrine glands, 3:713 Echocardiography anesthesia for, 3:48 B-mode, 3:45 disadvantages of, 3:48 Doppler, 3:45–46 heart evaluations using, 3:46–48 limitations of, 3:48 magnetic resonance imaging vs., 3:44 M-mode, 3:45–46 transthoracic, 3:555–556 two-dimensional, 3:45 ultrasound principles, 3:45 Ecogenetics, 1:292 ECT. See Electroconvulsive threshold testing Ectodysplasin-A, 3:702, 3:711, 3:720 Ectromelia virus, 3:391 EDIM. See Rotavirus EEG. See Electroencephalography Effector B cells, 4:91 Egg cylinder, 1:188, 1:190 Eicosanoids, 3:51 Eimeria cell biology, 2:531 clinical features, 2:531 diagnosis, 2:531
INDEX
Eimeria (continued) life cycle, 2:529, 2:531 prevention, 2:531 research implications, 2:531–532 taxonomy, 2:529 treatment and control, 2:531 Ejaculation, 3:101 EL1, 3:585 EL2, 3:585 EL3, 3:585 EL4, 3:585 EL mouse description of, 3:581 emotional stress in, 3:582 GFAP-positive cells in, 3:584 hippocampus of, 3:584–585 seizures in antiepileptic drugs for, 3:582 aspartate and, 3:584 caloric restriction testing, 3:583 induction of, 3:581–582 inheritance patterns, 3:585 ketogenic diet testing, 3:582–583 pathogenesis of, 3:583–585 PTZ-induced, 3:582 sexual dysfunction in, 3:583 Electrocardiography description of, 3:36–37 in mice, 3:37–38, 3:555 phenotyping uses of, 3:38–39, 3:555 recording platform for, 3:38 Electrochemiluminescent immunoassays, 3:176 Electroconvulsive shock, 3:576–577 Electroconvulsive threshold testing, 1:250 Electroencephalography, 1:250 Electrolytes calcium, 3:207–208 chloride, 3:207 measurement of, 3:207–208 phosphorus, 3:207 potassium, 3:207 sodium, 3:207 Electromyography, 1:250 Electron microscopy cilia-associated respiratory bacillus diagnostics, 2:459 Mycoplasma pulmonis diagnostics, 2:451 ELISA. See Enzyme-linked immunosorbent assay Elizabethan collars, 3:448 Embryo cryopreservation of, 3:114, 3:226 germfree mice, 3:226–227 implantation of, 3:102–103 in utero development of, 3:103 preimplantation development of, 3:102 Embryo transfer breeding colony production, 3:251 description of, 3:113–114, 3:226 Embryoid bodies, 3:159 Embryology comparative human advantages of working with mouse embryos, 1:183–185
CUMULATIVE
337
INDEX
Embryology (continued) early postimplantation period, 1:188, 1:190–192 gland development in later pregnancy, 1:192–197 inner cell mass fate, 1:186, 1:188 pregnancy stage duration, 1:185–186 preimplantation period, 1:186, 1:188 computer-aided methodologies gene expression databases, 1:199–200 overview, 1:197–198 text-based anatomical databases, 1:198–199 three-dimensional reconstructions of sectioned embryos overview, 1:200 Theiler stage 14 embryos, 1:201–203 Theiler stage 20 embryos, 1:203–204 cryopreservation of embryos, 1:218–219, 1:235 developmental stages, 1:168–169 embryo isolation early postimplantation, 1:171, 1:173, 1:175–177 preimplantation, 1:167, 1:169–170 gestational age determination, 1:167 histological analysis, 1:178–179, 1:181, 1:183 magnetic resonance imaging studies, 1:204–205 optical projection tomography studies, 1:205–206 rederivation, 1:220–221 Embryonal carcinoma cell growth factor requirements, 1:283 sources and culture, 1:282 Embryonic germ cell growth factor requirements, 1:283 sources and culture, 1:282 Embryonic stem cells chemical mutagenesis applications, 1:253 genotyping denaturing high-performance liquid chromatography, 1:256–257 single-strand conformational polymorphism, 1:256 temperature gradient capillary electrophoresis, 1:257 libraries of clones, 1:285 mutagens ethylmethanesulfonate, 1:255 ethylnitrosourea, 1:255 ICR191, 1:255–256 trimethylpsoralen, 1:256 phenotyping, 1:256 principles, 1:253–255 description of, 3:159 differentiation induction, 1:284 gene expression, 1:282–283 gene function studies, 1:285–286 gene-specific mutagenesis conditional mutagenesis, 1:264–265 gene targeting, 1:262–263 gene trapping, 1:263–264
Embryonic stem cells (continued) inducible mutagenesis, 1:265 RNA interference, 1:265–266 targeted trapping, 1:264 transgenic mouse, 1:262 growth factor requirements, 1:283 insertional mutagenesis, 1:285 karyotype, 1:283–284 sources and culture, 1:282 transplantation studies, 1:286 EMCV. See Encephalomyocarditis virus EMG. See Electromyography EMS. See Ethylmethanesulfonate Encephalitozoon cuniculi cell biology, 2:541 clinical features, 2:541–542 description of, 3:392 diagnosis, 2:542 life cycle, 2:541 prevention, 2:542–543 research implications, 2:543 taxonomy, 2:540–541 treatment and control, 2:542–543 Encephalomyocarditis virus antigenic properties, 2:315 biophysical properties, 2:312 clinical features, 2:315–316 control and prevention, 2:320 diagnosis, 2:319–320 epizootiology, 2:318–319 genome, 2:312–313 history of study, 2:311–312 propagation, 2:315 receptors, 2:314–315 structure, 2:313–314 Endo 180 receptor, 4:13 Endocrine hormones, 3:124 Endocrine system, 3:93–94 Endocrine theory of aging, 3:664–665 Endocrinology, 3:124 Endocytic pathway, 4:18 Endocytosis, 4:19 Endogenous antigen models, 4:209–213 α-Endosulfan, 3:346 ß-Endosulfan, 3:346 Endothelial nitric oxide synthase, 3:551 Endotoxin, 3:742 Endrin, 3:346 Energy gross, 3:324 measurement of, 3:324 metabolizable, 3:324, 3:330 peak intake of, 3:330 Energy density, 3:324 Energy requirements body composition effects on, 3:325 environmental temperature effects on, 3:325 estimates of, 3:324–330 factors that affect, 3:324–327 during gestation, 3:327, 3:329 for growth, 3:328–329 during lactation, 3:327, 3:329 maintenance-related, 3:325–328 nutrient composition of diet and, 3:325
Energy requirements (continued) of pups, 3:330 sex effects on, 3:325 strain effects on, 3:325 Engrailed-1, 3:717 Engrailed-2, 3:675 Enhanced green fluorescent protein, 4:140 Enrofloxacin Citrobacter rodentium management, 2:377 Corynebacterium bovis management, 2:401 Entamoeba muris cell biology, 2:527 clinical features, 2:527–528 diagnosis, 2:528 life cycle, 2:527 morphology, 2:527 prevention, 2:528 research implications, 2:528 taxonomy, 2:527 treatment and control, 2:528 Enteral administration, of drugs drinking water, 3:444–445 food supply, 3:445 intragastric, 3:445–447 intrathecal injection, 3:447 oral, 3:445 rectal, 3:446–447 water, 3:444–445 Enteric nervous pathway, 3:65 Enterobacteriaceae. See also specific organisms culture media, 2:373 genera, 2:366–367 growth characteristics, 2:367 virulence factors and pathogenicity islands, 2:367–369 Enterococci, 3:227 Enterohepatic circulation, 3:206 Environment puberty affected by, 3:94 reproduction affected by enrichment, 3:108 feed, 3:107–108 housing, 3:109 human interaction, 3:109 humidity, 3:107 light, 3:106, 3:238, 3:291 sound, 3:106 temperature, 3:106–107, 3:239 time of year, 3:108–109 vibration, 3:106 of research facilities air quality in, 3:295 ammonia, 3:293 carbon dioxide concentrations, 3:293 enrichment of, 3:314 lighting, 3:291–292 macroenvironment, 3:288–293 microenvironment, 3:292–294 monitoring of, 3:292–293 noise, 3:292 overview of, 3:287–288 relative humidity, 3:291 temperature, 3:290–292
338 Environmental Protection Agency, 3:371 Enzyme(s) alanine aminotransferase, 3:181, 3:198 aldolase, 3:200 alkaline phosphatase, 3:198 amylase, 3:200 aspartate aminotransferase, 3:181, 3:198–199 creatine kinase, 3:199–200 glutamate dehydrogenase, 3:200 lactate dehydrogenase, 3:181, 3:199 ornithine transcarbamoylase, 3:199 sorbitol dehydrogenase, 3:200 Enzyme-linked immunosorbent assay cardiovirus applications, 2:319 cilia-associated respiratory bacillus applications, 2:458 Clostridium piliforme applications, 2:354 Corynebacterium kutscheri applications, 2:404 description of, 3:396 Helicobacter applications, 2:427–428 kits for complement quantification using, 3:191 description of, 3:177–178, 3:188 lactate dehydrogenase-elevating virus applications, 2:227–228 lymphocytic choriomeningitis virus applications, 2:203–204, 2:722 mammalian reovirus applications, 2:257 minute virus of mice applications, 2:100 mouse adenovirus applications, 2:61 mouse cytomegalovirus applications, 2:32 mouse parvovirus applications, 2:100 mouse thymic virus applications, 2:34 mousepox virus applications, 2:87, 2:160–161 Mycoplasma pulmonis applications, 2:450 Pasteurellaceae applications, 2:495–496 pneumonia virus of mice applications, 2:304 rotavirus applications, 2:245 Sendai virus applications, 2:297–298 Eosinopenia, 3:414 Eosinophil(s) in airway hyperresponsiveness, 4:297 characteristics of, 3:150 description of, 4:33–34 inflammatory role of, 4:34 morphology of, 3:150 transcription factors that affect, 3:149 Eosinophilia, 4:294 Eotaxin, 3:196 Eotaxin-1, 4:296 Eotaxin-2, 4:296 Eperythrozoon coccoides, 3:145 Epfpq2, 3:624 Epfq1, 3:624 Epfq2, 3:624
CUMULATIVE
Epicardium, 3:27 Epidermal growth factor receptor, 3:597, 4:238 Epidermal growth factor signaling, 3:702 Epidermal T cells, 4:308 Epididymis anatomy of, 3:95–96 description of, 3:18 sections of, 3:96 sperm maturation in, 3:95 Epigenetics genome analysis, 1:108 overview of mouse studies, 1:10 Epiglottis, 3:50 Epilepsy anticonvulsants for, 3:566, 3:571 antiepileptic drugs, 3:566, 3:571 incidence of, 3:566 ketogenic diet for, 3:582–583 Mendelian forms of, 3:567 mouse models of cystatin B, 3:569–571 description of, 3:567 EL mouse. See EL mouse Frings mice, 3:571 GABAA ß3 subunit, 3:568–569 gene screening, 3:586 jerky mice, 3:571 Lafora disease, 3:570–571 progressive myoclonus epilepsies, 3:569–571 summary of, 3:585–586 SWXL-4 mice, 3:585 ubiquitin protein ligase E6-AP, 3:568–569 voltage-gated calcium channels, 3:572–573 voltage-gated K+ channel KCNA 1, 3:568 voltage-gated Na+ channel SCN2A, 3:567–568 multifactorial, 3:576–586 orphan mouse mutants description of, 3:573 Nhe1, 3:575–576 p35, 3:576 serotonin receptor, 3:575 stargazer, 3:573–574 weaver, 3:574–575 progressive myoclonus, 3:569–571 sexual dysfunction and, 3:583 slow wave, 3:575 sudden unexpected death in, 3:579 symptomatic, 3:576–578 Epilepsy prone mice, 3:580–581 Epilepsy-associated repeat, 3:571 Epileptic seizures characteristics of, 3:566 classification of, 3:566 EL mouse model. See EL mouse electroconvulsive shock-induced, 3:576–577 generalized, 3:566 kainic acid-induced, 3:577–578
INDEX
Epileptic seizures (continued) partial, 3:566 PTZ-induced, 3:577, 3:582 Epinephrine insulin release suppressed by, 3:183 reference ranges for, 3:181 Episodic ataxia type 1, 3:568 Epithelial cells, 3:51, 4:6 EPM2A, 3:570 Epstein-Barr virus, 4:283 Equipment alkali residues, 3:417 autoclave. See Autoclave; Autoclaving cage. See Cage laminar flow, 3:421 management of, 3:410–411 watering systems. See Watering systems Erbb2, transgenic mice, 2:598–602 Ergocalciferol, 3:339 ERK/JNK/p38, 4:216 ERV. See Expiratory reserve volume Erythrocyte(s) in aging mice, 3:161 blood smear evaluations, 3:145 decreased production of, 3:148 development of, 3:142 2,3-diphosphoglycerate concentrations at birth, 3:161 functions of, 3:142 hemagglutination of, 3:746 hematocrit, 3:144 histology of, 3:143 increased production of, 3:142–143, 3:148 life span of, 3:142, 3:147–148 morphology of, 3:143, 3:161 parameters for, 3:143–146 parasites that affect, 3:145 red blood cell count changes in, 3:146–148 description of, 3:141, 3:143–144 in young mice, 3:161 red blood cell indices, 3:144 red cell distribution width description of, 3:141, 3:143 hemorrhage effects on, 3:147 red cell mass absolute, 3:147 absolute decreased, 3:147 decreases in, 3:147–148 increases in, 3:146–147 relative decreased, 3:147 senescence of, 3:640 volume of description of, 3:143 splenectomy effects on, 3:162–163 Erythrocyte mass absolute, 3:147 absolute decreased, 3:147 decreases in, 3:147–148 increases in, 3:146–147 relative decreased, 3:147 Erythroid cells anucleate, 3:159 enucleation of, 3:159
CUMULATIVE
339
INDEX
Erythroid cells (continued) erythropoietin’s role, 3:142 from hemangioblasts, 3:158–159 in primitive hematopoiesis, 3:158–159 Erythropoiesis accelerated, 3:161, 3:163 androgen stimulation of, 3:161 primitive erythropoietin’s function during, 3:159 macrophages in, 3:159 megakaryocytes in, 3:159 signaling molecules in, 3:159–160 in spleen, 3:163 stress, 3:142 Erythropoietin in definitive erythropoiesis, 3:160 in erythrocyte development, 3:142 functions of, 3:142 in primitive erythropoiesis, 3:159 Erythropoietin receptors, 3:142, 3:159, 4:182 ES cell. See Embryonic stem cell Escherichia coli clinical features, 2:377 description of, 3:346 diagnosis, 2:377 properties, 2:377 Esophagus, 3:10–11, 3:16, 3:63–64 Esr1, 3:130 Essential fatty acids, 3:334 Estradiol, 3:202 Estrogen atheroprotective effects of, 3:551 definition of, 3:130 preovulatory increase in, 3:103 Estrogen receptors, 1:307–308, 3:130, 3:551 Estrogen replacement therapy, 3:551–552 Estrus cycle length of, 3:239, 3:262 onset of, 3:94 ovulation during, 3:99 phases of, 3:100 postpartum, 3:239 stages of, 3:100–101 ESTs. See Expressed sequence tags Ethion, 3:346 Ethosuximide, 3:573, 3:577 Ethylene diaamine tetraacetate, 3:138–139 Ethylene oxide sterilization, 3:362, 3:422 Ethylmethanesulfonate chemical mutagenesis, 1:231 embryonic stem cell mutagenesis, 1:255 Ethylnitrosourea advantages, 1:233 clinical relevance, 1:233 description of, 1:230 effectiveness measures, 1:235 gene mapping, 1:241 historical perspective, 1:232–233 principles, 1:109 resources, 1:110 Eumorphia, 3:531 Eustachian tube, 3:49
Euthanasia carbon dioxide asphyxiation, 3:481 cervical dislocation, 3:481 decapitation, 3:481–482 of fetuses, 3:482 after gavage, 3:446 of neonates, 3:482 Office of Laboratory Animal Welfare guidelines, 3:480–481 Excitement, leukocytes affected by, 3:152–153 Exclusion level, 3:311 Excretory ducts, 3:95–96 Exercise heart rate during, 3:40 stress test cardiovascular system responses to, 3:41 description of, 3:40–42 heart rate responses to, 3:40 swimming, 3:41 treadmill, 3:41–42 Ex-germfree animal, 3:218 Exocrine pancreas, 3:64 Exogen phase, of hair growth, 3:706, 3:708 Expansion colony definition of, 3:236 purpose of, 3:253–254 Expansion colony segment, 3:236 Experimental autoimmune encephalomyelitis, 4:308–309 Experimental design, 3:644–645 Expiration, 3:52 Expiratory reserve volume, 3:53–54 Expressed sequence tags, nomenclature, 1:90 Expressivity linkage mapping, 1:124–125 phenotype, 1:72 Extensor carpi radialis, 3:6 Extensor carpi radialis longus, 3:5 Extensor carpi ulnaris, 3:5 Extensor digitorum communis, 3:5 Extensor digitorum lateralis, 3:5–6 Extensor digitorum longus, 3:6 External jugular vein injection, 3:451–452 Extravascular hemolysis, 3:148 Extruded diet description of, 3:353–354 hardness of, 3:356 manufacturing process of, 3:357 softening of, 3:357 Eya, 4:65 Eye(s) anatomy of, 3:601–602 angiogenesis of, 3:599–601 aqueous outflow system in, 3:602 development of, 3:596 drainage structures for, 3:601–602 examination techniques for, 3:596 illness signs, 3:388 mutant phenotyping, 1:244–245 retina, 3:596
Eye research advances in, 3:596 glaucoma. See Glaucoma phenotypic variations, 3:597–598 relevance of mice in, 3:596–597 retinal degeneration. See Retinal degeneration
F 18F,
3:503, 3:505 F1 hybrids advantages of, 3:646–647 aging research using, 3:646–648 definition of, 2:628, 3:646 description of, 3:258 disadvantages of, 3:647 life span of, 3:646 Fab fragment, 4:21 Face masks, 3:313 Facialis nerve, 3:7 Facies diaphragmatica, 3:16 Facies parietalis, 3:16 Facies visceralis, 3:16 Familial Alzheimer’s disease, 3:683 Familial hypertrophic cardiomyopathy, 3:39 Farnoquinone, 3:340 Fas ligand, 3:194 Fas-associated death domain, 4:217 Fascia cruris, 3:6 Fascia lata, 3:6 Fascia thoracolumbalis, 3:4 Fat(s) body, 3:630–631 dietary description of, 3:334–335 free radical oxidation of, 3:365 infectious diseases and, 3:370 in purified diets, 3:359 Fat insulin receptor knock out mice, 3:665 Fat pad, 3:97 Fat-soluble vitamins, 3:339–340, 3:345, 3:365 Fatty acids, 3:334–335 Fc receptors FCαRI, 4:8 FCγRI, 4:7 FCεRI, 4:7–8, 4:295 FCγRIIB autoimmunity and, 4:264–266 B cell tolerance, 4:265–266 description of, 4:6–7, 4:142, 4:254 genetic linkage studies, 4:264–265 mice deficient in, 4:265 polymorphisms, 4:265 signaling of, 4:263 FCγRIII, 4:7 FCγRIV, 4:7 homologs, 4:262 IgG, 4:263–264 Langerhans cell expression of, 4:140 neonatal, 4:6 overview of, 4:5
340 Fc receptors (continued) poly-Ig receptor, 4:5–6 transmembrane ligand-binding protein, 4:5 Fcgr2, 4:264–265 FDA. See Food and Drug Administration Feces collection of, 3:458 microscopic examination of, 3:230 Federal Food, Drug, and Cosmetic Act, 3:428 Federal Insecticide, Fungicide, and Rodenticide Act, 3:428 Feed. See also Diet autoclaving description of, 3:304–305 hardness increased by, 3:356–357 packaging of, 3:359 autoclaving of description of, 3:225, 3:304–305, 3:362, 3:421–422 irradiation of diet vs., 3:366 moist heat, 3:362 nutrients affected by, 3:362–363 physical changes caused by, 3:363 toxicological risks with, 3:363 contamination of, 3:422 dichlorvos-containing pellets, 3:399 drug administration in, 3:445 estimating requirements for, 3:330–331 fenbendazole, 3:305, 3:353, 3:399, 3:403 gamma-irradiated, 3:305 insect contamination of, 3:422 packaging of, 3:359 pelleted autoclaving of, 3:356–357, 3:422 description of, 3:240, 3:353 hardness of, 3:355 illustration of, 3:445 manufacturing process of, 3:357 natural-ingredient diets, 3:358 quality of, 3:356 steam sterilization of, 3:422 summary of, 3:357 pigmented, 3:305 purified, 3:304 quality of, 3:422 reproduction affected by, 3:107–108 in research facilities, 3:304–305 shipping of, 3:422 specialty, 3:305 sterilization of description of, 3:225 ethylene oxide, 3:422 using autoclave. See Feed, autoclaving of storage of, 3:360–361, 3:422 Female(s) artificial insemination of, 3:227 breeding age for, 3:239 donor, for germfree mice production, 3:226–227 energy requirements for, 3:325 retirement of, 3:261 stress responses, 3:109 Female genital organs, 3:20–21
CUMULATIVE
Female germ cells, 3:93 Female reproductive tract anatomy of, 3:97–99 cervix, 3:98–99 description of, 3:97 evaluation of, 3:110 ovary, 3:97 oviduct, 3:97–98 uterus, 3:98 vagina, 3:99 Femoral artery catheterization, 3:476–477 Femoral vein catheterization, 3:476–477 Femur, 3:4 Fenbendazole, for pinworm management description of, 2:558–559 in feed, 3:305, 3:353, 3:399, 3:403 in water, 3:419 Fenitrothion, 3:346 Fentanyl citrate-fluanisone, 3:461–462 Fentanyl-fluanisone-midazolam, 3:31 Ferric chloride, 3:337 Ferric sulphate, 3:337 Fertility assessment of, 3:110 of males, 3:104, 3:111–112 Fertilization description of, 3:102 temperature effects on, 3:107 Fetal bovine serum, 3:735 Fetal hemoglobin, 3:160 Fetal-maternal interface, 4:284 Fetus euthanasia of, 3:482 resuscitation of, 3:467–468 Fever, 3:69 FGF. See Fibroblast growth factor Fiber, 3:335 Fibrinogen, 3:206, 3:208 Fibrinogen concentration, 3:141, 3:157–158 Fibroblast growth factors -2, 3:599, 3:720 -5, 3:708 -7, 3:703, 4:66 -10, 4:66 pluripotent cell culture, 1:283 Fibula, 3:4 Filter top cage, 3:242, 3:246, 3:293 Filth flies, 3:430–431 Fipronil, 2:568 Fire response, 1:42 Firefly luciferase, 3:506 First messengers, 3:124 FISH. See Fluorescent in situ hybridization Fissura interlobaris, 3:13 Fixatives, 3:483 Fixed-formula diet, 3:355 Flea human interaction, 2:735 rodent species, 2:735 Flexible film isolators, 3:219–220, 3:245 Flexor carpi radialis, 3:6 Flexor carpi ulnaris, 3:6 Flexor digiti longus, 3:6–7 Flexor digitorum longus et tibia, 3:7 Flexor digitorum profundus, 3:6
INDEX
FLICE, 4:95 Flies, 3:429–431 Flk-1, 3:158 Flow cytometer, 3:178 Fluid-filled catheters, indwelling, 3:33–34 Fluorescence imaging, 3:506–508 Fluorescence resonance energy transfer, 3:507 Fluorescent in situ hybridization chromosome banding, 1:153 chromosome structures, 1:153 cytogenetics, 1:150–152 gene mapping, 1:129–130 high resolution technique, 1:152 meiotic chromosomes, 1:158–159 painting of chromosomes, 1:153 primed in situ technology, 1:152 Fluoride, 3:336, 3:345 Fluoroimmunoassay, 3:176 Flying insects, 3:429 Foam cells, 3:51, 3:546 Folacin, 3:341 Folate, 3:342 Folic acid, 3:341 Follicle hair. See Hair follicles ovarian development of, 3:99–100 follicle stimulating hormone effects on, 3:201–202 function of, 3:99–100 Graafian, 3:99 number of, 3:99 primordial stage of, 3:99 secondary, 3:99 Follicle stimulating hormone description of, 3:94, 3:201–202 plasma levels of, 3:202 reference ranges for, 3:181 secretory pattern for, 3:202 spermatogenesis initiation by, 3:97 Follicle-associated epithelium, 4:69 Follicular dendritic cells B cell recruitment affected by, 4:93 description of, 4:71, 4:78, 4:140 Food. See Feed; Nutrients Food and Drug Administration, drug development role, 1:298 Food deprivation, 3:76. See also Diet restriction Food intake insulin effects on, 3:618 neuropeptides that affect, 3:619 phenotyping, 1:251 Footpad injections, 3:453 Forced oscillation technique, 3:59 Forceps restraint, 3:439, 3:443 Forelimb muscles of, 3:5–6 regions of, 3:2 Forkhead box N1 description of, 4:277 signaling, 3:702, 3:714 Formaldehyde gas, 3:224, 3:426 Forward migration, 3:256–257
CUMULATIVE
341
INDEX
Fostering of pups, 3:112 Fosterlings, 3:112 Foundation colony definition of, 3:236 development of, 3:252 founder animals, 3:251–252 isolator housing of, 3:245 of inbred stock, 3:253 of outbred stock, 3:255–256, 3:267 pedigree card for, 3:263 Foundry robots, 3:285–286 4-way cross stocks, 3:647, 3:649 Foxc1, 3:603–604 Foxc1w/Foxc1w, 3:704 Foxl1, 4:74 Foxn1nu, 4:277 Foxn1nu/Foxn1nu, 3:704 Foxn1w/Foxn1w, 3:710 Foxp3, 4:42 Foxp3+CD4+CD25+ Treg cells, 4:43 Friedreich’s ataxia, 3:682 Friend of GATA-1, 3:155 Frings mice, 3:571 Frizzled 6, 3:701 Fructose, 3:66 fsh, 4:123 FTY720, 4:202 Fumonisin B1, 3:348 Functional assays, 3:190 Functional magnetic resonance imaging, 3:502 Functional residual capacity, 3:44, 3:54, 3:57 Fungal infection. See also Dermatophytosis; Pneumocystis spp. animal models, 2:513–514 systemic and opportunistic infection diagnosis, 2:513 epidemiology, 2:511–512 history of study, 2:511 pathology, 2:512–513 taxonomy, 2:511 treatment and control, 2:513 Fungi, 3:742–743 Fur dying, 3:440 Fur mites. See also Demodex musculi; Myobia musculi; Myocoptes musculinus; Ornithonyssus bacoti; Psorergates simplex; Radfordia; Trichoecius romboutsi description of, 3:105 diagnostic testing for, 3:391, 3:394, 3:398 nits, 3:398 Fusarium roseum, 3:349 Fusion, 1:222 FVB mice, 3:260 FVB/N mice description of, 3:185 development, 2:653 phenotype, 2:653 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690
FVB/N mice (continued) nonneoplastic conditions, 2:672–681 neoplasia, 2:653 nonneoplastic conditions, 2:653 pathogen susceptibility, 2:654
G 67Ga,
3:503 GABAA ß3 subunit, 3:568–569 Gabrb3, 1:308 GABRB3, 3:569 Gadd45α, 4:253–254 Gadolinium-enhanced magnetic resonance imaging, 3:502 Gallbladder, 3:64–65 Gametogenesis, 1:226–227 Gamma camera, 3:502 Gamma-irradiated diets, 3:305 Ganglia cardiaca, 3:10 Ganglion cervicothoracicum sinistrum, 3:11 Ganglion stellatum dextrum et sinistrum, 3:10 Ganglion venae cavae cranialis sinistrae, 3:10 garbrb3, 3:569 Gas dilution tests, 3:54–55 Gas exchange, 3:50 Gaster, 3:14–15 Gastric cancer, 2:425–426 Gastric catheterization, 3:477–478 Gastritis, 2:424–425 Gastrointestinal stem cells, 3:66 Gastrointestinal tract bacteria in, 3:227, 3:229 drug administration into, 3:445–447 illness signs, 3:388 immune functions of, 3:66 necropsy evaluations, 3:482–483 Gastrulation, 1:171 GATA-1 description of, 4:34 megakaryocytes deficient in, 3:154–155 in splenic hematopoiesis, 3:163 GATA-3, 1:286 GATA-4, 3:159 Gaussian distribution, 3:182 Gavage, 3:445–447 G-banding, 1:148–149, 1:156 GBASE. See Genetic Database of the Mouse Gelled diet, 3:240 Gelled water, 3:419 Gene(s) annotation approaches, 1:101–102 databases, 1:102 families, 1:103 human gene comparison with mouse set, 1:102–103 mapping of. See Deletion mapping; Duplication-deficiency mapping; Fluorescent in situ hybridization; Linkage mapping; Mitotic mapping; Quantitative trait loci; Radiation hybrid mapping; Somatic cell hybrids
Gene(s) (continued) naming, 1:89, 1:290 orthology, 1:105 symbols, 1:89 Gene mutations, 3:25 Gene overexpression, 4:280 Gene targeting, 1:262–263, 3:537, 3:567, 4:238 Gene transfer chromosomal versus extrachromosomal insertion, 1:268–269 disease model development, 1:274–275 ex vivo, 1:268 expression regulation studies, 1:275 gene therapy overview, 1:268–269 preclinical studies, 1:275 in vivo, 1:268 vaccine development, 1:275–276 vectors conditional replication vectors, 1:269 development, 1:275 nonviral vectors, 1:268–270 replication deficient vectors, 1:269 viral vectors, 1:268, 1:270–274 Gene trapping applications, 1:264 description of, 3:621 loci nomenclature, 1:92 principles, 1:263–264 screening, 1:264 targeted trapping, 1:264 GeneNetwork/WebQTL, 3:530 General anesthesia, 3:179 Generalized seizures, 3:566, 3:574 Genetic Database of the Mouse, historical perspective, 1:7 Genetic linkage mapping, 1:5 Genetic mapping, 3:648–650 Genetic monitoring biochemical assays, 1:138–139 DNA tests, 1:140–143 genetic quality control program components, 1:137 monitoring program development, 1:137–138 mouse room procedures, 1:137 immunoassays, 1:139–140 origins of genetic differences, 1:136 overview, 1:135–136 Genetic structure aging research results affected by, 3:645 F1 hybrids, 3:646–647 4-way cross stocks, 3:647, 3:649 guidelines for selection of, 3:648–650 heterogeneous lines, 3:648 inbred strains, 3:645–646, 3:648 outbred stock, 3:648 Genetically engineered mice. See also specific strain description of, 3:648 tumor pathology studies in comparative human pathology accuracy, 2:582, 2:584, 2:612 digital imaging, 2:614
342 Genetically engineered mice (continued) morphometrics, 2:615 prospects, 2:616–617 reporting of results, 2:613–614 spontaneous tumor surveillance, 2:615–616 validation, 2:612–613 experimental design, 2:587, 2:592, 2:594 gene targets, 2:591 historical perspective, 2:584 Internet resources, 2:591–592 nomenclature conventions, 2:594–595 oncogenic event considerations molecular alterations and microscopic structure, 2:601–603 spontaneous and carcinogen-induced tumors, 2:595–596 uniqueness of genetically engineered mouse tumors, 2:596–601 progression metastasis versus microinvasion, 2:611–612 sequential microscopic changes, 2:605–606, 2:608–611 promoters for tissue-specific expression, 2:592, 2:601–602 signature phenotypes, 2:586 tissue context effects microscopic structure, 2:604–605 strain effects, 2:604–605 tumor biology, 2:603–604 weak oncogenes, 2:603 Genistein, 3:349 Genital hair follicles, 3:697 Genital organs. See also Reproductive tract female, 3:20–21 male, 3:18–19 Genital ridge description of, 3:93 primordial germ cells, 3:93 Genital system development and differentiation of, 3:92–93 gonads, 3:92–93 Genome sequencing approach, 1:100–101 historical perspective, 1:8 organization of gene expression, 1:108 reagents, 1:107 Genome size, 1:105 Genomic segmental polymorphism, 4:120 Geobacillus stearothermophilus, 3:225, 3:421 Geographic distribution of house mice, 1:16–18, 1:26–28 Germ cells, 3:92–93 Germfree mice. See also Breeding colony; Gnotobiotics altered Schaedler’s flora introduced to, 3:228–229 aseptic hysterotomy derivation of, 3:226 bacterial “cocktails” given to, 3:227–228 cecal volume in, 3:219, 3:227, 3:482 colonization resistance, 3:228
CUMULATIVE
Germfree mice (continued) defined flora associated with, 3:227–229, 3:247 definition of, 3:218 derivation of, 3:226–227 donor females, 3:226–227 feces examination, 3:230 genetically altered, 3:220 historical highlights of, 3:219 immune system in, 3:219 long-term maintenance of, 3:219 mating of, 3:226 opportunistic organisms and, 3:228 pups, 3:251–252 rearing of, 3:219 Germinal centers architecture of, 4:93 B cells differentiation of, 4:94 selection of, 4:95–96 IgE, 4:295 involution of, 4:96 kinetics of, 4:93 stromal support for, 4:93–94 Gerontological research advances in, 3:639 mechanism studies, 3:661–666 mouse models for, 3:639 overview of, 3:639 terminology associated with, 3:639–644 Gestation. See also Pregnancy description of, 3:103 energy requirements during, 3:327, 3:329 Gestational age, 1:167 Ghrelin description of, 3:128 food intake affected by, 3:184–185 Ghrl, 3:128 Giardia muris cell biology, 2:520–521 clinical features, 2:521 diagnosis, 2:521 life cycle, 2:520 morphology, 2:520 prevention, 2:521 research implications, 2:521, 2:523 taxonomy, 2:520 treatment and control, 2:521 Giemsa staining, chromosomes, 1:148 GIRK1, 3:574 GIRK2, 3:574 Girk2, 3:676 Girk2Lc, 3:677 Girk2wv, 3:676 Glandula adrenalis dextra, 3:17 Glandula adrenalis sinister, 3:17 Glandula ampullaris, 3:19 Glandula bulbourethralis, 3:18–19 Glandula clitoridis, 3:20–21 Glandula coagulationis, 3:19 Glandula lacrimalis extraorbitalis, 3:4 Glandula preputialis, 3:18–19 Glandula sublingualis, 3:8 Glandula vesiculosa, 3:18–19
INDEX
Glandular lacrimalis extraorbitalis et eius ductus, 3:5 Glandular mandibularis, 3:5, 3:8 Glandular parotidea, 3:5, 3:8 Glaucoma anatomy of, 3:601–602 characteristics of, 3:601 developmental, 3:603 genetic factors, 3:603–604 histologic findings, 3:604 in humans, 3:601 intraocular pressure, 3:601 myocillin and, 3:604–605 physiology of, 3:601–602 pigmentary forms of, 3:605–606 primary open angle, 3:604–605 stochastic factors, 3:603–604 Glomerular filtration rate, 3:73 Glomerulonephritis, 3:334 Glossopharyngeus nerve, 3:7 Gloves isolator, 3:221 latex, 3:313 nitrile, 3:314 personal protective equipment uses of, 3:313–314 Glucagon receptor, 1:309 Glucocorticoid-inducible tumor necrosis factor receptor, 4:277 Glucocorticoids adipose differentiation and, 3:618 description of, 3:130–131 erythroblast expansion affected by, 3:142 Gluconeogenesis, 3:182 Glucose determinations of, 3:183 function of, 3:182 insulin effects on, 3:182–183, 3:618 nonfasting level of, 3:655 plasma levels of, 3:183 reference range for, 3:181 Glucose tolerance tests, 3:183–184 Glue boards, 3:429–430 GLUT-1, 3:183 GLUT-7, 3:183 Glutamate, 3:584 Glutamate dehydrogenase, 3:200 Glutamic oxaloacetate transaminase, 3:198 Glutamic pyruvic transaminase, 3:198 Glutathione S-transferase, 1:312 Gluteus medius, 3:6 Gluteus superficialis, 3:4, 3:6 Glycerol-phosphate, 3:187 Glycogen synthase kinase 3ß, 4:67 Glycogenolysis, 3:182 Glycolipids, 4:141 Glycosylphosphatidylinositol, 4:3, 4:110 Gnotobiote, 3:218 Gnotobiotic animal, 3:218 Gnotobiotics. See also Germfree mice application of, 3:220 Association for Gnotobiotics, 3:232 autoclaves, 3:225 definition of, 3:218 historical highlights of, 3:218–220
CUMULATIVE
343
INDEX
Gnotobiotics (continued) isolators. See Isolators programs in, 3:219 Goblet cells, 3:66 Gonad development, 3:92–93 Gonadal sex, 3:92 Gonadotrophin-releasing hormone description of, 3:94 luteinizing hormone secretion affected by, 3:201 Good manufacturing practices, 3:735, 3:751 Gpnmb, 3:605 G-protein-coupled receptor kinases, 1:310 Graafian follicle description of, 3:99 granulosa cells of, 3:202 Gracilis, 3:7 Graft-versus-host disease, 4:283 Granulocyte macrophage colony stimulating factor, 3:148 Granulocyte-colony stimulating factor description of, 3:148 splenic erythropoiesis affected by, 3:163 Granulopoiesis, 3:163 Granulosa cells, 3:99 Grb2/RasGRP, 4:216 Green fluorescent protein, 3:506, 3:624 Grey lung agent, 2:454 Grid2, 3:676 Griseofulvin, 2:511 GRKs. See G-protein-coupled receptor kinases GRO, 3:192 Gross energy, 3:324 Ground diet, 3:354 Growth energy requirements for, 3:328–329 protein requirements for, 3:332 Growth factors atherosclerosis affected by, 3:545 leukocytes affected by, 3:153 neuronal, 3:677 receptors for, 3:677 Growth hormone description of, 3:127 reference ranges for, 3:181 transgenic mouse phenotype, 1:309 Growth hormone secretogogue receptor, 3:128 Growth rate, of house mice, 1:31–32 GST. See Glutathione S-transferase GTPase activating protein, 4:200 Guanine nucleotide exchange factor, 4:199, 4:216 Guard hairs, 3:695 Guidelines for Environmental Infection Control in Health Care Facilities, 3:423, 3:427 Gulo, 3:550 Gut description of, 3:65–66 embryogenesis of, 1:177 Gut-associated lymphoid tissue, 3:369
H H antigen, 2:367–369 Habitat selection, house mice, 1:37–38 Haemophilus influenzaemurium. See Pasteurellaceae Hair regrowth of, as aging biomarker, 3:655 shedding of, 3:708 Hair bonnets, 3:313 Hair cone, 3:698 Hair follicles anagen phase of, 3:706–708 catagen phase of, 3:706–708 cilia, 3:696–697 cuticle layers of, 3:695 cycling wave of, 3:710 development of bone morphogenetic proteins, 3:701–702 differentiation phase, 3:701 epithelial invagination, 3:699, 3:701 epithelial-mesenchymal interactions, 3:699 follicular formation, 3:701 inductive phase, 3:698–699 morphogenetic phase, 3:699–701 patterning, 3:701 exogen phase of, 3:706, 3:708 genital, 3:697 growth patterns of, 3:705–707 molecular signaling of, 3:701–705, 3:708–709 morphology of description of, 3:694–697 stages, 3:697–698 mystacial, 3:694, 3:705 in nude mice, 3:702–703 patterning of, 3:701 pelage, 3:694–696 perianal, 3:697, 3:711 pluripotent neural crest stem cells, 3:710 research of, 3:693 stem cells, 3:693, 3:709–710 steroid hormone effects on, 3:709 tail, 3:697 telogen phase of, 3:706, 3:708–709 tissue types, 3:694 vibrissae, 3:694, 3:696, 3:705 Hair germ, 3:698 Hair peg, 3:698 Hairless mice. See also Nude mice bedding considerations for, 3:241, 3:306 production index for, 3:260 Halogens, 3:309 Handling, 3:439–440, 3:529 Hantavirus, 3:391, 3:747 Haploid spermatids, 3:96–97 Haplotype analysis, 3:627–628 Hardwood bedding, 3:306 Harem breeding system description of, 3:252, 3:254, 3:258 males in, 3:261 Hassall’s corpuscles, 4:63
Hazardous agents biological, 3:280 classification of, 3:280 containment of, 3:279–281 radionuclides, 3:280–281 volatile agents, 3:280 waste as, 3:280 HCB, 3:346 α-HCH, 3:346 ß-HCH, 3:346 H2-DM, 4:20 H2-DO, 4:20 Head, 3:5 Hearing, 3:106 Heart anatomy of, 3:8–11, 3:27–29 atria of, 3:27 blood collection from, 3:455–456 conduction system of, 3:27 coronary arteries of, 3:27–28 coronary veins of, 3:28 description of, 3:26–27 echocardiography assessments, 3:46–48 electrical activity in, 3:37 embryogenesis, 1:176–177 fibrous connective tissue of, 3:27 layers of, 3:27 magnetic resonance imaging of, 3:45 mineralization of, 3:338 myocytes of, 3:29 necropsy evaluations, 3:483 size of, 3:26 three-dimensional reconstructions of sectioned embryos, 1:203–204 valves of, 3:27 ventricles of, 3:27 Heart failure, 3:553 Heart rate activity-based variations in, 3:40 body temperature effects on, 3:37 description of, 3:39–40 during exercise, 3:40 exercise stress responses, 3:40 radiotelemetry measurement of, 3:35 resting, 3:39–40 Heat adaptation, 3:69 Heating, ventilation, and air-conditioning system description of, 3:272–273, 3:288–290 maintenance of, 3:413 Heavy metals, 3:345–347 Hedgehog signaling, 3:711–712 Heinz bodies, 3:144 Helicobacter spp. classification, 2:409–410 colony management in prevention, 2:429–430 description of, 3:392, 3:397, 3:552 diagnosis culture, 2:427 enzyme-linked immunosorbent assay, 2:427–428 histology, 2:428 polymerase chain reaction, 2:427 epizootiology, 2:426–427
344 Helicobacter spp (continued) genomic diversity analysis, 2:428 H. bilis, 2:417–418 H. felis, 2:424 H. ganmani, 2:419 H. hepaticus history of study, 2:426 oxidative stress and cytotoxicity biomarkers, 2:416–417 pathogenesis, 2:410, 2:412 susceptibility of host, 2:412–415 tumorigenesis mechanisms, 2:415–416 H. mastomyrinus, 2:420–421 H. muricola, 2:420 H. muridarum, 2:419–420 H. pylori, 2:408, 2:424–425 H. rappini, 2:421 H. rodentium, 2:419 H. trogontum, 2:424 H. typhlonius, 2:419 history of study, 2:409–410 host range and tissue tropism, 2:409 human disease, 2:408 human infection, 2:729 mouse models gastric cancer, 2:425–426 gastritis, 2:424–425 hepatitis and hepatic cancer, 2:421–422 inflammatory bowel disease, 2:422–424 overview, 2:410 phylogenetic relationships, 2:408 properties of mouse isolates, 2:410–411 research-confounding effects, 2:426 sentinel mice in monitoring, 2:430 treatment, 2:428 Heligmosomoides polygyrus, 1:45, 2:559 Helminths. See also specific organisms cestodes, 2:559–561 description of, 4:308 human infection, 2:732–733 nematodes, 2:559 oxyurids, 2:552–556 Helper T cells cytokines secreted by, 4:91–92 description of, 3:189, 4:40–41, 4:89–90 Hemacytometer, 3:140 Hemagglutination description of, 3:746 inhibition assays, 3:396 Hemangioblasts description of, 3:158 erythroid cells derived from, 3:158–159 Hematocrit aging biomarker use of, 3:655 in aging mice, 3:161 definition of, 3:144 parameters for, 3:141 phlebotomy effects on, 3:138 Hematologic analyzers, 3:140, 3:142, 3:146 Hematologic tests artifacts associated with, 3:138 automated analyzers, 3:140, 3:142 clinical descriptive terms, 3:137 factors that affect, 3:136 guidelines for, 3:136
CUMULATIVE
Hematologic tests (continued) manual methods, 3:139–140 microhematocrit tube, 3:140 parameters used to assess, 3:141 reference intervals for, 3:136 results of, 3:136–137 statistical evaluation, 3:137 Hematology of aging mice, 3:161–162 information resources on, 3:135 overview of, 3:135 preanalytical variables, 3:135–136 textbook resources on, 3:135 of young mice, 3:161 Hematopoiesis definitive characteristics of, 3:160 description of, 3:135, 3:158 description of, 4:60 primitive description of, 3:135, 3:158 erythroid cells in, 3:158–159 onset of, 3:158 spleen’s role in, 3:162–163 stages of, 3:135 Hematopoietic stem cells description of, 3:641, 3:666, 4:33, 4:60 T cell precursor derivation from, 4:63 Hemicelluloses, 3:335 Hemispherium cerebri, 3:7 Hemizygous matings, 3:260 Hemoglobin concentration of, 3:141, 3:144 fetal, 3:160 α-globins, 3:160 mean cell, 3:141, 3:144 switching of, 3:160–161 in young mice, 3:161 Hemoglobin genes, 3:160–161 Hemolysis during blood collection, 3:182 ex vivo, 3:148 extravascular, 3:148 in vivo, 3:148 intravascular, 3:148 overt, 3:139 phenylhydrazine-induced, 3:163 red cell mass decreases caused by, 3:147–148 Hemolytic uremic syndrome, 2:366 Hemorrhage, 3:147. See also Bleeding Hemostasis description of, 3:157 parameters for, 3:141 platelet’s role in, 3:155 tests for evaluating, 3:157–158 Hepar-lobus dexter lateralis, 3:14 Hepatectomy, 3:466 Hepatitis Helicobacter hepaticus model, 2:422 lymphocytic choriomeningitis virus model, 2:194–196 murine cytomegalovirus myocarditis model, 2:21–22 Hepatitis virus. See Mouse hepatitis virus
INDEX
Hepatocytes bile acids secreted by, 3:206 description of, 3:65 Heptachlor, 3:346 Hereditary hemochromatosis, 4:121 Hermaphroditism, 2:634 Herpesviruses. See Mouse cytomegalovirus; Mouse thymic virus Heterogeneous lines, 3:648 Hexamethylene tetramine, 3:224 High performance liquid chromatography, 1:292 High-density lipoproteins description of, 3:65, 3:186 measurement of, 3:188 High-efficiency particulate air filters advantages of, 3:412 description of, 3:245, 3:300 evaluation of, 3:421 integrity of, 3:421 High-level disinfectants, 3:424 High-resolution x-ray computed tomography, 3:43–44 Hindlimb muscles of, 3:6–7 regions of, 3:2 Histamine, 3:369–370 Histidine, 3:333 H2-M4, 4:129 Holding rooms for behavior test, 3:529 description of, 3:274–276 lighting in, 3:292 temperature in, 3:291 Homeostasis failures, 3:675–677 Homeostatic chemokines, 3:195 Homologous recombination, 1:262–263 Homovanillic acid, 3:73 Homozygosity, 3:649 Horizontal flow mass air displacement units, 3:300, 3:302 Hormone(s) androgens, 3:130 binding of, 3:124 calcitonin, 3:129 1,25-dihydroxy vitamin D3, 3:129–130 estradiol, 3:202 estrogen atheroprotective effects of, 3:551 definition of, 3:130 preovulatory increase in, 3:103 follicle stimulating description of, 3:94, 3:201–202 plasma levels of, 3:202 reference ranges for, 3:181 secretory pattern for, 3:202 spermatogenesis initiation by, 3:97 ghrelin, 3:128 glucocorticoids, 3:130–131 growth hormone, 3:127 insulin-like growth factor-I, 3:127 insulin-like growth factor-II, 3:127–128 leptin, 3:130 luteinizing blood concentration affected by, 3:201
CUMULATIVE
345
INDEX
Hormone(s) (continued) α-chain of, 3:201 ß-chain of, 3:201 functions of, 3:201 reference ranges for, 3:181 secretory pattern for, 3:202 testosterone synthesis promoted by, 3:202 mechanism of action, 3:124–125 oxytocin, 3:203–204 parathyroid, 3:205 parathyroid hormone, 3:128–129 parathyroid hormone-related peptide, 3:128–129 progesterone, 3:203 prolactin, 3:203 renal regulation of, 3:70 testosterone. See Testosterone thyroid stimulating hormone, 3:128 thyroxine, 3:204–205 triiodothyronine, 3:204–205 types of, 3:124 vasopressin, 3:204 Hormone replacement therapy, 3:551–552 Hormone response elements, 3:125 Host cell proteins, 3:751 House flies, 3:429 Housing. See Cage Howell-Jolly bodies, 3:143 Hox homeobox signaling, 3:703, 3:717–718 Hoxa3, 4:64–65 Hoxc13, 3:703, 3:714 Hoxc13neo/Hoxc13neo, 3:704 Hoxd13, 3:622 HPLC. See High performance liquid chromatography H2-Q region, 4:126–127 Hr, 3:703 HS-40, 3:160 H2-T region, of Mhc, 4:127–128 Human ß-defensin-1, 4:32 Human interactions, 3:109 Human killer cell immunoglobulin-like receptors, 4:170 Humerus, 3:4 Humidity diet affected by, 3:361 relative, 3:291 reproduction affected by, 3:107 research facility environment, 3:291 Humoral immunity. See B cell Huntingtin, 3:680 Huntington’s disease, 3:680 HUS. See Hemolytic uremic syndrome HVAC system. See Heating, ventilation, and air-conditioning system Hyaline cartilage, 3:50 Hyaloid artery, 3:599 Hyaloid vascular system, 3:599–600 Hybrid strains authenticity of, 3:266–267 breeding, 1:65–66 definition, 1:82–83 F1, 3:258
Hybrid strains (continued) genetic quality control for, 3:266–267 nomenclature, 1:83 Hydrobromic acid, 3:461 Hydrocephalus, C57BL mice, 2:647 Hydrochloric acid corrosion caused by, 3:418 in drinking water, 3:308, 3:418 Hydrodynamic injection, gene delivery, 1:270 Hydrogen peroxide peracetic acid and, for isolator sterilization, 3:224 vaporized, 3:310 Hydrographs, 3:413 Hydroperoxyeicosatetraenoic acid, 3:186 6-Hydroxydopamine, 3:682 5-Hydroxyperoxyeicosatetraenoic acid, 3:197 Hymenolepis diminuta features and management, 2:560–561 human infection, 2:732 Hypercalcemia, 3:208 Hyperchromasia, 3:146 Hypergammaglobulinemia, 3:208 Hyperglycemia, 3:183 Hyperlipoproteinemia, 3:538 Hypermorphosis, 3:640–642 Hyperthermia, 3:69 Hypertrophic cardiomyopathy, 3:39 Hypoalbuminemia, 3:206 Hypochromasia, 3:146 Hypocretin-1, 3:184 Hypocretin-2, 3:184 Hypoglossus nerve, 3:7 Hypoglycemia, 3:183 Hypophysis, 3:7 Hypothalamus, 3:7, 3:94 Hypothermia anesthetic use of, 3:464–465 description of, 3:68 postoperative, 3:479 Hysterectomy derivation of germline mice, 3:112–113, 3:226 technique for, 3:467–468 Hysteresis, 3:55–56 Hysterotomy description of, 3:467–468 germfree mice derivation, 3:226
I 123I,
3:503 124I, 3:503 125I, 3:503 131I, 3:503 IAP. See Intracisternal A particles IBD. See Inflammatory bowel disease IC. See Inspiratory capacity ICH. See International Conference on Harmonization ICM. See Inner cell mass ICR191, embryonic stem cell mutagenesis, 1:255–256
ICSI. See Intracytoplasmic sperm injection Identification methods description of, 3:265–266, 3:440, 3:661 permanent, 3:441–443 semipermanent, 3:441 subcutaneous radio frequency transponders, 3:266, 3:441–443 temporary, 3:440–441 Iditol dehydrogenase, 3:200 IFA. See Immunofluorescence assay Igf1, 3:127 Igf2, 3:127–128 Ileum anatomy of, 3:15 catheterization of, 3:478 Iliaci externi lymph nodes, 3:22 Iliacus internus lymph node, 3:22 Iliofemoralis lymph node, 3:22 Illness, 3:387–388 Imaging advantages of, 3:491–492 anesthesia for, 3:492 bioluminescence, 3:506–507 computed tomography. See Computed tomography contrast agents used in, 3:492 cross-contamination issues, 3:493 data handling, 3:493 disadvantages of, 3:492 fluorescence, 3:506–508 future of, 3:509 general features of, 3:490–491 high-resolution x-ray computed tomography, 3:43–44 image characteristics, 3:490–491 infection control considerations, 3:493 logistical considerations, 3:492–493 longitudinal, 3:509 magnetic resonance imaging. See Magnetic resonance imaging magnetic resonance spectroscopy. See Magnetic resonance spectroscopy microCT scanners, 3:43–44, 3:494, 3:497 modalities for, 3:490–491 monitoring during, 3:492–493 multimodality, 3:509 noninvasive methods of, 3:43–48 nuclear. See Nuclear imaging optical, 3:506–508 overview of, 3:489–490 positioning for, 3:493 summary of, 3:509 ultrasound. See Ultrasound x-ray, 3:493–494 x-ray computed tomography, 3:493–494 Imaging facilities, 3:282–283 Immature dendritic cells, 4:144–145 Immune complexes, circulating, 3:191 Immune response, 4:87–88 Immune system adaptive cells of, 4:38–48 description of, 4:3 gastrointestinal tract’s role in, 3:66
346 Immune system (continued) innate cells of, 4:32–38 description of, 4:3 ligands of, 4:3–15 receptors of, 4:3–15 mutant phenotyping, 1:247 nutrition effects on, 3:369 Immunity, 3:370–371 Immunoassays chemiluminescent, 3:176 electrochemiluminescent, 3:176 fluoroimmunoassay, 3:176 immunoglobulin quantification using, 3:189–190 multiplex, 3:176, 3:178–179 viral contamination detected using, 3:746–747 Immunodeficiency, 3:389 Immunofluorescence antibody testing, 3:396 Immunofluorescence assay Clostridium piliforme diagnostics, 2:354 lymphocytic choriomeningitis virus diagnostics, 2:203–204, 2:722 mouse thymic virus diagnostics, 2:34 mousepox virus diagnostics, 2:160–161 Immunoglobulins classes of, 3:189 composition of, 3:189 in germfree mice, 3:219 IgA, 4:23 IgD, 4:23 IgE, 4:23, 4:294–295 IgG, 3:189, 4:22–23, 4:263–264 IgG2b, 4:8, 4:22 IgM, 4:8, 4:23 immunoassay quantification of, 3:189–190 membrane-anchored, 4:23 prenatal transfer of, 3:189 structure of, 4:43–44 Immunologic senescence, 3:642 Immunoreceptor tyrosine-based activation motifs, 4:83, 4:199, 4:215 Immunoreceptor tyrosine-based inhibitory motif, 4:6, 4:262 Immunoreceptor tyrosine-based switch motif, 4:28 Impressio duodenalis, 3:16 Impressio esophagica, 3:16 Impressio jejunalis, 3:16 Impressio ventricularis, 3:16 Imprinting chromosomal anomalies, 1:95 mutations, 1:80 111In, 3:503 In vitro fertilization principles, 1:212–213 rederivation, 1:220–221 Inbred strains. See also specific strains advantages of, 3:645–646 aging research using, 3:645–646, 3:648 atherosclerosis models, 3:536 attributes, 2:661 authenticity of, 3:266–267 breeding, 1:62–63, 3:253–254
CUMULATIVE
Inbred strains (continued) definition, 1:82, 2:628 description of, 3:105 development of, 3:173, 3:645 disadvantages of, 3:646 genetic quality control for, 3:266–267 nomenclature, 1:83 recombinant, 1:71, 1:84, 3:173, 3:629–630 record keeping information, 3:262 Incipient inbred, 2:628 Incisura cardiaca, 3:13 IND. See Investigational New Drug application Indexing washers, 3:302–303, 3:310 Indian hedgehog, 3:159 Indirect calorimetry, 3:325 Individually ventilated cage, 3:295–299, 3:412 Indocyanine green, 3:206 Inducible costimulator, 4:28 Inducible costimulator ligand, 4:28 Inducible mutagenesis, 1:265 Indwelling fluid-filled catheters, 3:33–34 Infanticide, 3:109 Infectious diseases atherosclerosis and, 3:552 from commercial vendors, 3:401–402 dietary influences on, 3:369–371 eradication of, 3:403–404 leukocyte response to, in aging mice, 3:162 monitoring for, 3:391–392 quality assurance programs to prevent, 3:389 from research colonies, 3:402–403 sources of, 3:401–403 types of, 3:391–392 from vermin, 3:402 Infectious ectromelia. See Mousepox Infectivity assays, 3:749 Inflammation eosinophils in, 4:34 interleukin-1 modulation of, 3:191 leukocytes affected by, 3:153 modulation of, 4:7 Inflammatory bowel disease, 2:422–424 Inflammatory chemokines, 3:195 Inflammatory diseases, 3:149 Inflammatory mediators, 3:545 Inflammatory responses, 3:62, 4:295 Infraspinatus, 3:5 Inguinalis superficialis lymph node, 3:22 Inhalant anesthesia, 3:463–464 Inhibitory receptors B cell activation thresholds and, 4:267–268 classes of, 4:262–263 description of, 4:262 natural killer cell receptors, 4:268 pathways of, 4:269–270 T cell, 4:268–269 Injectable anesthetics, 3:461–463 Injections contrast agents, 3:492 external jugular vein, 3:451–452
INDEX
Injections (continued) footpad, 3:453 intra-arterial, 3:451 intracranial, 3:452 intramuscular, 3:445, 3:450 intraosseous, 3:452 intraperitoneal, 3:450–451 intrathecal, 3:447 intrathoracic, 3:451 lateral tail vein, 3:451 retro-orbital, 3:452 subcutaneous, 3:449–450 Innate immune system activation of, 4:87 cells of, 4:32–38, 4:109 description of, 4:3 ligands of, 4:3–15 receptors of, 4:3–15 Inner cell mass, 1:186, 1:188, 3:102 Insect growth regulators, 3:430 Insecticides, 3:430 Insensible water loss, 3:76 Insertio musculi sartorii, 3:7 Insertio pleurae, 3:12 Inspiration, 3:52 Inspiratory capacity, 3:53, 3:57 Inspiratory reserve volume, 3:53–54 Insulin adiponectin and, 3:184 epinephrine effects on, 3:183 food intake regulated by, 3:618 glucose release rate affected by, 3:182–183 hormones that affect, 3:183 hypoglycemic response to, 3:183 nonfasting level of, 3:655 visfatin and, 3:184 Insulin receptor substrate-2, 3:184 Insulin resistance analytes involved with, 3:185 inducement of, 3:184 Insulin-like growth factor-I, 3:127 Insulin-like growth factor-I receptor, 3:127 Insulin-like growth factor-II, 3:127–128 Insulin-like growth factor-II receptor, 3:127–128 Integrated pest management program, 3:428–429 Integrins ß-, 3:160 clustering of, 4:196 description of, 4:196 knockout models, 4:201 leukocyte, 4:296–297 signaling, 4:203–204 T cell receptor-mediated activation defects, 4:199–201 Intercellular adhesion molecule-1, 4:81 Intercostales dorsal, 3:9 Interdigital pads, 3:715 Interferon(s) -α, 3:195 -τ, 3:187, 3:195, 4:30–31, 4:172 description of, 3:194–195 lactate dehydrogenase-elevating virus response, 2:222–223
CUMULATIVE
347
INDEX
Interferon(s) (continued) lymphocytic choriomeningitis virus persistence role, 2:201–202 mammalian reovirus response, 2:257 mouse adenovirus type 1 response, 2:59 mouse hepatitis virus response, 2:155 murine cytomegalovirus response, 2:27–28 Sendai virus response, 2:292–295 Interferon regulatory factor-2, 4:143 Interferon regulatory factor 5, 4:114 Interfollicular skin, 3:712–713 Interleukin-1 characteristics of, 3:191–192 description of, 4:30 inflammation modulation by, 3:191 murine cytomegalovirus response, 2:28 Interleukin-1 receptor, 3:191–192 Interleukin-1 receptor-associated kinase, 4:113 Interleukin-2, 3:192, 4:30, 4:170 Interleukin-2 receptor, 4:42 Interleukin-3, 3:150, 3:192, 4:30 Interleukin-4, 3:150, 3:192, 4:30, 4:43, 4:294 Interleukin-5, 3:150, 3:192, 4:30, 4:34, 4:297 Interleukin-6 characteristics of, 3:192 description of, 4:30, 4:93 insulin resistance induced by, 3:184 murine cytomegalovirus response, 2:28 Interleukin-7 deficiency of, 4:279 description of, 3:192, 4:30, 4:74 Interleukin-8, 3:192, 4:295 Interleukin-10, 3:192, 4:30, 4:236 Interleukin-11, 3:192–193 Interleukin-12, 3:150, 3:193, 4:30, 4:41, 4:144, 4:284, 4:294 Interleukin-13, 3:193, 4:30, 4:294 Interleukin-15 deficiency of, 4:279 description of, 4:30, 4:173 Interleukin-17, 3:193, 4:42 Interleukin-18, 3:193 Interleukin-20, 3:193 Interleukin-21, 3:193 Interleukin-23, 4:41 Intermediate-density lipoprotein, 3:188 International Conference on Harmonization, drug development role, 1:298–299 International System of Units, 3:139, 3:324 Interstitial cells of Cajal, 3:65 Interstitial dendritic cells, 4:36 Interstitial pneumonitis, murine cytomegalovirus myocarditis model, 2:20–21 Intertransversarii, 3:7 Intestinal alkaline phosphatase, 3:198 Intestinal crypts, 4:69 Intestinal loops, 3:468 Intestine anatomy of, 3:65–66 motility in, 3:65
Intestine (continued) necropsy evaluations, 3:483 small, 3:65–66, 3:483 Intestine roll, 3:483 Intra-arterial injection, 3:451 Intrabronchial administration, 3:449 Intracisternal A particles classification, 2:276 description of, 3:737 insertional mutagenesis, 2:272 Intracranial administration, 3:452 Intracrine hormones, 3:124 Intracytoplasmic sperm injection principles, 1:213–214 somatic nuclear transfer, 1:221–222 steps, 1:214 transgenic mouse preparation, 1:216 Intradermal administration, 3:449 Intragastric administration, 3:445–447 Intragastric catheters, 3:446 Intramuscular injection, 3:445, 3:450 Intranasal administration, 3:449 Intranodal administration, 3:452–453 Intraocular pressure, 3:601 Intraosseous injection, 3:452 Intraperitoneal administration, 3:445, 3:450–451 Intrasplenic administration, 3:453 Intrathecal catheterization, 3:479 Intrathecal injection, 3:447 Intratracheal administration, 3:449 Intravascular administration, 3:451–452 Intravascular hemolysis, 3:148 Intraventricular pressure, 3:30 Introitus vaginae, 3:3 Inulin, 3:73 Invertebrate pests, 3:429 Investigational New Drug application, drug development, 1:299 In-vivo imaging. See Imaging Iodine daily requirements for, 3:336 lability of, 3:337 Iodophors, 3:425 Ionizing radiation, 3:453–454 Iron daily requirements for, 3:336 reference range for, 3:181 Irradiation ionizing radiation, 3:453–454 of diet autoclaving of diet vs., 3:366 description of, 3:361, 3:363–364 dosages for, 3:364 factors that affect, 3:364 microorganisms affected by, 3:364–365 nutrient effects, 3:365–366 packaging, 3:364 process involved in, 3:364 reviews of, 3:364 of drinking water, 3:372 of parasites, 3:364 IRV. See Inspiratory reserve volume Ischiocavernosus, 3:19 Isoelectric focusing, 1:228
Isoflavones, 3:348 Isoflurane, 3:31, 3:463, 3:492 Isolated heart preparation, 3:29–30 Isolated lymphoid follicles, 4:69 Isolators air supply in, 3:223, 3:245 ancillary components, 3:221 animal manipulation inside of, 3:221 bacterial contamination of, 3:230–231 components of, 3:220–221 contamination of, 3:230–232 definition of, 3:220 ergonomics of, 3:225–226 flexible film, 3:219–220, 3:245 germicidal dip tank with, 3:223 gloves attached to, 3:221 HEPA filtration, 3:245 history of, 3:218–219 inspection of, 3:230 leakage testing of, 3:223 monitoring of, 3:231–232 positive pressure in, 3:223 PVC flexible film, 3:220–221 quarantining of animals in, 3:278 research facility use of, 3:299 semirigid, 3:220–221, 3:245, 3:299–300 sleeve length of, 3:225 stainless steel, 3:219, 3:221 sterilization of chemical, 3:223–225 chlorine dioxide for, 3:224 documentation of, 3:224 formaldehyde gas for, 3:224 hydrogen peroxide and peracetic acid for, 3:224 irradiation, 3:225 peracetic acid for, 3:223–224 steam, 3:225, 3:279 supply cylinders used with, 3:222–223 transfer port used with, 3:221–222 viral contamination of, 3:231 Isoleucine, 3:333 Itk, 4:200, 4:203 Itraconazole, 2:511 Ivermectin description of, 3:403 Heligmosomoides polygyrus management, 2:559 Myobia musculi management, 2:571–572 Myocoptes musculinus management, 2:574 pinworm management, 2:557–558 Polyplax serrata management, 2:568 IVF. See in vitro fertilization
J J chains, 4:6 Jacket, 3:443, 3:448 Jackson Laboratory, 1:4, 1:7–8 Jak3, 4:74 JAK3 tyrosine kinase, 4:279 Jak1-deficient mice, 4:183 Jak2-deficient mice, 4:183 Jak3-deficient mice, 4:183–184
348
CUMULATIVE
JAK-STAT pathway cytokine-activated, 4:180–181 regulation of, 4:181–183 signaling of, 4:183–189 JAM-A, 4:201 jams1, 3:571, 3:580 Januse kinases, 4:180, 4:183–184 Jejunum anatomy of, 3:15 catheterization of, 3:478 jerky, 3:571 Jerky mice, 3:571 Joule, 3:324 Jugular vein blood collection from, 3:179, 3:456–3:457 catheterization of, 3:475–476 injection into, 3:451–452 Juvenile monoclonic epilepsy, 3:570 Juxtacrine hormones, 3:124 Juxtaglomerular apparatus, 3:70
K Kainic acid-induced epileptic seizures, 3:577–578 Kallikrein-kinin system, 3:71 Karyotyping, 3:750 KCNA1, 3:568 Kcnj10, 3:577 K14–Cre mice, 3:699 K14–Cre(neo) mice, 3:699 K14–deltaN87 mice, 3:699 Keratin, 3:712 Keratinocytes, 4:32 Ketamine, 3:462 Ketamine-xylazine-acepromazine, 3:31 Ketogenic diet, 3:582–583 Ketone bodies, 3:583 Kidney(s) anatomy of, 3:17 autoimmune diseases that affect, 3:74 blood supply to, 3:74 clearance by, 3:73–74 diuretics response by, 3:74 embryologic development of, 3:70 function of, 3:69–70 function tests, 3:206–207 genetic abnormalities of, 3:74 genetic factors that affect, 3:72 glomerular volume of, 3:71 hormone regulation by, 3:70 juxtaglomerular apparatus of, 3:70 mineralization of, 3:338 morphophysiology of, 3:70–71 nephrectomy, 3:468 nephrons of, 3:70–71 polycystic, 3:74 prostaglandins, 3:71–72 protein-induced damage to, 3:334 sexual dimorphism of, 3:72 transplantation of, 3:468 tubular system of, 3:70 vascular system of, 3:70–71, 3:74 weight of, 3:71 zones of, 3:71
Killer cell immunoglobulin-like receptors, 4:262 KK mice, 3:627 Klebsiella sp. clinical features, 2:380 diagnosis, 2:380 epizootiology, 2:380 history of study, 2:379–380 K. pneumoniae, 3:392 properties, 2:380 Klossiella muris cell biology, 2:533 clinical features, 2:533 diagnosis, 2:533–534 history of study, 2:533 life cycle, 2:533 prevention, 2:534 research implications, 2:534 treatment and control, 2:534 Knock-in mouse drug target study examples, 1:306–313 mutations, 1:92 Knockout mice description of, 3:173, 3:557 drug candidate screening using, 3:175 drug target study examples, 1:306–313 historical perspective, 1:8 integrin, 4:201 limitations of, 3:621–622 obesity studies using, 3:621–623 resources, 3:621 T cell migration, 4:197–198, 4:202 with T cell receptor-mediated integrin activation defects, 4:199–201 K14-NOG mice, 3:700, 3:714 KRT-14-cre, 3:699 KRT-14–Dkk1 mice, 3:699 Kv1.1. channel, 3:568 K-virus, 3:391
L LAA. See Laboratory animal-associated allergy Label-retaining cells, 3:709 Laboratory animal-associated allergy allergens, 2:736 clinical signs, 2:738–739 diagnosis, 2:737–738 incidence, 2:735–737 pathogenesis, 2:737 treatment and prevention, 2:738–739 Laboratory Code, 1:84 Lacrimal fluid collection, 3:459 Lactate dehydrogenase description of, 3:199 reference range for, 3:181 Lactate dehydrogenase-elevating virus classification, 2:216 control of, 2:228 description of, 3:180, 3:391, 3:400–401, 3:746–747 diagnosis enzyme-linked immunosorbent assay, 2:227–228
INDEX
Lactate dehydrogenase-elevating virus (continued) lactate dehydrogenase activity, 2:227 polymerase chain reaction, 2:227 history of study, 2:216 host range, 2:226 immune response autoimmunity, 2:225 B cells, 2:224 cytokines, 2:222–223 immunosuppression, 2:224–225 macrophages, 2:223 natural killer cells, 2:223 T cells, 2:223–224 lactate dehydrogenase clearance impairment, 2:221–222 morphology, 2:216 pathology, 2:222 persistence, 2:222 physicochemical properties of, 2:216–217 polioencephalomyelitis, 2:225–226 prevention of, 2:228 receptor, 2:221 replication cell culture studies, 2:220–221 kinetics, 2:220 RNA synthesis, 2:218 sites, 2:219–220 stability, 2:218–219 strains, 2:219 structure of, 2:216–217 transmission, 2:226–227 tumor studies, 2:226 Lactation energy requirements during, 3:327, 3:329 environmental temperature effects on, 3:330 milk composition, 3:329 Lactobacillus spp. description of, 3:227 L. murinus, 3:229 Lafora bodies, 3:570 Lafora disease, 3:570–571 Laforin, 3:570–571 Lamina propria, 3:49 Laminar flow equipment, 3:421 Langendorff-work-performing heart preparation, 3:29–30 Langerhans cells, 4:139–140, 4:309 Langerin, 4:14 Laparotomy pack, 3:465 Large intestine, 3:65–66 Laryngeus recurrens sinister, 3:10 Laryngeus recurrens sinister et dexter et trachea, 3:11 Laryngopharynx, 3:49 Larynx, 3:49–50 Late-onset neurodegenerative diseases Alzheimer’s disease, 3:683–685 description of, 3:682 Parkinson’s disease, 3:682–683 tauopathies, 3:683 Lateral tail vein blood collection from, 3:456–457 injection into, 3:451
CUMULATIVE
349
INDEX
Latex gloves, 3:313 Latissimus dorsi, 3:4, 3:6 LCMV. See Lymphocytic choriomeningitis virus L-Deprenyl, 3:666–667 LDV. See Lactate dehydrogenase-elevating virus Lead, 3:345 leaner, 3:676, 3:685 Least-cost formula diet, 3:355 Leber congenital amaurosis, 3:607, 3:609 Lecithin:cholesterol acyltransferase, 3:186 Lee-Boot effect, pheromone response, 1:54 Lef1 null mice, 3:699, 3:723 Left anterior descending coronary artery, 3:28 Left atrium, 3:27 Left circumflex artery, 3:28 Left ventricle anatomy of, 3:27 M-mode echocardiography uses, 3:46 pressure measurements, 3:36 Left ventricular mass, 3:44–45 Lentivirus, 1:273–274 Lep, 3:130 Lepob, 3:630 Lepr, 3:130 Leprdb, 3:130, 3:630 Leptin description of, 3:94, 3:130 interleukin-1ß modulation by, 3:184 knockout mouse phenotype, 1:308–309 obesity and, 3:184, 3:618 production of, 3:184 proopiomelanocortin stimulated by, 3:184 resistance to, 3:185 Leptin receptor, 3:618, 3:620 Leptospirosis clinical signs, 2:726 control, 2:726–727 diagnosis, 2:726 host range, 2:725 humans, 2:726 reservoir and incidence, 2:726 serovars, 2:725–726 transmission, 2:726 Lethal mutations, 1:59–60 Leucine, 3:333 Leucine-rich glioma-inactivated 1, 3:571 Leucine-rich repeat motifs, 4:3, 4:110 Leukemia inhibitory factor, 1:283 Leukocyte(s) in aging mice, 3:161–162 alterations in number of, 3:152–154 automated hematologic analyzer identification of, 3:140 basophils, 3:150, 4:35 derivation of, 4:32–33 description of, 3:148, 4:32–33 differential count of, 3:151 enumeration of, 3:151–152 eosinophils. See Eosinophil(s) excitement effects on, 3:152–153 inflammation effects on, 3:153 integrins, 4:296–297
Leukocyte(s) (continued) lymphocyte. See Lymphocyte(s) monocytes, 3:150-151, 4:33 morphology of, 3:151–152 neoplasia effects on, 3:153 neutrophils. See Neutrophil(s) peripheral blood, 4:283–284 protease release by, 3:195–196 stress effects on, 3:152–153 Leukocyte adhesion defects, 3:154 Leukocyte receptor complex, 4:174 Leukotriene A4, 3:197 Levator labii superioris proprius, 3:5 Levator nasolabialis, 3:5 Lewy body, 3:682 Leydig cells, 3:95 Lgr7, 1:307 Lice. See Polyplax serrata Lien, 3:14–3:17 LIF. See Leukemia inhibitory factor Life span as biomarker of aging, 3:652–653 data analysis, 3:656 intervention to increase, 3:666–668 long-lived models, 3:651 maximum, 3:657 of erythrocytes, 3:142, 3:147–148 of F1 hybrids, 3:646 senescence and, 3:655–656 short-lived models, 3:651–652 Ligamentum arteriosum, 3:9 Ligamentum coronarium sinistrum, 3:16 Ligamentum falciforme et ligamentum teres hepatis, 3:16 Ligamentum hepatorenale, 3:16 Ligamentum pulmonale, 3:13 Ligamentum triangulare sinistrum, 3:16 Ligamentum vesicae laterale, 3:18, 3:20 Ligamentum vesicae laterale dextrum, 3:21 Ligamentum vesicae laterale sinistrum, 3:21 Ligamentum vesicae medianum, 3:17-18, 3:20–21 Light cycle breeding affected by, 3:238 14L:10D, 3:106 reproduction affected by, 3:106, 3:238, 3:291 Light traps, 3:429–430 Light:dark cycle behaviors affected by, 3:524–525 description of, 3:291, 3:414 Light-emitting diodes, 3:414 Lighting color temperature of, 3:414 description of, 3:413–414 intensity of, 3:413 research facility environment, 3:291–292 Lignans, 3:335, 3:348–349 Limb amputation, 3:458 Limulus amebocyte lysate assay, 3:742 Lindane, 3:346 Line, 3:236 Line outbreeding system, 3:256 LINEs. See Long interspersed nuclear elements
Lingua, 3:15 Linkage mapping, cross backcross, 1:120–124 backcross-intercross, 1:123 guidelines, 1:120 intercross, 1:122–124 ordering loci in multipoint crosses, 1:124 penetrance, expressivity, or modifier loci, 1:124–125 strain selection databases, 1:116 description of, 1:120 disequilibrium mapping, 1:127 marker types, 1:117–120 mutant genes, 1:116–117, 1:241 quantitative trait loci, 1:126–127 Linoleic acid, 3:334 Linolenate, 3:334 Linolenic acid, 3:334 Lipase, 3:66 Lipids functions of, 3:185–186 metabolism of, enzymes involved in, 3:188–189 types of, 3:185–186 Lipohyaline, 3:74 Lipooxygenases, 3:186, 3:197 Lipopolysaccharides description of, 3:69, 4:5 strains sensitive to, 4:110 virulence factors, 2:367–369 Lipoprotein(s). See also Cholesterol description of, 3:65 high-density description of, 3:65, 3:186 measurement of, 3:188 low-density description of, 3:186 measurement of, 3:188 oxidized, 3:186–187, 3:550 trapping of, 3:186 metabolism of, 3:538 transport of, 3:537 very low-density description of, 3:185–186 measurement of, 3:188 Lipoprotein (a), 3:538 Lipoprotein lipase, 3:185 Liquid diet, 3:354–355 Listeria monocytogenes, 3:228 Lithium, 3:336 Litter consolidation of, in breeding colony, 3:261 handling of, 3:440 milk energy content based on size of, 3:329 size of, in house mice, 1:36–37 Little mouse, 3:620–621 Liver anatomy of, 3:16, 3:64–65 cholesterol production, 3:65 comparative embryology, 1:196 hepatectomy, 3:466 hepatocytes, 3:65
350 Liver (continued) mouse urinary protein production in, 3:71 necrosis of, 3:205 regeneration of, 3:64–65 urea production by, 3:206 Liver function tests, 3:205–206 LKB1, 3:183 LNNA. See Local lymph node assay LOBUND Institute, 3:219–230 Lobus accessorius pulmonis dextri, 3:12–13 Lobus caudalis pulmonis dextri, 3:12–13 Lobus caudatus, 3:14 Lobus caudatus hepatis, 3:16 Lobus cranialis pulmonis dextri, 3:12–13 Lobus dexter hepatis lateralis, 3:15, 3:17 Lobus dexter hepatis medialis, 3:15, 3:17 Lobus dexter medialis, 3:14 Lobus dexter medialis hepatis, 3:16–17 Lobus dexter medialis lateralis, 3:16 Lobus medialis pulmonis dextri, 3:12–13 Lobus pancreatis dexter, 3:14 Lobus pancreatis sinister, 3:14 Lobus sinister hepatis lateralis, 3:15 Lobus sinister hepatis medialis, 3:15 Lobus sinister lateralis hepatis, 3:16 Lobus sinister medialis, 3:14 Lobus sinister medialis hepatis, 3:16 Local anesthetics, 3:461 Local lymph node assay, 1:304 Locus variants, nomenclature, 1:91–92 Long interspersed nuclear elements, 1:104 Long terminal repeats, 1:104 Long-lived models, 3:651 Long-term potentiation, 3:579 Loop of Henle, 3:71 Lou Gehrig’s disease. See Amyotrophic lateral sclerosis Low-density lipoprotein description of, 3:65, 3:186 measurement of, 3:188 oxidized, 3:186–187, 3:550 trapping of, 3:186 Low-density lipoprotein receptor, 3:185, 3:187, 3:557 Low-density lipoprotein receptor-related protein-1, 3:187, 3:548 Lower respiratory tract, 3:50–51 Low-level disinfectants, 3:424 Lowry method, 3:208 LPS. See Lipopolysaccharide L-selectin, 4:77 LTßR, 4:73 LTRs. See Long terminal repeats Lumbales aortici lymph nodes, 3:22 Lumbosacrocaudalis dorsalis lateralis, 3:7 Lumbosacrocaudalis ventralis lateralis, 3:7 Lung(s) acini, 3:51 alveolar duct, 3:51 anatomy of, 3:10–12, 3:50–51 blood supply to, 3:51–52 comparative embryology, 1:193–194 diffusion capacity of, 3:55, 3:61 embryology of, 1:193–194
CUMULATIVE
Lung(s) (continued) function assessments airway pressure, 3:56 description of, 3:53 diffusion capacity of lungs, 3:61 ex-vivo techniques, 3:55–56, 3:60–61 forced oscillation technique, 3:59 invasive methods, 3:56–58, 3:60–61 in-vivo techniques, 3:56–61 noninvasive methods, 3:58–61 pulmonary function tests. See Pulmonary function tests function phenotyping, 1:245 gas exchange in, 3:50 high-resolution x-ray computed tomography of, 3:44 lateral view of, 3:12 lobes of, 3:50–3:51 medial view of, 3:13 murine vs. human, 3:51 parenchyma of, 3:51 Lung compliance dynamic, 3:56, 3:58 pressure-volume curves for estimating of, 3:55 Lung volumes, 3:53–55 Luteal development, 3:103 Luteinizing hormone blood concentration affected by, 3:201 chain of, 3:201 ß-chain of, 3:201 circadian effects on, 3:99 description of, 3:94 functions of, 3:201 ovulation and, 3:99 reference ranges for, 3:181 secretory pattern for, 3:202 spermatogenesis initiation by, 3:97 testosterone synthesis promoted by, 3:202 Luteotropin, 3:103 Ly-17, 4:265 Ly49 receptors, 4:14–15, 4:170, 4:175, 4:268 Lymph, 3:460 Lymph nodes B cell entry and exit from, 4:76–77 description of, 3:21–22 development of, 4:69–70 peripheral, 4:69 Lymphocyte(s) in aging mice, 3:162 B. See B cell(s) description of, 3:148 excitement effects on, 3:153 lymphoid organ entry of, 4:77 morphology of, 3:150–3:151 natural killer cells, 4:37–38 recruitment of, 4:75 signaling of, 4:254–255 T. See T cell(s) Lymphocyte function-associated antigen-1, 4:176, 4:196, 4:233, 4:296 Lymphocytic choriomeningitis virus autoimmune disease susceptibility, 2:203 behavioral effects, 2:203
INDEX
Lymphocytic choriomeningitis virus (continued) classification, 2:180–181 contamination of biological material, 2:202 control and prevention, 2:204 description of, 3:226, 3:391, 3:733-744, 3:747 diagnosis molecular detection, 2:204 serology, 2:203–204 genetic susceptibility, 2:197–198 history of study, 2:180 host range, 2:186 in humans clinical signs, 2:722 diagnosis, 2:722 incidence of, 2:721 overview, 2:186–187, 2:720–721 reservoir, 2:721 susceptibility, 2:722 transmission mode, 2:721–722 treatment, 2:722 immunosuppression, 2:202–203 in laboratory mice autoimmune disease in transgenic mice, 2:197 hematopoietic disorders, 2:196–197 hepatitis, 2:194–196 immunopathogenesis, 2:187–188 prenatal and neonatal infection endocrine disorders, 2:191 immune complex disease, 2:189–191 wasting disease, 2:194 major histocompatibility complex, 2:197–198 natural history, 2:184–185 persistence roles B cells, 2:200–201 dendritic cells, 2:199 interferons, 2:201–202 natural killer cells, 2:201 overview, 2:198–199 T cells CD4+, 2:200 CD8+, 2:199–200 propagation cells, 2:183 mouse bioassays, 2:184 replication, 2:181–182 safety, 2:204–205 strains antigenic and genetic relationships, 2:182 biologic differences, 2:183 transmission horizontal, 2:185 vertical, 2:185–186 virion structure, 2:181 Lymphohematopoietic cell lineages, 4:281–283 Lymphoid enhancing factor, 4:67 Lymphoid follicles B cell migration to, 4:78–82 description of, 4:78
CUMULATIVE
351
INDEX
Lymphoid organs bone marrow. See Bone marrow location of, 4:59 molecular regulation of, 4:70–75 overview of, 4:59 primary, 4:59–68 secondary anatomy of, 4:68 B cell zones in, 4:78 cryptopatches, 4:69 dendritic cells, 4:143 formation of, 4:79–80 immune response function of, 4:68 location of, 4:69 lymphatic drainage to, 4:76 lymphocyte entry into, 4:77 microdomains in, 4:78–82 natural killer cells in, 4:171 overview of, 4:68–70 Peyer’s patches, 4:69 spleen. See Spleen thymus. See Thymus Lymphoid tissue-inducing cells description of, 4:73 development of, 4:73–74 LTα1ß2 induction on, 4:74 recruitment of, 4:74 Lymphonodi axillary proprius, 3:6 Lymphonodi cervicales superficiales, 3:6 Lymphonodi colici, 3:15 Lymphonodi ileocolicus, 3:15 Lymphonodi mandibulares, 3:8 Lymphonodus axillaris accessorius, 3:5 Lymphonodus jejunalis, 3:15 Lymphonodus pancreaticoduodenalis, 3:15 Lymphonodus retropharyngeus lateralis, 3:8 Lymphonodus subiliacus, 3:3 Lymphopoietin-1, 3:192 Lymphotoxin, 3:194 description of, 4:279–280 Lymphotoxin receptor null mutants, 4:279–280 Lyn, 4:269 Lysine, 3:333 Lysophosphatidic receptor, 1:307
M M1, 4:128 M5, 4:129 M6, 4:129 M10, 4:128 Machado-Joseph disease, 3:681 Macrocytosis, 3:146 Macrophage(s) apoptosis of, 3:187 characteristics of, 4:33 FCγRI expression on, 4:7 from TLR2-/- mice, 4:110 in granulomatous processes, 4:33 lactate dehydrogenase-elevating virus response, 2:223 murine cytomegalovirus immune response, 2:27
Macrophage(s) (continued) pneumonia. See Pneumonia in primitive hematopoiesis, 3:159 Macrophage colony-stimulating factor, 3:126 Macrophage inflammatory protein, 4:172 Macrophage inflammatory protein-1, 4:35, 4:296 Macrophage inflammatory protein-2, 4:14 Macrophage mannose receptor, 4:13 Macropinocytosis, 4:142 MAdCAM-1, 4:77 Magnesium daily requirements for, 3:336 nephrocalcinosis and, 3:338 reference range for, 3:181 Magnetic resonance imaging atherosclerosis progression evaluations, 3:556 cardiovascular applications of, 3:501–502 contrast-enhanced, 3:502 description of, 3:44–45 echocardiography vs., 3:44 embryo studies, 1:204–205 facilities for, 3:282–283 functional, 3:502 gadolinium-enhanced, 3:502 heart evaluations using, 3:45 left ventricular mass evaluations, 3:44–45 magnetic field gradients, 3:499 neuroimaging applications of, 3:500–501 principles of, 3:44, 3:498–499 resolution achieved using, 3:500 scanner components, 3:498 signal production, 3:498–500 structural abnormalities evaluations, 3:500–501 T1 relaxation, 3:500–3:501 T2 relaxation, 3:500 vascular imaging using, 3:45 Magnetic resonance spectroscopy description of, 3:45 in research facilities, 3:282–283 Mahogany mouse, 3:620 Maintenance energy requirements for, 3:325–328 protein requirements for, 3:332 Major histocompatibility complex antigen processing, 4:18–20 CD1 genes, 4:20–21 dendritic cell expression of, 4:138 description of, 4:15 history of study, 1:9 molecules class I, 4:15, 4:17–18, 4:308 class II, 4:17–18, 4:123 description of, 4:120 overview of, 4:119–120 receptors, 4:170 Major urinary protein, 3:207 Malarial parasites, 3:145 Malathion, 3:346–3:347 Male(s) breeding age for, 3:239 breeding lifespan of, 3:261
Male(s) (continued) energy requirements for, 3:325 fertility of, 3:104, 3:111–112 retirement of, 3:261 Male reproductive accessory glands, 3:96 description of, 3:94–95 epididymis, 3:95–96 evaluation of, 3:110 excretory ducts, 3:95–96 genital organs, 3:18–19 illustration of, 3:95 penis, 3:96 testes, 3:95 urethra, 3:96 Malocclusion C57BL mice, 2:648 features, 2:691 MaLR. See Mammalian apparent LTR-retrotransposons Mammalian apparent LTR-retrotransposons features, 2:276 insertional mutagenesis, 2:272 Mammalian Phenotype Browser, 3:530 Mammalian reovirus cardiorespiratory system infection, 2:254 cell culture growth studies, 2:251–252 central nervous system infection, 2:253–254 control and prevention, 2:258 diagnosis, 2:257–258 endocrine system effects, 2:255–256 genome, 2:247 hepatobiliary system infection, 2:254–255 history of study, 2:245–246 host entry, 2:252–253 host range, 2:257 human infection, 2:724 immune response, 2:256–257 stability, 2:249 strains mutants, 2:250–251 reassortants, 2:250 serotypes, 2:249–250 structure, 2:247–249 transmission, 2:257 vaccination, 2:248 Mammary glands abnormalities in, 3:721 anatomy of, 3:3 development of, 3:719–720 embryogenesis of, 3:718 molecular signaling, 3:720–723 morphology of, 3:718–719 postnatal changes in, 3:720 postpubertal, 3:719 prenatal development of, 3:719–720 sexual dimorphism in, 3:723 Mandibularis lymph nodes, 3:21 Manganese, 3:336 Mannose-binding lectin, 3:191 Mannose-binding lectin-associated serine proteases, 3:191 Manose-6-phosphate, 3:127 MAP. See Mouse antibody production
352 Mapping studies, 3:648–650 Marginal zone absence of, in neonatal period, 4:81 definition of, 4:78 macrophages, 4:14, 4:81 Margo acutus, 3:13 Margo basalis, 3:13 Margo obtusus, 3:13 Margo plicatus, 3:16 mass1, 3:571, 3:580 Mass air displacement units, 3:299–302 Masseter, 3:5, 3:8 Mast cells in allergic asthma, 4:295 description of, 4:35 IgE-activated, 4:294–295 Mastitis, Pasteurellaceae, 2:485 Maternal fetal interface, 4:284 Mating description of, 3:101–102 hemizygous, 3:260 systems for mouse production, 3:252 timed, 3:111–112, 3:261–262 Matrix metalloproteinases -9, 1:310 description of, 3:196, 3:546–3:547 Matrix-assisted laser desorption/ionization, 3:174 Maturity, 3:524 MAV-1. See Mouse adenovirus type 1 MAV-2. See Mouse adenovirus type 2 Maxilloturbinates, 3:49 Maximal electroshock seizure threshold, 3:577 MBL. See Mouse Brain Library MC3r, 3:184 MC4r, 3:184, 3:620 MCS. See Multispecies conserved sequences mDC-SIGN, 4:14 Meals, 3:353 Mean cell hemoglobin, 3:141, 3:144 Mean cell hemoglobin concentration, 3:144 Mean cell volume, 3:141, 3:144 Mean corpuscular hemoglobin, 3:141, 3:144 Mean platelet volume, 3:156 Measuring Behavior conference, 3:530 Mebendazole, 2:559 Mechanical washing equipment, 3:302–304 Medetomidine, 3:461 Mediastinales caudales lymph nodes, 3:21 Mediastinales craniales lymph nodes, 3:21-22 Mediastinalis cranialis dexter, 3:10 Mediastinales medii lymph nodes, 3:21 Medical Research Council, 3:324 Medicated diet, 3:353 Medulla oblongata, 3:7 Medulla spinalis, 3:7 Medullary epithelial cells, 4:63, 4:65, 4:67 Megaesophagus features, 2:691 strain 129 mice, 2:635 Megakaryocytes in bone marrow, 3:154 DNA content of, 3:154
CUMULATIVE
Megakaryocytes (continued) GATA-1 deficient, 3:154–155 in primitive hematopoiesis, 3:159 in spleen, 3:162 Megakaryocytopoiesis splenic, 3:163 thrombopoietin effects, 3:154 Meibomian glands, 3:711 Meiosis, 3:93 Meiotic chromosomes. See also Synaptonemal complex air-dried preparation analysis, 1:156–157 applications, 1:155 banding, 1:156 cell sources, 1:155–156 fluorescent in situ hybridization, 1:158–159 meiosis overview, 1:155 post-meiotic chromosome analysis, 1:159–160 preparation, 1:156 Melanin, 3:605 Melanocortin receptor-4 description of, 3:620 knockout mouse phenotype, 1:307 mutant phenotyping, 1:251 Meloxicam, 3:480 Membrane attack complex, 4:8 Membrane cofactor protein, 3:190 Membrane-anchored immunoglobulin, 4:23, 4:83 Membrane-bound G protein, 3:124 Memory B cells, 4:91 Memory T cells, 4:90 Menadione, 3:340 Mercury, 3:346 Mesangial cell, 3:72 Mesenchyme, 4:65 Mesentericus caudalis lymph node, 3:22 Mesoduodenum, 3:14 Mesometrium, 3:21 Mesosalpinx sinister, 3:20 Mesothelium, 3:27 Mesovarium, 3:21 Metabolic disorders, 1:251 Metabolic rate, 3:66–67 Metabolism ambient temperature effects on, 3:68 description of, 3:66–67 domestication effects on, 3:75 post-eating increases in, 3:325 Metabolizable energy, 3:324, 3:330 Metastasis, 2:611–612 Metestrus, 3:100–101 Methacholine, 4:293 Methemoglobin, 3:144 Methionine and cysteine, 3:333 Method detection limit, 3:351 Methoxychlor, 3:346 Methoxyflurane, 3:179, 3:183 Methyl methanesulfonate, 1:231 Methyl parathion, 3:346 6-Methylpurine deoxyriboside, 3:743–744 Met-RANTES, 3:196
INDEX
Metronidazole Clostridium perfringens management, 2:357 Giardia muris management, 2:521 MGD. See Mouse Genome Database MHC. See Major histocompatibility complex Mhc class I region, 4:125–126, 4:130 class II molecules, 4:123, 4:130 class III region, 4:124–125, 4:130 comparative map of, 4:121–130 DM, 4:123 DO, 4:123 DP, 4:123 DQ, 4:123 DR, 4:123 H2-M4, 4:129 H2-M region, 4:128 H2-Q region, 4:126–127 H2-T region, 4:127–128 M5, 4:129 M6, 4:129 M region, 4:129–130 non–class II molecules, 4:123 overview of, 4:119–120 polymorphism of, 4:120 regions of, 4:120 sequencing of, 4:120–121 MHV. See Mouse hepatitis virus Mice. See also specific strain aging-related classifications of, 3:644–645 animal care staff observations of, 3:387 behavior of, 3:238 as disease model, 3:174–175 domestic hierarchies of, 3:238–239 genetically engineered, 3:175 handling of, 3:439–440 humans and, differences between, 3:556–557 identification methods, 3:265–266 life span of, 3:645, 3:650 microbial status of, 3:389 nocturnal activity of, 3:238, 3:524–525 physiological parameters for, 3:25 Microbial contamination adventitious agents description of, 3:735–736 prevention of, 3:737–739 cell banks used to prevent, 3:738–739 contaminant removal or inactivation, 3:739–740 endogenous retroviruses, 3:736–737 laboratory practices to prevent, 3:739 manufacturing practices to prevent, 3:739 murine leukemia virus, 3:737 operator-induced, 3:739 sources of, 3:736 viruses quality control testing for, 3:740 removal or inactivation of, 3:739–740 Microbiological monitoring, 3:427–428 Microbiological quality control overview of, 3:734–735 polymerase chain reaction considerations for, 3:747
CUMULATIVE
353
INDEX
Microbiological quality control (continued) description of, 3:742 mycoplasma, 3:744 validation of, 3:747 viral genomic sequences detected using, 3:747–748 testing for amount of, 3:741 antibody-production tests, 3:746–747 bacteria, 3:742–743 endotoxin, 3:742 indications for, 3:740–741 infectivity assays, 3:749 methods, 3:741–742 mycoplasma, 3:743–744 viruses, 3:744–749 MicroCT, 3:43–44, 3:494, 3:497 Microcytosis, 3:146 ß2-Microglobulin, 4:15, 4:17 Microhematocrit tube, 3:140 Microisolation caging, 3:247 MicroRNA, 1:109 Midazolam, 3:461–3:462 Middle, 3:624 Middle abdomen, 3:2 Milk collection of, 3:459 composition of, 3:329 Millar catheter-tip microtransducers, 3:36 Mineralization, 3:338 Minerals ashing process for, 3:336 deficiency of, 3:337 dystrophic calcinosis, 3:338 immunity affected by, 3:370–371 measurement of, 3:336 in natural-ingredient diets, 3:337 nephrocalcinosis, 3:337–338 nutritionally important, 3:336–337 requirements for, 3:336–337 Ministry of Health, Labor, and Welfare, 1:298 MINK, 4:216 Minute virus of mice clinical signs of, 2:96 control of, 2:101 description of, 3:735 diagnosis, 2:100 epizootiology, 2:96–97 genome features, 2:94–95 history of study, 2:93–94 pathology and pathogenesis of, 2:98–100 physicochemical properties, 2:95–96 prevention of, 2:101 replication, 2:95 research applications, 2:101 Mirex, 3:346 Mismatch repair, 4:162–164 Mismatchings, 3:266–267 Mites. See Fur mites Mitochondria, 4:217–218 Mitogen-activated protein kinase kinase 6, 4:113 Mitogen-activated protein kinase pathways, 4:216
Mitotic chromosomes banding applications, 1:146–147 C-banding, 1:149–150 DAPI banding, 1:149 fluorescent in situ hybridization, 1:153 G-banding, 1:148–149 historical perspective, 1:5 Q-banding, 1:148–149 R-banding, 1:149 RBG-banding, 1:149 cell sources and preparation, 1:147–148 principles, 1:153–154 spectral karyotyping applications, 1:146–147, 1:154 Mitotic mapping, 1:131 Mitral valve, 3:27 Mixed inbred strains, 1:84–85 Mixed leukocyte reaction, 4:138 Mixed noninbred strains, 1:85 M-mode echocardiography, 3:45–46 MMS. See Methyl methanesulfonate MMTV. See Mouse mammary tumor virus Mob, 3:624 Mobe1, 3:624 Modified hole board test, 1:249 Modifier genes breeding strategies for chemical mutagenesis screening dominant modifiers, 1:238 recessive modifiers, 1:238–239, 1:241 linkage mapping, 1:124–125 Moist heat sterilization, 3:362 MOLD/Rk mice, 3:651 Molds, 3:346 Moloney murine leukemia virus, 3:748 Monitoring behavior, 3:516 blood pressure electrocardiography. See Electrocardiography indwelling fluid-filled catheters, 3:33–34 invasive, 3:33–36 noninvasive, 3:32–33 radiotelemetry, 3:34–35 tail-cuff measurements, 3:32–33 tethering techniques, 3:33 transducer-tipped catheters, 3:35–36 during imaging, 3:492–493 pest, 3:428–429 pulmonary function tests, 3:53 research facility environment, 3:292–293 water, 3:420 Monocrystalline ion oxide nanoparticles, 3:502 Monocyte(s), 3:150–151, 4:33 Monocyte chemoattractant protein-1, 3:544, 4:296 Monogamous breeding system, 3:252–253, 3:257 Monogenic audiogenic seizures, 3:571–573 Monomeric red fluorescent protein, 3:506 Monoxenic animal, 3:218 MoPn. See Chlamydia muridarum
Morris water maze, 3:518, 3:520 Morula aggregation, 1:218 Mosaic populations, 1:75 moth1, 3:610 Motor neuron diseases, 3:678–679 Mouse adenovirus type 1 control and prevention, 2:61–62 diagnosis, 2:61 genetic susceptibility, 2:61 genome E1, 2:51–52 E3, 2:52–53 E4, 2:53 major late promoter, 2:53 structure, 2:51 history of study, 2:50–51 host range and prevalence, 2:61 immune response cell-mediated immunity, 2:59 humoral immunity, 2:60 innate immunity, 2:58–59 model, 2:60 infection in mouse age effects, 2:56 cell tropism, 2:57–58 E3 mutants, 2:58 E1A mutants, 2:58 inoculation route effects, 2:57 persistence, 2:56 infection in vitro E3 mutants, 2:55–56 E1A mutants, 2:55 kinetics of replication, 2:53–54 receptor, 2:54 physical properties, 2:51 Mouse adenovirus type 2 history of study, 2:50–51 infection in mouse, 2:60–61 physical properties, 2:51 Mouse antibody production. See also Antibody assay for, 3:400 mouse hepatitis virus diagnostics, 2:161 mousepox virus prevention, 2:89 Sendai virus prevention, 2:298 Mouse Brain Library, features, 1:242 Mouse cytomegalovirus atherosclerosis and, 3:552 classification, 2:3–4 control, 2:32 description of, 3:105, 3:391 diagnosis enzyme-linked immunosorbent assay, 2:32 polymerase chain reaction, 2:32 serology, 2:32 history of study, 2:2 host range, 2:12–13 human cytomegalovirus similarities adrenalitis, 2:24 atherosclerosis, 2:24 central nervous system infection, 2:24–25 clinical significance, 2:2–3, 2:17 description of, 4:307–308
354 Mouse cytomegalovirus (continued) genome, 2:4–5 hemopoiesis studies, 2:26 hepatitis, 2:21–22 interstitial pneumonitis, 2:20–21 intrauterine infection and congenital disease embryonic development effects, 2:19 epidemiology, 2:18 gonadal tissue infection, 2:19–20 hearing loss, 2:25–26 reproduction effects, 2:20 myocarditis, 2:22–24 retinitis, 2:25 immune response B cell response, 2:28–29 cytokines, 2:27 dendritic cell, 2:27 evasion, 2:30–32 immunosuppression induction, 2:26–27 macrophage, 2:27 natural killer cells, 2:28 T cell CD4+, 2:30 CD8+, 2:29–30 laboratory mouse infection, 2:11–12 life cycle morphogenesis, 2:6–7 replication, 2:5–6 viral entry, 2:5 mouse biological control, 1:46 natural history, 2:11 natural killer cells, 4:172–173 pathogenesis age effects, 2:13 dose effects, 2:13 inoculation route effects, 2:13 latency and reactivation, 2:16–17 resistance mechanisms acute infection, 2:14–15 cell culture studies, 2:15–16 chronic resistance, 2:15 propagation in vitro cell growth cycle effects, 2:9–10 centrifugal enhancement, 2:9 kinetics of replication, 2:9 multicapsid virion production, 2:10 non-murine cells, 2:9 nonpermissive murine cells, 2:9 permissive murine cells, 2:8–9 in vivo, 2:10–11 species distribution of cytomegalovirus, 2:3–4 strains, 2:7–8 transmission mode, 2:12 vaccines, 2:32–33 virion structure, 2:4–5 Mouse genome, 3:490 Mouse Genome Database description of, 4:120 historical perspective, 1:7 Laboratory Code in strain designation, 1:84 strain name registration, 1:81
CUMULATIVE
Mouse Genome Sequencing Consortium, 3:25 Mouse Genomics Informatics Database System, 3:647 Mouse hepatitis virus cell interactions, 2:148–149 classification, 2:146 control, 2:169–170 description of, 3:390-391, 3:393, 3:399, 3:402, 3:525 diagnosis enzyme-linked immunosorbent assay, 2:160–161 immunofluorescence assay, 2:160–161 immunohistochemistry, 2:167 mouse antibody production, 2:161 pathology, 2:162–165, 2:167 polymerase chain reaction, 2:161–162 serology, 2:161 duration of infection, 2:144–145 genome mutation and recombination, 2:148 history of study, 2:142–143 host range, 2:145–146, 2:149 human infection, 2:723 immune response B cells, 2:155, 2:157 experimental brain disease, 2:155–156 immunomodulation, 2:157–158 interferons, 2:155 passively acquired maternal immunity, 2:156–157 reinfection immunity, 2:157 T cells, 2:154–155, 2:157 vaccination immunity, 2:157 isolates, 2:142–143 isolation and propagation, 2:158–160 natural history, 2:143–144 pathogenesis enterotropic infection, 2:150 experimental encephalitis and demyelination, 2:151–154 experimental hepatitis, 2:151 respiratory infection, 2:150 replication, 2:148 research-confounding effects, 2:625 surveillance, 2:168–169 transmission, 2:145 virion structure, 2:146–148 Mouse jacket, 3:443, 3:448 Mouse mammary tumor virus description of, 3:391, 4:123 host range, 2:271 loci, 2:275 receptors, 2:271 research-confounding effects, 2:625 tumor pathogenesis, 2:595 Mouse minute virus. See Minute virus of mice Mouse norovirus, 3:391 Mouse parvovirus clinical signs of infection, 2:96 control of, 2:101 diagnosis, 2:100 epizootiology, 2:96–97
INDEX
Mouse parvovirus (continued) genome features, 2:94–95 history of study, 2:94 pathology and pathogenesis, 2:97–98 physicochemical properties, 2:95–96 prevention of, 2:101 replication, 2:95 research applications, 2:101 Mouse Phenome Database, 3:173, 3:183, 3:518, 3:524, 3:530, 3:632 Mouse Phenome Project, 2:627 Mouse pneumonitis virus, 3:391 Mouse polyoma virus cell interactions in culture cell transformation, 2:108 productive and nonproductive infections, 2:107–108 description of, 3:391 history of study, 2:106–107 natural history, 2:108–109 prospects for study, 2:129–130 receptors and uptake, 2:122–123 regulatory sequences, 2:121–122 structure, 2:113 susceptibility genetics in inbred strains, 2:123–126 transgenic mouse studies JC virus T antigen, 2:127 polyoma T antigens, 2:127–128 polyoma virus regulatory sequences in transgene expression, 2:128 SV40 large T antigen, 2:126–127 tumor antigens genetic interactions, 2:119–120 molecular interactions, 2:118–119 pathogenicity determinants, 2:120–121 structures and functions, 2:116–118 tumor induction cancer modeling anti-apoptotic responses, 2:111–112 early progression, 2:110–111 genomic instability and progression, 2:111 immune response, 2:112 initiation, 2:110 invasion and metastasis, 2:112–113 profile, 2:109 sites, 2:107 tissue interactions, 2:109–110 VP1 pathogenicity determinants, 2:113–116 recombinant proteins, 2:113 self-assembly, 2:113 VP2, 2:116 VP3, 2:116 Mouse rotavirus, 3:391 Mouse sarcoma virus, 3:748 Mouse thymic virus description of, 3:391 diagnosis, 2:34–35 history of study, 2:33 pathogenesis, 2:34 properties, 2:33–34 Mouse urinary protein, 3:71 Mouse urinary syndrome, 2:639
CUMULATIVE
355
INDEX
Mousepox clinical disease age effects, 2:73 patterns, 2:73 sexual dimorphism, 2:73 control depopulation and disinfection, 2:87 rederivation of mouse strains, 2:88 serological screening, 2:88 vaccination, 2:87–88 diagnosis clinical signs, 2:86–87 enzyme-linked immunosorbent assay, 2:87 pathology, 2:87 polymerase chain reaction, 2:87 serology, 2:87 virus isolation, 2:87 ectromelia virus species distribution, 2:69 enzootic mousepox, 2:86 epidemiology, 2:84–85 epizootic mousepox, 2:85–86 history of study, 2:68–69 host range species, 2:83–84 strain susceptibility, 2:84 immune response adaptive immunity, 2:81–82 innate immunity, 2:80–81 resistance genetics, 2:82–83 pathogenesis footpad infection and viral spread, 2:75–76 inoculation routes and mechanisms arthropod vectors, 2:74 feeding, 2:74 intracerebral inoculation, 2:75 intradermal inoculation and scarification, 2:73–74 intranasal inoculation, 2:74–75 intraperitoneal inoculation, 2:74 intrauterine infection, 2:75 lower respiratory tract inoculation, 2:75 pathology intestine, 2:79–80 liver, 2:78 lymphoid tissue, 2:79 resistant mouse strains, 2:80 skin, 2:77–78 spleen, 2:78–79 prevention mouse antibody production, 2:89 quarantine, 2:88–89 sentinel surveillance, 2:88 propagation chick embryo, 2:72 replication cycle, 2:71–72 tissue culture, 2:72–73 strains Hampstead strain, 2:70–71 Ishibashi strain, 2:71 Moscow strain, 2:71 NAV strain, 2:71 NIH-79 strain, 2:71
Mousepox (continued) taxonomy, 2:68–69 virion properties composition, 2:70 morphology, 2:69–70 stability, 2:70 structure, 2:70 Mouse-specific reagents, 3:175–176 MPD. See Mouse Phenome Database MptV. See Murine pneumotropic virus MPV. See Mouse parvovirus MRI. See Magnetic resonance imaging MRL.lpr mice, 4:244–246 mSIGNR2, 4:13–14 Msx2 homeobox signaling, 3:703 Msx2–NOG mice, 3:699 Msx2tm1 Rilm/Msx2tm1 Rilm mice, 3:704 99mTc, 3:503 MTV. See Mouse thymic virus Mucosa-associated lymphoid tissue, 4:69 Mucosal epithelia, 4:32 Mullerian inhibiting substance, 3:93 Multimodality imaging, 3:509 Multiple sclerosis, 4:308–309 Multiplex immunoassays, 3:176, 3:178–179 Multispecies conserved sequences, 1:105–106 MuLV. See Murine leukemia virus Municipal water, 3:241, 3:307 Murine activating receptor-1, 4:175 Murine leukemia virus common integration site, 2:274 description of, 3:737 detection of, 3:746 endogenous, 3:748–749 Fv1 in susceptibility, 2:273–274 host range, 2:271 inbred mouse strain distribution, 2:271–272 insertional mutagenesis, 2:272–273 Moloney, 3:748 receptors, 2:271 tumor pathogenesis, 2:595 Murine pneumotropic virus features, 2:128 propagation, 2:128–129 prospects for study, 2:129–130 tumor antigens, 2:129 Murine typhus features, 2:725 human risks, 2:725 Mus behavior, 1:32, 1:34–35 diseases and control, 1:43–46 geographic origins, 1:2 house mice origin, radiation, and reproductive incompatibility, 1:17, 1:19 natural history, 1:26–31 phylogenetic relationships evolutionary trees, 1:2, 1:20 prospects for study, 1:21 species, 1:19, 1:21 subgenera, 1:19 physiology, 1:31–32
Mus (continued) population dynamics, 1:37–42 reproduction, 1:35–37 taxonomy conventions for recognizing house mouse lineages and inbred strains, 1:19 species and subspecies field mice, 1:16 geographic ranges, 1:16–18, 1:26–28 house mice, 1:16–17, 1:19 subgenera Coelomys, 1:14 Mus, 1:15 Nannomys, 1:14 Pyromys, 1:14 wild strain polymorphisms, 1:3 Muscles. See also specific muscle of body, 3:4 of forelimb, 3:5 of head, 3:5 of hindlimb, 3:6–7 respiratory, 3:52 Mutagenesis. See also Chemical mutagenesis conditional mutagenesis strain maintenance, 1:71–72 gene trap mutagenesis, 1:110 gene-specific mutagenesis conditional mutagenesis, 1:264–265 gene targeting, 1:262–263 gene trapping, 1:263–264 inducible mutagenesis, 1:265 RNA interference, 1:265–266 targeted trapping, 1:264 transgenic mouse, 1:262 germ cell sensitivity, 1:226 insertional mutagenesis of embryonic stem cells, 1:285 mapping of mutant gene, 1:125–126 mutation frequency determination, 1:227–228 spontaneous mutation rate, 1:226 naming of mutant phenotypes, 1:91 phenotyping. See Phenotyping radiation as mutagen, 1:229 Mutagenic Insertion and Chromosome Engineering Resource, 3:621–3:622 MVM. See Minute virus of mice Myc signaling, 3:712 transgenic mice, 2:597, 2:599, 2:602–603 Mycobacterium phlei, 3:416 Mycobacterium tuberculosis, 3:416, 4:308 Mycoplasma sp. description of, 3:734–736 indirect assays for, 3:743 M. arthritides, 2:453–454, 3:392, 3:397 M. collis, 2:454 M. muris, 2:454 M. neurolyticum, 2:454 M. pulmonis clinical signs, 2:441
356 Mycoplasma sp. (continued) culture, 2:440–441 description of, 3:392, 3:397 diagnosis culture, 2:450–451 electron microscopy, 2:451 enzyme-linked immunosorbent assay, 2:450 general considerations, 2:449–450 histopathology, 2:451 immunohistochemistry, 2:451 polymerase chain reaction, 2:452 geographic distribution, 2:448 history of study, 2:438–439 host range, 2:448 pathogenesis disease expression factors, 2:444–445 host injury, 2:445–446 immune response, 2:446–448 pathology genital disease, 2:443 polyarthritis, 2:443–444 respiratory disease, 2:441–443 prevalence of infection, 2:448–449 properties, 2:439–440 strains, 2:440 transmission, 2:449 microbiological quality control testing for, 3:743–744 Mycotoxins, 3:347–348 MyD88, 4:113–114 Myeloblasts, 3:148 Myelocytomatosis oncogene, 3:712 Myeloid dendritic cells, 4:112 Myeloid differentiation factor 88, 4:3 Myeloid:erythroid ratio description of, 3:145 splenectomy effects on, 3:163 Myeloperoxidase, 3:191 Myobia musculi clinical features, 2:571 description of, 3:398 diagnosis, 2:571 host range, 2:571 life cycle, 2:569, 2:571 morphology, 2:569 pathobiology, 2:571 prevention and control, 2:572 treatment, 2:571–572 MYOC, 3:604–605 Myocardial calcification, 3:27 Myocardial infarction, 3:553–554 Myocarditis, 2:22–24 Myocardium, 3:27 Myocillin, 3:604–605 Myocoptes musculinus clinical features, 2:573 description of, 3:398 diagnosis, 2:573 host range, 2:573 life cycle, 2:573 morphology, 2:572–573 pathobiology, 2:573 prevention and control, 2:573–574 treatment, 2:573
CUMULATIVE
Myocytes, 3:29 Myoid cells, 3:95 Myosin heavy chain promoter, 3:38 Myostatin, 1:309
N 13N,
3:503 Na+/H+ exchanger, 3:575 Na+H+ exchanger regulator factor-1, 3:70 Nails, 3:714–716 Nalbuphine, 3:461–462 Naloxone, 3:462 Nannomys, 1:14 Nanog, 1:283 Nasal cavity, 3:49 Nasal-associated lymphoid tissue, 4:69 Nasopharynx, 3:49 Nasoturbinates, 3:49 National Committee for Clinical Laboratory Standards, 3:138 National Institute of Aging, 3:668 National Institutes of Health, 3:410 National Research Council nutrient guidelines, 3:323–324 vitamin guidelines, 3:342 National Sanitation Foundation International, 3:301 Natural alleles, 3:626–630 Natural cytotoxicity receptors, 4:175 Natural killer cell(s) activating receptors, 4:174–175 activation of, 4:174–176 autoimmune diseases and, 4:173 cytokine and chemokine production by, 4:171–172 cytotoxicity functions of, 4:171 dendritic cells and, 4:172 description of, 4:37–38 development of, 4:170–171 discovery of, 4:169–170 function of, 4:171–174 inhibitory receptors, 4:174 interleukin-2 and, 4:171 lactate dehydrogenase-elevating virus response, 2:223 lymphocytic choriomeningitis virus persistence role, 2:201 major histocompatibility-recognizing receptors, 4:262 morphology of, 4:171 murine cytomegalovirus immune response, 2:28 myocarditis role, 2:23 reproductive functions of, 4:173–174 Sendai virus response, 2:295 summary of, 4:176 surface markers of, 4:171 tissue distribution of, 4:171 tumor immunity applications of, 4:172 uterine, 4:173, 4:284 viral immunity applications of, 4:172–173 Natural killer cell receptors description of, 4:14–15, 4:125 inhibitory, 4:268
INDEX
Natural killer cell receptors (continued) Ly49, 4:268 Natural killer cell stimulatory factor, 3:193 Natural killer cell-committed precursors, 4:170 Natural killer T cells, 4:43 Natural-ingredient diets blending of, 3:358 description of, 3:239, 3:304–305, 3:351 extrusion of, 3:358–359 manufacturing of, 3:358–359 packaging of, 3:359 pelleting of, 3:358 phytoestrogens in, 3:349 raw materials used in, 3:358 storage of, 3:360, 3:423 Naturalistic observation, 3:516 Neck glands of, 3:8 regions of, 3:2 Necropsy areas for, 3:281–282 diagnostic, 3:394 fixatives, 3:483 phenotyping, 1:251–253 technique for, 3:482–483 Negative costimulatory molecules, 4:237 Negative feedback, 3:94 Negative selection anti-CD3/peptide central tolerance models, 4:209 cell death mechanisms during, 4:235 costimulatory molecules in, 4:215 endogenous antigen models, 4:209–213 mediators of, 4:213–218 overview of, 4:208–209 signal transducers in, 4:215–216 T cell receptor in, 4:215 transcription factors in, 4:216–217 Neomycin, Citrobacter rodentium infection management, 2:377 Neonate drug administration to, 3:453 euthanasia of, 3:482 Fc receptors, 4:6 Neoplasia, 3:153 Nephrectomy, 3:468 Nephrocalcinosis, 3:337–338 Nephrons, 3:70–71 Nerve growth factor, 3:677 Nerve growth factor receptor, 3:703 Nervous mouse, 3:678 Nervus phrenicus sinister, 3:12 Nests. See also Bedding materials used to build, 3:108, 3:306, 3:314 thermoregulatory uses of, 3:239 N-ethyl-N-nitrosourea, 3:596, 3:625 Neu, 2:597 Neural degenerations, 3:679 Neuroleptanesthetics, 3:462 Neurologic system, 3:388 Neuronal necrosis, 3:415 Neuropeptide Y, 3:184, 3:624 Neurotrophin signaling, 3:703
CUMULATIVE
357
INDEX
Neurotrophins, 1:283 Neurulation, 1:173, 1:175–176 Neutropenia, 3:149 Neutrophil(s) in aging mice, 3:162 band, 3:153 characteristics of, 3:148–150 definition of, 4:33 excitement effects on, 3:153 function of, 3:148 functions of, 4:33 granulocyte-colony stimulating factor effects on, 3:148–149 half-life of, 3:149 inflammation effects on, 3:153 kinetics of, 3:149 morphology of, 3:149–150 transcription factors that affect, 3:149 transit time for, 3:149 Neutrophilia, 3:149 Neutrophilins, 3:708 Nhe1, 3:575 NHEJ, 4:164–165 Niacinamide, 3:340 Nickel, 3:336 Niclosamide, 2:732 Nicotinamide, 3:340 Nicotinic acid, 3:340 Nidd5, 3:624 Niemann-Pick type C disease, 3:677–678 Nitrate, 3:345 Nitrile gloves, 3:314 Nitrite, 3:345 Nitrosamines, 3:345, 3:350–351 Nits, 3:398 NKG2D, 4:15, 4:173, 4:175 NKR-P1C, 4:175 Nociception, phenotyping, 1:250–251 Nod2, 4:114 NOD-scid mice, 4:278 Noise audiogenic seizures caused by, 3:292, 3:415 autoclave-induced, 3:415 control of, 3:415 definition of, 3:414 from individually ventilated cages, 3:298 high levels of, 3:414 physiologic effects of, 3:414 in research facility environment, 3:292 ultrasonic, 3:292 white, 3:415 Nonciliated bronchiolar cells, 3:51 Nonciliated secretory cells, 3:50 Noncommercial breeding, 3:237 Non-critical infection risks, 3:424 Nonfasting glucose, 3:655 Nongenomic responses, 3:125 Noninvasive imaging, 3:43–44 Nonopioid analgesics, 3:480 Nonshivering thermogenesis, 3:68 Nonsteroidal anti-inflammatory drugs, 3:480 Norepinephrine, 3:181 Norovirus, 3:391 Nosocomial infections, 3:427
Nostrils, 3:49 Notch1, 3:703 Notch2, 3:703 Notch signaling, 3:703, 3:714 NPC1, 3:677 Npepps, 1:313 Npy, 3:577 Nr3c1, 3:130–131 NR2E3, 3:607 Ntp, 3:579 Nuclear factor-kB B cell receptor activation of, 4:84 description of, 4:72, 4:216 T cell activation of, 4:236 Nuclear imaging definition of, 3:502 event localization in, 3:503 positron emission tomography, 3:504–3:505 radionuclides, 3:503 single photon, 3:502–504 single photon emission computed tomography, 3:504 summary of, 3:505 Nuclear receptor subfamily 5A1, 3:93 5′-Nucleotidase, 3:200 Nucleus colony definition of, 3:253 mismatchings in, 3:266–267 Nucleus colony segment, 3:236 Nude mice athymic, 4:277 bedding considerations for, 3:241, 3:306 hair fibers in, 3:702–703 production index for, 3:260 Nur77, 4:217 Nutrients. See also Diet; Feed autoclaving effects on, 3:362–3:363 classification of, 3:324 fats, 3:334–335 fatty acids, 3:334–335 fiber, 3:335 irradiation effects on, 3:365–366 laboratory testing of, 3:351 National Research Council guidelines, 3:323–324 overview of, 3:323–324 protein. See Protein vitamins. See Vitamin(s) Nutrition. See also Diet; Feed for breeding colony, 3:240 immune system affected by, 3:369 postoperative, 3:480 NZB mice, 3:74 NZM2410 strain, 4:249–250 NZO mouse, 3:626 NZW mice, 3:74 [NZW × NZB]F1 mice, 4:247–249
O 15O,
3:503 O antigen, 2:367–369 Obesity bariatric surgery for, 3:618 body mass index criteria for, 3:618
Obesity (continued) comorbidities associated with, 3:618 contributing factors, 3:618–619 diabetes and, 3:184–185 energy requirements and, 3:325 future research, 3:631–632 gene-environment interactions, 3:630–631 gene-gene epistasis, 3:630 genetic influences, 3:619–620 leptin and, 3:184, 3:618 low birth weight and, 3:631 maternal effects, 3:631 mouse models of chemically mutagenized, 3:625–626 congenic strain analysis, 3:628–629 diet-induced, 3:630–631 haplotype analysis, 3:627–628 knockout, 3:621–623 multigenic, 3:626–630 natural alleles, 3:626–630 recombinant congenic strain, 3:629–630 recombinant inbred strain, 3:629–630 spontaneous single gene mutations, 3:620–621 transgenic, 3:623–624 multifactorial etiology of, 3:618–619 N-ethyl-N-nitrosourea studies, 3:625 prevalence of, 3:618 quantitative trait loci, 3:619–620 visfatin in, 3:184 Obliquus externus abdominis, 3:4 ob/ob mice development of, 3:620, 3:665 energy requirements for, 3:325 Obq3, 3:624 Obq10, 3:624 Obturator externus, 3:7 Ochratoxin, 3:346, 3:348 OCT 4, 3:93 Octomitus pulcher, 2:525 Oculomotorius nerve, 3:7 Odontoblasts, 3:63 Oesophagus, 3:16 Office of Laboratory Animal Welfare, 3:410, 3:480–481 Olfactory bulb ablation, 3:468–469 Olfactory bulbectomy, 3:468–469 Oligodendrocyte progenitor cell, 1:286 Omega-3 fatty acids, 3:334–335 Omentum majus, 3:14, 3:16 Omentum minus, 3:16 One-tailed tests, 3:658–659 Onychocytes, 3:714 Oocyte fertilization of, 3:102 follicles and, 3:99 growth of, 3:99 preimplantation development of, 3:102 OPC. See Oligodendrocyte progenitor cell Open formula diet, 3:355 Opioid analgesics, 3:480 Optic nerve colobomas of, 3:598 development of, 3:599 Optic stalk, 3:599
358 Optical imaging, 3:506–508 Optical projection tomography, 1:205–206 Opticus nerve, 3:7 Oral cavity, 3:63 Orbital sinus bleeding, 3:454–3:455 Orchidectomy, 3:470 Ordinal statistics, 3:656–657 Orexin A, 3:184 Orexin B, 3:184 Organogenesis LTßR ligation during, 4:73 signaling mutations effect on, 4:75 Ornithine transcarbamoylase, 3:199 Ornithonyssus bacoti features, 2:733 host range, 2:733 human infestation, 2:733–735 Oropharynx, 3:49 Orphan mouse mutants description of, 3:573 Nhe1, 3:575–576 p35, 3:576 serotonin receptor, 3:575 stargazer, 3:573–574 weaver, 3:574–575 Os ilium, 3:4 Os ischii, 3:4 Os penis, 3:96 Os pubis, 3:4 Osmolality, 3:181 Osmotic minipumps, 3:474 Osmotic pumps for intraperitoneal administration, 3:451 for subcutaneous administration, 3:450 Ossa carpi, 3:4 Ossa metacarpi, 3:4 Ossa metatarsi, 3:4 Osteoblasts description of, 3:125 dexamethasone effects on, 3:131 estrogen effects on, 3:130 glucocorticoids effect on, 3:131 thyroid stimulating hormone effects on, 3:128 Osteoclasts activation of, 3:126 in bone remodeling, 3:126 calcitonin gene-related peptide effects on, 3:129 description of, 3:125 parathyroid hormone effects on, 3:129 Osteocytes in bone remodeling, 3:126 description of, 3:125 Osteopenia, 3:642 Osteoporosis C57BL mice, 2:648 description of, 3:642 Osteoprotegerin, 3:126, 3:194 Otitis, 2:485 Outbred strains authenticity of, 3:267 breeding, 1:73, 1:75, 3:254–258 definition, 1:83, 2:628 description of, 3:648
CUMULATIVE
Outbred strains (continued) genetic quality control for, 3:267 nomenclature, 1:84 sources and origins, 2:662–663 Out-of-specification results, 3:751–752 Ova, 3:459–460 Ovalbumin, 4:237, 4:292 Ovarian follicles. See Follicle Ovarian teratoma, 1:129 Ovarian transplantation, 3:113, 3:470–471 Ovariectomy, 3:470–471 Ovaries comparative embryology, 1:196–197 cryopreservation of tissue, 1:219–220, 1:235 Ovariohysterectomy, 3:471 Ovarium dextrum, 3:20–21 Ovarium sinistrum, 3:20 Ovary anatomy of, 3:97–3:98 development of, 3:93 excision of, 3:460 gonadotrophin response, 3:94 Over-the-needle catheters, 3:474 Oviduct anatomy of, 3:97–98 excision of, 3:460 sperm in, 3:102 Ovulation description of, 3:99–100 inducement of, 3:460 mating before, 3:102 Oxantel, 2:559 Oxygen consumption, 3:41 Oxygen tension, 3:69 Oxytocin, 3:203–204, 3:459 Oxytocin receptor, 3:203 Ozone, 3:372
P p25, 3:683 p35, 3:576, 3:683 p53, 2:601 p63, 3:713 p21, 4:254 PA-C10, 3:34 Packaging of diet description of, 3:359 irradiated diet, 3:364 Packed cell volume, 3:140–141, 3:144 PAI. See Pathogenicity island Paired Ig-like receptor-B, 4:267 Pancreas comparative embryology, 1:196 description of, 3:15–16, 3:64 Pancreatic islets -cells, 3:183 ß-cells, 3:184 insulin released from, 3:182–183 Paneth cells, 3:66 Panhypopituitary dwarf mutation, 3:651, 3:665 Pantothenic acid, 3:341 Papillae mammae, 3:3
INDEX
Papillary stalk, 3:695 Para-aortic splanchnopleura, 3:135, 3:160 Parabiosis, 3:469 Paracetamol, 3:480 Paracrine hormones, 3:124 Paraformaldehyde, 3:310 Paralogs, 1:103 Paramesonephric duct, 3:93 Paraoxonase, 3:186–187 Parasites colony animal testing for, 3:397–398 erythrocyte, 3:145 external, 3:398 fur mites. See Fur mites internal, 3:398 irradiation of, 3:364 medications for, 3:403 pinworms. See Pinworms types of, 3:397–398 Parathion, 3:346 Parathyroid glands, 1:193, 1:195 Parathyroid hormone description of, 3:128–129, 3:205 hypercalcemia caused by increased levels of, 3:208 Parathyroid hormone-like peptide, 3:720 Parathyroid hormone-related peptide, 3:128–129, 3:205 Parathyroidectomy, 3:469 Parkinson’s disease, 3:666–667, 3:682–683 Parotid gland, 3:63 Parotideus lymph nodes, 3:21 Parotidoauricularis, 3:5 Parotidoauricularis et glandula, 3:4 Pars abdominalis, 3:3 Pars abdominalis esophagei et lymphonodi gastrici, 3:15 Pars anterior prostatae, 3:19 Pars ascendens duodeni et pancreas, 3:15 Pars cardiaca, 3:16 Pars cardiaca tunicae mucosae, 3:16 Pars cardiaca ventriculi, 3:15 Pars cervicalis, 3:3 Pars cervicalis esophagei, 3:15 Pars cervicalis thymi, 3:8 Pars cervicalis trunci sympathici dextri et sinistri, 3:10 Pars descendens duodeni, 3:15 Pars epithelium stratificatum squamosum tunicae mucosae, 3:16 Pars fundica et pylorica ventriculi, 3:15 Pars fundica tunicae mucosae, 3:16 Pars inguinalis, 3:3 Pars membranacea urethrae, 3:19 Pars pylorica tunicae mucosae, 3:16 Pars pylorica ventriculae, 3:16 Pars scapularis musculi deltoidei, 3:4 Pars thoracica caudalis, 3:3 Pars thoracica cranialis, 3:3 Pars thoracica esophagei, 3:15 Pars thoracica trunci sympathici dextri et sinistri, 3:10 Parthenogenesis, 1:214 Partial seizures, 3:566 Parturition, 3:103
CUMULATIVE
359
INDEX
Parvoviruses, 3:391. See also Minute virus of mice Pasteurella pneumotropica, 3:392–393, 3:397 Pasteurellaceae classification, 2:471, 2:480 co-pathogens and opportunism, 2:483 culture, 2:480–481 diagnosis culture chemotaxonomic criteria, 2:494–495 growth conditions, 2:492–493 organs, 2:493 phenotypic identification, 2:493–494 enzyme-linked immunosorbent assay, 2:495–496 polymerase chain reaction, 2:495 environmental sensitivity, 2:474–475 eradication in control, 2:497 geographic distribution, 2:491 history of study Actinobacillus, 2:472–473 Haemophilus, 2:473–474 overview, 2:470–471 Pasteurella, 2:471–472 host range, 2:488–489 human infection potential, 2:489–491 latency, 2:484 morbidity and mortality, 2:481–482 pathogenesis, 2:482 pathology, 2:486–487 phenotypic characteristics Actinobacillus muris, 2:477 growth factor-dependent bacteria, 2:479–480 Haemophilus influenzaemurium, 2:477–479 overview, 2:474–475 Pasteurella pneumotropica, 2:475–477 prevalence of infection, 2:491 prevention, 2:497–499 primary pathogenicity, 2:482–483 research-confounding effects, 2:487–488 storage, 2:475 target tissues conjunctivitis, 2:484–485 mastitis, 2:485 otitis, 2:485 overview, 2:481 respiratory tract, 2:484 urogenital tract, 2:485–486 transmission, 2:491–492 treatment, 2:496 Pasteurization, 3:361 Patella, 3:4 Pathogenic autoimmunity, 4:250–251 Pathogenicity islands, 2:369, 3:228 Pathogen-specific molecular patterns, 4:110 Pathology cilia-associated respiratory bacillus, 2:456 control and prevention, 2:453 lactate dehydrogenase-elevating virus, 2:222 minute virus of mice, 2:98–100 mouse hepatitis virus, 2:162–165, 2:167
Pathology (continued) mouse parvovirus, 2:97–98 mousepox, 2:77–80 Mycoplasma pulmonis genital disease, 2:443 polyarthritis, 2:443–444 respiratory disease, 2:441–443 Pasteurellaceae, 2:486–487 Pneumocystis murina, 2:509 pneumonia virus of mice, 2:301–302 Sendai virus, 2:290–292 treatment, 2:452–453 tumors. See Tumor pathology, in genetically engineered mice Pax1, 4:65 Pax9, 4:65 Pbwg1, 3:624 PCBs, 3:346 PCR. See Polymerase chain reaction PD-1, 4:237, 4:267–268 Pde6b, 3:679 Pde6brd1, 3:598 Pdgfa null mice, 3:704 PD-L1, 4:237 PD-L2, 4:28 Pectineus, 3:7 Pectoralis ascendens, 3:6 Pectoralis majoris, 3:4 Pedigree card, 3:262–263 Pedigree ledger, 3:263, 3:265 Pedigree tree, 3:265 Pelage hair follicles, 3:694–696 Pellets diet autoclaving of, 3:356–357, 3:422 description of, 3:240, 3:353 hardness of, 3:355 illustration of, 3:445 manufacturing process of, 3:357 natural-ingredient diets, 3:358 quality of, 3:356 steam sterilization of, 3:422 summary of, 3:357 drug administration using, 3:450 Pelvis, 3:2 Penetrance linkage mapping, 1:124–125 mutations, 1:72 Penis, 3:18–19, 3:96 Pentobarbital, 3:462–463 Pentraxins, 3:190 Pentylenetetrazol neurological phenotyping, 1:250 seizure test, 3:566 Pepducins, 3:196 Peptidoglycan, 4:110 Peracetic acid isolator sterilization using, 3:223–224 in research facilities, 3:310 Perianal hair follicles, 3:697, 3:711 Pericardium, 3:12 Peripheral blood leukocytes, 4:283–284 Peripheral nervous system, 3:674 Peripheral tolerance, 4:146, 4:266 periplaneta americana, 3:429
Peristalsis, 3:65 Peritoneal cells, 3:459 Permanent identification methods, 3:441–443 Permethrin Myobia musculi management, 2:572 Polyplax serrata management, 2:568 “Perox” channel scattergram, 3:152 Peroxisome proliferator activated receptor gamma signaling, 3:712 Peroxisome proliferator-activated receptor-α human gene knock-in mouse, 1:308 knockout mouse phenotype, 1:308 Peroxymonosulfate, 3:426 Personal protective equipment functions of, 3:313 in research facilities, 3:313–314 Pest(s) bait stations for, 3:429 cockroaches, 3:429–430 control of, 3:361 escaped mice, 3:429 filth flies, 3:430–431 flying insects, 3:429 glue boards for, 3:429–430 house flies, 3:429 integrated management program for, 3:428–429 invertebrate, 3:429 light traps for, 3:429–430 monitoring for, 3:428–429 prevention programs for, 3:429–431 wild mice, 3:429 Pesticides, 3:345–347, 3:428 Pet-I, 3:676 Peyer’s patches B cell entry and exit from, 4:76–77 description of, 4:69 PFGE. See Pulsed-field gel electrophoresis PGC. See Primordial germ cells Phagocytes, 4:10 Phagocytosis, 4:19 Phalanges digitorum, 3:4 Pharmacodynamics definition, 1:290 studies overview, 1:290–291 Pharmacogenomics definition, 1:292 mouse study prospects, 1:314–315 Pharmacokinetics ADME processes, 1:291 definition, 1:291 Pharynx, 3:49 Phenols, 3:310 Phenotypes allergen exposure and, 3:62 breathing pattern variations based on, 3:53 studies of, 3:25 Phenotypic shift, 3:640 Phenotyping allergologic phenotypes, 1:247 behavioral phenotyping, 1:247–249 cardiovascular disease, 1:245–246 clinical chemical and biochemical assays, 1:246–247
360 Phenotyping (continued) dysmorphological phenotyping, 1:243–244 electrocardiography for, 3:38–39 embryonic stem cell mutagenesis, 1:256 eye defects, 1:244–245 immune system defects, 1:247 lung function, 1:245 magnetic resonance imaging for, 3:45 metabolic disorders, 1:251 necropsy and pathology, 1:251–253 neurological phenotyping, 1:249–250 nociception, 1:250–251 phenotype gap, 1:241 protocols, 1:241–242 standardization data collection, 1:241 phenome databases, 1:242–243 Phenylalanine and tyrosine, 3:333 Phenylhydrazine-induced hemolysis, 3:163 Pheromones description of, 3:94, 4:129 pest traps using, 3:430 reproductive responses, 1:54 seasonal production of, 3:108 social cues transmitted by, 3:109 Phoenix valves, 3:290 Phosphatases, 4:174, 4:238 Phosphatidylinositol 3-kinase, 4:200–203 Phosphodiesterases PDE7A, 1:311 PDE4A/B, 1:311 Phosphoinositide 3-kinases, 3:193, 4:234 Phospholipase C-τ, 4:233 Phosphorus daily requirements for, 3:336 measurement of, 3:207 nephrocalcinosis, 3:338 reference range for, 3:181 Photoplethysmography, 3:32 Phrenicus dexter et sinister, 3:10 Phylloquinone, 3:340, 3:369 Physiology, 3:26 Phytates, 3:338 Phytoestrogens bone development affected by, 3:350 definition of, 3:348 description of, 3:107, 3:304 in diets, 3:348–350 isoflavones, 3:348 lignans, 3:348–349 reproduction affected by, 3:350 research variables affected by, 3:349–350 significance of, 3:349 uterus effects, 3:350 Pigmentary glaucoma, 3:605–606 Pigmented feed, 3:305 Pilocarpine, 3:458 Pilosebaceous unit, 3:711 Pinealectomy, 3:470 Pinealis, 3:7
CUMULATIVE
Pinworms. See also Aspiculuris spp.; Syphacia spp. anthelmintic-treated drinking water for, 3:309 Aspiculuris, 3:398 chemical disinfectant of, 3:225 description of, 3:105 diagnostic testing for, 3:391, 3:394, 3:398 eggs, 3:394, 3:398 eradication costs, 3:390 medicated diets for, 3:353 Syphacia, 3:398 Piperazine, 3:403 Pirimiphos, 3:346 Pituitary gland description of, 3:77 hormones secreted by, 3:94 hypophysectomy, 3:466–467 Placental lactogens, 3:103 Placodes, 3:699 Plague, 1:39–42 Planck’s constant, 3:498 Plaque, atherosclerotic bone marrow transfer studies of, 3:549 characteristics of, 3:540–3:543 development of, 3:548 matrix metalloproteinase effects on, 3:548 Plasma cells, 4:91 Plasma profiles, 3:178–179 Plasma protein profiling, 3:174 Plasmablasts, 4:92–93 Plasmacytoid dendritic cells description of, 4:37, 4:76–77, 4:142–143 maturation of, 4:143 toll-like receptor signaling in, 4:114 Plasmacytoma, 1:8–9 Plasmodium berghei, 3:145 Platelet(s) accelerated production of, 3:156 aggregation of, 3:157 biology of, 3:154–155 clumps of, 3:152, 3:155 decreased number of, 3:156–157 definition of, 3:154 development of, 3:154–155 -granules of, 3:155 hemostatic functions of, 3:155 life span of, 3:155, 3:157 morphology of, 3:155 parameters of, 3:156–157 production of, 3:154 scatter diagrams for, 3:156 size of, 3:156 thrombopoietin effects on, 3:156 volume of, 3:156 Platelet count, 3:141, 3:156 Platelet crit, 3:156 Platelet derived growth factor A-chain, 3:599 Platelet derived growth factor signaling, 3:703 Platelet distribution width, 3:156 Plethysmograph, 3:54 Plethysmography barometric, 3:59–61 body, 3:54
INDEX
Plethysmography (continued) description of, 4:292 photoplethysmography, 3:59 whole body, 3:59–60 Pleural pressure, 3:52 Plexus pulmonalis, 3:10 Plexus trachealis, 3:11 Plica vena cavae caudalis, 3:12 PLNA. See Popliteal lymph node assay Pluripotent cells. See Embryonal carcinoma cell; Embryonic germ cell; Embryonic stem cell pmn, 3:677 PMP. See Purine nucleoside phosphorylase Pneumocystis spp. P. carinii antibiotic-infused water to prevent, 3:309 description of, 3:220 testing for, 3:392 P. murina animal models of infection, 2:513 diagnosis, 2:509 epidemiology, 2:508–509 history of study, 2:508 morphology, 2:508 pathology, 2:509 taxonomy, 2:508 treatment and control, 2:509–510 Pneumonia, acidophilic macrophage C57BL mice, 2:649 features, 2:694 strain 129 mice, 2:634–635 Pneumonia virus of mice age effects, 2:301 classification, 2:298 clinical features, 2:300 control of, 2:304 description of, 3:391 diagnosis, 2:303–304 genome, 2:299 history of study, 2:298 host range, 2:302 immune response, 2:302 pathology gross changes, 2:301 microscopic changes, 2:302 prevention of, 2:304 propagation cell culture, 2:300 eggs, 2:300 mice, 2:300 sex differences, 2:301 strains, 2:299 structure, 2:299 susceptibility of inbred strains, 2:301 target sites, 2:300–301 transmission, 2:303 Pneumotropic virus. See Murine pneumotropic virus Point mutagenesis, 4:280–281 Polycarbon biphenyls, 3:347 Polychromasia, 3:143 Polycystic kidneys, 3:74 Polycythemia, 3:147
CUMULATIVE
361
INDEX
Polydipsia, 3:77 Polyethylene restraint collar, 3:444 Polygamous breeding system, 3:252, 3:257–3:258 Poly-Ig receptor, 4:5–6 Polymerase chain reaction biological material testing using, 3:400 cardiovirus uses, 2:320 cilia-associated respiratory bacillus uses, 2:459 Clostridium piliforme uses, 2:354 Corynebacterium bovis uses, 2:401 genetic monitoring, 1:141 Helicobacter uses, 2:427 lactate dehydrogenase-elevating virus uses, 2:227 lymphocytic choriomeningitis virus uses, 2:204 mammalian reovirus uses, 2:258 microbiological quality control using considerations for, 3:747 description of, 3:742 mycoplasma, 3:744 validation of, 3:747 viral genomic sequences detected using, 3:747–748 minute virus of mice uses, 2:100 mouse parvovirus uses, 2:100 mousepox virus uses, 2:87, 2:161–162 murine cytomegalovirus uses, 2:32 Mycoplasma pulmonis uses, 2:452 Pasteurellaceae uses, 2:495 Sendai virus uses, 2:297 serologic testing using, 3:396–397 Polyoma virus. See Mouse polyoma virus; Murine pneumotropic virus Polyplax serrata clinical features, 2:567 diagnosis, 2:567–568 host range, 2:567 life cycle, 2:566 morphology, 2:566 pathobiology, 2:567 prevention and control, 2:568 treatment, 2:568 Polyubiquitination, 4:237 Polyuria, 3:77 Pons, 3:7 Popliteal lymph node assay, 1:304 Popliteus lymph node, 3:22 Porphyromonas gingivalis, 3:552 Portal vein catheterization, 3:476 Portio vaginalis uteri, 3:21 Positional cloning, overview, 1:109 Positive flow mass air displacement units, 3:300 Positive selection, 4:208–209 Positron emission tomography, 3:504–3:505 Postanesthetic care, 3:479–480 Postoperative care, 3:479–480 Potassium daily requirements for, 3:336 measurement of, 3:207 reference range for, 3:181
Pou5fl, 4:127 Power analysis, 3:658–660, 3:667 Poxviruses. See Mousepox Ppgb, 3:622 Praziquantel, 2:732 Preanesthetic medications, 3:460–461 Preclinical testing. See Drug discovery Predator response, 1:34–35 Predictive validation, 3:653 Pregnancy description of, 3:103 energy requirements during, 3:327, 3:329 euthanasia during, 3:468 handling during, 3:440 human handling effects on, 3:109 progesterone’s role in, 3:203 stages of, 1:185–186 Pregnant mare serum gonadotrophin, 3:226 Preimplantation development, 3:102 Prekallikrein, 3:157 Prenatal mortality, 1:37 Preputial glands, 3:711 Preputium, 3:18–19 Preputium clitoridis, 3:21 Presenilin-1, 3:683–684 Presenilin-2, 3:683–684 Pressure-volume curves, 3:55–56 Primary open angle glaucoma, 3:604–605 Primitive erythropoiesis description of, 3:135 erythropoietin’s function during, 3:159 Primitive hematopoiesis erythroid cells in, 3:158–159 macrophages in, 3:159 megakaryocytes in, 3:159 onset of, 3:158 Primordial follicles, 3:99 Primordial germ cells description of, 3:92 embryogenesis of, 1:171, 1:173 in genital system development, 3:92–93 Prions, 3:734 Prkdcscid, 4:278 Prkwnk, 1:311 Probucol, 3:539, 3:550 Procarbazine, 1:229–230 Procedure laboratories, 3:278–279 Production colony definition of, 3:236 of outbred stock, 3:256 sections of, 3:259 Production colony segment, 3:236, 3:259 Production index, 3:259 Production report, 3:263–264 Production sales ratio, 3:265 Proestrus description of, 3:100–101 timed mating, 3:111 Progesterone description of, 3:102, 3:203 reference ranges for, 3:181 Programmed death-1, 4:28
Programming, 3:631 Progressive motor neuronopathy, 3:677 Progressive myoclonus epilepsies, 3:569–571 Progressive neuronal degeneration, 3:576 Prolactin, 3:77, 3:181, 3:203 Prolactin receptors, 3:103, 3:203 Promoters, 1:90 Promyelocytes, 3:148 Pronator teres, 3:6 Pronuclear microinjection principles, 1:214–216 transgenic mouse preparation, 1:216 Proopiomelanocortin, 3:184 Proparacaine hydrochloride, 3:179, 3:455 Prostaglandins D2, 3:196 E1, 3:196–197 E2, 3:72 F2α, 3:103, 3:196, 3:203 H2, 3:196 renal, 3:71–72 Prostata, 3:19 Prostate gland, 3:96 Protein body collection of, 3:459 dietary protein conversion to, 3:325 dietary amino acids, 3:331–333 for breeding, 3:332 in commercial diets, 3:334 composition of, 3:331 conversion to body protein, 3:325 digestible energy and, ratio between, 3:332 digestion of, 3:66 excretion of, 3:72–73 food intake effects on, 3:367 infectious diseases and, 3:370 kidney damage induced by, 3:334 measurement of, 3:331 quality of, 3:331 reference range for, 3:181 requirements for, 3:331–332 restriction of, 3:368 total serum, 3:208 turnover of, 3:367 Protein inhibitor of activated STATs description of, 4:180–182 in vivo functions of, 4:188 Pias1-deficient mice, 4:188 Piasx-deficient mice, 4:189 Piasy-deficient mice, 4:188–189 Protein kinase Cd, 4:254 Protein tyrosine kinase, 4:254 Protein tyrosine phosphatases description of, 4:180, 4:189 in vivo functions of, 4:189 JAK-STAT pathway regulation by, 4:182–183, 4:189 Proteinuria, 3:72, 3:207 Proteoglycans, 4:35 Proteomics, 3:174
362 Proteus mirabilis classification, 2:378 clinical features, 2:378 diagnosis, 2:379 epizootiology, 2:378–379 history of study, 2:377–378 pathogenesis, 2:378 properties, 2:378 treatment and control, 2:379 Prothrombin time, 3:141, 3:157, 3:206 Protozoa. See also specific organisms comparison of murine pathogens, 2:519 taxonomy, 2:518–519 P-selectin glycoprotein ligand 1, 4:296 Pseudogenes, 1:104 Pseudomonas aeruginosa clinical features, 2:382 control, 2:382–383 description of, 3:308, 3:372, 3:392 diagnosis, 2:382 epizootiology, 2:382 history of study, 2:380–381 pathogenesis, 2:381–382 properties, 2:381 spread of, 3:453 in watering systems, 3:418, 3:420 Pseudopregnancy, 3:103, 3:112 Psoas major, 3:7, 3:14 Psoas minor, 3:7 Psorergates simplex clinical features, 2:575 diagnosis, 2:575 host range, 2:574 life cycle, 2:574 morphology, 2:574 pathobiology, 2:575 prevention and control, 2:575 treatment, 2:575 PTEN knockout mouse, 2:599-603 prostate cancer signaling, 2:599–601 Pteroylmonoglutamic acid, 3:341 Pth, 3:128–129 Pthlh, 3:129 Pthrp, 3:720 Ptp1b, 4:189 Ptpra, 3:622 PTZ. See Pentylenetetrazol PTZ-induced epileptic seizures, 3:577, 3:582 PU.1, 3:142, 3:159, 4:34 Puberty description of, 3:94 onset of, 3:239 pheromones effect on, 3:94 signs of, 3:94 Pulmo sinister, 3:12–13 Pulmonary arteries, 3:52 Pulmonary cells, 3:459 Pulmonary circulation, 3:51–52 Pulmonary dynamic compliance, 3:56 Pulmonary function tests and testing airway pressure, 3:56 alveolar fluid transport, 3:61 barometric plethysmography, 3:59–61 body plethysmography, 3:54
CUMULATIVE
Pulmonary function tests and testing (continued) contraction of isolated airway segments, 3:55 definition of, 3:53 diffusion capacity of lungs, 3:61 ex-vivo techniques, 3:55–56 forced oscillation technique, 3:59 gas dilution, 3:54–55 in-vivo techniques, 3:56–61 in mice, 3:55–61 monitoring uses of, 3:53 pressure-volume curves, 3:55–56 spirometry, 3:54 Pulmonary resistance, 3:56, 3:58, 3:60 Pulmonary valve, 3:27 Pulmonary veins, 3:27 Pulmonary venules, 3:52 Pulsed vacuum sterilization, 3:305 Pulsed-field gel electrophoresis, 2:428 Pups caesarean section delivery of, 3:251 cannibalism of, 3:109 cross-fostering of, 3:252 cryoanesthesia of, 3:464–465 drug administration in, 3:453 energy requirements of, 3:330 fostering of, 3:112 growth of, 3:109 handling of, 3:440 infanticide of, 3:109 resuscitation of, 3:467–468 thymectomy in, 3:472 Purified diet for carcinogenicity studies, 3:352 composition of, 3:351–352 description of, 3:337, 3:351–352 manufacturing of, 3:359 vitamin levels in, 3:342 Purine nucleoside phosphorylase, 1:311 Purkinje cells degeneration of, 3:678 description of, 3:27 PVM. See Pneumonia virus of mice Pylorus, 3:16 Pyridoxal-5’ phosphate, 3:369 Pyridoxine, 3:341 Pyrimethamine Sarcocystis muris management, 2:533 Toxoplasma gondii management, 2:536 Pyrogen test, 3:742 Pyromys, 1:14
Q Q wave, 3:37 Qa2, 4:126 Q-banding, 1:148–149 QRS interval, 3:37 QT interval, 3:37 QTL. See Quantitative trait loci Quadriceps, 3:4 Quality assurance in clinical chemistry, 3:182 health care staff for, 3:389
INDEX
Quality assurance (continued) overview of, 3:386–387 Quality assurance program agents to be tested, 3:390 cage washers, 3:416 colony animal testing bacterial agents, 3:397–398 enzyme-linked immunosorbent assay, 3:396 frequency of, 3:395 Helicobacter spp., 3:397 hemagglutination inhibition assays, 3:396 immunofluorescence antibody testing, 3:396 Mycoplasma arthritidis, 3:397 Mycoplasma pulmonis, 3:397 number of animals to be tested, 3:395 parasites, 3:397–398 Pasteurella pneumotropica, 3:397 serologic tests, 3:395–396 sick or deceased animals, 3:394 variations in results, 3:394–395 viral genetic material, 3:396–397 components of, 3:390 costs of, 3:390 customization of, 3:390 importance of, 3:389 quarantine. See Quarantine sentinel animal testing, 3:393–394 serology used by, 3:393 testing frequency, 3:390, 3:393 Quantitative loci analysis, 3:578 Quantitative trait loci description of, 3:598 drug response gene mapping, 1:305–306 history of study, 1:7 linkage mapping, 1:126–127 mapping, 3:626–627, 3:649–650 natural alleles identified by, 3:626–627 nomenclature, 1:93–94 obesity, 3:619–620 single nucleotide polymorphisms, 1:107–108 Quarantine housing for, 3:278–280, 3:312, 3:399 importance of, 3:398 isolation, 3:399 of newly delivered animals, 3:393 process involved in, 3:399 testing during, 3:399–400 Quaternary ammonium compounds, 3:309 Quats, 3:425 Quiescent phase, of estrous cycle, 3:100
R Rabies clinical signs, 2:723 diagnosis of, 2:723 reservoir and incidence, 2:722 treatment of, 2:723 Rac GTPases, 4:202 Radappertization, 3:363
CUMULATIVE
363
INDEX
Radfordia spp. clinical features, 2:575 diagnosis, 2:575 host range, 2:575 life cycle, 2:575 morphology, 2:575 pathobiology, 2:575 prevention and control, 2:575–576 R. affinis, 3:398 treatment, 2:575–576 Radiation hybrid mapping, 1:130 Radicidation, 3:363 Radio frequency transponders, 3:266 Radioallergosorbent test, 2:738 Radionuclides, 3:280–281, 3:503 Radiopharmacy, 3:283 Radiotelemetry, 3:34–35 Radiotracers, 3:505 Radius, 3:4 Radix pulmonum, 3:10–11 Radurization, 3:363 RAG-1, 4:48 RAG-2, 4:48 Rag1, 4:278–279 Rag2, 1:286, 4:278–279 rag-1/2, 4:61 RAG/τc, 4:279 Rami arteriae et venae pulmonalis, 3:13 Rami cardiaci nervorum vagorum, 3:11 Rami pulmonales, 3:10–11 Ramus cardiacus nerve vagi dextri et sinistri, 3:10 Ramus communicans cum nervos sympathico, 3:10–11 Ramus muscularis dorsalis dexter, 3:17 Ramus muscularis dorsalis sinister, 3:17 Ramus ovaricae sinistrae, 3:21 Ramus thymicus dextra, 3:9–11 Ramus thymicus sinister, 3:9 Ramus uterinus arteriae, 3:21 Random bred colony, 3:267 RANKL description of, 3:126 parathyroid hormone affected by, 3:129 Rap1, 4:199–200 RapL, 4:199–200, 4:203 Ras, 2:597, 2:599–600, 2:603 Rasgrp1, 4:255 RAST. See Radioallergosorbent test Rat bite fever clinical signs, 2:727–728 diagnosis, 2:728 pathogens, 2:727 reservoir and incidence, 2:727 transmission, 2:727 Raw materials biologicals, 3:738 microbial contamination considerations, 3:738 in natural-ingredient diet, 3:358 R-banding, 1:149 RBG-banding, 1:149 Rearing behaviors, 3:109 Receptor activator of NF-kB ligand, 4:71 Receptor editing, 4:48
Receptor recombinase, 4:38 Recessive allele, 1:57–58 Recombinant congenic strains features, 1:71, 1:84 gene mapping, 1:128 Recombinant inbred strains definition, 2:628 description of, 3:173 features, 1:71, 1:84 gene mapping, 1:127–128 historical perspective, 1:7 intercross lines, 1:128 Recombination, genome analysis, 1:108 Recombination signal sequences, 4:38, 4:44 Records breeding cage-level, 3:262–263 description of, 3:104 pedigree card, 3:262–263 pedigree ledger, 3:263, 3:265 pedigree tree, 3:265 production report, 3:263–264 of sick mice, 3:387 Rectal administration of drugs, 3:446–447 Rectum, 3:15, 3:18 Rectus femoris, 3:4, 3:6–3:7 Red blood cell. See Erythrocyte(s) Red blood cell count changes in, 3:146–148 description of, 3:141, 3:143–144 in young mice, 3:161 Red blood cell indices, 3:144 Red cell distribution width description of, 3:141, 3:143 hemorrhage effects on, 3:147 Red cell mass absolute, 3:147 absolute decreased, 3:147 decreases in, 3:147–148 increases in, 3:146–147 relative decreased, 3:147 Rederivation embryo harvesting, 1:220 shipping, 1:220 surgical embryo transfer, 1:220–221 in vitro culture, 1:220 Reference colony, 3:236 Reference intervals, 3:136 References ranges definition of, 3:180 list of, 3:181 variability, 3:180, 3:182 Regio abdominis lateralis, 3:2 Regio analis, 3:2 Regio antebrachii, 3:2 Regio apicis caudae, 3:2 Regio articulationis coxae, 3:2 Regio articulationis humeri, 3:2 Regio articulationis temporomandibularis, 3:2 Regio auricularis et auricula, 3:2 Regio axillaris, 3:2 Regio brachii, 3:2 Regio buccalis, 3:2
Regio carpi, 3:2 Regio clitoridis, 3:2 Regio clunis, 3:2 Regio colli dorsalis, 3:2 Regio colli ventralis, 3:2 Regio corporis caudae, 3:2 Regio costalis, 3:2 Regio cruris, 3:2 Regio cubiti, 3:2 Regio dorsalis nasi, 3:2 Regio femoris, 3:2 Regio frontalis, 3:2 Regio genus, 3:2 Regio glutea, 3:2 Regio hypochondriaca, 3:2 Regio infraorbitalis, 3:2 Regio inguinalis, 3:2 Regio intermandibularis, 3:2 Regio interscapularis, 3:2 Regio lateralis nasi, 3:2 Regio lumbalis, 3:2 Regio mammaria abdominalis, 3:2 Regio mammaria inguinalis, 3:2 Regio mammaria thoracica, 3:2 Regio mandibularis, 3:2 Regio manus, 3:2 Regio masseterica, 3:2 Regio mentalis, 3:2 Regio naris et apex nasi, 3:2 Regio occipitalis, 3:2 Regio olecrani, 3:2 Regio oralis, 3:2 Regio orbitalis, 3:2 Regio parietalis, 3:2 Regio parotidea, 3:2 Regio pedis, 3:2 Regio perinealis, 3:2 Regio plicae lateris, 3:2 Regio presternalis, 3:2 Regio pubica, 3:2 Regio radicis caudae, 3:2 Regio sacralis, 3:2 Regio scapularis, 3:2 Regio sternalis, 3:2 Regio subhyoidea, 3:2 Regio supraorbitalis, 3:2 Regio tarsi, 3:2 Regio temporalis, 3:2 Regio trachealis, 3:2 Regio tricipitalis, 3:2 Regio tuberis coxae, 3:2 Regio tuberis ischiadici, 3:2 Regio umbilicalis, 3:2 Regio vertebralis thoracis, 3:2 Regio vulvae, 3:2 Regio xiphoidea, 3:2 Regio zygomatica, 3:2 Regulator of complement activation, 3:190 Regulatory T cells, 4:42 Related inbred strain, definition, 2:628 Relative decreased red cell mass, 3:147 Relative humidity description of, 3:291 in diet, 3:361 Reliability, 3:521–522
364 Ren dexter, 3:14, 3:17 Ren sinister, 3:14, 3:17–18, 3:20 Renal artery catheterization, 3:477 Renal clearance, 3:73–74 Renal corpuscle, 3:70 Renilla luciferase, 3:506 Renin-angiotensin system, 3:71 Reoviridae. See Mammalian reovirus; Rotavirus Reovirus-3, 3:391 Replication, 1:108 Replication protein A, 4:161 Repolarization, 3:37 Reproduction. See also Breeding artificial insemination, 1:212, 3:227 breeding records, 3:104 colony for evaluation of, 3:110 health status of, 3:105 maintenance of, 3:104–105 troubleshooting the performance of, 3:109–110 energy necessary for, 3:105 environmental effects enrichment, 3:108 feed, 3:107–108 housing, 3:109 human interaction, 3:109 humidity, 3:107 light, 3:106, 3:238, 3:291 sound, 3:106 temperature, 3:106–107, 3:239 time of year, 3:108–109 vibration, 3:106 in vitro fertilization principles, 1:212–213 rederivation, 1:220–221 intracytoplasmic sperm injection principles, 1:213–214 somatic nuclear transfer, 1:221–222 steps, 1:214 transgenic mouse preparation, 1:216 natural killer cells’ role in, 4:173–174 nesting material effects on, 3:306 overview of, 3:103–104 phytoestrogen effects on, 3:350 timed mating, 3:111–112 Reproductive system illness signs, 3:388 necropsy evaluations, 3:483 ontogeny of, 3:92–94 Reproductive tract development of, 3:93 female anatomy of, 3:97–99 cervix, 3:98–99 description of, 3:97 evaluation of, 3:110 ovary, 3:97 oviduct, 3:97–98 uterus, 3:98 vagina, 3:99 male accessory glands, 3:96 description of, 3:94–95
CUMULATIVE
Reproductive tract (continued) epididymis, 3:95–96 evaluation of, 3:110 excretory ducts, 3:95–96 illustration of, 3:95 penis, 3:96 testes, 3:95 urethra, 3:96 necropsy evaluations, 3:483 Research facilities animal receipt and transport, 3:312–313 animal receiving area, 3:284 architecture of, 3:272–287 automatic watering systems in, 3:241, 3:285–286, 3:308 automation in, 3:285–287, 3:412 barrier in, 3:273–274, 3:311 bedding used in, 3:305–306 biological safety cabinets Class I, 3:300–301 Class II, 3:301, 3:313 Class III, 3:302 illustration of, 3:281–3:282 building, 3:272–273 cages in. See Cage chemicals used in alcohols, 3:310 chlorine dioxide, 3:309–310 description of, 3:309 disinfectants, 3:309 halogens, 3:309 paraformaldehyde, 3:310 peracetic acid, 3:310 quaternary ammonium compounds, 3:309 synthetic phenols, 3:310 vaporized hydrogen peroxide, 3:310 circulation patterns in, 3:274–3:275 corridor systems in, 3:274–3:275 drinking water acidification of, 3:308 additives in, 3:308 anthelmintics added to, 3:309 antibiotics added to, 3:309 bisphenol A contamination, 3:307 chlorine added to, 3:308–309, 3:372, 3:418–419 hydrochloric acid added to, 3:308, 3:418 processing of, 3:307–308 reverse osmosis of, 3:307 steam sterilization of, 3:308 ultraviolet disinfection of, 3:307–308 variations in, 3:306–307 environment of air quality in, 3:295 ammonia, 3:293 carbon dioxide concentrations, 3:293 enrichment of, 3:314 lighting, 3:291–292 macroenvironment, 3:288–293 microenvironment, 3:292–294 monitoring of, 3:292–293 noise, 3:292 overview of, 3:287–288
INDEX
Research facilities (continued) relative humidity, 3:291 temperature, 3:290–292 exclusion level in, 3:311 feed used in, 3:304–305 floor plan, 3:273–274 hazardous agent containment, 3:279–281 heating, ventilation, and air-conditioning system, 3:272–273, 3:288–290 holding rooms description of, 3:274–276 lighting in, 3:292 temperature in, 3:291 imaging facilities, 3:282–283 information resources, 3:272 isolators, 3:299 material transport in, 3:311–312 mechanical washing equipment in, 3:302–304 necropsy facilities, 3:281–282 operational issues for, 3:311–314 personal protective equipment used in, 3:313–314 personnel in, 3:312 plan of, 3:272 procedure laboratories, 3:278–279 quarantine facility, 3:278–280, 3:312 rack installation in, 3:276 radiopharmacy in, 3:283 receiving area, 3:284 room-level exclusion, 3:311 security considerations, 3:273, 3:411 site selection for, 3:272–273 soiled cage wash, 3:311–312 standard operating procedures in, 3:311 summary of, 3:314 support areas, 3:284 ventilated cage. See Ventilated cage vibration considerations, 3:273 washers used in, 3:302–303, 3:310 water delivery automated systems, 3:241, 3:285–286 water bottles, 3:241, 3:286–290 Residual volume, 3:53–3:54 Resistin, 3:184 Resorcylic acid, 3:348 Respirators, 3:313 Respiratory muscles, 3:52 Respiratory rates, 3:52, 3:57 Respiratory system breathing patterns, 3:52–53 description of, 4:292 illness signs, 3:388 lungs. See Lung(s) physiology of, 3:48 Respiratory tract conducting zone, 3:49 description of, 3:48–49 larynx, 3:49–50 lower, 3:50–51 nasal cavity, 3:49 pharynx, 3:49 trachea, 3:50 upper, 3:49–50
CUMULATIVE
365
INDEX
Respiratory transfer impedance, 3:59 Respiratory zone, 3:49–50 Restenosis, 3:554 Resting heart rate, 3:39–40 Restraint for blood collection, 3:454 devices used for, 3:443–444 forceps, 3:439, 3:443 objective of, 3:442 polyethylene collar, 3:444 Restricted flora, 3:218 Restriction fragment length polymorphism, 1:118 Reticulocytes blood smear count of, 3:145 characteristics of, 3:144–145 definition of, 3:144 flow cytometric scatter for, 3:145 formation of, 3:143 hemorrhage effects on, 3:147 lyse-resistant, 3:152 Retina angiogenesis of, 3:599 astrocyte migration, 3:599 in C57BL/6 mice, 3:600 cells of, 3:607 degeneration of apoptosis and, 3:607 modifiers of, 3:609–611 mouse models of, 3:679 overview of, 3:605 photoreceptor degeneration, 3:607 primary, 3:607, 3:609 retinal folds associated with, 3:609 description of, 3:596 development of, 3:605, 3:607–3:608 dysplasia of, 3:601 lamination disorders of, 3:600–3:601 progenitor cells, 3:607 synaptic network, 3:607 Retinal degeneration-1, 3:598 Retinal pigment epithelium, 3:609 Retinitis pigmentosa description of, 3:607 murine cytomegalovirus myocarditis model, 2:25 retinoblastoma, 3:675 Retinoic acid inducible gene-I, 4:114 Retinoic acid–early inducible-1, 4:173 Retinol, 3:339, 3:342 Retroelement, 2:269–270 Retrograde perfusion, 3:29–30 Retro-orbital injection, 3:452 Retrotransposon insertional mutagenesis, 2:272 types, 2:270 Retroviruses. See also specific viruses description of, 3:736–737 gene transfer vectors, 1:272–273 infectivity assays for, 3:749 lentivirus vectors, 1:273–274 oncoretrovirus vectors, 1:273 quantitative assays for, 3:749 Reverse cholesterol transport, 3:186 Reverse osmosis, 3:307, 3:372, 3:420
Reverse transcriptase-polymerase chain reaction, 3:400, 3:748 RFLP. See Restriction fragment length polymorphism Riboflavin, 3:340 Ribosomal DNA, 1:150 Rickettsialpox clinical signs, 2:724–725 control and prevention, 2:725 geographic distribution, 2:724 Rieger’s malformation, 3:597 Right atrium, 3:27 Right coronary artery, 3:28 Right ventricle anatomy of, 3:27 pressure measurements, 3:36 Ring3, 4:123 Ringworm. See Dermatophytosis RNA interference history of study, 1:8 overview, 1:109 pharmacogenomic study prospects, 1:315 small interfering RNA delivery, 1:265–266 Rodent jacket, 3:443, 3:448 Rodent restraint bag, 3:443–444 Rodentolepis spp. R. microstoma, 2:561 R. nana features and management, 2:559–560 human infection, 2:732 Romanowsky-type stain, 3:140 Room level bioexclusion facility, 3:243–245 Roquin, 4:237–238 rora, 3:676 Rotavirus age effects, 2:243–244 cell culture growth studies, 2:240–241 control and prevention, 2:245 description of, 3:391 diagnosis, 2:246 diarrhea mechanisms, 2:242 genome, 2:238 history of study, 2:236–237 host range, 2:244–245 immune response, 2:242–243 pathogenesis, 2:241–242 stability, 2:238–239 strains electropherotypes, 2:239 groups, 2:239 murine strains, 2:240 serotypes, 2:239–240 structure, 2:237–238 RPE65, 3:609 RT1-N, 4:128 Runt-related transcription factor 1, 4:268 RV. See Residual volume
S S cells, 3:64 S wave, 3:37 SAA, 3:208 Sacculus rotundus, 3:15 Saccus cecus ventriculi, 3:16
Salicylazo-sulfapyridine, 3:367 Saliva collection, 3:458–459 Salivary glands, 3:63 Salmonella spp. classification, 2:369–370 clinical features humans, 2:729 mice, 2:371–372 description of, 3:346, 3:353 diagnosis, 2:372–373 epizootiology, 2:371 history of study, 2:370 pathogenesis, 2:371 properties, 2:370–371 reservoir and incidence, 2:728–729 S. enterica, 3:392 S. typhimurium, 4:112 SAMP-8 mice, 3:652 Sampling, 3:179–180 Sanitation background, 3:423 cage sanitation area chemical storage in, 3:277 clean activity, 3:277 description of, 3:276–277 location of, 3:273–274 mechanical equipment in, 3:277 soiled activity, 3:277, 3:285 disinfectants. See Disinfectants microbiological monitoring, 3:427–428 Saphenous vein blood collection, 3:456 Saponins, 3:351 Sarcocystis muris cell biology, 2:532 clinical features, 2:532–533 diagnosis, 2:533 history of study, 2:532 life cycle, 2:532 prevention, 2:533 research implications, 2:533 treatment and control, 2:533 Sarcopenia, 3:660 SC. See Synaptonemal complex Scapula, 3:4 Scavenger receptors, 3:187 Schistosoma mansoni, 3:150 Schlemm’s canal, 3:602–603 SCID mice, 3:260 SCID/BG mice, 3:260 SCL, 3:159 Scleral spur, 3:602 Scn2a, 3:568 S-cone syndrome, 3:607 “Scruff-of-the-neck” handling method, 3:440 Seasons mouse populations fluctuations, 1:38–39 reproduction affected by, 3:108–109 Sebaceous glands, 3:711–712 Second messengers, 3:125 Secondary follicle, 3:99 Secretin, 3:63 Security, 3:273, 3:411 Segregating inbred strains breeding, 1:63–64 nomenclature, 1:87
366 Seizures audiogenic definition of, 3:578 description of, 3:292, 3:415 in epilepsy prone mice, 3:580–581 experimental epilepsy model use of, 3:578–581 Frings mice, 3:571 genetic studies of, 3:580 interstrain variability in, 3:578–579 long-term potentiation and, 3:579 monogenic, 3:571–573 neurochemical findings, 3:579–580 neuropathologic findings, 3:579 serotonin levels and, 3:580 sudden unexpected death in epilepsy and, 3:579 susceptibility to, 3:578–579 EL mouse model. See EL mouse epileptic characteristics of, 3:566 classification of, 3:566 electroconvulsive shock-induced, 3:576–577 generalized, 3:566 kainic acid-induced, 3:577–578 partial, 3:566 PTZ-induced, 3:577, 3:582 quantitative trait loci mapping of drug response genes, 1:305–306 Selamectin, 2:558 Selectins, 4:296 Selenium, 3:336, 3:346, 3:370–371 Self-tolerance, 4:42–43 Semi-critical infection risks, 3:424 Semimembranosus, 3:6–7 Seminal vesicles, 3:96 Seminiferous tubules, 3:95 Semipermanent identification methods, 3:441 Semirigid isolators, 3:220–221, 3:245, 3:300 Semitendinosus, 3:6–7 Sendai virus age effects, 2:288 classification, 2:282 clinical features, 2:287 control of, 2:298 description of, 3:391, 3:402 diagnosis, 2:297–298 genome, 2:282–283 geographic distribution, 2:296 history of study, 2:282 host range, 2:296 human infection, 2:724 immune response adaptive immunity, 2:295–296 innate immunity, 2:292–295 pathology gross changes, 2:290 microscopic changes, 2:290–292 prevention of, 2:298 propagation cell culture, 2:286–287 eggs, 2:286 mice, 2:285–286
CUMULATIVE
Sendai virus (continued) receptors, 2:283 sex differences, 2:288 strains, 2:284–285 structure, 2:283–284 susceptibility of inbred strains, 2:288–290 target sites, 2:287–288 transmission, 2:297 Senescence aging vs., 3:640, 3:642–644 biological organization and, 3:640–642 disease vs., 3:642–644, 3:668 hypermorphosis-related, 3:640–641 immunologic, 3:642 life span and, 3:655–656 long-lived treatment models of, 3:651 onset of, 3:640 phenotypic shift, 3:640 rate biomarker of, 3:653 replication of symptoms of, 3:652 short-lived treatment models of, 3:651–652 T-cell, 3:640–641 Senescence-accelerated mice, 2:639 Sentinel animals aerosol exposure, 3:393–394 bedding transfer, 3:394 contact, 3:394 quality assurance testing of, 3:393–394 quarantine of, 3:399–400 soiled bedding exposure, 3:393–394 Sequence tagged sites, 1:90 Serial analysis of gene expression, 3:605 Serine protein inhibitor, 3:609 Serologic tests and testing disadvantages of, 3:395–396 enzyme-linked immunosorbent assay, 3:396 hemagglutination inhibition assays, 3:396 immunofluorescence antibody testing, 3:396 Serotonin, 3:580 Serotonin receptor, 3:575 Serratus ventralis, 3:4 Sertoli cells description of, 3:95 in spermatogenesis, 3:96 Serum reference range for, 3:181 storage of, 3:187 viral infections, 3:735 Serum amyloid P, 4:252 Serum amyloid protein, 3:190 Severe combined immune deficiency description of, 4:183 mouse models, 4:278, 4:307 Sevoflurane, 3:464 Sex chromosomal, 3:92 definition of, 3:92 determination and differentiation of, 3:92–94 energy requirements based on, 3:325 gonadal, 3:92 Sex-linked allele, 1:58–59
INDEX
Sexual dimorphism adrenal gland, 2:631 definition, 2:630 kidney, 2:631 parotid gland, 2:632 pathology. See specific organisms submandibular salivary gland, 2:631–632 Sexual dysfunction, 3:583 Sexual maturation, 1:36 SH2-containing protein tyrosine phosphatase, 4:83 5(S)-HETE, 3:197 12(S)-HETE, 3:197 15(S)-HETE, 3:197 SHH. See Sonic Hedgehog Shh null mice, 3:704 Shigella sonnei, 3:228 SHIP, 4:263–264, 4:270 Shipping of animals, 3:399 of feed, 3:422 SHIRPA protocol, 1:248–249 Shoe covers, 3:313 Short consensus repeat units, 4:10 Short interspersed nuclear elements, 1:104 Short-lived models, 3:651–652 SHP-1, 4:263, 4:269–270 SHP-2, 4:28, 4:263 Shp1, 4:189 Shp2, 4:189 Sialogogues, 3:458 Sick mice animal care staff observations of, 3:387 illness signs, 3:387–3:388 initial observations and actions, 3:388–389 reporting of, 3:387–389 testing of, 3:394 Signal-to-noise, 3:491 Signal-to-noise ratio, 3:43 Silica dioxide, 3:363 Silicon, 3:336 Simple sequence length polymorphism, 1:118–119 SINEs. See Short interspersed nuclear elements Single nucleotide polymorphisms comparative genome analysis, 1:106 description of, 3:649 genetic monitoring, 1:140–142 haplotype mapping, 1:126 linkage mapping, 1:118–120 quantitative trait loci, 1:107–108 Single photon nuclear imaging, 3:502–504 Single-photon emission computed tomography, 3:43, 3:504, 3:509 Single-strand conformational polymorphism, 1:256 Sinoatrial node, 3:27 Sipper tubes, for water delivery, 3:419 Six1, 4:65 SJL/J mice development, 2:654 phenotype, 2:654 spontaneous diseases
CUMULATIVE
367
INDEX
SJL/J mice (continued) comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:655 nonneoplastic conditions, 2:654 pathogen susceptibility, 2:654–655 Sjogren’s syndrome, 3:191 SKAP-55, 4:199 Skeleton, 3:4 Skeleton capitis, 3:4 SKH-1 mice bedding considerations for, 3:241 production index for, 3:260 Skin barrier function of, 4:32 cornification of, 4:32 drug administration through, 3:447–449 epidermis, 3:712 functions of, 3:692, 4:32 illness signs, 3:388 interfollicular, 3:712–713 production of, 3:693 Skin appendages hair follicles. See Hair follicles illustration of, 3:693 nails, 3:714–716 sebaceous glands, 3:711–712 sweat glands, 3:713 volar pads, 3:714–718 Skin grafts, 3:472–473 Skull, 3:2 SKY. See Spectral karyotyping Sle1, 4:249–250 Sle2, 4:251 Sle3/5, 4:250–251 Slow wave epilepsy, 3:575 SLP-76, 4:199 Slp, 4:124 SLT. See Specific locus test Small interfering RNA. See RNA interference Small intestine description of, 3:65–66 necropsy evaluations, 3:483 Smears blood evaluation of, 3:140, 3:145 preparation of, 3:139 reticulocyte count on, 3:145 bone marrow, 3:139–3:140 SMN, 3:678 α-Smooth muscle actin, 3:720 Snell dwarf mutation, 3:660, 3:665 SNPs. See Single nucleotide polymorphisms SNT. See Somatic nuclear transfer Social behavior, 1:32–34 Social cues pheromone transmission of, 3:109 puberty affected by, 3:94 Socs5 transgenic mice, 4:188
Sodium daily requirements for, 3:336 measurement of, 3:207 reference range for, 3:181 Sodium hypochlorite, 3:309, 3:419–420, 3:426 Sodium lamps, 3:291 Soiled bedding, 3:277, 3:285 Soiled cage wash, 3:311–312 Somatic cell hybrids, 1:130 Somatic cells, 3:93 Somatic hypermutation cytidine deamination in, 4:161 description of, 4:94–96, 4:156–157 mismatch repair proteins in, 4:164 proteins involved in, 4:158–160 Somatic nuclear transfer fusion, 1:222 intracytoplasmic sperm injection, 1:221–222 Somatostatin, 3:183 Sonic hedgehog description of, 3:703, 3:705 knockout mouse phenotype, 1:313 Sorbitol dehydrogenase, 3:200 Sound effects on reproduction, 3:106 Soya oil, 3:335 S1P1, 4:202 SP-A, 4:14 SPA-1, 4:200 Spatial resolution, 3:490 SP-D, 4:14 Specific dynamic action, 3:325 Specific dynamic effect, 3:325 Specific intracellular adhesion molecule-3 grabbing non-integrin family, 4:13 Specific locus test, 1:227 Specific minimal energy cost, 3:67 Specific pathogen free breeding colony, 3:247–248, 3:660 description of, 3:218, 3:312, 3:389, 3:525 Specimen collection bile, 3:454 blood. See Blood collection bone marrow, 3:458 cerebrospinal fluid, 3:458 feces, 3:458 lacrimal fluid, 3:459 lymph, 3:460 milk, 3:459 ova, 3:459–460 peritoneal cells, 3:459 pulmonary cells, 3:459 saliva, 3:458–459 sperm, 3:460 urine, 3:458, 3:460 Spectral Doppler echocardiography, 3:46 Spectral karyotyping applications, 1:146–147, 1:154 principles, 1:153–154 Sperm collection of, 3:460 genistein effects on, 3:350 maturation of, 3:95 motility of, 3:102
Spermatids, 3:96–97 Spermatogenesis events necessary for, 3:96–97 hormonal control of, 3:97 Sertoli cells in, 3:95–96 Spermatogonia, 3:96 Spermiogenesis, 3:97 Sphincter ani externus, 3:18, 3:20 Sphincter colli superficialis, 3:4 Sphincter of Oddi, 3:64 Spi-B, 4:95 Spinal and bulbar muscular atrophy, 3:681 Spinal muscular atrophy, 3:678 Spindle cell tumor, 2:596 Spine, 1:197 Spinocerebellar ataxia, 3:680–681 Spirometry, 3:54 Spironucleus muris cell biology, 2:524 clinical features, 2:524 diagnosis, 2:524 life cycle, 2:523 morphology, 2:523 prevention, 2:524 research implications, 2:524 taxonomy, 2:523 treatment and control, 2:524 Spleen accelerated erythropoiesis in, 3:163 anatomy of, 4:77 dendritic cells, 4:147–148 description of, 4:69 development of, 4:75–76 erythropoiesis in, 3:163 granulopoiesis, 3:163 hematopoietic role of, 3:162–163 hematopoietic stress effects on, 3:163 megakaryocytes in, 3:162 megakaryocytopoiesis in, 3:163 red pulp of, 4:77 white pulp of, 4:77 Splenectomy, 3:162–163, 3:471 Splice variants functions, 1:103–104 nomenclature, 1:90 Spontaneous disease. See specific strains Sprague Dawley rats, 3:128 Sry, 3:92 SSCP. See Single-strand conformational polymorphism SSLP. See Simple sequence length polymorphism ST segment, 3:37 staggerer, 3:676 Stainless steel isolators, 3:219, 3:221 Standard operating procedures, 3:311, 3:411 Staphylococcus spp. clinical features, 2:391–394 culture, 2:390 diagnosis, 2:394–395 epizootiology, 2:394 properties, 2:390 S. aureus, 2:729–730, 3:392, 3:742 strains, 2:390–391 treatment and control, 2:382–383
368 Stargazer, 3:573–574 stargazer, 3:573 Static microisolator cages, 3:294–295 STATs description of, 4:180–181 in vivo functions of, 4:185 Stat5a- and Stat5b-deficient mice, 4:186 Stat1-deficient mice, 4:184 Stat2-deficient mice, 4:184 Stat3-deficient mice, 4:184, 4:186 Stat4-deficient mice, 4:186 Stat6-deficient mice, 4:186 Stat1S727A-mutant mice, 4:184 Stat3S727A-mutant mice, 4:184, 4:186 Steam sterilization chemical-based, 3:421 description of, 3:219, 3:421 of isolators, 3:225, 3:279 of soiled materials, 3:312 research facility use of, 3:303 safety concerns, 3:421 time-temperature relationships, 3:421 Stearoyl-CoA desaturase-1, 3:185, 3:711 Stem cell(s) aging and, 3:665–666 damage to, leukocytes affected by, 3:153–154 embryonic. See Embryonic stem cells hair follicle, 3:693, 3:709–710 hematopoietic, 3:641, 3:666, 4:33 Stem cell factor, 4:170 Sterility, 1:60–61 Sterilization by irradiation, 3:364–365 definition of, 3:424 dry heat, 3:362 ethylene oxide, 3:362, 3:422 moist heat, 3:362 of cage, 3:280–281 of diet, 3:304–305, 3:361 of drinking water, 3:308 of isolators chemical, 3:223–225 chlorine dioxide for, 3:224 definition of, 3:236–237 documentation of, 3:224 formaldehyde gas for, 3:224 hydrogen peroxide and peracetic acid for, 3:224 irradiation, 3:225 peracetic acid for, 3:223–224 steam, 3:225, 3:279 of surgical instruments, 3:465 pulsed vacuum, 3:305 steam. See Steam sterilization Sternohyoideus, 3:5, 3:8 Sternooccipitalis, 3:4–3:5 Sternothyroideus, 3:8 Sternum anticlinalis, 3:4 Steroid hormones description of, 3:125 mechanism of action, 3:125 Steroid receptor coactivator-1, 3:202
CUMULATIVE
Stomach anatomy of, 3:16, 3:64 catheterization of, 3:477–478 musculature of, 3:64 Storage of bedding, 3:423 of feed, 3:360–361 vitamin losses caused by, 3:343–344 Strain. See specific strain Strain 129 historical perspective, 2:633 nomenclature, 2:633–634 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:636 nonneoplastic conditions, 2:634–636 related strains, 2:636 Stratum basalis, 3:712 Stratum corneum, 3:712 Stratum granulosum, 3:712 Stratum lucidum, 3:712 Strbp, 3:622 Streptobacillus moniliformis classification, 2:383 clinical features, 2:384 control, 2:384 diagnosis, 2:384 epizootiology, 2:384 history of study, 2:383 properties, 2:383 Streptococcus spp,. clinical features, 2:396–398 control of, 2:399 culture, 2:396 diagnosis, 2:398–399 epizootiology, 2:398 group B, 3:392 prevention of, 2:399 properties, 2:395–396 S. fecalis, 3:228 strains, 2:396 Stress convulsions and, 3:582 corticosterone levels affected by, 3:182 leukocytes affected by, 3:153 Stress erythropoiesis, 3:142 Stromal cells, 3:153–154 Sts-1, 4:238 Sts-2, 4:238 STSs. See Sequence tagged sites Subcutaneous drug administration description of, 3:445 injection, 3:449–450 osmotic pumps, 3:450 pellets, 3:450 Subcutaneous radio frequency transponders, 3:266, 3:441–443 Subfertility, 3:105 Subiliacus lymph node, 3:22 Sublingual gland, 3:63
INDEX
Submandibular bleeding, 3:457–458 Submaxillary gland, 3:63 Subscapularis, 3:6 Substrain definition, 1:82 nomenclature, 1:83 Substrain, definition, 2:628 Sudden unexpected death in epilepsy, 3:579 Sulfaquinoxaline, 2:533 Sulfhemoglobin, 3:144 Sulfobromophthalein, 3:206 Sulfur, 3:336 Superantigens, 4:213 Superoxide dismutase-1, 3:679 Suppressors of cytokine signaling proteins Cis transgenic mice, 4:188 description of, 4:180–181 in vivo functions of, 4:187 SOCS3, 3:184 Socs5 transgenic mice, 4:188 Socs1-deficient mice, 4:186–187 Socs2-deficient mice, 4:188 Socs3-deficient mice, 4:187–188 Supraspinatus, 3:6 Surface-enhanced laser desorption/ionization platform time-of-flight mass spectroscopy, 3:174 Surfactant, 3:51 Surfactant proteins, 4:14 Surgical procedures adrenal demedullation, 3:466 adrenalectomy, 3:466 analgesia after, 3:480–481 anesthesia for. See Anesthesia aseptic technique, 3:465–466 hepatectomy, 3:466 hypophysectomy, 3:466–467 hysterectomy, 3:467–468 hysterotomy, 3:467–468 instrument sterilization, 3:465 intestinal loops, 3:468 laparotomy pack, 3:465 nephrectomy, 3:468 nutritional support after, 3:480 olfactory bulb ablation, 3:468–469 olfactory bulbectomy, 3:468–469 orchidectomy, 3:470 ovarian transplantation, 3:470–471 ovariectomy, 3:470–471 ovariohysterectomy, 3:471 parabiosis, 3:469 parathyroidectomy, 3:469 pinealectomy, 3:470 postoperative care, 3:479–480 preconditioning before, 3:444 skin grafts, 3:472–473 splenectomy, 3:471 survival surgery, 3:465–466 testicular biopsy, 3:470 thymectomy, 3:471–472 thyroidectomy, 3:472 vagotomy, 3:473
CUMULATIVE
369
INDEX
Surgical procedures (continued) vascular catheterization. See Vascular catheterization vasectomy, 3:473–474 Survival diet restriction effects on, 3:366–367 protein restriction effects on, 3:368 SV40, 2:126–127, 2:597–599 SV40-T, 3:38 Swallowing, 3:63 Sweat glands, 3:713 Swimming exercise stress test, 3:41 Swiss mice description of, 3:260 development, 2:657 phenotype, 2:657–658 sources and origins, 2:662–663 spontaneous diseases comparison between strains and stocks, 2:663–672 glossaries neoplasms, 2:682–690 nonneoplastic conditions, 2:672–681 neoplasia, 2:659–660 nonneoplastic conditions, 2:658–659 related strains, 2:660 Swiss Webster mice, 3:260 SWR/J mice, 3:77 SWXL-4 mice, 3:585 Syk kinases, 4:23 Symphysis pelvina, 3:18, 3:20 Synaptonemal complex chromatin preparation for analysis, 1:157–158 formation, 1:155 immunostaining of proteins, 1:158–159 staining of surface-spread chromatin, 1:158 structure, 1:157 Syndecan-1, 4:93 Synteny, 1:106 Synthetic phenols, 3:310 Syphacia spp. description of, 3:398 S. muris, 2:559 S. obvelata diagnosis, 2:555 differentiation from Aspiculuris tetraptera, 2:553 human infection, 2:732–733 life cycle, 2:554 morphology, 2:553–554 research-confounding effects, 2:556 treatment, 2:556–559 Systemic lupus erythematosus antigen clearance, 4:252–253 description of, 3:74, 3:191, 4:251–254 immune complex clearance, 4:252–253 murine models of BXSB.yaa, 4:246–247 description of, 4:244 MRL.lpr, 4:244–246 NZM2410, 4:249–250 [NZW × NZB]F1, 4:247–249
Systemic lupus erythematosus (continued) summary of, 4:255–256 overview of, 4:243–244
T T1 cells, 4:85 T2 cells, 4:85 T cell(s) γδ, 4:39 activation of adaptor molecules, 4:238 antigen recognition and, 4:221, 4:233 description of, 4:88–90 E3 ubiquitin ligases, 4:237–238 humoral factors in, 4:236 negative costimulatory molecules, 4:237 negative regulation of, 4:236–239 phosphatases, 4:238 processes involved in, 4:233–234 adaptive immunity, 4:144–145, 4:208 aging biomarker use of, 3:655 in aging mice, 3:162 anergic, 4:237 antigen receptor binding of, 4:224 antigen-specific, 4:68, 4:145 apoptosis of, 4:236 autoimmunity mediated by, 4:234–235 B cells and, 4:62, 4:91–96 CD4+, 3:371, 4:39–40 CD8+, 3:371, 4:39–40 dendritic cells and, 4:88–89, 4:145 dendritic epidermal, 4:308 development of, 4:38–39, 4:62, 4:282, 4:307 differentiation of, 4:88–90 effector, 4:201, 4:236 epidermal, 4:308 helper cytokines secreted by, 4:91–92 description of, 3:189, 4:40–41, 4:89–90 homeostasis of, 4:236 integrin expression on, 4:196 interleukin-5 production by, 3:192 knockout models, 4:197–198, 4:202, 4:204 lactate dehydrogenase-elevating virus response, 2:223–224 lymphocytic choriomeningitis virus response CD4+ cells, 2:200 CD8+ cells, 2:199–200 description of, 2:187–188 mammalian reovirus response, 2:256 memory, 3:640, 4:90 migration of description of, 4:47, 4:201–202 knockout models, 4:197–198, 4:202, 4:204 transgenic models, 4:197–198, 4:204 mouse adenovirus type 1 response, 2:59 mouse hepatitis virus response, 2:154–155, 2:157 mouse polyoma virus response, 2:112
T cell(s) (continued) mousepox response, 2:81–82 murine cytomegalovirus immune response CD4+ cells, 2:30 CD8+ cells, 2:29–30 myocarditis role, 2:23 naïve, 3:640 natural killer, 4:43 nuclear factor-kB activation in, 4:236 phenotypic differentiation of, 4:40–41 precursors of, 4:63 priming of, 4:89 regulatory, 4:42, 4:235, 4:277 response of, 4:145 self-reactive, 4:42 self-tolerance, 4:42–43 Sendai virus response, 2:295–296 senescence of, 3:640–641 Th cells cytokines secreted by, 4:91–92 description of, 4:40–41, 4:89–90, 4:145 thymic, 4:39, 4:62 tolerance of, 4:235–236 transgenic models, 4:197–198, 4:204 T cell adaptor molecule, 4:255 T cell coreceptors, 4:25–26 T cell inhibitory receptors, 4:268–269 T cell receptor αß, 4:38 γδ rearrangement, 4:39 antigen-binding complex, 4:24–25 in clonal deletion, 4:215 description of, 4:24–25, 4:196 negative selection mediated by, 4:215 signal transduction, 4:234 signaling, 4:196–201 signal-transducing complex, 4:25 stimulation of, 4:235–236 transgenics, 4:209–212 V-D-J rearrangement, 4:38, 4:61 T cell specific adaptor, 4:238 T cell zone, 4:82 T1 relaxation, 3:500–501 T2 relaxation, 3:500 T wave, 3:37 Taenia taeniaeformis, 2:561 Tail cuff blood pressure measurements using, 3:32–33, 3:555 illustration of, 3:448 Tail hair follicles, 3:697 Tail length, 3:655 Tail tattooing, 3:265, 3:441 Tail tendon collagen denaturation rate, 3:655 Tail vein blood collection from, 3:456–457 catheterization of, 3:475 injection into, 3:451 Tap 1/2, 4:123 TAPA, 4:24 Tapasin, 4:18, 4:125 Targeted trapping, 1:264 Tattooing, 3:265, 3:441
370 Tauopathies, 3:683 Tbee, 3:677 T-box 3 transcription factor, 3:722 Tbsp, 4:123 Tcptp, 4:189 Teeth, 3:63 Telemetry, 3:555 Telogen phase, of hair growth, 3:706, 3:708–709 Telomere, 1:153 TEM. See Trimethylenemelamine Temperature ambient behavioral adaptations, 3:107 breeding affected by, 3:106–107, 3:239 energy requirements affected by, 3:325 in holding rooms, 3:291 reproduction affected by, 3:106–107, 3:239 research facility environment, 3:290–291 body heart rate affected by, 3:37 maintenance of, during electrocardiography, 3:37 thermoneutrality zone, 3:67–68 Temperature gradient capillary electrophoresis, 1:257 Temporal resolution, 3:490–491 Temporalis, 3:5 Temporary identification methods, 3:440–441 Tendo musculi peronei longi, 3:6 Tendo musculi tricipitis surae, 3:6 Tensor fasciae latae, 3:6–7 Teres major, 3:4, 3:6 Terminal bronchiole, 3:50 Terminal deoxynucleotidyl transferase dUTP nick-end labeling cells, 4:213 Territoriality, house mice, 1:32–34 Testes anatomy of, 3:95 biopsy of, 3:470 Testing. See Behavioral test Testis dexter, 3:19 Testis sinister, 3:18 Testosterone functions of, 3:202 luteinizing hormone effects on, 3:202 reference ranges for, 3:181 Test-retest reliability, 3:522 Tetracycline Citrobacter rodentium infection management, 2:377 Clostridium piliforme infection management, 2:355 Corynebacterium bovis management, 2:401 Mycoplasma pulmonis infection management, 2:452 TFH cells, 4:90 TGCE. See Temperature gradient capillary electrophoresis Th cells, 4:40–41, 4:89–90, 4:145, 4:291 Th17 cells, 4:41–42
CUMULATIVE
Th2 type immune response, 3:62 Theiler’s murine encephalomyelitis virus antigenic properties, 2:315 biophysical properties, 2:312 clinical course intracerebral inoculation, 2:316–318 oral inoculation, 2:316 control and prevention, 2:320 description of, 3:391 diagnosis, 2:319–320 epizootiology, 2:318–319 genome, 2:312–313 history of study, 2:311–312 immune response, 2:318 persistence, 2:317–318 propagation, 2:315 receptors, 2:314–315 structure, 2:313–314 Thermographs, 3:413 Thermoneutrality zone, 3:67–68 Thermoregulation basal metabolic rate, 3:67 cold adaptation, 3:68–69 description of, 3:67–68, 3:290 fever, 3:69 heat adaptation, 3:69 oxygen tension effects on, 3:69 Thiamine, 3:340, 3:369 Thimet, 3:346 Thoracic cavity, 3:12 Thoracic vagotomy, 3:473 Threonine, 3:333 Thrombopoiesis, 3:154 Thrombopoietin description of, 3:154 platelet production affected by, 3:156 Thromboxane A2, 3:196 Thromboxane B2, 3:196 Thymectomy, 3:471–472 Thymic epithelial cells cortical, 4:208 description of, 4:62, 4:67 origin of, 4:65 Thymic stromal lymphopoietin, 4:145 Thymocytes bone marrow, 4:208 description of, 4:64 double negative, 4:208 from transgenic mice, 4:200 T cell-epithelium interactions during selection of, 4:67–68 Thymus anatomy of, 4:62 cortical epithelial cells of, 4:63, 4:65 corticomedullary junction of, 4:63 dendritic cells in, 4:139 description of, 1:195–196 development of, 4:64–67, 4:208 epithelium of, 4:63 medullary epithelial cells of, 4:63, 4:65 mesenchyme of, 4:65 structure of, 4:62–63 T cell development in, 4:62–64 Thymus-independent antigen, 4:270 Thyroid cartilage, 3:50
INDEX
Thyroid hormone receptors, 3:125 Thyroid hormones, 3:125 Thyroid stimulating hormone characteristics of, 3:204 description of, 3:128 reference ranges for, 3:181 Thyroidectomy, 3:472 Thyrotropin-releasing hormone, 3:204 Thyroxine, 3:181, 3:204–205 Tibia, 3:4, 3:7 Tibialis caudalis, 3:7 Tibialis cranialis, 3:6 Tidal volume, 3:52–53, 3:57 Tight wire hanging time, 3:655 Timed matings, 3:111–112, 3:261–262 Tin, 3:336 Tissue nonspecific alkaline phosphatase, 3:198 Tissue oxygen consumption, 3:41 Tissue-specific antigens, 4:216 201Tl, 3:503 TLC. See Total lung capacity TLR4, 4:110 TLRs. See Toll-like receptors TMEV. See Theiler’s murine encephalomyelitis virus TMP. See Trimethylpsoralen Tnsf1a, 4:279 Toe clipping, 3:265, 3:442 Tolerance B cell, 4:48, 4:61 dendritic cell mediation of, 4:145–146 peripheral, 4:146, 4:266 T cell, 4:42–43, 4:235–236 Toll/interleukin-1 receptor homology domain, 4:3, 4:110 Toll-like receptors characteristics of, 4:3 definition of, 4:110 description of, 4:110 innate responses via, 4:144 mutations, 2:625 Salmonella susceptibility role, 2:371 signaling pathway for, 4:113–114 TLR1, 4:3, 4:110–111 TLR2, 4:3, 4:110–111 TLR3, 4:5, 4:112 TLR4, 4:5, 4:110 TLR5, 4:5, 4:112 TLR6, 4:5, 4:110–111 TLR7, 4:5, 4:112, 4:114 TLR8, 4:5, 4:112 TLR9, 4:5, 4:112, 4:114 TLR10, 4:5 TLR11, 4:5, 4:112–113 types of, 4:3–5 Toltrazuril, 2:531 Tongue, 1:192 Topical administration of drugs, 3:447–449 Total body water, 3:76–3:77 Total lung capacity, 3:53–3:54, 3:57 Total plasma cholesterol, 3:188 Total viable count, 3:365 Total white cell count, 3:141
CUMULATIVE
371
INDEX
Toxicology carcinogenicity studies, 1:302–303 genotoxicity, 1:302 immunotoxicity studies, 1:304 local tolerance studies, 1:301–302 overview, 1:300–301 photo-safety studies, 1:303 reproduction toxicity, 1:302 toxicokinetics, 1:301 Toxoplasma gondii cell biology, 2:535–536 clinical features, 2:536 description of, 4:112 diagnosis, 2:533 history of study, 2:534–535 life cycle, 2:535 prevention, 2:536 research implications, 2:536, 2:538 treatment and control, 2:536 Trace elements, 3:336 Trachea, 3:10, 3:12–3:13, 3:50 Tracheobronchiales lymph nodes, 3:21 Transcription factors description of, 4:216–217 in erythrocyte development, 3:142 leukocytes affected by, 3:149 SCL, 3:159 Transducer-tipped catheters, 3:35–36 Transfer port, 3:221–3:222 Transferrin receptor, 4:8 Transforming growth factor-ß, 3:705, 4:31, 4:236 Transforming growth factor-ß1, 3:193–194 Transgenic mice breeding colonies of, 3:258–259 Cis, 4:188 cytokine expression, 4:293 drug candidate screening using, 3:175 drug target study examples, 1:306–313 historical perspective, 1:7–8 intracytoplasmic sperm injection, 1:216 mutagenesis, 1:262 obesity studies using, 3:623–624 preclinical toxicity testing models, 1:302–303 production of, 3:258–259, 3:623 pronuclear microinjection, 1:214–216 Socs5, 4:188 suppressors of cytokine signaling, 4:186–187 T cell migration, 4:197–198 thymocytes from, 4:200 transgene nomenclature, 1:92–93 viral delivery-based transgenesis, 1:216 Transgenics T cell receptor, 4:209–212 Vß, 4:209, 4:213 Transmissible spongiform encephalopathies, 3:734 Transmission electron microscopy, 3:746 Transplantation bone marrow, 3:453–454 description of, 4:309 kidney, 3:468 ovarian, 3:113, 3:470–471
Transporter associated with antigen processing proteins, 4:18–19 Transpulmonary pressure, 3:56 Transthoracic echocardiography, 3:555–556 Trapezius, 3:4–3:6 Traps, 3:429 Treadmill exercise stress test, 3:41–42 Treg cells, 4:42, 4:235 Tribromoethanol, 3:461–462 Triceps brachii, 3:4–3:6 Trichoecius romboutsi clinical features, 2:576–577 diagnosis, 2:577 host range, 2:576 life cycle, 2:576 morphology, 2:576 pathobiology, 2:576 prevention and control, 2:577 treatment, 2:577 Trichomonas muris cell biology, 2:525 clinical features, 2:525 diagnosis, 2:525 life cycle, 2:524–525 morphology, 2:524–525 prevention, 2:525 research implications, 2:525 taxonomy, 2:524 treatment and control, 2:525 Trichuris muris, 2:559 Tricuspid valve, 3:27 TRIF-dependent pathway, 4:114 Triglycerides measurement of, 3:188 reference range for, 3:181 Triiodothyronine, 3:125, 3:138, 3:204–205 Trimethoprim, Pneumocystis murina management, 2:509–510 Trimethylenemelamine, 1:230 Trimethylpsoralen, 1:256 Triplet repeat disease models, 3:680–682 Trisodium citrate, 3:139 Trithion, 3:346 Trochlearis nerve, 3:7 Trophectoderm cells, 3:102 Trpv5, 1:309–310 Truncus brachiocephalicus, 3:9–10, 3:12 Truncus pulmonalis, 3:9 Truncus vagi dorsalis et aorta, 3:12 Trypanosoma musculi cell biology, 2:526 clinical features, 2:526–527 diagnosis, 2:527 life cycle, 2:526 morphology, 2:526 prevention, 2:527 taxonomy, 2:525–526 treatment and control, 2:527 Trypsin, 3:66 Tryptophan, 3:72 Tshr, 3:128 tub, 3:610, 3:620 Tuba uterina dexter, 3:21 Tuba uterina sinister, 3:20 Tubby hearing-1A, 3:610
Tubby mutation, 3:610 Tubby-like protein genes, 3:610 Tubulus rectus, 3:95 Tulp1, 3:610 Tulp2, 3:610 Tulp3, 3:610 Tumor antigens. See Mouse polyoma virus Helicobacter hepaticus mechanisms, 2:415–416, 2:422 spindle cell tumor features, 2:596 susceptibility of mouse strains AKR strain, 2:639 Balb/c, 2:641–642 C57BL, 2:649–650 C3H, 2:645–646 DBA, 2:651–652 FVB/N, 2:653 glossary of neoplasms, 2:682–689 SJL/J, 2:654 A strain, 2:637–638 strain 129, 2:636 Swiss mice, 2:659–660 Tumor necrosis factor-α burst forming units-erythroid stimulated by, 3:142 characteristics of, 3:194 converting enzyme, 3:194 description of, 4:31 insulin resistance induced by, 3:184 Tumor necrosis factor-ß, 3:194, 4:31 Tumor necrosis factor immediate family, 4:75 Tumor necrosis factor receptors, 4:70–71, 4:217 Tumor necrosis factor-receptor superfamily, 3:194–195 description of, 4:70–71 signaling events, 4:71–72 Tumor necrosis factor-related activation-induced cytokines, 3:194 Tumor necrosis factor-related apoptosis–inducing ligand, 4:171, 4:217 Tumor pathology, in genetically engineered mice comparative human pathology accuracy, 2:582, 2:584, 2:612 digital imaging, 2:614 morphometrics, 2:615 prospects, 2:616–617 reporting of results, 2:613–614 spontaneous tumor surveillance, 2:615–616 validation, 2:612–613 experimental design, 2:587, 2:592, 2:594 gene targets, 2:591 historical perspective, 2:584 Internet resources, 2:591–592 nomenclature conventions, 2:594–595 oncogenic event considerations molecular alterations and microscopic structure, 2:601–603
372
CUMULATIVE
Tumor pathology, in genetically engineered mice (continued) spontaneous and carcinogen-induced tumors, 2:595–596 uniqueness of genetically engineered mouse tumors, 2:596–601 progression metastasis versus microinvasion, 2:611–612 sequential microscopic changes, 2:605–606, 2:608–611 signature phenotypes, 2:586 tissue context effects microscopic structure, 2:604–605 strain effects, 2:604–605 tumor biology, 2:603–604 weak oncogenes, 2:603 tissue-specific expression promoters, 2:592, 2:601–602 Tunica albuginea, 3:95 Tunnel washer, 3:302–303, 3:310, 3:415–417 Turbinates, 3:49 Two-dimensional gel electrophoresis, 3:174 Two-tailed tests, 3:658–659 Tyk2-deficient mice, 4:184 Tylosin Clostridium perfringens infection management, 2:357 Mycoplasma pulmonis infection management, 2:452 Type I errors, 3:658–659 Type II errors, 3:658–659 Tyrosinase, 3:604 Tyrosine kinase receptors, 3:677 Tyrosine phosphatase-1B, 3:622 Tyrp1b, 3:605 Tyzzer’s disease. See Clostridium spp., C. piliforme
U UBE3A, 3:569 Ubiquitin, 3:682 Ubiquitin protein ligase E6-AP, 3:568–569 Ubr1, 3:622 UCH-L1, 3:682–683 α2u-Goblin, 3:71 UL-16 binding protein–like transcript-1, 4:173 Ulcerative dermatitis, C57BL mice, 2:648–649 Ulna, 3:4 Ultrafiltered diet, 3:354 Ultrasmall superparamagnetic iron oxide particles, 3:502 Ultrasonic noise, 3:292 Ultrasound advantages of, 3:496 attenuation, 3:495–496 contrast-enhanced, 3:497–498 Doppler effect, 3:497 in utero imaging using, 3:496, 3:499–500
Ultrasound (continued) physiologic information measured using, 3:497 principles of, 3:45, 3:494–495 properties of, 3:495, 3:497 real-time imaging uses of, 3:496 transducers used in, 3:45 two-dimensional, 3:45 Ultraviolet disinfection, of drinking water, 3:307–308 Unconjugated bilirubin, 3:205 Uncoupling protein-2, 3:620 Undernutrition, 3:367–368 Unfolded protein response, 3:187 Unverricht-Lundborg disease, 3:570 Upper respiratory tract, 3:49–50 Uracil N-glycosylase, 4:161 Urea nitrogen, 3:181, 3:206–207 Urease positive bacteria, 3:230 Ureter dexter et lymphonodus aorticus dexter, 3:17 Ureter sinister, 3:18–3:19 Ureter sinister et lymphonodus aorticus sinister, 3:17 Ureter sinister et vena renalis sinistra, 3:14 Urethane, 3:31 Urethra, 3:20–21, 3:96 Urethral plug, 3:583 Urethralis, 3:19 Urethralis et radix penis, 3:18 Uridine phosphorylase-1, 1:311 Urinalysis, 3:207 Urinary bladder catheterization of, 3:479 volume of, 3:179 Urinary system, 3:388 Urine antidiuretic hormone effects on, 3:70 collection of, 3:179–180, 3:458, 3:460 constituents of, 3:71–3:73 nephrocalcinosis and, 3:338 protein excretion in, 3:72–73 specific gravity of, 3:207 strain differences in, 3:72 volume of, 3:72, 3:181 Urine concentrating ability, 3:655 Urogenital sinus, 3:93 U.S. Biologics Control Act, 3:732 Uterine natural killer cells, 4:173, 4:284 Uterotubal junction, 3:102 Uterus anatomy of, 3:98 corpus of, 3:98 phytoestrogen effects on, 3:350 receptivity of, 3:102–103 Uveoscleral outflow, 3:602
V Vß transgenics, 4:209, 4:213 Vaccination mousepox, 2:87–88, 2:157 murine cytomegalovirus, 2:32–33 Mycoplasma pulmonis, 2:453
INDEX
Vagina anatomy of, 3:20, 3:99 daidzein effects on, 3:350 estrous cycle stage identified by appearance of, 3:100–101 evaluation of, 3:110 genistein effects on, 3:350 phytoestrogen effects on, 3:350 puberty-related opening of, 3:94 Vaginae, 3:21 Vagotomy, 3:473 Vagus nerve, 3:7, 3:65 Valine, 3:333 Vanadium, 3:336 Vancomycin, 2:360 Vaporized hydrogen peroxide, 3:310, 3:426 Variable air volume systems, 3:288 Variable-formula diet, 3:355 Variant Creutzfeldt-Jakob disease, 3:734 Vascular cannulation, 3:452 Vascular catheterization arteries, 3:475 carotid artery, 3:476 catheters used in, 3:474 femoral artery, 3:476–477 femoral vein, 3:476–477 indications for, 3:474 jugular vein, 3:475 nonsurgical approach, 3:474 portal vein, 3:476 renal artery, 3:477 tail vein, 3:475 Vascular cell adhesion molecule-1, 4:81, 4:296 Vascular endothelial growth factor, 3:158, 3:599, 3:601 Vasectomy, 3:473–474 Vasopressin, 3:77, 3:204 Vasopressin receptors, 3:204 Vastus lateralis, 3:6 Vastus medialis, 3:7 Vav1, 4:199 VC. See Vital capacity V-D-J rearrangement, 4:38, 4:61, 4:155–156 Vdr, 3:129 Vena azygos sinister, 3:9 Vena cava caudalis, 3:9, 3:11–12, 3:16–18 Vena cava cranialis dextra, 3:8–11 Vena cava cranialis sinistra, 3:9–11 Vena epigastrica cranialis superficialis, 3:3 Vena jugularis externa dextra, 3:9 Vena ovarica sinistra, 3:21 Vena portae, 3:16 Vena subclavia dextra, 3:9 Vena testicularis dextra, 3:19 Vena thoracica interna dextra, 3:9 Venae ovaricae sinistrae, 3:21 Venae pulmonales, 3:9, 3:11 Venae uterinus sinistrae, 3:21 Venipuncture dorsal pedal, 3:456–457 lateral tail, 3:457 Venous system, 1:193–194 Ventilated cage air quality concerns, 3:295 blowers, 3:298
CUMULATIVE
373
INDEX
Ventilated cage (continued) considerations in using, 3:298 description of, 3:284 excessive ventilation, 3:297–298 individually, 3:295–299, 3:412 intracage supply/intracage exhaust, 3:295–296 intracage supply/perimeter capture, 3:295–296 sanitation considerations, 3:299 Ventilated racks, 3:412 Ventilation, 3:53 Ventriculus dexter, 3:9, 3:11 Ventriculus sinister, 3:9, 3:11 Vermin, 3:402 Vertebrae, 1:197 Vertebrae caudales, 3:4 Vertebrae cervicales, 3:4 Vertebrae lumbales, 3:4 Vertebrae sacrales, 3:4 Vertebrae thoracicae, 3:4 Vertical flow changing station, 3:303 Very low-density lipoprotein description of, 3:185–186 measurement of, 3:188 in mice, 3:537 Very low-density lipoprotein receptor, 3:187 Vesica fellea, 3:15–17 Vesica urina, 3:20 Vesica urinaria, 3:17–19, 3:21 Vesica urinaria et ligamenta, 3:15 Vestibule, 3:50 Vestibulocochlearis nerve, 3:7 Vestibulum vaginae, 3:21 Veterinary pathologist, 3:389 Vibration from individually ventilated cages, 3:298–299 reproduction affected by, 3:106 Vibrissae hair follicles, 3:694, 3:696 Villi, of small intestine, 3:65–66 Virus. See also specific virus in biological materials, 3:400–401 genomic sequences, 3:747–748 hemagglutination methods, 3:746 immunoassays for detecting, 3:746–747 isolation of, 3:744–746 microbiological quality control testing for, 3:744–749 polymerase chain reaction testing, 3:746–748 removal of, from biologicals, 3:739–740 reproduction in mice infected with, 3:105 safety testing for, 3:745 transmission electron microscopy detection of, 3:746 types of, 3:391, 3:733 validation studies for, 3:739 Virus-Serum-Toxin Act, 3:732 Visfatin, 3:184 Vital capacity, 3:53–54, 3:57 Vitamin(s) autoclaving effects on, 3:362–363 classification of, 3:339 deficiency diseases, 3:343–344
Vitamin(s) (continued) diet restriction effects on, 3:368–369 excess of, 3:345 extrusion, 3:343 fat-soluble, 3:339–340, 3:345, 3:365 immunity affected by, 3:370 irradiation effects on, 3:365 measurement of, 3:339, 3:342 National Research Council guidelines, 3:342 premixes, 3:343–344 in purified diets, 3:342 requirements, 3:342–343 stability of, 3:343–344 storage losses of, 3:343–344 toxicities, 3:345 water-soluble, 3:340–341 Vitamin A1, 3:339, 3:342, 3:345, 3:368 Vitamin A2, 3:339, 3:342, 3:345, 3:368 Vitamin B1 autoclaving effects on, 3:362 description of, 3:340, 3:342 Vitamin B2, 3:340, 3:342 Vitamin B3, 3:340 Vitamin B4, 3:340–341 Vitamin B5, 3:341 Vitamin B6, 3:341–342 Vitamin B7, 3:341 Vitamin B9, 3:341 Vitamin B12, 3:341–342 Vitamin C, 3:550–551 Vitamin D2, 3:339 Vitamin D3, 3:339, 3:342 Vitamin D receptor, 3:129, 3:714 Vitamin D response elements, 3:129 Vitamin E, 3:340, 3:342, 3:345, 3:368–370, 3:550 Vitamin H, 3:341 Vitamin K1, 3:340, 3:344 Vitamin K2, 3:340, 3:344 Vitamin K3, 3:340, 3:342–344, 3:362 Vivarium. See Research facilities VL30 elements, 2:276 Volar pads, 3:714–718 Volatile hazardous agents, 3:280 Voltage-gated calcium channels, 3:572–573 Voltage-gated K+ channel KCNA 1, 3:568 Voltage-gated Na+ channel SCN2A, 3:567–568 Vomeronasal organ comparative embryology, 1:197 description of, 3:49 Vomitoxin, 3:348
W W0.75, 3:324 Waardenburg syndrome, 3:679 Wasting disease, 2:194 Water absorption of, 3:66 access methods for, 3:241 body content of, 3:76–77 for breeding colony, 3:241
Water (continued) drinking acidification of, 3:308, 3:372, 3:418 additives in, 3:308 anthelmintics added to, 3:309 antibiotics added to, 3:309 automatic systems for, 3:241, 3:285–286 bisphenol A contamination, 3:307 chlorine added to, 3:308–309, 3:372, 3:418–419 contaminants in, 3:241 delivery of, 3:241, 3:286–290, 3:307 drug administration in, 3:444–445 hydrochloric acid added to, 3:308, 3:418 irradiation of, 3:372 mechanical filtration of, 3:372 microorganisms in, 3:371 monitoring of, 3:420 municipal sources of, 3:241, 3:307 ozone treatment of, 3:372 processing of, 3:307–308 quality of, 3:371–372, 3:418 restriction of, 3:371 reverse osmosis of, 3:307, 3:372 steam sterilization of, 3:308 sterilization of, 3:225, 3:308 ultraviolet disinfection of, 3:307–308 variations in, 3:306–307 functions of, 3:74–75 gelled, 3:419 intake of, 3:75–76 loss of, 3:76 monitoring of, 3:420 mouse models used to study, 3:75–76 quality of, 3:417 for room level bioexclusion facilities, 3:244–245 surface, 3:307 turnover of, 3:76 well, 3:307 Water balance, house mice, 1:32 Water to food ratio, 3:76 Watering systems automatic chlorine added to, 3:308–309 cleaning of, 3:420 description of, 3:241, 3:285–286, 3:419–420 flush systems, 3:419–420 pressure in, 3:420 recirculating systems, 3:419–420 steam autoclaving of, 3:420 bottles chlorine dissipation in, 3:308 description of, 3:241, 3:286, 3:419 illustration of, 3:287–290 inspection of, 3:419 research facility use of, 3:307 stoppers for, 3:307 sipper tubes, 3:419 Water-soluble vitamins, 3:340–341 Weaning, 3:239 weaver, 3:574–575, 3:676
374 Well water, 3:307 Wensinck’s glycerol broth, 3:420 Wg1, 3:624 What’s Wrong with My Mouse?, 3:519, 3:530 White blood cell count, 3:151 White noise, 3:415 Whitten effect, 1:54 Whole body plethysmography, 3:59–60 Wild-derived mice allelic diversity of, 3:650–651 definition of, 3:650 evolution of, 3:650 Wilms’ tumor homolog 1, 3:93 Wlds, 3:677 Wnt, 2:598–599, 2:603–604 Wnt glycoproteins, 4:67 Wnt signaling in hair follicle morphogenesis, 3:705 in mammary gland development, 3:722–723
CUMULATIVE
Wnt signaling (continued) in sebaceous gland development, 3:712 in volar pad development, 3:718 Wobbler mouse, 3:677 Wolffian duct, 3:70, 3:93 Wound healing, 3:655
X XCR1, 3:197 Xiap, 4:280 X-linked immunodeficiency, 4:307 XO oocyte, gene mapping, 1:131 X-ray computed tomography, 3:493–494 X-ray imaging, 3:493–494 Xylazine, 3:461
Y Yellow fever vaccine, 3:735 Yolk sac, 1:190–192
INDEX
Z Z score, 3:659 ZAP-70, 4:199, 4:234, 4:307 Zearalenone, 3:346, 3:348 Zigzag hairs, 3:695–696 Zinc, 3:336, 3:371 Zoonoses. See also specific diseases allergy. See Laboratory animal-associated allergy arthropod infestation, 2:733–735 bacterial disease, 2:725–730 bites, 2:735 definition, 2:720 dermatophytosis, 2:730–731 helminth disease, 2:732–744 rickettsial disease, 2:724–725 viruses, 2:720–724 Zygomaticus, 3:5
